PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Borio, L; Inglesby, T; Peters, CJ; Schmaljohn, AL; Hughes, JM; Jahrling, PB; Ksiazek, T; Johnson, KM; Meyerhoff, A; O'Toole, T; Ascher, MS; Bartlett, J; Breman, JG; Eitzen, EM; Hamburg, M; Hauer, J; Henderson, A; Johnson, RT; Kwik, G; Layton, M; Lillibridge, S; Nabel, GJ; Osterholm, MT; Perl, TM; Russell, P; Tonat, K				Borio, L; Inglesby, T; Peters, CJ; Schmaljohn, AL; Hughes, JM; Jahrling, PB; Ksiazek, T; Johnson, KM; Meyerhoff, A; O'Toole, T; Ascher, MS; Bartlett, J; Breman, JG; Eitzen, EM; Hamburg, M; Hauer, J; Henderson, A; Johnson, RT; Kwik, G; Layton, M; Lillibridge, S; Nabel, GJ; Osterholm, MT; Perl, TM; Russell, P; Tonat, K		Working Grp Civilian Biodef	Hemorrhagic fever viruses as biological weapons - Medical and public health management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RIFT-VALLEY FEVER; LASSA FEVER; EBOLA-VIRUS; MARBURG-VIRUS; RHESUS-MONKEYS; JUNIN VIRUS; WEST-AFRICA; EXPERIMENTAL-INFECTION; NEUTRALIZING ANTIBODY; EPIDEMIOLOGIC ASPECTS	Objective To develop consensus-based recommendations for measures to be taken by medical and public health professionals if hemorrhagic fever viruses (HFVs) are used as biological weapons against a civilian population. Participants The Working Group on Civilian Biodefense included 26 representatives from academic medical centers, public health, military services, governmental agencies, and other emergency management institutions. Evidence MEDLINE was searched from January 1966 to January 2002. Retrieved references, relevant material published prior to 1966, and additional sources identified by participants were reviewed. Consensus Process Three formal drafts of the statement that synthesized information obtained in the evidence-gathering process were reviewed by the working group. Each draft incorporated comments and judgments of the members. All members approved the final draft. Conclusions Weapons disseminating a number of HFVs could cause an outbreak of an undifferentiated febrile illness 2 to 21 days later, associated with clinical manifestations that could include rash, hemorrhagic diathesis, and shock. The mode of transmission and clinical course would vary depending on the specific pathogen. Diagnosis may be delayed given clinicians' unfamiliarity with these diseases, heterogeneous clinical presentation within an infected cohort, and lack of widely available diagnostic tests. Initiation of ribavirin therapy in the early phases of illness may be useful in treatment of some of these viruses, although extensive experience is lacking. There are no licensed vaccines to treat the diseases caused by HFVs.	Johns Hopkins Sch Med, Johns Hopkins Ctr Civilian Biodef Strategies, Baltimore, MD 21202 USA; Johns Hopkins Sch Publ Hlth, Johns Hopkins Ctr Civilian Biodef Strategies, Baltimore, MD 21202 USA; Johns Hopkins Sch Publ Hlth, Dept Microbiol, Baltimore, MD 21202 USA; Johns Hopkins Sch Med, Dept Microbiol, Baltimore, MD 21202 USA; Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21202 USA; Johns Hopkins Sch Publ Hlth, Dept Neurosci, Baltimore, MD 21202 USA; Johns Hopkins Sch Med, Div Infect Dis, Baltimore, MD USA; Univ Texas, Med Branch, Ctr Biodef, Galveston, TX 77550 USA; NIH, Ctr Clin, Dept Crit Care Med, Bethesda, MD 20892 USA; NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA; NIH, Vaccine Res Ctr, Bethesda, MD 20892 USA; USA, Med Res Inst Infect Dis, Frederick, MD USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA; US FDA, Off Commiss, Rockville, MD 20857 USA; US Dept HHS, Off Emergency Preparedness, Rockville, MD USA; US Dept HHS, Off Publ Hlth Preparedness, Washington, DC 20201 USA; Nucl Threat Initiat, Washington, DC USA; New York City Dept Hlth, Bur Communicable Dis, New York, NY 10013 USA; Univ Minnesota, Ctr Infect Dis Res & Policy, Minneapolis, MN USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); National Institutes of Health (NIH) - USA; Centers for Disease Control & Prevention - USA; University of New Mexico; University of New Mexico; US Food & Drug Administration (FDA); New York City Department of Health & Mental Hygiene; University of Minnesota System; University of Minnesota Twin Cities	Borio, L (corresponding author), Johns Hopkins Sch Med, Johns Hopkins Ctr Civilian Biodef Strategies, 111 Market Pl,Suite 830, Baltimore, MD 21202 USA.	Lborio@jhsph.edu						Abd El-Rahim IHA, 1999, REV SCI TECH OIE, V18, P741, DOI 10.20506/rst.18.3.1195; Adhikari Prabha M R, 1993, Indian J Med Sci, V47, P124; Alibek K, 1999, BIOHAZARD CHILLING T; [Anonymous], 1994, Epidemiol Bull, V15, P4; [Anonymous], 2000, 7 INT COMM TAX VIR; Armstrong LR, 1999, INFECT CONT HOSP EP, V20, P176, DOI 10.1086/501607; Arnon SS, 2001, JAMA-J AM MED ASSOC, V285, P1059, DOI 10.1001/jama.285.8.1059; BANERJEE K, 1979, INDIAN J MED RES, V69, P363; BARON RC, 1983, B WORLD HEALTH ORGAN, V61, P997; BAZHUTIN NB, 1992, VOP VIRUSOL+, V37, P153; BRIGGILER A, 1987, MEDICINA-BUENOS AIRE, V47, P565; BUCKLEY SM, 1970, AM J TROP MED HYG, V19, P680, DOI 10.4269/ajtmh.1970.19.680; Burke J, 1978, B WORLD HEALTH ORGAN, V56, P271; Butler JC, 1996, INFECT DIS CLIN N AM, V10, P917, DOI 10.1016/S0891-5520(05)70333-0; Bwaka MA, 1999, J INFECT DIS, V179, pS1, DOI 10.1086/514308; CAREY DE, 1972, T ROY SOC TROP MED H, V66, P402, DOI 10.1016/0035-9203(72)90271-4; *CDCP, 2002, CAT A AG; *CDCP WHO, 2002, INF CONTR VIR HEM FE; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P73; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P475; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P709; Chen JP, 2000, BLOOD COAGUL FIBRIN, V11, P461, DOI 10.1097/00001721-200007000-00010; CLAYTON AJ, 1977, B WORLD HEALTH ORGAN, V55, P435; Colebunders R, 2000, J INFECTION, V40, P16, DOI 10.1053/jinf.1999.0603; COOPER CB, 1982, BRIT MED J, V285, P1003, DOI 10.1136/bmj.285.6347.1003; COSGRIFF TM, 1989, REV INFECT DIS, V11, pS807; CRAVEN RB, 1991, TXB HUMAN VIROLOGY; *CTR NONPR STUD, 2002, CHEM BIOL WEAP POSS; CUMMINS D, 1990, AM J TROP MED HYG, V42, P470, DOI 10.4269/ajtmh.1990.42.470; CUNHA BA, 2000, TICKBORNE INFECTIOUS; DALGARD DW, 1992, LAB ANIM SCI, V42, P152; DANDAWATE CN, 1994, INDIAN J MED RES, V99, P152; Deng IM, 1978, B WORLD HEALTH ORGAN, V56, P247; Dennis DT, 2001, JAMA-J AM MED ASSOC, V285, P2763, DOI 10.1001/jama.285.21.2763; Dowell SF, 1999, J INFECT DIS, V179, pS87, DOI 10.1086/514284; Eck EK, 1997, INFECT CONT HOSP EP, V18, P122; EMOND RTD, 1977, BMJ-BRIT MED J, V2, P541, DOI 10.1136/bmj.2.6086.541; ENRIA DA, 1984, LANCET, V2, P255, DOI 10.1016/S0140-6736(84)90299-X; ENRIA DA, 1994, ANTIVIR RES, V23, P23, DOI 10.1016/0166-3542(94)90030-2; Feldmann H, 1999, ARCH VIROL, P159; Fennelly KP, 1997, CLIN CHEST MED, V18, P1, DOI 10.1016/S0272-5231(05)70352-X; Fisher-Hoch SP, 2000, J VIROL, V74, P6777, DOI 10.1128/JVI.74.15.6777-6783.2000; Formenty P, 1999, J INFECT DIS, V179, pS48, DOI 10.1086/514285; FRAME JD, 1989, REV INFECT DIS, V11, pS783; FRAME JD, 1984, T ROY SOC TROP MED H, V78, P319, DOI 10.1016/0035-9203(84)90107-X; FRAME JD, 1970, AM J TROP MED HYG, V19, P670, DOI 10.4269/ajtmh.1970.19.670; Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399; GARGAN TP, 1988, AM J TROP MED HYG, V38, P440, DOI 10.4269/ajtmh.1988.38.440; Garner JS, 1996, INFECT CONT HOSP EP, V17, P54, DOI 10.1017/S0195941700006123; GEAR JHS, 1989, REV INFECT DIS, V11, pS777; GEAR JSS, 1975, BRIT MED J, V4, P489, DOI 10.1136/bmj.4.5995.489; Gershon RRM, 1998, J OCCUP ENVIRON MED, V40, P497, DOI 10.1097/00043764-199805000-00014; Guimard Y, 1999, J INFECT DIS, V179, pS268, DOI 10.1086/514315; Gupta M, 2001, J VIROL, V75, P4649, DOI 10.1128/JVI.75.10.4649-4654.2001; HALSTEAD SB, 1979, J INFECT DIS, V140, P527, DOI 10.1093/infdis/140.4.527; Henderson DA, 1999, JAMA-J AM MED ASSOC, V281, P2127, DOI 10.1001/jama.281.22.2127; Hevey M, 1998, VIROLOGY, V251, P28, DOI 10.1006/viro.1998.9367; HUGGINS JW, 1989, REV INFECT DIS, V11, pS750; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; IYER C G, 1959, Indian J Med Sci, V13, P1011; Jaax N, 1995, LANCET, V346, P1669, DOI 10.1016/S0140-6736(95)92841-3; Jaax NK, 1996, ARCH PATHOL LAB MED, V120, P140; JAHRLING P, 1989, TXB MILITARY MED, V1; JAHRLING PB, 1980, J INFECT DIS, V141, P580, DOI 10.1093/infdis/141.5.580; JOHNSON E, 1995, INT J EXP PATHOL, V76, P227; JOHNSON KM, 1966, AM J TROP MED HYG, V15, P103, DOI 10.4269/ajtmh.1966.15.103; JOHNSON KM, 1965, SCIENCE, V150, P1618, DOI 10.1126/science.150.3703.1618; JOUAN A, 1989, RES VIROLOGY, V140, P175, DOI 10.1016/S0923-2516(89)80096-2; KEANE E, 1977, BRIT MED J, V1, P1399, DOI 10.1136/bmj.1.6073.1399; Kelly DA, 2001, HEPATOLOGY, V34, p342A; KENYON RH, 1986, ANTIMICROB AGENTS CH, V29, P521, DOI 10.1128/AAC.29.3.521; KENYON RH, 1992, INTERVIROLOGY, V33, P23; Khan AS, 1999, J INFECT DIS, V179, pS76, DOI 10.1086/514306; Kilgore PE, 1997, CLIN INFECT DIS, V24, P718, DOI 10.1093/clind/24.4.718; KUMING BS, 1977, BRIT J OPHTHALMOL, V61, P265, DOI 10.1136/bjo.61.4.265; LAUGHLIN LW, 1979, T ROY SOC TROP MED H, V73, P630, DOI 10.1016/0035-9203(79)90006-3; LEDUC JW, 1989, REV INFECT DIS, V11, pS730; LEIFER E, 1970, AM J TROP MED HYG, V19, P677, DOI 10.4269/ajtmh.1970.19.677; Lub M Iu, 1995, Vopr Virusol, V40, P158; Maiztegui JI, 1998, J INFECT DIS, V177, P277, DOI 10.1086/514211; MAIZTEGUI JI, 1979, LANCET, V2, P1216; MANDELL GL, 2000, MANDELL DOUGLAS BENN; MCCORMICK JB, 1986, NEW ENGL J MED, V314, P20, DOI 10.1056/NEJM198601023140104; MCCORMICK JB, 1987, J INFECT DIS, V155, P445, DOI 10.1093/infdis/155.3.445; MCKEE KT, 1992, INTERVIROLOGY, V34, P154; McKinney R., 1999, BIOSAFETY MICROBIOLO; MEEGAN JM, 1979, T ROY SOC TROP MED H, V73, P618, DOI 10.1016/0035-9203(79)90004-X; MERTENS PE, 1973, AM J TROP MED HYG, V22, P780, DOI 10.4269/ajtmh.1973.22.780; Miller J, 2002, GERMS BIOL WEAPONS A; Monath T P, 2001, Lancet Infect Dis, V1, P11, DOI 10.1016/S1473-3099(01)00016-0; MONATH TP, 1973, AM J TROP MED HYG, V22, P773, DOI 10.4269/ajtmh.1973.22.773; MONATH TP, 1974, AM J TROP MED HYG, V23, P1140, DOI 10.4269/ajtmh.1974.23.1140; MONATH TP, 1981, AM J TROP MED HYG, V30, P431, DOI 10.4269/ajtmh.1981.30.431; MONSON MH, 1984, T ROY SOC TROP MED H, V78, P549, DOI 10.1016/0035-9203(84)90082-8; MORROW CA, 1989, J STRUCT GEOL, V11, P815, DOI 10.1016/0191-8141(89)90100-4; Mupapa K, 1999, J INFECT DIS, V179, pS18, DOI 10.1086/514298; Muyembe-Tamfum JJ, 1999, J INFECT DIS, V179, pS259, DOI 10.1086/514302; *NAT I OCC SAF HLT, 1996, PUBL NAT I OCC SAF H; Nathan N, 2001, LANCET, V358, P2129, DOI 10.1016/S0140-6736(01)07185-9; NIKLASSON B, 1985, VACCINE, V3, P123, DOI 10.1016/0264-410X(85)90061-1; PAVRI K, 1989, REV INFECT DIS, V11, pS854; PETERS CJ, 1974, AM J EPIDEMIOL, V99, P425, DOI 10.1093/oxfordjournals.aje.a121631; Peters CJ, 1999, ANNU REV MED, V50, P531, DOI 10.1146/annurev.med.50.1.531; PETERS CJ, 1989, REV INFECT DIS, V11, pS743; Peters CJ, 1996, ARCH VIROL, P141; PETERS CJ, 1988, ARCH VIROL, V99, P31, DOI 10.1007/BF01311021; Pittman PR, 1999, VACCINE, V18, P181, DOI 10.1016/S0264-410X(99)00218-2; Richards GA, 2000, CRIT CARE MED, V28, P240, DOI 10.1097/00003246-200001000-00041; Rodriguez LL, 1999, J INFECT DIS, V179, pS170, DOI 10.1086/514291; Roels TH, 1999, J INFECT DIS, V179, pS92, DOI 10.1086/514286; Rowe AK, 1999, J INFECT DIS, V179, pS28, DOI 10.1086/514318; Ryabchikova EI, 1999, J INFECT DIS, V179, pS199, DOI 10.1086/514293; SAMOILOVICH SR, 1983, AM J TROP MED HYG, V32, P825, DOI 10.4269/ajtmh.1983.32.825; SCHNITTLER HJ, 1993, J CLIN INVEST, V91, P1301, DOI 10.1172/JCI116329; Schou S, 2000, COMPARATIVE MED, V50, P108; SCHOU S, 2000, COMPARATIVE MED, V50, P2108; Seiler P, 2000, J VIROL, V74, P5896, DOI 10.1128/JVI.74.13.5896-5901.2000; Shawky S, 2000, SAUDI MED J, V21, P1109; Shetty AK, 2000, PEDIATR PULM, V29, P69; Shu H L, 1969, Ger Med Mon, V14, P7; SIMPSON DIH, 1969, T ROY SOC TROP MED H, V63, P303, DOI 10.1016/0035-9203(69)90002-9; Slenczka WG, 1999, CURR TOP MICROBIOL, V235, P49; SMITH DH, 1982, LANCET, V1, P816; SMITHBURN KC, 1949, J IMMUNOL, V62, P213; Solomon T, 2001, J INFECTION, V42, P104, DOI 10.1053/jinf.2001.0802; STEPHENSON EH, 1984, J MED VIROL, V14, P295, DOI 10.1002/jmv.1890140402; STILLE W, 1968, DEUT MED WOCHENSCHR, V93, P572, DOI 10.1055/s-0028-1105099; Strausbaugh L J, 1978, J Egypt Public Health Assoc, V53, P181; Sullivan NJ, 2000, NATURE, V408, P605, DOI 10.1038/35046108; SWANAPOEL R, 1994, INFECTIOUS DIS LIVES, V1; SWANEPOEL R, 1987, AM J TROP MED HYG, V36, P120, DOI 10.4269/ajtmh.1987.36.120; Turell MJ, 1998, J MED ENTOMOL, V35, P132, DOI 10.1093/jmedent/35.2.132; Vanderzanden L, 1998, VIROLOGY, V246, P134, DOI 10.1006/viro.1998.9176; WHITE HA, 1972, T ROY SOC TROP MED H, V66, P390, DOI 10.1016/0035-9203(72)90269-6; *WHO, 2000, FACT SHEET 179 LASS; *WHO, 2002, AC HAEM FEV SYNDR; Zaki SR, 1999, J INFECT DIS, V179, pS36, DOI 10.1086/514319; ZWEIGHAFT RM, 1977, NEW ENGL J MED, V297, P803, DOI 10.1056/NEJM197710132971504; 1988, MMWR MORB MORTAL S3, V37, P1	140	458	501	1	303	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	2002	287	18					2391	2405		10.1001/jama.287.18.2391	http://dx.doi.org/10.1001/jama.287.18.2391			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548PF	11988060				2022-12-28	WOS:000175397000028
J	Mandelblatt, JS; Lawrence, WF; Womack, SM; Jacobson, D; Yi, B; Hwang, YT; Gold, K; Barter, J; Shah, K				Mandelblatt, JS; Lawrence, WF; Womack, SM; Jacobson, D; Yi, B; Hwang, YT; Gold, K; Barter, J; Shah, K			Benefits and costs of using HPV testing to screen for cervical cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-PAPILLOMAVIRUS INFECTION; SQUAMOUS INTRAEPITHELIAL LESIONS; CYTOLOGICALLY NORMAL WOMEN; POLYMERASE-CHAIN-REACTION; HIGH-RISK HPV; HYBRID CAPTURE ASSAY; NATURAL-HISTORY; YOUNG-WOMEN; UNDETERMINED SIGNIFICANCE; EPIDEMIOLOGIC EVIDENCE	Context Despite quality assurance standards, Papanicolaou (Pap) test characteristics remain less than optimal. Objective To compare the societal costs and benefits of human papillomavirus (HPV) testing, Pap testing, and their combination to screen for cervical cancer. Design, Setting, and Population A simulation model of neoplasia natural history was used to estimate the societal costs and quality-adjusted life expectancy associated with 18 different general population screening strategies: Pap plus HPV testing, Pap testing alone, and HPV testing alone every 2 or 3 years among hypothetical longitudinal cohorts of US women beginning at age 20 years and continuing to 65 years, 75 years, or death. Main Outcome Measure Discounted costs per quality-adjusted life-year (QALY) saved of each screening strategy. Results Maximal savings in lives were achieved by screening every 2 years until death with combined HPV and Pap testing at an incremental cost of $76183 per QALY compared with Pap testing alone every 2 years. Stopping biennial screening with HPV and Pap testing at age 75 years captures 97.8% of the benefits of lifetime screening at a cost of $70347 per QALY. Combined biennial HPV and Pap testing to age 65 years captures 86.6% of the benefits achievable by continuing to screen until age 75 years. Human papillomavirus screening alone was equally effective as Pap testing alone at any given screening interval or age of screening cessation but was more costly and therefore was dominated. In sensitivity analyses, HPV testing would be more effective and less costly than Pap testing at a cost threshold of $5 for an HPV test. Conclusions Screening with HPV plus Pap tests every 2 years appears to save additional years of life at reasonable costs compared with Pap testing alone. Applying age limits to screening is a viable option to maintain benefits while reducing costs.	Georgetown Univ, Med Ctr & Clin & Econ Outcomes Core, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr & Clin & Econ Outcomes Core, Lombardi Canc Ctr, Dept Med, Washington, DC 20007 USA; Georgetown Univ, Med Ctr & Clin & Econ Outcomes Core, Lombardi Canc Ctr, Dept Obstet & Gynecol, Washington, DC 20007 USA; SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA; Roswell Pk Canc Inst, Dept Canc Prevent Epidemiol & Biostat, Buffalo, NY 14263 USA; Tufts Univ, Dept Community Hlth Family Med, Sch Med, Boston, MA 02111 USA; Georgetown Univ, Sch Med, Dept Biomath & Biostat, Washington, DC USA; Johns Hopkins Sch Med, Dept Microbiol, Baltimore, MD USA; Johns Hopkins Sch Publ Hlth, Dept Microbiol, Baltimore, MD USA	Georgetown University; Georgetown University; Georgetown University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Roswell Park Cancer Institute; Tufts University; Georgetown University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Mandelblatt, JS (corresponding author), Georgetown Univ, Med Ctr & Clin & Econ Outcomes Core, Lombardi Canc Ctr, Dept Oncol, 2233 Wisconsin Ave NW,Suite 317, Washington, DC 20007 USA.	mandelbj@georgetown.edu			NATIONAL INSTITUTE ON AGING [R01AG015340] Funding Source: NIH RePORTER; NIA NIH HHS [R01-AG15340] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adam E, 2000, AM J OBSTET GYNECOL, V182, P257, DOI 10.1016/S0002-9378(00)70208-0; BAQUET CR, 1991, J NATL CANCER I, V83, P551, DOI 10.1093/jnci/83.8.551; BAUER HM, 1993, SEX TRANSM DIS, V20, P274, DOI 10.1097/00007435-199309000-00007; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; Blackman D K, 1999, MMWR CDC Surveill Summ, V48, P1; BORST M, 1991, J REPROD MED, V36, P95; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BOYES DA, 1982, CLIN INVEST MED, V5, P1; Brisson J, 1996, J INFECT DIS, V173, P794, DOI 10.1093/infdis/173.4.794; Brown AD, 1999, JAMA-J AM MED ASSOC, V281, P347, DOI 10.1001/jama.281.4.347; BUR M, 1995, ACTA CYTOL, V39, P631; Burk RD, 1996, SEX TRANSM DIS, V23, P333, DOI 10.1097/00007435-199607000-00013; Clavel C, 1998, INT J CANCER, V75, P525, DOI 10.1002/(SICI)1097-0215(19980209)75:4&lt;525::AID-IJC6&gt;3.0.CO;2-V; COLGAN TJ, 1995, ACTA CYTOL, V39, P1191; COPPLESON LW, 1975, AM J OBSTET GYNECOL, V122, P127, DOI 10.1016/0002-9378(75)90627-4; Costa S, 2000, ACTA CYTOL, V44, P310, DOI 10.1159/000328471; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; CREASMAN WT, 1981, GYNECOL ONCOL, V12, pS306, DOI 10.1016/0090-8258(81)90084-6; Cuzick J, 1999, BRIT J CANCER, V81, P554, DOI 10.1038/sj.bjc.6690730; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; Cuzick J, 2000, BRIT J CANCER, V83, P561, DOI 10.1054/bjoc.2000.1375; CUZICK J, 1999, HEALTH TECHNOL ASSES, V3, P1; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; EDDY DM, 1987, CANCER, V60, P1117, DOI 10.1002/1097-0142(19870901)60:5<1117::AID-CNCR2820600533>3.0.CO;2-H; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; Efron B, 1998, INTRO BOOTSTRAP; ELUFNETO J, 1994, BRIT J CANCER, V69, P114, DOI 10.1038/bjc.1994.18; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; FAHS MC, 1992, ANN INTERN MED, V117, P520, DOI 10.7326/0003-4819-117-6-520; FINK DJ, 1988, CA-CANCER J CLIN, V38, P127, DOI 10.3322/canjclin.38.2.127; Frisch M, 2000, JNCI-J NATL CANCER I, V92, P1500, DOI 10.1093/jnci/92.18.1500; GAARENSTROOM KN, 1994, INT J GYNECOL CANCER, V4, P73, DOI 10.1046/j.1525-1438.1994.04020073.x; Gjoen K, 1996, APMIS, V104, P68, DOI 10.1111/j.1699-0463.1996.tb00688.x; Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002; Gold MR, 1996, COST EFFECTIVENESS H; Goldie SJ, 1999, ANN INTERN MED, V130, P97, DOI 10.7326/0003-4819-130-2-199901190-00003; Helms LJ, 1999, MED CARE, V37, P652, DOI 10.1097/00005650-199907000-00005; HERRERO R, 1997, PAN AM J PUBLIC HLTH, V1, P362; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HILDESHEIM A, 1993, SEX TRANSM DIS, V20, P279, DOI 10.1097/00007435-199309000-00008; Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252; Hunink MGM, 1998, MED DECIS MAKING, V18, P337, DOI 10.1177/0272989X9801800312; HUTCHINSON ML, 1992, ACTA CYTOL, V36, P499; Jenkins D, 1996, INT J CANCER, V65, P768; Jenkins D, 2001, CURR OPIN INFECT DIS, V14, P53, DOI 10.1097/00001432-200102000-00010; JONES WB, 1995, CANCER, V76, P1934, DOI 10.1002/1097-0142(19951115)76:10+<1934::AID-CNCR2820761310>3.0.CO;2-8; KATAJA V, 1990, EUR J EPIDEMIOL, V6, P9, DOI 10.1007/BF00155542; Keys HM, 1999, NEW ENGL J MED, V340, P1154, DOI 10.1056/NEJM199904153401503; Kiviat N, 1996, AM J OBSTET GYNECOL, V175, P1099, DOI 10.1016/S0002-9378(96)70011-X; KOOPMANSCHAP MA, 1990, INT J CANCER, V45, P410, DOI 10.1002/ijc.2910450305; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Koutsky Laura, 1997, American Journal of Medicine, V102, P3; Kuhn L, 2000, JNCI-J NATL CANCER I, V92, P818, DOI 10.1093/jnci/92.10.818; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; LEY C, 1991, JNCI-J NATL CANCER I, V83, P997, DOI 10.1093/jnci/83.14.997; Liaw KL, 1999, J NATL CANCER I, V91, P954, DOI 10.1093/jnci/91.11.954; Londesborough P, 1996, INT J CANCER, V69, P364; Lorincz A T, 1996, J Obstet Gynaecol Res, V22, P629; Lorincz AT, 1996, OBSTET GYN CLIN N AM, V23, P707; Luce BR, 1996, COST EFFECTIVENESS H, P176; MANDELBLATT J, 1986, JAMA-J AM MED ASSOC, V256, P367, DOI 10.1001/jama.256.3.367; MANDELBLATT J, IN PRESS J NATL CANC; Mandelblatt J S, 2000, J Am Med Womens Assoc (1972), V55, P210; Mandelblatt JS, 1997, J GEN INTERN MED, V12, P551, DOI 10.1046/j.1525-1497.1997.07107.x; Mandelblatt JS, 1999, CANCER EPIDEM BIOMAR, V8, P97; MANGO LJ, 1994, CANCER LETT, V77, P155, DOI 10.1016/0304-3835(94)90098-1; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; MCCRORY DC, 1999, 5 AG HLTH CAR POL RE; Meijer C J, 1992, IARC Sci Publ, P271; MELKERT PWJ, 1993, INT J CANCER, V53, P919, DOI 10.1002/ijc.2910530609; Mitchell MF, 1998, OBSTET GYNECOL, V92, P737, DOI 10.1097/00006250-199811000-00001; Morris M, 1999, NEW ENGL J MED, V340, P1137, DOI 10.1056/NEJM199904153401501; MOSCICKI AB, 1993, OBSTET GYNECOL, V82, P578; Moscicki AB, 1998, J PEDIATR-US, V132, P277, DOI 10.1016/S0022-3476(98)70445-7; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; MULLER C, 1990, COSTS EFFECTIVENESS; MUNOZ H, 1992, EPIDEMIOLOGY CERVICA, P251; Myers ER, 2000, OBSTET GYNECOL, V96, P645, DOI 10.1016/S0029-7844(00)00979-0; Myers ER, 2000, AM J EPIDEMIOL, V151, P1158, DOI 10.1093/oxfordjournals.aje.a010166; Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009; *NAT CTR HLTH STAT, 1995, NAT HLTH INT SURV 19, V10; *NAT CTR HLTH STAT, 1998, VIT HLTH STAT; *NCI, 2000, SURV EP END RES; *NCI, 1999, SEER CANC INC PUBL U; NELSON JH, 1989, CA-CANCER J CLIN, V39, P157, DOI 10.3322/canjclin.39.3.157; *NIH CONS STAT, 1996, CERV CANC; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; NUOVO G, 1992, GYNECOL ONCOL, V46, P304, DOI 10.1016/0090-8258(92)90221-4; PARKIN DM, 1986, J EPIDEMIOL COMMUN H, V40, P143, DOI 10.1136/jech.40.2.143; Peyton CL, 1998, J CLIN MICROBIOL, V36, P3248, DOI 10.1128/JCM.36.11.3248-3254.1998; RADER JS, 1991, J REPROD MED, V36, P291; RATMAN S, 2000, CANCER EPIDEM BIOMAR, V9, P945; REID R, 1991, AM J OBSTET GYNECOL, V164, P1461, DOI 10.1016/0002-9378(91)91425-V; REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305; Riethmuller D, 1999, DIAGN MOL PATHOL, V8, P157, DOI 10.1097/00019606-199909000-00009; Rose PG, 1999, NEW ENGL J MED, V340, P1144, DOI 10.1056/NEJM199904153401502; Rozendaal L, 1996, INT J CANCER, V68, P766, DOI 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z; Sawaya GF, 2000, ANN INTERN MED, V133, P942, DOI 10.7326/0003-4819-133-12-200012190-00009; SAWAYA GF, IN PRESS J AM GERIAT; Schechter CB, 1996, ACTA CYTOL, V40, P1272; Schiffman M, 2000, JAMA-J AM MED ASSOC, V283, P87, DOI 10.1001/jama.283.1.87; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SCHIFFMAN MH, 1995, J CLIN MICROBIOL, V33, P545, DOI 10.1128/JCM.33.3.545-550.1995; SCHIFFMAN MH, 1994, CANCER RES, V54, pS1944; Schneider A, 1996, AM J OBSTET GYNECOL, V174, P1534, DOI 10.1016/S0002-9378(96)70602-6; Schneider A, 2000, INT J CANCER, V89, P529, DOI 10.1002/1097-0215(20001120)89:6&lt;529::AID-IJC11&gt;3.0.CO;2-G; Sellors JW, 2000, CAN MED ASSOC J, V163, P513; Serwadda D, 1999, J INFECT DIS, V180, P1316, DOI 10.1086/315026; Shah KV, 1996, INT J GYNECOL PATHOL, V15, P127, DOI 10.1097/00004347-199604000-00006; SHEN LH, 1995, OBSTET GYNECOL, V86, P499, DOI 10.1016/S0029-7844(95)80004-2; SHERLAWJOHNSON C, 1986, OBSTET GYNECOL, V67, P665; SHERMAN ME, 1994, AM J CLIN PATHOL, V102, P182, DOI 10.1093/ajcp/102.2.182; Sherman ME, 1997, CANCER CYTOPATHOL, V81, P89; SHINGLETON HM, 1987, CANC CERVIX DIAGNOSI; Sigurdsson K, 1997, INT J CANCER, V72, P446, DOI 10.1002/(SICI)1097-0215(19970729)72:3<446::AID-IJC12>3.3.CO;2-Q; Smith CCT, 1996, PLATELETS, V7, P231, DOI 10.3109/09537109609023583; Smith EM, 1997, GYNECOL ONCOL, V65, P441, DOI 10.1006/gyno.1997.4703; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Svare EI, 1998, EUR J CANCER, V34, P1230, DOI 10.1016/S0959-8049(98)00131-2; SYRJANEN K, 1992, OBSTET GYNECOL, V79, P675; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; VANBALLEGOOIJEN M, 1995, EUR J CANCER, V31A, P1672, DOI 10.1016/0959-8049(95)00243-C; vanBallegooijen M, 1997, BRIT J CANCER, V76, P651, DOI 10.1038/bjc.1997.440; VANBALLEGOOIJEN M, 1990, EUR J CANCER, V26, P941, DOI 10.1016/0277-5379(90)90615-Z; VANDENVELDE C, 1992, J MED VIROL, V36, P279, DOI 10.1002/jmv.1890360409; VANOORTMARSSEN GJ, 1991, BRIT J CANCER, V64, P559, DOI 10.1038/bjc.1991.350; WALBOOMERS JMM, 1995, J CLIN PATHOL, V48, P728, DOI 10.1136/jcp.48.8.728; WAUGH N, 1996, CYTOPATHOLOGY, V7, P4; Wheeler CM, 1996, OBSTET GYNECOL, V88, P261, DOI 10.1016/0029-7844(96)00120-2; WHEELER CM, 1993, SEX TRANSM DIS, V20, P286, DOI 10.1097/00007435-199309000-00009; Wright TC, 2000, JAMA-J AM MED ASSOC, V283, P81, DOI 10.1001/jama.283.1.81	132	216	231	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	2002	287	18					2372	2381		10.1001/jama.287.18.2372	http://dx.doi.org/10.1001/jama.287.18.2372			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548PF	11988058	Bronze			2022-12-28	WOS:000175397000026
J	Godfray, HCJ				Godfray, HCJ			Challenges for taxonomy - The discipline will have to reinvent itself if it is to survive and flourish.	NATURE			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Dept Biol Sci, Ascot SL5 7PY, Berks, England	Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Godfray, HCJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Dept Biol Sci, Silwood Pk, Ascot SL5 7PY, Berks, England.								0	363	400	0	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	2002	417	6884					17	19		10.1038/417017a	http://dx.doi.org/10.1038/417017a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986643				2022-12-28	WOS:000175307200018
J	Bransford, KJ; Lai, JA				Bransford, KJ; Lai, JA			Global climate change and air pollution: Common origins with common solutions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPOSURE; OZONE		Phys Social Responsibil, Washington, DC USA; Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA	Virginia Commonwealth University	Bransford, KJ (corresponding author), Phys Social Responsibil, Washington, DC USA.							BATES DV, 1995, ENVIRON HEALTH PERSP, V103, P49, DOI 10.2307/3432345; DETELS R, 1991, AM J PUBLIC HEALTH, V81, P350, DOI 10.2105/AJPH.81.3.350; Galizia A, 1999, ENVIRON HEALTH PERSP, V107, P675, DOI 10.2307/3434461; Gong H, 1998, AM J RESP CRIT CARE, V158, P538, DOI 10.1164/ajrccm.158.2.9709034; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; *NAT AC SCI, 2001, CLIM CHANG SCI AN SO; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; SPELLMAN F, 1999, ENV SCI TECHNOLOGY; *US ARM CORPS ENG, 1996, OCC EXP OZ; *US EPA, 2002, AIR TRENDS 1995 SUMM; *US EPA, 1997, HLTH ENV EFF GROUND	12	5	5	3	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2285	2285		10.1001/jama.287.17.2285	http://dx.doi.org/10.1001/jama.287.17.2285			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980533	hybrid			2022-12-28	WOS:000175260600032
J	Rees, J				Rees, J			Complex disease and the new clinical sciences	SCIENCE			English	Editorial Material							MEDICINE; INNOVATION; PSORIASIS; INDUSTRY	Medical research today is dominated by a genocentric point of view. At the same time, clinical discovery and patient-oriented research have become less common. Here, I suggest that these developments are interdependent, each representing the flip side of an inaccurate view of how clinical advance occurs.	Univ Edinburgh, Dept Dermatol, Syst Grp, Edinburgh EH3 9YW, Midlothian, Scotland	University of Edinburgh	Rees, J (corresponding author), Univ Edinburgh, Dept Dermatol, Syst Grp, Lauriston Bldg,Lauriston Pl, Edinburgh EH3 9YW, Midlothian, Scotland.							Altschuler EL, 2000, LANCET, V356, P1360, DOI 10.1016/S0140-6736(05)74277-X; ANDERSON PW, 1972, SCIENCE, V177, P393, DOI 10.1126/science.177.4047.393; Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; Bellamy R, 1998, THORAX, V53, P588, DOI 10.1136/thx.53.7.588; Dill KA, 1999, NATURE, V400, P309, DOI 10.1038/22415; Drews J, 1997, NAT BIOTECHNOL, V15, P1318, DOI 10.1038/nbt1297-1318; Dyson FJ, 1998, SCIENCE, V280, P1014, DOI 10.1126/science.280.5366.1014; Goldstein JL, 1997, J CLIN INVEST, V99, P2803, DOI 10.1172/JCI119470; Grimes DA, 2002, LANCET, V359, P57, DOI 10.1016/S0140-6736(02)07283-5; Holtzman NA, 2000, NEW ENGL J MED, V343, P141, DOI 10.1056/NEJM200007133430213; HOPPER JL, 1998, ENCY BIOSTATISTICS; Horrobin DF, 2000, J ROY SOC MED, V93, P341, DOI 10.1177/014107680009300702; HORROBIN DF, IN PRESS LANCET; JANSSEN P, 1999, PSYCHOPHARMACOLOGIST, V2, pCH3; MARSHALL BJ, 1984, LANCET, V1, P1311; PARRISH JA, 1974, NEW ENGL J MED, V291, P1207, DOI 10.1056/NEJM197412052912301; PECK GL, 1979, NEW ENGL J MED, V300, P329, DOI 10.1056/NEJM197902153000701; Rees J, 2001, CLIN MED, V1, P393, DOI 10.7861/clinmedicine.1-5-393; Rosenberg LE, 1999, SCIENCE, V283, P331, DOI 10.1126/science.283.5400.331; Rothman K., 1998, MODERN EPIDEMIOLOGY; Schechter AN, 1999, NATURE, V401, P424, DOI 10.1038/46672; SHUSTER S, 1984, BRIT J DERMATOL, V111, P235, DOI 10.1111/j.1365-2133.1984.tb04050.x; SHUSTER S, 1987, TRIANGLE, V26, P125; Simon H. A., 1991, MODELS MY LIFE; VANWEELDEN H, 1988, BRIT J DERMATOL, V119, P11; WEATHERALL DJ, 1991, BRIT MED J, V302, P1002, DOI 10.1136/bmj.302.6783.1002; Weiss KM, 2000, NAT GENET, V26, P151, DOI 10.1038/79866	27	105	108	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					698	701		10.1126/science.296.5568.698	http://dx.doi.org/10.1126/science.296.5568.698			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976444				2022-12-28	WOS:000175281700043
J	Sanyal, S; Sandstrom, DJ; Hoeffer, CA; Ramaswami, M				Sanyal, S; Sandstrom, DJ; Hoeffer, CA; Ramaswami, M			AP-1 functions upstream of CREB to control synaptic plasticity in Drosophila	NATURE			English	Article							LONG-TERM-MEMORY; TRANSCRIPTION FACTOR; GENETIC DISSECTION; NERVOUS-SYSTEM; DORSAL CLOSURE; C-FOS; EXPRESSION; COMPONENTS; INDUCTION; NEURONS	Activity-regulated gene expression mediates many aspects of neural plasticity, including long-term memory. In the prevailing view, patterned synaptic activity causes kinase-mediated activation of the transcription factor cyclic AMP response-element-binding protein, CREB. Together with appropriate cofactors, CREB then transcriptionally induces a group of 'immediate-early' transcription factors and, eventually, effector proteins that establish or consolidate synaptic change(1). Here, using a Drosophila model synapse, we analyse cellular functions and regulation of the best known immediate-early transcription factor, AP-1; a heterodimer of the basic leucine zipper proteins Fos and Jun(2). We observe that AP-1 positively regulates both synaptic strength and synapse number, thus showing a greater range of influence than CREB3. Observations from genetic epistasis and RNA quantification experiments indicate that AP-1 acts upstream of CREB, regulates levels of CREB messenger RNA, and functions at the top of the hierarchy of transcription factors known to regulate long-term plasticity. A Jun-kinase signalling module provides a CREB-independent route for neuronal AP-1 activation; thus, CREB regulation of AP-1 expression(4) may, in some neurons, constitute a positive feedback loop rather than the primary step in AP-1 activation.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Div Neurobiol, Arizona Res Labs, Tucson, AZ 85721 USA	University of Arizona; University of Arizona	Ramaswami, M (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.			Ramaswami, Mani/0000-0001-7631-0468; Sanyal, Subhabrata/0000-0003-2590-2732; Sandstrom, David/0000-0001-6235-7118				BAILEY CH, 1992, SCIENCE, V256, P645, DOI 10.1126/science.1585177; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BARTON O, 1979, COMPREHENSIVE ORGANI, V2, P83; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Cheung US, 1999, J NEUROBIOL, V40, P1, DOI 10.1002/(SICI)1097-4695(199907)40:1<1::AID-NEU1>3.0.CO;2-1; CURRAN T, 1995, J NEUROBIOL, V26, P403, DOI 10.1002/neu.480260312; Davis GW, 1998, CURR OPIN NEUROBIOL, V8, P149, DOI 10.1016/S0959-4388(98)80018-4; Davis GW, 1996, NEURON, V17, P669, DOI 10.1016/S0896-6273(00)80199-3; DeZazzo J, 2000, NEURON, V27, P145, DOI 10.1016/S0896-6273(00)00016-7; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Josselyn SA, 2001, J NEUROSCI, V21, P2404, DOI 10.1523/JNEUROSCI.21-07-02404.2001; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kelz MB, 1999, NATURE, V401, P272, DOI 10.1038/45790; Kockel L, 2001, ONCOGENE, V20, P2347, DOI 10.1038/sj.onc.1204300; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Osterwalder T, 2001, P NATL ACAD SCI USA, V98, P12596, DOI 10.1073/pnas.221303298; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; Sagasti A, 2001, CELL, V105, P221, DOI 10.1016/S0092-8674(01)00313-0; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; Schwarzschild MA, 1997, J NEUROSCI, V17, P3455; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; Zeitlinger J, 1997, EMBO J, V16, P7393, DOI 10.1093/emboj/16.24.7393; ZHONG Y, 1992, J NEUROSCI, V12, P644	28	129	134	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					870	874		10.1038/416870a	http://dx.doi.org/10.1038/416870a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976688				2022-12-28	WOS:000175163800056
J	Reif, JH				Reif, JH			Computing: Successes and challenges	SCIENCE			English	Editorial Material							MOLECULAR COMPUTATION		Duke Univ, Dept Comp Sci, Durham, NC 27708 USA	Duke University	Reif, JH (corresponding author), Duke Univ, Dept Comp Sci, Durham, NC 27708 USA.	reif@cs.duke.edu						ADLEMAN LM, 1994, SCIENCE, V266, P1021, DOI 10.1126/science.7973651; Benenson Y, 2001, NATURE, V414, P430, DOI 10.1038/35106533; Braich RS, 2002, SCIENCE, V296, P499, DOI 10.1126/science.1069528; Faulhammer D, 2000, P NATL ACAD SCI USA, V97, P1385, DOI 10.1073/pnas.97.4.1385; Komiya K., 2001, LNCS, V2054, P17, DOI [10.1007/3-540-44992-2_2, DOI 10.1007/3-540-44992-2_2]; Liu QH, 2000, NATURE, V403, P175, DOI 10.1038/35003155; Mao CD, 2000, NATURE, V407, P493, DOI 10.1038/35035038; Reif JH, 1998, SPR S DISC MATH, P72; REIF JH, 2000, LECT NOTES COMPUTER, V2054, P173	9	44	48	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	2002	296	5567					478	479		10.1126/science.1070978	http://dx.doi.org/10.1126/science.1070978			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964464	Green Submitted			2022-12-28	WOS:000175179400029
J	Smith, TM; Karl, TR; Reynolds, RW				Smith, TM; Karl, TR; Reynolds, RW			Climate modeling: How accurate are climate simulations?	SCIENCE			English	Editorial Material							SURFACE-TEMPERATURE		Natl Climat Ctr, Asheville, NC 28801 USA	National Center Atmospheric Research (NCAR) - USA	Smith, TM (corresponding author), Natl Climat Ctr, 151 Patton Ave, Asheville, NC 28801 USA.		Smith, Thomas M./F-5626-2010	Smith, Thomas M./0000-0001-7469-7849				DELWORTH TL, UNPUB; FOLLAND CK, 1995, Q J ROY METEOR SOC, V121, P319, DOI 10.1002/qj.49712152206; Houghton J. T., 2001, CLIMATE CHANGE 2001; KARL TR, 1999, ADEQUACY CLIMATE OBS; Parker D., 1999, WMO WORKSH ADV MAR C, V99, P194; PARKER DE, 1994, J GEOPHYS RES-ATMOS, V99, P14373, DOI 10.1029/94JD00548; SMITH TM, 1994, J CLIMATE, V7, P949, DOI 10.1175/1520-0442(1994)007<0949:OAOSSS>2.0.CO;2; Smith TM, 2002, J CLIMATE, V15, P73, DOI 10.1175/1520-0442(2002)015<0073:BCFHSS>2.0.CO;2; SMITH TW, UNPUB; Wielicki BA, 2002, SCIENCE, V295, P841, DOI 10.1126/science.1065837	10	13	16	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					483	484		10.1126/science.1070365	http://dx.doi.org/10.1126/science.1070365			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964468				2022-12-28	WOS:000175179400033
J	Royle, NJ; Hartley, IR; Parker, GA				Royle, NJ; Hartley, IR; Parker, GA			Sexual conflict reduces offspring fitness in zebra finches	NATURE			English	Article							MALE PARENTAL CARE; MALE-REMOVAL; EVOLUTION; BIRDS; BEHAVIOR; SIZE	Parental care is often costly(1); hence, in sexually reproducing species where both male and female parents rear their offspring (biparental care), sexual conflict over parental investment can arise(2). Such conflict occurs because each care-giver would benefit from withholding parental investment for use with another partner, leading to a reduction in the amount of care given by one parent at the expense of the other(3-5). Here we report experiments to explore the prediction from theory that parents rearing offspring alone may provide greater parental investment than when rearing offspring together with a partner(3,5). We found that when the number of offspring per parent, and hence the potential workload, were kept constant, offspring received a greater per capita parental investment from single females than from both parents working together, and that males reared by single mothers were more sexually attractive as adults than their biparentally reared siblings. This difference between single- and two-parent families is due to a reduction in care provided by females when they care together with a male, rather than laziness by males or differences in the begging behaviour of chicks, supporting the claim that sexual conflict in biparental care can reduce the quality of offspring raised(3,5).	Univ Lancaster, IENS, Sch Biol Sci, Lancaster LA1 4YQ, England; Univ Liverpool, Sch Biol Sci, Populat & Evolutionary Biol Res Grp, Liverpool L69 3GS, Merseyside, England	Lancaster University; University of Liverpool	Hartley, IR (corresponding author), Univ Lancaster, IENS, Sch Biol Sci, Lancaster LA1 4YQ, England.	i.hartley@lancaster.ac.uk	Royle, Nick J/H-2802-2015; Parker, Geoff/C-4337-2008	Royle, Nick J/0000-0002-1617-3884; Parker, Geoff/0000-0003-4795-6352; Hartley, Ian/0000-0002-7592-3921				BART J, 1989, BEHAV ECOL SOCIOBIOL, V24, P109, DOI 10.1007/BF00299642; Bennett ATD, 1996, NATURE, V380, P433, DOI 10.1038/380433a0; Birkhead TR, 1998, SPERM COMPETITION SE; Chapman T, 1996, NATURE, V381, P189, DOI 10.1038/381189a0; CHASE ID, 1980, AM NAT, V115, P827, DOI 10.1086/283603; Clutton-Brock T. H., 1991, EVOLUTION PARENTAL C; Gavrilets S, 2000, NATURE, V403, P886, DOI 10.1038/35002564; Godfray HCJ, 1999, MG BEH ECOL, P100; Houston A.I., 1985, P471; Hurst LD, 1996, Q REV BIOL, V71, P317, DOI 10.1086/419442; Lessells CM, 1999, MG BEH ECOL, P75; LESSELLS CM, IN PRESS PHIL T R B; Markman S, 1996, ANIM BEHAV, V52, P437, DOI 10.1006/anbe.1996.0188; McNamara JM, 1999, NATURE, V401, P368, DOI 10.1038/43869; MCNAMARA JM, IN PRESS BEHAV ECOL; Mock D. W., 1997, EVOLUTION SIBLING RI; Moore AJ, 2001, P ROY SOC B-BIOL SCI, V268, P517, DOI 10.1098/rspb.2000.1399; PARKER GA, 1985, ANIM BEHAV, V33, P519, DOI 10.1016/S0003-3472(85)80075-0; Parker GA, 1998, PHILOS T R SOC B, V353, P261, DOI 10.1098/rstb.1998.0208; Partridge L, 1998, SCIENCE, V281, P2003, DOI 10.1126/science.281.5385.2003; Pomiankowski A, 1999, MG BEH ECOL, P121; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; SASVARI L, 1986, J ANIM ECOL, V55, P553, DOI 10.2307/4738; SMITH CC, 1974, AM NAT, V108, P499, DOI 10.1086/282929; Smith HG, 2000, P ROY SOC B-BIOL SCI, V267, P2163, DOI 10.1098/rspb.2000.1264; Stockley P, 1997, TRENDS ECOL EVOL, V12, P154, DOI 10.1016/S0169-5347(97)01000-8; Trivers R. L., 1972, SEXUAL SELECTION DES, P136, DOI DOI 10.1002/AJPA.1330400226; Westneat David F., 1996, Trends in Ecology and Evolution, V11, P87, DOI 10.1016/0169-5347(96)81049-4; WHITTINGHAM LA, 1994, ETHOLOGY, V96, P260; WOLF L, 1990, ANIM BEHAV, V39, P125, DOI 10.1016/S0003-3472(05)80732-8	30	119	119	1	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	2002	416	6882					733	736		10.1038/416733a	http://dx.doi.org/10.1038/416733a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961554				2022-12-28	WOS:000175033500041
J	Queller, DC; Strassmann, JE				Queller, DC; Strassmann, JE			The many selves of social insects	SCIENCE			English	Article							INTRAGENOMIC CONFLICT; KIN RECOGNITION; HONEY-BEE; HYMENOPTERA; SELECTION; SUPERORGANISM; COLONY; ANT	Social insects show multiple Levels of self identity. Most individuals are sterile workers who selflessly Labor for their colony, which is often viewed as a superorganism. The superorganism protects itself with colony recognition systems based on learned odors, typically cuticular hydrocarbons. Transfer of these odors within the colony obscures separate clan identities. Residual individual interests do appear to cause conflicts within colonies over sex ratio, male production, caste, and reproductive dominance. However, genomic imprinting theory predicts that the individual's maternal and paternal genes will evolve separate infraorganismal identities, perhaps Leaving virtually no coherent individual identity.	Rice Univ, Dept Ecol & Evolutionary Biol, Houston, TX 77251 USA	Rice University	Queller, DC (corresponding author), Rice Univ, Dept Ecol & Evolutionary Biol, POB 1892,Mail Stop 170, Houston, TX 77251 USA.			Strassmann, Joan/0000-0003-0638-8440				Alexander R. D., 1979, DARWINISM HUMAN AFFA; AMITH JM, 1995, MAJOR TRANSITIONS EV; Boulay R, 2000, ANIM BEHAV, V59, P1127, DOI 10.1006/anbe.2000.1408; BOURKE AFG, 1994, J THEOR BIOL, V167, P283, DOI 10.1006/jtbi.1994.1070; Bourke AFG, 1999, BEHAV ECOL SOCIOBIOL, V46, P287, DOI 10.1007/s002650050622; Breed MD, 1998, BIOSCIENCE, V48, P463, DOI 10.2307/1313244; Clement Jean-Luc, 1998, P126; COSMIDES LM, 1981, J THEOR BIOL, V89, P83, DOI 10.1016/0022-5193(81)90181-8; Dani FR, 2001, ANIM BEHAV, V62, P165, DOI 10.1006/anbe.2001.1714; GETZ WM, 1982, J THEOR BIOL, V99, P585, DOI 10.1016/0022-5193(82)90212-0; HAIG D, 1995, J EVOLUTION BIOL, V8, P265, DOI 10.1046/j.1420-9101.1995.8030265.x; Haig D, 2000, ANNU REV ECOL SYST, V31, P9, DOI 10.1146/annurev.ecolsys.31.1.9; HAIG D, 1992, J THEOR BIOL, V156, P401, DOI 10.1016/S0022-5193(05)80683-6; HAIG D, 1989, AM NAT, V134, P147, DOI 10.1086/284971; Hamilton W, 1972, ANNU REV ECOL SYST, V3, P193, DOI 10.1146/annurev.es.03.110172.001205; HAMILTON WD, 1964, J THEOR BIOL, V7, P17, DOI 10.1016/0022-5193(64)90039-6; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hurst LD, 1996, Q REV BIOL, V71, P317, DOI 10.1086/419442; Keller L, 1998, NATURE, V394, P573, DOI 10.1038/29064; Keller L, 1997, TRENDS ECOL EVOL, V12, P99, DOI 10.1016/S0169-5347(96)10065-3; LACY RC, 1983, AM NAT, V121, P489, DOI 10.1086/284078; Lahav S, 1999, NATURWISSENSCHAFTEN, V86, P246, DOI 10.1007/s001140050609; LEIGH EG, 1977, P NATL ACAD SCI USA, V74, P4542, DOI 10.1073/pnas.74.10.4542; Lenoir A, 2001, INSECT SOC, V48, P101, DOI 10.1007/PL00001751; Lenoir A, 1999, INFORMATION PROCESSING IN SOCIAL INSECTS, P219; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; NONACS P, 1990, P NATL ACAD SCI USA, V87, P9670, DOI 10.1073/pnas.87.24.9670; Passera L, 2001, SCIENCE, V293, P1308, DOI 10.1126/science.1062076; Peters JM, 1999, P ROY SOC B-BIOL SCI, V266, P379, DOI 10.1098/rspb.1999.0648; Queller DC, 1998, BIOSCIENCE, V48, P165, DOI 10.2307/1313262; RATNIEKS FLW, 1988, AM NAT, V132, P217, DOI 10.1086/284846; Ratnieks FLW, 2001, BEHAV ECOL SOCIOBIOL, V50, P467, DOI 10.1007/s002650100388; RATNIEKS FLW, 1989, NATURE, V342, P796, DOI 10.1038/342796a0; Rawls J., 1971, THEORY JUSTICE; Reeve Hudson Kern, 1998, P118; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; SEELEY TD, 1989, AM SCI, V77, P546; Singer Theresa L., 1998, P104; TRIVERS RL, 1976, SCIENCE, V191, P249, DOI 10.1126/science.1108197; TRIVERS RL, 1998, P R SOC LONDON B, V265, P2393; Vander Meer Robert K., 1998, P79; Wheeler William Morton, 1911, Journal of Morphology Philadelphia, V22, DOI 10.1002/jmor.1050220206; WILSON DS, 1989, J THEOR BIOL, V136, P337, DOI 10.1016/S0022-5193(89)80169-9	43	55	57	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					311	313		10.1126/science.1070671	http://dx.doi.org/10.1126/science.1070671			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951035				2022-12-28	WOS:000175000300046
J	Sibert, JR; Lyons, RA; Smith, BA; Cornall, P; Sumner, V; Craven, MA; Kemp, AM				Sibert, JR; Lyons, RA; Smith, BA; Cornall, P; Sumner, V; Craven, MA; Kemp, AM		Safe Water Information Monitor Col	Preventing deaths by drowning in children in the United Kingdom: have we made progress in 10 years? Population based incidence study	BRITISH MEDICAL JOURNAL			English	Article									Univ Wales Coll Med, Collaborat Accid Prevent & Injury Control, Dept Child Hlth, Llandough Hosp, Penarth CF64 2XX, S Glam, Wales; Univ Wales Coll Med, Collaborat Accid Prevent & Injury Control, Dept Epidemiol Stat, Llandough Hosp, Penarth CF64 2XX, S Glam, Wales; Univ Wales Coll Med, Collaborat Accid Prevent & Injury Control, Dept Publ Hlth, Llandough Hosp, Penarth CF64 2XX, S Glam, Wales; Royal Soc Prevent Accid, Water & Leisure, Birmingham B5 7ST, W Midlands, England; Royal Life Saving Soc, Broom B50 4HN, Warwick, England	Cardiff University; Cardiff University; Cardiff University	Sibert, JR (corresponding author), Univ Wales Coll Med, Collaborat Accid Prevent & Injury Control, Dept Child Hlth, Llandough Hosp, Penarth CF64 2XX, S Glam, Wales.		Lyons, Ronan/G-7741-2012	Lyons, Ronan/0000-0001-5225-000X				KEMP A, 1992, BRIT MED J, V304, P1143, DOI 10.1136/bmj.304.6835.1143; KEMP AM, 1991, BRIT MED J, V302, P931, DOI 10.1136/bmj.302.6782.931; KEMP AM, 1993, ARCH DIS CHILD, V68, P684, DOI 10.1136/adc.68.5.684; Webb EVJ, 1997, DEV MED CHILD NEUROL, V39, P150	4	16	16	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 4	2002	324	7345					1070	1071		10.1136/bmj.324.7345.1070	http://dx.doi.org/10.1136/bmj.324.7345.1070			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YY	11991912	Green Accepted, Green Published, Bronze			2022-12-28	WOS:000175476500020
J	Lee, SW; Mao, CB; Flynn, CE; Belcher, AM				Lee, SW; Mao, CB; Flynn, CE; Belcher, AM			Ordering of quantum dots using genetically engineered viruses	SCIENCE			English	Article							LIQUID-CRYSTALS; NANOPARTICLES; PHASE	A liquid crystal system was used for the fabrication of a highly ordered composite material from genetically engineered M13 bacteriophage and zinc sulfide (ZnS) nanocrystals. The bacteriophage, which formed the basis of the self-ordering system, were selected to have a specific recognition moiety for ZnS crystal surfaces. The bacteriophage were coupled with ZnS solution precursors and spontaneously evolved a self-supporting hybrid film material that was ordered at the nanoscale and at the micrometer scale into similar to72-micrometer domains, which were continuous over a centimeter length scale. In addition, suspensions were prepared in which the lyotropic liquid crystalline phase behavior of the hybrid material was controlled by solvent concentration and by the use of a magnetic field.	Univ Texas, Inst Cellular & Mol Biol, Ctr Nano & Mol Sci & Technol, Texas Mat Inst,Dept Chem & Biochem, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Belcher, AM (corresponding author), MIT, Dept Mat Sci & Engn & Biol Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Lee, Seung-Wuk/AAS-3031-2020	Mao, Chuanbin/0000-0002-8142-3659				ALIVISATOS AP, 1996, NATURE, V381, P56; Braun PV, 1999, J AM CHEM SOC, V121, P7302, DOI 10.1021/ja9833725; Chen JT, 1996, SCIENCE, V273, P343, DOI 10.1126/science.273.5273.343; Dogic Z, 2000, LANGMUIR, V16, P7820, DOI 10.1021/la000446t; Dogic Z, 1997, PHYS REV LETT, V78, P2417, DOI 10.1103/PhysRevLett.78.2417; Douglas T, 1998, NATURE, V393, P152, DOI 10.1038/30211; Duan XF, 2000, APPL PHYS LETT, V76, P1116, DOI 10.1063/1.125956; FLYNN CP, UNPUB; Fowler CE, 2001, ADV MATER, V13, P1266, DOI 10.1002/1521-4095(200108)13:16<1266::AID-ADMA1266>3.0.CO;2-9; GRAY GW, 1984, SMECTIC LIQUID CRYST, P23; Issaenko SA, 1999, PHYS REV E, V60, P578, DOI 10.1103/PhysRevE.60.578; LAPOINTE J, 1973, MOL CRYST LIQ CRYST, V19, P269, DOI 10.1080/15421407308084657; MAO C, UNPUB; MATHIAS JP, 1994, J AM CHEM SOC, V116, P4326, DOI 10.1021/ja00089a022; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Norris DJ, 1996, PHYS REV B, V53, P16347, DOI 10.1103/PhysRevB.53.16347; SEMENOV AN, 1986, ZH EKSP TEOR FIZ, V63, P70; SONIN AA, 1998, FREELY SUSPENDED LIQ, P25; Whaley SR, 2000, NATURE, V405, P665, DOI 10.1038/35015043; Yu SJM, 1997, NATURE, V389, P167, DOI 10.1038/38254	20	843	902	5	302	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					892	895		10.1126/science.1068054	http://dx.doi.org/10.1126/science.1068054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988570				2022-12-28	WOS:000175442500039
J	Mennill, DJ; Ratcliffe, LM; Boag, PT				Mennill, DJ; Ratcliffe, LM; Boag, PT			Female eavesdropping on male song contests in songbirds	SCIENCE			English	Editorial Material							BLACK-CAPPED CHICKADEES		Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Mennill, DJ (corresponding author), Queens Univ, Dept Biol, Kingston, ON K7L 3N6, Canada.		Boag, Peter T/B-2907-2014	Boag, Peter T/0000-0003-0050-2089; Mennill, Daniel/0000-0001-9314-6700				MCGREGOR PK, 2000, MCGREGOR PK, V2, P71; Otter K, 1998, BEHAV ECOL SOCIOBIOL, V43, P25, DOI 10.1007/s002650050463; Otter K, 1999, P ROY SOC B-BIOL SCI, V266, P1305, DOI 10.1098/rspb.1999.0779; SMITH SM, 1988, BEHAVIOUR, V107, P15, DOI 10.1163/156853988X00160	4	268	281	0	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					873	873		10.1126/science.296.5569.873	http://dx.doi.org/10.1126/science.296.5569.873			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988564				2022-12-28	WOS:000175442500033
J	Sun, G; Ji, Q; Dilcher, DL; Zheng, SL; Nixon, KC; Wang, XF				Sun, G; Ji, Q; Dilcher, DL; Zheng, SL; Nixon, KC; Wang, XF			Archaefructaceae, a new basal angiosperm family	SCIENCE			English	Article							SEED PLANT PHYLOGENY; NORTHEAST CHINA; CRETACEOUS AGE; CLADISTICS; GNETALES; ORIGIN; RBCL	Archaefructaceae is proposed as a new basal angiosperm family of herbaceous aquatic plants. This family consists of the fossils Archaefructus liaoningensis and A. sinensis sp. nov. Complete plants from roots to fertile shoots are known. Their age is a minimum of 124.6 million years from the Yixian Formation, Liaoning, China. They are a sister clade to all angiosperms when their characters are included in a combined three-gene molecular and morphological analysis. Their reproductive axes lack petals. and sepals and bear stamens in pairs below conduplicate carpels.	Jilin Univ, Res Ctr Palaeontol, Changchun 130026, Peoples R China; Chinese Acad Geosci, Inst Geol, Beijing 100037, Peoples R China; Univ Florida, Florida Museum Nat Hist, Gainesville, FL 32611 USA; Shenyang Inst Geol & Mineral Resources, Shenyang 110032, Peoples R China; Cornell Univ, LH Bailey Hortorium, Ithaca, NY 14853 USA; Acad Sinica, Nanjing Inst Geol & Palaeontol, Nanjing 210008, Peoples R China	Jilin University; Chinese Academy of Geological Sciences; State University System of Florida; University of Florida; Cornell University; Chinese Academy of Sciences	Sun, G (corresponding author), Jilin Univ, Res Ctr Palaeontol, Changchun 130026, Peoples R China.	sunge@jtu.edu.cn; dilcher@ftmnh.ufl.edu						[Anonymous], 1964, YORKSHIRE JURASSIC F; Arber EAN, 1908, ANN BOT-LONDON, V22, P489, DOI 10.1093/oxfordjournals.aob.a089185; Bernhardt Peter, 1996, P192; Burger William, 1996, P111; CRANE PR, 1985, ANN MO BOT GARD, V72, P716, DOI 10.2307/2399221; Crepet W.L., 1974, PALAEONTOGRAPHICA AB, V148, P144; Crepet William L., 1996, P25; CRONQUIST A, 1981, INTEGRATED SYSTEM CL; D'Arcy WG., 1996, ANTHER FORM FUNCTION, P1; Delevoryas T., 1968, PALAEONTOGRAPHICA AB, V121, P122; Doludenko MP., 1976, JURASSIC FLORA KARAT; DONOGHUE MJ, 1989, INT CONGR SER, V824, P181; DOYLE JA, 1986, BOT REV, V52, P321, DOI 10.1007/BF02861082; Doyle JA, 1998, MOL PHYLOGENET EVOL, V9, P448, DOI 10.1006/mpev.1998.0506; Doyle JA, 2000, INT J PLANT SCI, V161, pS121, DOI 10.1086/317578; Endress P. K., 1994, DIVERSITY EVOLUTIONA; Endress Peter K., 1996, P92; Friis EM, 2001, NATURE, V410, P357, DOI 10.1038/35066557; Friis EM, 2000, INT J PLANT SCI, V161, pS169, DOI 10.1086/317570; Hagemann W., 1984, CONT PROBLEMS PLANT, P301; Hufford Larry, 1996, P58; Ji Qiang, 1999, Professional Papers of Stratigraphy and Palaeontology, V27, P74; Ji SA, 1999, NATURE, V398, P573, DOI 10.1038/19221; Krassilov VA, 1997, ANGIOSPERM ORIGINS M; LEINS P, 1991, BOT ACTA, V104, P336, DOI 10.1111/j.1438-8677.1991.tb00239.x; LO CH, 1999, GEOCHEMICA, V28, P406; LOCONTE H, 1990, BRITTONIA, V42, P197, DOI 10.2307/2807216; LOCONTE H, 1991, CLADISTICS, V7, P267, DOI 10.1111/j.1096-0031.1991.tb00038.x; Nandi OI, 1998, ANN MO BOT GARD, V85, P137, DOI 10.2307/2992003; Nixon KC, 1999, CLADISTICS, V15, P407, DOI 10.1111/j.1096-0031.1999.tb00277.x; NIXON KC, 1994, ANN MO BOT GARD, V81, P484, DOI 10.2307/2399901; SMITH PE, 1995, CAN J EARTH SCI, V32, P1426, DOI 10.1139/e95-115; Soltis DE, 2000, BOT J LINN SOC, V133, P381, DOI [10.1111/j.1095-8339.2000.tb01588.x, 10.1006/bojl.2000.0380]; Sun G, 1998, SCIENCE, V282, P1692, DOI 10.1126/science.282.5394.1692; Sun G, 2001, EARLY ANGIOSPERMS TH; Swisher CC, 1999, NATURE, V400, P58, DOI 10.1038/21872; VONWETTSTEIN RR, 1907, HDB SYSTEMATISCHEN B; WANG DF, 1983, B CHINESE ACAD GEOL, V7, P65; WANG SE, 2000, JURASSIC SYSTEM STRA; WARD J V, 1989, Pollen et Spores, V31, P113; ZANE MC, IN PRESS P NATL ACAD; Zhang Jun-Feng, 1999, Palaeoworld, V11, P150	42	334	385	5	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					899	904		10.1126/science.1069439	http://dx.doi.org/10.1126/science.1069439			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988572				2022-12-28	WOS:000175442500041
J	Crawford, LM				Crawford, LM			Data bank submissions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Rockville, MD 20857 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2203	2203		10.1001/jama.287.17.2203	http://dx.doi.org/10.1001/jama.287.17.2203			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980508				2022-12-28	WOS:000175260600007
J	[Anonymous]				[Anonymous]			The globalisation of the NHS	LANCET			English	Editorial Material																		2002, LANCET, V359, P1373	1	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	2002	359	9316					1447	1448						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988237				2022-12-28	WOS:000175279100001
J	Shannon, MF; Rao, S				Shannon, MF; Rao, S			Transcription - Of Chips and ChIPs	SCIENCE			English	Editorial Material							GENE-EXPRESSION; CELL-CYCLE; DOMAINS		Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research	Shannon, MF (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia.		Rao, Sudha/AAW-5192-2020	Rao, Sudha/0000-0001-9547-947X				Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cohen BA, 2000, NAT GENET, V26, P183, DOI 10.1038/79896; Dillon N, 2000, BIOESSAYS, V22, P657, DOI 10.1002/1521-1878(200007)22:7<657::AID-BIES8>3.3.CO;2-U; Futcher B, 2000, CURR OPIN CELL BIOL, V12, P710, DOI 10.1016/S0955-0674(00)00156-3; Gaudet J, 2002, SCIENCE, V295, P821, DOI 10.1126/science.1065175; Horner MA, 1998, GENE DEV, V12, P1947, DOI 10.1101/gad.12.13.1947; Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095; Lieb JD, 2001, NAT GENET, V28, P327, DOI 10.1038/ng569; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Markstein M, 2002, P NATL ACAD SCI USA, V99, P763, DOI 10.1073/pnas.012591199; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Simon I, 2001, CELL, V106, P697, DOI 10.1016/S0092-8674(01)00494-9; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; van Steensel B, 2001, NAT GENET, V27, P304, DOI 10.1038/85871; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Young RA, 2000, CELL, V102, P9, DOI 10.1016/S0092-8674(00)00005-2	19	25	29	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					666	+		10.1126/science.1062936	http://dx.doi.org/10.1126/science.1062936			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976432				2022-12-28	WOS:000175281700032
J	Reimann, JDR; Jackson, PK				Reimann, JDR; Jackson, PK			Emi1 is required for cytostatic factor arrest in vertebrate eggs	NATURE			English	Article							CLEAVING XENOPUS-EMBRYOS; MOS PROTO-ONCOGENE; OOCYTE MATURATION; METAPHASE ARREST; FROG OOCYTES; MAP KINASE; CYCLIN-B; ACTIVATION; EXTRACTS; FERTILIZATION	Vertebrate eggs are arrested at metaphase of meiosis II with stable cyclin B and high cyclin B/Cdc2 kinase activity. The ability of the anaphase-promoting complex/cyclosome (APC), an E3 ubiquitin ligase, to trigger cyclin B destruction and metaphase exit is blocked in eggs by the activity of cytostatic factor (CSF) (reviewed in ref. 1). CSF was defined as an activity in mature oocytes that caused mitotic arrest when injected into dividing embryos(2). Fertilization causes a transient increase in cytoplasmic calcium concentration leading to CSF inactivation, APC activation, cyclin B destruction and mitotic exit(3). The APC activator Cdc20 is required for APC activation after fertilization(4,5). We show here that the APC(cdc20) inhibitor Emi1 (ref. 6) is necessary and sufficient to inhibit the APC and to prevent mitotic exit in CSF-arrested eggs. CSF extracts immunodepleted of Emi1 degrade cyclin B, and exit from mitosis prematurely in the absence of calcium. Addition of Emi1 to these Emi1-depleted extracts blocks premature inactivation of the CSF-arrested state. Emi1 is required to arrest unfertilized eggs at metaphase of meiosis II and seems to be the long-sought mediator of CSF activity.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Jackson, PK (corresponding author), Stanford Univ, Dept Pathol, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA.			Jackson, Peter/0000-0002-1742-2539				Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; Bhatt RR, 1999, SCIENCE, V286, P1362, DOI 10.1126/science.286.5443.1362; Castro A, 2001, MOL BIOL CELL, V12, P2660, DOI 10.1091/mbc.12.9.2660; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; Ferrell JE, 1999, BIOESSAYS, V21, P833, DOI 10.1002/(SICI)1521-1878(199910)21:10<833::AID-BIES5>3.0.CO;2-P; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; Gross SD, 2000, CURR BIOL, V10, P430, DOI 10.1016/S0960-9822(00)00425-5; Gross SD, 1999, SCIENCE, V286, P1365, DOI 10.1126/science.286.5443.1365; Guadagno TM, 1998, SCIENCE, V282, P1312, DOI 10.1126/science.282.5392.1312; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Lorca T, 1998, EMBO J, V17, P3565, DOI 10.1093/emboj/17.13.3565; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; Masui Y, 2000, NAT REV MOL CELL BIO, V1, P228, DOI 10.1038/35043096; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; Sohaskey ML, 1999, MOL BIOL CELL, V10, P3729, DOI 10.1091/mbc.10.11.3729; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Taieb FE, 2001, CURR BIOL, V11, P508, DOI 10.1016/S0960-9822(01)00145-2; Vorlaufer E, 1998, MOL BIOL CELL, V9, P1817, DOI 10.1091/mbc.9.7.1817; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0	31	104	108	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					850	854		10.1038/416850a	http://dx.doi.org/10.1038/416850a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976684				2022-12-28	WOS:000175163800052
J	Willis, BM; Levy, BS				Willis, BM; Levy, BS			Child prostitution: global health burden, research needs, and interventions	LANCET			English	Article							SEX WORKERS	Child prostitution is a significant global problem that has yet to receive appropriate medical and public health attention. Worldwide, an estimated 1 million children are forced into prostitution every year and the total number of prostituted children could be as high as 10 million. Inadequate data exist on the health problems faced by prostituted children, who are at high risk of infectious disease, pregnancy, mental illness, substance abuse, and violence. Child prostitution, like other forms of child sexual abuse, is not only a cause of death and high morbidity in millions of children, but also a gross violation of their rights and dignity. In this article we estimate morbidity and mortality among prostituted children, and propose research strategies and interventions to mitigate such health consequences. Our estimates underscore the need for health professionals to collaborate with individuals and organisations that provide direct services to prostituted children. Health professionals can help efforts to prevent child prostitution through identifying contributing factors, recording the magnitude and health effects of the problem, and assisting children who have escaped prostitution. They can also help governments, UN agencies, and non-governmental organisations (NGOs) to implement policies, laws, and programmes to prevent child prostitution and mitigate its effects on children's health.	Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Tufts Univ, Sch Med, Dept Family Med & Community Hlth, Boston, MA 02111 USA	Centers for Disease Control & Prevention - USA; Tufts University	Willis, BM (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.							*A GUTTM I, 1999, FACTS BRIEF TEEN SEX; Adedoyin M, 1995, Afr J Med Med Sci, V24, P27; Bellei NCJ, 1996, T ROY SOC TROP MED H, V90, P122, DOI 10.1016/S0035-9203(96)90107-8; Carr S, 1996, AIDS CARE, V8, P489, DOI 10.1080/09540129650125678; DEISHER RW, 1989, AM J DIS CHILD, V143, P1162, DOI 10.1001/archpedi.1989.02150220052020; Economic and Social Commission for Asia and the Pacific, 2000, SEX AB SEX EXPL CHIL; *ECPAT, 1999, STEP FORW APP 1; *ECPAT, ECPAT TAKSV PREV PRO; Farley M, 1998, FEM PSYCHOL, V8, P405, DOI 10.1177/0959353598084002; Joesoef MR, 1998, INT J STD AIDS, V9, P756, DOI 10.1258/0956462981921521; Lim L. L., 1998, SEX SECTOR EC SOCIAL; *PHYS HUM RIGHTS, 1997, COMM SEX EXPL WOM CH; Silbert MH., 1981, CHILD ABUSE NEGLECT, V5, P407, DOI [10.1016/0145-2134(81)90050-8, DOI 10.1016/0145-2134(81)90050-8]; Tanaka M, 1996, GENITOURIN MED, V72, P358; *UN, 1996, INT REP SPEC RAPP CO; *UN EC SOC COMM AS, COMM SEX EXPL CHILDR; *UNAIDS, 2000, REP GLOB HIV AIDS EP; *UNICEF, 1995, PROGR NAT CHILD RIGH; *UNICEF, 1997, STAT WORLDS CHILDR, P36; United Nations, 2002, OPT PROT CONV RIGHTS; United Nations Economic and Social Council, 1996, REP SPEC RAPP SAL CH; Ward H, 1999, SEX TRANSM INFECT, V75, P340, DOI 10.1136/sti.75.5.340; *WHO, IN HIV AIDS SEX TRAN; *WORLD C COMM SEX, 1996, AG ACT; 2000, OREGONIAN       0420; 1998, ECONOMIST       0214, P21	27	108	112	3	20	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1417	1422		10.1016/S0140-6736(02)08355-1	http://dx.doi.org/10.1016/S0140-6736(02)08355-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	542ZQ	11978356	Green Submitted			2022-12-28	WOS:000175076200030
J	Finney, BP; Gregory-Eaves, I; Douglas, MSV; Smol, JP				Finney, BP; Gregory-Eaves, I; Douglas, MSV; Smol, JP			Fisheries productivity in the northeastern Pacific Ocean over the past 2,200 years	NATURE			English	Article							SANTA-BARBARA BASIN; SOCKEYE-SALMON; CLIMATE; LAKE; RECONSTRUCTION; COLUMBIA; IMPACTS; HISTORY; TRENDS; GULF	Historical catch records suggest that climatic variability has had basin-wide effects on the northern Pacific and its fish populations, such as salmon, sardines and anchovies(1-7). However, these records are too short to define the nature and frequency of patterns. We reconstructed similar to2,200-year records of sockeye salmon abundance from sediment cores obtained from salmon nursery lakes on Kodiak island, Alaska. Large shifts in abundance, which far exceed the decadal-scale variability recorded during the past 300 years(1-8), occurred over the past two millennia. A marked, multi-centennial decline in Alaskan sockeye salmon was apparent from similar to100 BC to AD 800, but salmon were consistently more abundant from AD 1200 to 1900. Over the past two millennia, the abundances of Pacific sardine and Northern anchovy off the California coast, and of Alaskan salmon, show several synchronous patterns of variability. But sardines and anchovies vary out of phase with Alaskan salmon over low frequency, which differs from the pattern detected in historical records(5,6). The coherent patterns observed across large regions demonstrate the strong role of climatic forcing in regulating northeastern Pacific fish stocks.	Univ Alaska Fairbanks, Inst Marine Sci, Fairbanks, AK 99775 USA; Queens Univ, Dept Biol, PEARL, Kingston, ON K7L 3N6, Canada; Univ Toronto, Dept Geol, PAL, Toronto, ON M5S 3B1, Canada	University of Alaska System; University of Alaska Fairbanks; Queens University - Canada; University of Toronto	Finney, BP (corresponding author), Univ Alaska Fairbanks, Inst Marine Sci, Fairbanks, AK 99775 USA.	finney@ims.uaf.edu	Smol, John P/A-8838-2015; Gregory-Eaves, Irene/U-9325-2019	Gregory-Eaves, Irene/0000-0002-0380-5061; Smol, John/0000-0002-2499-6696				BAUMGARTNER TR, 1992, CAL COOP OCEAN FISH, V33, P24; Beamish RJ, 1999, CAN J FISH AQUAT SCI, V56, P516, DOI 10.1139/cjfas-56-3-516; BEAMISH RJ, 1993, CAN J FISH AQUAT SCI, V50, P1002, DOI 10.1139/f93-116; BENNETT J, 1999, THESIS QUEENS U ONTA; Brodeur R.D., 1992, Fisheries Oceanography, V1, P32, DOI 10.1111/j.1365-2419.1992.tb00023.x; Burger CV, 2000, CAN J FISH AQUAT SCI, V57, P2096, DOI 10.1139/cjfas-57-10-2096; Burgner R. L., 1991, PACIFIC SALMON LIFE, P1; Calkin PE, 2001, QUATERNARY SCI REV, V20, P449, DOI 10.1016/S0277-3791(00)00105-0; CLARK DW, 1988, ARCTIC ANTHROPOL, V35, P172; ENNIS GL, 1983, CAN J BOT, V61, P1983, DOI 10.1139/b83-214; Finney BP, 2000, SCIENCE, V290, P795, DOI 10.1126/science.290.5492.795; Francis RC, 1998, FISH OCEANOGR, V7, P1, DOI 10.1046/j.1365-2419.1998.00052.x; Francis Robert C., 1994, Fisheries Oceanography, V3, P279, DOI 10.1111/j.1365-2419.1994.tb00105.x; Gargett AE, 1997, FISH OCEANOGR, V6, P109, DOI 10.1046/j.1365-2419.1997.00033.x; GILPIN LM, 1995, THESIS U CALIFORNIA; Hare SR, 2000, PROG OCEANOGR, V47, P103, DOI 10.1016/S0079-6611(00)00033-1; Jackson JBC, 2001, SCIENCE, V293, P629, DOI 10.1126/science.1059199; JUILLETLECLERC A, 1987, NATURE, V329, P146, DOI 10.1038/329146a0; KENNETT JP, 1995, NATURE, V377, P510, DOI 10.1038/377510a0; KNECT R, 1995, THESIS BRYN MAWR COL; Lluch-Belda D, 1999, LARGE MARINE ECOSYSTEMS OF THE PACIFIC RIM: ASSESSMENT, SUSTAINABILITY, AND MANAGEMENT, P42; Luckman BH, 1997, HOLOCENE, V7, P375, DOI 10.1177/095968369700700401; Mantua NJ, 1997, B AM METEOROL SOC, V78, P1069, DOI 10.1175/1520-0477(1997)078<1069:APICOW>2.0.CO;2; MILLS RO, 1994, ARCTIC ANTHROPOL, V31, P126; Pienitz R, 2000, HOLOCENE, V10, P673, DOI 10.1191/09596830094935; PISIAS NG, 1978, QUATERNARY RES, V10, P366, DOI 10.1016/0033-5894(78)90027-3; Tunnicliffe V, 2001, MAR GEOL, V174, P197, DOI 10.1016/S0025-3227(00)00150-X; VENRICK EL, 1987, SCIENCE, V238, P70, DOI 10.1126/science.238.4823.70; Welch DW, 1998, CAN J FISH AQUAT SCI, V55, P937, DOI 10.1139/cjfas-55-4-937; Wilson SE, 1996, CAN J FISH AQUAT SCI, V53, P1580, DOI 10.1139/cjfas-53-7-1580	30	221	241	1	81	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	2002	416	6882					729	733		10.1038/416729a	http://dx.doi.org/10.1038/416729a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961553				2022-12-28	WOS:000175033500040
J	Remondes, M; Schuman, EM				Remondes, M; Schuman, EM			Direct cortical input modulates plasticity and spiking in CA1 pyramidal neurons	NATURE			English	Article							ENTORHINAL CORTEX; HIPPOCAMPUS; PLACE; CELLS; RAT; ORGANIZATION; REGION	The hippocampus is necessary for the acquisition and retrieval of declarative memories(1,2). The best-characterized sensory input to the hippocampus is the perforant path projection from layer II of entorhinal cortex (EC) to the dentate gyrus(3,4). Signals are then processed sequentially in the hippocampal CA fields before returning to the cortex via CA1 pyramidal neuron spikes. There is another EC input-the temporoammonic (TA) pathway-consisting of axons from layer III EC neurons that make synaptic contacts on the distal dendrites of CA1 neurons(3,5,6). Here we show that this pathway modulates both the plasticity and the output of the rat hippocampal formation. Bursts of TA activity can, depending on their timing, either increase or decrease the probability of Schaffer-collateral (SC)-evoked CA1 spikes. TA bursts can also significantly reduce the magnitude of synaptic potentiation at SC-CA1 synapses. The TA-CA1 synapse itself exhibits both long-term depression (LTD) and long-term potentiation (LTP). This capacity for bi-directional plasticity can, in turn, regulate the TA modulation of CA1 activity: LTP or LTD of the TA pathway either enhances or diminishes the gating of CA1 spikes and plasticity inhibition, respectively.	CALTECH, Howard Hughes Med Inst, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Schuman, EM (corresponding author), CALTECH, Howard Hughes Med Inst, Div Biol, 216-76, Pasadena, CA 91125 USA.		Schuman, Erin M/D-6204-2011	Remondes, Miguel/0000-0001-9321-3985				AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; BRUN VH, 2001, SOC NEUR ABSTR, P31; Chrobak JJ, 1998, J NEUROSCI, V18, P388; Chrobak JJ, 2000, HIPPOCAMPUS, V10, P457, DOI 10.1002/1098-1063(2000)10:4<457::AID-HIPO12>3.0.CO;2-Z; COLBERT CM, 1992, J NEUROPHYSIOL, V68, P1; Dvorak-Carbone H, 1999, J NEUROPHYSIOL, V81, P1036, DOI 10.1152/jn.1999.81.3.1036; Dvorak-Carbone H, 1999, J NEUROPHYSIOL, V82, P3213, DOI 10.1152/jn.1999.82.6.3213; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; EMPSON RM, 1995, J PHYSIOL-LONDON, V484, P707, DOI 10.1113/jphysiol.1995.sp020697; JARRARD LE, 1984, BEHAV NEUROSCI, V98, P946, DOI 10.1037/0735-7044.98.6.946; Jarrard LE, 1995, BEHAV BRAIN RES, V71, P1, DOI 10.1016/0166-4328(95)00034-8; Levy B, 1998, GENET MED, V1, P4; MACCAFERRI G, 1995, NEURON, V15, P137, DOI 10.1016/0896-6273(95)90071-3; MCNAUGHTON BL, 1989, EXP BRAIN RES, V76, P485, DOI 10.1007/BF00248904; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Muller R, 1996, NEURON, V17, P813, DOI 10.1016/S0896-6273(00)80214-7; Ramon y Cajal S., 2018, BEAUTIFUL BRAIN DRAW; STEWARD O, 1976, J COMP NEUROL, V169, P347, DOI 10.1002/cne.901690306; WITTER MP, 1989, PROG NEUROBIOL, V33, P161, DOI 10.1016/0301-0082(89)90009-9	19	155	158	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					736	740		10.1038/416736a	http://dx.doi.org/10.1038/416736a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961555				2022-12-28	WOS:000175033500042
J	Smith, R				Smith, R			In search of "non-disease"	BRITISH MEDICAL JOURNAL			English	Review									BMJ, London WC1H 9JR, England		Smith, R (corresponding author), BMJ, BMA House, London WC1H 9JR, England.							BAILEY M, USE ESTEEMED MED J I; CAMPBELL EJM, 1979, BMJ-BRIT MED J, V2, P757, DOI 10.1136/bmj.2.6193.757; Foucault M., 1973, BIRTH CLIN; ILLICH I, 1976, LIMITS MED; MEADOR CK, 1965, NEW ENGL J MED, V272, P92, DOI 10.1056/NEJM196501142720208; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, P59	6	123	132	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					883	885		10.1136/bmj.324.7342.883	http://dx.doi.org/10.1136/bmj.324.7342.883			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950739	Green Published			2022-12-28	WOS:000175052200024
J	Ghosh, S; Karin, M				Ghosh, S; Karin, M			Missing pieces in the NF-kappa B puzzle	CELL			English	Review							TUMOR-NECROSIS-FACTOR; NUCLEAR EXPORT SIGNAL; SEVERE LIVER DEGENERATION; ACTIVATED PROTEIN-KINASE; GAMMA-DEFICIENT MICE; DEATH DOMAIN KINASE; IKK-BETA SUBUNIT; TRANSCRIPTION FACTOR; DNA-BINDING; CRYSTAL-STRUCTURE	The regulation of the transcription factor NF-kappaB activity occurs at several levels including controlled cytoplasmic-nuclear shuttling and modulation of its transcriptional activity. A critical component in NF-kappaB regulation is the IkappaB kinase (IKK) complex. This review is focused on recent progress as well as unanswered questions regarding the regulation and function of NF-kappaB and IKK.	Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem,Sect Immunobiol, New Haven, CT 06520 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; Yale University; University of California System; University of California San Diego	Ghosh, S (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem,Sect Immunobiol, 333 Cedar St, New Haven, CT 06520 USA.			Ghosh, Sankar/0000-0002-3227-0588				Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Fagarasan S, 2000, J EXP MED, V191, P1477, DOI 10.1084/jem.191.9.1477; Fisher DL, 2000, EMBO J, V19, P1516, DOI 10.1093/emboj/19.7.1516; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goes FS, 2001, EUR J BIOCHEM, V268, P2281, DOI 10.1046/j.1432-1327.2001.02105.x; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hong X, 2001, FEBS LETT, V499, P133, DOI 10.1016/S0014-5793(01)02535-2; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Malek S, 2001, J BIOL CHEM, V276, P45225, DOI 10.1074/jbc.M105865200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; MOSIALOS G, 1993, ONCOGENE, V8, P721; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; Poljak L, 1999, J IMMUNOL, V163, P6581; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; ROTHWARF DM, 1909, NK KAPPA B ACTIVATIO; Rudolph D, 2000, GENE DEV, V14, P854; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Tam WF, 2001, J BIOL CHEM, V276, P7701, DOI 10.1074/jbc.C000916200; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; Thompson JS, 2001, SCIENCE, V293, P2108, DOI 10.1126/science.1061965; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837; ZHANG JD, 1994, ONCOGENE, V9, P1931; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	151	3148	3304	2	95	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR	2002	109			S			S81	S96		10.1016/S0092-8674(02)00703-1	http://dx.doi.org/10.1016/S0092-8674(02)00703-1			16	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	544UY	11983155	Bronze			2022-12-28	WOS:000175181100008
J	Fujimoto, Y; Tu, LL; Miller, AS; Bock, C; Fujimoto, M; Doyle, C; Steeber, DA; Tedder, TF				Fujimoto, Y; Tu, LL; Miller, AS; Bock, C; Fujimoto, M; Doyle, C; Steeber, DA; Tedder, TF			CD83 expression influences CD4(+) T cell development in the thymus	CELL			English	Article							BLOOD DENDRITIC CELLS; CLASS-II MHC; POSITIVE SELECTION; ACTIVATED LYMPHOCYTES; LINEAGE COMMITMENT; SURFACE EXPRESSION; ANTIGEN RECEPTOR; LANGERHANS CELLS; DEFICIENT MICE; MURINE CD83	T lymphocyte selection and lineage commitment in the thymus requires multiple signals. Herein, CD4(+) T cell generation required engagement of CD83, a surface molecule expressed by thymic epithelial and dendritic cells. CD83-deficient (CD83(-/-)) mice had a specific block in CD4(+) single-positive thymocyte development without increased CD4(+)CD8(+) double- or CD8(+) single-positive thymocytes. This resulted in a selective 75%-90% reduction in peripheral CD4(+) T cells, predominantly within the naive subset. Wild-type thymocytes and bone marrow stem cells failed to differentiate into mature CD4(+) T cells when transferred into CD83(-/-) mice, while CD83(-/-) thymocytes and stem cells developed normally in wild-type mice. Thereby, CD83 expression represents an additional regulatory component for CD4(+) T cell development in the thymus.	Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Duke University	Tedder, TF (corresponding author), Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA.			Fujimoto, Manabu/0000-0002-3062-4872	NCI NIH HHS [CA81776, CA54464] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA054464, R01CA081776, R01CA054464] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson G, 1996, ANNU REV IMMUNOL, V14, P73, DOI 10.1146/annurev.immunol.14.1.73; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; Ardavin C, 1997, IMMUNOL TODAY, V18, P350, DOI 10.1016/S0167-5699(97)01090-6; Basson MA, 1998, J EXP MED, V187, P1249; Berchtold S, 1999, FEBS LETT, V461, P211, DOI 10.1016/S0014-5793(99)01465-9; Bommhardt U, 1997, EUR J IMMUNOL, V27, P1152, DOI 10.1002/eji.1830270516; Brocker T, 1997, J EXP MED, V186, P1223, DOI 10.1084/jem.186.8.1223; Brugnera E, 2000, IMMUNITY, V13, P59, DOI 10.1016/S1074-7613(00)00008-X; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; Cibotti R, 1997, IMMUNITY, V6, P245, DOI 10.1016/S1074-7613(00)80327-1; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; Cramer SO, 2000, INT IMMUNOL, V12, P1347, DOI 10.1093/intimm/12.9.1347; Dave VP, 1998, P NATL ACAD SCI USA, V95, P8187, DOI 10.1073/pnas.95.14.8187; ENGEL P, 1995, IMMUNITY, V3, P39, DOI 10.1016/1074-7613(95)90157-4; ENGEL P, 1995, LEUKOCYTE TYPING, V5, P693; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; Hernandez-Hoyos G, 2000, IMMUNITY, V12, P313, DOI 10.1016/S1074-7613(00)80184-3; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iwata M, 1996, EUR J IMMUNOL, V26, P2081, DOI 10.1002/eji.1830260918; Jameson SC, 1998, CURR OPIN IMMUNOL, V10, P214, DOI 10.1016/S0952-7915(98)80251-3; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOZLOW EJ, 1993, BLOOD, V81, P454, DOI 10.1182/blood.V81.2.454.454; KRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981; Kruse M, 2000, J EXP MED, V191, P1581, DOI 10.1084/jem.191.9.1581; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; Lechmann M, 2001, J EXP MED, V194, P1813, DOI 10.1084/jem.194.12.1813; Lucas B, 1996, IMMUNITY, V5, P461, DOI 10.1016/S1074-7613(00)80502-6; LUNDBERG K, 1995, J EXP MED, V181, P1643, DOI 10.1084/jem.181.5.1643; Matechak EO, 1996, IMMUNITY, V4, P337, DOI 10.1016/S1074-7613(00)80247-2; MATZINGER P, 1989, NATURE, V338, P74, DOI 10.1038/338074a0; MCCARTHY SA, 1988, NATURE, V336, P76, DOI 10.1038/336076a0; McKinsey TA, 2000, MOL IMMUNOL, V37, P783, DOI 10.1016/S0161-5890(00)00099-7; NAKAYAMA T, 1990, SCIENCE, V249, P1558, DOI 10.1126/science.2120773; Ohoka Y, 1996, INT IMMUNOL, V8, P297, DOI 10.1093/intimm/8.3.297; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; ROBEY EA, 1991, CELL, V64, P99, DOI 10.1016/0092-8674(91)90212-H; ROBINSON JH, 1977, CLIN EXP IMMUNOL, V27, P322; Sant'Angelo DB, 1998, IMMUNITY, V9, P179, DOI 10.1016/S1074-7613(00)80600-7; Scholler N, 2001, J IMMUNOL, V166, P3865, DOI 10.4049/jimmunol.166.6.3865; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; Steinman RM, 2000, CELL, V100, P491, DOI 10.1016/S0092-8674(00)80684-4; Suzuki H, 1998, EUR J IMMUNOL, V28, P3252, DOI 10.1002/(SICI)1521-4141(199810)28:10<3252::AID-IMMU3252>3.0.CO;2-G; SUZUKI H, 1995, IMMUNITY, V2, P413, DOI 10.1016/1074-7613(95)90149-3; TAKAHAMA Y, 1994, NATURE, V371, P67, DOI 10.1038/371067a0; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Twist CJ, 1998, IMMUNOGENETICS, V48, P383, DOI 10.1007/s002510050449; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WEISSMAN D, 1995, P NATL ACAD SCI USA, V92, P826, DOI 10.1073/pnas.92.3.826; WILKINSON RW, 1995, J IMMUNOL, V155, P5234; Yasutomo K, 2000, J IMMUNOL, V165, P3015, DOI 10.4049/jimmunol.165.6.3015; Yasutomo K, 2000, NATURE, V404, P506, DOI 10.1038/35006664; ZHOU LJ, 1992, J IMMUNOL, V149, P735; ZHOU LJ, 1995, BLOOD, V86, P3295, DOI 10.1182/blood.V86.9.3295.bloodjournal8693295; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	58	167	184	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 22	2002	108	6					755	767		10.1016/S0092-8674(02)00673-6	http://dx.doi.org/10.1016/S0092-8674(02)00673-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955430	Bronze			2022-12-28	WOS:000174563000006
J	Forcet, C; Stein, E; Pays, L; Corset, R; Llambi, F; Tessler-Lavigne, M; Mehlen, P				Forcet, C; Stein, E; Pays, L; Corset, R; Llambi, F; Tessler-Lavigne, M; Mehlen, P			Netrin-1-mediated axon outgrowth requires deleted in colorectal cancer-dependent MAPK activation	NATURE			English	Article							RECEPTOR TYROSINE KINASE; ADENOSINE A2B RECEPTOR; ADHESION MOLECULE L1; NEURITE OUTGROWTH; SIGNALING PATHWAY; NETRIN RECEPTOR; GROWTH CONES; PC12 CELLS; DCC-GENE; IN-VIVO	Neuronal growth cones are guided to their targets by attractive and repulsive guidance cues(1). In mammals, netrin-1 is a bifunctional cue, attracting some axons and repelling others(2-5). Deleted in colorectal cancer (Dcc) is a receptor for netrin-1 that mediates its chemoattractive effect on commissural axons(6,7), but the signalling mechanisms that transduce this effect are poorly understood. Here we show that Dcc activates mitogen-activated protein kinase (MAPK) signalling, by means of extracellular signal-regulated kinase (ERK)-1 and -2, on netrin-1 binding in both transfected cells and commissural neurons. This activation is associated with recruitment of ERK-1/2 to a Dcc receptor complex. Inhibition of ERK-1/2 antagonizes netrin-dependent axon outgrowth and orientation. Thus, activation of MAPK signalling through Dcc contributes to netrin signalling in axon growth and guidance.	Univ Lyon, CNRS, UMR 5534,Apoptosis Differentiat Lab, Mol & Cellular Genet Ctr, F-69622 Villeurbanne, France; Howard Hughes Med Inst, Dept Biol Sci, Stanford, CA 94035 USA	Centre National de la Recherche Scientifique (CNRS); Howard Hughes Medical Institute	Mehlen, P (corresponding author), Univ Lyon, CNRS, UMR 5534,Apoptosis Differentiat Lab, Mol & Cellular Genet Ctr, F-69622 Villeurbanne, France.		Stein, Elke/E-8107-2013	Stein, Elke/0000-0001-8965-5692; Pays, Laurent/0000-0003-0720-2273				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Birkenkamp KU, 2000, BRIT J PHARMACOL, V131, P99, DOI 10.1038/sj.bjp.0703534; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Corset V, 2000, NATURE, V407, P747, DOI 10.1038/35037600; de la Torre JR, 1997, NEURON, V19, P1211, DOI 10.1016/S0896-6273(00)80413-4; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FUKUDA M, 1995, ONCOGENE, V11, P239; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Kamiguchi H, 2000, J NEUROSCI, V20, P3676, DOI 10.1523/JNEUROSCI.20-10-03676.2000; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kolkova K, 2000, J NEUROSCI, V20, P2238; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Schaefer AW, 1999, J BIOL CHEM, V274, P37965, DOI 10.1074/jbc.274.53.37965; Schmid RS, 2000, J NEUROSCI, V20, P4177; Schmid RS, 1999, J NEUROBIOL, V38, P542, DOI 10.1002/(SICI)1097-4695(199903)38:4<542::AID-NEU9>3.3.CO;2-T; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Sgambato V, 1998, J NEUROSCI, V18, P214; Stein E, 2001, SCIENCE, V291, P1976, DOI 10.1126/science.1059391; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059	29	200	213	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 23	2002	417	6887					443	447		10.1038/nature748	http://dx.doi.org/10.1038/nature748			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	554HZ	11986622				2022-12-28	WOS:000175730900039
J	Ludwig, DS				Ludwig, DS			The glycemic index - Physiological mechanisms relating to obesity, diabetes, and cardiovascular disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-HEART-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; INSULIN-RESISTANCE; PLASMA-GLUCOSE; BLOOD-GLUCOSE; DIETARY FIBER; LIPID-METABOLISM; CHRONIC HYPERGLYCEMIA; POSTPRANDIAL STATE; STARCH PROMOTES	The glycemic index was proposed in 1981 as an alternative system for classifying carbohydrate-containing food. Since then, several hundred scientific articles and numerous popular diet books have been published on the topic. However, the clinical significance of the glycemic index remains the subject of debate. The purpose of this review is to examine the physiological effects of the glycemic index and the relevance of these effects in preventing and treating obesity, diabetes, and cardiovascular disease.	Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Ludwig, DS (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.	david.ludwig@tch.harvard.edu		Ludwig, David/0000-0003-3307-8544	NIDDK NIH HHS [1R01DK059240, 1K08DK02440] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059240, K08DK002440] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen FM, 1920, J EXP MED, V31, P381, DOI 10.1084/jem.31.4.381; [Anonymous], 1999, CAN J DIABETES CARE, V23, P56; Balkau B, 1998, DIABETES CARE, V21, P360, DOI 10.2337/diacare.21.3.360; BANTLE JP, 1983, NEW ENGL J MED, V309, P7, DOI 10.1056/NEJM198307073090102; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; BORNET FRJ, 1987, AM J CLIN NUTR, V45, P588, DOI 10.1093/ajcn/45.3.588; Bouche C, 2000, DIABETES, V49, pA40; BRAND JC, 1991, DIABETES CARE, V14, P95, DOI 10.2337/diacare.14.2.95; BRANDMILLER J, 1999, GLUCOSE REVOLUTION A; BRUN JF, 1995, DIABETOLOGIA, V38, P494; Buyken AE, 2001, AM J CLIN NUTR, V73, P574; BYRNES SE, 1995, J NUTR, V125, P1430; Cahill G F Jr, 1970, N Engl J Med, V282, P668, DOI 10.1056/NEJM197003052821026; Campfield LA, 1996, NEUROSCI BIOBEHAV R, V20, P133, DOI 10.1016/0149-7634(95)00043-E; CAMPFIELD LA, 1990, INT J OBESITY, V14, P15; Ceriello A, 2000, DIABETES-METAB RES, V16, P125, DOI 10.1002/(SICI)1520-7560(200003/04)16:2<125::AID-DMRR90>3.0.CO;2-4; Ceriello A, 1998, EUR J CLIN INVEST, V28, P329; Ceriello A, 1999, METABOLISM, V48, P1503, DOI 10.1016/S0026-0495(99)90237-8; CHEW I, 1988, AM J CLIN NUTR, V47, P53, DOI 10.1093/ajcn/47.1.53; Clapp JF, 1997, ARCH GYNECOL OBSTET, V260, P101; Collier GR., 1988, DIABETES NUTR METAB, V1, P11; Coulston AM, 1997, DIABETES CARE, V20, P241, DOI 10.2337/diacare.20.3.241; COULSTON AM, 1984, AM J CLIN NUTR, V40, P965, DOI 10.1093/ajcn/40.5.965; COULSTON AM, 1987, DIABETES CARE, V10, P395, DOI 10.2337/diacare.10.4.395; Coutinho M, 1999, DIABETES CARE, V22, P233, DOI 10.2337/diacare.22.2.233; Cusin Isabelle, 1992, International Journal of Obesity, V16, pS1; de Vegt F, 1999, DIABETOLOGIA, V42, P926, DOI 10.1007/s001250051249; DELPRATO S, 1994, DIABETOLOGIA, V37, P1025, DOI 10.1007/BF00400466; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; Ebbeling C B, 2001, Adv Pediatr, V48, P179; ESTRICH D, 1967, DIABETES, V16, P232, DOI 10.2337/diab.16.4.232; *FAO UN, 1997, CARB HUM NUTR SUMM J; Febbraio MA, 2000, J APPL PHYSIOL, V89, P1845, DOI 10.1152/jappl.2000.89.5.1845; FONTVIEILLE AM, 1992, DIABETIC MED, V9, P444, DOI 10.1111/j.1464-5491.1992.tb01815.x; Fontvieille AM., 1988, DIABETES NUTR METAB, V1, P139; Ford ES, 2001, ARCH INTERN MED, V161, P572, DOI 10.1001/archinte.161.4.572; FOSTERPOWELL K, 1995, AM J CLIN NUTR, V62, p871S, DOI 10.1093/ajcn/62.4.871S; Franz MJ, 2002, DIABETES CARE, V25, P148, DOI 10.2337/diacare.25.1.148; FRIEDMAN MI, 1983, AM J PHYSIOL, V244, pR374, DOI 10.1152/ajpregu.1983.244.3.R374; Frost G, 1998, METABOLISM, V47, P1245, DOI 10.1016/S0026-0495(98)90331-6; Frost G, 1999, LANCET, V353, P1045, DOI 10.1016/S0140-6736(98)07164-5; FROST G, 1994, DIABETIC MED, V11, P397, DOI 10.1111/j.1464-5491.1994.tb00292.x; Giacco R, 2000, DIABETES CARE, V23, P1461, DOI 10.2337/diacare.23.10.1461; Gilbertson HR, 2001, DIABETES CARE, V24, P1137, DOI 10.2337/diacare.24.7.1137; GRANFELDT Y, 1991, EUR J CLIN NUTR, V45, P489; Grill V, 2000, CELL MOL LIFE SCI, V57, P429, DOI 10.1007/PL00000705; Harris S, 1924, J AMER MED ASSOC, V83, P729, DOI 10.1001/jama.1924.02660100003002; Hauner H, 1999, INT J OBESITY, V23, pS12, DOI 10.1038/sj.ijo.0800956; Higgins JA, 1996, J NUTR, V126, P596, DOI 10.1093/jn/126.3.596; Hu FB, 2000, NEW ENGL J MED, V343, P530, DOI 10.1056/NEJM200008243430802; Jarvi AE, 1999, DIABETES CARE, V22, P10, DOI 10.2337/diacare.22.1.10; JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362; JENKINS DJA, 1987, AM J CLIN NUTR, V46, P968, DOI 10.1093/ajcn/46.6.968; JENKINS DJA, 1990, DIABETES, V39, P775, DOI 10.2337/diabetes.39.7.775; JENKINS DJA, 1988, AM J CLIN NUTR, V48, P248, DOI 10.1093/ajcn/48.2.248; JENKINS DJA, 1987, AM J CLIN NUTR, V46, P66, DOI 10.1093/ajcn/46.1.66; JENKINS DJA, 1989, NEW ENGL J MED, V321, P929, DOI 10.1056/NEJM198910053211403; JENKINS DJA, 1985, AM J CLIN NUTR, V42, P604, DOI 10.1093/ajcn/42.4.604; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; Juan CC, 1999, METABOLISM, V48, P465, DOI 10.1016/S0026-0495(99)90105-1; Kabir M, 1998, J NUTR, V128, P1878, DOI 10.1093/jn/128.11.1878; Kabir M, 1998, J NUTR, V128, P35, DOI 10.1093/jn/128.1.35; Kiens B, 1996, AM J CLIN NUTR, V63, P47, DOI 10.1093/ajcn/63.1.47; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Laedtke T, 2000, AM J PHYSIOL-ENDOC M, V279, pE520, DOI 10.1152/ajpendo.2000.279.3.E520; Lafrance L, 1998, DIABETIC MED, V15, P972, DOI 10.1002/(SICI)1096-9136(1998110)15:11<972::AID-DIA704>3.0.CO;2-2; Lang V, 1999, AM J CLIN NUTR, V69, P1183; LEAHY JL, 1988, J CLIN INVEST, V81, P1407, DOI 10.1172/JCI113470; Lefebvre P, 1998, DIABETIC MED, V15, pS63, DOI 10.1002/(SICI)1096-9136(1998120)15:4+<S63::AID-DIA737>3.3.CO;2-Z; LererMetzger M, 1996, BRIT J NUTR, V75, P723, DOI 10.1079/BJN19960176; LEVRAN A, 1981, DIABETES, V30, P996, DOI 10.2337/diabetes.30.12.996; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Liu SM, 2001, AM J CLIN NUTR, V73, P560; Ludwig DS, 2000, J NUTR, V130, p280S, DOI 10.1093/jn/130.2.280S; Ludwig DS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e26; Luscombe ND, 1999, EUR J CLIN NUTR, V53, P473, DOI 10.1038/sj.ejcn.1600779; Mann JI, 2000, EUR J CLIN NUTR, V54, P353, DOI 10.1038/sj.ejcn.1600962; MARFELLA R, 1995, AM J PHYSIOL-ENDOC M, V268, pE1167, DOI 10.1152/ajpendo.1995.268.6.E1167; MARSOOBIAN V, 1995, AM J CLIN NUTR, V61, P373, DOI 10.1093/ajcn/61.2.373; Mather K, 2001, J VASC RES, V38, P415, DOI 10.1159/000051074; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; Meyer KA, 2000, AM J CLIN NUTR, V71, P921; MILLER JCB, 1994, AM J CLIN NUTR, V59, p747S, DOI 10.1093/ajcn/59.3.747S; Pawlak DB, 2001, J NUTR, V131, P99, DOI 10.1093/jn/131.1.99; PAWLAK DB, 2000, OBES RES, V8, pS128; Perlstein R., 1997, Australian Journal of Nutrition and Dietetics, V54, P57; *PHS, 1988, SURG GEN REP NUTR HL; Reaven G M, 2000, Curr Atheroscler Rep, V2, P503, DOI 10.1007/s11883-000-0050-z; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Reaven GM, 2000, SYNDROME X OVERCOMIN; REILLYPARDO M, 2001, B KRAUS CALORIES CAR; RITZ P, 1991, AM J CLIN NUTR, V54, P855, DOI 10.1093/ajcn/54.5.855; RODIN J, 1985, METABOLISM, V34, P826, DOI 10.1016/0026-0495(85)90106-4; ROLLS B, 2000, VOLUMETRICS WRIGHT C; ROSSETTI L, 1990, DIABETES CARE, V13, P610, DOI 10.2337/diacare.13.6.610; SAKO Y, 1990, DIABETES, V39, P1580, DOI 10.2337/diabetes.39.12.1580; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545; SEARS B, 1995, ZONE; SLABBER M, 1994, AM J CLIN NUTR, V60, P48, DOI 10.1093/ajcn/60.1.48; Spieth LE, 2000, ARCH PEDIAT ADOL MED, V154, P947, DOI 10.1001/archpedi.154.9.947; STEPHAN T, 1972, AM J MED SCI, V264, P41, DOI 10.1097/00000441-197207000-00006; STEWARD HL, 1998, SUGAR BUSTERS CUT SU; Tanaka Y, 1999, P NATL ACAD SCI USA, V96, P10857, DOI 10.1073/pnas.96.19.10857; Temelkova-Kurktschiev TS, 2000, DIABETES CARE, V23, P1830, DOI 10.2337/diacare.23.12.1830; THOMPSON DA, 1977, SCIENCE, V198, P1065, DOI 10.1126/science.929188; Title LM, 2000, J AM COLL CARDIOL, V36, P2185, DOI 10.1016/S0735-1097(00)00980-3; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; van Dam RM, 2000, EUR J CLIN NUTR, V54, P726, DOI 10.1038/sj.ejcn.1601086; WAHLQVIST ML, 1978, AM J CLIN NUTR, V31, P1998, DOI 10.1093/ajcn/31.11.1998; WELCH IM, 1987, CLIN SCI, V72, P209, DOI 10.1042/cs0720209; Wilson JD, 1998, WILLIAMS TXB ENDOCRI; Wolever TMS, 1996, J NUTR, V126, P2807; WOLEVER TMS, 1988, AM J CLIN NUTR, V48, P1041, DOI 10.1093/ajcn/48.4.1041; WOLEVER TMS, 1995, DIABETES CARE, V18, P962, DOI 10.2337/diacare.18.7.962; WOLEVER TMS, 1989, J AM COLL NUTR, V8, P235; WOLEVER TMS, 1986, AM J CLIN NUTR, V43, P167, DOI 10.1093/ajcn/43.1.167; WOLEVER TMS, 1992, DIABETIC MED, V9, P451, DOI 10.1111/j.1464-5491.1992.tb01816.x; WOLEVER TMS, 1991, AM J CLIN NUTR, V54, P846, DOI 10.1093/ajcn/54.5.846; WOLEVER TMS, 1992, DIABETES CARE, V15, P562, DOI 10.2337/diacare.15.4.562	120	1178	1220	4	247	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	2002	287	18					2414	2423		10.1001/jama.287.18.2414	http://dx.doi.org/10.1001/jama.287.18.2414			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548PF	11988062				2022-12-28	WOS:000175397000030
J	Jarman, B; Hurwitz, B; Cook, A; Bajekal, M; Lee, A				Jarman, B; Hurwitz, B; Cook, A; Bajekal, M; Lee, A			Effects of community based nurses specialising in Parkinson's disease on health outcome and costs: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							QUESTIONNAIRE; MANAGEMENT; VALIDATION; PDQ-39	Objective To determine the effects of community based nurses specialising in Parkinson's disease on health outcomes and healthcare costs. Design Two year randomised controlled trial. Setting 438 general practices in nine randomly selected health authority areas of England. Participants 1859 patients with Parkinson's disease identified by die participating general practices. Main outcome measures Survival, stand-up test, dot in square test. bone fracture, global health question, PDQ-39, Euroqol, and healthcare costs. Results After two years 315 (17.3%) patients had died, although mortality did not differ between those who were attended by nurse specialists and those receiving standard care from their general practitioner (hazard ratio for nurse group v control group 0.91, 95%, confidence interval 0.73 to 1.13). No significant differences were found between the two groups for the stand-up test (odds ratio 1.15, 0.93 to 1.42) and clot in square score (difference - 0.7, - 3.25 to 1.84). Scores on the global health question were significantly better in patients attended by nurse specialists than in controls (difference - 0.23, - 0.4 to - 0.06), but no difference was observed in the results of die PDQ-39 or Euroqol questionnaires, Direct costs for patient health care increased by an average of pound2658 during the study, although not differentially between groups: the average increase was S:266 lower among patients attended by a nurse specialist (- pound981 to pound449). Conclusions Nurse specialists in Parkinson's disease had little effect oil the clinical condition of patients, but they did improve their patients' sense of wellbeing, with no increase in patients healthcare costs.	Univ London Imperial Coll Sci Technol & Med, Ctr Primary Care & Social Med, Dept Primary Hlth Care & Gen Practice, London W6 8RP, England	Imperial College London	Hurwitz, B (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Primary Care & Social Med, Dept Primary Hlth Care & Gen Practice, London W6 8RP, England.							BENSHLOMO Y, 1995, BRIT J GEN PRACT, V45, P261; CALNE DB, 1993, NEW ENGL J MED, V329, P1021; *COLL HLTH, 1994, NEEDS PEOPL PARK DIS; GERSTENBRAND F, 1973, NERVENARZT, V44, P428; *HAYM MED, 1996, MONTHL IND MED SPEC; Hurwitz B, 1999, Adv Neurol, V80, P431; JAHANSHAHI M, 1994, BEHAV NEUROL, V7, P189, DOI 10.3233/BEN-1994-73-414; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; JENKINSON C, 1995, AGE AGEING, V24, P505, DOI 10.1093/ageing/24.6.505; Jenkinson C, 1998, PARKINSONS DIS QUEST; Lees AJ, 1995, BRIT MED J, V311, P1602, DOI 10.1136/bmj.311.7020.1602; MacMahon DG, 1998, J NEUROL, V245, pS19, DOI 10.1007/PL00007732; MACMAHON DG, 2000, MOV DISORD S3, V15, P178; MARSDEN CD, 1994, J NEUROL NEUROSUR PS, V57, P672, DOI 10.1136/jnnp.57.6.672; Munchau A, 2000, POSTGRAD MED J, V76, P602, DOI 10.1136/pmj.76.900.602; MUTCH WJ, 1986, BRIT MED J, V292, P534, DOI 10.1136/bmj.292.6519.534; MUTCH WJ, 1986, BRIT MED J, V293, P675, DOI 10.1136/bmj.293.6548.675; NETTEN A, 1996, UNIT COSTS HLTH SOCI; *PARK DIS SOC, 1999, PARK DIS NURS; PETO V, 1995, QUAL LIFE RES, V4, P241, DOI 10.1007/BF02260863; Peto V, 2001, AGE AGEING, V30, P299, DOI 10.1093/ageing/30.4.299; Reynolds H, 2000, INT J NURS STUD, V37, P337, DOI 10.1016/S0020-7489(00)00013-4; RIDSDALE L, 1995, BRIT J GEN PRACT, V394, P226; *SCH NURS MIDW, 2000, KNOWL BAS PRACT PEOP; Schrag A, 2000, BRIT MED J, V321, P21, DOI 10.1136/bmj.321.7252.21; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Wade DT, 1994, MEASUREMENT NEUROLOG; Williams A, 1995, 136 U YORK CTR HLTH; WILSONBARNETT J, 1994, INT J NURS STUD, V31, P561, DOI 10.1016/0020-7489(94)90066-3	29	69	69	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 4	2002	324	7345					1072	1075		10.1136/bmj.324.7345.1072	http://dx.doi.org/10.1136/bmj.324.7345.1072			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YY	11991913	Bronze, Green Published			2022-12-28	WOS:000175476500021
J	Barker, AF				Barker, AF			Medical progress - Bronchiectasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESOLUTION COMPUTED-TOMOGRAPHY; OBSTRUCTIVE PULMONARY-DISEASE; PRIMARY CILIARY DYSKINESIA; THIN-SECTION CT; PSEUDOMONAS-AERUGINOSA; RHEUMATOID-ARTHRITIS; SURGICAL-MANAGEMENT; CHRONIC-BRONCHITIS; INTERFERON-GAMMA; CYSTIC-FIBROSIS		Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care, Portland, OR 97201 USA	Oregon Health & Science University	Barker, AF (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Div Pulm & Crit Care, Portland, OR 97201 USA.	barkera@ohsu.edu						Agasthian T, 1996, ANN THORAC SURG, V62, P976, DOI 10.1016/0003-4975(96)00469-9; Angrill J, 2002, THORAX, V57, P15, DOI 10.1136/thorax.57.1.15; Angrill J, 2001, AM J RESP CRIT CARE, V164, P1628, DOI 10.1164/ajrccm.164.9.2105083; Arcasoy SM, 1999, NEW ENGL J MED, V340, P1081, DOI 10.1056/NEJM199904083401406; Ashour M, 1999, WORLD J SURG, V23, P1096, DOI 10.1007/s002689900630; BAHOUS J, 1984, B EUR PHYSIOPATH RES, V20, P375; Barker AF, 2000, AM J RESP CRIT CARE, V162, P481, DOI 10.1164/ajrccm.162.2.9910086; BUCKLEY RH, 1991, NEW ENGL J MED, V325, P110, DOI 10.1056/NEJM199107113250207; Bush A, 1998, EUR RESPIR J, V12, P982, DOI 10.1183/09031936.98.12040982; CAMUS P, 1993, MEDICINE, V72, P151; Camus P, 2000, EUR RESPIR J, V15, P5, DOI 10.1183/09031936.00.15100500; Cartier Y, 1999, AM J ROENTGENOL, V173, P47, DOI 10.2214/ajr.173.1.10397098; Chauhan B, 1996, J CLIN INVEST, V97, P2324, DOI 10.1172/JCI118675; Chiang T C, 1999, Zhonghua Yi Xue Za Zhi (Taipei), V62, P690; CHRISTENSEN EF, 1990, CHEST, V97, P645, DOI 10.1378/chest.97.3.645; Cohen M, 1999, CHEST, V116, P1063, DOI 10.1378/chest.116.4.1063; Cole P J, 1986, Eur J Respir Dis Suppl, V147, P6; CORTET B, 1995, ANN RHEUM DIS, V54, P815, DOI 10.1136/ard.54.10.815; Cunningham-Rundles C, 1999, CLIN IMMUNOL, V92, P34, DOI 10.1006/clim.1999.4725; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DeGracia J, 1996, AM J RESP CRIT CARE, V153, P650, DOI 10.1164/ajrccm.153.2.8564113; DESAI SR, 1994, BRIT J RADIOL, V67, P257, DOI 10.1259/0007-1285-67-795-257; ELBORN JS, 1992, RESP MED, V86, P121, DOI 10.1016/S0954-6111(06)80227-1; Fujimoto T, 2001, ANN THORAC SURG, V72, P1711, DOI 10.1016/S0003-4975(01)03085-5; Gaga M, 1998, THORAX, V53, P685, DOI 10.1136/thx.53.8.685; Hansell DM, 1998, RADIOL CLIN N AM, V36, P107, DOI 10.1016/S0033-8389(05)70009-9; HASSAN WU, 1995, ANN RHEUM DIS, V54, P308, DOI 10.1136/ard.54.4.308; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; Hill SL, 1998, THORAX, V53, P463, DOI 10.1136/thx.53.6.463; Ho PL, 1998, CHEST, V114, P1594, DOI 10.1378/chest.114.6.1594; HOLLAND SM, 1994, NEW ENGL J MED, V330, P1348, DOI 10.1056/NEJM199405123301904; HOLMES AH, 1992, Q J MED, V85, P875; Huang JH, 1998, AM J RESP CRIT CARE, V157, P377, DOI 10.1164/ajrccm.157.2.9706012; Huang JH, 1999, CHEST, V115, P1033, DOI 10.1378/chest.115.4.1033; Johnston IDA, 1998, NEW ENGL J MED, V338, P581, DOI 10.1056/NEJM199802263380904; Jones A, 2000, HEART LUNG, V29, P125; KANG EY, 1995, RADIOLOGY, V195, P649, DOI 10.1148/radiology.195.3.7753989; KAUFFMAN HF, 1995, AM J RESP CRIT CARE, V151, P2109, DOI 10.1164/ajrccm.151.6.7767565; Keistinen T, 1997, EUR RESPIR J, V10, P2784, DOI 10.1183/09031936.97.10122784; KLINGMAN KL, 1995, AM J RESP CRIT CARE, V152, P1072, DOI 10.1164/ajrccm.152.3.7663786; KWON KY, 1995, HUM PATHOL, V26, P302, DOI 10.1016/0046-8177(95)90062-4; LAENNEC RTH, 1962, TREATISE DIS CHEST, P78; LEMAUVIEL L, 1991, WESTERN J MED, V155, P280; LIMPER AH, 1990, ANN INTERN MED, V112, P604, DOI 10.7326/0003-4819-112-8-604; Lin HC, 1997, AM J RESP CRIT CARE, V155, P2024, DOI 10.1164/ajrccm.155.6.9196111; Loubeyre P, 1996, CHEST, V109, P360, DOI 10.1378/chest.109.2.360; LYNCH DA, 1993, RADIOLOGY, V188, P829, DOI 10.1148/radiology.188.3.8351357; Lynch DA, 1999, AM J ROENTGENOL, V173, P53, DOI 10.2214/ajr.173.1.10397099; Mahadeva R, 2000, EUR RESPIR J, V15, P41, DOI 10.1034/j.1399-3003.2000.15a09.x; Mal H, 1999, CHEST, V115, P996, DOI 10.1378/chest.115.4.996; Manson D, 1997, PEDIATR RADIOL, V27, P794, DOI 10.1007/s002470050235; MCGUINNESS G, 1993, J COMPUT ASSIST TOMO, V17, P260, DOI 10.1097/00004728-199303000-00015; MCGUINNESS G, 1994, CHEST, V105, P1155, DOI 10.1378/chest.105.4.1155; MCMAHON MJ, 1993, ANN RHEUM DIS, V52, P776, DOI 10.1136/ard.52.11.776; Miszkiel KA, 1997, THORAX, V52, P260, DOI 10.1136/thx.52.3.260; MUNRO NC, 1990, THORAX, V45, P135, DOI 10.1136/thx.45.2.135; MURPHY MB, 1984, THORAX, V39, P179, DOI 10.1136/thx.39.3.179; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; NICOTRA MB, 1995, CHEST, V108, P955, DOI 10.1378/chest.108.4.955; O'Brien C, 2000, THORAX, V55, P635, DOI 10.1136/thorax.55.8.635; O'Donnell AE, 1998, CHEST, V113, P1329, DOI 10.1378/chest.113.5.1329; Omran H, 2000, AM J RESP CELL MOL, V23, P696, DOI 10.1165/ajrcmb.23.5.4257; Pang G, 2000, AM J RESP CRIT CARE, V161, P718, DOI 10.1164/ajrccm.161.3.9812047; PANG J, 1989, THORAX, V44, P948, DOI 10.1136/thx.44.11.948; PANG JA, 1989, AM REV RESPIR DIS, V139, P14, DOI 10.1164/ajrccm/139.1.14; Pasteur MC, 2000, AM J RESP CRIT CARE, V162, P1277, DOI 10.1164/ajrccm.162.4.9906120; Pennarun G, 1999, AM J HUM GENET, V65, P1508, DOI 10.1086/302683; Pomerantz BJ, 2001, J THORAC CARDIOV SUR, V121, P448, DOI 10.1067/mtc.2001.112339; Pomerantz M, 1996, ANN THORAC SURG, V62, P990, DOI 10.1016/0003-4975(96)00534-6; PRINCE DS, 1989, NEW ENGL J MED, V321, P863, DOI 10.1056/NEJM198909283211304; Pryor JA, 1999, EUR RESPIR J, V14, P1418, DOI 10.1183/09031936.99.14614189; RAYNER CFJ, 1994, J ANTIMICROB CHEMOTH, V34, P149, DOI 10.1093/jac/34.1.149; Reed W, 2000, AM J RESP CELL MOL, V23, P734, DOI 10.1165/ajrcmb.23.6.4045; REID LM, 1950, THORAX, V5, P233, DOI 10.1136/thx.5.3.233; RICHMANEISENSTAT JBY, 1993, AM J PHYSIOL, V264, pL413, DOI 10.1152/ajplung.1993.264.4.L413; Roberts HR, 2000, THORAX, V55, P198, DOI 10.1136/thorax.55.3.198; Rodrigo MJ, 1997, CLIN DIAGN LAB IMMUN, V4, P168, DOI 10.1128/CDLI.4.2.168-172.1997; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; Seijo LM, 2001, NEW ENGL J MED, V344, P740, DOI 10.1056/NEJM200103083441007; SHADICK NA, 1994, MEDICINE, V73, P161, DOI 10.1097/00005792-199405000-00005; Shah PL, 1999, EUR RESPIR J, V14, P1340, DOI 10.1183/09031936.99.14613409; Sheikh S, 1997, CHEST, V112, P1202, DOI 10.1378/chest.112.5.1202; Shum DKY, 2000, AM J RESP CRIT CARE, V162, P1925, DOI 10.1164/ajrccm.162.5.9907064; SILVA JRLE, 1989, THORAX, V44, P668, DOI 10.1136/thx.44.8.668; Singleton R, 2000, PEDIATR PULM, V29, P182, DOI 10.1002/(SICI)1099-0496(200003)29:3<182::AID-PPUL5>3.0.CO;2-T; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Swinson DR, 1997, BRIT J RHEUMATOL, V36, P689; TAMAOKI J, 1992, AM REV RESPIR DIS, V145, P548, DOI 10.1164/ajrccm/145.3.548; THOMAS RD, 1993, ACTA RADIOL, V34, P489; Tsang KW, 2000, CHEST, V117, P420, DOI 10.1378/chest.117.2.420; Tsang KWT, 1999, EUR RESPIR J, V13, P361, DOI 10.1183/09031936.99.13236199; Tsang KWT, 1998, AM J RESP CRIT CARE, V158, P723, DOI 10.1164/ajrccm.158.3.9710090; Tsang KWT, 1999, EUR RESPIR J, V14, P1206, DOI 10.1183/09031936.99.14512069; UMETSU DT, 1985, NEW ENGL J MED, V313, P1247, DOI 10.1056/NEJM198511143132002; vanderBruggenBogaarts BAHA, 1996, J COMPUT ASSIST TOMO, V20, P15, DOI 10.1097/00004728-199601000-00004; Wallace RJ, 1997, AM J RESP CRIT CARE, V156, pS1, DOI 10.1164/ajrccm.156.2.atsstatement; WESTCOTT JL, 1986, RADIOLOGY, V161, P665, DOI 10.1148/radiology.161.3.3786716; Wilson CB, 1997, AM J RESP CRIT CARE, V156, P536, DOI 10.1164/ajrccm.156.2.9607083; WONGYOUCHEONG JJ, 1992, CLIN RADIOL, V45, P256, DOI 10.1016/S0009-9260(05)80010-8; Yankaskas JR, 1998, CHEST, V113, P217, DOI 10.1378/chest.113.1.217	100	412	429	4	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					1383	1393		10.1056/NEJMra012519	http://dx.doi.org/10.1056/NEJMra012519			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546MZ	11986413				2022-12-28	WOS:000175279000008
J	Steinbrook, R				Steinbrook, R			Improving protection for research subjects	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		*AAHRPP, 2002, OP BUS READ ACC APPL; Angell M, 2000, NEW ENGL J MED, V342, P1516, DOI 10.1056/NEJM200005183422009; *ASS ACCR HUM RES, 2002, FIN STAND; *ASS AM MED COLL, 2001, TASK FORC FIN CONFL; BORROR KC, 2001, COMMUNICATION   1130; Burman WJ, 2001, ANN INTERN MED, V134, P152, DOI 10.7326/0003-4819-134-2-200101160-00016; Christian MC, 2002, NEW ENGL J MED, V346, P1405, DOI 10.1056/NEJM200205023461814; *DEP HHS, 1998, OE1019700193 DEP HHS; *DEP HHS, 2000, OE1019700197 DEP HHS; *GEN ACC OFF, 2001, GAO0289 GEN ACC OFF; HEINRICH J, 2001, GAO01775T GEN ACC OF; *I MED, 2000, GAOHEHS00155 GEN ACC; KRANISH M, 2002, BOSTON GLOBE    1222, pA1; LAMANTIA C, 2001, FINAL REPORT ADVERSE; *NAT BIOETH ADV CO, 2001, ETH POL ISS RES INV, V1; *NCQA, 2001, VA LAUNCH 1 EV ACCR; *NIH, 2002, FY 2003 PRES BUDG; *NIH, 2002, HUM SUBJ RES ENH PRO; *NY STAT DEP HLTH, 1996, CAS REP DEATH U ROCH; Shalala D, 2000, NEW ENGL J MED, V343, P808, DOI 10.1056/NEJM200009143431112; SOLOV D, 2001, CLEVELAND PLAIN 1221, pA1; Steinbrook R, 2002, NEW ENGL J MED, V346, P716, DOI 10.1056/NEJM200202283460924; 1991, CFR, V45, P46	23	80	82	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					1425	1430		10.1056/NEJM200205023461828	http://dx.doi.org/10.1056/NEJM200205023461828			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546MZ	11986426				2022-12-28	WOS:000175279000037
J	Zhu, S; Stavrovskaya, IG; Drozda, M; Kim, BYS; Ona, V; Li, MW; Sarang, S; Liu, AS; Hartley, DM; Du, CW; Gullans, S; Ferrante, RJ; Przedborski, S; Kristal, BS; Friedlander, RM				Zhu, S; Stavrovskaya, IG; Drozda, M; Kim, BYS; Ona, V; Li, MW; Sarang, S; Liu, AS; Hartley, DM; Du, CW; Gullans, S; Ferrante, RJ; Przedborski, S; Kristal, BS; Friedlander, RM			Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice	NATURE			English	Article							MITOCHONDRIAL PERMEABILITY TRANSITION; TRANSGENIC MOUSE MODEL; CELL-DEATH; ACTIVATION; DISEASE; DEGENERATION; EXPRESSION; CASPASE-1; APOPTOSIS; MUTATION	Minocycline mediates neuroprotection in experimental models of neurodegeneration. It inhibits the activity(1-6) of caspase-1, caspase-3, inducible form of nitric oxide synthetase (iNOS) and p38 mitogen-activated protein kinase (MAPK). Although minocycline does not directly inhibit these enzymes, the effects may result from interference with upstream mechanisms resulting in their secondary activation. Because the above-mentioned factors are important in amyotrophic lateral sclerosis (ALS), we tested minocycline in mice with ALS(7-9). Here we report that minocycline delays disease onset and extends survival in ALS mice. Given the broad efficacy of minocycline, understanding its mechanisms of action is of great importance. We find that minocycline inhibits mitochondrial permeability-transition-mediated cytochrome c release. Minocycline-mediated inhibition of cytochrome c release is demonstrated in vivo, in cells, and in isolated mitochondria. Understanding the mechanism of action of minocycline will assist in the development and testing of more powerful and effective analogues. Because of the safety record of minocycline, and its ability to penetrate the blood-brain barrier, this drug may be a novel therapy for ALS(10).	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg,Neuroapoptosis Lab, Boston, MA 02115 USA; Burke Med Res Inst, White Plains, NY 10605 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA; Columbia Univ, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Dept Pathol, New York, NY 10032 USA; Vedford VA Med Ctr, Ctr Geriatr Res Educ & Clin, Bedford, MA 01730 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Neurosci, New York, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Columbia University; Columbia University; Geriatric Research Education & Clinical Center; Boston University; Boston University; Boston University; Cornell University; Cornell University	Friedlander, RM (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg,Neuroapoptosis Lab, Boston, MA 02115 USA.		Friedlander, Robert M/A-2845-2016	Friedlander, Robert M/0000-0003-4423-9219; Kim, Betty Y.S./0000-0001-6890-8355				Almer G, 1999, J NEUROCHEM, V72, P2415, DOI 10.1046/j.1471-4159.1999.0722415.x; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BROGDEN RN, 1975, DRUGS, V9, P251, DOI 10.2165/00003495-197509040-00005; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guegn C, 2001, J NEUROSCI, V21, P6569, DOI 10.1523/JNEUROSCI.21-17-06569.2001; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Krasnikov BF, 1997, FEBS LETT, V419, P137, DOI 10.1016/S0014-5793(97)01450-6; Kristal BS, 2000, DEV NEUROSCI-BASEL, V22, P376, DOI 10.1159/000017463; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Lai J C, 1979, Methods Enzymol, V55, P51; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mejia ROS, 2001, NEUROSURGERY, V48, P1393, DOI 10.1097/00006123-200106000-00051; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Rowland LP, 2001, NEW ENGL J MED, V344, P1688, DOI 10.1056/NEJM200105313442207; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030	30	861	911	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	2002	417	6884					74	78		10.1038/417074a	http://dx.doi.org/10.1038/417074a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986668				2022-12-28	WOS:000175307200040
J	Alexander, MH; Capecchi, G; Werner, HJ				Alexander, MH; Capecchi, G; Werner, HJ			Theoretical study of the validity of the Born-Oppenheimer approximation in the Cl+H-2 -> HCl+H reaction	SCIENCE			English	Article							POTENTIAL-ENERGY SURFACE; CLASSICAL TRAJECTORY CALCULATIONS; THERMAL RATE-CONSTANT; SPIN-ORBIT; CL+H-2 REACTION; MOLECULAR-BEAM; F+H-2 REACTION; F+H-2->HF+H REACTION; ROTATIONAL STATES; RATE COEFFICIENTS	Reactivity of the excited spin-orbit state of Cl with H-2 to yield ground-state HCl products is forbidden by the Born-Oppenheimer (BO) approximation. We used new ab initio potential energy surfaces and exact quantum scattering calculations to explore the extent of electronic nonadiabaticity in this reaction. in direct contrast to recent experiments, we predict that the BO-allowed reaction of the ground spin-orbit state will be much more efficient than the BO-forbidden reaction of the excited spin-orbit state. Also, Coriolis coupling opens up an electronically nonadiabatic inelastic channel, which competes substantially with reaction.	Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA; Univ Maryland, Inst Phys Sci & Technol, College Pk, MD 20742 USA; Univ Stuttgart, Inst Theoret Chem, D-75069 Stuttgart, Germany	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park; University of Stuttgart	Alexander, MH (corresponding author), Univ Maryland, Dept Chem & Biochem, College Pk, MD 20742 USA.		Werner, Hans-Joachim/G-9509-2011	Werner, Hans-Joachim/0000-0002-0435-539X				Alagia M, 1996, SCIENCE, V273, P1519, DOI 10.1126/science.273.5281.1519; ALEXANDER MH, 1993, J CHEM PHYS, V99, P1752, DOI 10.1063/1.465292; Alexander MH, 2000, J CHEM PHYS, V113, P11084, DOI 10.1063/1.1326850; Allison T. C., 1996, GAS PHASE REACTION S, P111; Allison TC, 1996, J PHYS CHEM-US, V100, P13575, DOI 10.1021/jp960781j; Aoiz FJ, 1999, J CHEM PHYS, V111, P4013, DOI 10.1063/1.479703; Aoiz FJ, 2001, J CHEM PHYS, V115, P2074, DOI 10.1063/1.1385155; Aoiz FJ, 1996, J PHYS CHEM-US, V100, P18108, DOI 10.1021/jp962059r; Aquilanti V, 1998, J CHEM PHYS, V109, P3805, DOI 10.1063/1.476980; Balucani N, 2000, CHEM PHYS LETT, V328, P500, DOI 10.1016/S0009-2614(00)00947-7; Bian WS, 2000, J CHEM PHYS, V112, P220, DOI 10.1063/1.480574; CAPECCHI G, UNPUB; Casavecchia P, 2000, REP PROG PHYS, V63, P355, DOI 10.1088/0034-4885/63/3/203; Castillo JF, 1996, J CHEM PHYS, V104, P6531, DOI 10.1063/1.471373; DAGDIGIAN PJ, 1987, CHEM REV, V87, P1, DOI 10.1021/cr00077a001; Dong F, 2001, J CHEM PHYS, V115, P1197, DOI 10.1063/1.1378834; DONOVAN RJ, 1970, CHEM REV, V70, P489, DOI 10.1021/cr60266a003; FAUBEL M, 1994, J CHEM PHYS, V101, P2106, DOI 10.1063/1.467718; Hartke B, 1997, CHEM PHYS LETT, V280, P430, DOI 10.1016/S0009-2614(97)01209-8; KNOWLES PJ, 1988, CHEM PHYS LETT, V145, P514, DOI 10.1016/0009-2614(88)87412-8; Lee SH, 1999, J CHEM PHYS, V110, P8229, DOI 10.1063/1.478735; Lee SH, 1999, J CHEM PHYS, V111, P6253, DOI 10.1063/1.479930; LEFEBVREBRION H, 1986, PERTURBATIONS SPECTR, P118; Manthe U, 1999, CHEM PHYS LETT, V313, P647, DOI 10.1016/S0009-2614(99)00998-7; Mielke SL, 1996, J PHYS CHEM-US, V100, P13588, DOI 10.1021/jp960782b; Moore C, 1971, 35 NSRDSNBS; NEUMARK DM, 1985, J CHEM PHYS, V82, P3045, DOI 10.1063/1.448254; POUILLY B, 1985, J PHYS B-AT MOL OPT, V18, P1953, DOI 10.1088/0022-3700/18/10/013; REBENTROST F, 1975, J CHEM PHYS, V63, P3737, DOI 10.1063/1.431865; SCHATZ GC, 1995, J PHYS CHEM-US, V99, P7522, DOI 10.1021/j100019a038; Shen CS, 2001, CHEM PHYS, V272, P61, DOI 10.1016/S0301-0104(01)00445-1; SHULER KE, 1953, J CHEM PHYS, V21, P624, DOI 10.1063/1.1698979; Skouteris D, 1999, SCIENCE, V286, P1713, DOI 10.1126/science.286.5445.1713; Skouteris D, 2001, J CHEM PHYS, V114, P10662, DOI 10.1063/1.1372764; Skouteris D, 2000, COMPUT PHYS COMMUN, V133, P128, DOI 10.1016/S0010-4655(00)00167-3; Stark K, 1996, J CHEM PHYS, V104, P6515, DOI 10.1063/1.471372; Wang HB, 1997, J CHEM PHYS, V107, P7194, DOI 10.1063/1.474959; WERNER HJ, 1988, J CHEM PHYS, V89, P5803, DOI 10.1063/1.455556; Yang BH, 2000, J CHEM PHYS, V113, P1434, DOI 10.1063/1.481933	39	145	145	2	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					715	718		10.1126/science.1070472	http://dx.doi.org/10.1126/science.1070472			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976448				2022-12-28	WOS:000175281700048
J	Kruger, J; Thomas, CM; Golstein, C; Dixon, MS; Smoker, M; Tang, SK; Mulder, L; Jones, JDG				Kruger, J; Thomas, CM; Golstein, C; Dixon, MS; Smoker, M; Tang, SK; Mulder, L; Jones, JDG			A tomato cysteine protease required for Cf-2-dependent disease resistance and suppression of autonecrosis	SCIENCE			English	Article							CLADOSPORIUM-FULVUM; DEFENSE; PLANTS; ACTIVATION; DROSOPHILA; PROTEINS; GENES; CF-2	Little is known of how plant disease resistance (R) proteins recognize pathogens and activate plant defenses. Rcr3 is specifically required for the function of Cf-2, a Lycopersicon pimpinellifolium gene bred into cultivated tomato (Lycopersicon esculentum) for resistance to Cladosporium fulvum. Rcr3 encodes a secreted papain-like cysteine endoprotease. Genetic analysis shows Rcr3 is allelic to the L. pimpinellifolium Ne gene, which suppresses the Cf-2-dependent autonecrosis conditioned by its L. esculentum allele, ne (necrosis). Rcr3 alleles from these two species encode proteins that differ by only seven amino acids, Possible roles of Rcr3 in Cf-2-dependent defense and autonecrosis are discussed.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Southampton, Sch Biol Sci, Southampton SO16 7PX, Hants, England; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of East Anglia; Indiana University System; Indiana University Bloomington; University of Southampton; University of North Carolina; University of North Carolina Chapel Hill	Jones, JDG (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England.		Jones, Jonathan DG/J-5129-2012	Jones, Jonathan DG/0000-0002-4953-261X; Smoker, Matthew/0000-0002-7003-616X				Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; DEWIT PJGM, 1986, PHYSIOL MOL PLANT P, V29, P159, DOI 10.1016/S0048-4059(86)80018-2; Dixon MS, 1998, PLANT CELL, V10, P1915, DOI 10.1105/tpc.10.11.1915; Dixon MS, 1996, CELL, V84, P451, DOI 10.1016/S0092-8674(00)81290-8; Dixon MS, 2000, P NATL ACAD SCI USA, V97, P8807, DOI 10.1073/pnas.97.16.8807; Estelle M, 2001, CURR OPIN PLANT BIOL, V4, P254, DOI 10.1016/S1369-5266(00)00169-2; Groves MR, 1996, STRUCTURE, V4, P1193, DOI 10.1016/S0969-2126(96)00127-X; HOLMANS PA, UNPUB; Joosten MHAJ, 1999, ANNU REV PHYTOPATHOL, V37, P335, DOI 10.1146/annurev.phyto.37.1.335; LANGFORD AN, 1948, CAN J RES C, V26, P35, DOI 10.1139/cjr48c-006; LeMosy EK, 2001, P NATL ACAD SCI USA, V98, P5055, DOI 10.1073/pnas.081026598; Levashina EA, 1999, SCIENCE, V285, P1917, DOI 10.1126/science.285.5435.1917; Li J, 2001, P NATL ACAD SCI USA, V98, P5916, DOI 10.1073/pnas.091065998; LUDERER R, UNPUB; MICHAUD D, 1993, ELECTROPHORESIS, V14, P94, DOI 10.1002/elps.1150140117; Minami A, 1995, PLANT CELL PHYSIOL, V36, P1599; Pechan T, 2000, PLANT CELL, V12, P1031, DOI 10.1105/tpc.12.7.1031; Romeis T, 2001, EMBO J, V20, P5556, DOI 10.1093/emboj/20.20.5556; Solomon M, 1999, PLANT CELL, V11, P431, DOI 10.1105/tpc.11.3.431; TANG S, 1998, THESIS U E ANGLIA; Vervoort J, 1997, FEBS LETT, V404, P153, DOI 10.1016/S0014-5793(97)00117-8	21	306	317	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					744	747		10.1126/science.1069288	http://dx.doi.org/10.1126/science.1069288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976458				2022-12-28	WOS:000175281700058
J	Nishimura, EK; Jordan, SA; Oshima, H; Yoshida, H; Osawa, M; Moriyama, M; Jackson, IJ; Barrandon, Y; Miyachi, Y; Nishikawa, S				Nishimura, EK; Jordan, SA; Oshima, H; Yoshida, H; Osawa, M; Moriyama, M; Jackson, IJ; Barrandon, Y; Miyachi, Y; Nishikawa, S			Dominant role of the niche in melanocyte stem-cell fate determination	NATURE			English	Article							C-KIT ANTIBODY; EXPRESSION; MIGRATION; SKIN; MICE; DIFFERENTIATION; PROLIFERATION; MELANOGENESIS; EMBRYOS; WAVE	Stem cells-which have the capacity to self-renew and generate differentiated progeny-are thought to be maintained in a specific environment known as a niche(1-3). The localization of the niche, however, remains largely obscure for most stem-cell systems. Melanocytes (pigment cells) in hair follicles proliferate and differentiate closely coupled to the hair regeneration cycle(4). Here we report that stem cells of the melanocyte lineage can be identified, using Dct-lacZ transgenic mice(5,6), in the lower permanent portion of mouse hair follicles throughout the hair cycle. It is only the population in this region that fulfils the criteria for stem cells, being immature, slow cycling, self-maintaining and fully competent in regenerating progeny on activation at early anagen (the growing phase of hair follicles). Induction of the repigmentation process in K14-steel factor transgenic mice(7) demonstrates that a portion of amplifying stem-cell progeny can migrate out from the niche and retain sufficient self-renewing capability to function as stem cells after repopulation into vacant niches. Our data indicate that the niche has a dominant role in the fate determination of melanocyte stem-cell progeny.	Kyoto Univ, Grad Sch Med, Dept Mol Genet, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, Kyoto 6068507, Japan; Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Ecole Normale Super, F-75230 Paris 05, France; Riken Ctr Dev Biol, Chuo Ku, Kobe, Hyogo 6500047, Japan	Kyoto University; Kyoto University; University of Edinburgh; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); RIKEN	Nishikawa, S (corresponding author), Kyoto Univ, Grad Sch Med, Dept Mol Genet, Sakyo Ku, Shogoin Kawaharacho 53, Kyoto 6068507, Japan.			Osawa, Masatake/0000-0002-5318-9826; Jackson, Ian/0000-0001-6526-0688				Botchkareva NV, 2001, FASEB J, V15, P645, DOI 10.1096/fj.00-0368com; CHASE HB, 1951, PHYSIOL ZOOL, V24, P1; COOK AG, 1958, EMBRYOLOGY, V6, P530; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; FITZPATRICK TB, 1987, DERMATOLOGY GEN MED, P810; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; Jordan SF, 2000, MECH DEVELOP, V92, P135, DOI 10.1016/S0925-4773(99)00332-9; Kunisada T, 1998, DEVELOPMENT, V125, P2915; Kunisada T, 1998, J EXP MED, V187, P1565, DOI 10.1084/jem.187.10.1565; LAVKER RM, 1993, J INVEST DERMATOL, V101, P16; LOEFFLER M, 1997, STEM CELLS, P5; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; MANN SJ, 1962, ANAT RECORD, V144, P135, DOI 10.1002/ar.1091440208; MAYER TC, 1973, DEV BIOL, V34, P39, DOI 10.1016/0012-1606(73)90337-0; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; Nishimura EK, 1999, DEV BIOL, V215, P155, DOI 10.1006/dbio.1999.9478; OGAWA M, 1993, DEVELOPMENT, V117, P1089; OKURA M, 1995, J INVEST DERMATOL, V105, P322, DOI 10.1111/1523-1747.ep12319939; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; SCHOFIELD R, 1978, BLOOD CELLS, V4, P7; SILVER AF, 1969, EXPERIENTIA, V25, P299, DOI 10.1007/BF02034407; Silvers WK, 1979, COAT COLOURS MICE MO; Slominski A, 1996, J INVEST DERMATOL, V106, P1203, DOI 10.1111/1523-1747.ep12348479; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; SUGIYAMA S, 1979, J ULTRA MOL STRUCT R, V67, P40, DOI 10.1016/S0022-5320(79)80016-7; Tobin DJ, 1998, J INVEST DERMATOL, V111, P941, DOI 10.1046/j.1523-1747.1998.00417.x; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Xie T, 2000, SCIENCE, V290, P328, DOI 10.1126/science.290.5490.328; Yoshida H, 1996, DEV DYNAM, V207, P222; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689	30	621	661	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					854	860		10.1038/416854a	http://dx.doi.org/10.1038/416854a			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976685				2022-12-28	WOS:000175163800053
J	MacDonald, HR				MacDonald, HR			Immunology: T before NK	SCIENCE			English	Editorial Material							CD1D TETRAMERS; CELLS		Ludwig Inst Canc Res, CH-1066 Epalinges, Switzerland	Ludwig Institute for Cancer Research	MacDonald, HR (corresponding author), Ludwig Inst Canc Res, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland.							Bendelac A, 2001, NAT REV IMMUNOL, V1, P177, DOI 10.1038/35105052; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Benlagha K, 2000, J EXP MED, V191, P1895, DOI 10.1084/jem.191.11.1895; Benlagha K, 2002, SCIENCE, V296, P553, DOI 10.1126/science.1069017; Gapin L, 2001, NAT IMMUNOL, V2, P971, DOI 10.1038/ni710; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Ikarashi Y, 2001, J EXP MED, V194, P1179, DOI 10.1084/jem.194.8.1179; MacDonald HR, 1998, J EXP MED, V187, P2109, DOI 10.1084/jem.187.12.2109; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; MOSSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145; Pellicci DG, 2002, J EXP MED, V195, P835, DOI 10.1084/jem.20011544	11	13	15	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					481	482		10.1126/science.1071492	http://dx.doi.org/10.1126/science.1071492			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964466				2022-12-28	WOS:000175179400031
J	Aversano, T; Aversano, LT; Passamani, E; Knatterud, GL; Terrin, ML; Williams, DO; Forman, SA				Aversano, T; Aversano, LT; Passamani, E; Knatterud, GL; Terrin, ML; Williams, DO; Forman, SA		Atlant Cardiovascular Patient Outcomes	Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASSOCIATION TASK-FORCE; PRIMARY ANGIOPLASTY; PERFORATION; MANAGEMENT; GUIDELINES; COMMITTEE	Context Trials comparing primary percutaneous coronary intervention (PCI) and thrombolytic therapy for treatment of acute myocardial infarction (MI) suggest primary PC] is the superior therapy, although they differ with respect to the durability of benefit. Because PCI is often limited to hospitals that have on-site cardiac surgery programs, most acute MI patients do not have access to this therapy. Objective To determine whether treatment of acute MI with primary PCI is superior to thrombolytic therapy at hospitals without on-site cardiac surgery and, if so, whether superiority is durable. Design The Atlantic Cardiovascular Patient Outcomes Research Team (C-PORT) trial, a prospective, randomized trial conducted from July 1996 through December 1999. Setting Eleven community hospitals in Massachusetts and Maryland without on-site cardiac surgery or extant PCI programs. Patients Four hundred fifty-one thrombolytic-eligible patients with acute MI of less than 12 hours' duration associated with ST-segment elevation on electrocardiogram. Interventions After a formal primary PC[ development program was completed at all sites, patients were randomly assigned to receive primary PCI (n =225) or accelerated tissue plasminogen activator (bolus dose of 15 mg and an infusion of 0.75 mg/kg for 30 minutes followed by 0.5 mg/kg for 60 minutes; n =226). After initiation of assigned treatment, all care was determined by treating physicians. Main Outcome Measures Six-month composite incidence of death, recurrent MI, and stroke; median hospital length of stay. Results The incidence of the composite end point was reduced in the primary PCI group at 6 weeks (10.7% vs 17.7%; P=.03) and 6 months (12.4% vs 19.9%; P=.03) after index MI. Six-month rates for individual outcomes were 6.2% vs 7.1% for death (P=72), 5.3% vs 10.6% for recurrent MI (P=.04), and 2.2% vs 4.0% for stroke (P=.28) for primary PCI vs thrombolytic therapy, respectively. Median length of stay was also reduced in the primary PCI group (4.5 vs 6.0 days; P=.02). Conclusions Compared with thrombolytic therapy, treatment of patients with primary PCI at hospitals without on-site cardiac surgery is associated with better clinical outcomes for 6 months after index MI and a shorter hospital stay.	Johns Hopkins Med Inst, Baltimore, MD 21205 USA; Suburban Hosp, Bethesda, MD USA; Maryland Med Res Inst, Baltimore, MD USA; Rhode Isl Hosp, Providence, RI USA; Brown Univ, Providence, RI 02912 USA	Johns Hopkins University; Johns Hopkins Medicine; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University	Aversano, T (corresponding author), Johns Hopkins Univ Hosp, Blalock 524,600 N Wolfe St, Baltimore, MD 21210 USA.							Betriu A, 1997, NEW ENGL J MED, V336, P1621; Cannon CP, 2000, JAMA-J AM MED ASSOC, V283, P2941, DOI 10.1001/jama.283.22.2941; ELLIS SG, 1994, CIRCULATION, V90, P2725, DOI 10.1161/01.CIR.90.6.2725; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Magid DJ, 2000, JAMA-J AM MED ASSOC, V284, P3131, DOI 10.1001/jama.284.24.3131; Nunn CM, 1999, J AM COLL CARDIOL, V33, P640, DOI 10.1016/S0735-1097(98)00622-6; Ramsdale DR, 1998, CATHETER CARDIO DIAG, V45, P310, DOI 10.1002/(SICI)1097-0304(199811)45:3<310::AID-CCD20>3.3.CO;2-A; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; RYAN TJ, 1993, J AM COLL CARDIOL, V22, P2033, DOI 10.1016/0735-1097(93)90794-2; Smith SC, 2001, J AM COLL CARDIOL, V37, P2215, DOI 10.1016/S0735-1097(01)01344-4; Stone GW, 1997, J AM COLL CARDIOL, V29, P901, DOI 10.1016/S0735-1097(97)00041-7; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; Zijlstra F, 1999, NEW ENGL J MED, V341, P1413, DOI 10.1056/NEJM199911043411901; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	18	261	278	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2002	287	15					1943	1951		10.1001/jama.287.15.1943	http://dx.doi.org/10.1001/jama.287.15.1943			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NC	11960536	Bronze			2022-12-28	WOS:000174989800022
J	Hasty, P; Vijg, J				Hasty, P; Vijg, J			Aging - Genomic priorities in aging	SCIENCE			English	Editorial Material							REPAIR GENE XPA; MICE; DEFICIENT		Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Barshop Ctr Longev & Aging Studies, San Antonio, TX 78245 USA; S Texas Vet Hlth Care Syst, Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	Hasty, P (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA.			Hasty, Paul/0000-0003-3046-0131				de Boer J, 1998, MOL CELL, V1, P981, DOI 10.1016/S1097-2765(00)80098-2; de Boer J, 2002, SCIENCE, V296, P1276, DOI 10.1126/science.1070174; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Giese H, 1999, ONCOGENE, V18, P1257, DOI 10.1038/sj.onc.1202404; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Lim DS, 2000, MOL CELL BIOL, V20, P3772, DOI 10.1128/MCB.20.11.3772-3780.2000; Masoro EJ, 1995, HDB PHYSL, P3; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770	11	32	37	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 17	2002	296	5571					1250	1251		10.1126/science.1071808	http://dx.doi.org/10.1126/science.1071808			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	554BL	11951000				2022-12-28	WOS:000175713000033
J	Nathan, DG				Nathan, DG			Careers in translational clinical research - Historical perspectives, future challenges	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INSTITUTES-OF-HEALTH; INVESTIGATOR; SCIENTIST		Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute	Nathan, DG (corresponding author), Dana Farber Canc Inst, 44 Binney St,Room D1642, Boston, MA 02115 USA.	david_nathan@dfci.harvard.edu			NATIONAL CANCER INSTITUTE [P30CA006516] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054785] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA06516] Funding Source: Medline; NCRR NIH HHS [M01 RR02172] Funding Source: Medline; NHLBI NIH HHS [P50 HL54785] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahrens E.H., 1992, CRISIS CLIN RES OVER; *ASS AM MED COLL, 2001, 2001 MED SCH GRAD QU; *ASS MA MED COLL, 1999, HLTH PUBL ENS FUT CL, V1; Biagioli Mario., 2000, J COLL UNIV LAW, V27, P83; Blumenthal D, 1996, HEALTH AFFAIR, V15, P200, DOI 10.1377/hlthaff.15.2.200; BUSH V, 1980, 3 CENTURIES SCI AM S, V1; CULLITON BJ, 1995, NAT MED, V1, P281, DOI 10.1038/nm0495-281; EVANS RM, 1993, ED PHYSICIAN SCH; GILL GN, 1984, AM SCHOLAR, V53, P353; Goldstein JL, 1997, J CLIN INVEST, V99, P2803, DOI 10.1172/JCI119470; HIRSCH J, 2000, ROCK U CENT HIST C R; Ley TJ, 2002, NEW ENGL J MED, V346, P368, DOI 10.1056/NEJM200201313460515; MIDER GB, 1976, ADV AM MED ESSAYS BI, V2, P806; Moy E, 1997, JAMA-J AM MED ASSOC, V278, P217, DOI 10.1001/jama.278.3.217; Nathan D, 2001, NAT REV CANCER, V1, P240, DOI 10.1038/35106102; Nathan DG, 2000, NAT MED, V6, P1201, DOI 10.1038/81282; Nathan DG, 2002, NEW ENGL J MED, V346, P372, DOI 10.1056/NEJM200201313460516; Nathan DG, 1998, JAMA-J AM MED ASSOC, V280, P1427, DOI 10.1001/jama.280.16.1427; *NIH DIR PAN CLIN, 1997, REP ADV COMM NIH DIR; Schrier RW, 1997, ACAD MED, V72, P589, DOI 10.1097/00001888-199707000-00010; SHANNON JA, 1967, J MED EDUC, V42, P97, DOI 10.1097/00001888-196702000-00001; SHANNON JA, 1976, J MED EDUC, V51, P1; Shine KI, 1997, JAMA-J AM MED ASSOC, V278, P245, DOI 10.1001/jama.278.3.245; Shulman LE, 1996, ACAD MED, V71, P362, DOI 10.1097/00001888-199604000-00013; SWAIN DC, 1962, SCIENCE, V138, P1233, DOI 10.1126/science.138.3546.1233; Thompson JN, 1997, JAMA-J AM MED ASSOC, V278, P241, DOI 10.1001/jama.278.3.241; Williams GH, 1997, JAMA-J AM MED ASSOC, V278, P227, DOI 10.1001/jama.278.3.227; WYNGAARDEN JB, 1979, NEW ENGL J MED, V301, P1254, DOI 10.1056/NEJM197912063012303; [No title captured]; 2002, NIH HIST DATABASE	30	77	78	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	2002	287	18					2424	2427		10.1001/jama.287.18.2424	http://dx.doi.org/10.1001/jama.287.18.2424			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548PF	11988063				2022-12-28	WOS:000175397000031
J	Bayat, A				Bayat, A			Science, medicine, and the future - Bioinformatics	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GENOME SEQUENCE; BIOLOGY		Univ Manchester, Ctr Integrated Genom Med Res, Manchester M13 9PT, Lancs, England	University of Manchester	Bayat, A (corresponding author), Univ Manchester, Ctr Integrated Genom Med Res, Manchester M13 9PT, Lancs, England.	ardeshir.bayat@man.ac.uk		BAYAT, ARDESHIR/0000-0002-4116-6491				Benton D, 1996, TRENDS BIOTECHNOL, V14, P261, DOI 10.1016/0167-7799(96)10037-8; Burley SK, 1999, NAT GENET, V23, P151, DOI 10.1038/13783; Butler D, 2001, NATURE, V409, P758, DOI 10.1038/35057400; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DEBOUK C, 2000, ANN REV PHARM TOXICO, V10, P193; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Graeber TG, 2001, NAT GENET, V29, P295, DOI 10.1038/ng755; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Maggio ET, 2001, TRENDS BIOTECHNOL, V19, P266, DOI 10.1016/S0167-7799(01)01666-3; Myers EW, 2000, SCIENCE, V287, P2196, DOI 10.1126/science.287.5461.2196; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Stein L, 2001, NAT REV GENET, V2, P493, DOI 10.1038/35080529; Tsoka S, 2000, FEBS LETT, V480, P42, DOI 10.1016/S0014-5793(00)01776-2; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	19	69	77	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 27	2002	324	7344					1018	1022		10.1136/bmj.324.7344.1018	http://dx.doi.org/10.1136/bmj.324.7344.1018			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547UP	11976246	Green Published			2022-12-28	WOS:000175350900024
J	Channer, K; Morris, F				Channer, K; Morris, F			ABC of clinical electrocardiography - Myocardial ischaemia	BRITISH MEDICAL JOURNAL			English	Article									Royal Hallamshire Hosp, Sheffield, S Yorkshire, England; No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England	University of Sheffield; Northern General Hospital	Channer, K (corresponding author), Royal Hallamshire Hosp, Glossop Rd, Sheffield, S Yorkshire, England.								0	24	26	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 27	2002	324	7344					1023	1026		10.1136/bmj.324.7344.1023	http://dx.doi.org/10.1136/bmj.324.7344.1023			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547UP	11976247	Green Published			2022-12-28	WOS:000175350900025
J	Douglass, J; Aroni, R; Goeman, D; Stewart, K; Sawyer, S; Thien, F; Abramson, M				Douglass, J; Aroni, R; Goeman, D; Stewart, K; Sawyer, S; Thien, F; Abramson, M			A qualitative study of action plans for asthma	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT PLANS; ADULT ASTHMA; MEDICATIONS	Objectives To investigate the perspectives of patients with asthma on die use of all action plan and the implementation of this plan during an asthma attack that culminated in a visit to an emergency department. Design Qualitative Study. Setting Tertiary teaching hospital, suburban hospital, and rural hospital. Participants 62 patients aged 18 to 69 years who presented to an emergency department with asthma over a two month period. Results 29 participants described having action plans given to them by their doctors. Most patients with action plans reinterpreted their plan from the perspective of their own experiences with asthma. 33 patients did not have an action plan, the most common reason being that they had not been given one by their doctor. Sonic Occupational groups were significantly less likely to have been given an action plan by their doctor than others. Most patients with an action plan found them useful for management of their asthma. Conclusions Action plans were viewed positively by patients. Participants modified their prescribed plan according to their experience of asthma. To facilitate the implementation of a prescribed action plan, doctors laced to acknowledge and include the patient's personal experience of their disease.	Alfred Hosp, Dept Allergy Asthma & Immunol, Prahran, Vic 3181, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Prahran, Vic 3181, Australia; La Trobe Univ, Sch Publ Hlth, Bundoora, Vic 3083, Australia; Cooperat Res Ctr Asthma, Camperdown, NSW 2050, Australia; Monash Univ, Victorian Coll Pharm, Parkville, Vic 3052, Australia; Univ Melbourne, Parkville, Vic 3052, Australia; Royal Childrens Hosp, Ctr Adolescent Hlth, Parkville, Vic 3052, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; La Trobe University; Monash University; University of Melbourne; Royal Children's Hospital Melbourne	Douglass, J (corresponding author), Alfred Hosp, Dept Allergy Asthma & Immunol, Prahran, Vic 3181, Australia.		Abramson, Michael/AAQ-2671-2020	Abramson, Michael/0000-0002-9954-0538; Thien, Francis/0000-0003-0925-6566; Douglass, Jo/0000-0002-1200-8048				Abramson MJ, 2001, AM J RESP CRIT CARE, V163, P12, DOI 10.1164/ajrccm.163.1.9910042; Allen RM, 1998, J ASTHMA, V35, P537, DOI 10.3109/02770909809048956; Australian Bureau of Statistics, 1997, ASCO AUSTR STAND CLA; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954, DOI 10.1183/09031936.94.07050954; Clark NM, 2000, BMJ-BRIT MED J, V320, P572, DOI 10.1136/bmj.320.7234.572; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; Fontana A., 1994, HDB QUALITATIVE RES, P361; GIBSON PG, 2000, COCHRANE LIB; GIBSON PG, 2000, CVOCHRANE LIB; GIBSON PG, 1998, COCHRANE LIB; *GLOB IN ASTHM, 2001, ASTHM MAN PREV PRACT; Graham I, 1996, LANCET, V347, P4, DOI 10.1016/S0140-6736(96)91550-0; Jones A, 2000, BMJ-BRIT MED J, V321, P1507, DOI 10.1136/bmj.321.7275.1507; MacDougall C, 1997, QUAL HEALTH RES, V7, P532, DOI 10.1177/104973239700700407; Marks GB, 2000, MED J AUSTRALIA, V173, P407, DOI 10.5694/j.1326-5377.2000.tb139268.x; *NAT ASTHM COUNC A, 2002, ASTHM MAN HDB 2002; Ruffin R, 2001, IMMUNOL CELL BIOL, V79, P191, DOI 10.1046/j.1440-1711.2001.00991.x; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	20	76	76	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 27	2002	324	7344					1003	1005		10.1136/bmj.324.7344.1003	http://dx.doi.org/10.1136/bmj.324.7344.1003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547UP	11976240	Bronze, Green Published			2022-12-28	WOS:000175350900018
J	Garcia-Moreno, C				Garcia-Moreno, C			Dilemmas and opportunities for an appropriate health-service response to violence against women	LANCET			English	Article							INTIMATE PARTNER VIOLENCE; PRIMARY-CARE PHYSICIANS; DOMESTIC VIOLENCE; FAMILY VIOLENCE; BATTERED WOMEN; ABUSE; IDENTIFICATION; MANAGEMENT; PROVIDERS; EMERGENCY	This article is an overview of the role of health services in secondary and tertiary prevention of intimate partner violence. In it, I review the evidence, which comes mostly from developed countries, on the effectiveness and limitations of in-service training programmes to identify and care for women who have experienced intimate partner violence. I also discuss recent Initiatives in developing countries to integrate concerns on gender-based violence into health-care services at different levels, some of the dilemmas and challenges posed by the current approaches to intimate partner violence, and recommendations for future interventions.	WHO, Dept Gender & Womens Hlth, CH-1211 Geneva, Switzerland	World Health Organization	Garcia-Moreno, C (corresponding author), WHO, Dept Gender & Womens Hlth, 20 Ave Appia, CH-1211 Geneva, Switzerland.							*AM COLL OBST GYN, 1993, ACOG TECHN B, V209; BAUER HM, 1995, CAMB Q HEALTHC ETHIC, V4, P459, DOI 10.1017/S0963180100006289; *BRIT MED ASS, 1998, DOM VIOL HLTH CAR IS; BROWN R, 1992, JAMA-J AM MED ASSOC, V267, P3184; Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; Campbell JC, 2001, ACAD EMERG MED, V8, P131, DOI 10.1111/j.1553-2712.2001.tb01277.x; Cole TB, 2000, JAMA-J AM MED ASSOC, V284, P551, DOI 10.1001/jama.284.5.551; Covington DL, 1997, J ADOLESCENT HEALTH, V21, P18, DOI 10.1016/S1054-139X(97)00007-4; Davies J, 1996, Aust N Z J Ment Health Nurs, V5, P20; DOLIVEIRA AFP, IN PRESS LANCET; Gerbert B, 1999, ANN INTERN MED, V131, P578, DOI 10.7326/0003-4819-131-8-199910190-00005; Gielen AC, 2000, AM J PREV MED, V19, P279, DOI 10.1016/S0749-3797(00)00234-8; GRISSO JA, IN PRESS J WOMENS HL; Hadley S M, 1995, Womens Health Issues, V5, P189, DOI 10.1016/1049-3867(95)00055-0; HAQUE YA, IN PRESS J OBSTET GY; Jacobs T, 2001, HLTH SECTOR RESPONSE; Janssen PA, 1998, WOMEN HEALTH ISS, V8, P317, DOI 10.1016/S1049-3867(98)00023-1; Jewkes R, 2002, LANCET, V359, P1423, DOI 10.1016/S0140-6736(02)08357-5; Kim J, 2002, SOC SCI MED, V54, P1243, DOI 10.1016/S0277-9536(01)00093-4; Landenburger K, 1989, Issues Ment Health Nurs, V10, P209, DOI 10.3109/01612848909140846; Larkin GL, 1999, ANN EMERG MED, V33, P669, DOI 10.1016/S0196-0644(99)70196-4; MCFARLANE J, 1992, JAMA-J AM MED ASSOC, V267, P3176, DOI 10.1001/jama.267.23.3176; McFarlane J, 1994, MCN Am J Matern Child Nurs, V19, P321; MCLEER SV, 1989, AM J PUBLIC HEALTH, V79, P65, DOI 10.2105/AJPH.79.1.65; MCLEER SV, 1989, ANN EMERG MED, V18, P651, DOI 10.1016/S0196-0644(89)80521-9; OCONNOR M, IN PRESS J OBSTET GY; *PAN AM HLTH ORG, 1998, RUT CRIT QUE SIG MUJ; Parsons LH, 1997, OBSTET GYNECOL, V90, P596, DOI 10.1016/S0029-7844(97)00420-1; Plichta S, 1992, Womens Health Issues, V2, P154, DOI 10.1016/S1049-3867(05)80264-6; RAMOSJIMENEZ P, 2001, INTEGRATING DOMESTIC; Rodriguez MA, 1999, JAMA-J AM MED ASSOC, V282, P468, DOI 10.1001/jama.282.5.468; Rodriguez MA, 1996, ARCH FAM MED, V5, P153, DOI 10.1001/archfami.5.3.153; *ROYAL COLL MIDW, 1997, 19 ROYAL COLL MIDW; SUGG NK, 1992, JAMA-J AM MED ASSOC, V267, P3157, DOI 10.1001/jama.267.23.3157; Sugg NK, 1999, ARCH FAM MED, V8, P301, DOI 10.1001/archfami.8.4.301; Thompson RS, 2000, AM J PREV MED, V19, P253, DOI 10.1016/S0749-3797(00)00231-2; TILDEN VP, 1994, AM J PUBLIC HEALTH, V84, P628, DOI 10.2105/AJPH.84.4.628; Waalen J, 2000, AM J PREV MED, V19, P230, DOI 10.1016/S0749-3797(00)00229-4; WARSHAW C, 1993, J WOMENS HEALTH, V2, P73; Wiist WH, 1999, AM J PUBLIC HEALTH, V89, P1217, DOI 10.2105/AJPH.89.8.1217; *WOM AID, 1999, VIOL WOM HLTH ISS RE; Wues J, VIOLENCE WOMEN, V5, P110, DOI DOI 10.1177/1077801299005002002; 1991, MMWR MORB MORTAL WKL, V40, P428	43	123	131	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1509	1514		10.1016/S0140-6736(02)08417-9	http://dx.doi.org/10.1016/S0140-6736(02)08417-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	546NA	11988263				2022-12-28	WOS:000175279100027
J	Paine, RT				Paine, RT			Trophic controt of production in a rocky intertidal community	SCIENCE			English	Article							ECOSYSTEM PROCESSES; BIODIVERSITY; COMPETITION; DIVERSITY	In the low intertidal zone at Tatoosh Island, Washington, United States, minimal estimates of primary production can vary from 0 to an average of 86 kilograms of wet mass per square meter per year when the grazing assemblage is manipulated. Highly productive annual kelps (Laminariales) replace less productive perennial species when macroscopic grazers are reduced or absent, resulting in monodominant assemblages of Alaria marginata. Experiments were repeated in seven consecutive years. Increased species richness makes no significant additional contribution to annual production. Rather, a competitively superior species is favored when its enemies are reduced, suggesting that terrestrial perspectives on the rote of biodiversity that are developed without considering consumers may not be general.	Univ Washington, Dept Zool, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Paine, RT (corresponding author), Univ Washington, Dept Zool, Seattle, WA 98195 USA.							[Anonymous], 1997, NATURES SERVICES; DAYTON PK, 1975, ECOL MONOGR, V45, P137, DOI 10.2307/1942404; Druehl L. P., 1981, BIOL SEAWEEDS, V17, P306; DUGGINS DO, 1985, OECOLOGIA, V67, P183, DOI 10.1007/BF00384282; Emmerson MC, 2001, NATURE, V411, P73, DOI 10.1038/35075055; EWEL JJ, 1991, ECOL APPL, V1, P289, DOI 10.2307/1941758; Gleason H.A., 1926, B TORREY BOT CLUB, V53, P7, DOI DOI 10.2307/2479933; Grime JP, 1997, SCIENCE, V277, P1260, DOI 10.1126/science.277.5330.1260; HART TB, 1989, AM NAT, V133, P613, DOI 10.1086/284941; Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123; Hooper DU, 1997, SCIENCE, V277, P1302, DOI 10.1126/science.277.5330.1302; HUBBLE SP, 2001, UNIFIED THEORY BIODI; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; KINZIE AP, 2001, FUNCTIONAL COSNEQUEN, P1; KVITEK RG, 1989, MAR MAMMAL SCI, V5, P266, DOI 10.1111/j.1748-7692.1989.tb00340.x; LEIGH EG, 1987, P NATL ACAD SCI USA, V84, P1314, DOI 10.1073/pnas.84.5.1314; Loreau M, 2001, NATURE, V412, P72, DOI 10.1038/35083573; MACARTHUR R, 1962, AM NAT, V96, P167, DOI 10.1086/282219; MANN KH, 1973, SCIENCE, V182, P975, DOI 10.1126/science.182.4116.975; Markel RW, 1998, MAR ECOL PROG SER, V166, P151, DOI 10.3354/meps166151; Mulder CPH, 1999, ECOL LETT, V2, P237; PAINE R T, 1977, Special Publication Academy of Natural Sciences Philadelphia, V12, P245; PAINE RT, 1984, ECOLOGY, V65, P1339, DOI 10.2307/1939114; PAINE RT, 1992, NATURE, V355, P73, DOI 10.1038/355073a0; STENECK RS, 1994, OIKOS, V69, P476, DOI 10.2307/3545860; Sundene O., 1962, NYTT MAG BOT, V9, P155; Tilman D, 2000, NATURE, V405, P208, DOI 10.1038/35012217; Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0; Tilman D, 2001, SCIENCE, V294, P843, DOI 10.1126/science.1060391; Torti SD, 2001, AM NAT, V157, P141, DOI 10.1086/318629	30	166	176	1	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					736	739		10.1126/science.1069811	http://dx.doi.org/10.1126/science.1069811			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976455				2022-12-28	WOS:000175281700055
J	Mintzes, B				Mintzes, B			Direct to consumer advertising is medicalising normal human experience	BRITISH MEDICAL JOURNAL			English	Article									Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Mintzes, B (corresponding author), Univ British Columbia, Ctr Hlth Serv & Policy Res, 429-2194 Hlth Serv Mall, Vancouver, BC V6T 1Z3, Canada.							Bell RA, 2000, J FAM PRACTICE, V49, P1092; GREEN CJ, 1997, 972T BCOHTA; *IMS HLTH, 2002, IMS HLTH REP PHARM D; Kawachi I., 1996, CONTESTED GROUND PUB; Mintzes B, 2002, BRIT MED J, V324, P278, DOI 10.1136/bmj.324.7332.278; MORAIS RJ, 1998, PHARM EXECUTIVE  OCT, P63; Pfizer and Canadian Lipid Nurses' Network, 2001, CHATELAINE, V74, P74; Pignone M, 2000, BRIT MED J, V321, P983, DOI 10.1136/bmj.321.7267.983; Pressman A, 2001, OSTEOPOROSIS INT, V12, P337, DOI 10.1007/s001980170099; *RES MED IND ASS N, 2000, DTC ADV CAN ENH PUBL; *REUT MED NEWS, 2002, EUR DIR TO CONS DRUG; SHERWOOD LM, 1996, COMMUNICATION   0315; *THER IN, 2001, THERAPEUTICS LETT, P43; THOMAS L, 1980, MEDUSA SNAIL; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; *WHO, 1993, 173 EURICPDSE WHO	16	96	98	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					908	909		10.1136/bmj.324.7342.908	http://dx.doi.org/10.1136/bmj.324.7342.908			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950745	Green Published			2022-12-28	WOS:000175052200031
J	Rigg, JRA; Jamrozik, K; Myles, PS; Silbert, BS; Peyton, PJ; Parsons, RW; Collins, KS				Rigg, JRA; Jamrozik, K; Myles, PS; Silbert, BS; Peyton, PJ; Parsons, RW; Collins, KS		MASTER Anaesthesia Trial Study Grp	Epidural anaesthesia and analgesia and outcome of major surgery: a randomised trial	LANCET			English	Article							ABDOMINAL AORTIC-SURGERY; POSTOPERATIVE ANALGESIA; GENERAL-ANESTHESIA; SURGICAL PATIENTS; METAANALYSES; BUPIVACAINE; FENTANYL; AUDIT; NEED	Background Epidural block is widely used to manage major abdominal surgery and postoperative analgesia, but its risks. and benefits are uncertain. We compared adverse outcomes in high-risk patients managed for major surgery with epidural block or alternative analgesic regimens with general anaesthesia in a multicentre randomised trial. Methods 915 patients undergoing major abdominal surgery with one of nine defined comorbid states to identify high-risk status were randomly assigned intraoperative epidural anaesthesia and postoperative epidural analgesia for 72 h with general anaesthesia (site of epidural selected to provide optimum block) or control. The primary endpoint was death at 30 days or major postsurgical morbidity. Analysis by intention to treat involved 447 patients assigned epidural and 441 control. Findings 255 patients (57.1%) in the epidural group and 268 (60.7%) in the control group had at least one morbidity endpoint or died (p=0.29). Mortality at 30 days was low in both groups (epidural 23 [5.1%], control 19 [4.3%], p=0.67). Only one of eight categories of morbid endpoints in individual systems (respiratory failure) occurred less frequently in patients managed with epidural techniques (23% vs 30%, p=0.02). Postoperative epidural analgesia was associated with lower pain scores during the first 3 postoperative days. There were no major adverse consequences of epidural-catheter insertion. Interpretation Most adverse morbid outcomes in high-risk patients undergoing major abdominal surgery are not reduced by use of combined epidural and general anaesthesia and postoperative epidural analgesia. However, the improvement in analgesia, reduction in respiratory failure, and the low risk of serious adverse consequences suggest that many high-risk patients undergoing major intra-abdominal surgery will receive substantial benefit from combined general and epidural anaesthesia intraoperatively with continuing postoperative epidural analgesia.	Univ Western Australia, Dept Publ Hlth, Crawley, WA, Australia; Imperial Coll Fac Med, London, England; Alfred Hosp, Dept Anaesthesia, Melbourne, Vic, Australia; Monash Univ, Melbourne, Vic 3004, Australia; St Vincents Hosp, Melbourne, Vic, Australia; Austin & Repatriat Med Ctr, Melbourne, Vic, Australia	University of Western Australia; Imperial College London; Florey Institute of Neuroscience & Mental Health; Monash University; St Vincent's Hospital Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health	Rigg, JRA (corresponding author), St John God Hlth Care, Off Safety & Qual, 175 Cambridge St, Subiaco, WA 6008, Australia.	john.rigg@sjog.org.au	Myles, Paul/AAU-9524-2020	Myles, Paul/0000-0002-3324-5456				ABE O, 1992, LANCET, V339, P71; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Ballantyne JC, 1998, ANESTH ANALG, V86, P598, DOI 10.1097/00000539-199803000-00032; BARON JF, 1991, ANESTHESIOLOGY, V75, P611, DOI 10.1097/00000542-199110000-00010; Bode RH, 1996, ANESTHESIOLOGY, V84, P3, DOI 10.1097/00000542-199601000-00002; Broekema AA, 1996, ANESTH ANALG, V82, P754, DOI 10.1097/00000539-199604000-00014; Burstal R, 1998, ANAESTH INTENS CARE, V26, P165, DOI 10.1177/0310057X9802600206; CASASOLA OD, 1994, ANESTHESIOLOGY, V81, P368; CLARKE MJ, 1994, BRIT MED J, V309, P1007, DOI 10.1136/bmj.309.6960.1007; COLLINS R, 1987, STAT MED, V6, P245, DOI 10.1002/sim.4780060308; DAVIES MJ, 1993, ANAESTH INTENS CARE, V21, P790, DOI 10.1177/0310057X9302100607; *EARL BREAST CANC, 1992, LANCET, V339, P1; HJORTSO NC, 1985, ACTA ANAESTH SCAND, V29, P790, DOI 10.1111/j.1399-6576.1985.tb02302.x; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; LIU S, 1995, ANESTHESIOLOGY, V82, P1474, DOI 10.1097/00000542-199506000-00019; Liu SS, 1998, ANESTHESIOLOGY, V88, P688, DOI 10.1097/00000542-199803000-00020; MCPEEK B, 1987, ANESTHESIOLOGY, V66, P723, DOI 10.1097/00000542-198706000-00001; Park WY, 2001, ANN SURG, V234, P560; Pogue J, 1998, LANCET, V351, P47, DOI 10.1016/S0140-6736(97)08461-4; Rigg J R, 1998, Curr Opin Anaesthesiol, V11, P327, DOI 10.1097/00001503-199806000-00016; Rigg JR, 1997, ANAESTH INTENS CARE, V25, P282, DOI 10.1177/0310057X9702500314; RIGG JRA, 1991, ANAESTH INTENS CARE, V19, P404, DOI 10.1177/0310057X9101900318; Rigg JRA, 2000, CONTROL CLIN TRIALS, V21, P244, DOI 10.1016/S0197-2456(00)00045-3; Rigg JRA, 1997, ANESTHESIOLOGY, V86, P1008, DOI 10.1097/00000542-199704000-00037; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; SACKETT DL, 1985, CLIN EPIDEMIOLOGY BA, P171; SCOTT DA, 1995, ANESTHESIOLOGY, V83, P727, DOI 10.1097/00000542-199510000-00012; Sniderman AD, 1999, LANCET, V354, P327, DOI 10.1016/S0140-6736(98)11185-6; TUMAN KJ, 1991, ANESTH ANALG, V73, P696; YEAGER MP, 1987, ANESTHESIOLOGY, V66, P729, DOI 10.1097/00000542-198706000-00004; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421	31	637	667	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1276	1282		10.1016/S0140-6736(02)08266-1	http://dx.doi.org/10.1016/S0140-6736(02)08266-1			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965272				2022-12-28	WOS:000174989700009
J	Knight, JC; Russett, PS				Knight, JC; Russett, PS			Applied optics: New ways to guide light	SCIENCE			English	Editorial Material							SILICA; FIBERS; AIR		Univ Bath, Dept Phys, Bath BA2 7AY, Avon, England	University of Bath	Knight, JC (corresponding author), Univ Bath, Dept Phys, Claverton Down, Bath BA2 7AY, Avon, England.	j.c.knight@bath.ac.uk	Knight, Jonathan C/D-3879-2011	Knight, Jonathan C/0000-0002-0802-8804				Allan DC, 2001, NATO SCI SER II-MATH, V563, P305; BIRKS TA, 1995, ELECTRON LETT, V31, P1941, DOI 10.1049/el:19951306; Broeng J, 2000, OPT LETT, V25, P96, DOI 10.1364/OL.25.000096; Cregan RF, 1999, SCIENCE, V285, P1537, DOI 10.1126/science.285.5433.1537; Eggleton BJ, 2001, OPT EXPRESS, V9, P698, DOI 10.1364/OE.9.000698; Holzwarth R, 2000, PHYS REV LETT, V85, P2264, DOI 10.1103/PhysRevLett.85.2264; KAISER P, 1974, AT&T TECH J, V53, P1021, DOI 10.1002/j.1538-7305.1974.tb02780.x; Knight JC, 1996, OPT LETT, V21, P1547, DOI 10.1364/OL.21.001547; Ranka JK, 2000, OPT LETT, V25, P25, DOI 10.1364/OL.25.000025; Suzuki K, 2001, OPT EXPRESS, V9, P676, DOI 10.1364/OE.9.000676	10	190	221	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					276	277		10.1126/science.1070033	http://dx.doi.org/10.1126/science.1070033			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951025				2022-12-28	WOS:000175000300036
J	Sen Gupta, S; Stadler, M; Noser, CA; Ghosh, A; Steinhoff, B; Lenoir, D; Horwitz, CP; Schramm, KW; Collins, TJ				Sen Gupta, S; Stadler, M; Noser, CA; Ghosh, A; Steinhoff, B; Lenoir, D; Horwitz, CP; Schramm, KW; Collins, TJ			Rapid total destruction of chlorophenols by activated hydrogen peroxide	SCIENCE			English	Article							PHOSPHOREUM TOXICITY BIOASSAY; ROBUST OXIDATION CATALYSTS; IRON TETRASULFOPHTHALOCYANINE; DESIGNING LIGANDS; DEGRADATION; 2,4,6-TRICHLOROPHENOL; PENTACHLOROPHENOL; PRODUCT; H2O2	A practical, inexpensive, green chemical process for degrading environmental pollutants is greatly needed, especially for persistent chlorinated pollutants. Here we describe the activation of hydrogen peroxide by tetraamidomacrocylic ligand (TAML) iron catalysts, to destroy the priority pollutants pentachlorophenol (PCP) and 2,4,6-trichlorophenol (TCP). In water, in minutes, under ambient conditions of temperature and pressure, PCP and TCP are completely destroyed at catalyst:substrate ratios of 1:715 and 1:2000, respectively. The fate of about 90% of the carbon and about 99% of the chlorine has been determined in each case. Neither dioxins nor any other toxic compounds are detectable products, and the catalysts themselves show Low toxicity.	Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA; GSF Forschungszentrum Umwelt & Gesundheit, Inst Okol Chem, D-85758 Neuherberg, Germany	Carnegie Mellon University; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Collins, TJ (corresponding author), Carnegie Mellon Univ, Dept Chem, 4400 5th Ave, Pittsburgh, PA 15213 USA.		Schramm, Karl-Werner/C-7438-2013; Lenoir, Dieter/A-2996-2011; Lenoir, Dieter/AAF-9217-2019; Collins, Terrence J/A-9807-2017	Schramm, Karl-Werner/0000-0002-8945-4062; Collins, Terrence J/0000-0003-2611-9184	NIGMS NIH HHS [GM44867-05] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044867] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartos MJ, 1998, COORDIN CHEM REV, V174, P361, DOI 10.1016/S0010-8545(98)00142-8; Benitez FJ, 1999, IND ENG CHEM RES, V38, P1341, DOI 10.1021/ie980441f; COLLINS TJ, 1994, ACCOUNTS CHEM RES, V27, P279, DOI 10.1021/ar00045a004; Fukushima M, 2001, ENVIRON SCI TECHNOL, V35, P1771, DOI 10.1021/es001088j; Hadasch A, 1998, NEW J CHEM, V22, P45, DOI 10.1039/a706741k; HALL JA, 1999, P 53 APPITA ANN C 19, V2, P455; Hatta T, 1999, J BIOSCI BIOENG, V87, P267, DOI 10.1016/S1389-1723(99)80030-9; Hemmert C, 1999, J MOL CATAL A-CHEM, V137, P205, DOI 10.1016/S1381-1169(98)00131-9; Horwitz CP, 1998, J AM CHEM SOC, V120, P4867, DOI 10.1021/ja972891p; KAISER KLE, 1988, TOXIC ASSESS, V3, P195, DOI 10.1002/tox.2540030209; McAllister KA, 1996, BIODEGRADATION, V7, P1, DOI 10.1007/BF00056556; MILLS G, 1993, ENVIRON SCI TECHNOL, V27, P1681, DOI 10.1021/es00045a027; NASH T, 1953, BIOCHEM J, V55, P416, DOI 10.1042/bj0550416; OEBERG LG, 1992, CHEMOSPHERE, V25, P49; PAL N, 1995, BIOTECHNOL BIOENG, V46, P599, DOI 10.1002/bit.260460613; Pifer A, 1999, J AM CHEM SOC, V121, P7485, DOI 10.1021/ja990244n; Ramamoorthy S., 1997, CHLORINATED ORGANIC; RIBO JM, 1987, TOXIC ASSESS, V2, P305; SIMANDI LI, 1977, J CHEM SOC PERK T 2, P1794, DOI 10.1039/p29770001794; SOROKIN A, 1995, SCIENCE, V268, P1163, DOI 10.1126/science.268.5214.1163; Sorokin A, 1996, CHEM-EUR J, V2, P1308, DOI 10.1002/chem.19960021019; Sorokin A, 1996, J AM CHEM SOC, V118, P7410, DOI 10.1021/ja960177m; VUOCOLO LD, 2000, THESIS CARNEGIE MELL; [No title captured]	24	334	365	6	179	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					326	328		10.1126/science.1069297	http://dx.doi.org/10.1126/science.1069297			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951040				2022-12-28	WOS:000175000300051
J	de Vries, N; van Riel, PLCM; van de Putte, LBA				de Vries, N; van Riel, PLCM; van de Putte, LBA			Research in complex diseases	LANCET			English	Editorial Material							CHIMERIC MONOCLONAL-ANTIBODY; NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; CA2		Univ Amsterdam, Acad Med Ctr Amsterdam FL1 218, Div Clin Immunol & Rheumatol, NL-1100 DE Amsterdam, Netherlands; Univ Med Ctr, Dept Rheumatol & Clin Immunol, Utrecht, Netherlands; Univ Med Ctr St Radboud, Dept Rheumatol, Nijmegen, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; Utrecht University Medical Center; Radboud University Nijmegen	de Vries, N (corresponding author), Univ Amsterdam, Acad Med Ctr Amsterdam FL1 218, Div Clin Immunol & Rheumatol, POB 22700, NL-1100 DE Amsterdam, Netherlands.		van Riel, P.L.C.M./H-8082-2014; de Vries, Niek/J-9348-2013	de Vries, Niek/0000-0002-6257-8604				ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Fox DA, 1997, PERSPECT BIOL MED, V40, P479; LAWRENCE JS, 1970, ANN RHEUM DIS, V29, P357, DOI 10.1136/ard.29.4.357; MCKUSICK VA, 1998, MENDELIAN INHERITANC, P28; ROTHMAN KJ, 1997, OXFORD TXB PUBLIC HL, P617; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502	6	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1243	1245		10.1016/S0140-6736(02)08223-5	http://dx.doi.org/10.1016/S0140-6736(02)08223-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955559				2022-12-28	WOS:000174846300031
J	Saba, J; Haverkamp, G; Gray, G; McIntyre, J; Mmiro, F; Ndugwa, C; Coovadia, HM; Moodley, J; Kilewo, C; Massawe, A; Kituuka, P; Okong, P; von Briesen, H; Goudsmit, J; Biberfeld, G; Grulich, A; Weverling, GJ; Lange, JMA				Saba, J; Haverkamp, G; Gray, G; McIntyre, J; Mmiro, F; Ndugwa, C; Coovadia, HM; Moodley, J; Kilewo, C; Massawe, A; Kituuka, P; Okong, P; von Briesen, H; Goudsmit, J; Biberfeld, G; Grulich, A; Weverling, GJ; Lange, JMA		Petra Study Team	Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; PERINATAL TRANSMISSION; VIRAL LOAD; VERTICAL TRANSMISSION; ORAL ZIDOVUDINE; DOSE NEVIRAPINE; PREGNANT-WOMEN; COTE-DIVOIRE; TYPE-1 RNA; INFECTION	Background Large reductions in transmission of HIV-1 from mother to child have been achieved in more-developed countries due to the use of antiretrovirals. Short-course regimens, suitable for resource-poor countries, have also been shown to significantly reduce peripartum HIV-1 transmission. We assessed the efficacy of short-course regimens with zidovudine and lamivudine in a predominantly breastfeeding population. Methods We did a randomised, double-blind, placebo-controlled trial in South Africa, Uganda, and Tanzania. Between June, 1996, and January, 2000, HIV-1-infected mothers were randomised to one of four regimens: A, zidovudine plus lamivudine starting at 36 weeks' gestation, followed by oral intrapartum dosing and by 7 days' postpartum dosing of mothers and infants; B, as regimen A, but without the prepartum component; C, intrapartum zidovudine and lamivudine only; or placebo. From Feb 18, 1998, onward, women were only randomised to one of the active treatment groups. Primary outcomes were HIV-1 infection and child mortality at week 6 and month 18 after birth. Analysis was by intention to treat of those randomised before Feb 18, 1998. Findings 1797 HIV-1-infected women were identified. Week 6 HIV-1 transmission rates were 5.7% for group A, 8.9% for group B, 14.2% for group C, and 15.3% for the placebo group. Respective relative risks for HIV-1 transmission in the treatment groups compared with placebo were 0.37 (95% Cl 0.21-0.65), 0.58 (0.36-0.94), and 0.93 (0.62-1.40). For the combined endpoint of HIV-1 infection and infant mortality at week 6 rates were 7.0%, 11.6%, 17.5%, and 18.1%, respectively, with relative risks of 0.39 (0.24-0.64), 0.64 (0.42-0.97), and 0.97 (0.68-1.38). 1081 (74%) of the women analysed initiated breastfeeding. Based on an interval-censored survival analysis, HIV-1 infection rates at month 18 were 15% (95% Cl 9-23), 18% (12-26), 20% (13-30) and 22% (16-30), respectively. Interpretation Although at week 6 after birth, regimens A and B were effective in reducing HIV-1 transmission, benefits have diminished considerably after 18 months of follow-up. Introduction of short-course regimens to prevent mother-to-child transmission of HIV-1 in less-developed countries should be accompanied by interventions to minimise the risk of subsequent transmission via breastfeeding.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, IATEC, NL-1100 DE Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Lange, JMA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, IATEC, POB 22700, NL-1100 DE Amsterdam, Netherlands.	j.lange@amc.uva.nl	Moodley, Dhayendre/U-6802-2019					Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; [Anonymous], 1986, Weekly Epidemiological Record, V61, P69; Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; Blanche S, 1999, LANCET, V354, P1084, DOI 10.1016/S0140-6736(99)07219-0; Bobat R, 1996, PEDIATR INFECT DIS J, V15, P604, DOI 10.1097/00006454-199607000-00009; Cao YZ, 1997, NAT MED, V3, P549, DOI 10.1038/nm0597-549; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COOVADIA HM, IN PRESS SEMIN PERIN; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; Coutsoudis A, 1999, AIDS, V13, P1517, DOI 10.1097/00002030-199908200-00012; Coutsoudis A, 2001, AIDS, V15, P379, DOI 10.1097/00002030-200102160-00011; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; De Baar MP, 1999, J CLIN MICROBIOL, V37, P1813, DOI 10.1128/JCM.37.6.1813-1818.1999; de Baar MP, 2001, J CLIN MICROBIOL, V39, P1378, DOI 10.1128/JCM.39.4.1378-1384.2001; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; DITRAME ANRS 049 Study Grp, 1999, LANCET, V354, P2050, DOI 10.1016/S0140-6736(99)04388-3; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; GRAY G, 1996, 11 INT C AIDS VANC; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; HAVLIR D, 1995, J INFECT DIS, V171, P537, DOI 10.1093/infdis/171.3.537; Ioannidis JPA, 2001, J INFECT DIS, V183, P539, DOI 10.1086/318530; Jackson JB, 2000, AIDS, V14, pF111, DOI 10.1097/00002030-200007280-00001; Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118; Kuhn L, 1997, AM J PUBLIC HEALTH, V87, P926, DOI 10.2105/AJPH.87.6.926; Lallemant M, 2000, NEW ENGL J MED, V343, P982, DOI 10.1056/NEJM200010053431401; LANGE J, 1999, 2 C GLOB STRAT PREV; Lindegren ML, 1999, JAMA-J AM MED ASSOC, V282, P531, DOI 10.1001/jama.282.6.531; Lipshultz SE, 2000, NEW ENGL J MED, V343, P759, DOI 10.1056/NEJM200009143431102; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; Lyamuya E, 2000, J CLIN VIROL, V17, P57, DOI 10.1016/S1386-6532(00)00073-1; Mandelbrot L, 1998, JAMA-J AM MED ASSOC, V280, P55, DOI 10.1001/jama.280.1.55; Miotti PG, 1999, JAMA-J AM MED ASSOC, V282, P744, DOI 10.1001/jama.282.8.744; Mock PA, 1999, AIDS, V13, P407, DOI 10.1097/00002030-199902250-00014; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Mofenson LM, 1999, AIDS, V13, pS205; MOODLEY D, 2000, 13 INT AIDS C JUL 9; Moodley J, 1998, J INFECT DIS, V178, P1327, DOI 10.1086/314431; Morris AAM, 1999, LANCET, V354, P1046, DOI 10.1016/S0140-6736(99)00301-3; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SIMONON A, 1994, J ACQ IMMUN DEF SYND, V7, P952; SMITH M, 1999, 2 C GLOB STRAT PREV; TOUSSAINT S, 1999, 2 C GLOB STRAT PREV; VANHEESWIJK R, 2000, THESIS UTRECHT U, P172; VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; Wade NA, 1998, NEW ENGL J MED, V339, P1409, DOI 10.1056/NEJM199811123392001; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	53	308	315	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	2002	359	9313					1178	1186						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955535				2022-12-28	WOS:000174846300007
J	Cho, NK; Keyes, L; Johnson, E; Heller, J; Ryner, L; Karim, F; Krasnow, MA				Cho, NK; Keyes, L; Johnson, E; Heller, J; Ryner, L; Karim, F; Krasnow, MA			Developmental control of blood cell migration by the Drosophila VEGF pathway	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; HEMATOPOIETIC STEM-CELLS; APOPTOTIC CELLS; RECEPTOR FLT-1; PROTEIN; DEATH; CROQUEMORT; DISTINCT; LINEAGE	We show that a vascular endothelial growth factor (VEGF) pathway controls embryonic migrations of blood cells (hemocytes) in Drosophila. The VEGF receptor homolog is expressed in hemocytes, and three VEGF homologs are expressed along hemocyte migration routes. A receptor mutation arrests progression of blood cell movement. Mutations in Vegf17E or Vegf27Cb have no effect, but simultaneous inactivation of all three Vegf genes phenocopied the receptor mutant, and ectopic expression of Vegf27Cb redirected migration. Genetic experiments indicate that the VEGF pathway functions independently of pathways governing hemocyte homing on apoptotic cells. The results suggest that the Drosophila VEGF pathway guides developmental migrations of blood cells, and we speculate that the ancestral function of VEGF pathways was to guide blood cell movement.	Stanford Univ, Howard Hughes Med Inst, Dept Biochem, Stanford, CA 94305 USA; Exelixis Inc, Dept Genet, San Francisco, CA USA	Howard Hughes Medical Institute; Stanford University; Exelixis, Inc.	Krasnow, MA (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Biochem, Stanford, CA 94305 USA.							ABRAMS JM, 1993, DEVELOPMENT, V117, P29; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernardoni R, 1997, DEV BIOL, V191, P118; BRAND AH, 1993, DEVELOPMENT, V118, P401; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CHAMPION S, 1986, CELL, V44, P781, DOI 10.1016/0092-8674(86)90844-5; Choi K, 1998, DEVELOPMENT, V125, P725; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Clauss M, 2000, SEMIN THROMB HEMOST, V26, P561, DOI 10.1055/s-2000-13213; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FESSLER JH, 1989, ANNU REV CELL BIOL, V5, P309, DOI 10.1146/annurev.cb.05.110189.001521; Franc NC, 1996, IMMUNITY, V4, P431, DOI 10.1016/S1074-7613(00)80410-0; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Heino TI, 2001, MECH DEVELOP, V109, P69, DOI 10.1016/S0925-4773(01)00510-X; Hirsch E, 1996, NATURE, V380, P171, DOI 10.1038/380171a0; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; Lee T, 1996, DEVELOPMENT, V122, P409; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; NELSON RE, 1994, EMBO J, V13, P3438, DOI 10.1002/j.1460-2075.1994.tb06649.x; ONEILL JW, 1994, BIOTECHNIQUES, V17, P870; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; RODEWALD HR, 1995, CURR OPIN IMMUNOL, V7, P176, DOI 10.1016/0952-7915(95)80002-6; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHEN H, 1993, BLOOD, V81, P2767; Shiga Y, 1996, DEV GROWTH DIFFER, V38, P99; TEPASS U, 1994, DEVELOPMENT, V120, P1829; ZHOU L, 1995, CURR BIOL, V5, P784, DOI 10.1016/S0960-9822(95)00155-2	40	223	226	0	12	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 22	2002	108	6					865	876		10.1016/S0092-8674(02)00676-1	http://dx.doi.org/10.1016/S0092-8674(02)00676-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955438	Bronze			2022-12-28	WOS:000174563000014
J	Margot, JL; Nolan, MC; Benner, LAM; Ostro, SJ; Jurgens, RF; Giorgini, JD; Slade, MA; Campbell, DB				Margot, JL; Nolan, MC; Benner, LAM; Ostro, SJ; Jurgens, RF; Giorgini, JD; Slade, MA; Campbell, DB			Binary asteroids in the near-Earth object population	SCIENCE			English	Article							TIDAL DISRUPTION; DOUBLET CRATERS; SATELLITES; DISCOVERY; DENSITY	Radar images of near-Earth asteroid 2000 DP107 show that it is composed of an similar to800-meter-diameter primary and an similar to300-meter-diameter secondary revolving around their common center of mass. The orbital period of 1.755 +/- 0.007 days and semimajor axis of 2620 160 meters constrain the total mass of the system to 4.6 +/- 0.5 x 10(11) kilograms and the bulk density of the primary to 1.7 +/- 1.1 grams per cubic centimeter. This system and other binary near-Earth asteroids have spheroidal primaries spinning near the breakup point for strengthless bodies, suggesting that the binaries formed by spin-up and fission, probably as a result of tidal disruption during close planetary encounters. About 16% of near-Earth asteroids larger than 200 meters in diameter may be binary systems.	CALTECH, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Natl Astron & Ionosphere Ctr, Arecibo, PR 00612 USA; Cornell Univ, Ithaca, NY 14853 USA	California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Cornell University	Margot, JL (corresponding author), CALTECH, MC 150-21, Pasadena, CA 91125 USA.		Nolan, Michael C/H-4980-2012; Margot, Jean-Luc/A-6154-2012	Nolan, Michael C/0000-0001-8316-0680; Margot, Jean-Luc/0000-0001-9798-1797				Asphaug E, 1996, ICARUS, V121, P225, DOI 10.1006/icar.1996.0083; Benner L.A.M., 2001, 7632 IAU; BENNER LAM, 2001, 7730 IAU; Bottke WF, 1996, NATURE, V381, P51, DOI 10.1038/381051a0; Brown M. E., 2001, 7588 IAU; CHAPMAN CR, 1995, NATURE, V374, P783, DOI 10.1038/374783a0; Consolmagno GJ, 1998, METEORIT PLANET SCI, V33, P1231, DOI 10.1111/j.1945-5100.1998.tb01308.x; Durda DD, 1996, ICARUS, V120, P212, DOI 10.1006/icar.1996.0046; Farinella P, 1998, ICARUS, V132, P378, DOI 10.1006/icar.1997.5872; Gladman BJ, 1997, SCIENCE, V277, P197, DOI 10.1126/science.277.5323.197; GOLDREICH P, 1966, ICARUS, V5, P375, DOI 10.1016/0019-1035(66)90051-0; GREENBERG R, 1981, ASTRON J, V86, P912, DOI 10.1086/112968; HARTMANN WK, 1979, ASTEROIDS, V1, P466; HUDSON RS, 1993, REMOTE SENSING REV, V8, P195, DOI DOI 10.1080/02757259309532195; MARGOT JL, 2001, 7703 IAU; MARGOT JL, 2000, 7503 IAU; MELOSH HJ, 1991, ICARUS, V94, P171, DOI 10.1016/0019-1035(91)90148-M; Merline WJ, 1999, NATURE, V401, P565, DOI 10.1038/44089; MERLINE WJ, 2000, 7503 IAU; MERLINE WJ, 2002, 7827 IAU; Murray C. D., 1999, SOLAR SYSTEM DYNAMIC; NOLAN MC, 2000, 7518 IAU; NOLAN MC, 2002, 7824 IAU; Ostro SJ, 2001, METEORIT PLANET SCI, V36, P1225, DOI 10.1111/j.1945-5100.2001.tb01956.x; OSTRO SJ, 2000, 7496 IAU; Peale SJ, 1999, ANNU REV ASTRON ASTR, V37, P533, DOI 10.1146/annurev.astro.37.1.533; Pravec P, 2000, ICARUS, V148, P12, DOI 10.1006/icar.2000.6482; PRAVEC P, 2000, 7504 IAU; Richardson DC, 1998, ICARUS, V134, P47, DOI 10.1006/icar.1998.5954; SRIDHAR S, 1992, ICARUS, V95, P86, DOI 10.1016/0019-1035(92)90193-B; Stokes GH, 2000, ICARUS, V148, P21, DOI 10.1006/icar.2000.6493; van Flandern T. C., 1979, ASTEROIDS, P443; Veverka J, 1999, ICARUS, V140, P3, DOI 10.1006/icar.1999.6120; WEIDENSCHILLING SJ, 1980, ICARUS, V44, P807, DOI 10.1016/0019-1035(80)90147-5; [No title captured]	35	222	224	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 24	2002	296	5572					1445	1448		10.1126/science.1072094	http://dx.doi.org/10.1126/science.1072094			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	557LP	11951001				2022-12-28	WOS:000175910300042
J	Corrigan, M; Cupples, ME; Stevenson, M				Corrigan, M; Cupples, ME; Stevenson, M			Quitting and restarting smoking: cohort study of patients with angina in primary care	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; HIGH CARDIOVASCULAR RISK; 5-YEAR FOLLOW-UP; HEALTH PROMOTION		Queens Univ Belfast, Dept Gen Practice, Belfast BT9 7HR, Antrim, North Ireland; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT9 5EE, Antrim, North Ireland	Queens University Belfast; Queens University Belfast	Corrigan, M (corresponding author), Queens Univ Belfast, Dept Gen Practice, Belfast BT9 7HR, Antrim, North Ireland.			Cupples, Margaret/0000-0002-4248-9700				CUPPLES ME, 1994, BRIT MED J, V309, P993, DOI 10.1136/bmj.309.6960.993; Cupples ME, 1999, BMJ-BRIT MED J, V319, P687, DOI 10.1136/bmj.319.7211.687; *DEP HLTH, 2000, COR HEART DIS NAT SE; Ockene JK, 2000, HEALTH PSYCHOL, V19, P17, DOI 10.1037/0278-6133.19.Suppl1.17; Rosal MC, 1998, HEALTH PSYCHOL, V17, P476, DOI 10.1037/0278-6133.17.5.476	5	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 27	2002	324	7344					1016	1017		10.1136/bmj.324.7344.1016	http://dx.doi.org/10.1136/bmj.324.7344.1016			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547UP	11976245	Bronze, Green Published			2022-12-28	WOS:000175350900023
J	Anderson, VJ; Lekkerkerker, HNW				Anderson, VJ; Lekkerkerker, HNW			Insights into phase transition kinetics from colloid science	NATURE			English	Review							SPINODAL DECOMPOSITION; CRYSTAL-NUCLEATION; PROTEIN CRYSTALLIZATION; POLYMER MIXTURES; TRANSIENT GELS; MONTE-CARLO; FREE-ENERGY; AGGREGATION; DYNAMICS; GELATION	Colloids display intriguing transitions between gas, liquid, solid and liquid crystalline phases. Such phase transitions are ubiquitous in nature and have been studied for decades. However, the predictions of phase diagrams are not always realized; systems often become undercooled, supersaturated, or trapped in gel-like states. In many cases the end products strongly depend on the starting position in the phase diagram and discrepancies between predictions and actual observations are due to the intricacies of the dynamics of phase transitions. Colloid science aims to understand the underlying mechanisms of these transitions. Important advances have been made, for example, with new imaging techniques that allow direct observation of individual colloidal particles undergoing phase transitions, revealing some of the secrets of the complex pathways involved.	Univ Utrecht, Debye Inst, Vant Hoff Lab Phys & Colloid Chem, NL-3584 CH Utrecht, Netherlands	Utrecht University	Lekkerkerker, HNW (corresponding author), Univ Utrecht, Debye Inst, Vant Hoff Lab Phys & Colloid Chem, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	h.n.w.lekkerkerker@chem.uu.n						ALEXANDER S, 1978, PHYS REV LETT, V41, P702, DOI 10.1103/PhysRevLett.41.702; Anderson VJ, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.011403; Angell CA, 2000, J APPL PHYS, V88, P3113, DOI 10.1063/1.1286035; ASAKURA S, 1954, J CHEM PHYS, V22, P1255, DOI 10.1063/1.1740347; ASNAGHI D, 1992, PHYS REV A, V45, P1018, DOI 10.1103/PhysRevA.45.1018; ASNAGHI D, 1994, MRS BULL, V19, P14, DOI 10.1557/S0883769400036514; Auer S, 2001, NATURE, V413, P711, DOI 10.1038/35099513; Auer S, 2001, NATURE, V409, P1020, DOI 10.1038/35059035; BERLAND CR, 1992, P NATL ACAD SCI USA, V89, P1214, DOI 10.1073/pnas.89.4.1214; BIBETTE J, 1992, PHYS REV LETT, V69, P981, DOI 10.1103/PhysRevLett.69.981; Bolhuis PG, 1996, PHYS REV E, V54, P634, DOI 10.1103/PhysRevE.54.634; Bos MTA, 1996, PHYS REV E, V53, P5044, DOI 10.1103/PhysRevE.53.5044; Broide ML, 1996, PHYS REV E, V53, P6325, DOI 10.1103/PhysRevE.53.6325; Bruce AD, 1997, PHYS REV LETT, V79, P3002, DOI 10.1103/PhysRevLett.79.3002; CAHN JW, 1969, J AM CERAM SOC, V52, P118, DOI 10.1111/j.1151-2916.1969.tb11194.x; CARPINETI M, 1992, PHYS REV LETT, V68, P3327, DOI 10.1103/PhysRevLett.68.3327; CIPALLETTI L, 2001, PHYS REV LETT, V86, P6042; Cui BX, 2001, J CHEM PHYS, V114, P9142, DOI 10.1063/1.1369129; de Hoog EHA, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.021407; Debenedetti PG, 2001, NATURE, V410, P259, DOI 10.1038/35065704; Dinsmore AD, 2001, APPL OPTICS, V40, P4152, DOI 10.1364/AO.40.004152; Dixit NM, 2000, J COLLOID INTERF SCI, V228, P359, DOI 10.1006/jcis.2000.6944; Elliot MS, 2001, J PHYS-CONDENS MAT, V13, pL553, DOI 10.1088/0953-8984/13/23/104; Evans RML, 1998, PHYS REV LETT, V81, P1326, DOI 10.1103/PhysRevLett.81.1326; Evans RML, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.011404; Evans RML, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.031403; EVANS RML, 2000, J PHYS CONDENS MATT, V14, P2507; Finet S, 1998, EUR BIOPHYS J BIOPHY, V27, P263, DOI 10.1007/s002490050133; Gasser U, 2001, SCIENCE, V292, P258, DOI 10.1126/science.1058457; GISLER T, 1998, PHYS REV LETT, V80, P778; Haas C, 1999, J CRYST GROWTH, V196, P388, DOI 10.1016/S0022-0248(98)00831-8; Haas C, 2000, J PHYS CHEM B, V104, P368, DOI 10.1021/jp993210a; Hobbie EK, 1999, LANGMUIR, V15, P8807, DOI 10.1021/la990397o; Hobbie EK, 1998, PHYS REV LETT, V81, P3996, DOI 10.1103/PhysRevLett.81.3996; Kegel WK, 2000, LANGMUIR, V16, P939, DOI 10.1021/la990661d; Kegel WK, 2000, SCIENCE, V287, P290, DOI 10.1126/science.287.5451.290; Kofke DA, 1999, PHYS REV E, V59, P618, DOI 10.1103/PhysRevE.59.618; Krall AH, 1998, PHYS REV LETT, V80, P778, DOI 10.1103/PhysRevLett.80.778; Liu AJ, 1998, NATURE, V396, P21, DOI 10.1038/23819; Lomakin A, 1999, P NATL ACAD SCI USA, V96, P9465, DOI 10.1073/pnas.96.17.9465; McPherson A, 1999, J CRYST GROWTH, V196, P572, DOI 10.1016/S0022-0248(98)00853-7; Moussaid A, 1999, PHYS REV LETT, V82, P225, DOI 10.1103/PhysRevLett.82.225; Muschol M, 1997, J CHEM PHYS, V107, P1953, DOI 10.1063/1.474547; Noro MG, 1999, EUROPHYS LETT, V48, P332, DOI 10.1209/epl/i1999-00485-9; Oxtoby DW, 2001, NATURE, V413, P694, DOI 10.1038/35099662; Peters EAJF, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.021404; Peters R, 1998, ACTA CRYSTALLOGR D, V54, P873, DOI 10.1107/S0907444998002455; Poon WCK, 1997, ADV COLLOID INTERFAC, V73, P71, DOI 10.1016/S0001-8686(97)90003-8; Poon WCK, 1999, PHYS REV LETT, V83, P1239, DOI 10.1103/PhysRevLett.83.1239; Poon WCK, 1997, PHYS REV E, V55, P3762, DOI 10.1103/PhysRevE.55.3762; Poulin P, 1999, EUR PHYS J B, V7, P277, DOI 10.1007/s100510050614; Pronk S, 1999, J CHEM PHYS, V110, P4589, DOI 10.1063/1.478339; PUSEY PN, 1986, NATURE, V320, P340, DOI 10.1038/320340a0; PUSEY PN, 1989, PHYS REV LETT, V63, P2753, DOI 10.1103/PhysRevLett.63.2753; Renth F, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.031402; ROUW PW, 1989, PHYSICA A, V156, P876, DOI 10.1016/0378-4371(89)90025-3; Sear RP, 2001, J CHEM PHYS, V114, P3170, DOI 10.1063/1.1340582; Segre PN, 2001, PHYS REV LETT, V86, P6042, DOI 10.1103/PhysRevLett.86.6042; SHIH WY, 1987, PHYS REV A, V36, P5015, DOI 10.1103/PhysRevA.36.5015; Soga KG, 1999, J CHEM PHYS, V110, P2280, DOI 10.1063/1.477881; Starrs L, 2002, J PHYS-CONDENS MAT, V14, P2485, DOI 10.1088/0953-8984/14/10/302; Tanaka H, 2000, PHYS REV LETT, V85, P1338, DOI 10.1103/PhysRevLett.85.1338; Tanaka S, 1999, J CHEM PHYS, V111, P10330, DOI 10.1063/1.480381; tenWolde PR, 1997, SCIENCE, V277, P1975, DOI 10.1126/science.277.5334.1975; Terao T, 1998, PHYS REV E, V58, P3490, DOI 10.1103/PhysRevE.58.3490; THOMSON JA, 1987, P NATL ACAD SCI USA, V84, P7079, DOI 10.1073/pnas.84.20.7079; Trappe V, 2001, NATURE, V411, P772, DOI 10.1038/35081021; Verhaegh NAM, 1999, PHYSICA A, V264, P64, DOI 10.1016/S0378-4371(98)00420-8; Verhaegh NAM, 1997, PHYSICA A, V242, P104, DOI 10.1016/S0378-4371(97)00184-2; von Smoluchowski M, 1917, Z PHYS CHEM-STOCH VE, V92, P129; VRIJ A, 1976, PURE APPL CHEM, V48, P471, DOI 10.1351/pac197648040471; Weeks ER, 2000, SCIENCE, V287, P627, DOI 10.1126/science.287.5453.627; Weeks JR, 2000, J PHYS-CONDENS MAT, V12, P9599, DOI 10.1088/0953-8984/12/46/307; WEITZ DA, 1985, PHYS REV LETT, V54, P1416, DOI 10.1103/PhysRevLett.54.1416; Williams SR, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.021506; Zhu JX, 1997, NATURE, V387, P883, DOI 10.1038/43141	76	808	818	11	511	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	2002	416	6883					811	815		10.1038/416811a	http://dx.doi.org/10.1038/416811a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976674	Green Published			2022-12-28	WOS:000175163800042
J	Downing, AL; Leibold, MA				Downing, AL; Leibold, MA			Ecosystem consequences of species richness and composition in pond food webs	NATURE			English	Article							PLANT DIVERSITY; BIODIVERSITY; PRODUCTIVITY	Resolving current concerns about the role of biodiversity on ecosystems calls for understanding the separate roles of changes in species numbers and of composition. Recent work shows that primary productivity often, but not always, saturates with species richness within single trophic levels(1-8). However, any interpretation of such patterns must consider that variation in biodiversity is necessarily associated with changes in species composition (identity)(9-12), and that changes in biodiversity often occur across multiple trophic levels(13,14). Here we present results from a mesocosm experiment in which we independently manipulated species richness and species composition across multiple trophic levels in pond food webs. In contrast to previous studies that focused on single trophic levels, we found that productivity is either idiosyncratic or increases with respect to species richness, and that richness influences trophic structure. However, the composition of species within richness levels can have equally or more marked effects on ecosystems than average effects of richness per se. Indirect evidence suggests that richness and associated changes in species composition affect ecosystem attributes through indirect effects and trophic interactions among species, features that are highly characteristic of natural, complex ecosystems.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Downing, AL (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.	aldownin@owu.edu						Aarssen LW, 1997, OIKOS, V80, P183, DOI 10.2307/3546531; Chapin FS, 2000, NATURE, V405, P234, DOI 10.1038/35012241; DERUITER PC, 1995, SCIENCE, V269, P1257, DOI 10.1126/science.269.5228.1257; Grime JP, 1997, SCIENCE, V277, P1260, DOI 10.1126/science.277.5330.1260; Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123; Hooper DU, 1997, SCIENCE, V277, P1302, DOI 10.1126/science.277.5330.1302; Huston M A, 2000, Science, V289, P1255; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; Lund OT, 1979, HDB COMMON METHODS L; MARTINEZ ND, 1991, ECOL MONOGR, V61, P367, DOI 10.2307/2937047; McCollum EW, 1998, ECOLOGY, V79, P1980; McGradySteed J, 1997, NATURE, V390, P162, DOI 10.1038/36561; Mikola J, 1998, OECOLOGIA, V117, P396, DOI 10.1007/s004420050673; Naeem S, 2000, NATURE, V403, P762, DOI 10.1038/35001568; NAEEM S, 1994, NATURE, V368, P734, DOI 10.1038/368734a0; Norberg J, 2000, OECOLOGIA, V122, P264, DOI 10.1007/PL00008855; Petchey OL, 1999, NATURE, V402, P69, DOI 10.1038/47023; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; SANDJENSEN K, 1991, AQUAT BOT, V41, P137, DOI 10.1016/0304-3770(91)90042-4; Schlapfer F, 1999, OIKOS, V84, P346, DOI 10.2307/3546733; Schwartz MW, 2000, OECOLOGIA, V122, P297, DOI 10.1007/s004420050035; Symstad AJ, 1998, OIKOS, V81, P389, DOI 10.2307/3547058; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; Tilman D, 1997, P NATL ACAD SCI USA, V94, P1857, DOI 10.1073/pnas.94.5.1857; Tilman D, 1996, NATURE, V379, P718, DOI 10.1038/379718a0; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; Wetzel RG, 2001, LIMNOLOGY, Vthird, P331; Wilcove DS, 1998, BIOSCIENCE, V48, P607, DOI 10.2307/1313420; WOOTTON JT, 1994, ANNU REV ECOL SYST, V25, P443, DOI 10.1146/annurev.es.25.110194.002303; Yodzis Peter, 1996, P192	30	169	174	0	96	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	2002	416	6883					837	841		10.1038/416837a	http://dx.doi.org/10.1038/416837a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976680				2022-12-28	WOS:000175163800048
J	Enomoto, R; Tanimori, T; Naito, T; Yoshida, T; Yanagita, S; Mori, M; Edwards, PG; Asahara, A; Bicknell, GV; Gunji, S; Hara, S; Hara, T; Hayashi, S; Itoh, C; Kabuki, S; Kajino, F; Katagiri, H; Kataoka, J; Kawachi, A; Kifune, T; Kubo, H; Kushida, J; Maeda, S; Maeshiro, A; Matsubara, Y; Mizumoto, Y; Moriya, M; Muraishi, H; Muraki, Y; Nakase, T; Nishijima, K; Ohishi, M; Okumura, K; Patterson, JR; Sakurazawa, K; Suzuki, R; Swaby, DL; Takano, K; Takano, T; Tokanai, F; Tsuchiya, K; Tsunoo, H; Uruma, K; Watanabe, A; Yoshikoshi, T				Enomoto, R; Tanimori, T; Naito, T; Yoshida, T; Yanagita, S; Mori, M; Edwards, PG; Asahara, A; Bicknell, GV; Gunji, S; Hara, S; Hara, T; Hayashi, S; Itoh, C; Kabuki, S; Kajino, F; Katagiri, H; Kataoka, J; Kawachi, A; Kifune, T; Kubo, H; Kushida, J; Maeda, S; Maeshiro, A; Matsubara, Y; Mizumoto, Y; Moriya, M; Muraishi, H; Muraki, Y; Nakase, T; Nishijima, K; Ohishi, M; Okumura, K; Patterson, JR; Sakurazawa, K; Suzuki, R; Swaby, DL; Takano, K; Takano, T; Tokanai, F; Tsuchiya, K; Tsunoo, H; Uruma, K; Watanabe, A; Yoshikoshi, T			The acceleration of cosmic-ray protons in the supernova remnant RX J1713.7-3946	NATURE			English	Article							TEV GAMMA-RAYS; SHOCK ACCELERATION; SN 1006; EMISSION; RADIATION; SHELL; DISCOVERY; ORIGIN	Protons with energies up to similar to10(15) eV are the main component(1) of cosmic rays, but evidence for the specific locations where they could have been accelerated to these energies has been lacking(2). Electrons are known to be accelerated to cosmic-ray energies in supernova remnants(3,4), and the shock waves associated with such remnants, when they hit the surrounding interstellar medium, could also provide the energy to accelerate protons. The signature of such a process would be the decay of pions (pi(0)), which are generated when the protons collide with atoms and molecules in an interstellar cloud: pion decay results in gamma-rays with a particular spectral-energy distribution(5,6). Here we report the observation of cascade showers of optical photons resulting from g-rays at energies of similar to10(12) eV hitting Earth's upper atmosphere, in the direction of the supernova remnant RX J1713.7-3946. The spectrum is a good match to that predicted by pion decay, and cannot be explained by other mechanisms.	Univ Tokyo, Inst Cosm Ray Res, Chiba 2778582, Japan; Kyoto Univ, Dept Phys, Sakyo Ku, Kyoto 6068502, Japan; Yamanashi Gakuin Univ, Fac Management Informat, Yamanashi 4008575, Japan; Ibaraki Univ, Fac Sci, Ibaraki 3108512, Japan; Inst Space & Astronaut Sci, Kanagawa 2298510, Japan; Australian Natl Univ, Mt Stromlo & Siding Spring Observ, Weston, ACT 2611, Australia; Yamagata Univ, Dept Phys, Yamagata 9008560, Japan; Tokyo Inst Technol, Dept Phys, Meguro Ku, Tokyo 1528551, Japan; Konan Univ, Dept Phys, Kobe, Hyogo 6588501, Japan; Shinshu Univ, Fac Engn, Nagano 3808553, Japan; Nagoya Univ, Solar Terr Environm Lab, Aichi 4648601, Japan; Natl Astron Observ Japan, Tokyo 1818588, Japan; Ibaraki Prefectural Univ Hlth Sci, Ibaraki 3000394, Japan; Tokai Univ, Dept Phys, Kanagawa 2591292, Japan; Univ Adelaide, Dept Phys & Math Phys, Adelaide, SA 5005, Australia; Osaka City Univ, Dept Phys, Osaka 5588585, Japan	University of Tokyo; Kyoto University; Ibaraki University; Japan Aerospace Exploration Agency (JAXA); Institute of Space & Astronautical Science (ISAS); Australian National University; Yamagata University; Tokyo Institute of Technology; Konan University; Shinshu University; Nagoya University; National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ); Tokai University; University of Adelaide; Osaka Metropolitan University	Enomoto, R (corresponding author), Univ Tokyo, Inst Cosm Ray Res, Chiba 2778582, Japan.	enomoto@icrr.u-tokyo.ac.jp		Mori, Masaki/0000-0003-2921-1592; Muraishi, Hiroshi/0000-0003-3054-5725; Ohishi, Michiko/0000-0002-5056-0968; Katagiri, Hideaki/0000-0003-2347-8819				Aharonian FA, 2000, ASTROPHYS J, V539, P317, DOI 10.1086/309225; AHARONIAN FA, 1994, ASTRON ASTROPHYS, V285, P645; Aharonian FA, 1999, ASTRON ASTROPHYS, V351, P330; Aharonian FA, 1997, MON NOT R ASTRON SOC, V291, P162, DOI 10.1093/mnras/291.1.162; Butt YM, 2001, ASTROPHYS J, V562, pL167, DOI 10.1086/324592; Ellison DC, 2001, ASTROPHYS J, V563, P191, DOI 10.1086/323687; Enomoto R, 2002, ASTROPART PHYS, V16, P235, DOI 10.1016/S0927-6505(01)00112-8; ENOMOTO R, 2001, P 27 INT COSM RAY C, V6, P2477; Hartman RC, 1999, ASTROPHYS J SUPPL S, V123, P79, DOI 10.1086/313231; Hillas A. M, 1985, 19TH P INT COSM RAY, V3, P445; ISHIZAKI Y, SPECTRA LARGE SCALE; Koyama K, 1997, PUBL ASTRON SOC JPN, V49, pL7, DOI 10.1093/pasj/49.3.L7; KOYAMA K, 1995, NATURE, V378, P255, DOI 10.1038/378255a0; Mastichiadis A, 1996, ASTRON ASTROPHYS, V311, pL5; MATHIS JS, 1983, ASTRON ASTROPHYS, V128, P212; Muraishi H, 2000, ASTRON ASTROPHYS, V354, pL57; NAITO T, 1994, J PHYS G NUCL PARTIC, V20, P477, DOI 10.1088/0954-3899/20/3/009; Naito T, 1999, ASTRON NACHR, V320, P205, DOI 10.1002/1521-3994(199908)320:4/5<205::AID-ASNA205>3.0.CO;2-B; Pfeffermann E., 1996, 263 MPE, P267; POHL M, 2001, IN PRESS P 27 INT CO; Rybichi G. B., 1979, RAD PROCESSES ASTROP; SIKORA M, 1994, ASTROPHYS J, V421, P153, DOI 10.1086/173633; SIMPSON JA, 1983, ANNU REV NUCL PART S, V33, P323, DOI 10.1146/annurev.ns.33.120183.001543; Slane P, 1999, ASTROPHYS J, V525, P357, DOI 10.1086/307893; Tanimori T, 1998, ASTROPHYS J, V497, pL25, DOI 10.1086/311267; TANIMORI T, 2001, P 27 INT COSM RAY C, V6, P2465; TOMIDA H, 1999, THESIS KYOTO U; Walsh AJ, 1997, MON NOT R ASTRON SOC, V291, P261, DOI 10.1093/mnras/291.2.261; YOSHIDA T, 1997, ESA, P85	29	217	222	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	2002	416	6883					823	826		10.1038/416823a	http://dx.doi.org/10.1038/416823a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976676	Green Submitted			2022-12-28	WOS:000175163800044
J	Behague, DP; Victora, CG; Barros, FC				Behague, DP; Victora, CG; Barros, FC			Consumer demand for caesarean sections in Brazil: population based birth cohort study linking ethnographic an epidemiological methods	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DELIVERY; RATES	Objectives To investigate why some women prefer caesarean sections and how decisions to medicalise birthing are influenced by patients, doctors, and die sociomedical environment Design Population based birth cohort study, using ethnographic and epidemiological methods. Setting Epidemiological study: women living in die urban area of Pelotas, Brazil who gave birth in hospital during the study. Ethnographic study: subsample of 80 women selected at random from the birth cohort. Nineteen medical staff were interviewed. Participants 5304 women who gave birth in any of the city's hospitals in 1993. Main outcome measures Birth by caesarean section or vaginal delivery. Results In both samples women from families with higher incomes and higher levels of education had caesarean sections more often dian other women. Many lower to middle class women sought caesarean sections to avoid what they considered poor quality care and medical neglect, resulting from social prejudice. These women used medicalised prenatal and birthing health care to increase their chance of acquiring a caesarean section, particularly if they had social power in the home. Both social power and women's behaviour towards seeking medicalised health care remained significantly associated with type of birth after controlling for family income mid maternal education. Conclusions Fear of substandard care is behind many poor women's preferences for a caesarean section. Variables pertaining to women's role in the process of redefining and negotiating medical risks were much stronger correlates of caesarean section rates than income or education. The unequal distribution of medical technology has altered concepts of good and normal birthing. Arguments supporting interventionist birthing for all on the basis of equal access to health care must be reviewed.	Univ Fed Pelotas, Dept Social Med, BR-96001970 Pelotas, RS, Brazil; Ctr Latinoamer Perinatol, Montevideo, Uruguay	Universidade Federal de Pelotas	Behague, DP (corresponding author), McGill Univ, Dept Anthropol, Montreal, PQ H3A 2T7, Canada.	dbehague@aol.com	Victora, Cesar Gomes/Y-2455-2019; Sandall, Jane/D-4146-2009; Barros, Fernando C/D-4857-2013; Victora, Cesar G/D-4476-2013	Victora, Cesar Gomes/0000-0002-2465-2180; Sandall, Jane/0000-0003-2000-743X; Victora, Cesar G/0000-0002-2465-2180; Behague, Dominique/0000-0001-8621-6942				AlMufti R, 1996, LANCET, V347, P544, DOI 10.1016/S0140-6736(96)91176-9; [Anonymous], 1985, LANCET, V2, P436; [Anonymous], 1997, LANCET, V349, P815; Ash AK, 1997, LANCET, V349, P1557, DOI 10.1016/S0140-6736(05)62143-5; BARROS F C, 1985, World Health Forum, V6, P322; Barros FC, 1996, LANCET, V347, P839, DOI 10.1016/S0140-6736(96)90922-8; Belizan JM, 1999, BMJ-BRIT MED J, V319, P1397, DOI 10.1136/bmj.319.7222.1397; Bewley S, 1996, LANCET, V347, P1189, DOI 10.1016/S0140-6736(96)90648-0; CHALMERS I, 1989, EFFECTIVE CARE PREGN, V2; Cosminsky S, 1982, ETHNOGRAPHY FERTILIT, P205; DAVISFLOYD RE, 1994, SOC SCI MED, V38, P1125, DOI 10.1016/0277-9536(94)90228-3; Geary M, 1998, LANCET, V351, P1177, DOI 10.1016/S0140-6736(05)79120-0; HAINES A, 1993, BRIT MED J, V306, P503, DOI 10.1136/bmj.306.6876.503; Hemminki E, 1996, AM J OBSTET GYNECOL, V174, P1569, DOI 10.1016/S0002-9378(96)70608-7; Kaufert P., 1993, KNOWLEDGE POWER PRAC, P32; KLAUS MH, 1986, BMJ-BRIT MED J, V293, P585, DOI 10.1136/bmj.293.6547.585; LILFORD RJ, 1990, BRIT J OBSTET GYNAEC, V97, P883, DOI 10.1111/j.1471-0528.1990.tb02442.x; LOCICERO AK, 1993, SOC SCI MED, V37, P1261, DOI 10.1016/0277-9536(93)90337-4; MacCormack Carol P., 1982, ETHNOGRAPHY FERTILIT; MCCLAIN CS, 1987, CULT MED PSYCHIAT, V11, P495, DOI 10.1007/BF00048495; Murray SF, 1997, LANCET, V349, P64, DOI 10.1016/S0140-6736(05)62208-8; Paterson-Brown S, 1998, BMJ-BRIT MED J, V317, P462; SARGENT C, 1987, SOC SCI MED, V25, P1269, DOI 10.1016/0277-9536(87)90125-0; SOUZA CD, 1994, CAMB Q HEALTHC ETHIC, V3, P358, DOI 10.1017/S096318010000517X; Thurmond AS, 1999, J ULTRAS MED, V18, P13; VICTORA CG, 1992, EPIDEMIOLOGIA DESIGU	26	185	203	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 20	2002	324	7343					942	+		10.1136/bmj.324.7343.942	http://dx.doi.org/10.1136/bmj.324.7343.942			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	544UF	11964338	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000175179500015
J	Pinkney, J; Williams, G				Pinkney, J; Williams, G			Ghrelin gets hungry	LANCET			English	Editorial Material							GROWTH-HORMONE DEFICIENCY; QUALITY-OF-LIFE		Univ Liverpool, Univ Hosp Aintree,Ctr Clin Sci, Dept Med, Diabet & Endocrinol Res Grp, Liverpool L9 7AL, Merseyside, England	University of Liverpool	Pinkney, J (corresponding author), Univ Liverpool, Univ Hosp Aintree,Ctr Clin Sci, Dept Med, Diabet & Endocrinol Res Grp, Liverpool L9 7AL, Merseyside, England.							Ariyasu H, 2001, J CLIN ENDOCR METAB, V86, P4753, DOI 10.1210/jc.86.10.4753; Arvat E, 2000, J ENDOCRINOL INVEST, V23, P493, DOI 10.1007/BF03343763; Bing C, 2000, CANCER RES, V60, P2405; Cummings DE, 2001, DIABETES, V50, P1714, DOI 10.2337/diabetes.50.8.1714; Date Y, 2002, DIABETES, V51, P124, DOI 10.2337/diabetes.51.1.124; Kamegai J, 2001, DIABETES, V50, P2438, DOI 10.2337/diabetes.50.11.2438; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kojima M, 2001, TRENDS ENDOCRIN MET, V12, P118, DOI 10.1016/S1043-2760(00)00362-3; Lee HM, 2002, ENDOCRINOLOGY, V143, P185, DOI 10.1210/en.143.1.185; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Palmiter RD, 1998, RECENT PROG HORM RES, V53, P163; Shintani M, 2001, DIABETES, V50, P227, DOI 10.2337/diabetes.50.2.227; Tschop M, 2001, DIABETES, V50, P707, DOI 10.2337/diabetes.50.4.707; Wallymahmed ME, 1997, CLIN ENDOCRINOL, V47, P439, DOI 10.1046/j.1365-2265.1997.2801076.x; Wallymahmed ME, 1999, CLIN ENDOCRINOL, V51, P333; Williams G, 2001, PHYSIOL BEHAV, V74, P683, DOI 10.1016/S0031-9384(01)00612-6; Wisse BE, 2001, ENDOCRINOLOGY, V142, P3292, DOI 10.1210/en.142.8.3292; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540	19	23	26	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1360	1361		10.1016/S0140-6736(02)08387-3	http://dx.doi.org/10.1016/S0140-6736(02)08387-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978327				2022-12-28	WOS:000175076200002
J	Serghides, L; Kain, KC				Serghides, L; Kain, KC			Mechanism of protection induced by vitamin A in falciparum malaria	LANCET			English	Article							PLASMODIUM-FALCIPARUM	Supplementation with vitamin A potentiates host resistance to malaria, however, the underlying mechanism is unknown. We tested the effects of 9-cis-retinolc acid, a metabolite of vitamin A, on CD36 expression, non-opsonic phagocytic clearance of parasitised erythrocytes, and TNFalpha production in human monocytes and macrophages. We found reduced secretion of TNFalpha, upregulated CD36 expression, and increased phagocytosis of Plasmodium falciparum-parasitised erythrocytes. Increased parasite clearance and reduced proinflammatory cytokine responses to Infection might partly explain the beneficial effects of supplementation with vitamin A in malaria.	Toronto Gen Hosp, Dept Med, Div Infect Dis, Trop Dis Unit, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto	Kain, KC (corresponding author), Toronto Gen Hosp, Dept Med, Div Infect Dis, Trop Dis Unit, Toronto, ON M5G 2C4, Canada.		Serghides, Lena/C-7968-2018	Serghides, Lena/0000-0002-2817-6134; Kain, Kevin/0000-0001-6068-1272				McGilvray ID, 2000, BLOOD, V96, P3231, DOI 10.1182/blood.V96.9.3231; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; Serghides L, 2001, J IMMUNOL, V166, P6742, DOI 10.4049/jimmunol.166.11.6742; Shankar AH, 2000, J INFECT DIS, V182, pS37, DOI 10.1086/315906; Shankar AH, 1999, LANCET, V354, P203, DOI 10.1016/S0140-6736(98)08293-2	5	47	49	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1404	1406		10.1016/S0140-6736(02)08360-5	http://dx.doi.org/10.1016/S0140-6736(02)08360-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978340				2022-12-28	WOS:000175076200015
J	Cannon, RO				Cannon, RO			Perspective - Restenosis after angioplasty	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NHLBI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Cannon, RO (corresponding author), NHLBI, Bldg 10, Bethesda, MD 20892 USA.								0	10	11	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	2002	346	16					1182	1183		10.1056/NEJM200204183461602	http://dx.doi.org/10.1056/NEJM200204183461602			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542FT	11961145				2022-12-28	WOS:000175033400001
J	Childers, SE; Ciufo, S; Lovley, DR				Childers, SE; Ciufo, S; Lovley, DR			Geobacter metallireducens accesses insoluble Fe(III) oxide by chemotaxis	NATURE			English	Article							IRON REDUCTION; IV PILI; OXIDATION; MICROORGANISM; BIOGENESIS; MANGANESE; SEDIMENTS; MOTILITY; BENZENE; AQUIFER	Microorganisms that use insoluble Fe(III) oxide as an electron acceptor can have an important function in the carbon and nutrient cycles of aquatic sediments and in the bioremediation of organic and metal contaminants in groundwater(1,2). Although Fe(III) oxides are often abundant, Fe(III)-reducing microbes are faced with the problem of how to access effectively an electron acceptor that can not diffuse to the cell. Fe(III)-reducing microorganisms in the genus Shewanella have resolved this problem by releasing soluble quinones that can carry electrons from the cell surface to Fe(III) oxide that is at a distance from the cell(3,4). Here we report that another Fe(III)-reducer, Geobacter metallireducens, has an alternative strategy for accessing Fe( III) oxides. Geobacter metallireducens specifically expresses flagella and pili only when grown on insoluble Fe(III) or Mn(IV) oxide, and is chemotactic towards Fe(II) and Mn( II) under these conditions. These results suggest that G. metallireducens senses when soluble electron acceptors are depleted and then synthesizes the appropriate appendages to permit it to search for, and establish contact with, insoluble Fe( III) or Mn( IV) oxide. This approach to the use of an insoluble electron acceptor may explain why Geobacter species predominate over other Fe( III) oxide-reducing microorganisms in a wide variety of sedimentary environments(5-8).	Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Lovley, DR (corresponding author), Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA.							Alm RA, 1997, GENE, V192, P89, DOI 10.1016/S0378-1119(96)00805-0; HENRICHSEN J, 1983, ANNU REV MICROBIOL, V37, P81, DOI 10.1146/annurev.mi.37.100183.000501; Lovley D. R., 2000, FE 3 MN4 REDUCTION E, P3; LOVLEY DR, 1987, NATURE, V330, P252, DOI 10.1038/330252a0; LOVLEY DR, 1989, NATURE, V339, P297, DOI 10.1038/339297a0; LOVLEY DR, 1988, APPL ENVIRON MICROB, V54, P1472, DOI 10.1128/AEM.54.6.1472-1480.1988; LOVLEY DR, 1993, ARCH MICROBIOL, V159, P336, DOI 10.1007/BF00290916; Macnab RM, 1996, ESCHERICHIA COLI SAL, V1, P123; NEALSON KH, 1995, APPL ENVIRON MICROB, V61, P1551, DOI 10.1128/AEM.61.4.1551-1554.1995; NEVIN KP, 2000, ASM 100 GEN M ASM WA, P598; NEVIN KP, 2001, ASM 101 GEN M ASM WA, P588; Newman DK, 2000, NATURE, V405, P94, DOI 10.1038/35011098; Parales RE, 2000, APPL ENVIRON MICROB, V66, P4098, DOI 10.1128/AEM.66.9.4098-4104.2000; PHILLIPS EJP, 1987, SOIL SCI SOC AM J, V51, P938, DOI 10.2136/sssaj1987.03615995005100040021x; Roling WFM, 2001, APPL ENVIRON MICROB, V67, P4619, DOI 10.1128/AEM.67.10.4619-4629.2001; Rooney-Varga JN, 1999, APPL ENVIRON MICROB, V65, P3056; Snoeyenbos-West OL, 2000, MICROBIAL ECOL, V39, P153, DOI 10.1007/s002480000018; Stein LY, 2001, ENVIRON MICROBIOL, V3, P10, DOI 10.1046/j.1462-2920.2001.00154.x; STROM MS, 1993, ANNU REV MICROBIOL, V47, P565, DOI 10.1146/annurev.micro.47.1.565; Thamdrup B, 2000, ADV MICROB ECOL, V16, P41; Wall D, 1999, MOL MICROBIOL, V32, P1, DOI 10.1046/j.1365-2958.1999.01339.x; Wu SS, 1997, J BACTERIOL, V179, P7748, DOI 10.1128/jb.179.24.7748-7758.1997	22	306	331	19	245	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					767	769		10.1038/416767a	http://dx.doi.org/10.1038/416767a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961561				2022-12-28	WOS:000175033500049
J	Niimura, H; Tei, C				Niimura, H; Tei, C			Coronary-artery fistula with a giant aneurysm	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Kagoshima Univ, Kagoshima 8908520, Japan	Kagoshima University	Niimura, H (corresponding author), Kagoshima Univ, Kagoshima 8908520, Japan.		Niimura, Hideshi/H-1814-2012						0	3	3	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	2002	346	16					1211	1211		10.1056/NEJMicm000094	http://dx.doi.org/10.1056/NEJMicm000094			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542FT	11961150				2022-12-28	WOS:000175033400006
J	McNutt, RA; Abrams, R; Aron, DC				McNutt, RA; Abrams, R; Aron, DC		Patient Safety Comm	Patient safety efforts should focus on medical errors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN ORDER ENTRY; ADVERSE EVENTS; STRATEGY		Rush Presbyterian St Lukes Med Ctr, Dept Med, Chicago, IL 60612 USA; Louis Stokes Cleveland Dept Vet Affairs Med Ctr, VA Qual Scholars Program, Cleveland, OH USA; Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA	Rush University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Case Western Reserve University	McNutt, RA (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Med, 1700 W Van Buren, Chicago, IL 60612 USA.							Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; Berwick DM, 2001, BMJ-BRIT MED J, V322, P247, DOI 10.1136/bmj.322.7281.247; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Burroughs T E, 2000, Jt Comm J Qual Improv, V26, P439; Cook RI, 1994, HUMAN ERROR MED, P255; Dettmer H. W., 1997, GOLDRATTS THEORY CON; Feldman L, 1997, SURGERY, V122, P711, DOI 10.1016/S0039-6060(97)90078-7; Goldratt E. M., 1992, GOAL; Goldratt EM, 1994, ITS NOT LUCK; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; HOGARTH RM, 1987, JUDGEMENT CHOICE; *I MED, 2002, CROSS QUAL CHASM NEW; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; Leape LL, 2000, JAMA-J AM MED ASSOC, V284, P95, DOI 10.1001/jama.284.1.95; McDonald CJ, 2000, JAMA-J AM MED ASSOC, V284, P93, DOI 10.1001/jama.284.1.93; McNutt Robert, 2002, Eff Clin Pract, V5, P23; Nolan TW, 2000, BMJ-BRIT MED J, V320, P771, DOI 10.1136/bmj.320.7237.771; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; PERROW C, 1999, NORMAL ACCIDENTS LIV; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V104, P587, DOI 10.1093/oxfordjournals.aje.a112335; Sox H C Jr, 2000, Eff Clin Pract, V3, P277; Teich JM, 2000, ARCH INTERN MED, V160, P2741, DOI 10.1001/archinte.160.18.2741; Welsh CH, 1996, J GEN INTERN MED, V11, P454, DOI 10.1007/BF02599039	26	61	63	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2002	287	15					1997	2001		10.1001/jama.287.15.1997	http://dx.doi.org/10.1001/jama.287.15.1997			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NC	11960545				2022-12-28	WOS:000174989800031
J	Favreau, JT; Ryu, ML; Braunstein, G; Orshansky, G; Park, SS; Coody, GL; Love, LA; Fong, TL				Favreau, JT; Ryu, ML; Braunstein, G; Orshansky, G; Park, SS; Coody, GL; Love, LA; Fong, TL			Severe hepatotoxicity associated with the dietary supplement LipoKinetix	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; PHENYLPROPANOLAMINE; POTENTIATION; OBESITY	Background: LipoKinetix (Syntrax, Cape Girardeau, Missouri) is a dietary supplement marketed for weight loss. Objective: To describe a possible causal association between LipoKinetix and hepatotoxicity. Design: Case series. Setting: Outpatient clinic, tertiary care hospital, and U.S. Food and Drug Administration databases. Intervention: Routine medical and supportive care. Measurements: Clinical and laboratory evaluation. Results: All patients developed acute hepatotoxicity within 3 months of starting LipoKinetix. At presentation, symptoms and results of laboratory tests were characteristic of acute hepatitis. All patients recovered spontaneously after LipoKinetix use was discontinued. Three of the seven patients, including one who developed fulminant hepatic failure complicated by cerebral edema,were taking LipoKinetix alone at the time of presentation. Of the four patients who were taking multiple supplements, two resumed taking supplements other than LipoKinetix without incident. Conclusions: The use of LipoKinetix may be associated with hepatotoxicity, Despite extensive evaluations, no other cause for hepatotoxicity could be identified in the seven patients studied.	Univ Calif Los Angeles, Cedars Sinai Med Ctrm,Sch Med, Dept Internal Med, Burns & Allen Res Inst, Los Angeles, CA 90048 USA; US FDA, Ctr Food Safety & Appl Nutr, Washington, DC 20204 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Food & Drug Administration (FDA)	Favreau, JT (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctrm,Sch Med, Dept Internal Med, Burns & Allen Res Inst, Becker Bldg 120,8700 Beverly Blvd, Los Angeles, CA 90048 USA.	joya.favreau@cshs.org						Abo-Khatwa A. N., 1996, Natural Toxins, V4, P96, DOI 10.1002/19960402NT7; Allison DB, 1999, JAMA-J AM MED ASSOC, V282, P1530, DOI 10.1001/jama.282.16.1530; Bensky D, 1993, CHINESE HERBAL MED M; BRAUNSTEIN GD, 1986, WESTERN J MED, V145, P388; Dahm L.J., 1996, HEPATOLOGY TXB LIVER, P875; DUNBABIN DW, 1992, MED J AUSTRALIA, V157, P835; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; FONG TL, 1992, J CLIN GASTROENTEROL, V14, P240, DOI 10.1097/00004836-199204000-00010; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; HOFFMANN BB, 1990, GOODMAN GILMANS PHAR, P229; JAMES RC, 1993, TOXICOL APPL PHARM, V118, P159, DOI 10.1006/taap.1993.1021; Kaplowitz N, 2000, J HEPATOL, V32, P39, DOI 10.1016/S0168-8278(00)80414-6; KEW J, 1993, BRIT MED J, V306, P506, DOI 10.1136/bmj.306.6876.506; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; Nadir A, 1996, AM J GASTROENTEROL, V91, P1436; PERHARIC L, 1993, LANCET, V342, P180, DOI 10.1016/0140-6736(93)91389-4; ROBERTS SM, 1991, TOXICOL APPL PHARM, V111, P175, DOI 10.1016/0041-008X(91)90022-7; Slifman NR, 1998, NEW ENGL J MED, V339, P806, DOI 10.1056/NEJM199809173391204; Vessey DA, 1996, HEPATHOLOGY TXB LIVE, V9, P257	19	119	121	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2002	136	8					590	595		10.7326/0003-4819-136-8-200204160-00008	http://dx.doi.org/10.7326/0003-4819-136-8-200204160-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	543WY	11955027				2022-12-28	WOS:000175125800004
J	Stern, MP; Williams, K; Haffner, SA				Stern, MP; Williams, K; Haffner, SA			Identification of persons at high risk for type 2 diabetes mellitus: Do we need the oral glucose tolerance test?	ANNALS OF INTERNAL MEDICINE			English	Article							OPERATING CHARACTERISTIC CURVES; AREAS	Background: The standard method of identifying persons at high risk for type 2 diabetes mellitus involves detection of impaired glucose tolerance, which requires a costly and inconvenient 2-hour oral glucose tolerance test. Because clinical trials have indicated that diabetes is preventable by using behavioral or pharmacologic interventions, less expensive methods of identifying high-risk persons are needed. Objective: To determine whether multivariable models are superior to glucose tolerance tests for identifying persons at high risk for diabetes mellitus. Design: Prospective cohort study. Setting: San Antonio, Texas. Participants: 1791 Mexican Americans and 1112 non-Hispanic whites without diabetes at baseline who were randomly selected from census tracts. Measurements: Medical history; body mass index; blood pressure; fasting and 2-hour plasma glucose levels; fasting serum total, low-density lipoprotein, and high-density lipoprotein cholesterol levels; and triglyceride level. Results: For prediction of 7.5-year incidence of type 2 diabetes, the area under the receiver-operating characteristic (ROC) curve for a multivariable model involving readily available clinical variables was significantly (P < 0.001) greater than the area under the ROC curve for the 2-hour glucose value alone (84.3% vs. 77.5%). Impaired glucose tolerance represents a single point on the latter curve. Adding the 2-hour glucose measurement to the multivariable model increased the area under its ROC curve, but only from 84.3% to 85.7%. Conclusion: Persons at high risk for diabetes mellitus are better identified by using a simple prediction model than by relying exclusively on the results of a 2-hour oral glucose tolerance test. Although adding the 2-hour glucose variable to the model enhanced prediction, the resulting slight improvement entails greater cost and inconvenience.	Univ Texas, Hlth Sci Ctr, Dept Med, Div Clin Epidemiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Stern, MP (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med, Div Clin Epidemiol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	stern@uthscsa.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036820, R01HL024799] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL24799, R01 HL36820] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Burke JP, 1999, ARCH INTERN MED, V159, P1450, DOI 10.1001/archinte.159.13.1450; Burke JP, 1998, DIABETES CARE, V21, P1266, DOI 10.2337/diacare.21.8.1266; CHIASSON JL, IN PRESS LANCET; CLEVES M, 1999, STATA TECHNICAL B, V52, P19; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Gavin JR, 1997, DIABETES CARE, V20, P1183; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Harrell FE, 2001, REGRESSION MODELING, P87, DOI 10.1007/978-1-4757-3462-1; HARRIS M, 1979, DIABETES, V28, P1039; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; LITTLE RR, 1988, DIABETES, V37, P60, DOI 10.2337/diabetes.37.1.60; REAVEN GM, 1972, LANCET, V1, P1247; *SAS I, 2001, SAS VERS 8 0; STERN MP, 1984, AM J EPIDEMIOL, V120, P834, DOI 10.1093/oxfordjournals.aje.a113956; STERN MP, 1989, JAMA-J AM MED ASSOC, V262, P360, DOI 10.1001/jama.262.3.360; STOLK RP, 1995, DIABETES CARE, V18, P1045, DOI 10.2337/diacare.18.7.1045; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; *WHO DEP NONC DIS, 1999, DEF DIAGN CLASS DIAB; *WHO EXP COMM DIAB, 1980, WHO TECH REP SER, V646, P9	19	396	411	0	31	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2002	136	8					575	581		10.7326/0003-4819-136-8-200204160-00006	http://dx.doi.org/10.7326/0003-4819-136-8-200204160-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	543WY	11955025				2022-12-28	WOS:000175125800002
J	Clark, TG; Altman, DG; De Stavola, BL				Clark, TG; Altman, DG; De Stavola, BL			Quantification of the completeness of follow-up	LANCET			English	Article								Completeness of follow-up is important, especially In clinical trials, since unequal follow-up In the treatment groups can bias the analysis of results. In survival studies, information on participants who do not complete the study is often omitted because their data can be Included up to the time at which they were lost to follow-up. We propose a simple measure of completeness that Is the ratio of the total observed person-time and the potential person-time of follow-up in a study. Our measure is easy to calculate, can be Illustrated pictorially, and can be used to Identify subgroups with especially poor follow-up.	Inst Hlth Sci, Ctr Stat Med, Oxford OX3 7LF, England; London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Med Stat Unit, London W1CE 7HT, England	University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Clark, TG (corresponding author), Inst Hlth Sci, Ctr Stat Med, Oxford OX3 7LF, England.	taane.clark@cancer.org.uk	Clark, Taane G./AAM-2570-2020	Clark, Taane G./0000-0001-8985-9265; De Stavola, Bianca Lucia/0000-0001-7853-0528				CHRISTENSEN E, 1985, GASTROENTEROLOGY, V89, P1084, DOI 10.1016/0016-5085(85)90213-6; Clark TG, 2001, BRIT J CANCER, V85, P944, DOI 10.1054/bjoc.2001.2030; CUZICK J, 1990, BRIT J HAEMATOL, V75, P506, DOI 10.1111/j.1365-2141.1990.tb07790.x; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X	5	308	309	1	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	2002	359	9314					1309	1310		10.1016/S0140-6736(02)08272-7	http://dx.doi.org/10.1016/S0140-6736(02)08272-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965278				2022-12-28	WOS:000174989700015
J	Mackey, D; Holt, BF; Wiig, A; Dangl, JL				Mackey, D; Holt, BF; Wiig, A; Dangl, JL			RIN4 interacts with Pseudomonas syringae type III effector molecules and is required for RPM1-mediated resistance in Arabidopsis	CELL			English	Article							PLANT-DISEASE-RESISTANCE; HYPERSENSITIVE CELL-DEATH; LEUCINE-RICH REPEATS; FOR-GENE CONCEPT; SIGNAL-TRANSDUCTION; AVIRULENCE GENES; PROTEINS; RPM1; SPECIFICITY; VIRULENCE	In Arabidopsis, RPM1 confers resistance against Pseudomonas syringae expressing either of two sequence unrelated type III effectors, AvrRpm1 or AvrB. An RPM1-interacting protein (RIN4) coimmunoprecipitates from plant cell extracts with AvrB, AvrRpm1, or RPM1. Reduction of RIN4 protein levels inhibits both the hypersensitive response and the restriction of pathogen growth controlled by RPM1. RIN4 reduction causes diminution of RPM1. RIN4 reduction results in heightened resistance to virulent Peronospora parasitica and P. syringae, and ectopic defense gene expression. Thus, RIN4 positively regulates RPM1-mediated resistance yet is, formally, a negative regulator of basal defense responses. AvrRpm1 and AvrB induce RIN4 phosphorylation. This may enhance RIN4 activity as a negative regulator of plant defense, facilitating pathogen growth. RPM1 may "guard" against pathogens that use AvrRpm1 and AvrB to manipulate RIN4 activity.	Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Dangl, JL (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Cooker Hall CB 3280, Chapel Hill, NC 27599 USA.		Holt, Ben F/D-1513-2011					Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; Aravind L, 1999, TRENDS BIOCHEM SCI, V24, P47, DOI 10.1016/S0968-0004(98)01341-3; ASHFIELD T, 1995, GENETICS, V141, P1597; BAKER CJ, 1991, PHYTOPATHOLOGY, V81, P1504, DOI 10.1094/Phyto-81-1504; Banerjee D, 2001, GENETICS, V158, P439; Beers EP, 2001, CURR OPIN PLANT BIOL, V4, P561, DOI 10.1016/S1369-5266(00)00216-8; BISGROVE SR, 1994, PLANT CELL, V6, P927, DOI 10.1105/tpc.6.7.927; Boyes DC, 1998, P NATL ACAD SCI USA, V95, P15849, DOI 10.1073/pnas.95.26.15849; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chen ZY, 2000, MOL PLANT MICROBE IN, V13, P1312, DOI 10.1094/MPMI.2000.13.12.1312; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Dangl J. L., 1992, Methods in Arabidopsis research., P393; DANGL JL, 1992, PLANT CELL, V4, P1359, DOI 10.1105/tpc.4.11.1359; Dangl JL, 2001, NATURE, V411, P826, DOI 10.1038/35081161; Dangl JL, 1996, PLANT CELL, V8, P1793, DOI 10.1105/tpc.8.10.1793; DIETRICH A, 1990, J BIOL CHEM, V265, P6360; Duan YP, 1999, MOL PLANT MICROBE IN, V12, P556, DOI 10.1094/MPMI.1999.12.6.556; Ellis J, 2000, TRENDS PLANT SCI, V5, P373, DOI 10.1016/S1360-1385(00)01694-0; Feys BJ, 2000, TRENDS GENET, V16, P449, DOI 10.1016/S0168-9525(00)02107-7; FINLEY RL, 1996, GENE PROBES PRACTICA; FLOR HH, 1971, ANNU REV PHYTOPATHOL, V9, P275, DOI 10.1146/annurev.py.09.090171.001423; Glazebrook J, 2001, CURR OPIN PLANT BIOL, V4, P301, DOI 10.1016/S1369-5266(00)00177-1; Gopalan S, 1996, PLANT CELL, V8, P1095, DOI 10.1105/tpc.8.7.1095; Grant M, 2000, PLANT J, V23, P441, DOI 10.1046/j.1365-313x.2000.00804.x; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; GYURIUS J, 1996, CELL, V75, P791; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004; Jones DA, 1996, ADV BOT RES ADV PLAN, V24, P90; Kajava AV, 1998, J MOL BIOL, V277, P519, DOI 10.1006/jmbi.1998.1643; Leister RT, 2000, PLANT J, V22, P345, DOI 10.1046/j.1365-313x.2000.00744.x; Leister RT, 1996, P NATL ACAD SCI USA, V93, P15497, DOI 10.1073/pnas.93.26.15497; Luck JE, 2000, PLANT CELL, V12, P1367, DOI 10.1105/tpc.12.8.1367; McDowell JM, 2000, TRENDS BIOCHEM SCI, V25, P79, DOI 10.1016/S0968-0004(99)01532-7; McDowell JM, 1998, PLANT CELL, V10, P1861, DOI 10.1105/tpc.10.11.1861; MOREL JB, 1997, CELL DEATH DIFFER, V19, P17; Nimchuk Z, 2000, CELL, V101, P353, DOI 10.1016/S0092-8674(00)80846-6; Nimchuk Z, 2001, CURR OPIN PLANT BIOL, V4, P288, DOI 10.1016/S1369-5266(00)00175-8; Petersen M, 2000, CELL, V103, P1111, DOI 10.1016/S0092-8674(00)00213-0; RITTER C, 1995, MOL PLANT MICROBE IN, V8, P444, DOI 10.1094/MPMI-8-0444; Scheel D, 1998, CURR OPIN PLANT BIOL, V1, P305, DOI 10.1016/1369-5266(88)80051-7; Shan LB, 2000, PLANT CELL, V12, P2323, DOI 10.1105/tpc.12.12.2323; TOMERO P, 2001, PLANT J, V28, P475; TOMERO P, 2002, IN PRESS PLANT CELL; Tsiamis G, 2000, EMBO J, V19, P3204, DOI 10.1093/emboj/19.13.3204; van der Biezen EA, 2000, P NATL ACAD SCI USA, V97, P3747, DOI 10.1073/pnas.060392397; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; van der Biezen EA, 1998, TRENDS BIOCHEM SCI, V23, P454, DOI 10.1016/S0968-0004(98)01311-5; VandenAckerveken G, 1996, CELL, V87, P1307, DOI 10.1016/S0092-8674(00)81825-5; Vogel J, 2000, P NATL ACAD SCI USA, V97, P1897, DOI 10.1073/pnas.030531997	50	835	876	10	171	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 22	2002	108	6					743	754		10.1016/S0092-8674(02)00661-X	http://dx.doi.org/10.1016/S0092-8674(02)00661-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955429	Bronze, Green Published			2022-12-28	WOS:000174563000005
J	Lendlein, A; Langer, R				Lendlein, A; Langer, R			Biodegradable, elastic shape-memory polymers for potential biomedical applications	SCIENCE			English	Article							POLYETHER-BASED POLYURETHANES; THERMOMECHANICAL PROPERTIES; BEHAVIOR; POLYNORBORNENE; COPOLYMERS; SERIES	The introduction of biodegradable implant materials as well as minimally invasive surgical procedures in medicine has substantially improved health care within the past few decades. This report describes a group of degradable thermoplastic polymers that are able to change their shape after an increase in temperature. Their shape-memory capability enables bulky implants to be placed in the body through small incisions or to perform complex mechanical deformations automatically. A smart degradable suture was created to illustrate the potential of these shape-memory thermoplastics in biomedical applications.	mnemoSci GmbH, D-52074 Aachen, Germany; Rhein Westfal TH Aachen, Inst Tech & Macromol Chem, Aachen, Germany; MIT, Dept Chem Engn, Cambridge, MA 02139 USA	RWTH Aachen University; Massachusetts Institute of Technology (MIT)	Lendlein, A (corresponding author), mnemoSci GmbH, Pauwelsstr 19, D-52074 Aachen, Germany.	a.lendlein@mnemoscience.de	Lendlein, Andreas/K-9553-2013	Lendlein, Andreas/0000-0003-4126-4670				CHARLESBY A, 1960, ATOMIC RAD POLYM, P198; CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056; Fu K, 2000, PHARM RES-DORDR, V17, P100, DOI 10.1023/A:1007582911958; GRABLOWITZ HG, UNPUB; Hodgson NCF, 2000, ANN SURG, V231, P436, DOI 10.1097/00000658-200003000-00018; Hoer J, 2001, LANGENBECK ARCH SURG, V386, P218, DOI 10.1007/s004230000196; Hooper KA, 1998, J BIOMED MATER RES, V41, P443, DOI 10.1002/(SICI)1097-4636(19980905)41:3<443::AID-JBM14>3.0.CO;2-J; HU ZB, 1995, SCIENCE, V269, P525, DOI 10.1126/science.269.5223.525; Hunter J. G., 1993, MINIMALLY INVASIVE S; Kagami Y, 1996, MACROMOL RAPID COMM, V17, P539, DOI 10.1002/marc.1996.030170806; Kim BK, 1996, POLYMER, V37, P5781, DOI 10.1016/S0032-3861(96)00442-9; Lendlein A, 2001, P NATL ACAD SCI USA, V98, P842, DOI 10.1073/pnas.031571398; Lendlein A, 1999, CHEM UNSERER ZEIT, V33, P279, DOI 10.1002/ciuz.19990330505; Lendlein A, 2000, MACROMOL CHEM PHYS, V201, P1067; Lin JR, 1998, J APPL POLYM SCI, V69, P1563, DOI 10.1002/(SICI)1097-4628(19980822)69:8<1563::AID-APP11>3.0.CO;2-W; Lin JR, 1998, J APPL POLYM SCI, V69, P1575, DOI 10.1002/(SICI)1097-4628(19980822)69:8<1575::AID-APP12>3.0.CO;2-U; MAK AFT, 1998, HDB BIOMATERIAL PROP, P66; OSADA Y, 1995, NATURE, V376, P219, DOI 10.1038/376219a0; SAKURAI K, 1993, J APPL POLYM SCI, V47, P937, DOI 10.1002/app.1993.070470521; SAKURAI K, 1994, POLYMER, V35, P4238, DOI 10.1016/0032-3861(94)90602-5; SAKURAI K, 1989, J APPL POLYM SCI, V38, P1191, DOI 10.1002/app.1989.070380616; SCHETKY LM, 1979, SCI AM, V241, P74, DOI 10.1038/scientificamerican1179-74; SPANELBOROWSKI K, 1989, RES EXP MED, V189, P69, DOI 10.1007/BF01856032; SWAIN MV, 1986, NATURE, V322, P234, DOI 10.1038/322234a0; Takahashi T, 1996, J APPL POLYM SCI, V60, P1061; Tobushi H, 1996, P SOC PHOTO-OPT INS, V2716, P46, DOI 10.1117/12.232168; Tobushi H, 1996, J PHYS IV, V6, P377, DOI 10.1051/jp4:1996136; Van Humbeeck J, 1999, MAT SCI ENG A-STRUCT, V273, P134, DOI 10.1016/S0921-5093(99)00293-2	28	1747	2027	71	1739	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	2002	296	5573					1673	1676		10.1126/science.1066102	http://dx.doi.org/10.1126/science.1066102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	558PR	11976407				2022-12-28	WOS:000175976200053
J	Nohturfft, A; Losick, R				Nohturfft, A; Losick, R			Cell biology - Fats, flies, and palmitate	SCIENCE			English	Editorial Material									Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Nohturfft, A (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.			Nohturfft, Axel/0000-0001-9484-3209				Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; Yoshikawa T, 2002, J BIOL CHEM, V277, P1705, DOI 10.1074/jbc.M105711200	5	9	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					857	858		10.1126/science.1072154	http://dx.doi.org/10.1126/science.1072154			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988558				2022-12-28	WOS:000175442500027
J	van Meer, G				van Meer, G			Cell biology - The different hues of lipid rafts	SCIENCE			English	Editorial Material							GPI-ANCHORED PROTEINS; CHOLESTEROL; MEMBRANES; LOCALIZATION; ACYLATION		Univ Utrecht, Biomembrane Inst, CBLE, Dept Membrane Enzymol, NL-3584 CH Utrecht, Netherlands	Utrecht University	van Meer, G (corresponding author), Univ Utrecht, Biomembrane Inst, CBLE, Dept Membrane Enzymol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		van Meer, Gerrit/AAH-1560-2021	van Meer, Gerrit/0000-0002-5976-6436				Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Dietrich C, 2001, P NATL ACAD SCI USA, V98, P10642, DOI 10.1073/pnas.191168698; Hao MM, 2001, P NATL ACAD SCI USA, V98, P13072, DOI 10.1073/pnas.231377398; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Liang XQ, 2001, J BIOL CHEM, V276, P30987, DOI 10.1074/jbc.M104018200; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; Milhiet PE, 2002, J BIOL CHEM, V277, P875, DOI 10.1074/jbc.C100654200; Pierce SK, 2002, NAT REV IMMUNOL, V2, P96, DOI 10.1038/nri726; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zhang M, 2001, J BIOL CHEM, V276, P3417, DOI 10.1074/jbc.M005393200	12	86	90	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					855	+		10.1126/science.1071491	http://dx.doi.org/10.1126/science.1071491			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988557	Green Submitted			2022-12-28	WOS:000175442500026
J	Douek, DC; Brenchley, JM; Betts, MR; Ambrozak, DR; Hill, BJ; Okamoto, Y; Casazza, JP; Kuruppu, J; Kuntsman, K; Wolinsky, S; Grossman, Z; Dybul, M; Oxenius, A; Price, DA; Connors, M; Koup, RA				Douek, DC; Brenchley, JM; Betts, MR; Ambrozak, DR; Hill, BJ; Okamoto, Y; Casazza, JP; Kuruppu, J; Kuntsman, K; Wolinsky, S; Grossman, Z; Dybul, M; Oxenius, A; Price, DA; Connors, M; Koup, RA			HIV preferentially infects HIV-specific CD4(+) T cells	NATURE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; ANTIGENIC-STIMULATION; IMMUNE-RESPONSES; CD8(+); DISCONTINUATION; IDENTIFICATION; INDIVIDUALS; REPLICATION; RESERVOIR; DYNAMICS	HIV infection is associated with the progressive loss of CD4(+) T cells through their destruction or decreased production(1,2). A central, yet unresolved issue of HIV disease is the mechanism for this loss, and in particular whether HIV-specific CD4(+) T cells are preferentially affected(3-5). Here we show that HIV-specific memory CD4(+) T cells in infected individuals contain more HIV viral DNA than other memory CD4(+) T cells, at all stages of HIV disease. Additionally, following viral rebound during interruption of antiretroviral therapy, the frequency of HIV viral DNA in the HIV-specific pool of memory CD4(+) T cells increases to a greater extent than in memory CD4(+) T cells of other specificities. These findings show that HIV-specific CD4(+) T cells are preferentially infected by HIV in vivo. This provides a potential mechanism to explain the loss of HIV-specific CD4(+) T-cell responses, and consequently the loss of immunological control of HIV replication(6). Furthermore, the phenomenon of HIV specifically infecting the very cells that respond to it adds a cautionary note to the practice of structured therapy interruption.	NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA; NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; NCI, Dept Expt Transplantat & Immunol, Med Branch, NIH, Bethesda, MD 20892 USA; Univ Texas, SW Med Ctr, Dept Med, Dallas, TX 75390 USA; Northwestern Univ, Sch Med, Dept Infect Dis, Chicago, IL 60611 USA; Tel Aviv Univ, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; NIAID, Immunol Lab, NIH, Bethesda, MD 20892 USA; John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Northwestern University; Tel Aviv University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Oxford	Douek, DC (corresponding author), NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA.	ddouek@mail.nih.gov	Price, David A/C-7876-2013; Brenchley, Jason/AAC-5085-2019; Oxenius, Annette/G-7794-2015; Wolinsky, Steven/B-2893-2012; Grossman, Zvi/A-9643-2008	Price, David A/0000-0001-9416-2737; Wolinsky, Steven/0000-0002-9625-6697; Kuruppu, Janaki/0000-0003-0833-6126; Brenchley, Jason/0000-0001-8357-2984	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI005034, Z01AI005014, ZIAAI000855, Z01AI000855, ZIAAI005014, Z01AI005034] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Altfeld M, 2001, NAT MED, V7, P881, DOI 10.1038/90901; Altfeld M, 2001, J EXP MED, V193, P169, DOI 10.1084/jem.193.2.169; Betts MR, 2001, J VIROL, V75, P11983, DOI 10.1128/JVI.75.24.11983-11991.2001; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Blancou P, 2001, P NATL ACAD SCI USA, V98, P13237, DOI 10.1073/pnas.231348598; CARCHEDI G, 1975, ECON SOC, V4, P1, DOI 10.1080/03085147500000001; Cheynier R, 1998, NAT MED, V4, P421, DOI 10.1038/nm0498-421; Chun TW, 1997, J VIROL, V71, P4436, DOI 10.1128/JVI.71.6.4436-4444.1997; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Deeks SG, 2001, NEW ENGL J MED, V344, P472, DOI 10.1056/NEJM200102153440702; Dybul M, 2001, P NATL ACAD SCI USA, V98, P15161, DOI 10.1073/pnas.261568398; Eckstein DA, 2001, IMMUNITY, V15, P671, DOI 10.1016/S1074-7613(01)00217-5; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Grossman Z, 1998, P NATL ACAD SCI USA, V95, P6314, DOI 10.1073/pnas.95.11.6314; Haase AT, 1996, SCIENCE, V274, P985, DOI 10.1126/science.274.5289.985; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Hanon E, 2000, IMMUNITY, V13, P657, DOI 10.1016/S1074-7613(00)00065-0; Kalams SA, 1999, J VIROL, V73, P6715, DOI 10.1128/JVI.73.8.6715-6720.1999; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; McNeil AC, 2001, P NATL ACAD SCI USA, V98, P13878, DOI 10.1073/pnas.251539598; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Pitcher CJ, 1999, NAT MED, V5, P518, DOI 10.1038/8400; Rosenberg ES, 2000, NATURE, V407, P523, DOI 10.1038/35035103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowland-Jones S, 1999, LANCET, V354, P5, DOI 10.1016/S0140-6736(99)90017-X; Waldrop SL, 1997, J CLIN INVEST, V99, P1739, DOI 10.1172/JCI119338; Wilson JDK, 2000, J INFECT DIS, V182, P792, DOI 10.1086/315764; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	32	950	980	5	62	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	MAY 2	2002	417	6884					95	98		10.1038/417095a	http://dx.doi.org/10.1038/417095a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986671				2022-12-28	WOS:000175307200045
J	Crawford, LM				Crawford, LM			Patient safety news	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Rockville, MD 20857 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2203	2203		10.1001/jama.287.17.2203	http://dx.doi.org/10.1001/jama.287.17.2203			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980508				2022-12-28	WOS:000175260600008
J	Johnson, M				Johnson, M			Spintronics - Spin accumulation in mesoscopic systems	NATURE			English	Article							GOLD-FILMS; POLARIZATION; CHARGE; METAL		USN, Res Lab, Washington, DC 20375 USA	United States Department of Defense; United States Navy; Naval Research Laboratory	Johnson, M (corresponding author), USN, Res Lab, Washington, DC 20375 USA.	mjbooj@anvil.nrl.navy.mil						Jedema FJ, 2001, NATURE, V410, P345, DOI 10.1038/35066533; JOHNSON M, 1988, PHYS REV LETT, V60, P377, DOI 10.1103/PhysRevLett.60.377; JOHNSON M, 1993, PHYS REV LETT, V70, P2142, DOI 10.1103/PhysRevLett.70.2142; JOHNSON M, 1994, J APPL PHYS, V75, P6714, DOI 10.1063/1.356848; JOHNSON M, 1985, PHYS REV LETT, V55, P1790, DOI 10.1103/PhysRevLett.55.1790; JOHNSON M, 1988, PHYS REV B, V37, P5312, DOI 10.1103/PhysRevB.37.5312; JOHNSON M, 1987, PHYS REV B, V35, P4959, DOI 10.1103/PhysRevB.35.4959; Rashba EI, 2000, PHYS REV B, V62, pR16267, DOI 10.1103/PhysRevB.62.R16267; SILSBEE RH, 1980, B MAGN RESON, V2, P284; Soulen RJ, 1998, SCIENCE, V282, P85, DOI 10.1126/science.282.5386.85	10	19	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	2002	416	6883					809	810		10.1038/416809a	http://dx.doi.org/10.1038/416809a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976672	Bronze			2022-12-28	WOS:000175163800040
J	Fleisher, LA				Fleisher, LA			Preoperative evaluation of the patient with hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							POSTOPERATIVE MYOCARDIAL-ISCHEMIA; MAJOR VASCULAR-SURGERY; CARDIAC MORBIDITY; RISK; PREDICTORS; INFARCTION; ANESTHESIA; MORTALITY; UPDATE; INDEX		Johns Hopkins Univ, Sch Med, Dept Anesthesiol, Baltimore, MD 21287 USA	Johns Hopkins University	Fleisher, LA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol, 600 N Wolfe St,Carnegie 280, Baltimore, MD 21287 USA.	lfleishe@jhmi.edu	Lee A, Fleisher/Q-9894-2019					American Heart Association, 2002, HEART STROK STAT UPD; Ang-Lee MK, 2001, JAMA-J AM MED ASSOC, V286, P208, DOI 10.1001/jama.286.2.208; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; ARONSON S, 2001, ANESTH ANALG, V92, pS45; Bertrand M, 2001, ANESTH ANALG, V92, P26; Boersma E, 2001, JAMA-J AM MED ASSOC, V285, P1865, DOI 10.1001/jama.285.14.1865; CORIAT P, 1994, ANESTHESIOLOGY, V81, P299, DOI 10.1097/00000542-199408000-00006; Eagle KA, 2002, J AM COLL CARDIOL, V39, P542, DOI 10.1016/S0735-1097(01)01788-0; FLEISHER LA, 1995, J CLIN ANESTH, V7, P97, DOI 10.1016/0952-8180(94)00030-8; GOLDMAN L, 1979, ANESTHESIOLOGY, V50, P285, DOI 10.1097/00000542-197904000-00002; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HOLLENBERG M, 1992, JAMA-J AM MED ASSOC, V268, P205, DOI 10.1001/jama.268.2.205; JONAS WB, 1999, ESSENTIALS COMPLEMEN, P118; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; LANDESBERG G, 1993, LANCET, V341, P715, DOI 10.1016/0140-6736(93)90486-Z; Landesberg G, 1997, J VASC SURG, V26, P570, DOI 10.1016/S0741-5214(97)70054-5; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; LEUNG JM, 1990, ANESTHESIOLOGY, V73, P802, DOI 10.1097/00000542-199011000-00002; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; PROBSTFIELD JL, 1991, JAMA-J AM MED ASSOC, V265, P3255; Prys-Roberts C, 2001, ANAESTHESIA, V56, P505, DOI 10.1046/j.1365-2044.2001.02136.x; PRYSROBERTS C, 1973, BRIT J ANAESTH, V45, P671, DOI 10.1093/bja/45.7.671; PRYSROBERTS C, 1971, BRIT J ANAESTH, V43, P122, DOI 10.1093/bja/43.2.122; STONE JG, 1988, ANESTHESIOLOGY, V68, P495, DOI 10.1097/00000542-198804000-00004; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005	27	38	39	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2002	287	16					2043	2046		10.1001/jama.287.16.2043	http://dx.doi.org/10.1001/jama.287.16.2043			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZK	11966361				2022-12-28	WOS:000175075700001
J	Allen, EH				Allen, EH			Clinical picture - Scapular calcinosis	LANCET			English	Editorial Material									Oregon Hlth Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97201 USA	Oregon Health & Science University	Allen, EH (corresponding author), Oregon Hlth Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR 97201 USA.								0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1372	1372		10.1016/S0140-6736(02)08349-6	http://dx.doi.org/10.1016/S0140-6736(02)08349-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978333	Bronze			2022-12-28	WOS:000175076200008
J	Spero, HJ; Lea, DW				Spero, HJ; Lea, DW			The cause of carbon isotope minimum events on glacial terminations	SCIENCE			English	Article							ANTARCTIC INTERMEDIATE WATER; PLANKTONIC-FORAMINIFERA; ATMOSPHERIC CO2; SURFACE-WATER; PACIFIC DEEP; SEA-ICE; OCEAN; CIRCULATION; CLIMATE; AGE	The occurrence of carbon isotope minima at the beginning of glacial terminations is a common feature of planktic foraminifera carbon isotopic records from the Indo-Pacific, sub-Antarctic, and South Atlantic. We use the delta(13)C record of a thermocline-dwelling foraminifera, Neogloboquadrina dutertrei, and surface temperature estimates from the eastern equatorial Pacific to demonstrate that the onset of delta(13)C minimum events and the initiation of Southern Ocean warming occurred simultaneously. Timing agreement between the marine record and the delta(13)C minimum in an Antarctic atmospheric record suggests that the deglacial events were a response to the breakdown of surface water stratification, renewed Circumpolar Deep Water upwelling, and advection of low delta(13)C waters to the convergence zone at the sub-Antarctic front. On the basis of age agreement between the absolute delta(13)C minimum in surface records and the shift from low to high delta(13)C in the deep South Atlantic, we suggest that the delta(13)C rise that marks the end of the carbon isotope minima was due to the resumption of North Atlantic Deep Water influence in the Southern Ocean.	Univ Calif Davis, Dept Geol, Davis, CA 95616 USA; Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA	University of California System; University of California Davis; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Spero, HJ (corresponding author), Univ Calif Davis, Dept Geol, Davis, CA 95616 USA.	spero@geology.ucdavis.edu		Spero, Howard/0000-0001-5465-8607				Bemis BE, 1998, PALEOCEANOGRAPHY, V13, P150, DOI 10.1029/98PA00070; BROECKER WS, 1990, RADIOCARBON, V32, P119, DOI 10.1017/S003382220004011X; CHARLES CD, 1992, NATURE, V355, P416, DOI 10.1038/355416a0; CHARLES CD, 1990, NATO ADV SCI I C-MAT, V308, P519; Curry WB, 1987, PALEOCEANOGRAPHY, V2, P489, DOI 10.1029/PA002i005p00489; FAIRBANKS RG, 1982, NATURE, V298, P841, DOI 10.1038/298841a0; Francois R, 1997, NATURE, V389, P929, DOI 10.1038/40073; Gildor H, 2000, PALEOCEANOGRAPHY, V15, P605, DOI 10.1029/1999PA000461; Hanawa K., 2001, OCEAN CIRCULATION CL, P373, DOI DOI 10.1016/S0074-6142(01)80129-7; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; LUKAS R, 1986, PROG OCEANOGR, V16, P63, DOI 10.1016/0079-6611(86)90007-8; LYNCHSTIEGLITZ J, 1994, PALEOCEANOGRAPHY, V9, P7, DOI 10.1029/93PA02446; Mackensen A, 2001, GLOBAL PLANET CHANGE, V30, P197, DOI 10.1016/S0921-8181(01)00102-3; MAQUEDA MAM, 2002, GEOPHYS RES LETT, V29, DOI DOI 10.1029/2001G6013240; MARINO BD, 1992, NATURE, V357, P461, DOI 10.1038/357461a0; Millero FJ, 1998, DEEP-SEA RES PT II, V45, P1115, DOI 10.1016/S0967-0645(98)00016-2; Mix AC, 1991, PALEOCEANOGRAPHY, V6, P205, DOI 10.1029/90PA02303; Ninnemann US, 1997, PALEOCEANOGRAPHY, V12, P560, DOI 10.1029/97PA01032; Oppo DW, 1989, PALEOCEANOGRAPHY, V4, P333, DOI 10.1029/PA004i004p00333; OPPO DW, 1987, EARTH PLANET SC LETT, V86, P1, DOI 10.1016/0012-821X(87)90183-X; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; SCHNEIDER RR, 1992, UPWELLING SYSTEMS EV, P285; SHACKLETON NJ, 1983, NATURE, V306, P319, DOI 10.1038/306319a0; SHACKLETON NJ, 1977, FATE FOSSIL FUEL OCE; SHACKLETON NJ, 1988, NATURE, V335, P708, DOI 10.1038/335708a0; SHACKLETON NJ, TR16331B; Sigman DM, 2000, NATURE, V407, P859, DOI 10.1038/35038000; Smith HJ, 1999, NATURE, V400, P248, DOI 10.1038/22291; SOWERS T, 1993, PALEOCEANOGRAPHY, V8, P737, DOI 10.1029/93PA02328; SPERO HJ, UNPUB; Stephens BB, 2000, NATURE, V404, P171, DOI 10.1038/35004556; TAYLOR KC, 1993, NATURE, V366, P549, DOI 10.1038/366549a0; Toggweiler JR, 1999, PALEOCEANOGRAPHY, V14, P571, DOI 10.1029/1999PA900033; TOGGWEILER JR, 1991, J GEOPHYS RES-OCEANS, V96, P20467, DOI 10.1029/91JC02063; TSUCHIYA M, 1991, DEEP-SEA RES, V38, pS273, DOI 10.1016/S0198-0149(12)80013-6; TSUCHIYA M, 1989, PROG OCEANOGR, V23, P101, DOI 10.1016/0079-6611(89)90012-8	36	183	198	2	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	2002	296	5567					522	525		10.1126/science.1069401	http://dx.doi.org/10.1126/science.1069401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964477				2022-12-28	WOS:000175179400044
J	Tajkhorshid, E; Nollert, P; Jensen, MO; Miercke, LJW; O'Connell, J; Stroud, RM; Schulten, K				Tajkhorshid, E; Nollert, P; Jensen, MO; Miercke, LJW; O'Connell, J; Stroud, RM; Schulten, K			Control of the selectivity of the aquaporin water channel family by global orientational tuning	SCIENCE			English	Article							MOLECULAR-DYNAMICS; ESCHERICHIA-COLI; PROTEIN; TRANSPORT	Aquaporins are transmembrane channels found in cell membranes of all life forms. We examine their apparently paradoxical property, facilitation of efficient permeation of water while excluding protons, which is of critical importance to preserving the electrochemical potential across the cell membrane. We have determined the structure of the Escherichia coli aquaglyceroporin GlpF with bound water, in native (2.7 angstroms) and in W48F/F200T mutant (2.1 angstroms) forms, and carried out 12-nanosecond molecular dynamics simulations that define the spatial and temporal probability distribution and orientation of a single file of seven to nine water molecules inside the channel. Two conserved asparagines force a central water molecule to serve strictly as a hydrogen bond donor to its neighboring water molecules. Assisted by the electrostatic potential generated by two half-membrane spanning loops, this dictates opposite orientations of water molecules in the two halves of the channel, and thus prevents the formation of a "proton wire," while permitting rapid water diffusion. Both simulations and observations revealed a more regular distribution of channel water and an increased water permeability for the W48F/F200T mutant.	Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Illinois, Beckman Inst, Theoret Biophys Grp, Urbana, IL 61801 USA	University of California System; University of California San Francisco; University of Illinois System; University of Illinois Urbana-Champaign	Stroud, RM (corresponding author), Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	stroud@msg.ucsf.edu; schulte@ks.uiuc.edu	Stroud, Rhonda/GQZ-0151-2022; Tajkhorshid, Emad/A-1249-2010; Tajkhorshid, Emad/AAN-8323-2021; Schulten, Klaus/D-5561-2009	Stroud, Rhonda/0000-0001-5242-8015; Tajkhorshid, Emad/0000-0001-8434-1010				Agre P, 1998, J BIOL CHEM, V273, P14659, DOI 10.1074/jbc.273.24.14659; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Borgnia MJ, 1999, J MOL BIOL, V291, P1169, DOI 10.1006/jmbi.1999.3032; Borgnia MJ, 2001, P NATL ACAD SCI USA, V98, P2888, DOI 10.1073/pnas.051628098; BRUNGER A, 1996, CNS PROGRAM; Cowin JP, 1999, NATURE, V398, P405, DOI 10.1038/18848; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; de Grotthuss C, 1806, ANN CHIM, V58, P54; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; HELLER KB, 1980, J BACTERIOL, V144, P274, DOI 10.1128/JB.144.1.274-278.1980; Heymann JB, 1999, NEWS PHYSIOL SCI, V14, P187; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Jensen MO, 2001, STRUCTURE, V9, P1083, DOI 10.1016/S0969-2126(01)00668-2; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kale L, 1999, J COMPUT PHYS, V151, P283, DOI 10.1006/jcph.1999.6201; KURINOV IV, 1995, ACTA CRYSTALLOGR D, V51, P98, DOI 10.1107/S0907444994009261; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; Nollert P, 2001, FEBS LETT, V504, P112, DOI 10.1016/S0014-5793(01)02710-7; Pomes R, 1996, BIOPHYS J, V71, P19, DOI 10.1016/S0006-3495(96)79211-1; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; SCHULTEN Z, 1986, METHOD ENZYMOL, V127, P419; SMART O, HOLE2 PROGRAM; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Vitkup D, 2000, NAT STRUCT BIOL, V7, P34; ZEIDEL ML, 1994, BIOCHEMISTRY-US, V33, P1606, DOI 10.1021/bi00172a042	27	711	750	7	195	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	2002	296	5567					525	530		10.1126/science.1067778	http://dx.doi.org/10.1126/science.1067778			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964478				2022-12-28	WOS:000175179400045
J	Drenkard, E; Ausubel, FM				Drenkard, E; Ausubel, FM			Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation	NATURE			English	Article							SMALL-COLONY VARIANTS; BROWN BLOTCH DISEASE; CYSTIC-FIBROSIS; ESCHERICHIA-COLI; SURFACE HYDROPHOBICITY; PERSISTENT INFECTIONS; BACTERIAL BIOFILMS; AERUGINOSA; STRAINS; MULTIPLE	Colonization of the lungs of cystic fibrosis (CF) patients by the opportunistic bacterial pathogen Pseudomonas aeruginosa is the principal cause of mortality in CF populations(1,2). Pseudomonas aeruginosa infections generally persist despite the use of long-term antibiotic therapy(1,3). This has been explained by postulating that P. aeruginosa forms an antibiotic-resistant biofilm(4,5) consisting of bacterial communities embedded in an exopolysaccharide matrix. Alternatively, it has been proposed that resistant P. aeruginosa variants may be selected in the CF respiratory tract by antimicrobial therapy itself(1,6). Here we report that both explanations are correct, and are interrelated. We found that antibiotic-resistant phenotypic variants of P. aeruginosa with enhanced ability to form biofilms arise at high frequency both in vitro and in the lungs of CF patients. We also identified a regulatory protein (PvrR) that controls the conversion between antibiotic-resistant and antibiotic-susceptible forms. Compounds that affect PvrR function could have an important role in the treatment of CF infections.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Ausubel, FM (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.							Andrews JM, 2001, J ANTIMICROB CHEMOTH, V48, P5, DOI 10.1093/jac/48.suppl_1.5; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bloemberg GV, 1997, APPL ENVIRON MICROB, V63, P4543, DOI 10.1128/AEM.63.11.4543-4551.1997; Christensen BB, 1999, METHOD ENZYMOL, V310, P20; Costerton JW, 1999, SCIENCE, V284, P1318, DOI 10.1126/science.284.5418.1318; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; DRUMM B, 1989, J CLIN INVEST, V84, P1588, DOI 10.1172/JCI114336; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; GREWAL SIS, 1995, J BACTERIOL, V177, P4658, DOI 10.1128/jb.177.16.4658-4668.1995; Han B, 1997, MOL MICROBIOL, V25, P211, DOI 10.1046/j.1365-2958.1997.4411811.x; Haussler S, 1999, CLIN INFECT DIS, V29, P621, DOI 10.1086/598644; Henderson IR, 1999, MOL MICROBIOL, V33, P919, DOI 10.1046/j.1365-2958.1999.01555.x; Hentzer M, 2001, J BACTERIOL, V183, P5395, DOI 10.1128/JB.183.18.5395-5401.2001; HOIBY N, 1993, ANNU REV MED, V44, P1, DOI 10.1146/annurev.me.44.020193.000245; HOLLOWAY BW, 1979, MICROBIOL REV, V43, P73, DOI 10.1128/MMBR.43.1.73-102.1979; Lewis K, 2001, ANTIMICROB AGENTS CH, V45, P999, DOI 10.1128/AAC.45.4.999-1007.2001; Mah TFC, 2001, TRENDS MICROBIOL, V9, P34, DOI 10.1016/S0966-842X(00)01913-2; McNamara PJ, 2000, INT J ANTIMICROB AG, V14, P117, DOI 10.1016/S0924-8579(99)00170-3; O'Toole GA, 1998, MOL MICROBIOL, V28, P449, DOI 10.1046/j.1365-2958.1998.00797.x; Oliver A, 2000, SCIENCE, V288, P1251, DOI 10.1126/science.288.5469.1251; RAHME LG, 1995, SCIENCE, V268, P1899, DOI 10.1126/science.7604262; SAMADPOUR M, 1988, J CLIN MICROBIOL, V26, P2319, DOI 10.1128/JCM.26.11.2319-2323.1988; SCHWEIZER HP, 1991, GENE, V97, P109, DOI 10.1016/0378-1119(91)90016-5; SHERMAN PM, 1985, INFECT IMMUN, V49, P797, DOI 10.1128/IAI.49.3.797-804.1985; Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; SPEERT DP, 1990, J CLIN MICROBIOL, V28, P188, DOI 10.1128/JCM.28.2.188-194.1990	28	715	756	6	211	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					740	743		10.1038/416740a	http://dx.doi.org/10.1038/416740a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961556				2022-12-28	WOS:000175033500043
J	Hacein-Bey-Abina, S; Le Deist, F; Carlier, F; Bouneaud, C; Hue, C; De Villartay, JP; Thrasher, AJ; Wulffraat, N; Sorensen, R; Dupuis-Girod, S; Fischer, A; Cavazzana-Calvo, M; Davies, EG; Kuis, W; Lundlaan, WHK; Leiva, L				Hacein-Bey-Abina, S; Le Deist, F; Carlier, F; Bouneaud, C; Hue, C; De Villartay, JP; Thrasher, AJ; Wulffraat, N; Sorensen, R; Dupuis-Girod, S; Fischer, A; Cavazzana-Calvo, M; Davies, EG; Kuis, W; Lundlaan, WHK; Leiva, L			Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; THYMIC FUNCTION; GAMMA-CHAIN; MUTATIONS; DNA	Background: X-linked severe combined immunodeficiency due to a mutation in the gene encoding the common gamma(gamma) chain is a lethal condition that can be cured by allogeneic stem-cell transplantation. We investigated whether infusion of autologous hematopoietic stem cells that had been transduced in vitro with the gammac gene can restore the immune system in patients with severe combined immunodeficiency. Methods: CD34+ bone marrow cells from five boys with X-linked severe combined immunodeficiency were transduced ex vivo with the use of a defective retroviral vector. Integration and expression of the gammac transgene and development of lymphocyte subgroups and their functions were sequentially analyzed over a period of up to 2.5 years after gene transfer. Results: No adverse effects resulted from the procedure. Transduced T cells and natural killer cells appeared in the blood of four of the five patients within four months. The numbers and phenotypes of T cells, the repertoire of T-cell receptors, and the in vitro proliferative responses of T cells to several antigens after immunization were nearly normal up to two years after treatment. Thymopoiesis was documented by the presence of naive T cells and T-cell antigen-receptor episomes and the development of a normal-sized thymus gland. The frequency of transduced B cells was low, but serum immunoglobulin levels and antibody production after immunization were sufficient to avoid the need for intravenous immunoglobulin. Correction of the immunodeficiency eradicated established infections and allowed patients to have a normal life. Conclusions: Ex vivo gene therapy with gammac can safely correct the immune deficiency of patients with X-linked severe combined immunodeficiency.	Hop Necker Enfants Malad, Lab Therapie Cellulaire & Gen, 149 Rue Sevres, F-75015 Paris, France; Hop Necker Enfants Malad, Lab INSERM, Paris, France; Hop Necker Enfants Malad, Lab Immunol Pediat, Paris, France; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, Paris, France; Inst Pasteur, Unite Biol Gene, Paris, France; Inst Child Hlth, Mol Immunol Unit, London, England; Wilhelmina Kinderziekenhuis Lundlaan, Dept Immunol & Hematol, Utrecht, Netherlands; Louisiana State Univ, Hlth Sci Ctr, Dept Pediat, New Orleans, LA USA; Great Ormond St Hosp Sick Children, Natl Hlth Serv Trust, London, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of London; University College London; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Cavazzana-Calvo, M (corresponding author), Hop Necker Enfants Malad, Lab Therapie Cellulaire & Gen, 149 Rue Sevres, F-75015 Paris, France.	cavazzan@necker.fr	de Villartay, jean pierre/H-9353-2017; Wulffraat, Nico M/AAE-8929-2020; Dupuis-Girod, Sophie/D-6268-2014	de Villartay, jean pierre/0000-0001-5987-0463; Wulffraat, Nico M/0000-0001-9548-5562; Cavazzana, Marina/0000-0002-0264-0891; Dupuis-Girod, Sophie/0000-0002-8834-5526; Thrasher, Adrian/0000-0002-6097-6115				Berzins SP, 1998, J EXP MED, V187, P1839, DOI 10.1084/jem.187.11.1839; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Bunting KD, 1998, NAT MED, V4, P58, DOI 10.1038/nm0198-058; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Haddad E, 1999, BLOOD, V94, P2923, DOI 10.1182/blood.V94.8.2923.420k44_2923_2930; Haddad E, 1998, BLOOD, V91, P3646; Hanazono Y, 1999, BLOOD, V94, P2263, DOI 10.1182/blood.V94.7.2263.419k36_2263_2270; ISSAAD C, 1993, BLOOD, V81, P2916; Kong FK, 1999, P NATL ACAD SCI USA, V96, P1536, DOI 10.1073/pnas.96.4.1536; Kung C, 2000, NAT MED, V6, P343; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mackall CL, 1996, J IMMUNOL, V156, P4609; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PANNETIER C, 1993, P NATL ACAD SCI USA, V90, P4319, DOI 10.1073/pnas.90.9.4319; Patel DD, 2000, NEW ENGL J MED, V342, P1325, DOI 10.1056/NEJM200005043421804; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X; Towers GJ, 1999, J GENE MED, V1, P352, DOI 10.1002/(SICI)1521-2254(199909/10)1:5<352::AID-JGM57>3.0.CO;2-I; White H, 2000, EUR J IMMUNOL, V30, P732	24	817	871	1	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	2002	346	16					1185	1193		10.1056/NEJMoa012616	http://dx.doi.org/10.1056/NEJMoa012616			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542FT	11961146				2022-12-28	WOS:000175033400002
J	Matzinger, P				Matzinger, P			The danger model: A renewed sense of self	SCIENCE			English	Article							VERSUS-HOST-DISEASE; TOLL-LIKE RECEPTORS; T-CELLS; NETWORK THEORY; INNATE; RECOGNITION; INDUCTION; TOLERANCE; EVOLUTION; REJECTION		NIAID, Cellular & Mol Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Matzinger, P (corresponding author), NIAID, Cellular & Mol Immunol Lab, NIH, Bethesda, MD 20892 USA.	pcm@helix.nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000581, Z01AI000581] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Aliberti J, 2000, NAT IMMUNOL, V1, P83, DOI 10.1038/76957; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; Benlagha K, 2000, SEMIN IMMUNOL, V12, P537, DOI 10.1006/smim.2000.0276; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Boismenu R, 1997, CURR OPIN IMMUNOL, V9, P57, DOI 10.1016/S0952-7915(97)80159-8; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; Burnet F., 1959, CLONAL SELECTION THE, DOI DOI 10.5962/BHL.TITLE.8281; Coley W.B., 1898, J AM MED ASS, VXXXI, P389; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; COUTINHO A, 1995, SCAND J IMMUNOL, V42, P3, DOI 10.1111/j.1365-3083.1995.tb03619.x; D'Alessandro AM, 1998, SURGERY, V124, P604, DOI 10.1067/msy.1998.91482; Devitt A, 1998, NATURE, V392, P505, DOI 10.1038/33169; Fuqua C, 2001, ANNU REV GENET, V35, P439, DOI 10.1146/annurev.genet.35.102401.090913; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Groh V, 1998, SCIENCE, V279, P1737, DOI 10.1126/science.279.5357.1737; HALL SS, 1998, COMMOTION BLOOD, P198; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; HEIDT PJ, 1992, J MED, V23, P161; Hill GR, 1997, BLOOD, V90, P3204, DOI 10.1182/blood.V90.8.3204; Iciek LA, 1997, J IMMUNOL, V158, P4769; Inohara N, 2001, ONCOGENE, V20, P6473, DOI 10.1038/sj.onc.1204787; Ishii KJ, 2001, J IMMUNOL, V167, P2602, DOI 10.4049/jimmunol.167.5.2602; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; KIMATA H, 1994, EUR J IMMUNOL, V24, P2262, DOI 10.1002/eji.1830240950; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; KOSHLAND DE, 1990, SCIENCE, V248, P1273, DOI 10.1126/science.2356462; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LENSCHOW DJ, 1995, TRANSPLANTATION, V60, P1171, DOI 10.1097/00007890-199511270-00019; LINDENMANN J, 1967, J EXP MED, V126, P93, DOI 10.1084/jem.126.1.93; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Matzinger P, 2001, SCAND J IMMUNOL, V54, P4, DOI 10.1046/j.1365-3083.2001.00974.x; MATZINGER P, 1996, J NIH RES, V8, P35; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Morita CT, 1996, RES IMMUNOL, V147, P347, DOI 10.1016/0923-2494(96)89649-0; OWEN RD, 1945, SCIENCE, V102, P400, DOI 10.1126/science.102.2651.400; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Schwartz M, 2001, J MOL MED-JMM, V78, P594, DOI 10.1007/s001090000172; SEONG SY, COMMUNICATION; Thomas JM, 1999, TRANSPLANTATION, V68, P1660, DOI 10.1097/00007890-199912150-00009	51	2966	3169	4	213	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	2002	296	5566					301	305		10.1126/science.1071059	http://dx.doi.org/10.1126/science.1071059			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951032	Green Submitted			2022-12-28	WOS:000175000300043
J	Zayas, CF; Perlino, C; Caliendo, A; Jackson, D; Martinez, EJ; Tso, P; Heffron, TG; Logan, JL; Herwaldt, BL; Moore, AC; Steurer, FJ; Bern, C; Maguire, JH				Zayas, CF; Perlino, C; Caliendo, A; Jackson, D; Martinez, EJ; Tso, P; Heffron, TG; Logan, JL; Herwaldt, BL; Moore, AC; Steurer, FJ; Bern, C; Maguire, JH		CDC	Chagas disease after organ transplantation - United States, 2001 (Reprinted from MMWR, vol 51, pg 210-212, 2002)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint									Emory Univ, Sch Med, Atlanta, GA 30322 USA; Univ Arizona, Coll Med, Tucson, AZ 85721 USA; CDC, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA	Emory University; University of Arizona; Centers for Disease Control & Prevention - USA	Zayas, CF (corresponding author), Emory Univ, Sch Med, Atlanta, GA 30322 USA.							Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P210	1	17	17	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 10	2002	287	14					1795	1796						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539QJ	11958178				2022-12-28	WOS:000174881700009
J	Beckerman, KP				Beckerman, KP			Mothers, orphans, and prevention of paediatric AIDS	LANCET			English	Editorial Material							WOMEN; HIV-1; TRANSMISSION; RESISTANCE; NEVIRAPINE; MORTALITY		Univ Calif San Francisco, San Francisco Gen Hosp, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Beckerman, KP (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94110 USA.	kpb@itsa.ucsf.edu						Baleta A, 2002, LANCET, V359, P1132, DOI 10.1016/S0140-6736(02)08188-6; Bangsberg DR, 2000, AIDS, V14, P357, DOI 10.1097/00002030-200003100-00008; BELLAMY C, 2001, NY TIMES        0326; Deeks SG, 2001, J ACQ IMMUN DEF SYND, V26, pS25, DOI 10.1097/00126334-200103011-00004; Eshleman SH, 2001, AIDS, V15, P1951, DOI 10.1097/00002030-200110190-00006; Farmer P, 2001, LANCET, V358, P404, DOI 10.1016/S0140-6736(01)05550-7; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hunter S, 2000, CHILDREN BRINK EXECU; *IND MEM FAC HARV, 2002, CONS STAT ANT TREATM; Ioannidis JPA, 2001, J INFECT DIS, V183, P539, DOI 10.1086/318530; Karim SA, 2002, LANCET, V359, P992, DOI 10.1016/S0140-6736(02)08063-7; McDermott JM, 1996, AM J TROP MED HYG, V55, P66, DOI 10.4269/ajtmh.1996.55.66; *MON AIDS PAND NET, 2000, STAT TRENDS HIV AIDS; Nduati R, 2001, LANCET, V357, P1651, DOI 10.1016/S0140-6736(00)04820-0; ROSENBERG T, 2001, NY TIMES MAGAZI 0128, P26; Specter Michael, 2001, NEW YORKER, P74; *UNAIDS, 2001, AIDS EP UPD	17	14	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	2002	359	9313					1168	1169		10.1016/S0140-6736(02)08248-X	http://dx.doi.org/10.1016/S0140-6736(02)08248-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955530				2022-12-28	WOS:000174846300002
J	Braun, J; Brandt, J; Listing, J; Zink, A; Alten, R; Golder, W; Gromica-Ihle, E; Kellner, H; Krause, A; Schneider, M; Sorensen, H; Zeidler, H; Thriene, W; Sieper, J				Braun, J; Brandt, J; Listing, J; Zink, A; Alten, R; Golder, W; Gromica-Ihle, E; Kellner, H; Krause, A; Schneider, M; Sorensen, H; Zeidler, H; Thriene, W; Sieper, J			Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial	LANCET			English	Article							ALPHA MONOCLONAL-ANTIBODY; RHEUMATOID-ARTHRITIS; DISEASE-ACTIVITY; INDEX; BATH; SPONDYLOARTHROPATHIES; SPONDYLARTHROPATHIES; METHOTREXATE; PREVALENCE; HLA-B27	Background Treatment options for patients with ankylosing spondylitis are few. We aimed to assess the effectiveness of infliximab, an antibody to tumour necrosis factor (TNF)-alpha, in treatment of such patients. Methods In this 12-week placebo-controlled multicentre study, we randomly assigned 35 patients with active ankylosing spondylitis to intravenous infliximab (5 mg/kg) and 35 to placebo at weeks 0, 2, and 6. One patient in the infliximab group was withdrawn from the study. Our primary outcome was regression of disease activity of at least 50%. To assess response, we used validated clinical criteria from the ankylosing spondylitis assessment working group, including disease activity (BASDAI), functional indices (BASFI), metrology (BASMI), and quality of life (short form 36). Analyses were done by intention to treat. Findings 18 (53%) of 34 patients on infliximab had a regression of disease activity at week 12 of at least 50% compared with three (9%) of 35 on placebo (difference 44% [95% Cl 23-61], p<0.0001). Function and quality of life also improved significantly on infliximab but not on placebo (p<0.0001 and p<0.0001,, respectively). Treatment with infliximab was generally well tolerated, but three patients had to stop treatment because of systemic tuberculosis, allergic granulomatosis of the lung, or mild leucopenia. Interpretation Our results show that treatment with infliximab is effective in patients with active ankylosing spondylitis. Since there are some potentially serious adverse effects, we recommend that this treatment mainly be used in co-operation with rheumatological centres.	Ctr Rheumazentrum Ruhrgebiet, D-44652 Herne, Germany; Free Univ Berlin, Benjamin Franklin Hosp, Dept Rheumatol, D-1000 Berlin, Germany; Free Univ Berlin, Benjamin Franklin Hosp, Dept Radiol, D-1000 Berlin, Germany; German Rheumatism Res Ctr, Dept Epidemiol, Berlin, Germany; Schlosspk Clin, Berlin, Germany; Humboldt Univ, Charite, Dept Rheumatol, Berlin, Germany; Rheumatol Clin, Berlin, Germany; Univ Munich, Dept Rheumatol, Munich, Germany; Univ Dusseldorf, Dept Rheumatol, D-4000 Dusseldorf, Germany; Immanuel Hosp, Berlin, Germany; Hannover Med Sch, Dept Rheumatol, Hannover, Germany; Essex Pharma, Munich, Germany	Rheumazentrum Ruhrgebiet; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Deutsches Rheuma-Forschungszentrum (DRFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; Heinrich Heine University Dusseldorf; Hannover Medical School	Braun, J (corresponding author), Rheumazentrum Ruhrgebiet, Landgrafenstr 15, D-44652 Herne, Germany.	J.Braun@rheumazentrum-ruhrgebiet.de	Braun, Juergen/E-8127-2013; Alten, Rieke/M-1045-2019	Braun, Juergen/0000-0002-9156-5095; 				Anderson JJ, 2001, ARTHRITIS RHEUM-US, V44, P1876, DOI 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F; Antonio C, 1999, ARTHRITIS RHEUM, V42, pS371; Boonen A, 2001, ANN RHEUM DIS, V60, P353, DOI 10.1136/ard.60.4.353; Brandt J, 2000, ARTHRITIS RHEUM-US, V43, P1346, DOI 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E; Brandt J, 2001, ARTHRITIS RHEUM, V44, P2936, DOI 10.1002/1529-0131(200112)44:12<2936::AID-ART483>3.0.CO;2-M; BRANDT J, 2002, J RHEUMATOL, V44, P2936; Braun J, 1998, RHEUM DIS CLIN N AM, V24, P697, DOI 10.1016/S0889-857X(05)70038-7; BRAUN J, 1994, ARTHRITIS RHEUM, V37, P1039, DOI 10.1002/art.1780370709; Braun J, 1998, ARTHRITIS RHEUM-US, V41, P58, DOI 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G; BRAUN J, 1995, ARTHRITIS RHEUM, V38, P499, DOI 10.1002/art.1780380407; Braun J, 2000, ANN RHEUM DIS, V59, P85, DOI 10.1136/ard.59.12.985; Dougados M, 2001, ARTHRITIS RHEUM-US, V44, P180, DOI 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K; GARRETT S, 1994, J RHEUMATOL, V21, P2286; HOLM S, 1979, SCAND J STAT, V6, P65; JENKINSON TR, 1994, J RHEUMATOL, V21, P1694; Jones SD, 1996, J RHEUMATOL, V23, P487; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Khan MA, 2000, CURR OPIN RHEUMATOL, V12, P235, DOI 10.1097/00002281-200007000-00001; Leirisalo-Repo M, 1998, RHEUM DIS CLIN N AM, V24, P737, DOI 10.1016/S0889-857X(05)70039-9; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Mackay K, 1998, ARTHRITIS RHEUM-US, V41, P2263, DOI 10.1002/1529-0131(199812)41:12<2263::AID-ART23>3.3.CO;2-9; Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140-6736(99)05246-0; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; Sandborn WJ, 1999, INFLAMM BOWEL DIS, V5, P119, DOI 10.1097/00054725-199905000-00008; SIEPER J, 1995, ARTHRITIS RHEUM, V38, P1547, DOI 10.1002/art.1780381105; Spoorenberg A, 1999, J RHEUMATOL, V26, P997; Spoorenberg A, 1999, J RHEUMATOL, V26, P980; Van den Bosch F, 2000, LANCET, V356, P1821, DOI 10.1016/S0140-6736(00)03239-6; vanderHeijde D, 1997, J RHEUMATOL, V24, P2225; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; vanOosten BW, 1996, NEUROLOGY, V47, P1531, DOI 10.1212/WNL.47.6.1531; Ward MM, 1999, ARTHRIT CARE RES, V12, P247, DOI 10.1002/1529-0131(199908)12:4<247::AID-ART3>3.0.CO;2-H; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Zink A, 2000, J RHEUMATOL, V27, P613	34	991	1045	1	38	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	2002	359	9313					1187	1193		10.1016/S0140-6736(02)08215-6	http://dx.doi.org/10.1016/S0140-6736(02)08215-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955536				2022-12-28	WOS:000174846300008
J	Verstreken, P; Kjaerulff, O; Lloyd, TE; Atkinson, R; Zhou, Y; Meinertzhagen, IA; Bellen, HJ				Verstreken, P; Kjaerulff, O; Lloyd, TE; Atkinson, R; Zhou, Y; Meinertzhagen, IA; Bellen, HJ			Endophilin mutations block clathrin-mediated endocytosis but not neurotransmitter release	CELL			English	Article							TUMOR-SUPPRESSOR GENE; SYNAPTIC VESICLES; TRANSMITTER RELEASE; DROSOPHILA MUTANT; RAPID ENDOCYTOSIS; BINDING PARTNERS; ACTIVE ZONE; DYNAMIN; EXOCYTOSIS; PROTEINS	We have identified mutations in Drosophila endophilin to study its function in vivo. Endophilin is required presynaptically at the neuromuscular junction, and absence of Endophilin dramatically impairs endocytosis in vivo. Mutant larvae that lack Endophilin fail to take up FM1-43 dye in synaptic boutons, indicating an inability to retrieve synaptic membrane. This defect is accompanied by an expansion of the presynaptic membrane, and a depletion of vesicles from the bouton lumen. Interestingly, mutant larvae are still able to sustain release at 15%-20% of the normal rate during high-frequency stimulation. We propose that kiss-and-run maintains neurotransmission at active zones of the larval NMJ in endophilin animals.	Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Dalhousie Univ, Ctr Life Sci, Inst Neurosci, Halifax, NS, Canada	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Dalhousie University	Bellen, HJ (corresponding author), Baylor Coll Med, Program Dev Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	hbellen@bcm.tmc.edu	Verstreken, Patrik/AAC-7591-2022; Kjaerulff, Ole/Q-6996-2018	Verstreken, Patrik/0000-0002-5073-5393; Kjaerulff, Ole/0000-0002-8654-1435; Lloyd, Thomas/0000-0003-4756-3700; Bellen, Hugo/0000-0001-5992-5989				AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Ales E, 1999, NAT CELL BIOL, V1, P40, DOI 10.1038/9012; ALMERS W, 1990, NEURON, V4, P813, DOI 10.1016/0896-6273(90)90134-2; ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; BELLEN HJ, 2000, DROSOPHILA PROTOCOLS, P175; BETZ WJ, 1995, CURR BIOL, V5, P1098, DOI 10.1016/S0960-9822(95)00220-X; BETZ WJ, 1993, J PHYSIOL-LONDON, V460, P287, DOI 10.1113/jphysiol.1993.sp019472; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; Delgado R, 2000, NEURON, V28, P941, DOI 10.1016/S0896-6273(00)00165-3; Dornan S, 1997, MOL BIOL CELL, V8, P1391, DOI 10.1091/mbc.8.8.1391; Estes PS, 1996, J NEUROSCI, V16, P5443; Fergestad T, 2001, J NEUROSCI, V21, P1218; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; GonzalezGaitan M, 1997, CELL, V88, P767, DOI 10.1016/S0092-8674(00)81923-6; GUICHET, IN PRESS EMBO J; Hannah MJ, 1999, ANNU REV CELL DEV BI, V15, P733, DOI 10.1146/annurev.cellbio.15.1.733; Henkel AW, 1995, J NEUROSCI, V15, P8246; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; IKEDA K, 1988, J PHYSIOL-LONDON, V406, P215, DOI 10.1113/jphysiol.1988.sp017377; JAN LY, 1982, P NATL ACAD SCI-BIOL, V79, P2700, DOI 10.1073/pnas.79.8.2700; JAN LY, 1976, J PHYSIOL-LONDON, V262, P189, DOI 10.1113/jphysiol.1976.sp011592; Jarousse N, 2001, CURR OPIN CELL BIOL, V13, P461, DOI 10.1016/S0955-0674(00)00237-4; Kawasaki F, 2000, NAT NEUROSCI, V3, P859, DOI 10.1038/78753; Klingauf J, 1998, NATURE, V394, P581, DOI 10.1038/29079; KOENIG JH, 1983, J CELL BIOL, V96, P1517, DOI 10.1083/jcb.96.6.1517; Koenig JH, 1996, J CELL BIOL, V135, P797, DOI 10.1083/jcb.135.3.797; Koenig JH, 1999, J NEUROPHYSIOL, V81, P1495, DOI 10.1152/jn.1999.81.4.1495; Koenig JH, 1998, P NATL ACAD SCI USA, V95, P12677, DOI 10.1073/pnas.95.21.12677; Kuromi H, 1998, NEURON, V20, P917, DOI 10.1016/S0896-6273(00)80473-0; Kuromi H, 2000, NEURON, V27, P133, DOI 10.1016/S0896-6273(00)00015-5; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; Li J, 1999, PHILOS T ROY SOC B, V354, P299, DOI 10.1098/rstb.1999.0381; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; Lloyd TE, 2002, CELL, V108, P261, DOI 10.1016/S0092-8674(02)00611-6; Lloyd TE, 2000, NEURON, V26, P45, DOI 10.1016/S0896-6273(00)81136-8; Loewen CA, 2001, GENESIS, V31, P30, DOI 10.1002/gene.10002; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; MARTIN AR, 1955, J PHYSIOL-LONDON, V130, P114, DOI 10.1113/jphysiol.1955.sp005397; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Palfrey HC, 1998, NEUROSCIENCE, V83, P969, DOI 10.1016/S0306-4522(97)00453-3; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; Richards DA, 2000, NEURON, V27, P551, DOI 10.1016/S0896-6273(00)00065-9; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; SCHULZE KL, 1994, NEURON, V13, P1099, DOI 10.1016/0896-6273(94)90048-5; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Stevens CF, 2000, P NATL ACAD SCI USA, V97, P12828, DOI 10.1073/pnas.230438697; STEWART BA, 1994, J COMP PHYSIOL A, V175, P179, DOI 10.1007/BF00215114; Valtorta F, 2001, TRENDS CELL BIOL, V11, P324, DOI 10.1016/S0962-8924(01)02058-X; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9; Zhou HM, 2001, J NEUROSCI, V21, P3749, DOI 10.1523/JNEUROSCI.21-11-03749.2001	59	251	256	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	2002	109	1					101	112		10.1016/S0092-8674(02)00688-8	http://dx.doi.org/10.1016/S0092-8674(02)00688-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955450	Bronze			2022-12-28	WOS:000174888300012
J	Chiba, N; van Zanten, SJOV; Sinclair, P; Ferguson, RA; Escobedo, S; Grace, E				Chiba, N; van Zanten, SJOV; Sinclair, P; Ferguson, RA; Escobedo, S; Grace, E			Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							GASTROESOPHAGEAL REFLUX DISEASE; NONULCER DYSPEPSIA; GASTROINTESTINAL SYMPTOMS; CONSENSUS CONFERENCE; ERADICATION; MANAGEMENT; VALIDATION; METAANALYSIS; SEVERITY; HEALTH	Objective To determine whether a "test for Helicobacter pylori and treat" strategy improves symptoms in patients with uninvestigated dyspepsia in primary care. Design Randomised placebo controlled trial. Setting 36 family practices in Canada. Participants 294 patients positive for H pylori (C-13-urea breath test) with symptoms of dyspepsia of at least moderate severity in the preceding month. Intervention Participants were randomised to mice daily treatment for 7 days with omeprazole 20 mg, metronidazole 500 mg, and clarithromycin 250 mg or omeprazole 20 mg, placebo metronidazole,and placebo clarithromycin. Patients were then managed by their family physicians according to their usual care. Main outcome measures Treatment success defined as no symptoms or minimal symptoms of dyspepsia at the end of one year. Societal healthcare costs collected prospectively for a secondary evaluation of actual mean costs. Results In the intention to treat population (n=294), eradication treatment was significantly more effective than placebo in achieving treatment success (50%) v 36%; P=0.02; absolute risk reduction=141%; number needed to treat=7, 95% confidence interval 4 to 63). Eradication treatment cured H pylori infection in 80% of evaluable patients. Treatment Success at one year was greater in patients negative for H pylori than in those positive for H pylori (54% v 391,16; P=0.02). Eradication treatment reduced mean annual cost by $C53 (-86 to 180) per patient. Conclusions A "test for H pylori with C-13-urea breath test and eradicate" strategy shows significant symptomatic benefit at 12 months in the management of primary care patients with uninvestigated dyspepsia.	McMaster Univ, Div Gastroenterol, Hamilton, ON L8N 3Z5, Canada; Dalhousie Univ, Div Gastroenterol, Halifax, NS B3H 2Y9, Canada; AstraZeneca Canada Inc, Mississauga, ON L4Y 1M4, Canada	McMaster University; Dalhousie University; AstraZeneca	Chiba, N (corresponding author), Surrey GI Clin Res, 105-21 Surrey St W, Guelph, ON N1H 3R3, Canada.							BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; Chiba N, 2000, GUT, V47, pA113; Chiba N, 1998, CAN J GASTROENTEROL, V12, P83, DOI 10.1155/1998/175926; Chiba N, 1998, EUR J SURG, V164, P14, DOI 10.1080/11024159850191184; Chiba N, 1999, CAN J GASTROENTEROL, V13, P681; Chiba N, 2000, CAN J GASTROENTEROL, V14, P27, DOI 10.1155/2000/916417; Costa M, 2000, GUT, V47, P1; DRUMMOND MF, 1997, METHODS EC EVALUATIO, P205; Huang JQ, 1998, GASTROENTEROLOGY, V114, P1169, DOI 10.1016/S0016-5085(98)70422-6; Hunt RH, 1999, CAN J GASTROENTEROL, V13, P213, DOI 10.1155/1999/180751; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Junghard O, 1998, EUR J SURG, V164, P106; Laine L, 2001, ANN INTERN MED, V134, P361, DOI 10.7326/0003-4819-134-5-200103060-00008; LAINE L, 1996, AM J MED S, V100, P52; Lam SJ, 1998, J GASTROEN HEPATOL, V13, P1, DOI 10.1111/j.1440-1746.1998.tb00537.x; Malfertheiner P, 1997, GUT, V41, P8; McColl KEL, 2000, AM J GASTROENTEROL, V95, P101; Moayyedi P, 2001, GASTROENTEROLOGY, V121, P1120, DOI 10.1053/gast.2001.29332; Moayyedi P, 1997, BRIT MED J, V314, P119, DOI 10.1136/bmj.314.7074.119; Moayyedi P, 2000, BRIT MED J, V321, P659, DOI 10.1136/bmj.321.7262.659; Mock T, 1999, CLIN BIOCHEM, V32, P59, DOI 10.1016/S0009-9120(98)00082-4; *STAT CAN, 1996, LAB FORC UNP WORK CA; SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722; Talley NJ, 1999, GUT, V45, P37; Talley NJ, 1998, GASTROENTEROLOGY, V114, P582, DOI 10.1016/S0016-5085(98)70542-6; Thompson SG, 2000, BRIT MED J, V320, P1197, DOI 10.1136/bmj.320.7243.1197; Thomson ABR, 2001, GASTROENTEROLOGY, V120, pA50; Tougas G, 1999, AM J GASTROENTEROL, V94, P2845, DOI 10.1111/j.1572-0241.1999.01427.x; Tytgat GNJ, 2001, GASTROENTEROLOGY, V120, P787, DOI 10.1053/gast.2001.23052; van Zanten SJOV, 2000, CAN MED ASSOC J, V162, pS3; VANZANTEN SJOV, 1993, J CLIN EPIDEMIOL, V46, P273, DOI 10.1016/0895-4356(93)90075-C; Vinod H., 1993, HDB STAT, V11, P629; Wiklund IK, 1998, EUR J SURG, V164, P41	33	154	160	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 27	2002	324	7344					1012	+		10.1136/bmj.324.7344.1012	http://dx.doi.org/10.1136/bmj.324.7344.1012			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547UP	11976244	Green Published			2022-12-28	WOS:000175350900022
J	Grant, PR; Grant, BR				Grant, PR; Grant, BR			Unpredictable evolution in a 30-year study of Darwin's finches	SCIENCE			English	Article							NATURAL-SELECTION; 2 POPULATIONS; BODY-SIZE; EL-NINO; HYBRIDIZATION; GALAPAGOS; BIRD	Evolution can be predicted in the short term from a knowledge of selection and inheritance. However, in the long term evolution is unpredictable because environments, which determine the directions and magnitudes of selection coefficients, fluctuate unpredictably. These two features of evolution, the predictable and unpredictable, are demonstrated in a study of two populations of Darwin's finches on the Galapagos island of Daphne Major. From 1972 to 2001, Geospiza fortis (medium ground finch) and Geospiza scandens (cactus finch) changed several times in body size and two beak traits. Natural selection occurred frequently in both species and varied from unidirectional to oscillating, episodic to gradual. Hybridization occurred repeatedly though rarely, resulting in elevated phenotypic variances in G. scandens and a change in beak shape. The phenotypic states of both species at the end of the 30-year study could not have been predicted at the beginning. Continuous, long-term studies are needed to detect and interpret rare but important events and nonuniform evolutionary change.	Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	Princeton University	Grant, PR (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Washington Rd, Princeton, NJ 08544 USA.							ANDERSON WW, 1991, P NATL ACAD SCI USA, V88, P10367, DOI 10.1073/pnas.88.22.10367; Arnold M. L., 1997, NATURAL HYBRIDIZATIO; Barbraud C, 2000, J EVOLUTION BIOL, V13, P81; BOAG PT, 1981, SCIENCE, V214, P82, DOI 10.1126/science.214.4516.82; Brown JH, 2001, SCIENCE, V293, P643, DOI 10.1126/science.293.5530.643; CARLSON HL, 1968, POPULATION BIOL EVOL, P123; Carney SE, 2000, EVOLUTION, V54, P462, DOI 10.1111/j.0014-3820.2000.tb00049.x; Cowie RH, 1998, BIOL J LINN SOC, V65, P233, DOI 10.1006/bijl.1998.0250; EHRLICH PR, 1965, EVOLUTION, V20, P165; Endler J. A., 1986, NATURAL SELECTION WI; Etterson JR, 2001, SCIENCE, V294, P151, DOI 10.1126/science.1063656; FORD H. D., 1930, TRANS ENT SOC LONDON, V78, P345; GIBBS HL, 1987, NATURE, V327, P511, DOI 10.1038/327511a0; Grant B. R., 1989, EVOLUTIONARY DYNAMIC; Grant P.R., 1999, RECOGNITION STATES L, V2; Grant Peter R., 1996, P343, DOI 10.1016/B978-012178075-3/50013-1; GRANT PR, 1994, EVOLUTION, V48, P297, DOI 10.1111/j.1558-5646.1994.tb01313.x; GRANT PR, 1992, SCIENCE, V256, P193, DOI 10.1126/science.256.5054.193; GRANT PR, 1993, PHILOS T R SOC B, V340, P127, DOI 10.1098/rstb.1993.0052; Grant PR, 2001, GENETICA, V112, P359, DOI 10.1023/A:1013363032724; GRANT PR, 1992, ECOLOGY, V73, P766, DOI 10.2307/1940156; Grant PR, 2000, P ROY SOC B-BIOL SCI, V267, P131, DOI 10.1098/rspb.2000.0977; Grant PR, 2000, ADAPTIVE GENETIC VARIATION IN THE WILD, P3; GRANT PR, 1995, EVOLUTION, V49, P241, DOI 10.1111/j.1558-5646.1995.tb02236.x; GRANT PR, 1998, ENDLESS FORMS SPECIE, P404; Guilderson TP, 1998, SCIENCE, V281, P240, DOI 10.1126/science.281.5374.240; Halkka O, 2001, BIOL J LINN SOC, V74, P571, DOI 10.1111/j.1095-8312.2001.tb01414.x; Hoekstra HE, 2001, P NATL ACAD SCI USA, V98, P9157, DOI 10.1073/pnas.161281098; JONES DA, 1989, TRENDS ECOL EVOL, V4, P298, DOI 10.1016/0169-5347(89)90025-6; Kareiva P.M., 1993, BIOTIC INTERACTIONS; Keller LF, 1998, EVOLUTION, V52, P240, DOI 10.1111/j.1558-5646.1998.tb05157.x; Keller LF, 2001, HEREDITY, V87, P325, DOI 10.1046/j.1365-2540.2001.00900.x; Kingsolver JG, 2001, AM NAT, V157, P245, DOI 10.1086/319193; Kruuk LEB, 2001, AM NAT, V158, P557, DOI 10.1086/323585; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6608; Likens G.E., 1989, SPACE FOR TIME SUBST, DOI DOI 10.1007/978-1-4615-7358-6; MAJERUS MEN, 1998, MELANISMS EVOLUTION; Merila J, 2001, NATURE, V412, P76, DOI 10.1038/35083580; PRICE TD, 1984, EVOLUTION, V38, P327, DOI 10.1111/j.1558-5646.1984.tb00291.x; PRICE TD, 1984, NATURE, V309, P787, DOI 10.1038/309787a0; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; Reznick DN, 1997, SCIENCE, V275, P1934, DOI 10.1126/science.275.5308.1934; Sinervo B, 2000, NATURE, V406, P985, DOI 10.1038/35023149; SOKAL R, 1996, BIOMETRY PRINCIPLES; Teotonio H, 2001, EVOLUTION, V55, P653, DOI 10.1554/0014-3820(2001)055[0653:PRE]2.0.CO;2; Veen T, 2001, NATURE, V411, P45, DOI 10.1038/35075000; Visser ME, 1998, P ROY SOC B-BIOL SCI, V265, P1867, DOI 10.1098/rspb.1998.0514; Zhang RH, 1998, NATURE, V391, P879, DOI 10.1038/36081	48	890	912	28	861	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					707	711		10.1126/science.1070315	http://dx.doi.org/10.1126/science.1070315			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976447				2022-12-28	WOS:000175281700046
J	Dixit, S; Crain, J; Poon, WCK; Finney, JL; Soper, AK				Dixit, S; Crain, J; Poon, WCK; Finney, JL; Soper, AK			Molecular segregation observed in a concentrated alcohol-water solution	NATURE			English	Article							FREQUENCY RAMAN-SPECTROSCOPY; AQUEOUS-SOLUTIONS; METHANOL MIXTURES; TERTIARY BUTANOL; NEUTRON-DIFFRACTION; SELF-ASSOCIATION; SIMULATION; HYDRATION; SOLVENT; ICE	When a simple alcohol such as methanol or ethanol is mixed with water(1,2), the entropy of the system increases far less than expected for an ideal solution of randomly mixed molecules(3). This well-known effect has been attributed to hydrophobic headgroups creating ice-like or clathrate-like structures in the surrounding water(4), although experimental support for this hypothesis is scarce(5-7). In fact, an increasing amount of experimental and theoretical work suggests that the hydrophobic headgroups of alcohol molecules in aqueous solution cluster together(2,8-10). However, a consistent description of the details of this self-association is lacking(11-13). Here we use neutron diffraction with isotope substitution to probe the molecular-scale structure of a concentrated alcohol-water mixture (7:3 molar ratio). Our data indicate that most of the water molecules exist as small hydrogen-bonded strings and clusters in a 'fluid' of close-packed methyl groups, with water clusters bridging neighbouring methanol hydroxyl groups through hydrogen bonding. This behaviour suggests that the anomalous thermodynamics of water-alcohol systems arises from incomplete mixing at the molecular level and from retention of remnants of the three-dimensional hydrogen-bonded network structure of bulk water.	Rutherford Appleton Lab, ISIS Facil, Didcot OX11 0QX, Oxon, England; Univ Edinburgh, Dept Phys & Astron, Edinburgh EH9 3JZ, Midlothian, Scotland; UCL, Dept Phys & Astron, London WC1E 6BE, England	UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory; University of Edinburgh; University of London; University College London	Soper, AK (corresponding author), Rutherford Appleton Lab, ISIS Facil, Didcot OX11 0QX, Oxon, England.	a.k.soper@rl.ac.uk	Finney, John L/C-2175-2008; Poon, Wilson C K/B-5960-2013; Poon, Wilson/V-3495-2019	Poon, Wilson C K/0000-0003-0760-7940; Poon, Wilson/0000-0003-0760-7940; Soper, Alan/0000-0002-7903-8356				Bowron DT, 1998, J PHYS CHEM B, V102, P3551, DOI 10.1021/jp972780c; Bowron DT, 2001, J CHEM PHYS, V114, P6203, DOI 10.1063/1.1354167; DANGELO M, 1994, J CHEM PHYS, V100, P3107, DOI 10.1063/1.466452; Dixit S, 2000, J PHYS-CONDENS MAT, V12, pL323, DOI 10.1088/0953-8984/12/21/103; Egashira K, 1998, J PHYS CHEM B, V102, P4054, DOI 10.1021/jp9806359; FERRARIO M, 1990, J CHEM PHYS, V93, P5156, DOI 10.1063/1.458652; Finney JL, 2000, J PHYS-CONDENS MAT, V12, pA123, DOI 10.1088/0953-8984/12/8A/313; FRANK HS, 1945, J CHEM PHYS, V13, P507, DOI 10.1063/1.1723985; FRANKS F, 1985, WATER SCI REV, V1, P171; FRANKS F, 1966, Q REV CHEM SOC, V20, P1, DOI 10.1039/qr9662000001; Laaksonen A, 1997, J PHYS CHEM A, V101, P5910, DOI 10.1021/jp970673c; MURRELL JN, 1994, PROPERTIES LIQUIDS S, P102; Murthy SSN, 1999, J PHYS CHEM A, V103, P7927, DOI 10.1021/jp990518t; PALINKAS G, 1991, CHEM PHYS, V158, P65, DOI 10.1016/0301-0104(91)87055-Z; SOPER AK, 1993, PHYS REV LETT, V71, P4346, DOI 10.1103/PhysRevLett.71.4346; Soper AK, 2000, CHEM PHYS, V258, P121, DOI 10.1016/S0301-0104(00)00179-8; SOPER AK, 1992, J CHEM PHYS, V97, P1320, DOI 10.1063/1.463259; Soper AK, 1996, CHEM PHYS, V202, P295, DOI 10.1016/0301-0104(95)00357-6; Soper AK, 2001, MOL PHYS, V99, P1503, DOI 10.1080/00268970110056889; TANAKA H, 1992, J CHEM PHYS, V97, P2626, DOI 10.1063/1.463051; Tsai J, 1996, J CHEM PHYS, V104, P9417, DOI 10.1063/1.471686; TURNER J, 1994, J CHEM PHYS, V101, P6116, DOI 10.1063/1.467327; Wakisaka A, 2001, J MOL LIQ, V90, P175, DOI 10.1016/S0167-7322(01)00120-9; Yamaguchi T, 1999, MOL PHYS, V97, P603, DOI 10.1080/00268979909482859; Yoshida K, 2001, Z NATURFORSCH A, V56, P529	25	812	820	7	334	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					829	832		10.1038/416829a	http://dx.doi.org/10.1038/416829a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976678				2022-12-28	WOS:000175163800046
J	Markowitz, DH; Mark, EJ; Lee, A; Ryan, ET				Markowitz, DH; Mark, EJ; Lee, A; Ryan, ET			A 43-year-old man with renal carcinoma and worsening dyspnea - Microembolic carcinoma in the lung, with pulmonary hemorrhage.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							OBLITERANS ORGANIZING PNEUMONIA; TUMOR EMBOLISM; BRONCHOALVEOLAR LAVAGE; DIAGNOSIS; ASPERGILLOSIS; HEMOPTYSIS; CT		Univ Massachusetts, Div Pulm Allergy & Crit Care Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Markowitz, DH (corresponding author), Univ Massachusetts, Div Pulm Allergy & Crit Care Med, Worcester, MA 01605 USA.							Ahmed AA, 1999, ARCH PATHOL LAB MED, V123, P437; ALTEMUS LR, 1967, ARCH INTERN MED, V119, P32, DOI 10.1001/archinte.119.1.32; Bassiri AG, 1997, AM J RESP CRIT CARE, V155, P2089, DOI 10.1164/ajrccm.155.6.9196119; BENDITT JO, 1988, ANN INTERN MED, V109, P674, DOI 10.7326/0003-4819-109-8-674; CORDIER JF, 1989, CHEST, V96, P999, DOI 10.1378/chest.96.5.999; DAVIS BW, 1987, J UROLOGY, V137, P857, DOI 10.1016/S0022-5347(17)44273-X; Edelstein PH, 1995, CLIN INFECT DIS, V21, pS265, DOI 10.1093/clind/21.Supplement_3.S265; FITZPATRICK TM, 1991, CHEST, V99, P498, DOI 10.1378/chest.99.2.498; FROUDARAKIS M, 1995, EUR RESPIR J, V8, P1972, DOI 10.1183/09031936.95.08111972; GOLDMAN SM, 1979, AM J ROENTGENOL, V132, P419, DOI 10.2214/ajr.132.3.419; GOODMAN LR, 1995, AM J ROENTGENOL, V164, P1369, DOI 10.2214/ajr.164.6.7754875; Hall MC, 1998, UROLOGY, V52, P594, DOI 10.1016/S0090-4295(98)00295-7; Heffner J E, 1988, Semin Respir Infect, V3, P352; KAHN FW, 1986, AM J CLIN PATHOL, V86, P518, DOI 10.1093/ajcp/86.4.518; KANE RD, 1975, CANCER, V36, P1473, DOI 10.1002/1097-0142(197510)36:4<1473::AID-CNCR2820360440>3.0.CO;2-D; LEVY H, 1992, RESP MED, V86, P243, DOI 10.1016/S0954-6111(06)80062-4; LINEHAN WM, 1997, CANCER PRINCIPLES PR, V1, P1271; Mroz BJ, 1997, CHEST, V111, P1775, DOI 10.1378/chest.111.6.1775; POTENTE G, 1992, COMPUT MED IMAG GRAP, V16, P277, DOI 10.1016/0895-6111(92)90030-D; Schriner KW, 1991, MAYO CLIN P, V66, P439; SCHRINER RW, 1991, MAYO CLIN PROC, V66, P143, DOI 10.1016/S0025-6196(12)60485-6; SOARES FA, 1991, ARCH PATHOL LAB MED, V115, P127; YUTANI C, 1993, ACTA PATHOL JAPON, V43, P135	23	1	1	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1309	1317		10.1056/NEJMcpc010052	http://dx.doi.org/10.1056/NEJMcpc010052			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544GX	11973368				2022-12-28	WOS:000175150800009
J	Sharpe, J; Ahlgren, U; Perry, P; Hill, B; Ross, A; Hecksher-Sorensen, J; Baldock, R; Davidson, D				Sharpe, J; Ahlgren, U; Perry, P; Hill, B; Ross, A; Hecksher-Sorensen, J; Baldock, R; Davidson, D			Optical projection tomography as a tool for 3D microscopy and gene expression studies	SCIENCE			English	Article							AXIAL SKELETON; VISUALIZATION	Current techniques for three-dimensional (3D) optical microscopy (deconvolution, confocal. microscopy, and optical coherence tomography) generate 3D data by "optically sectioning" the specimen. This places severe constraints on the maximum thickness of a specimen that can be imaged. We have developed a microscopy technique that uses optical projection tomography (OPT) to produce high-resolution 3D images of both fluorescent and nonfluorescent biological specimens with a thickness of up to 15 millimeters. OPT microscopy allows the rapid mapping of the tissue distribution of RNA and protein expression in intact embryos or organ systems and can therefore be instrumental in studies of developmental biology or gene function.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Sharpe, J (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	james.sharpe@hgu.mrc.ac.uk	Sharpe, James/L-1150-2014; Hecksher-Sørensen, Jacob/AAB-3424-2021; Sharpe, James/AAB-7948-2019	Sharpe, James/0000-0002-1434-9743; Baldock, Richard/0000-0003-0332-6877; Ahlgren, Ulf/0000-0001-5923-8572	Medical Research Council [MC_U127527203] Funding Source: Medline; MRC [MC_U127527203] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahlgren U, 1996, DEVELOPMENT, V122, P1409; AHLGREN U, UNPUB; Akazawa H, 2000, GENES CELLS, V5, P499, DOI 10.1046/j.1365-2443.2000.00339.x; ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; Boppart SA, 1996, DEV BIOL, V177, P54, DOI 10.1006/dbio.1996.0144; Chen K, 2000, J BIOMED OPT, V5, P144, DOI 10.1117/1.429981; Davidson D, 2001, NAT REV GENET, V2, P409, DOI 10.1038/35076500; Dhenain M, 2001, DEV BIOL, V232, P458, DOI 10.1006/dbio.2001.0189; JACOBS RE, 1994, SCIENCE, V263, P681, DOI 10.1126/science.7508143; Kak A.V., 1988, PRINCIPLES COMPUTERI, DOI DOI 10.1137/1.9780898719277.CH7; Lettice LA, 1999, P NATL ACAD SCI USA, V96, P9695, DOI 10.1073/pnas.96.17.9695; Louie AY, 2000, NAT BIOTECHNOL, V18, P321, DOI 10.1038/73780; POTTER SM, 1996, SCANNING, V18, P147; Streicher J, 2000, NAT GENET, V25, P147, DOI 10.1038/75989; Tribioli C, 1999, DEVELOPMENT, V126, P5699; Weninger WJ, 2002, NAT GENET, V30, P59, DOI 10.1038/ng785; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15	17	894	937	7	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	2002	296	5567					541	545		10.1126/science.1068206	http://dx.doi.org/10.1126/science.1068206			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964482				2022-12-28	WOS:000175179400049
J	Lesnefsky, EJ				Lesnefsky, EJ			The IONA study: preparing the myocardium for ischaemia?	LANCET			English	Editorial Material							POTASSIUM CHANNELS; ELDERLY PATIENTS; INFARCTION; ANGIOPLASTY; NICORANDIL; ANGINA		Case Western Reserve Univ, Dept Med, Div Cardiol, Cleveland, OH 44106 USA; Lous Stokes Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Med Serv, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; University Hospitals of Cleveland	Lesnefsky, EJ (corresponding author), Case Western Reserve Univ, Dept Med, Div Cardiol, Cleveland, OH 44106 USA.							Bahr RD, 2000, AM HEART J, V140, P126, DOI 10.1067/mhj.2000.106641; Bolli R, 2000, CIRC RES, V87, P972, DOI 10.1161/01.RES.87.11.972; Fukuzawa S, 2000, J NUCL CARDIOL, V7, P447, DOI 10.1067/mnc.2000.107273; Garratt KN, 1999, J AM COLL CARDIOL, V33, P119, DOI 10.1016/S0735-1097(98)00557-9; Grover GJ, 2000, J MOL CELL CARDIOL, V32, P677, DOI 10.1006/jmcc.2000.1111; Ishihara M, 2000, AM HEART J, V139, P881, DOI 10.1016/S0002-8703(00)90021-8; Kato T, 2001, AM HEART J, V141, P940, DOI 10.1067/mhj.2001.114369; Lee TM, 2002, CIRCULATION, V105, P334, DOI 10.1161/hc0302.102572; Lesnefsky EJ, 1996, J AM COLL CARDIOL, V28, P331, DOI 10.1016/0735-1097(96)00148-9; Lu EX, 1998, THORAC CARDIOV SURG, V46, P28, DOI 10.1055/s-2007-1010180; Murata M, 2001, CIRC RES, V89, P891, DOI 10.1161/hh2201.100205; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Pain T, 2000, CIRC RES, V87, P460; Sato T, 2000, J AM COLL CARDIOL, V35, P514, DOI 10.1016/S0735-1097(99)00552-5	14	8	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1262	1263		10.1016/S0140-6736(02)08280-6	http://dx.doi.org/10.1016/S0140-6736(02)08280-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965265				2022-12-28	WOS:000174989700002
J	Ma, YM; Pannicke, U; Schwarz, K; Lieber, MR				Ma, YM; Pannicke, U; Schwarz, K; Lieber, MR			Hairpin opening and overhang processing by an Artemis/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination	CELL			English	Article							DNA-LIGASE-IV; STRAND BREAK REPAIR; SEVERE COMBINED IMMUNODEFICIENCY; COMBINED IMMUNE-DEFICIENCY; SACCHAROMYCES-CEREVISIAE; INCREASED SENSITIVITY; GENE REARRANGEMENT; CODING SEGMENTS; XRCC4 PROTEIN; SCID MUTATION	Mutations in the Artemis protein in humans result in hypersensitivity to DNA double-strand break-inducing agents and absence of B and T lymphocytes (radiosensitive severe combined immune deficiency [RS-SCID]). Here, we report that Artemis forms a complex with the 469 kDa DNA-dependent protein kinase (DNA-PKcs) in the absence of DNA. The purified Artemis protein alone possesses single-strand-specific 5' to 3' exonuclease activity. Upon complex formation, DNA-PKcs phosphorylates Artemis, and Artemis acquires endonucleolytic activity on 5' and 3' overhangs, as well as hairpins. Finally, the Artemis:DNA-PKcs complex can open hairpins generated by the RAG complex. Thus, DNA-PKcs regulates Artemis by both phosphorylation and complex formation to permit enzymatic activities that are critical for the hairpin-opening step of V(D)J recombination and for the 5' and 3' overhang processing in nonhomologous DNA end joining.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Pathol, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biol Sci, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA; Univ Ulm, Dept Transfus Med, German Red Cross Blood Donat Serv Baden Wuertt, Inst Ulm, D-89081 Ulm, Germany	University of Southern California; University of Southern California; University of Southern California; University of Southern California; Ulm University	Lieber, MR (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Rm 5428,1441 Eastlake Ave, Los Angeles, CA 90033 USA.		Pannicke, Ulrich/D-7348-2014	Lieber, Michael/0000-0003-3700-6345; Lieber, Michael/0000-0001-8809-0909				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; ANDERSON CW, 1996, MOL ANAL DNA REARRAN, P91; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; BLOMMERS MJJ, 1989, BIOCHEMISTRY-US, V28, P7491, DOI 10.1021/bi00444a049; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Chiu CY, 1998, J MOL BIOL, V284, P1075, DOI 10.1006/jmbi.1998.2212; Dronkert MLG, 2000, MOL CELL BIOL, V20, P4553, DOI 10.1128/MCB.20.13.4553-4561.2000; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gauss GH, 1996, MOL CELL BIOL, V16, P258; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Grawunder U, 1998, CURR OPIN IMMUNOL, V10, P172, DOI 10.1016/S0952-7915(98)80246-X; Hammarsten O, 1998, P NATL ACAD SCI USA, V95, P525, DOI 10.1073/pnas.95.2.525; Harfst E, 2000, MOL IMMUNOL, V37, P915, DOI 10.1016/S0161-5890(01)00008-6; HARRINGTON J, 1992, MOL CELL BIOL, V12, P4758, DOI 10.1128/MCB.12.10.4758; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENRIQUES JAP, 1980, GENETICS, V95, P273; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; HOWARD FB, 1991, BIOCHEMISTRY-US, V30, P779, DOI 10.1021/bi00217a030; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.biochem.63.1.991; Leuther KK, 1999, EMBO J, V18, P1114, DOI 10.1093/emboj/18.5.1114; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; Lieber MR, 1998, AM J PATHOL, V153, P1323, DOI 10.1016/S0002-9440(10)65716-1; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Lobachev KS, 2002, CELL, V108, P183, DOI 10.1016/S0092-8674(02)00614-1; MA Y, 2002, IN PRESS J BIOL CHEM, V277; Ma YM, 2001, BIOCHEMISTRY-US, V40, P9638, DOI 10.1021/bi010932v; MCCORMACK WT, 1989, CELL, V56, P785, DOI 10.1016/0092-8674(89)90683-1; Modesti M, 1999, EMBO J, V18, P2008, DOI 10.1093/emboj/18.7.2008; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Moshous D, 2000, HUM MOL GENET, V9, P583, DOI 10.1093/hmg/9.4.583; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; Paul W., 1999, FUNDAMENTAL IMMUNOLO; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; RAGHUNATHAN G, 1991, BIOCHEMISTRY-US, V30, P782, DOI 10.1021/bi00217a031; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Schlissel MS, 1998, MOL CELL BIOL, V18, P2029, DOI 10.1128/MCB.18.4.2029; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; SCHWARZ K, 1991, J EXP MED, V174, P1039, DOI 10.1084/jem.174.5.1039; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vanasse GJ, 1999, BLOOD, V94, P3997, DOI 10.1182/blood.V94.12.3997.424k44_3997_4010; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; Villa A, 2001, BLOOD, V97, P81, DOI 10.1182/blood.V97.1.81; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; West CE, 2000, PLANT J, V24, P67, DOI 10.1046/j.1365-313x.2000.00856.x; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Wilson TE, 1999, J BIOL CHEM, V274, P23599, DOI 10.1074/jbc.274.33.23599; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; Yeo TC, 2000, MOL IMMUNOL, V37, P1131, DOI 10.1016/S0161-5890(01)00026-8; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	65	788	810	1	43	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 22	2002	108	6					781	794		10.1016/S0092-8674(02)00671-2	http://dx.doi.org/10.1016/S0092-8674(02)00671-2			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955432	Bronze			2022-12-28	WOS:000174563000008
J	Kapranov, P; Cawley, SE; Drenkow, J; Bekiranov, S; Strausberg, RL; Fodor, SPA; Gingeras, TR				Kapranov, P; Cawley, SE; Drenkow, J; Bekiranov, S; Strausberg, RL; Fodor, SPA; Gingeras, TR			Large-scale transcriptional activity in chromosomes 21 and 22	SCIENCE			English	Article							DNA-SEQUENCE; DIGEORGE; GENES; MAP	The sequences of the human chromosomes 21 and 22 indicate that there are approximately 770 well-characterized and predicted genes. In this study, empirically derived maps identifying active areas of RNA transcription on these chromosomes have been constructed with the use of cytosolic polyadenylated RNA obtained from 11 human cell lines. Oligonucleotide arrays containing probes spaced on average every 35 base pairs along these chromosomes were used. When compared with the sequence annotations available for these chromosomes, it is noted that as much as an order of magnitude more of the genomic sequence is transcribed than accounted for by the predicted and characterized exons.	Affymetrix, Santa Clara, CA 95051 USA; NCI, Bethesda, MD 20892 USA	Affymetrix; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gingeras, TR (corresponding author), Affymetrix, Santa Clara, CA 95051 USA.	tom_gingeras@affymetrix.com						BUDARF ML, 1995, NAT GENET, V10, P269, DOI 10.1038/ng0795-269; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Edelmann L, 2001, GENOME RES, V11, P208, DOI 10.1101/gr.GR-1431R; Erdmann VA, 2001, CELL MOL LIFE SCI, V58, P960, DOI 10.1007/PL00000913; Gong WK, 1996, HUM MOL GENET, V5, P789, DOI 10.1093/hmg/5.6.789; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Huttenhofer A, 2001, EMBO J, V20, P2943, DOI 10.1093/emboj/20.11.2943; Kelley RL, 2000, CELL, V103, P9, DOI 10.1016/S0092-8674(00)00099-4; Li M., 1994, American Journal of Human Genetics, V55, pA10; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Wright FA, 2001, GENOME BIOL, V2	14	653	688	2	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	2002	296	5569					916	919		10.1126/science.1068597	http://dx.doi.org/10.1126/science.1068597			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988577				2022-12-28	WOS:000175442500046
J	Gillooly, JF; Charnov, EL; West, GB; Savage, VM; Brown, JH				Gillooly, JF; Charnov, EL; West, GB; Savage, VM; Brown, JH			Effects of size and temperature on developmental time	NATURE			English	Article							EMBRYONIC-DEVELOPMENT TIME; N-P STOICHIOMETRY; INCUBATION-TEMPERATURE; LIFE-HISTORY; BODY-SIZE; EGG SIZE; ZOOPLANKTON; GROWTH; REPRODUCTION; LONGEVITY	Body size and temperature are the two most important variables affecting nearly all biological rates and times(1-7). The relationship of size and temperature to development is of particular interest, because during ontogeny size changes and temperature often varies(8-12).Here we derive a general model, based on first principles of allometry and biochemical kinetics, that predicts the time of ontogenetic development as a function of body mass and temperature. The model fits embryonic development times spanning a wide range of egg sizes and incubation temperatures for birds and aquatic ectotherms (fish, amphibians, aquatic insects and zooplankton). The model also describes nearly 75% of the variation in post-embryonic development among a diverse sample of zooplankton. The remaining variation is partially explained by stoichiometry, specifically the whole-body carbon to phosphorus ratio. Development in other animals at other life stages is also described by this model. These results suggest a general definition of biological time that is approximately invariant and common to all organisms.	Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Santa Fe Inst, Santa Fe, NM 87501 USA; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA; Washington Univ, Dept Phys, St Louis, MO 63130 USA	University of New Mexico; The Santa Fe Institute; United States Department of Energy (DOE); Los Alamos National Laboratory; Washington University (WUSTL)	Gillooly, JF (corresponding author), Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA.	gillooly@unm.edu						ANDERSEN T, 1991, LIMNOL OCEANOGR, V36, P807, DOI 10.4319/lo.1991.36.4.0807; ANDERSON DH, 1994, LIMNOL OCEANOGR, V39, P1517, DOI 10.4319/lo.1994.39.7.1517; Calder W.A. III., 1974, Publications Nuttall Orn Club, VNo. 15, P86; Calder WA., 1984, SIZE FUNCTION LIFE H; COSSINS AH, 1987, TEMEPRATURE BIOL ANI; Elser JJ, 1996, BIOSCIENCE, V46, P674, DOI 10.2307/1312897; FORAN JA, 1986, OIKOS, V46, P185, DOI 10.2307/3565466; GEILING WT, 1972, LIMNOL OCEANOGR, V17, P304, DOI 10.4319/lo.1972.17.2.0304; Gillooly JF, 2001, SCIENCE, V293, P2248, DOI 10.1126/science.1061967; Gillooly JF, 2000, FRESHWATER BIOL, V44, P595, DOI 10.1046/j.1365-2427.2000.00607.x; Gillooly JF, 2000, J ZOOL, V251, P369, DOI 10.1017/S095283690000710X; Gillooly JF, 2000, J PLANKTON RES, V22, P241, DOI 10.1093/plankt/22.2.241; HANAZATO T, 1985, Japanese Journal of Limnology, V46, P185; Heinroth O., 1922, Journal fuer Ornithologie Leipzig, V70, P172, DOI 10.1007/BF02537515; HESSEN DO, 1991, ARCH HYDROBIOL, V121, P343; KANKAALA P, 1981, OIKOS, V36, P137, DOI 10.2307/3544438; LINDSTEDT SL, 1981, Q REV BIOL, V56, P1, DOI 10.1086/412080; MAIER G, 1990, HYDROBIOLOGIA, V203, P165, DOI 10.1007/BF00005685; Main TM, 1997, LIMNOL OCEANOGR, V42, P1474, DOI 10.4319/lo.1997.42.6.1474; McLeese JM, 1996, GEN COMP ENDOCR, V102, P47, DOI 10.1006/gcen.1996.0045; MUNRO IG, 1974, OECOLOGIA, V16, P355, DOI 10.1007/BF00344742; PAULY D, 1988, ENVIRON BIOL FISH, V22, P261, DOI 10.1007/BF00004892; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; RAVEN JA, 1988, NEW PHYTOL, V110, P441, DOI 10.1111/j.1469-8137.1988.tb00282.x; SCHMIDTNIELSEN K, 1983, SCALING WHY IS ANIMA; Scott W.B., 1988, CAN B FISH AQUAT SCI, V219; Somero G. N., 1997, HDB PHYSL, P1391; VETTER RAH, 1995, J COMP PHYSIOL B, V165, P46, DOI 10.1007/BF00264685; West GB, 2001, NATURE, V413, P628, DOI 10.1038/35098076; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122	30	581	609	8	417	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	2002	417	6884					70	73		10.1038/417070a	http://dx.doi.org/10.1038/417070a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986667	Green Published			2022-12-28	WOS:000175307200039
J	Swenson, ER; Maggiorini, M; Mongovin, S; Gibbs, JSR; Greve, I; Mairbaurl, HH; Bartsch, P				Swenson, ER; Maggiorini, M; Mongovin, S; Gibbs, JSR; Greve, I; Mairbaurl, HH; Bartsch, P			Pathogenesis of high-altitude pulmonary edema - Inflammation is not an etiologic factor	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MOUNTAIN-SICKNESS; EXHALED NITRIC-OXIDE; BRONCHOALVEOLAR LAVAGE; STRESS FAILURE; BLOOD-FLOW; HYPOXIA; LUNG; REDISTRIBUTION; FLUID; HEMODYNAMICS	Context The pathogenesis of high-altitude pulmonary edema (HAPE) is considered an altered permeability of the alveolar-capillary barrier secondary to intense pulmonary vasoconstriction and high capillary pressure, but previous bronchoalveolar lavage (BAL) findings in well-established HAPE are also consistent with inflammatory etiologic characteristics. Objectives To determine whether inflammation is a primary event in HAPE and to define the temporal sequence of events in HAPE. Design, Setting, and Participants Case study from July through August 1999 of 10 subjects with susceptibility to HAPE and 6 subjects resistant to HAPE, all of whom are nonprofessional alpinists with previous mountaineering experience above 3000 m. Main Outcome Measures Pulmonary artery pressure measurements and BAL findings at low altitude (490 m) and shortly before or at the onset of HAPE at an altitude of 4559 m. Results Subjects who were HAPE susceptible had higher mean (SD) pulmonary artery systolic blood pressures at 4559 m compared with HAPE-resistant subjects (66 vs 37 mm Hg; P=.004). Despite development of HAPE in the majority of HAPE-susceptible subjects, there were no differences in BAL fluid total leukocyte counts between resistant and susceptible subjects or between counts taken at low and high altitudes. Subjects who developed HAPE had BAL fluid with high concentrations of plasma-derived proteins and erythrocytes, but there was no increase in plasma concentrations of surfactant protein A and Clara cell protein. The chest radiograph score was 12.7 for the 3 HAPE-susceptible subjects who developed HAPE before BAL was performed; they were lavaged within 3 to 5 hours. The remainder of the HAPE-susceptible group was lavaged before edema was apparent on radiographs. However, 6 subjects from the HAPE-susceptible group who developed HAPE on the following day had a score on bronchoscopy of 1.5, which increased to 4.6, reflective of mild pulmonary edema. In HAPE cases, there were no elevations in a number of proinflammatory cytokines and eicosanoid and nitric oxide metabolites. Conclusions Early HAPE is characterized by high pulmonary artery pressures that lead to a protein-rich and mildly hemorrhagic edema, with normal levels of leukocytes, cytokines, and eicosanoids. HAPE is a form of hydrostatic pulmonary edema with altered alveolar-capillary permeability.	Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Med Serv, Seattle, WA 98195 USA; Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Res Serv, Seattle, WA 98195 USA; Univ Zurich Hosp, Dept Internal Med, Med Intens Care Unit, Zurich, Switzerland; Univ London Imperial Coll Sci Technol & Med, Sch Sci Technol & Med, Natl Heart & Lung Inst, London, England; Univ Clin Heidelberg, Dept Med, Div Sports Med, Heidelberg, Germany	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Zurich; University Zurich Hospital; Imperial College London; Ruprecht Karls University Heidelberg	Swenson, ER (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, Pulm & Crit Care Sect, S-111-Pulm,1660 S Columbian Way, Seattle, WA 98108 USA.	eswenson@u.washington.edu		Maggiorini, Marco/0000-0001-8180-2117				Ali MH, 1999, AM J PHYSIOL-LUNG C, V277, pL1057, DOI 10.1152/ajplung.1999.277.5.L1057; Anand IS, 1998, CIRCULATION, V98, P2441, DOI 10.1161/01.CIR.98.22.2441; AUDI SH, 1991, J APPL PHYSIOL, V70, P2126, DOI 10.1152/jappl.1991.70.5.2126; BACHOFEN H, 1993, AM REV RESPIR DIS, V147, P989, DOI 10.1164/ajrccm/147.4.989; Bartsch P, 2000, CHEST, V117, P1393, DOI 10.1378/chest.117.5.1393; BARTSCH P, 1989, J APPL PHYSIOL, V66, P2136, DOI 10.1152/jappl.1989.66.5.2136; BARTSCH P, 1991, NEW ENGL J MED, V325, P1284, DOI 10.1056/NEJM199110313251805; Bartsch P, 1997, RESPIRATION, V64, P435; BRAMAN RS, 1989, ANAL CHEM, V61, P2715, DOI 10.1021/ac00199a007; Busch T, 2001, AM J RESP CRIT CARE, V163, P368, DOI 10.1164/ajrccm.163.2.2001134; Carpenter TC, 1998, J APPL PHYSIOL, V84, P1048, DOI 10.1152/jappl.1998.84.3.1048; CRAPO JD, 1993, AM REV RESPIR DIS, V147, P790, DOI 10.1164/ajrccm/147.4.790; Droma Y, 1996, EUR RESPIR J, V9, P1947, DOI 10.1183/09031936.96.09091947; Duplain H, 2000, AM J RESP CRIT CARE, V162, P221, DOI 10.1164/ajrccm.162.1.9908039; Durmowicz AG, 1997, J PEDIATR-US, V130, P838, DOI 10.1016/S0022-3476(97)80033-9; Greene KE, 1999, AM J RESP CRIT CARE, V160, P1843, DOI 10.1164/ajrccm.160.6.9901117; HACKETT PH, 1992, INT J SPORTS MED, V13, pS68, DOI 10.1055/s-2007-1024599; Hanaoka M, 1998, CIRCULATION, V97, P1124, DOI 10.1161/01.CIR.97.12.1124; Hanaoka M, 2000, CIRCULATION, V101, P1418, DOI 10.1161/01.CIR.101.12.1418; Hermans C, 1999, EUR RESPIR J, V13, P1014, DOI 10.1034/j.1399-3003.1999.13e14.x; HOMIK LA, 1988, J APPL PHYSIOL, V63, P521; HULTGREN HN, 1971, CIRCULATION, V44, P759, DOI 10.1161/01.CIR.44.5.759; HULTGREN HN, 1964, CIRCULATION, V29, P393, DOI 10.1161/01.CIR.29.3.393; Irwin DC, 2001, HIGH ALT MED BIOL, V2, P349, DOI 10.1089/15270290152608525; Kaminsky DA, 1996, CHEST, V110, P939, DOI 10.1378/chest.110.4.939; Kleger GR, 1996, J APPL PHYSIOL, V81, P1917, DOI 10.1152/jappl.1996.81.5.1917; KOBAYASHI T, 1987, CHEST, V92, P814, DOI 10.1378/chest.92.5.814; Kubo K, 1998, RESP PHYSIOL, V111, P301, DOI 10.1016/S0034-5687(98)00006-1; Kubo K, 1996, THORAX, V51, P739, DOI 10.1136/thx.51.7.739; Kuwahira I, 2001, INT J SPORTS MED, V22, P393, DOI 10.1055/s-2001-16239; Leeper-Woodford SK, 1999, AM J PHYSIOL-LUNG C, V276, pL909, DOI 10.1152/ajplung.1999.276.6.L909; Maggiorini M, 2001, CIRCULATION, V103, P2078; Mann CM, 1998, J APPL PHYSIOL, V84, P2010, DOI 10.1152/jappl.1998.84.6.2010; MARON MB, 1987, J APPL PHYSIOL, V62, P470, DOI 10.1152/jappl.1987.62.2.470; MAYATEPEK E, 1993, J CLIN INVEST, V91, P881, DOI 10.1172/JCI116309; Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703; Mundy AL, 2000, BRIT J ANAESTH, V85, P570, DOI 10.1093/bja/85.4.570; Naldini A, 1997, J CELL PHYSIOL, V173, P335, DOI 10.1002/(SICI)1097-4652(199712)173:3<335::AID-JCP5>3.3.CO;2-T; Neal CR, 1996, J PHYSIOL-LONDON, V492, P39, DOI 10.1113/jphysiol.1996.sp021287; OELZ O, 1989, LANCET, V2, P1241; ONO S, 1993, J APPL PHYSIOL, V74, P1534, DOI 10.1152/jappl.1993.74.4.1534; ROACH RC, 1993, HYPOXIA AND MOLECULAR MEDICINE, P272; Scherrer U, 1996, NEW ENGL J MED, V334, P624, DOI 10.1056/NEJM199603073341003; Schoene RB, 2001, LUNG BIOL HEALTH DIS, V161, P777; SCHOENE RB, 1986, JAMA-J AM MED ASSOC, V256, P63, DOI 10.1001/jama.256.1.63; SCHOENE RB, 1988, J APPL PHYSIOL, V64, P2605, DOI 10.1152/jappl.1988.64.6.2605; Schutte H, 1996, EUR RESPIR J, V9, P1858, DOI 10.1183/09031936.96.09091858; Smith WS, 1997, CHEST, V111, P1326, DOI 10.1378/chest.111.5.1326; TSUKIMOTO K, 1994, J APPL PHYSIOL, V76, P321, DOI 10.1152/jappl.1994.76.1.321; VISWANATHAN R, 1979, RESPIRATION, V37, P142, DOI 10.1159/000194023; VOCK P, 1989, RADIOLOGY, V170, P661, DOI 10.1148/radiology.170.3.2916019; WEST JB, 1995, EUR RESPIR J, V8, P523; WEST JB, 1991, J APPL PHYSIOL, V70, P1731, DOI 10.1152/jappl.1991.70.4.1731; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657	55	233	248	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2228	2235		10.1001/jama.287.17.2228	http://dx.doi.org/10.1001/jama.287.17.2228			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980523	Bronze			2022-12-28	WOS:000175260600023
J	Narod, S				Narod, S			What options for treatment of hereditary breast cancer?	LANCET			English	Editorial Material							MUTATION CARRIERS; WOMEN; RISK; SURVEILLANCE; MAMMOGRAPHY; BRCA1; GENE		Sunnybrook & Womens Coll Hlth Sci Ctr, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Narod, S (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada.	steven.narod@swchsc.on.ca	Narod, Steven A/AAA-6112-2022					Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Brunet JS, 1998, J NATL CANCER I, V90, P761, DOI 10.1093/jnci/90.10.761; Goffin J, 2001, J NATL CANCER I, V93, P1754, DOI 10.1093/jnci/93.22.1754; Kuhl CK, 2000, RADIOLOGY, V215, P267, DOI 10.1148/radiology.215.1.r00ap01267; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; MA L, 1992, J NATL CANCER I, V84, P781, DOI 10.1093/jnci/84.10.781; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X; PORTER PL, 1991, J NATL CANCER I, V91, P2020; Stoutjesdijk MJ, 2001, JNCI-J NATL CANCER I, V93, P1095, DOI 10.1093/jnci/93.14.1095; Tabar L, 1999, CANCER, V86, P449, DOI 10.1002/(SICI)1097-0142(19990801)86:3<449::AID-CNCR13>3.0.CO;2-Q; Warner E, 2001, J CLIN ONCOL, V19, P3524, DOI 10.1200/JCO.2001.19.15.3524	12	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	2002	359	9316					1451	1452		10.1016/S0140-6736(02)08465-9	http://dx.doi.org/10.1016/S0140-6736(02)08465-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988240				2022-12-28	WOS:000175279100004
J	Voyles, PM; Muller, DA; Grazul, JL; Citrin, PH; Gossmann, HJL				Voyles, PM; Muller, DA; Grazul, JL; Citrin, PH; Gossmann, HJL			Atomic-scale imaging of individual dopant atoms and clusters in highly n-type bulk Si	NATURE			English	Article							ELECTRICAL DEACTIVATION; SILICON; VISIBILITY; DIFFUSION	As silicon-based transistors in integrated circuits grow smaller, the concentration of charge carriers generated by the introduction of impurity dopant atoms must steadily increase. Current technology, however, is rapidly approaching the limit at which introducing additional dopant atoms ceases to generate additional charge carriers because the dopants form electrically inactive clusters(1). Using annular dark-field scanning transmission electron microscopy, we report the direct, atomic-resolution observation of individual antimony (Sb) dopant atoms in crystalline Si, and identify the Sb clusters responsible for the saturation of charge carriers. The size, structure, and distribution of these clusters are determined with a Sb-atom detection efficiency of almost 100%. Although single heavy atoms on surfaces or supporting films have been visualized previously(2-4), our technique permits the imaging of individual dopants and clusters as they exist within actual devices.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA; Agere Syst, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T; Broadcom; LSI Corporation	Muller, DA (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.	davidm@bell-labs.com	Muller, David/A-7745-2010	Muller, David/0000-0003-4129-0473; Voyles, Paul/0000-0001-9438-4284				Bertin E, 1996, ASTRON ASTROPHYS SUP, V117, P393, DOI 10.1051/aas:1996164; Chadi DJ, 1997, PHYS REV LETT, V79, P4834, DOI 10.1103/PhysRevLett.79.4834; Citrin PH, 1999, PHYS REV LETT, V83, P3234, DOI 10.1103/PhysRevLett.83.3234; CREWE AV, 1970, SCIENCE, V168, P1338, DOI 10.1126/science.168.3937.1338; Dellby N, 2001, J ELECTRON MICROSC, V50, P177, DOI 10.1093/jmicro/50.3.177; FAIR RB, 1973, J APPL PHYS, V44, P273, DOI 10.1063/1.1661873; GOSSMANN HJ, 1993, J APPL PHYS, V73, P8237, DOI 10.1063/1.353441; GOSSMANN HJ, 2000, MATER RES SOC S, V610; HILLYARD S, 1995, ULTRAMICROSCOPY, V58, P6, DOI 10.1016/0304-3991(94)00173-K; HILLYARD S, 1993, ULTRAMICROSCOPY, V52, P325, DOI 10.1016/0304-3991(93)90043-W; HOWIE A, 1979, J MICROSC-OXFORD, V117, P11, DOI 10.1111/j.1365-2818.1979.tb00228.x; *INT SEMATECH, 2000, INT TEHN ROADM SEM U; Kirkland E. J., 2020, ADV COMPUTING ELECT, V3, DOI 10.1007/978-1-4419-6533-2#; KIRKLAND EJ, 1987, ULTRAMICROSCOPY, V23, P77, DOI 10.1016/0304-3991(87)90229-4; KLEPEIS SJ, 1988, MATER RES SOC S P, P179; LAWTHER DW, 1995, APPL PHYS LETT, V67, P3575, DOI 10.1063/1.115322; LOANE RF, 1988, ACTA CRYSTALLOGR A, V44, P912, DOI 10.1107/S0108767388006403; MATHIOT D, 1983, APPL PHYS LETT, V42, P1043, DOI 10.1063/1.93836; Muller DA, 2001, J ELECTRON MICROSC, V50, P219, DOI 10.1093/jmicro/50.3.219; MULLER EW, 1957, J APPL PHYS, V28, P1, DOI 10.1063/1.1722557; Nellist PD, 1996, SCIENCE, V274, P413, DOI 10.1126/science.274.5286.413; Packan PA, 1999, SCIENCE, V285, P2079, DOI 10.1126/science.285.5436.2079; PANDEY KC, 1988, PHYS REV LETT, V61, P1282, DOI 10.1103/PhysRevLett.61.1282; PENNYCOOK SJ, 1984, APPL PHYS LETT, V45, P385, DOI 10.1063/1.95229; Ramamoorthy M, 1996, PHYS REV LETT, V76, P4753, DOI 10.1103/PhysRevLett.76.4753; Saarinen K, 1999, PHYS REV LETT, V82, P1883, DOI 10.1103/PhysRevLett.82.1883; WILLIAMS JS, 1982, J APPL PHYS, V53, P8663, DOI 10.1063/1.330463	27	352	360	2	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	2002	416	6883					826	829		10.1038/416826a	http://dx.doi.org/10.1038/416826a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976677				2022-12-28	WOS:000175163800045
J	Adjuik, M; Agnamey, P; Babiker, A; Borrmann, S; Brasseur, P; Cisse, M; Cobelens, F; Diallo, S; Faucher, JF; Garner, P; Gikunda, S; Kremsner, PG; Krishna, S; Lell, B; Loolpapit, M; Matsiegui, PB; Missinou, MA; Mwanza, J; Ntoumi, F; Olliaro, P; Osimbo, P; Rezbach, P; Some, E; Taylor, WRJ				Adjuik, M; Agnamey, P; Babiker, A; Borrmann, S; Brasseur, P; Cisse, M; Cobelens, F; Diallo, S; Faucher, JF; Garner, P; Gikunda, S; Kremsner, PG; Krishna, S; Lell, B; Loolpapit, M; Matsiegui, PB; Missinou, MA; Mwanza, J; Ntoumi, F; Olliaro, P; Osimbo, P; Rezbach, P; Some, E; Taylor, WRJ			Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial	LANCET			English	Article							PYRIMETHAMINE-SULFADOXINE; ANTIMALARIAL-DRUG; DOUBLE-BLIND; EFFICACY; CHLOROQUINE; RESISTANCE; COMBINATION; ARTEMETHER; BENFLUMETOL; SAFETY	Background Increasing drug resistance limits the choice of efficacious chemotherapy against Plasmodium falciparum malaria in Africa. Amodiaquine still retains efficacy against P falciparum in many African countries. We assessed the safety, treatment efficacy, and effect on gametocyte carriage of adding artesunate to amodiaquine in three randomised trials in Kenya, Senegal, and Gabon. Methods We enrolled 941 children (400 in Kenya, 321 in Senegal, and 220 in Gabon) who were 10 years or older and who had uncomplicated P falciparum malaria. Patients were randomly assigned amodiaquine (10 mg/kg per day for 3 days) plus artesunate (4 mg/kg per day for 3 days) or amodiaquine (as above) and placebo (for 3 days). The primary endpoints were parasitological cure rates at days 14 and 28. Analysis was by intention to treat and by an evaluability method. Findings Both regimens were well tolerated. Six patients in the amodiaquine-artesunate group and five in the amodiaquine group developed early, drug-induced vomiting, necessitating alternative treatment. By intention-to-treat analysis, the day-14 cure rates for amodiaquine-artesunate versus amodiaquine were: 175/192 (91%) versus 140/188 (74%) in Kenya (Delta=16.7% [95% CI 9.3-24.1], p<0.0001), 148/160 (93%) versus 147/157 (94%) in Senegal (-1.1% [-6.7 to 4.5], p=0.7), and 92/94 (98%) versus 86/96 (90%) in Gabon (8.3% [1.5-15.1], p=0.02). The corresponding rates for day 28 were: 123/180 (68%) versus 75/183 (41%) in Kenya (27.3% [17.5-37.2], p<0.0001), 130/159 (82%) versus 123/156 (79%) in Senegal (2.9% [-5.9 to 11.7], p=0.5), and 80/94 (85%) versus 70/98 (71%) in Gabon (13.7% [2.2-25.2], p=0.02). Similar rates were obtained by evaluability analysis. Interpretation The combination of artesunate and amodiaquine improved treatment efficacy in Gabon and Kenya, and was equivalent in Senegal. Amodiaquine-artesunate is a potential combination for use in Africa. Further investigations to assess the potential effect on the evolution of drug resistance, disease transmission, and safety of amodiaquine-artesunate are warranted.	WHO, TDR, CH-1211 Geneva, Switzerland; Navrongo Hlth Res Ctr, Navrongo, Ghana; Univ Rouen, Dept Parasitol, F-76821 Mont St Aignan, France; MRC, Clin Trials Unit, London W1N 4AL, England; Ctr Hosp, Oussouye, Senegal; Albert Schweitzer Hosp, Med Res Unit, Lambarene, Gabon; Univ Tubingen, Dept Parasitol, D-72074 Tubingen, Germany; Univ Amsterdam, Acad Med Ctr, Dept Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands; Univ Cheick Anta Diop, Dept Parasitol, Dakar, Senegal; Univ Liverpool, Liverpool Sch Trop Med, Int Hlth Res Grp, Liverpool L3 5QA, Merseyside, England; AMREF, Nairobi, Kenya; Univ London St Georges Hosp, Dept Infect Dis, London, England; Migori Dist Hosp, Minist Hlth, Nairobi, Kenya	World Health Organization; Navrongo Health Research Center; Universite de Rouen Normandie; Medical Research Council Clinical Trials Unit; Eberhard Karls University of Tubingen; University of Amsterdam; Academic Medical Center Amsterdam; Liverpool School of Tropical Medicine; University of Liverpool; African Medical & Research Foundation (AMREF); St Georges University London	Taylor, WRJ (corresponding author), WHO, TDR, Ave Appla 20, CH-1211 Geneva, Switzerland.	Taylorw@who.ch	Garner, Paul/Y-8385-2019; Garner, Paul/HII-5856-2022; Borrmann, Steffen/G-1838-2013	Garner, Paul/0000-0002-0607-6941; Borrmann, Steffen/0000-0001-9189-4393; Cobelens, Frank/0000-0002-4367-1133; Krishna, Sanjeev/0000-0003-0066-0634				Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1; Brasseur P, 1999, T ROY SOC TROP MED H, V93, P645, DOI 10.1016/S0035-9203(99)90083-4; Chan ISF, 1999, BIOMETRICS, V55, P1202, DOI 10.1111/j.0006-341X.1999.01202.x; CONTAMIN H, 1995, J CLIN MICROBIOL, V33, P944, DOI 10.1128/JCM.33.4.944-951.1995; Edwards IR, 2000, LANCET, V356, P1255, DOI 10.1016/S0140-6736(00)02799-9; Guiyedi V, 2001, B SOC PATHOL EXOT, V94, P253; Hatz C, 1998, TROP MED INT HEALTH, V3, P498, DOI 10.1046/j.1365-3156.1998.00250.x; HOLLIS S, 1999, WHAT MEANT INTENTION, P670; Kshirsagar NA, 2000, AM J TROP MED HYG, V62, P402, DOI 10.4269/ajtmh.2000.62.402; LUZZI GA, 1993, DRUG SAFETY, V8, P295, DOI 10.2165/00002018-199308040-00004; Nosten F, 2000, LANCET, V356, P297, DOI 10.1016/S0140-6736(00)02505-8; Ogutu BR, 2000, T ROY SOC TROP MED H, V94, P83, DOI 10.1016/S0035-9203(00)90450-4; Olliaro P, 1996, LANCET, V348, P1196, DOI 10.1016/S0140-6736(96)06217-4; Orrell C, 2001, T ROY SOC TROP MED H, V95, P517, DOI 10.1016/S0035-9203(01)90024-0; PHILLIPSHOWARD PA, 1990, B WORLD HEALTH ORGAN, V68, P493; Planche T, 2001, AM J TROP MED HYG, V65, P599, DOI 10.4269/ajtmh.2001.65.599; Price R, 1999, AM J TROP MED HYG, V60, P1019, DOI 10.4269/ajtmh.1999.60.1019; Radloff PD, 1996, LANCET, V347, P1511, DOI 10.1016/S0140-6736(96)90671-6; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; Sokhna CS, 1997, B SOC PATHOL EXOT, V90, P83; Staedke SG, 2001, LANCET, V358, P368, DOI 10.1016/S0140-6736(01)05557-X; Sylla EHK, 2000, T ROY SOC TROP MED H, V94, P652, DOI 10.1016/S0035-9203(00)90219-0; Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7; van Vugt M, 1999, AM J TROP MED HYG, V60, P936, DOI 10.4269/ajtmh.1999.60.936; Von Seidlein L, 1998, AM J TROP MED HYG, V58, P638; von Seidlein L, 2000, LANCET, V355, P352, DOI 10.1016/S0140-6736(99)10237-X; vonSeidlein L, 1997, J INFECT DIS, V176, P1113, DOI 10.1086/516524; White NJ, 1996, PARASITOL TODAY, V12, P399, DOI 10.1016/0169-4758(96)10055-7; White NJ, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P301; *WHO, 1965, WHO TECH REP SER, V529; [No title captured]	31	237	241	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	2002	359	9315					1365	1372		10.1016/S0140-6736(02)08348-4	http://dx.doi.org/10.1016/S0140-6736(02)08348-4			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978332				2022-12-28	WOS:000175076200007
J	Waksman, R; Ajani, AE; White, RL; Chan, RC; Satler, LF; Kent, KM; Pichard, AD; Pinnow, EE; Bui, AB; Ramee, S; Teirstein, P; Lindsay, J				Waksman, R; Ajani, AE; White, RL; Chan, RC; Satler, LF; Kent, KM; Pichard, AD; Pinnow, EE; Bui, AB; Ramee, S; Teirstein, P; Lindsay, J			Intravascular gamma radiation for in-stent restenosis in saphenous-vein bypass grafts	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY SURGERY; BALLOON ANGIOPLASTY; INTRACORONARY BRACHYTHERAPY; MULTICENTER; RECURRENCE; OCCLUSION; STENOSIS; LESIONS; TRIAL; CASS	Background: Intracoronary radiation therapy is effective in reducing the recurrence of in-stent stenosis in native coronary arteries. We examined the effects of intravascular gamma radiation in patients with in-stent restenosis of saphenous-vein bypass grafts. Methods: A total of 120 patients with in-stent restenosis in saphenous-vein grafts, the majority of whom had diffuse lesions, underwent balloon angioplasty, atherectomy, additional stenting, or a combination of these procedures. If the intervention was successful, the patients were randomly assigned in a double-blind fashion to intravascular treatment with a ribbon containing either iridium-192 or nonradioactive seeds. The prescribed dose, delivered at a distance of 2 mm from the source, was 14 to 15 Gy in vessels that were 2.5 to 4.0 mm in diameter and 18 Gy in vessels with a diameter that exceeded 4.0 mm. The primary end points were death from cardiac causes, Q-wave myocardial infarction, revascularization of the target vessel, and a composite of these events at 12 months. Results: Revascularization and radiation therapy were successfully accomplished in all patients. At six months, the restenosis rate was lower in the 60 patients assigned to the iridium-192 group than in the 60 assigned to the placebo group (21 percent vs. 44 percent, P=0.005). At 12 months, the rate of revascularization of the target lesion was 70 percent lower in the iridium-192 group than in the placebo group (17 percent vs. 57 percent, P<0.001), and the rate of major cardiac events was 49 percent lower (32 percent vs. 63 percent, P<0.001). Conclusions: The results of our study support the use of gamma-radiation therapy for the treatment of in-stent restenosis in patients with bypass grafts.	Washington Hosp Ctr, Div Cardiol, Washington, DC 20010 USA; Washington Hosp, Washington Canc Inst, Washington, DC USA; Scripps Res Inst, San Diego, CA USA; Oschner Clin, New Orleans, LA USA; Cordis Corp, Miami, FL 33102 USA	MedStar Washington Hospital Center; Scripps Research Institute; Ochsner Health System; Johnson & Johnson; Johnson & Johnson USA	Waksman, R (corresponding author), Washington Hosp Ctr, Div Cardiol, 110 Irving St NW,Suite 4B-1, Washington, DC 20010 USA.							BOURASSA MG, 1985, CIRCULATION, V72, P71; Costa MA, 1999, CIRCULATION, V100, P789, DOI 10.1161/01.CIR.100.8.789; DEFEYTER PIMJ, 1993, J AM COLL CARDIOL, V21, P1539, DOI 10.1016/0735-1097(93)90366-9; DOUGLAS JS, 1983, J AM COLL CARDIOL, V2, P745, DOI 10.1016/S0735-1097(83)80315-5; FOSTER ED, 1984, ANN THORAC SURG, V38, P563, DOI 10.1016/S0003-4975(10)62312-0; Gruberg L, 1999, AM J CARDIOL, V84, P1381, DOI 10.1016/S0002-9149(99)00580-9; HOLMES DR, 1995, CIRCULATION, V91, P1966, DOI 10.1161/01.CIR.91.7.1966; JOHNSON WD, 1984, AM HEART J, V108, P1190, DOI 10.1016/0002-8703(84)90741-5; Koster R, 1999, J AM COLL CARDIOL, V34, P25, DOI 10.1016/S0735-1097(99)00167-9; Le May MR, 1999, AM J CARDIOL, V83, P681, DOI 10.1016/S0002-9149(98)00970-9; Leon MB, 2001, NEW ENGL J MED, V344, P250, DOI 10.1056/NEJM200101253440402; Mehran R, 1997, CIRCULATION, V96, P2183; PIANA RN, 1994, J AM COLL CARDIOL, V23, P1296, DOI 10.1016/0735-1097(94)90370-0; PLATKO WP, 1989, J AM COLL CARDIOL, V14, P1645, DOI 10.1016/0735-1097(89)90010-7; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; Teirstein PS, 1997, NEW ENGL J MED, V336, P1697, DOI 10.1056/NEJM199706123362402; Waksman R, 2001, CIRCULATION, V103, P2332; Waksman R, 2000, CIRCULATION, V101, P2165, DOI 10.1161/01.CIR.101.18.2165; Waksman R, 2000, J AM COLL CARDIOL, V36, P65, DOI 10.1016/S0735-1097(00)00681-1	19	95	99	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	2002	346	16					1194	1199		10.1056/NEJMoa012579	http://dx.doi.org/10.1056/NEJMoa012579			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542FT	11961147	Bronze			2022-12-28	WOS:000175033400003
J	Keriel, A; Stary, A; Sarasin, A; Rochette-Egly, C; Egly, JM				Keriel, A; Stary, A; Sarasin, A; Rochette-Egly, C; Egly, JM			XPD mutations prevent TFIIH-dependent transactivation by nuclear receptors and phosphorylation of RAR alpha	CELL			English	Article							TRANSCRIPTION FACTOR TFIIH; RNA-POLYMERASE-II; NUCLEOTIDE EXCISION-REPAIR; ACTIVATION FUNCTION AF-1; C-TERMINAL DOMAIN; XERODERMA-PIGMENTOSUM; DNA-REPAIR; ESTROGEN-RECEPTOR; PROTEIN-KINASE; SKIN-CANCER	Inherited mutations in the XPD subunit of the general transcription/repair factor TFIIH yield the rare genetic disorder Xeroderma pigmentosum (XP), the phenotypes of which cannot be explained solely on the basis of a DNA repair defect. In cells derived from XP-D patients, we observed a reduction of the ligand-dependent transactivation mediated by several nuclear receptors (RARalpha, ERalpha, and AR). We demonstrate that the XPD mutation alters cdk7 function in RARalpha phosphorylation. Transactivation is restored upon overexpression of either the wild-type XPD or the RARalphaS77E (a mutation which mimics phosphorylated RARalpha). Thus, we demonstrate that the cdk7 kinase of TFIIH phosphorylates the nuclear receptor, then allowing ligand-dependent control of the activation of the hormone-responsive genes.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; CNRS, UPR 2169, Lab Genet Instabil & Canc, F-94801 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS)	Egly, JM (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.		stary, anne/GRY-3781-2022; Keriel, Anne/N-3753-2017	Keriel, Anne/0000-0003-3340-299X				Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Coin F, 1998, NAT GENET, V20, P184, DOI 10.1038/2491; Coin F, 1999, EMBO J, V18, P1357, DOI 10.1093/emboj/18.5.1357; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; de Boer J, 1998, CANCER RES, V58, P89; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; Delmotte MH, 1999, J BIOL CHEM, V274, P38225, DOI 10.1074/jbc.274.53.38225; Dilworth FJ, 2000, MOL CELL, V6, P1049, DOI 10.1016/S1097-2765(00)00103-9; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GERARD M, 1991, J BIOL CHEM, V266, P20940; Glass CK, 2000, GENE DEV, V14, P121; GUZDER SN, 1994, NATURE, V369, P578, DOI 10.1038/369578a0; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; JOHNSON RT, 1985, J CELL SCI, V76, P115; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KERIEL A, 2001, CDK ACTIVATING KINAS, pCH8; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501; Larochelle S, 1998, GENE DEV, V12, P370, DOI 10.1101/gad.12.3.370; Leclerc V, 2000, EMBO J, V19, P1567, DOI 10.1093/emboj/19.7.1567; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Niles RM, 2000, NUTRITION, V16, P1084, DOI 10.1016/S0899-9007(00)00436-6; Reardon JT, 1996, P NATL ACAD SCI USA, V93, P6482, DOI 10.1073/pnas.93.13.6482; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; Takayama K, 1996, AM J HUM GENET, V58, P263; Taylor EM, 1997, P NATL ACAD SCI USA, V94, P8658, DOI 10.1073/pnas.94.16.8658; Thomas D, 2000, CURR BIOL, V10, pR341, DOI 10.1016/S0960-9822(00)00462-0; Tirode F, 1999, MOL CELL, V3, P87, DOI 10.1016/S1097-2765(00)80177-X; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; van Steeg H, 1999, MOL MED TODAY, V5, P86, DOI 10.1016/S1357-4310(98)01394-X; Vermeulen W, 2000, NAT GENET, V26, P307, DOI 10.1038/81603; Winkler GS, 1998, J BIOL CHEM, V273, P1092, DOI 10.1074/jbc.273.2.1092; Winkler GS, 2000, J BIOL CHEM, V275, P4258, DOI 10.1074/jbc.275.6.4258	56	157	158	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	2002	109	1					125	135		10.1016/S0092-8674(02)00692-X	http://dx.doi.org/10.1016/S0092-8674(02)00692-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955452	Bronze			2022-12-28	WOS:000174888300014
J	Klass, KD; Zompro, O; Kristensen, NP; Adis, J				Klass, KD; Zompro, O; Kristensen, NP; Adis, J			Mantophasmatodea: A new insect order with extant members in the afrotropics	SCIENCE			English	Article							PHYLOGENY; ABDOMEN; DICTYOPTERA; MORPHOLOGY	A new insect order, Mantophasmatodea, is described on the basis of museum specimens of a new genus with two species: Mantophasma zephyra gen. et sp. nov. (one female from Namibia) and M. subsolana sp. nov. (one male from Tanzania). This is the first time since 1914 that a newly described extant insect taxon has proved unplaceable within a recognized order. Mantophasmatodeans are apterous carnivores. Their closest phylogenetic relationships may be to Grylloblattodea (ice-crawlers) and/or Phasmatodea (stick insects), but the morphological evidence is ambiguous. Raptophasma Zompro from Baltic amber is assigned to the Mantophasmatodea, revealing a wider previous range for the lineage.	Univ Copenhagen, Zool Museum, DK-2100 Copenhagen, Denmark; AG Tropenokol, Max Planck Inst Limnol, D-24306 Plon, Germany; Staatliche Nat Hist Sammlungen Dresden, Museum Tierkunde, D-01109 Dresden, Germany	University of Copenhagen; Max Planck Society	Klass, KD (corresponding author), Univ Copenhagen, Zool Museum, Univ Pk 15, DK-2100 Copenhagen, Denmark.	klass@snsd.de; zompro@mpil.ploen.mpg.de	Kristensen, Niels/A-8795-2013					Arillo Antonio, 1997, Bulletin de la Societe Entomologique de France, V102, P11; Beutel RG, 2001, J ZOOL SYST EVOL RES, V39, P177, DOI 10.1046/j.1439-0469.2001.00155.x; CHOPARD L, 1938, BIOL ORTHOPTERES; GUNTHER K, 1933, Z NATURWISS, V68, P403; Hinton HE, 1981, BIOL INSECT EGGS; Klass KD, 1998, ZOOL ANZ, V237, P15; Klass KD, 1999, DEUT ENTOMOL Z, V46, P3; Klass KD, 2000, ZOOL ANZ, V239, P231; Klass KD, 2001, ZOOL J LINN SOC-LOND, V131, P251, DOI 10.1111/j.1096-3642.2001.tb02239.x; KRISTENSEN NP, 1989, INT CONGR SER, V824, P295; KRISTENSEN NP, 1991, INSECTS AUSTR, V1, pCH5; Sellick J, 1997, ITAL J ZOOL, V64, P97, DOI 10.1080/11250009709356178; Staniczek AH, 2000, ZOOL ANZ, V239, P147; Tilgner EH, 1999, DEUT ENTOMOL Z, V46, P149, DOI 10.1002/mmnd.19990460203; Walker E. M., 1943, ANN ENT SOC AMERICA, V36, P681; WALKER E. M., 1949, CANADIAN JOUR RES SECT D ZOOL SCI, V27, P309; Wheeler WC, 2001, CLADISTICS, V17, P113, DOI [10.1111/j.1096-0031.2001.tb00115.x, 10.1006/clad.2000.0147]; Zompro Oliver, 2001, Mitteilungen aus dem Geologisch-Palaeontologischen Institut der Universitaet Hamburg, V85, P229	18	124	148	5	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 24	2002	296	5572					1456	1459		10.1126/science.1069397	http://dx.doi.org/10.1126/science.1069397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	557LP	11964441				2022-12-28	WOS:000175910300045
J	Garvey, CJ; Hanlon, R				Garvey, CJ; Hanlon, R			Computed tomography in clinical practice	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CT FLUOROSCOPY		Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Garvey, CJ (corresponding author), Royal Liverpool Univ Hosp, Liverpool L7 8XP, Merseyside, England.	Conall.garvey@rlbuh-tr.nwest.nhs.uk						Budoff MJ, 1999, CLIN CARDIOL, V22, P554, DOI 10.1002/clc.4960220904; Carlson SK, 2001, RADIOLOGY, V219, P515, DOI 10.1148/radiology.219.2.r01ma41515; Dawson P, 2001, CLIN RADIOL, V56, P302, DOI 10.1053/crad.2000.0651; GLUECKER T, 2001, MULTISLICE CT, P77; Hara AK, 2001, RADIOLOGY, V219, P461, DOI 10.1148/radiology.219.2.r01ma28461; HOUNDFIELD GN, 1973, BRIT J RADIOL, V46, P1016, DOI 10.1259/0007-1285-46-552-1016; Katada K, 1996, RADIOLOGY, V200, P851, DOI 10.1148/radiology.200.3.8756943; Lewis MA, 2001, BRIT J RADIOL, V74, P779, DOI 10.1259/bjr.74.885.740779; *NAT RAD PROT BOAR, 1990, DOC NRPB PAT DOS RED, V1; Ohnesorge B, 2000, RADIOLOGY, V217, P564, DOI 10.1148/radiology.217.2.r00nv30564; Rabin DN, 2000, CHEST, V118, P488, DOI 10.1378/chest.118.2.488; Rubin GD, 1999, J COMPUT ASSIST TOMO, V23, pS83; Rubin GD, 2001, RADIOLOGY, V221, P146, DOI 10.1148/radiol.2211001325; Shrimpton PC, 1998, BRIT J RADIOL, V71, P1, DOI 10.1259/bjr.71.841.9534691; Stanford W, 1999, RADIOL CLIN N AM, V37, P257, DOI 10.1016/S0033-8389(05)70095-6; The Royal College of Radiologists, 1998, MAK BEST US DEP CLIN, V4th; Vining D J, 1997, Gastrointest Endosc Clin N Am, V7, P285; Wagner LK, 2000, RADIOLOGY, V216, P9, DOI 10.1148/radiology.216.1.r00jl489	18	35	36	1	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 4	2002	324	7345					1077	1080		10.1136/bmj.324.7345.1077	http://dx.doi.org/10.1136/bmj.324.7345.1077			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YY	11991915	Green Published			2022-12-28	WOS:000175476500023
J	Hiscock, H; Wake, M				Hiscock, H; Wake, M			Randomised controlled trial of behavioural infant sleep intervention to improve infant sleep and maternal mood	BRITISH MEDICAL JOURNAL			English	Article							POSTNATAL DEPRESSION SCALE; YOUNG-CHILDREN; COMMUNITY; DISRUPTIONS; TEMPERAMENT; MANAGEMENT; VALIDATION	Objective To compare the effect of a behavioural sleep intervention with written information about normal sleep on infant sleep problems and maternal depression. Design Randomised controlled trial. Setting Well child clinics, Melbourne, Australia Participants 156 mothers of infants aged 6-12 months with severe sleep problems according to the parents. Main outcome measures Maternal report of infant sleep problem; scores on Edinburgh postnatal depression scale at two and four months. Intervention Discussion on behavioural infant Sleep intervention (controlled crying) delivered over three consultations. Results At two months more sleep problems had resolved in tire intervention group than in the control group (53/76 v 36/76, P=0.005). Overall depression scores fell further in the intervention group than in the control group (mean change - 3.7, 95% confidence interval - 4.7 to - 2.7, v - 2.5, - 1.7 to - 3.4, P=0.06). For the Subgroup of mothers with depression scores of 10 and over more sleep problems had resolved in the intervention group than in die control group (26/33 v 13/33, P=0.001). In this subgroup depression scores also fell further for intervention mothers than control mothers at two months (- 6.0, - 7.5 to - 4.0, v - 3.7, - 4.9 to - 2.6, P=0.01) and at four months (- 6.5, - 7.9 to 5.1 v - 4.2, -5.9 to - 2.5, P=0.04). By four months, changes in sleep problems and depression scores were similar. Conclusions Behavioural intervention significantly reduces infant sleep problems at two but not four months. Maternal report of symptoms of depression decreased significantly at two months, and this was sustained at four months for mothers with high depression scores.	Royal Childrens Hosp, Ctr Community Child Hlth, Melbourne, Vic 3052, Australia	Royal Children's Hospital Melbourne	Hiscock, H (corresponding author), Royal Childrens Hosp, Ctr Community Child Hlth, Melbourne, Vic 3052, Australia.		Wake, Melissa/J-1396-2012; Hiscock, Harriet/M-6882-2013	Wake, Melissa/0000-0001-7501-9257; Hiscock, Harriet/0000-0003-3017-2770				ADAMS LA, 1989, PEDIATRICS, V84, P756; Appleby L, 1997, BRIT MED J, V314, P932, DOI 10.1136/bmj.314.7085.932; Armstrong KL, 1998, J PAEDIATR CHILD H, V34, P260, DOI 10.1046/j.1440-1754.1998.00213.x; ARMSTRONG KL, 1994, MED J AUSTRALIA, V161, P202, DOI 10.5694/j.1326-5377.1994.tb127383.x; ASTBURY J, 1994, AUST J PUBLIC HEALTH, V18, P176; BOYCE PM, 1994, MED J AUSTRALIA, V161, P471, DOI 10.5694/j.1326-5377.1994.tb127558.x; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; COOPER PJ, 1988, BRIT J PSYCHIAT, V152, P799, DOI 10.1192/bjp.152.6.799; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; France KG, 1996, CHILD ADOL PSYCH CL, V5, P581, DOI 10.1016/S1056-4993(18)30350-X; Hearn G, 1998, BRIT J GEN PRACT, V48, P1064; Hiscock H, 2001, PEDIATRICS, V107, P1317, DOI 10.1542/peds.107.6.1317; HOLDEN JM, 1989, BRIT MED J, V298, P223, DOI 10.1136/bmj.298.6668.223; JONES DPH, 1983, ARCH DIS CHILD, V58, P442, DOI 10.1136/adc.58.6.442; KERR S, 1994, CHILD CARE HLTH DEV, V20, P379, DOI 10.1111/j.1365-2214.1994.tb00400.x; LEESON R, 1994, CHILD CARE HLTH DEV, V20, P89, DOI 10.1111/j.1365-2214.1994.tb00856.x; MINDE K, 1993, J CHILD PSYCHOL PSYC, V34, P521, DOI 10.1111/j.1469-7610.1993.tb01033.x; MURRAY L, 1990, BRIT J PSYCHIAT, V157, P288, DOI 10.1192/bjp.157.2.288; Murray L, 1997, ARCH DIS CHILD, V77, P99, DOI 10.1136/adc.77.2.99; RICHMAN N, 1981, J AM ACAD CHILD PSY, V20, P281, DOI 10.1016/S0002-7138(09)60989-4; RICKERT VI, 1988, PEDIATRICS, V81, P203; SANSON A, 1987, INFANT BEHAV DEV, V10, P97, DOI 10.1016/0163-6383(87)90009-9; SEYMOUR FW, 1989, J CHILD PSYCHOL PSYC, V30, P913, DOI 10.1111/j.1469-7610.1989.tb00293.x; SHARPLEY CF, 1984, EDUC PSYCHOL MEAS, V44, P1045, DOI 10.1177/0013164484444029; SMITH J, 1995, J AM ACAD CHILD PSY, V34, P168, DOI 10.1097/00004583-199502000-00012; Ware J, 1992, MEASURING FUNCTIONIN; WEIR IK, 1988, CHILD CARE HLTH DEV, V14, P355, DOI 10.1111/j.1365-2214.1988.tb00587.x; ZUCKERMAN B, 1987, PEDIATRICS, V80, P664; [No title captured]	29	182	186	0	27	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 4	2002	324	7345					1062	1065		10.1136/bmj.324.7345.1062	http://dx.doi.org/10.1136/bmj.324.7345.1062			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	549YY	11991909	Green Published, Bronze			2022-12-28	WOS:000175476500017
J	Melville, WK; Matusov, P				Melville, WK; Matusov, P			Distribution of breaking waves at the ocean surface	NATURE			English	Article							WHITECAP COVERAGE; GRAVITY-WAVES; WIND; DISSIPATION; SPECTRA; SPEED	Surface waves play an important role in the exchange of mass, momentum and energy between the atmosphere and the ocean. The development of the wave field depends on wind, wave-wave and wave-current interactions and wave dissipation owing to breaking, which is accompanied by momentum fluxes from waves to currents. Wave breaking supports air-sea fluxes of heat and gas(1,2), which have a profound effect on weather and climate. But wave breaking is poorly quantified and understood. Here we present measurements of wave breaking, using aerial imaging and analysis, and provide a statistical description of related sea-surface processes. We find that the distribution of the length of breaking fronts per unit area of sea surface is proportional to the cube of the wind speed and that, within the measured range of the speed of the wave fronts, the length of breaking fronts per unit area is an exponential function of the speed of the front. We also find that the fraction of the ocean surface mixed by breaking waves, which is important for air-sea exchange, is dominated by wave breaking at low velocities and short wavelengths.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography	Melville, WK (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.							Andreas EL, 1998, J PHYS OCEANOGR, V28, P2175, DOI 10.1175/1520-0485(1998)028<2175:ANSSGF>2.0.CO;2; Ardhuin F, 2001, J PHYS OCEANOGR, V31, P1498, DOI 10.1175/1520-0485(2001)031<1498:AHELMF>2.0.CO;2; BANNER ML, 1989, J FLUID MECH, V198, P321, DOI 10.1017/S0022112089000157; DONELAN M, 1972, NATURE, V239, P449, DOI 10.1038/239449a0; DUNCAN JH, 1981, P ROY SOC LOND A MAT, V377, P331, DOI 10.1098/rspa.1981.0127; Fedorov AV, 1998, PHYS FLUIDS, V10, P1315, DOI 10.1063/1.869657; HARA T, UNPUB J FLUID MECH; JAHNE B, 1990, J GEOPHYS RES-OCEANS, V95, P11531, DOI 10.1029/JC095iC07p11531; Jessup AT, 1997, NATURE, V385, P52, DOI 10.1038/385052a0; LAMARRE E, 1994, J ACOUST SOC AM, V95, P1317, DOI 10.1121/1.408572; LAMARRE E, 1991, NATURE, V351, P469, DOI 10.1038/351469a0; LOEWEN MR, 1991, J FLUID MECH, V224, P601, DOI 10.1017/S0022112091001891; MADSEN OS, 1989, COASTAL ENG 1988, P492; MELVILLE WK, 1994, J PHYS OCEANOGR, V24, P2041, DOI 10.1175/1520-0485(1994)024<2041:EDBBW>2.0.CO;2; Melville WK, 1996, ANNU REV FLUID MECH, V28, P279, DOI 10.1146/annurev.fl.28.010196.001431; MELVILLE WK, 1985, NATURE, V317, P514, DOI 10.1038/317514a0; MONAHAN EC, 1980, J PHYS OCEANOGR, V10, P2094, DOI 10.1175/1520-0485(1980)010<2094:OPLDOO>2.0.CO;2; Phillips O.M., 1977, DYNAMICS UPPER OCEAN, V2nd ed.; PHILLIPS OM, 1985, J FLUID MECH, V156, P505, DOI 10.1017/S0022112085002221; Phillips OM, 2001, J PHYS OCEANOGR, V31, P450, DOI 10.1175/1520-0485(2001)031<0450:HRRRMO>2.0.CO;2; RAPP RJ, 1990, PHILOS T ROY SOC A, V331, P735, DOI 10.1098/rsta.1990.0098; Terrill EJ, 2001, J GEOPHYS RES-OCEANS, V106, P16815, DOI 10.1029/2000JC000496; WILLERT CE, 1991, EXP FLUIDS, V10, P181; WU J, 1988, J PHYS OCEANOGR, V18, P1448, DOI 10.1175/1520-0485(1988)018<1448:VOWCWW>2.0.CO;2	24	167	172	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	2002	417	6884					58	63		10.1038/417058a	http://dx.doi.org/10.1038/417058a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986664				2022-12-28	WOS:000175307200036
J	Mehta, SH; Cox, A; Hoover, DR; Wang, XH; Mao, Q; Ray, S; Strathdee, SA; Vlahov, D; Thomas, DL				Mehta, SH; Cox, A; Hoover, DR; Wang, XH; Mao, Q; Ray, S; Strathdee, SA; Vlahov, D; Thomas, DL			Protection against persistence of hepatitis C	LANCET			English	Article							INJECTION-DRUG USERS; VIRUS-INFECTION; INTERFERON-ALPHA-2B; CHIMPANZEES; VACCINATION; REINFECTION; PREVALENCE; RIBAVIRIN; CHILDREN; IMMUNITY	Background Neither previous hepatitis C virus (HCV) infection nor vaccination with HCV-derived antigens protects against reinfection. However, HCV infection and vaccination in chimpanzees has been shown to reduce the magnitude and duration of viraemia with re-challenge. We aimed to establish whether similar immunity could be achieved in man. Methods From a study of injecting drug users, we identified 164 people who had no evidence of previous HCV infection and 98 individuals who had been previously, but were not currently, infected with HCV. We compared the incidence and persistence of HCV viraemia in these two groups over four consecutive 6-month periods. Findings Of participants without previous infection, the incidence of HCV infection was 21% (35/164). By contrast, people previously infected were half as likely to develop new viraemia (12% [12/98]), even after accounting for risk behaviour (hazard ratio, 0.45: 95% CI 0.23-0.88). Furthermore, in HIV-1-negative people, those previously infected were 12 times less likely than people infected for the first time to develop persistent infection (odds ratio 0.05, 95% CI 0.01-0.30), and median peak HCV RNA concentration was two logs lower. HCV persisted in six of six HIV-1-positive people, even in one man who had previously cleared HCV infection when he was HIV-1 negative. Interpretation There is an alarming frequency of HCV infection and persistence among injecting drug users. Our data suggest that immunity against viral persistence can be acquired, and that vaccines should be tested to reduce the burden of HCV-related liver disease.	Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA; Rutgers State Univ, Dept Stat, Newark, NJ 07102 USA; Rutgers State Univ, Ctr Hlth Hlth Care Policy & Aging Res, Newark, NJ 07102 USA; New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA; Third Mil Med Univ, SW Hosp, Chongqing, Peoples R China	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Rutgers State University Newark; Rutgers State University New Brunswick; Rutgers State University Newark; Rutgers State University New Brunswick; New York Academy of Medicine; Army Medical University	Thomas, DL (corresponding author), 424 N Bond St,Room 102, Baltimore, MD 21231 USA.		Ray, Stuart C./B-7527-2008; Strathdee, Steffanie A/B-9042-2009	Ray, Stuart C./0000-0002-1051-7260; Cox, Andrea/0000-0002-9331-2462	NIAID NIH HHS [AI 40035, U19 AI040035] Funding Source: Medline; NIDA NIH HHS [DA 08009, DA 10627, DA 06007, DA 04334] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010627, F31DA006007, R01DA004334, R37DA004334, R56DA004334] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; Bassett SE, 2001, HEPATOLOGY, V33, P1479, DOI 10.1053/jhep.2001.24371; Chang MH, 1997, NEW ENGL J MED, V336, P1855, DOI 10.1056/NEJM199706263362602; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; Forns X, 2000, HEPATOLOGY, V32, P618, DOI 10.1053/jhep.2000.9877; Garfein RS, 1996, AM J PUBLIC HEALTH, V86, P655, DOI 10.2105/AJPH.86.5.655; Global surveillance and control of hepatitis C, 1999, J VIRAL HEPAT, V6, P35; ISHAK K, 1995, J HEPATOL, V22, P696, DOI 10.1016/0168-8278(95)80226-6; LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Payen JL, 1998, GASTROEN CLIN BIOL, V22, P469; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; PRINCE AM, 1992, J INFECT DIS, V165, P438, DOI 10.1093/infdis/165.3.438; Proust B, 2000, J CLIN MICROBIOL, V38, P3125, DOI 10.1128/JCM.38.8.3125-3127.2000; Ray SC, 2000, J INFECT DIS, V182, P698, DOI 10.1086/315786; Saldanha J, 2002, VOX SANG, V82, P24, DOI 10.1046/j.1423-0410.2002.00132.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; Takaki A, 2000, NAT MED, V6, P578, DOI 10.1038/75063; Thomas DL, 2000, JAMA-J AM MED ASSOC, V284, P450, DOI 10.1001/jama.284.4.450; TONG MJ, 1995, NEW ENGL J MED, V332, P1463, DOI 10.1056/NEJM199506013322202; Villano SA, 1999, HEPATOLOGY, V29, P908, DOI 10.1002/hep.510290311; Villano SA, 1997, J CLIN MICROBIOL, V35, P3274, DOI 10.1128/JCM.35.12.3274-3277.1997; Vlahov D, 1991, NIDA Res Monogr, V109, P75; 1997, HEPATOLOGY S1, V26, pS2; 1997, WKLY EPIDEMIOL REC, V72, P341	26	355	370	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1478	1483		10.1016/S0140-6736(02)08435-0	http://dx.doi.org/10.1016/S0140-6736(02)08435-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988247				2022-12-28	WOS:000175279100011
J	Dickson, B; Yashayaev, I; Meincke, J; Turrell, B; Dye, S; Holfort, J				Dickson, B; Yashayaev, I; Meincke, J; Turrell, B; Dye, S; Holfort, J			Rapid freshening of the deep North Atlantic Ocean over the past four decades	NATURE			English	Article							OSCILLATION; CIRCULATION; TRENDS; WATER; SEA	The overflow and descent of cold, dense water from the sills of the Denmark Strait and the Faroe-Shetland channel into the North Atlantic Ocean is the principal means of ventilating the deep oceans, and is therefore a key element of the global thermohaline circulation. Most computer simulations of the ocean system in a climate with increasing atmospheric greenhouse-gas concentrations predict a weakening thermohaline circulation in the North Atlantic as the subpolar seas become fresher and warmer(1-3), and it is assumed that this signal will be transferred to the deep ocean by the two overflows. From observations it has not been possible to detect whether the ocean's overturning circulation is changing, but recent evidence suggests that the transport over the sills may be slackening(4). Here we show, through the analysis of long hydrographic records, that the system of overflow and entrainment that ventilates the deep Atlantic has steadily changed over the past four decades. We find that these changes have already led to sustained and widespread freshening of the deep ocean.	Ctr Environm Fisheries & Aquaculture Sci, Lowestoft NR33 OHT, Suffolk, England; Bedford Inst Oceanog, Dartmouth, NS B2Y 4A2, Canada; Inst Meereskunde, D-22529 Hamburg, Germany; Marine Lab, Aberdeen AB11 9DB, Scotland	Centre for Environment Fisheries & Aquaculture Science; Bedford Institute of Oceanography	Dickson, B (corresponding author), Ctr Environm Fisheries & Aquaculture Sci, Lowestoft NR33 OHT, Suffolk, England.		Dye, Stephen R/C-9456-2011; Turrell, William R/A-4185-2011	Dye, Stephen R/0000-0002-4182-8475; Turrell, William/0000-0002-1889-1468; Yashayaev, Igor/0000-0002-6976-7803				Blindheim J, 2000, DEEP-SEA RES PT I, V47, P655, DOI 10.1016/S0967-0637(99)00070-9; BREWER PG, 1983, SCIENCE, V222, P1237, DOI 10.1126/science.222.4629.1237; Curry RG, 2001, J PHYS OCEANOGR, V31, P3374, DOI 10.1175/1520-0485(2001)031<3374:OGCCAW>2.0.CO;2; Delworth TL, 2000, J CLIMATE, V13, P3721, DOI 10.1175/1520-0442(2000)013<3721:IOTRTI>2.0.CO;2; Dickson R, 1996, PROG OCEANOGR, V38, P241, DOI 10.1016/S0079-6611(97)00002-5; Dickson RR, 2000, J CLIMATE, V13, P2671, DOI 10.1175/1520-0442(2000)013<2671:TAORTT>2.0.CO;2; DICKSON RR, 1994, J GEOPHYS RES-OCEANS, V99, P12319, DOI 10.1029/94JC00530; Girton JB, 2001, GEOPHYS RES LETT, V28, P1619, DOI 10.1029/2000GL011970; Gordon AL, 1982, J MAR RES, V40, P199; Hansen B, 2000, PROG OCEANOGR, V45, P109, DOI 10.1016/S0079-6611(99)00052-X; Hansen B, 2001, NATURE, V411, P927, DOI 10.1038/35082034; Houghton J.T., 2001, IPCC CLIMATE CHANGE; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; HURRELL JW, IN PRESS ECOLOGICAL; Lascaratos A, 1999, PROG OCEANOGR, V44, P5, DOI 10.1016/S0079-6611(99)00019-1; LAZIER JRN, 1995, NATURAL CLIMATE VARI, P295; Rahmstorf S, 1999, CLIMATIC CHANGE, V43, P353, DOI 10.1023/A:1005474526406; SWIFT JH, 1984, GEOPHYS MONOGR, V29, P39; Sy A, 1997, NATURE, V386, P675, DOI 10.1038/386675a0; Thompson DWJ, 2000, J CLIMATE, V13, P1018, DOI 10.1175/1520-0442(2000)013<1018:AMITEC>2.0.CO;2; Turrell WR, 1999, DEEP-SEA RES PT I, V46, P1, DOI 10.1016/S0967-0637(98)00067-3; VERDUIN J, 1999, EUROPEAN SUBPOLAR OC, V2, P1; Vinje T, 1998, J GEOPHYS RES-OCEANS, V103, P10437, DOI 10.1029/97JC03360; Vinje T, 2001, J CLIMATE, V14, P3508, DOI 10.1175/1520-0442(2001)014<3508:FSIFAA>2.0.CO;2	24	359	379	2	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					832	837		10.1038/416832a	http://dx.doi.org/10.1038/416832a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976679				2022-12-28	WOS:000175163800047
J	Sampson, HA				Sampson, HA			Clinical practice - Peanut allergy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TREE-NUT-ALLERGY; ANAPHYLACTIC REACTIONS; FOOD ALLERGY; CHILDREN; SENSITIZATION; POPULATION; ALLERGENICITY; REGISTRY; INFANCY		CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10538 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Sampson, HA (corresponding author), CUNY Mt Sinai Sch Med, Dept Pediat, Box 1198,1 Gustave L Levy Pl, New York, NY 10538 USA.	hugh.sampson@mssm.edu						AAAI Board Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; Altschul AS, 2001, J ALLERGY CLIN IMMUN, V108, P468, DOI 10.1067/mai.2001.117794; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Burks W, 1998, ALLERGY, V53, P725, DOI 10.1111/j.1398-9995.1998.tb03967.x; Chiu L, 2001, J ALLERGY CLIN IMMUN, V107, pS192; *COMM PED EM MED, 1999, PEDIATRICS, V104, P957; *COMM TOX CHEM FOO, 1998, PEAN ALL, P1; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Frank L, 1999, PEDIATR ALLERGY IMMU, V10, P27, DOI 10.1034/j.1399-3038.1999.101010.x; Furlong TJ, 2001, J ALLERGY CLIN IMMUN, V108, P867, DOI 10.1067/mai.2001.119157; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171, DOI 10.1067/mai.2000.106041; Grundy J, 2001, J ALLERGY CLIN IMMUN, V107, pS231; HATAHET R, 1994, REV FR ALLERGOL, V34, P377, DOI 10.1016/S0335-7457(05)80243-6; Hourihane JO, 1997, BRIT MED J, V314, P1084, DOI 10.1136/bmj.314.7087.1084; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; SAAVEDRADELGADO AM, 1989, ALLERGY PROC, V10, P291, DOI 10.2500/108854189778959957; Sampson HA, 1996, BRIT MED J, V312, P1050; Sampson HA, 1998, ALLERGY, V53, P125, DOI 10.1111/j.1398-9995.1998.tb04982.x; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 2001, PEDIAT ALLERG IMM-UK, V12, P91, DOI 10.1034/j.1399-3038.2001.121420.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI [10.1067/mai.2000.108105, 10.1067/mai.2000.110158]; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Sicherer SH, 1998, PEDIATRICS, V102, DOI 10.1542/peds.102.1.e6; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, P186, DOI 10.1016/S0091-6749(99)70133-8; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; ZEIGER, 1989, J ALLERGY CLIN IMMUN, V84, P677	38	118	122	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1294	1299		10.1056/NEJMcp012667	http://dx.doi.org/10.1056/NEJMcp012667			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544GX	11973367				2022-12-28	WOS:000175150800007
J	Benatar, D; Hudson, DA				Benatar, D; Hudson, DA			A tale of two novel transplants not done: the ethics of limb allografts	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HAND TRANSPLANTATION; NERVE		Univ Cape Town, Dept Philosophy, ZA-7700 Rondebosch, South Africa; Univ Cape Town, Dept Plast & Reconstruct Surg, ZA-7925 Observatory, South Africa	University of Cape Town; University of Cape Town	Benatar, D (corresponding author), Univ Cape Town, Dept Philosophy, ZA-7700 Rondebosch, South Africa.	dbenatar@humanities.uct.ac.za						Allan CH, 2000, HAND CLIN, V16, P67; Bolitho DG, 1999, J HAND SURG-AM, V24A, P16; DAIGLE JP, 1991, MICROSURG, V12, P221, DOI 10.1002/micr.1920120312; Dror Y, 1999, TRANSPLANTATION, V67, P990, DOI 10.1097/00007890-199904150-00010; Dubernard JM, 1999, LANCET, V353, P1315, DOI 10.1016/S0140-6736(99)02062-0; First MR, 1998, TRANSPLANT P, V30, P2768, DOI 10.1016/S0041-1345(98)00805-7; Foucher G, 1999, LANCET, V353, P1286, DOI 10.1016/S0140-6736(99)00112-9; Francois CG, 2000, MICROSURG, V20, P360, DOI 10.1002/1098-2752(2000)20:8<360::AID-MICR4>3.3.CO;2-5; GROBBELAAR AO, 1994, J HAND SURG-BRIT EUR, V19B, P696, DOI 10.1016/0266-7681(94)90237-2; HUDSON DA, 1993, J HAND SURG-BRIT EUR, V18B, P171, DOI 10.1016/0266-7681(93)90098-Z; Hudson DA, 1997, J HAND SURG-BRIT EUR, V22B, P54, DOI 10.1016/S0266-7681(97)80017-4; Lee WPA, 1999, J HAND SURG-AM, V24A, P906; Lundborg G, 2000, J HAND SURG-AM, V25A, P391, DOI 10.1053/jhsu.2000.4165; Newell KA, 1996, TRANSPLANTATION, V62, P370, DOI 10.1097/00007890-199608150-00012; NOLAN LK, 1998, J HAND SURG A, V18, P153; OPELZ G, 1993, LANCET, V342, P1514, DOI 10.1016/S0140-6736(05)80084-4; PENN I, 1994, SURG CLIN N AM, V74, P1247, DOI 10.1016/S0039-6109(16)46444-3; Vanderhooft E, 2000, HAND CLIN, V16, P93	18	9	9	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 20	2002	324	7343					971	973		10.1136/bmj.324.7343.971	http://dx.doi.org/10.1136/bmj.324.7343.971			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544UF	11964346	Green Published			2022-12-28	WOS:000175179500023
J	Benlagha, K; Kyin, T; Beavis, A; Teyton, L; Bendelac, A				Benlagha, K; Kyin, T; Beavis, A; Teyton, L; Bendelac, A			A thymic precursor to the NK T cell lineage	SCIENCE			English	Article							CLASS-I MOLECULES; CD1D TETRAMERS; THYMOCYTES; SELECTION; RECOGNITION	CD1d-restricted autoreactive natural killer (NK1.1(+)) T cells function as regulatory cells in various disease conditions. Using improved tetramer tracking methodology, we identified a NK1.1(-) thymic precursor and followed its differentiation and emigration to tissues by direct cell transfer and in situ cell labeling studies. A major lineage expansion occurred within the thymus after positive selection and before NK receptor expression. Surprisingly, cytokine analysis of the developmental intermediates between NK- and NK+ stages showed a T helper cell T(H)2 to T(H)1 conversion, suggesting that the regulatory functions of NK T cells may be developmentally controlled. These findings characterize novel thymic and postthymic developmental pathways that expand autoreactive cells and differentiate them into regulatory cells.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Princeton University; Scripps Research Institute	Bendelac, A (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.		Benlagha, Kamel/I-5035-2016; Benlagha, Kamel/GLQ-8342-2022	benlagha, kamel/0000-0002-3251-9195	NATIONAL CANCER INSTITUTE [R01CA087060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038339, R37AI038339] Funding Source: NIH RePORTER; NCI NIH HHS [CA87060] Funding Source: Medline; NIAID NIH HHS [AI62267, AI38339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; Bendelac A, 2001, NAT REV IMMUNOL, V1, P177, DOI 10.1038/35105052; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; BENDELAC A, 1994, SCIENCE, V263, P1774, DOI 10.1126/science.7907820; Bendelac A, 1996, J EXP MED, V184, P1285, DOI 10.1084/jem.184.4.1285; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; Benlagha K, 2000, J EXP MED, V191, P1895, DOI 10.1084/jem.191.11.1895; BENLAGHA K, UNPUB; Coles MC, 2000, J IMMUNOL, V164, P2412, DOI 10.4049/jimmunol.164.5.2412; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Gapin L, 2001, NAT IMMUNOL, V2, P971, DOI 10.1038/ni710; Godfrey DI, 2000, IMMUNOL TODAY, V21, P573, DOI 10.1016/S0167-5699(00)01735-7; Ikarashi Y, 2001, J EXP MED, V194, P1179, DOI 10.1084/jem.194.8.1179; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Loza MJ, 2001, NAT IMMUNOL, V2, P917, DOI 10.1038/ni1001-917; MacDonald HR, 1998, J EXP MED, V187, P2109, DOI 10.1084/jem.187.12.2109; MAKINO Y, 1993, J EXP MED, V177, P1399, DOI 10.1084/jem.177.5.1399; Makino Y, 1996, P NATL ACAD SCI USA, V93, P6516, DOI 10.1073/pnas.93.13.6516; Matsuda JL, 2000, J EXP MED, V192, P741, DOI 10.1084/jem.192.5.741; Park SH, 1998, J IMMUNOL, V160, P3128; Sato H, 1999, P NATL ACAD SCI USA, V96, P7439, DOI 10.1073/pnas.96.13.7439; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Shimamura M, 1997, EUR J IMMUNOL, V27, P1576, DOI 10.1002/eji.1830270638; Shimamura M, 1997, J IMMUNOL, V158, P3682; TAKAHAMA Y, 1991, J IMMUNOL, V146, P1134; Tilloy F, 1999, EUR J IMMUNOL, V29, P3313, DOI 10.1002/(SICI)1521-4141(199910)29:10<3313::AID-IMMU3313>3.3.CO;2-#	27	410	416	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					553	555		10.1126/science.1069017	http://dx.doi.org/10.1126/science.1069017			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11968185				2022-12-28	WOS:000175179400053
J	Sasaki, A; Ashikari, M; Ueguchi-Tanaka, M; Itoh, H; Nishimura, A; Swapan, D; Ishiyama, K; Saito, T; Kobayashi, M; Khush, GS; Kitano, H; Matsuoka, M				Sasaki, A; Ashikari, M; Ueguchi-Tanaka, M; Itoh, H; Nishimura, A; Swapan, D; Ishiyama, K; Saito, T; Kobayashi, M; Khush, GS; Kitano, H; Matsuoka, M			Green revolution: A mutant gibberellin-synthesis gene in rice - New insight into the rice variant that helped to avert famine over thirty years ago.	NATURE			English	Editorial Material							20-OXIDASE; CLONING		Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan	Nagoya University; Nagoya University	Sasaki, A (corresponding author), Nagoya Univ, Biosci Ctr, Nagoya, Aichi 4648601, Japan.		Khush, Gurdev Singh/C-5109-2009; Kobayashi, Masatomo/A-5945-2016					Dalrymple DG, 1986, Development and spread of high -yielding wheat varieties in developing countries, V7th; HARGROVE TR, 1979, BIOSCIENCE, V29, P731, DOI 10.2307/1307667; Hedden P, 2000, TRENDS PLANT SCI, V5, P523, DOI 10.1016/S1360-1385(00)01790-8; HOOLEY R, 1994, PLANT MOL BIOL, V26, P1529, DOI 10.1007/BF00016489; Khush GS, 1999, GENOME, V42, P646, DOI 10.1139/gen-42-4-646; Maeda H, 1997, BREEDING SCI, V47, P317; Peng JR, 1999, NATURE, V400, P256, DOI 10.1038/22307; Ross JJ, 1997, PHYSIOL PLANTARUM, V100, P550, DOI 10.1034/j.1399-3054.1997.1000317.x; Toyomasu T, 1997, PHYSIOL PLANTARUM, V99, P111, DOI 10.1034/j.1399-3054.1997.990116.x; XU YL, 1995, P NATL ACAD SCI USA, V92, P6640, DOI 10.1073/pnas.92.14.6640; ZHANG WG, 1991, PLANT CELL, V3, P1155, DOI 10.1105/tpc.3.11.1155	11	805	940	31	360	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					701	702		10.1038/416701a	http://dx.doi.org/10.1038/416701a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961544				2022-12-28	WOS:000175033500031
J	Freeman, GK; Horder, JP; Howie, JGR; Hungin, AP; Hill, AP; Shah, NC; Wilson, A				Freeman, GK; Horder, JP; Howie, JGR; Hungin, AP; Hill, AP; Shah, NC; Wilson, A			Evolving general practice consultation in Britain: issues of length and context	BRITISH MEDICAL JOURNAL			English	Article							BOOKING INTERVALS; CARE; CONTINUITY; QUALITY; WORK; PRACTITIONERS; STRESS; TIME		Univ London Imperial Coll Sci Technol & Med, Ctr Primary Care & Social Med, London W6 8RP, England; Royal Coll Gen Practitioners, London SW7 1PU, England; Univ Edinburgh, Dept Gen Practice, Edinburgh EH8 9DX, Midlothian, Scotland; Univ Durham, Ctr Hlth Studies, Durham DH1 3HN, England; Kilburn Pk Med Ctr, London NW6, England; Univ Leicester, Dept Gen Practice & Primary Hlth Care, Leicester LE5 4PW, Leics, England	Imperial College London; University of Edinburgh; Durham University; University of Leicester	Freeman, GK (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Primary Care & Social Med, London W6 8RP, England.			hungin, amritpal Pali/0000-0001-7275-8927				AIREY C, 1999, NATL SURVEYS NHS PAT; ARBER S, 1982, BRIT MED J, V284, P478, DOI 10.1136/bmj.284.6314.478; Balint M., 1957, DOCTOR; De Maeseneer J, 2000, BRIT MED J, V320, P1616, DOI 10.1136/bmj.320.7250.1616; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Freeman G, 1997, BRIT MED J, V314, P1870, DOI 10.1136/bmj.314.7098.1870; Freeman G., 2001, CONTINUITY CARE REPO; *GEN MED COUNC, 2001, DRAFT REC UND MED ED; Hart JT, 1988, NEW KIND DOCTOR GEN; Hart Julian Tudor, 1998, Health Expect, V1, P3, DOI 10.1046/j.1369-6513.1998.00001.x; HILL AP, 2000, WHATS GONE WRONG HLT, P75; HJORTDAHL P, 1991, BRIT MED J, V303, P1181, DOI 10.1136/bmj.303.6811.1181; HOWIE JGR, 1992, BRIT J GEN PRACT, V42, P181; HOWIE JGR, 1991, BRIT J GEN PRACT, V41, P48; Howie JGR, 1999, BMJ-BRIT MED J, V319, P738, DOI 10.1136/bmj.319.7212.738; KIBBE DC, 1993, J FAM PRACTICE, V36, P304; Mechanic D, 2001, BRIT MED J, V323, P266, DOI 10.1136/bmj.323.7307.266; Morrison I, 2000, BRIT MED J, V321, P1541, DOI 10.1136/bmj.321.7276.1541; Shah NC, 1999, BRIT J GEN PRACT, V49, P497; STOTT NCH, 1979, J R COLL GEN PRACT, V29, P210; Tuckett D., 1985, M EXPERTS APPROACH S; Williams M, 1998, BRIT J GEN PRACT, V48, P1783; WILSON A, 1991, BRIT J GEN PRACT, V41, P184; [No title captured]	24	131	132	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					880	882		10.1136/bmj.324.7342.880	http://dx.doi.org/10.1136/bmj.324.7342.880			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950738	Green Published, Bronze			2022-12-28	WOS:000175052200023
J	Compston, A; Coles, A				Compston, A; Coles, A			Multiple sclerosis	LANCET			English	Review							INTERFERON BETA-1B; CONTROLLED-TRIAL; DOUBLE-BLIND; CHLAMYDIA-PNEUMONIAE; AXONAL CONDUCTION; NATURAL-HISTORY; PROGRESSIVE MS; BRAIN ATROPHY; MRI; METHYLPREDNISOLONE	Multiple sclerosis is the prototype inflammatory autoimmune disorder of the central nervous system and, with a lifetime risk of one in 400, potentially the most common cause of neurological disability in young adults. As with all complex traits, the disorder results from an interplay between as yet unidentified environmental factors and susceptibility genes. Together, these factors trigger a cascade of events, involving engagement of the immune system, acute inflammatory injury of axons and glia, recovery of function and structural repair, post-inflammatory gliosis, and neurodegeneration. The sequential involvement of these processes underlies the clinical course characterised by episodes with recovery, episodes leaving persistent deficits, and secondary progression. The aim of treatment is to reduce the frequency, and limit the lasting effects, of relapses, relieve symptoms, prevent disability arising from disease progression, and promote tissue repair. Despite limited success in each of these categories, everyone touched by multiple sclerosis looks for a better dividend from applying an improved understanding of the pathogenesis to clinical management.	Univ Cambridge, Addenbrookes Hosp, Neurol Unit, Sch Clin, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Compston, A (corresponding author), Univ Cambridge, Addenbrookes Hosp, Neurol Unit, Sch Clin, Cambridge CB2 2QQ, England.	alastair.compston@medschl.cam.ac.uk	Mayeux, Richard/E-9788-2013; Calabrese, Massimiliano/I-6195-2012; Carroll, June C/K-2096-2017	Mayeux, Richard/0000-0001-6519-9696; Carroll, June C/0000-0002-5893-4194; Coles, Alasdair/0000-0003-4738-0760				[Anonymous], 1999, Neurology, V53, P457; Appel H, 2001, J IMMUNOL, V166, P5279, DOI 10.4049/jimmunol.166.8.5279; Ascherio A, 2001, NEW ENGL J MED, V344, P327, DOI 10.1056/NEJM200102013440502; Barnes D, 1997, LANCET, V349, P902, DOI 10.1016/S0140-6736(96)06453-7; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; BECK RW, 1992, NEW ENGL J MED, V326, P581, DOI 10.1056/NEJM199202273260901; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Bjartmar C, 2001, NEUROLOGY, V57, P1248, DOI 10.1212/WNL.57.7.1248; Brex PA, 2002, NEW ENGL J MED, V346, P158, DOI 10.1056/NEJMoa011341; Brex PA, 1999, J NEUROL SCI, V166, P16, DOI 10.1016/S0022-510X(99)00105-7; Brodsky M, 1997, NEUROLOGY, V49, P1404; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; CHANG A, N ENGL J MED, V346, P165; Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#; Comi G, 2001, LANCET, V357, P1576, DOI 10.1016/S0140-6736(00)04725-5; Comi G, 2000, J NEUROL, V247, P376, DOI 10.1007/s004150050605; Compston A, 1999, PHILOS T R SOC B, V354, P1623, DOI 10.1098/rstb.1999.0507; COMPSTON A, 2001, BRAIN DIS THERAPEUTI, P11; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Confavreux C, 2001, NEW ENGL J MED, V344, P319, DOI 10.1056/NEJM200102013440501; Confavreux C, 2000, NEW ENGL J MED, V343, P1430, DOI 10.1056/NEJM200011163432001; Derfuss T, 2001, BRAIN, V124, P1325, DOI 10.1093/brain/124.7.1325; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Edan G, 1997, J NEUROL NEUROSUR PS, V62, P112, DOI 10.1136/jnnp.62.2.112; ENGLAND JD, 1990, P NATL ACAD SCI USA, V87, P6777, DOI 10.1073/pnas.87.17.6777; Fowler CJ, 1997, BAILLIERE CLIN NEUR, V6, P447; Francis G, 2001, NEUROLOGY, V56, P1628; Freeman JA, 1999, NEUROLOGY, V52, P50, DOI 10.1212/WNL.52.1.50; Goodkin DE, 2000, NEUROLOGY, V54, P2352; Hall GL, 1997, TRENDS NEUROSCI, V20, P63, DOI 10.1016/S0166-2236(96)10071-0; HARDING AE, 1992, BRAIN, V115, P979, DOI 10.1093/brain/115.4.979; HICKMAN SJ, IN PRESS MULTIPLE SC; HILL J, 1987, CAN J NEUROL SCI, V14, P273; HOMES J, 1995, BR J MED EC, V18, P181; HUYNH HK, 1995, J NEUROIMMUNOL, V60, P63, DOI 10.1016/0165-5728(95)00054-6; Jacobs LD, 2000, NEW ENGL J MED, V343, P898, DOI 10.1056/NEJM200009283431301; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Jeffery ND, 1997, BRAIN, V120, P27, DOI 10.1093/brain/120.1.27; JOHNSON KP, 1995, NEUROLOGY, V45, P1268, DOI 10.1212/WNL.45.7.1268; Kappos L, 1998, LANCET, V352, P1491, DOI 10.1016/S0140-6736(98)10039-9; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Karp CL, 2001, CURR OPIN NEUROL, V14, P361, DOI 10.1097/00019052-200106000-00016; Kohama I, 2001, J NEUROSCI, V21, P944, DOI 10.1523/JNEUROSCI.21-03-00944.2001; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Millefiorini E, 1997, J NEUROL, V244, P153, DOI 10.1007/s004150050066; Miller DH, 1999, PHILOS T R SOC B, V354, P1687, DOI 10.1098/rstb.1999.0512; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; Molyneux PD, 2000, BRAIN, V123, P2256, DOI 10.1093/brain/123.11.2256; Neuhaus O, 2001, NEUROLOGY, V56, P702, DOI 10.1212/WNL.56.6.702; Palace J, 1997, LANCET, V350, P261, DOI 10.1016/S0140-6736(97)24030-4; PANITCH H, 1997, ANN NEUROL, V42, P459; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; Pericak-Vance MA, 2001, MULT SCLER, V7, P3; Rammohan KW, 2002, J NEUROL NEUROSUR PS, V72, P179, DOI 10.1136/jnnp.72.2.179; Redford EJ, 1997, BRAIN, V120, P2149, DOI 10.1093/brain/120.12.2149; REVESZ T, 1994, BRAIN, V117, P759, DOI 10.1093/brain/117.4.759; Rice GPA, 2000, NEUROLOGY, V54, P1145, DOI 10.1212/WNL.54.5.1145; Rudick RA, 1999, NEUROLOGY, V53, P1698, DOI 10.1212/WNL.53.8.1698; Sarchielli P, 1997, J NEUROIMMUNOL, V80, P76, DOI 10.1016/S0165-5728(97)00136-7; SAWCER S, IN PRESS BRAIN; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; *SEC PROGR EFF CLI, 2001, NEUROLOGY, V56, P1505; Simon JH, 2001, NEUROLOGY, V57, P1888, DOI 10.1212/WNL.57.10.1888; SMITH KJ, 1981, BRAIN, V104, P383, DOI 10.1093/brain/104.2.383; Smith KJ, 2001, ANN NEUROL, V49, P470; Sriram S, 1999, ANN NEUROL, V46, P6, DOI 10.1002/1531-8249(199907)46:1<6::AID-ANA4>3.3.CO;2-D; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Tubridy N, 1999, NEUROLOGY, V53, P466, DOI 10.1212/WNL.53.3.466; vanOosten BW, 1996, NEUROLOGY, V47, P1531, DOI 10.1212/WNL.47.6.1531; WEINSHENKER BG, 1989, BRAIN, V112, P1419, DOI 10.1093/brain/112.6.1419; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; Werring DJ, 2000, J NEUROL NEUROSUR PS, V68, P441, DOI 10.1136/jnnp.68.4.441; Wilkins A, 2001, GLIA, V36, P48, DOI 10.1002/glia.1094; Wolswijk G, 1998, PROG BRAIN RES, V117, P233; YUDKIN PL, 1991, LANCET, V338, P1051, DOI 10.1016/0140-6736(91)91909-E; Zhang JW, 2001, CRIT REV IMMUNOL, V21, P41; Zivadinov R, 2001, NEUROLOGY, V57, P1239, DOI 10.1212/WNL.57.7.1239	81	1528	1595	0	205	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	2002	359	9313					1221	1231		10.1016/S0140-6736(02)08220-X	http://dx.doi.org/10.1016/S0140-6736(02)08220-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955556				2022-12-28	WOS:000174846300028
J	Zhou, Q; Anderson, DJ				Zhou, Q; Anderson, DJ			The bHLH transcription factors OLIG2 and OLIG1 couple neuronal and glial subtype specification	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; SPINAL-CORD OLIGODENDROCYTES; VENTRAL NEURAL-TUBE; LIM HOMEOBOX GENES; MOTOR-NEURONS; PROGENITOR CELLS; MAMMALIAN-CELLS; ACHAETE-SCUTE; EXPRESSION; LINEAGE	OLIG1 and OLIG2 are basic-helix-loop-helix (bHLH) transcription factors expressed in the pMN domain of the spinal cord, which sequentially generates motoneurons and oligodendrocytes. In Olig1/2 double-mutant mice, motoneurons are largely eliminated, and oligodendrocyte differentiation is abolished. Lineage tracing data suggest that Olig1(-/-)2(-/-) pMN progenitors instead generate V2 interneurons and then astrocytes. This apparent conversion likely reflects independent roles for OLIG1/2 in specifying motoneuron and oligodendrocyte fates. Olig genes therefore couple neuronal and glial subtype specification, unlike proneural bHLH factors that control the neuron versus glia decision. Our results suggest that in the spinal cord, Olig and proneural genes comprise a combinatorial code for the specification of neurons, astrocytes, and oligodendrocytes, the three fundamental cell types of the central nervous system.	CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Anderson, DJ (corresponding author), CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA.			Zhou, Qiao/0000-0002-0099-3909	NINDS NIH HHS [R01-NS23476] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023476] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson DJ, 2001, NEURON, V30, P19, DOI 10.1016/S0896-6273(01)00260-4; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; Dubreuil V, 2000, DEVELOPMENT, V127, P5191; Farah MH, 2000, DEVELOPMENT, V127, P693; Fisher A, 1998, BIOESSAYS, V20, P298, DOI 10.1002/(SICI)1521-1878(199804)20:4&lt;298::AID-BIES6&gt;3.0.CO;2-M; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gradwohl G, 1996, DEV BIOL, V180, P227, DOI 10.1006/dbio.1996.0297; Hall A, 1996, DEVELOPMENT, V122, P4085; Hardy RJ, 1997, J NEUROSCI RES, V50, P139, DOI 10.1002/(SICI)1097-4547(19971015)50:2<139::AID-JNR3>3.0.CO;2-G; Hojo M, 2000, DEVELOPMENT, V127, P2515; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kania A, 2000, CELL, V102, P161, DOI 10.1016/S0092-8674(00)00022-2; LEBER SM, 1990, J NEUROSCI, V10, P2451; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; LO L, 2002, IN PRESS DEVELOPMENT; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; Lu QR, 2001, NAT NEUROSCI, V4, P973, DOI 10.1038/nn718; LU QR, 2002, IN PRESS CELL, V109, P61; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; Ma QF, 1996, CELL, V87, P43, DOI 10.1016/S0092-8674(00)81321-5; McCormick MB, 1996, MOL CELL BIOL, V16, P5792; Miller RH, 1996, TRENDS NEUROSCI, V19, P92, DOI 10.1016/S0166-2236(96)80036-1; Mizuguchi R, 2001, NEURON, V31, P757, DOI 10.1016/S0896-6273(01)00413-5; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Parras CM, 2002, GENE DEV, V16, P324, DOI 10.1101/gad.940902; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Pringle NP, 1998, NEURON, V20, P883, DOI 10.1016/S0896-6273(00)80470-5; RAFF MC, 1989, SCIENCE, V243, P1450, DOI 10.1126/science.2648568; Richardson WD, 2000, GLIA, V29, P136, DOI 10.1002/(SICI)1098-1136(20000115)29:2<136::AID-GLIA6>3.0.CO;2-G; Richardson WD, 1997, DEV NEUROSCI-BASEL, V19, P58, DOI 10.1159/000111186; Satow T, 2001, J NEUROSCI, V21, P1265; Scardigli R, 2001, NEURON, V31, P203, DOI 10.1016/S0896-6273(01)00358-0; Sharma K, 1998, CELL, V95, P817, DOI 10.1016/S0092-8674(00)81704-3; Sun T, 2001, CURR BIOL, V11, P1413, DOI 10.1016/S0960-9822(01)00441-9; Sun T, 1998, MOL CELL NEUROSCI, V12, P228, DOI 10.1006/mcne.1998.0711; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; TAEBAYASHI H, 2000, MECH DEVELOP, V99, P143; Tomita K, 2000, EMBO J, V19, P5460, DOI 10.1093/emboj/19.20.5460; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Vallstedt A, 2001, NEURON, V31, P743, DOI 10.1016/S0896-6273(01)00412-3; Vetter M, 2001, NEURON, V29, P559, DOI 10.1016/S0896-6273(01)00231-8; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Woodruff RH, 2001, INT J DEV NEUROSCI, V19, P379, DOI 10.1016/S0736-5748(00)00083-6; Zhou Q, 2001, NEURON, V31, P791, DOI 10.1016/S0896-6273(01)00414-7; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3	53	785	816	1	22	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	2002	109	1					61	73		10.1016/S0092-8674(02)00677-3	http://dx.doi.org/10.1016/S0092-8674(02)00677-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955447	Bronze			2022-12-28	WOS:000174888300009
J	Price, MA; Kalderon, D				Price, MA; Kalderon, D			Proteolysis of the Hedgehog signaling effector Cubitus interruptus requires phosphorylation by glycogen synthase kinase 3 and casein kinase 1	CELL			English	Article							DEPENDENT PROTEIN-KINASE; KAPPA-B-ALPHA; BETA-CATENIN; TRANSCRIPTIONAL ACTIVATOR; LIMB DEVELOPMENT; REPRESSOR FORMS; IMAGINAL DISCS; GLI PROTEINS; DOUBLE-TIME; I-EPSILON	The secreted signaling molecule Hedgehog regulates gene expression in target cells in part by preventing proteolysis of the full-length Cubitus interruptus (Ci-155) transcriptional activator to the Ci-75 repressor form. Ci-155 proteolysis depends on phosphorylation at three sites by Protein Kinase A (PKA). We show that these phosphoserines prime further phosphorylation at adjacent Glycogen Synthase Kinase 3 (GSK3) and Casein Kinase I (CK1) sites. Alteration of the GSK3 or CK1 sites prevents Ci-155 proteolysis and activates Ci in the absence of Hedgehog. Ci-155 proteolysis is also inhibited if cells lack activity of the Drosophila GSK3, Shaggy, previously implicated in Wingless signaling. Conversely, Ci-155 levels are reduced in Hedgehog-responding cells by overexpression of PKA and the Drosophila CK1, Double-time, a regulator of circadian rhythms.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Kalderon, D (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041815] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41815] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Aza-Blanc P, 2000, DEVELOPMENT, V127, P4293; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BLAIR SS, 1994, DEV BIOL, V162, P229, DOI 10.1006/dbio.1994.1081; Chen CH, 1999, CELL, V98, P305, DOI 10.1016/S0092-8674(00)81960-1; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; Chen Y, 1999, DEVELOPMENT, V126, P3607; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; DENT P, 1989, FEBS LETT, V248, P67, DOI 10.1016/0014-5793(89)80433-8; Dominguez M, 1996, SCIENCE, V272, P1621, DOI 10.1126/science.272.5268.1621; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FLOTOW H, 1989, J BIOL CHEM, V264, P9126; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Harlow E., 1988, ANTIBODIES LAB MANUA; Hepker J, 1999, DEVELOPMENT, V126, P3669; Heslip TR, 1997, DEVELOPMENT, V124, P1069; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Methot N, 2000, DEVELOPMENT, V127, P4001; Methot N, 2001, DEVELOPMENT, V128, P733; Morrison DK, 2000, J CELL BIOL, V150, pF57, DOI 10.1083/jcb.150.2.F57; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Pai LM, 1997, DEVELOPMENT, V124, P2255; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Price MA, 1999, DEVELOPMENT, V126, P4331; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; von Mering C, 1999, CURR BIOL, V9, P1319, DOI 10.1016/S0960-9822(00)80054-8; Von Ohlen T, 1997, MECH DEVELOP, V68, P149, DOI 10.1016/S0925-4773(97)00150-0; Wang GL, 1999, GENE DEV, V13, P2828, DOI 10.1101/gad.13.21.2828; Wang QT, 1999, DEVELOPMENT, V126, P5097; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Zilian O, 1999, DEVELOPMENT, V126, P5409	54	309	321	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 22	2002	108	6					823	835		10.1016/S0092-8674(02)00664-5	http://dx.doi.org/10.1016/S0092-8674(02)00664-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955435	Bronze			2022-12-28	WOS:000174563000011
J	Smith, BO; Mallin, RL; Krych-Goldberg, M; Wang, XF; Hauhart, RE; Bromek, K; Uhrin, D; Atkinson, JP; Barlow, PN				Smith, BO; Mallin, RL; Krych-Goldberg, M; Wang, XF; Hauhart, RE; Bromek, K; Uhrin, D; Atkinson, JP; Barlow, PN			Structure of the C3b binding site of CR1 (CD35), the immune adherence receptor	CELL			English	Article							TRIPLE-RESONANCE EXPERIMENTS; COMPLEMENT RECEPTOR-TYPE-1; C3B/C4B RECEPTOR; CRYSTAL-STRUCTURE; C-13-LABELED PROTEINS; IMPROVED SENSITIVITY; DIPOLAR COUPLINGS; NMR-SPECTROSCOPY; LIGAND-BINDING; ACTIVE-SITES	Complement receptor type 1 (CR1 or CD35) is a multiple modular protein that mediates the immune adherence phenomenon, a fundamental event for destroying microbes and initiating an immunological response. It fulfills this role through binding C3b/C4b-opsonized foreign antigens. The structure of the principal C3b/C4b binding site (residues 901-1095) of CR1 is reported, revealing three complement control protein modules (modules 15-17) in an extended head-to-tail arrangement with flexibility at the 16-17 junction. Structure-guided mutagenesis identified a positively charged surface region on module 15 that is critical for C4b binding. This patch, together with basic side chains of module 16 exposed on the same face of CR1 is required for C3b binding. These studies reveal the initial structural details of one of the first receptor-ligand interactions to be identified in immunobiology.	Univ Edinburgh, Edinburgh Prot Interact Ctr, Edinburgh EH9 3JR, Midlothian, Scotland; Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA	University of Edinburgh; Washington University (WUSTL)	Barlow, PN (corresponding author), Univ Edinburgh, Edinburgh Prot Interact Ctr, Joseph Black Chem Bldg,W Mains Rd, Edinburgh EH9 3JR, Midlothian, Scotland.		Barlow, Paul N/G-2853-2011; Smith, Brian/AAJ-9393-2020; Smith, Brian O/J-1899-2015	Smith, Brian/0000-0003-3363-4168; Smith, Brian O/0000-0003-3363-4168; Atkinson, John/0000-0002-2514-3441	PHS HHS [R01 A141592] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aitio H, 2000, J MAGN RESON, V143, P391, DOI 10.1006/jmre.1999.2010; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BARLOW PN, 1993, J MOL BIOL, V232, P268, DOI 10.1006/jmbi.1993.1381; Blom AM, 2000, MOL IMMUNOL, V37, P445, DOI 10.1016/S0161-5890(00)00059-6; Bork P, 1996, Q REV BIOPHYS, V29, P119, DOI 10.1017/S0033583500005783; Bouma B, 1999, EMBO J, V18, P5166, DOI 10.1093/emboj/18.19.5166; Casasnovas JM, 1999, EMBO J, V18, P2911, DOI 10.1093/emboj/18.11.2911; Clark NS, 1996, PROTEIN ENG, V9, P877, DOI 10.1093/protein/9.10.877; COLE JL, 1985, P NATL ACAD SCI USA, V82, P859, DOI 10.1073/pnas.82.3.859; Copie V, 1998, J MOL BIOL, V277, P663; Engelke J, 1995, J MAGN RESON SER B, V109, P318, DOI 10.1006/jmrb.1995.9988; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; Henderson CE, 2001, J MOL BIOL, V307, P323, DOI 10.1006/jmbi.2000.4477; HOURCADE D, 1988, J EXP MED, V168, P1255, DOI 10.1084/jem.168.4.1255; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kirkitadze MD, 1999, BIOCHEMISTRY-US, V38, P7019, DOI 10.1021/bi982453a; Kirkitadze MD, 1999, FEBS LETT, V459, P133, DOI 10.1016/S0014-5793(99)01205-3; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Kirkitadze MD, 1999, PROG COLL POL SCI S, V113, P164; KLICKSTEIN LB, 1988, J EXP MED, V168, P1699, DOI 10.1084/jem.168.5.1699; KLICKSTEIN LB, 1987, J EXP MED, V165, P1095, DOI 10.1084/jem.165.4.1095; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P9446; KRYCH M, 1991, P NATL ACAD SCI USA, V88, P4353, DOI 10.1073/pnas.88.10.4353; Krych M, 1998, J BIOL CHEM, V273, P8623, DOI 10.1074/jbc.273.15.8623; KRYCH M, 1994, J BIOL CHEM, V269, P13273; Krych-Goldberg M, 1999, J BIOL CHEM, V274, P31160, DOI 10.1074/jbc.274.44.31160; Krych-Goldberg M, 2001, IMMUNOL REV, V180, P112, DOI 10.1034/j.1600-065X.2001.1800110.x; Kuttner-Kondo LA, 2001, J IMMUNOL, V167, P2164, DOI 10.4049/jimmunol.167.4.2164; KuttnerKondo L, 1996, PROTEIN ENG, V9, P1143, DOI 10.1093/protein/9.12.1143; Liszewski M.K., 1998, HUMAN COMPLEMENT SYS, P149; Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754; Mori S, 1997, J AM CHEM SOC, V119, P6844, DOI 10.1021/ja963351f; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8; NELSON DS, 1963, ADV IMMUNOL, V3, P131, DOI 10.1016/S0065-2776(08)60812-3; NELSON RA, 1953, SCIENCE, V118, P733, DOI 10.1126/science.118.3077.733; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Oran AE, 1999, J BIOL CHEM, V274, P5120, DOI 10.1074/jbc.274.8.5120; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; REID KBM, 1989, IMMUNOL TODAY, V10, P177, DOI 10.1016/0167-5699(89)90317-4; Reilly BD, 1997, CLIN EXP IMMUNOL, V110, P310; Rowe JA, 2000, J IMMUNOL, V165, P6341, DOI 10.4049/jimmunol.165.11.6341; Rowe JA, 1997, NATURE, V388, P292, DOI 10.1038/40888; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salzmann M, 1999, J AM CHEM SOC, V121, P844, DOI 10.1021/ja9834226; Schwarzenbacher R, 1999, EMBO J, V18, P6228, DOI 10.1093/emboj/18.22.6228; Smith HRC, 2000, J EXP MED, V191, P1341, DOI 10.1084/jem.191.8.1341; Subramanian VB, 1996, J IMMUNOL, V157, P1242; Szakonyi G, 2001, SCIENCE, V292, P1725, DOI 10.1126/science.1059118; Uhrin D, 2000, J MAGN RESON, V142, P288, DOI 10.1006/jmre.1999.1951; Villoutreix BO, 1998, PROTEINS, V31, P391, DOI 10.1002/(SICI)1097-0134(19980601)31:4<391::AID-PROT6>3.0.CO;2-L; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; WONG WW, 1991, J IMMUNOL, V146, P656; YAMAZAKI T, 1993, J AM CHEM SOC, V115, P11054, DOI 10.1021/ja00076a099; [No title captured]	64	88	92	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 22	2002	108	6					769	780		10.1016/S0092-8674(02)00672-4	http://dx.doi.org/10.1016/S0092-8674(02)00672-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955431	Bronze			2022-12-28	WOS:000174563000007
J	Yoon, SS; Byles, J				Yoon, SS; Byles, J			Perceptions of stroke in the general public and patients with stroke: a qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUTE ISCHEMIC-STROKE; ADMISSION; DELAY; EDUCATION; SYMPTOMS; TIME; RISK	Objectives To gain insight into people's thoughts on stroke and to inform the development of educational strategies in the community. Design Focus group discussions: two groups of people who had a stroke and their carers, and two groups of members of the general public. Setting New South Wales, Australia. Participants 35 people participated: 11 from the general public, 14 people who had had a stroke, and 10 carers or partners. Main outcome measures Views on risk factors, symptoms, treatment, information resources, and prevention. Results All groups reported similar knowledge of risk factors. People generally mentioned stress, diet, high blood pressure, age, and smoking as causes of stroke. Participants in die community group gave little attention to symptoms. Some participants who had had a stroke did not initially identify their experience as stroke because the symptoms were not the same as those they had read about. There were mixed feelings about the extent of involvement in management decisions during hospital admission. Some felt sufficiently involved, some wanted to be more involved, and others felt incapable of being actively involved. Conclusions Symptoms of stroke are not easy to recognise because they vary so much. Presentation of information about stroke by hospital and community health services should be improved. Simple and understandable educational materials should be developed and their effectiveness monitored.	Univ Newcastle, Fac Med & Hlth Sci, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia	University of Newcastle	Yoon, SS (corresponding author), Univ Newcastle, Fac Med & Hlth Sci, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia.	sungsyoon@yahoo.com	Byles, Julie E/C-5062-2008	Byles, Julie E/0000-0002-3984-6877				ALBERTS MJ, 1992, STROKE, V23, P352, DOI 10.1161/01.STR.23.3.352; Alberts MJ, 1998, NEUROLOGY, V51, pS53, DOI 10.1212/WNL.51.3_Suppl_3.S53; Babbie E.R., 2015, PRACTICE SOCIAL RES, V14th; BABBIE F, 1992, PRACTICE SOCIAL RES; BARSAN WG, 1993, ARCH INTERN MED, V153, P2558, DOI 10.1001/archinte.153.22.2558; Bernard H., 1988, RES METHODS ANTHR; Black JA, 1976, METHODS ISSUES SOCIA; Canto JG, 2000, JAMA-J AM MED ASSOC, V283, P3223, DOI 10.1001/jama.283.24.3223; del Zoppo GJ, 1998, STROKE, V29, P4, DOI 10.1161/01.STR.29.1.4; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; Dracup K, 1997, MED J AUSTRALIA, V166, P233, DOI 10.5694/j.1326-5377.1997.tb140101.x; Evans R L, 1994, Disabil Rehabil, V16, P110; FELDMANN E, 1993, STROKE, V24, P1805, DOI 10.1161/01.STR.24.12.1805; FERRO JM, 1994, CEREBROVASC DIS, V4, P72, DOI 10.1159/000108455; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HARPER GD, 1992, STROKE, V23, P835, DOI 10.1161/01.STR.23.6.835; HARTFORD M, 1993, HEART LUNG, V22, P64; *HEART STROK HLTH, 2001, HEART STROK REG; Hendricks V. M., 1992, SNOWBALL SAMPLING PI; HILL MN, 1989, CLIN EXP HYPERTENS A, V11, P1187, DOI 10.3109/10641968909035399; Legato MJ, 1997, J WOMENS HEALTH, V6, P189, DOI 10.1089/jwh.1997.6.189; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Moser D K, 1993, Prog Cardiovasc Nurs, V8, P6; *NAT STROK ASS, 2002, STROK RISK FACT THEI; SCHWARZ B, 1994, EUR HEART J, V15, P1595, DOI 10.1093/oxfordjournals.eurheartj.a060439; SCOLARI, 1999, ETHNOGRAPH V5 0; Stern EB, 1999, STROKE, V30, P720, DOI 10.1161/01.STR.30.4.720; Wester P, 1999, STROKE, V30, P40, DOI 10.1161/01.STR.30.1.40; Wood VA, 1996, J PUBLIC HEALTH MED, V18, P423, DOI 10.1093/oxfordjournals.pubmed.a024540; Yoon S.S., 2002, BIOMED CENTRAL PUB H, V1, P14; Yoon SS, 2001, STROKE, V32, P1926, DOI 10.1161/01.STR.32.8.1926	31	77	84	1	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 4	2002	324	7345					1065	1068B		10.1136/bmj.324.7345.1065	http://dx.doi.org/10.1136/bmj.324.7345.1065			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YY	11991910	Green Published, Bronze			2022-12-28	WOS:000175476500018
J	Clark, TA; Sugnet, CW; Ares, M				Clark, TA; Sugnet, CW; Ares, M			Genomewide analysis of mRNA processing in yeast using splicing-specific microarrays	SCIENCE			English	Article							CAP-BINDING COMPLEX; NUCLEAR RIBONUCLEOPROTEIN PARTICLE; SACCHAROMYCES-CEREVISIAE; DEBRANCHING ENZYME; GENE-EXPRESSION; PROTEIN; COMMITMENT; SEQUENCES; INTRONS; PRP4	Introns interrupt almost every eukaryotic protein-coding gene, yet how the splicing apparatus interprets the genome during messenger RNA (mRNA) synthesis is poorly understood. We designed microarrays to distinguish spliced from unspliced RNA for each intron-containing yeast gene and measured genomewide effects on splicing caused by loss of 18 different mRNA processing factors. After accommodating changes in transcription and decay by using gene-specific indexes, functional relationships between mRNA processing factors can be identified through their common effects on spliced and unspliced RNA. Groups of genes with different dependencies on mRNA processing factors are also apparent. Quantitative polymerase chain reactions confirm the array-based finding that Prp17p and Prp18p are not dispensable for removal of introns with short branchpoint-to-3' splice site distances.	Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Baskin Sch Engn, Dept Comp Sci, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Baskin Sch Engn, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Ares, M (corresponding author), Univ Calif Santa Cruz, Dept Mol Cell & Dev Biol, Santa Cruz, CA 95064 USA.	ares@biology.ucsc.edu		Clark, Tyson/0000-0002-7779-3227; Ares, Manny/0000-0002-2552-9168	NCI NIH HHS [CA77813] Funding Source: Medline; NIGMS NIH HHS [GM40478] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA077813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040478] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BJORN SP, 1989, MOL CELL BIOL, V9, P3698, DOI 10.1128/MCB.9.9.3698; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; CLARK T, UNPUB; Colot HV, 1996, GENE DEV, V10, P1699, DOI 10.1101/gad.10.13.1699; Davis CA, 2000, NUCLEIC ACIDS RES, V28, P1700, DOI 10.1093/nar/28.8.1700; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Fortes P, 1999, MOL CELL BIOL, V19, P6543; HE F, 1993, P NATL ACAD SCI USA, V90, P7034, DOI 10.1073/pnas.90.15.7034; JONES MH, 1995, P NATL ACAD SCI USA, V92, P9687, DOI 10.1073/pnas.92.21.9687; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lelivelt MJ, 1999, MOL CELL BIOL, V19, P6710; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; Modrek B, 2002, NAT GENET, V30, P13, DOI 10.1038/ng0102-13; Ooi SL, 1998, RNA, V4, P1096, DOI 10.1017/S1355838298980785; Perriman R, 2000, GENE DEV, V14, P97; PIKIELNY CW, 1985, CELL, V41, P119, DOI 10.1016/0092-8674(85)90066-2; Puig O, 1999, GENE DEV, V13, P569, DOI 10.1101/gad.13.5.569; Rain JC, 1997, EMBO J, V16, P1759, DOI 10.1093/emboj/16.7.1759; Shen EC, 2000, J BIOL CHEM, V275, P23718, DOI 10.1074/jbc.M002312200; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; Spingola M, 1999, RNA, V5, P221, DOI 10.1017/S1355838299981682; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Yan D, 1998, MOL CELL BIOL, V18, P5000, DOI 10.1128/MCB.18.9.5000; Zhang XP, 1997, NUCLEIC ACIDS RES, V25, P2146, DOI 10.1093/nar/25.11.2146	27	292	309	1	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					907	910		10.1126/science.1069415	http://dx.doi.org/10.1126/science.1069415			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988574				2022-12-28	WOS:000175442500043
J	Zacharias, DA; Violin, JD; Newton, AC; Tsien, RY				Zacharias, DA; Violin, JD; Newton, AC; Tsien, RY			Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells	SCIENCE			English	Article							GREEN FLUORESCENT PROTEIN; RESONANCE ENERGY-TRANSFER; GPI-ANCHORED PROTEINS; CAVEOLAE; RAFTS; RECEPTORS; DOMAINS; SURFACE	Many proteins associated with the plasma membrane are known to partition into submicroscopic sphingolipid- and cholesterol-rich domains called lipid rafts, but the determinants dictating this segregation of proteins in the membrane are poorly understood. We suppressed the tendency of Aequorea fluorescent proteins to dimerize and targeted these variants to the plasma membrane using several different types of lipid anchors. Fluorescence resonance energy transfer measurements in living cells revealed that acyl but not prenyl modifications promote clustering in lipid rafts. Thus the nature of the lipid anchor on a protein is sufficient to determine submicroscopic localization within the plasma membrane.	Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Tsien, RY (corresponding author), Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.	rtsien@ucsd.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177, R37NS027177] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54441] Funding Source: Medline; NIGMS NIH HHS [2T32 GM07752] Funding Source: Medline; NINDS NIH HHS [NS27177] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; Phillips GN, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P77; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Pyenta PS, 2001, BIOPHYS J, V80, P2120, DOI 10.1016/S0006-3495(01)76185-1; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246	22	1701	1746	3	160	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	2002	296	5569					913	916		10.1126/science.1068539	http://dx.doi.org/10.1126/science.1068539			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988576				2022-12-28	WOS:000175442500045
J	Ebihara, T; Sasaki, H				Ebihara, T; Sasaki, H			Bronchiectasis with Mycobacterium avium complex infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Tohoku Univ, Sch Med, Sendai, Miyagi 9808574, Japan	Tohoku University	Ebihara, T (corresponding author), Tohoku Univ, Sch Med, Sendai, Miyagi 9808574, Japan.		EBIHARA, TAKAE/M-9420-2019	EBIHARA, TAKAE/0000-0003-2325-7637					0	4	4	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					1372	1372		10.1056/NEJMicm010899	http://dx.doi.org/10.1056/NEJMicm010899			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546MZ	11986411				2022-12-28	WOS:000175279000005
J	Crawford, LM				Crawford, LM			FDA-PPTA workshop	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Rockville, MD 20857 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2203	2203		10.1001/jama.287.17.2203	http://dx.doi.org/10.1001/jama.287.17.2203			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980508				2022-12-28	WOS:000175260600006
J	Jedema, FJ; Filip, AT; van Wees, BJ				Jedema, FJ; Filip, AT; van Wees, BJ			Spintronics - Spin accumulation in mesoscopic systems - Reply	NATURE			English	Editorial Material							INJECTION		Univ Groningen, Dept Appl Phys, NL-9747 AG Groningen, Netherlands; Univ Groningen, Ctr Mat Sci, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Jedema, FJ (corresponding author), Univ Groningen, Dept Appl Phys, NL-9747 AG Groningen, Netherlands.	b.j.van.wees@phys.rug.nl	van, bart/U-1770-2017					Fert A, 1996, PHYS REV B, V53, P6554, DOI 10.1103/PhysRevB.53.6554; Hershfield S, 1997, PHYS REV B, V56, P3296, DOI 10.1103/PhysRevB.56.3296; Jedema FJ, 2002, J SUPERCOND, V15, P27, DOI 10.1023/A:1014071009340; Jedema FJ, 2001, NATURE, V410, P345, DOI 10.1038/35066533; Schmidt G, 2000, PHYS REV B, V62, pR4790, DOI 10.1103/PhysRevB.62.R4790	5	8	8	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	2002	416	6883					810	810		10.1038/416810a	http://dx.doi.org/10.1038/416810a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976673	Bronze			2022-12-28	WOS:000175163800041
J	Lam, YA; Lawson, TG; Velayutham, M; Zweier, JL; Pickart, CM				Lam, YA; Lawson, TG; Velayutham, M; Zweier, JL; Pickart, CM			A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal	NATURE			English	Article							MULTIUBIQUITIN-CHAIN-BINDING; UBIQUITIN; PROTEIN; IDENTIFICATION; PROTEOLYSIS; INHIBITION; SUBCOMPLEX; MCB1	The 26S proteasome is the chief site of regulatory protein turnover in eukaryotic cells(1). It comprises one 20S catalytic complex (composed of four stacked rings of seven members) and two axially positioned 19S regulatory complexes (each containing about 18 subunits) that control substrate access to the catalytic chamber(2). In most cases, targeting to the 26S proteasome depends on tagging of the substrate with a specific type of polyubiquitin chain(3-6). Recognition of this signal is followed by substrate unfolding and translocation, which are presumably catalysed by one or more of six distinct AAA ATPases located in the base-a ring-like 19S subdomain that abuts the axial pore of the 20S complex and exhibits chaperone activity in vitro(7-9). Despite the importance of polyubiquitin chain recognition in proteasome function, the site of this signal's interaction with the 19S complex has not been identified previously. Here we use crosslinking to a reactive polyubiquitin chain to show that a specific ATPase subunit, S6' (also known as Rpt5), contacts the bound chain. The interaction of this signal with 26S proteasomes is modulated by ATP hydrolysis. Our results suggest that productive recognition of the proteolytic signal, as well as proteasome assembly and substrate unfolding, are ATP-dependent events.	Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, EPR Ctr, Baltimore, MD 21205 USA; Bates Coll, Dept Chem, Lewiston, ME 04240 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Pickart, CM (corresponding author), Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD 21205 USA.							Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Beal RE, 1998, BIOCHEMISTRY-US, V37, P2925, DOI 10.1021/bi972514p; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; COOK WJ, 1994, J MOL BIOL, V236, P601, DOI 10.1006/jmbi.1994.1169; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; DeMartino GN, 1996, J BIOL CHEM, V271, P3112, DOI 10.1074/jbc.271.6.3112; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Hartmann-Petersen R, 2001, ARCH BIOCHEM BIOPHYS, V386, P89, DOI 10.1006/abbi.2000.2178; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOFFMAN L, 1992, J BIOL CHEM, V267, P22362; Hoffman L, 1996, J BIOL CHEM, V271, P32538, DOI 10.1074/jbc.271.51.32538; Kohler A, 2001, MOL CELL, V7, P1143, DOI 10.1016/S1097-2765(01)00274-X; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Qin PZ, 2001, BIOCHEMISTRY-US, V40, P6929, DOI 10.1021/bi010294g; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Sankarapandi S, 1999, J BIOL CHEM, V274, P1226, DOI 10.1074/jbc.274.3.1226; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; VIJAYKUMAR S, 1987, J MOL BIOL, V194, P531, DOI 10.1016/0022-2836(87)90679-6; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015	28	344	350	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					763	767		10.1038/416763a	http://dx.doi.org/10.1038/416763a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961560				2022-12-28	WOS:000175033500048
J	Martin, JM; Green, M; Barbadora, KA; Wald, ER				Martin, JM; Green, M; Barbadora, KA; Wald, ER			Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROUP-A STREPTOCOCCI; MACROLIDE RESISTANCE; GEL-ELECTROPHORESIS; RHEUMATIC-FEVER; PYOGENES; ANTIBIOTICS; SUSCEPTIBILITY; PHARYNGITIS; CLINDAMYCIN; INFECTIONS	Background: Resistance to erythromycin has been very uncommon among group A streptococci in the United States. Methods: As part of a longitudinal study, we obtained surveillance throat cultures twice monthly and with each new respiratory tract illness from children in kindergarten through grade 8 at one school in Pittsburgh. Screening for resistance to erythromycin and clindamycin was initially accomplished with use of the Kirby-Bauer disk-diffusion test. The minimal inhibitory concentration of resistant isolates was determined by the E test. A double disk-diffusion test was used to characterize the resistance phenotype, and the polymerase-chain-reaction assay was used to identify the resistance gene. The molecular relatedness of strains was determined by field-inversion gel electrophoresis. Results: A total of 1794 throat cultures were obtained from 100 children between October 2000 and May 2001, of which 318 cultures (18 percent) from 60 of the children were positive for group A streptococci. Forty-eight percent of these isolates (153 of 318) were resistant to erythromycin. None were resistant to clindamycin. Results of the double disk-diffusion test indicated the presence of the M phenotype of erythromycin resistance. Molecular typing indicated that the outbreak was due to a single strain of group A streptococci. Of 100 randomly selected isolates of group A streptococci obtained from the community between April and June 2001, 38 were resistant to erythromycin. Conclusions: In January 2001, during a longitudinal study of schoolchildren, we detected the emergence of erythromycin resistance in pharyngeal isolates of group A streptococci. This clonal outbreak also affected the wider community.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat,Div Allergy Immunol & Infect Dis, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Martin, JM (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat,Div Allergy Immunol & Infect Dis, 3705 5th Ave, Pittsburgh, PA 15213 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI001713] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR000084] Funding Source: Medline; NIAID NIH HHS [K23 AI001713, 5K23 AI01713-02] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Avanzini C, 2000, MICROB DRUG RESIST, V6, P289, DOI 10.1089/mdr.2000.6.289; Bassetti M, 2000, EMERG INFECT DIS, V6, P180, DOI 10.3201/eid0602.000212; Beall B, 1996, J CLIN MICROBIOL, V34, P953, DOI 10.1128/JCM.34.4.953-958.1996; Betriu C, 1999, DIAGN MICR INFEC DIS, V33, P255, DOI 10.1016/S0732-8893(98)00155-2; Bingen E, 2000, ANTIMICROB AGENTS CH, V44, P1453, DOI 10.1128/AAC.44.6.1453-1457.2000; BISNO AL, 1991, NEW ENGL J MED, V325, P783, DOI 10.1056/NEJM199109123251106; Bisno AL, 1997, CLIN INFECT DIS, V25, P574, DOI 10.1086/513768; Cha S, 2001, J Infect Chemother, V7, P81, DOI 10.1007/s101560100013; CHERRY D, 2001, ADV DATA VITAL HLTH, V322; Cizman M, 2001, J ANTIMICROB CHEMOTH, V47, P475, DOI 10.1093/jac/47.4.475; Cocuzza CE, 1997, MICROB DRUG RESIST, V3, P371, DOI 10.1089/mdr.1997.3.371; COONAN KM, 1994, PEDIATR INFECT DIS J, V13, P630, DOI 10.1097/00006454-199407000-00009; Descheemaeker P, 2000, J ANTIMICROB CHEMOTH, V45, P167, DOI 10.1093/jac/45.2.167; Facinelli B, 2001, LANCET, V358, P30, DOI 10.1016/S0140-6736(00)05253-3; FUJITA K, 1994, PEDIATR INFECT DIS J, V13, P1075, DOI 10.1097/00006454-199412000-00001; Garcia-Bermejo I, 1998, ANTIMICROB AGENTS CH, V42, P989, DOI 10.1128/AAC.42.4.989; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Hyde TB, 2001, JAMA-J AM MED ASSOC, V286, P1857, DOI 10.1001/jama.286.15.1857; Kaplan EL, 1999, PEDIATR INFECT DIS J, V18, P1069, DOI 10.1097/00006454-199912000-00008; KAPLAN EL, 1994, CIRCULATION, V89, pA98; Kaplan EL, 1997, CLIN INFECT DIS, V24, pS89, DOI 10.1093/clinids/24.Supplement_1.S89; KAPLAN EL, 1993, CIRCULATION, V88, P1964, DOI 10.1161/01.CIR.88.4.1964; Linder JA, 2001, JAMA-J AM MED ASSOC, V286, P1181, DOI 10.1001/jama.286.10.1181; Martin JM, 2000, CLIN INFECT DIS, V31, P233; Martin JM, 1998, J INFECT DIS, V177, P504, DOI 10.1086/517387; MARTIN JM, 1999, CLIN INFECT DIS, V29, P984; *NAT COMM CLIN LAB, 2001, M100S11 NCCLS; PICKERING LK, 2000, 2000 RED BOOK REPORT, P526; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; Seppala H, 1995, CLIN INFECT DIS, V21, P1378, DOI 10.1093/clinids/21.6.1378; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; Sutcliffe J, 1996, ANTIMICROB AGENTS CH, V40, P1817, DOI 10.1128/AAC.40.8.1817; Syrogiannopoulos GA, 2001, PEDIATR INFECT DIS J, V20, P863, DOI 10.1097/00006454-200109000-00008; Syrogiannopoulos George A., 2001, Pediatric Infectious Disease Journal, V20, P1131; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Valisena S, 1999, EUR J CLIN MICROBIOL, V18, P260, DOI 10.1007/s100960050274; Varaldo PE, 1999, CLIN INFECT DIS, V29, P869, DOI 10.1086/520451	38	183	189	1	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 18	2002	346	16					1200	1206		10.1056/NEJMoa013169	http://dx.doi.org/10.1056/NEJMoa013169			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542FT	11961148				2022-12-28	WOS:000175033400004
J	Erkinjuntti, T; Kurz, A; Gauthier, S; Bullock, R; Lilienfeld, S; Damaraju, CV				Erkinjuntti, T; Kurz, A; Gauthier, S; Bullock, R; Lilienfeld, S; Damaraju, CV			Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial	LANCET			English	Article							PLACEBO-CONTROLLED TRIAL; DIAGNOSIS; CRITERIA; SAFETY; AD	Background Vascular dementia is the second commonest form of dementia, and vascular factors contribute to the development of dementia in many patients with Alzheimer's disease. Galantamine amplifies the acetylcholine response by inhibiting acetylcholinesterase and modulating nicotinic receptors. It has shown broad, sustained benefits in patients with Alzheimer's disease. We investigated the effects of galantamine in patients with a diagnosis of probable vascular dementia or Alzheimer's disease combined with cerebrovascular disease. Methods Eligible patients were randomly assigned galantamine 24 mg/day (n=396) or placebo (n=196) in a multicentre, double-blind, 6-month trial. Primary endpoints were cognition (Alzheimer's disease assessment scale, cognitive subscale [ADAS-cog]) and global functioning (clinician's interview-based impression of change plus caregiver input [CIBIC-plus]). Secondary endpoints included assessments of activities of daily living and behavioural symptoms. Patients were monitored for adverse events, Analyses were on the basis of observed case or last observation carried forward. Findings Galantamine showed greater efficacy than placebo on ADAS-cog (galantamine change -.1.7 [SE 0.4] vs placebo 1.0 [0.5]; treatment effect 2.7 points; p<0.0001) and CIBIC-plus (213 [74%] vs 95 [59%] patients remained stable or improved, p=0.001). Activities of daily living and behavioural symptoms were also significantly improved compared with placebo (p=0.002 and p=0.016, respectively). Galantamine was well tolerated. Interpretation Galantamine showed a therapeutic effect on all key areas of cognitive and non-cognitive abilities in this group of dementia patients.	Univ Helsinki, Cent Hosp, Dept Clin Neurosci, Memory Res Unit, FIN-00290 Helsinki, Finland; Tech Univ Munich, Dept Psychiat & Psychotherapy, D-8000 Munich, Germany; McGill Ctr Studies Aging, Quebec City, PQ, Canada; Kingshill Res Ctr, Swindon, Wilts, England; Janssen Res Fdn, Titusville, NJ USA	University of Helsinki; Helsinki University Central Hospital; Technical University of Munich; University of Munich; McGill University; Johnson & Johnson; Johnson & Johnson USA	Erkinjuntti, T (corresponding author), Univ Helsinki, Cent Hosp, Dept Clin Neurosci, Memory Res Unit, POB 300, FIN-00290 Helsinki, Finland.							Bores GM, 1996, J PHARMACOL EXP THER, V277, P728; Cummings JL, 1997, NEUROLOGY, V48, pS10, DOI 10.1212/WNL.48.5_Suppl_6.10S; Di Carlo A, 2000, NEUROLOGY, V54, pS28; Erkinjuntti T, 1999, CNS DRUGS, V12, P35, DOI 10.2165/00023210-199912010-00004; ERKINJUNTTI T, 1993, CEREBROVASC DIS, V3, P3, DOI 10.1159/000108661; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fratiglioni L, 2000, NEUROLOGY, V54, pS10; GAUTHIER S, 2001, INT J CLIN PRACT, V120, pS29; Gelinas I, 1999, AM J OCCUP THER, V53, P471, DOI 10.5014/ajot.53.5.471; Gold G, 1997, NEUROLOGY, V49, P690, DOI 10.1212/WNL.49.3.690; Kalangos A, 1999, ANN VASC SURG, V13, P115, DOI 10.1007/s100169900229; Kumar V, 2000, EUR J NEUROL, V7, P159, DOI 10.1046/j.1468-1331.2000.00046.x; Lobo A, 2000, NEUROLOGY, V54, pS4; Maelicke A, 2000, EUR J PHARMACOL, V393, P165, DOI 10.1016/S0014-2999(00)00093-5; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mendez MF, 1999, J NEUROPSYCH CLIN N, V11, P268, DOI 10.1176/jnp.11.2.268; Raskind MA, 2000, NEUROLOGY, V54, P2261, DOI 10.1212/WNL.54.12.2261; Rockwood K, 1999, ALZ DIS ASSOC DIS, V13, pS59, DOI 10.1097/00002093-199912001-00010; Rockwood K, 2000, NEUROLOGY, V54, P447, DOI 10.1212/WNL.54.2.447; ROMAN G, 2001, INT J CLIN PRACT S, V120, pS9; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; Skoog I, 1999, ALZ DIS ASSOC DIS, V13, pS106, DOI 10.1097/00002093-199912003-00016; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; Tariot PN, 2000, NEUROLOGY, V54, P2269, DOI 10.1212/WNL.54.12.2269; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Wilcock GK, 2000, BRIT MED J, V321, P1445, DOI 10.1136/bmj.321.7274.1445	29	502	532	0	32	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1283	1290		10.1016/S0140-6736(02)08267-3	http://dx.doi.org/10.1016/S0140-6736(02)08267-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965273				2022-12-28	WOS:000174989700010
J	Quine, L				Quine, L			Workplace bullying in junior doctors: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							NHS		Univ Kent, Dept Psychol, Ctr Res Hlth Behav, Canterbury CT2 7NP, Kent, England	University of Kent	Quine, L (corresponding author), Univ Kent, Dept Psychol, Ctr Res Hlth Behav, Canterbury CT2 7NP, Kent, England.							BJORKQVIST K, 1994, AGGRESSIVE BEHAV, V20, P173, DOI 10.1002/1098-2337(1994)20:3<173::AID-AB2480200304>3.0.CO;2-D; Daugherty SR, 1998, JAMA-J AM MED ASSOC, V279, P1194, DOI 10.1001/jama.279.15.1194; Esmail A, 1997, BRIT MED J, V314, P618, DOI 10.1136/bmj.314.7081.618; Kassebaum DG, 1998, ACAD MED, V73, P1149, DOI 10.1097/00001888-199811000-00011; Quine L, 1999, BRIT MED J, V318, P228, DOI 10.1136/bmj.318.7178.228	5	145	153	3	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					878	879		10.1136/bmj.324.7342.878	http://dx.doi.org/10.1136/bmj.324.7342.878			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	542PA	11950736	Green Published, Bronze			2022-12-28	WOS:000175052200021
J	Ransohoff, DF				Ransohoff, DF			Lessons from the UK sigmoidoscopy screening trial	LANCET			English	Editorial Material							COLORECTAL-CANCER; ASYMPTOMATIC ADULTS; SURVEILLANCE		Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Ransohoff, DF (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.							Imperiale TF, 2000, NEW ENGL J MED, V343, P169, DOI 10.1056/NEJM200007203430302; Imperiale TF, 2001, GASTROENTEROLOGY, V120, pA15; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; Prorok PC, 2000, CONTROL CLIN TRIALS, V21, p273S, DOI 10.1016/S0197-2456(00)00098-2; RANSOHOFF DF, 1993, JAMA-J AM MED ASSOC, V269, P1278, DOI 10.1001/jama.269.10.1278; RANSOHOFF DF, 1991, ANN INTERN MED, V114, P177, DOI 10.7326/0003-4819-114-3-177; Ransohoff DF, 1999, GASTROINTEST ENDOSC, V49, pS67, DOI 10.1016/S0016-5107(99)70529-8; Ransohoff DF, 2002, NEW ENGL J MED, V346, P40, DOI 10.1056/NEJMcp010886; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1993, JAMA-J AM MED ASSOC, V269, P1294, DOI 10.1001/jama.269.10.1294; Smith RA, 2001, CA-CANCER J CLIN, V51, P38, DOI 10.3322/canjclin.51.1.38; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; US Preventive Services Task Force, 1996, SCREEN COL CANC GUID, P89; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594	14	21	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1266	1267		10.1016/S0140-6736(02)08284-3	http://dx.doi.org/10.1016/S0140-6736(02)08284-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965269				2022-12-28	WOS:000174989700006
J	Schrag, DP; Linsley, BK				Schrag, DP; Linsley, BK			Paleoclimate: Corals, chemistry, and climate	SCIENCE			English	Editorial Material							SEA-SURFACE TEMPERATURE; SR/CA		Harvard Univ, Dept Earth & Planetary Sci, Lab Geochem Oceanog, Cambridge, MA 02138 USA; SUNY Albany, Dept Earth & Atmospher Sci, Albany, NY 12222 USA	Harvard University; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Schrag, DP (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, Lab Geochem Oceanog, 20 Oxford St, Cambridge, MA 02138 USA.	schrag@eps.harvard.edu; blinsley@albany.edu						Alibert C, 1997, PALEOCEANOGRAPHY, V12, P345, DOI 10.1029/97PA00318; BECK JW, 1992, SCIENCE, V257, P644, DOI 10.1126/science.257.5070.644; Cohen AL, 2002, SCIENCE, V296, P331, DOI 10.1126/science.1069330; Cohen AL, 2001, PALEOCEANOGRAPHY, V16, P20, DOI 10.1029/1999PA000478; DEVILLIERS S, 1995, SCIENCE, V269, P1247, DOI 10.1126/science.269.5228.1247; Lea DW, 1999, GEOCHIM COSMOCHIM AC, V63, P2369, DOI 10.1016/S0016-7037(99)00197-0; Levi Y, 1998, CHEM-EUR J, V4, P389, DOI 10.1002/(SICI)1521-3765(19980310)4:3<389::AID-CHEM389>3.0.CO;2-X; Linsley BK, 2000, SCIENCE, V290, P1145, DOI 10.1126/science.290.5494.1145; Raz S, 2000, ADV MATER, V12, P38, DOI 10.1002/(SICI)1521-4095(200001)12:1<38::AID-ADMA38>3.0.CO;2-I; Stoll HM, 2000, GEOCHEM GEOPHY GEOSY, V1, DOI 10.1029/1999GC000015	10	19	25	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	2002	296	5566					277	278		10.1126/science.1071561	http://dx.doi.org/10.1126/science.1071561			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951026				2022-12-28	WOS:000175000300037
J	Piguet, V; Friedli, A; Pessina, PA; Chavaz, P; Saurat, JH				Piguet, V; Friedli, A; Pessina, PA; Chavaz, P; Saurat, JH			Aching alopecia	LANCET			English	Editorial Material									Univ Hosp Geneva, Dept Dermatol, CH-1211 Geneva, Switzerland	University of Geneva	Piguet, V (corresponding author), Univ Hosp Geneva, Dept Dermatol, CH-1211 Geneva, Switzerland.			Piguet, Vincent/0000-0001-6079-4517					0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1199	1199		10.1016/S0140-6736(02)08217-X	http://dx.doi.org/10.1016/S0140-6736(02)08217-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955538				2022-12-28	WOS:000174846300010
J	Li, QL; Ito, K; Sakakura, C; Fukamachi, H; Inoue, K; Chi, XZ; Lee, KY; Nomura, S; Lee, CW; Han, SB; Kim, HM; Kim, WJ; Yamamoto, H; Yamashita, N; Yano, T; Ikeda, T; Itohara, S; Inazawa, J; Abe, T; Hagiwara, A; Yamagishi, H; Ooe, A; Kaneda, A; Sugimura, T; Ushijima, T; Bae, SC; Ito, Y				Li, QL; Ito, K; Sakakura, C; Fukamachi, H; Inoue, K; Chi, XZ; Lee, KY; Nomura, S; Lee, CW; Han, SB; Kim, HM; Kim, WJ; Yamamoto, H; Yamashita, N; Yano, T; Ikeda, T; Itohara, S; Inazawa, J; Abe, T; Hagiwara, A; Yamagishi, H; Ooe, A; Kaneda, A; Sugimura, T; Ushijima, T; Bae, SC; Ito, Y			Causal relationship between the loss of RUNX3 expression and gastric cancer	CELL			English	Article							CONFORMATION POLYMORPHISM ANALYSIS; CLEIDOCRANIAL DYSPLASIA; FREQUENT LOSS; EPITHELIAL-CELLS; GENE; MUTATIONS; DOMAIN; HETEROZYGOSITY; DIFFERENTIATION; AMPLIFICATION	Runx3/Pebp2alphaC null mouse gastric mucosa exhibits hyperplasias due to stimulated proliferation and suppressed apoptosis in epithelial cells, and the cells are resistant to growth-inhibitory and apoptosis-inducing action of TGF-beta, indicating that Runx3 is a major growth regulator of gastric epithelial cells. Between 45% and 60% of human gastric cancer cells do not significantly express RUNX3 due to hemizygous deletion and hypermethylation of the RUNX3 promoter region. Tumorigenicity of human gastric cancer cell lines in nude mice was inversely related to their level of RUNX3 expression, and a mutation (R122C) occurring within the conserved Runt domain abolished the tumor-suppressive effect of RUNX3, suggesting that a lack of RUNX3 function is causally related to the genesis and progression of human gastric cancer.	Chungbuk Natl Univ, Coll Med, Dept Biochem, Inst Med Res, Cheongju 361763, South Korea; Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Prefectural Univ Med, Dept Digest Surg, Kamigyo Ku, Kyoto 6020841, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Osaka Univ, Grad Sch Med, Dept Pathol, Suita, Osaka 5650871, Japan; Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea; Chungbuk Natl Univ, Coll Med, Dept Urol, Cheongju 361763, South Korea; Kyoto Univ, Inst Virus Res, Lab Adv Biol Informat, Sakyo Ku, Kyoto 6068507, Japan; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 1040045, Japan; Tokyo Med & Dent Univ, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan	Chungbuk National University; Kyoto University; Kyoto Prefectural University of Medicine; University of Tokyo; Osaka University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungbuk National University; Kyoto University; National Cancer Center - Japan; Tokyo Medical & Dental University (TMDU)	Bae, SC (corresponding author), Chungbuk Natl Univ, Coll Med, Dept Biochem, Inst Med Res, Cheongju 361763, South Korea.		Itohara, Shigeyoshi/I-8769-2012; Li, Qinglin/K-2570-2015; Ushijima, Toshikazu/AAP-5742-2021	Itohara, Shigeyoshi/0000-0002-2410-9989; Li, Qinglin/0000-0002-4125-1944; Ushijima, Toshikazu/0000-0003-3405-7817				BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cleary ML, 1999, NAT GENET, V23, P134, DOI 10.1038/13761; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Ezaki T, 1996, BRIT J CANCER, V73, P424, DOI 10.1038/bjc.1996.76; FUKAMACHI H, 1992, J CELL SCI, V103, P511; FUKAMACHI H, 1994, DIFFERENTIATION, V56, P83, DOI 10.1046/j.1432-0436.1994.56120083.x; FUKUSHIGE S, 1986, MOL CELL BIOL, V6, P955, DOI 10.1128/MCB.6.3.955; GOMI H, 1995, NEURON, V14, P29, DOI 10.1016/0896-6273(95)90238-4; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Huang D, 1998, DEVELOPMENT, V125, P3235; Ishino S, 1998, CANCER, V83, P360, DOI 10.1002/(SICI)1097-0142(19980715)83:2<360::AID-CNCR21>3.0.CO;2-Q; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Matsubara Y, 1998, BIOCHEM BIOPH RES CO, V253, P477, DOI 10.1006/bbrc.1998.9808; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nam S, 2002, MOL CELL BIOL, V22, P547, DOI 10.1128/MCB.22.2.547-554.2002; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Osato M, 1999, BLOOD, V93, P1817, DOI 10.1182/blood.V93.6.1817.406k36_1817_1824; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; REGECAMBRIN G, 1992, CANCER GENET CYTOGEN, V64, P170, DOI 10.1016/0165-4608(92)90350-H; SANO T, 1991, CANCER RES, V51, P2926; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SOBIN IH, 1997, TNM CLASSIFICATION M; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; TAMURA G, 1991, CANCER RES, V51, P3056; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; UCHINO S, 1992, CANCER RES, V52, P3099; USHIJIMA T, 1995, MUTAT RES-ENVIR MUTA, V334, P283, DOI 10.1016/0165-1161(95)90065-9; Yamada K, 1997, HUM MOL GENET, V6, P2223, DOI 10.1093/hmg/6.13.2223; Zhou G, 1999, HUM MOL GENET, V8, P2311, DOI 10.1093/hmg/8.12.2311	40	885	981	0	43	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	2002	109	1					113	124		10.1016/S0092-8674(02)00690-6	http://dx.doi.org/10.1016/S0092-8674(02)00690-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955451	Bronze			2022-12-28	WOS:000174888300013
J	O'Shea, JJ; Gadina, M; Schreiber, RD				O'Shea, JJ; Gadina, M; Schreiber, RD			Cytokine signaling in 2002: New surprises in the Jak/Stat pathway	CELL			English	Review							MICE LACKING SUPPRESSOR; IFN-GAMMA; IMMUNE-RESPONSE; TRANSCRIPTIONAL RESPONSES; PSEUDOKINASE DOMAIN; GENE-EXPRESSION; TYROSINE KINASE; CELL EXPANSION; EXPORT SIGNAL; JANUS KINASES	The importance of Jak-Stat pathway signaling in regulating cytokine-dependent gene expression and cellular development/survival is well established. Nevertheless, advances continue to be made in defining Jak-Stat pathway effects on different cellular processes and in different organisms. This review focuses on recent advances in the field and highlights some of the most active areas of Jak-Stat pathway research.	NIAMSD, Mol Immunol & Inflammat Branch, NIH, Rockville, MD 20852 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63105 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Washington University (WUSTL)	O'Shea, JJ (corresponding author), NIAMSD, Mol Immunol & Inflammat Branch, NIH, Rockville, MD 20852 USA.	osheaj@arb.niams.nih.gov	Schreiber, Robert/Q-7550-2019; Schreiber, Robert D/A-1276-2013; Gadina, Massimo/R-4195-2019	Schreiber, Robert D/0000-0001-6311-0432; Schreiber, Robert/0000-0003-1590-2341	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041106, Z01AR041106] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; Asao H, 2001, J IMMUNOL, V167, P1, DOI 10.4049/jimmunol.167.1.1; Baird AM, 2000, J IMMUNOL, V165, P3680, DOI 10.4049/jimmunol.165.7.3680; Begitt A, 2000, P NATL ACAD SCI USA, V97, P10418, DOI 10.1073/pnas.190318397; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Cacalano NA, 2001, NAT CELL BIOL, V3, P460, DOI 10.1038/35074525; Chen M, 2000, MOL CELL BIOL, V20, P947, DOI 10.1128/MCB.20.3.947-956.2000; Chen Q, 2000, NATURE, V407, P916, DOI 10.1038/35038103; Chitnis T, 2001, J CLIN INVEST, V108, P739, DOI 10.1172/JCI200112563; DAMELL JE, 1994, SCIENCE, V264, P1415; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dupuis S, 2001, SCIENCE, V293, P300, DOI 10.1126/science.1061154; Endo K, 2000, FEBS LETT, V477, P55, DOI 10.1016/S0014-5793(00)01760-9; Enninga J, 2002, SCIENCE, V295, P1523, DOI 10.1126/science.1067861; Farrar JD, 2000, NAT IMMUNOL, V1, P65, DOI 10.1038/76932; Frantsve J, 2001, MOL CELL BIOL, V21, P3547, DOI 10.1128/MCB.21.10.3547-3557.2001; Frucht DM, 2001, GENES IMMUN, V2, P422, DOI 10.1038/sj.gene.6363802; Frucht DM, 2001, TRENDS IMMUNOL, V22, P556, DOI 10.1016/S1471-4906(01)02005-1; Fukuzawa M, 2001, MOL CELL, V7, P779, DOI 10.1016/S1097-2765(01)00222-2; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Gongora R, 2001, IMMUNITY, V14, P727, DOI 10.1016/S1074-7613(01)00152-2; Gozalo-Sanmillan S, 2001, J IMMUNOL, V166, P727, DOI 10.4049/jimmunol.166.2.727; Guo ZH, 2000, SCIENCE, V288, P2042, DOI 10.1126/science.288.5473.2042; Hilkens CMU, 2001, FEBS LETT, V505, P87, DOI 10.1016/S0014-5793(01)02783-1; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jinks TM, 2000, MOL CELL, V5, P581, DOI 10.1016/S1097-2765(00)80451-7; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kieslinger M, 2000, GENE DEV, V14, P232; Kiger AA, 2001, SCIENCE, V294, P2542, DOI 10.1126/science.1066707; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lawless VA, 2000, J IMMUNOL, V165, P6803, DOI 10.4049/jimmunol.165.12.6803; Lee CK, 2000, J IMMUNOL, V165, P3571, DOI 10.4049/jimmunol.165.7.3571; Lentsch AB, 2001, J CLIN INVEST, V108, P1475, DOI 10.1172/JCI13763; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Lillemeier BF, 2001, EMBO J, V20, P2508, DOI 10.1093/emboj/20.10.2508; Matsukawa A, 2001, J EXP MED, V193, P679, DOI 10.1084/jem.193.6.679; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; MCBRIDE KM, 2002, IN PRESS EMBO J; Melen K, 2001, J BIOL CHEM, V276, P16447, DOI 10.1074/jbc.M008821200; Metcalf D, 2002, P NATL ACAD SCI USA, V99, P943, DOI 10.1073/pnas.022628499; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Naka T, 2001, IMMUNITY, V14, P535, DOI 10.1016/S1074-7613(01)00132-7; Nguyen KB, 2000, NAT IMMUNOL, V1, P70, DOI 10.1038/76940; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Notorangelo LD, 2001, HUM MUTAT, V18, P255; O'Brien KB, 2002, J BIOL CHEM, V277, P8673, DOI 10.1074/jbc.M109165200; Okamura H, 2001, CURR OPIN CELL BIOL, V13, P239, DOI 10.1016/S0955-0674(00)00203-9; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Pandey A, 2000, J BIOL CHEM, V275, P38633, DOI 10.1074/jbc.M007849200; Parisien JP, 2001, VIROLOGY, V283, P230, DOI 10.1006/viro.2001.0856; Park C, 2000, IMMUNITY, V13, P795, DOI 10.1016/S1074-7613(00)00077-7; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; PAULSON M, 2002, NAT CELL BIOL, V21, P21; RADTKE S, 2002, IN PRESS J BIOL CHEM; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Roberts AW, 2001, P NATL ACAD SCI USA, V98, P9324, DOI 10.1073/pnas.161271798; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Sahni M, 2001, DEVELOPMENT, V128, P2119; Sano S, 2001, IMMUNITY, V15, P261, DOI 10.1016/S1074-7613(01)00180-7; Schwaller J, 2000, MOL CELL, V6, P693, DOI 10.1016/S1097-2765(00)00067-8; Sefton L, 2000, NATURE, V405, P970, DOI 10.1038/35016119; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Snow JW, 2002, BLOOD, V99, P95, DOI 10.1182/blood.V99.1.95; Suzuki K, 2000, INT IMMUNOL, V12, P123, DOI 10.1093/intimm/12.2.123; Takahashi I, 2001, J IMMUNOL, V167, P3156, DOI 10.4049/jimmunol.167.6.3156; Terabe M, 2000, NAT IMMUNOL, V1, P515, DOI 10.1038/82771; Tulina N, 2001, SCIENCE, V294, P2546, DOI 10.1126/science.1066700; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wen RR, 2001, MOL CELL BIOL, V21, P678, DOI 10.1128/MCB.21.2.678-689.2001; Williams JG, 2000, CURR OPIN GENET DEV, V10, P503, DOI 10.1016/S0959-437X(00)00119-2; Wurster AL, 2000, ONCOGENE, V19, P2577, DOI 10.1038/sj.onc.1203485; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Yamada M, 2001, MOL CELL BIOL, V21, P3807, DOI 10.1128/MCB.21.11.3807-3819.2001; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yeh TC, 2000, P NATL ACAD SCI USA, V97, P8991, DOI 10.1073/pnas.160130297; Yoo JY, 2002, CELL, V108, P331, DOI 10.1016/S0092-8674(02)00636-0; Yoshida H, 2001, IMMUNITY, V15, P569, DOI 10.1016/S1074-7613(01)00206-0; Zeidler MP, 2000, ONCOGENE, V19, P2598, DOI 10.1038/sj.onc.1203482; Zhang JG, 2001, P NATL ACAD SCI USA, V98, P13261, DOI 10.1073/pnas.231486498; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7; Zhu JF, 2001, J IMMUNOL, V166, P7276, DOI 10.4049/jimmunol.166.12.7276	105	872	950	2	70	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR	2002	109			S			S121	S131		10.1016/S0092-8674(02)00701-8	http://dx.doi.org/10.1016/S0092-8674(02)00701-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	544UY	11983158	Bronze			2022-12-28	WOS:000175181100011
J	Finger, FP; White, JG				Finger, FP; White, JG			Fusion and fission: Membrane trafficking in animal cytokinesis	CELL			English	Review							PHOSPHATIDYLETHANOLAMINE; CELLULARIZATION; REDISTRIBUTION; EXOCYTOSIS; SYNTAXIN; PROTEIN	Cytokinesis is the physical act of separating daughter cells, allowing them to become separate entities. Recent studies have revealed that membrane insertion for furrowing and scission of the residual bridge is a key aspect of animal cytokinesis.	Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; Univ Wisconsin, Dept Anat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Finger, FP (corresponding author), Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA.							Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Burgess RW, 1997, J CELL BIOL, V138, P861, DOI 10.1083/jcb.138.4.861; Conner SD, 1999, MOL BIOL CELL, V10, P2735, DOI 10.1091/mbc.10.8.2735; Emoto K, 1996, P NATL ACAD SCI USA, V93, P12867, DOI 10.1073/pnas.93.23.12867; Emoto K, 2000, J CELL BIOL, V149, P1215, DOI 10.1083/jcb.149.6.1215; Field CM, 1999, TRENDS CELL BIOL, V9, P387, DOI 10.1016/S0962-8924(99)01632-3; Jantsch-Plunger V, 1999, CURR BIOL, V9, P738, DOI 10.1016/S0960-9822(99)80333-9; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Prokopenko SN, 2000, J CELL BIOL, V148, P843, DOI 10.1083/jcb.148.5.843; Reddy A, 2001, CELL, V106, P157, DOI 10.1016/S0092-8674(01)00421-4; Sisson JC, 2000, J CELL BIOL, V151, P905, DOI 10.1083/jcb.151.4.905; Skop AR, 2001, CURR BIOL, V11, P735, DOI 10.1016/S0960-9822(01)00231-7; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720	16	81	81	1	9	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 22	2002	108	6					727	730		10.1016/S0092-8674(02)00668-2	http://dx.doi.org/10.1016/S0092-8674(02)00668-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955425	Bronze			2022-12-28	WOS:000174563000001
J	Liu, CM; Li, YM; Semenov, M; Han, C; Baeg, GH; Tan, Y; Zhang, ZH; Lin, XH; He, X				Liu, CM; Li, YM; Semenov, M; Han, C; Baeg, GH; Tan, Y; Zhang, ZH; Lin, XH; He, X			Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism	CELL			English	Article							F-BOX PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; WNT SIGNALING PATHWAY; KAPPA-B-ALPHA; NEGATIVE REGULATOR; FUNCTIONAL INTERACTION; SUBSTRATE-SPECIFICITY; AXIS FORMATION; I-EPSILON; XENOPUS	Writ regulation of beta-catenin degradation is essential for development and carcinogenesis. beta-catenin degradation is initiated upon amino-terminal serine/threonine phosphorylation, which is believed to be performed by glycogen synthase kinase-3 (GSK-3) in complex with tumor suppressor proteins Axin and adnomatous polyposis coli (APC). Here we describe another Axin-associated kinase, whose phosphorylation of beta-catenin precedes and is required for subsequent GSK-3 phosphorylation of beta-catenin. This "priming" kinase is casein kinase 1alpha (CK1alpha). Depletion of CK1alpha inhibits beta-catenin phosphorylation and degradation and causes abnormal embryogenesis associated with excessive Wnt/beta-catenin signaling. Our study uncovers distinct roles and steps of beta-catenin phosphorylation, identifies CK1alpha as a component in Wnt/beta-catenin signaling, and has implications to pathogenesis/therapeutics of human cancers and diabetes.	Harvard Univ, Sch Med, Childrens Hosp, Dept Neurol,Div Neurosci, Boston, MA 02115 USA; Childrens Hosp, Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Burnham Inst, Ctr Neurosci & Aging, La Jolla, CA 92037 USA; Cell Signaling Inc, Beverly, MA 01915 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Cincinnati Children's Hospital Medical Center; Harvard University; Harvard Medical School; Sanford Burnham Prebys Medical Discovery Institute	He, X (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Dept Neurol,Div Neurosci, Boston, MA 02115 USA.	xi.he@tch.harvard.edu	Baeg, Gyeong-Hun/A-2951-2008	Han, Chun/0000-0001-7319-8095				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Jho EH, 1999, BIOCHEM BIOPH RES CO, V266, P28, DOI 10.1006/bbrc.1999.1760; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lee E, 2001, J CELL BIOL, V154, P983, DOI 10.1083/jcb.200102074; LEHMANN R, 1994, METHOD CELL BIOL, V44, P575, DOI 10.1016/S0091-679X(08)60933-4; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Polakis P, 2000, GENE DEV, V14, P1837; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Weston CR, 2001, SCIENCE, V292, P2439, DOI 10.1126/science.1063279; Willert K, 1999, DEVELOPMENT, V126, P4165; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WOODGETT JR, 2001, SCI STKE, pRE12; Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	67	1574	1627	2	111	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	2002	108	6					837	847		10.1016/S0092-8674(02)00685-2	http://dx.doi.org/10.1016/S0092-8674(02)00685-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955436	Bronze			2022-12-28	WOS:000174563000012
J	Padera, TP; Kadambi, A; di Tomaso, E; Carreira, CM; Brown, EB; Boucher, Y; Choi, NC; Mathisen, D; Wain, J; Mark, EJ; Munn, LL; Jain, RK				Padera, TP; Kadambi, A; di Tomaso, E; Carreira, CM; Brown, EB; Boucher, Y; Choi, NC; Mathisen, D; Wain, J; Mark, EJ; Munn, LL; Jain, RK			Lymphatic metastasis in the absence of functional intratumor lymphatics	SCIENCE			English	Article							GROWTH-FACTOR-C; TUMOR LYMPHANGIOGENESIS; VESSELS; SYSTEM; RECRUITMENT; INDUCTION; LYVE-1; CANCER	Lymphatic metastasis contributes to mortality from solid tumors. Whether metastasizing cancer cells reach lymph nodes via intratumor lymphatic vessels is unknown. Here, we examine functional lymphatics associated with mouse tumors expressing normal or elevated levels of vascular endothelial growth factor-C (VEGF-C), a molecule that stimulates lymphangiogenesis. Although VEGF-C overexpression increased lymphatic surface area in the tumor margin and lymphatic metastasis, these tumors contained no functional lymphatics, as assessed by four independent functional assays and immunohistochemical staining. These findings suggest that the functional lymphatics in the tumor margin alone are sufficient for lymphatic metastasis and should be targeted therapeutically.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol,EL Steele Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital	Jain, RK (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol,EL Steele Lab, 100 Blossom St, Boston, MA 02114 USA.		Munn, Lance L/L-3950-2016; Padera, Timothy/R-2982-2019; Jain, Rakesh K/I-1384-2017	Munn, Lance L/0000-0003-0698-7232; Padera, Timothy/0000-0002-3453-9384; Jain, Rakesh K/0000-0001-7571-3548	NCI NIH HHS [R24-CA85140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA085140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown EB, 2001, NAT MED, V7, P864, DOI 10.1038/89997; Carreira CM, 2001, CANCER RES, V61, P8079; GULLINO PM, 1985, BIOL RESPONSES CANC, V4, P1; Helmlinger G, 1997, NAT BIOTECHNOL, V15, P778, DOI 10.1038/nbt0897-778; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; JAIN RK, 1994, SCI AM, V271, P58, DOI 10.1038/scientificamerican0794-58; Jain RK, 2002, JNCI-J NATL CANCER I, V94, P785, DOI 10.1093/jnci/94.11.785; Jain RK, 2002, J NATL CANCER I, V94, P417; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Kadambi A, 2001, CANCER RES, V61, P2404; Karpanen T, 2001, J EXP MED, V194, pF37, DOI 10.1084/jem.194.6.F37; Karpanen T, 2001, CANCER RES, V61, P1786; Lee FC, 1933, ARCH SURG-CHICAGO, V26, P602, DOI 10.1001/archsurg.1933.01170040065004; Leu AJ, 2000, CANCER RES, V60, P4324; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Padera TP, 2002, MOL IMAGING, V1, P9, DOI 10.1162/153535002753395662; Pepper MS, 2001, CLIN CANCER RES, V7, P462; Rofstad EK, 2002, CANCER RES, V62, P661; SCHMIDSCHONBEIN GW, 1990, PHYSIOL REV, V70, P987, DOI 10.1152/physrev.1990.70.4.987; Skobe M, 2001, AM J PATHOL, V159, P893, DOI 10.1016/S0002-9440(10)61765-8; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Sleeman JP, 2001, MICROSC RES TECHNIQ, V55, P61, DOI 10.1002/jemt.1157; TODOROKI T, 1985, J SURG ONCOL, V29, P207, DOI 10.1002/jso.2930290402; Trzewik J, 2001, FASEB J, V15, P1711, DOI 10.1096/fj.01-0067com; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1	26	748	838	4	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 7	2002	296	5574					1883	1886		10.1126/science.1071420	http://dx.doi.org/10.1126/science.1071420			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	559YP	11976409				2022-12-28	WOS:000176054300053
J	Brundtland, GH				Brundtland, GH			Afghanistan: Rebuilding a health system	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									WHO, CH-1211 Geneva, Switzerland	World Health Organization	Brundtland, GH (corresponding author), WHO, CH-1211 Geneva, Switzerland.								0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	2002	287	18					2354	2354		10.1001/jama.287.18.2354	http://dx.doi.org/10.1001/jama.287.18.2354			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548PF	11988045				2022-12-28	WOS:000175397000009
J	Ceballos, G; Ehrlich, PR				Ceballos, G; Ehrlich, PR			Mammal population losses and the extinction crisis	SCIENCE			English	Article							CONSERVATION; DYNAMICS; PATTERNS; RISK	The disappearance of populations is a prelude to species extinction. No geographically explicit estimates have been made of current population tosses of major indicator taxa. Here we compare historic and present distributions of 173 declining mammal species from six continents. These species have collectively lost over 50% of their historic range area, mostly where human activities are intensive. This implies a serious loss of ecosystem services and goods. It also signals a substantial threat to species diversity.	Univ Nacl Autonoma Mexico, Inst Ecol, Mexico City 04510, DF, Mexico; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Universidad Nacional Autonoma de Mexico; Stanford University	Ceballos, G (corresponding author), Univ Nacl Autonoma Mexico, Inst Ecol, Apdo Postal 70-275, Mexico City 04510, DF, Mexico.	gceballo@miranda.ecologia.unam.mx; pre@Stanford.edu						BAILEY C, 1996, LANDSCOPE, V11, P41; Balmford A, 2001, SCIENCE, V291, P2616, DOI 10.1126/science.291.5513.2616; Brown J. H., 1998, BIOGEOGRAPHY; Cardillo M, 2001, CONSERV BIOL, V15, P1435, DOI 10.1046/j.1523-1739.2001.00286.x; CEBALLOS G, 1995, CONSERV BIOL, V9, P559, DOI 10.1046/j.1523-1739.1995.09030559.x; Channell R, 2000, J BIOGEOGR, V27, P169, DOI 10.1046/j.1365-2699.2000.00382.x; CLOUDSLEY-THOMPSON J L, 1974, Environmental Conservation, V1, P5; DAFONSECA GAB, 1985, BIOL CONSERV, V34, P17, DOI 10.1016/0006-3207(85)90055-2; Daily G. C., 1997, Nature's services: societal dependence on natural ecosystems., P113; Fa JE, 2000, CONSERV BIOL, V14, P1602, DOI [10.1046/j.1523-1739.2000.99067.x, 10.1111/j.1523-1739.2000.99067.x]; Fox MD, 1986, NATURAL LEGACY ECOLO, P235; Friend J.A., 1990, Proceedings of the Ecological Society of Australia, V16, P369; Gittleman JL, 2001, SCIENCE, V291, P997, DOI 10.1126/science.291.5506.997; Hilton-Taylor C., 2000, 2000 IUCN RED LIST T; Hughes JB, 1997, SCIENCE, V278, P689, DOI 10.1126/science.278.5338.689; Kingdon J, 2011, KINGDON FIELD GUIDE, V4th; Kinnear JE, 1998, WILDLIFE RES, V25, P81, DOI 10.1071/WR96072; Laidlaw RK, 2000, CONSERV BIOL, V14, P1639, DOI 10.1046/j.1523-1739.2000.99073.x; LINDENMAYER DB, 1995, RISK EXTINCTION RANK; LOMOLINO MV, 1995, J MAMMAL, V76, P335, DOI 10.2307/1382345; MacPhee R.D.E., 1999, EXTINCTIONS NEAR TIM; MacPhee RDE, 2001, SCIENCE, V292, P217; MitchellJones A.J., 1999, ATLAS EUROPEAN MAMMA; Mittermeier RA, 1999, HOT SPOTS EARTHS BIO; MURPHY DD, 1988, BIOL CONSERV, V46, P183, DOI 10.1016/0006-3207(88)90067-5; Myers N, 2000, NATURE, V403, P853, DOI 10.1038/35002501; PIMM SL, 1995, SCIENCE, V269, P347, DOI 10.1126/science.269.5222.347; Roig V.G., 1991, P239; SANTIAPILLAI C, 1993, RHINOCEROS BIOLOGY AND CONSERVATION, P257; Scott J. A., 1986, BUTTERFLIES N AM NAT; Seidensticker J., 1999, RIDING TIGER TIGER C; Short J, 1998, BIOL CONSERV, V86, P365, DOI 10.1016/S0006-3207(98)00026-3; SHORT J, 1994, J MAMMAL, V75, P288, DOI 10.2307/1382547; Southern, 1977, HDB BRIT MAMMALS; WILKIE DS, 2000, IMPACTS COMMERCIAL L, P375	35	585	610	11	263	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	2002	296	5569					904	907		10.1126/science.1069349	http://dx.doi.org/10.1126/science.1069349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988573				2022-12-28	WOS:000175442500042
J	Maslov, S; Sneppen, K				Maslov, S; Sneppen, K			Specificity and stability in topology of protein networks	SCIENCE			English	Article								Molecular networks guide the biochemistry of a living cell on multiple levels: Its metabolic and signaling pathways are shaped by the network of interacting proteins, whose production, in turn, is controlled by the genetic regulatory network. To address topological properties of these two networks, we quantified correlations between connectivities of interacting nodes and compared them to a null model of a network, in which all links were randomly rewired. We found that for both interaction and regulatory networks, links between highly connected proteins are systematically suppressed, whereas those between a highly connected and low-connected pairs of proteins are favored. This effect decreases the likelihood of cross talk between different functional modules of the cell and increases the overall robustness of a network by localizing effects of deleterious perturbations.	Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA; Norwegian Univ Sci & Technol, Dept Phys, N-7491 Trondheim, Norway	United States Department of Energy (DOE); Brookhaven National Laboratory; Norwegian University of Science & Technology (NTNU)	Maslov, S (corresponding author), Brookhaven Natl Lab, Dept Phys, Upton, NY 11973 USA.	mastov@bnl.gov	Maslov, Sergei/C-2397-2009	Maslov, Sergei/0000-0002-3701-492X; Sneppen, Kim/0000-0001-9820-3567				Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Broder A, 2000, COMPUT NETW, V33, P309, DOI 10.1016/S1389-1286(00)00083-9; Costanzo MC, 2001, NUCLEIC ACIDS RES, V29, P75, DOI 10.1093/nar/29.1.75; Fell DA, 2000, NAT BIOTECHNOL, V18, P1121, DOI 10.1038/81025; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Hartwell LH, 1999, NATURE, V402, pC47, DOI 10.1038/35011540; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jeong H, 2000, NATURE, V407, P651, DOI 10.1038/35036627; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Pastor-Satorras R, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.258701; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wagner A, 2001, MOL BIOL EVOL, V18, P1283, DOI 10.1093/oxfordjournals.molbev.a003913	14	2113	2170	15	197	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	2002	296	5569					910	913		10.1126/science.1065103	http://dx.doi.org/10.1126/science.1065103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988575	Green Submitted			2022-12-28	WOS:000175442500044
J	Sillaber, I; Rammes, G; Zimmermann, S; Mahal, B; Zieglgansberger, W; Wurst, W; Holsboer, F; Spanagel, R				Sillaber, I; Rammes, G; Zimmermann, S; Mahal, B; Zieglgansberger, W; Wurst, W; Holsboer, F; Spanagel, R			Enhanced and delayed stress-induced alcohol drinking in mice lacking functional CRH1 receptors	SCIENCE			English	Article							CORTICOTROPIN-RELEASING FACTOR; SUBUNIT EXPRESSION; BRAIN; HORMONE-RECEPTOR-1; CONSUMPTION; ETHANOL; PEPTIDE; SYSTEM; REWARD; UPDATE	There is a relation between stress and alcohol drinking. We show that the corticotropin-releasing hormone (CRH) system that mediates endocrine and behavioral responses to stress plays a role in the control of long-term alcohol drinking. In mice lacking a functional CRH1 receptor, stress leads to enhanced and progressively increasing alcohol intake. The effect of repeated stress on alcohol drinking behavior appeared with a delay and persisted throughout life. It was associated with an up-regulation of the N-methyl-D-aspartate receptor subunit NR2B. Alterations in the CRH1 receptor gene and adaptional changes in NR2B subunits may constitute a genetic risk factor for stress-induced alcohol drinking and alcoholism.	Max Planck Inst Psychiat, D-80804 Munich, Germany; Natl Res Ctr Environm & Hlth, Inst Mammalian Genet, D-85764 Munich, Germany; Univ Heidelberg, Cent Inst Mental Hlth, D-68159 Mannheim, Germany	Max Planck Society; University of Munich; Central Institute of Mental Health; Ruprecht Karls University Heidelberg	Sillaber, I (corresponding author), Max Planck Inst Psychiat, Kraepelinstr 2-10, D-80804 Munich, Germany.			Wurst, Wolfgang/0000-0003-4422-7410				ABEL EL, 1994, PHYSIOL BEHAV, V56, P795, DOI 10.1016/0031-9384(94)90245-3; Allgaier C, 1999, BRIT J PHARMACOL, V126, P121, DOI 10.1038/sj.bjp.0702284; BARTANUSZ V, 1995, NEUROSCIENCE, V66, P247, DOI 10.1016/0306-4522(95)00084-V; CHALMERS DT, 1995, J NEUROSCI, V15, P6340; CHU B, 1995, J NEUROCHEM, V65, P140; Crabbe JC, 1996, NAT GENET, V14, P98, DOI 10.1038/ng0996-98; DeSouza EB, 1995, PSYCHONEUROENDOCRINO, V20, P789, DOI 10.1016/0306-4530(95)00011-9; Heinrichs SC, 1995, ANN NY ACAD SCI, V771, P92, DOI 10.1111/j.1749-6632.1995.tb44673.x; KOOLHAAS JM, 1997, ACTA PHYSL SCAND S, V640, P69; Kreek MJ, 1998, DRUG ALCOHOL DEPEN, V51, P23, DOI 10.1016/S0376-8716(98)00064-7; LaForge KS, 2000, EUR J PHARMACOL, V410, P249, DOI 10.1016/S0014-2999(00)00819-0; Muller MB, 2000, ENDOCRINOLOGY, V141, P4262, DOI 10.1210/en.141.11.4262; O'Malley SS, 2002, PSYCHOPHARMACOLOGY, V160, P19, DOI 10.1007/s002130100919; POHORECKY LA, 1990, ALCOHOL ALCOHOLISM, V25, P263, DOI 10.1093/oxfordjournals.alcalc.a045000; POHORECKY LA, 1991, ALCOHOL CLIN EXP RES, V15, P438, DOI 10.1111/j.1530-0277.1991.tb00543.x; Rammes G, 2001, NEUROPHARMACOLOGY, V40, P749, DOI 10.1016/S0028-3908(01)00008-9; Sarnyai Z, 2001, PHARMACOL REV, V53, P209; SAUVAGE M, UNPUB; Schuckit MA, 1998, J STUD ALCOHOL, V59, P485, DOI 10.15288/jsa.1998.59.485; SCHUCKIT MA, 1985, JAMA-J AM MED ASSOC, V254, P2614, DOI 10.1001/jama.254.18.2614; SCHUMANN G, IN PRESS MOL PSYCHIA; Spanagel R, 1999, TRENDS NEUROSCI, V22, P521, DOI 10.1016/S0166-2236(99)01447-2; SPANAGEL R, 2002, THERAPEUTIC POTENTIA, pCH12; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Timpl P, 1998, NAT GENET, V19, P162, DOI 10.1038/520; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; Wand GS, 2002, NEUROPSYCHOPHARMACOL, V26, P106, DOI 10.1016/S0893-133X(01)00294-9; Winkler A, 1999, MOL BRAIN RES, V72, P166, DOI 10.1016/S0169-328X(99)00218-1	28	175	180	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					931	933		10.1126/science.1069836	http://dx.doi.org/10.1126/science.1069836			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988580				2022-12-28	WOS:000175442500050
J	Schultz, C; Temming, P; Gembruch, U; Strunk, T; Bucsky, P				Schultz, C; Temming, P; Gembruch, U; Strunk, T; Bucsky, P			Polyclonal intravenous immunoglobulin to prevent brain injury in preterm infants	LANCET			English	Letter									Med Univ Lubeck, Dept Paediat, D-23568 Lubeck, Germany; Med Univ Lubeck, Dept Obstet & Gynaecol, D-23568 Lubeck, Germany	University of Lubeck; University of Lubeck	Schultz, C (corresponding author), Med Univ Lubeck, Dept Paediat, D-23568 Lubeck, Germany.		Strunk, Tobias/AIE-3407-2022; Ketteler, Petra/M-4743-2016; Gembruch, Ulrich/Q-8228-2017	Strunk, Tobias/0000-0001-7079-2339; Ketteler, Petra/0000-0002-8138-0441; Gembruch, Ulrich/0000-0001-8284-4669				BRETT FM, 1995, J NEUROPATH EXP NEUR, V54, P766, DOI 10.1097/00005072-199511000-00003; Duggan PJ, 2001, LANCET, V358, P1699, DOI 10.1016/S0140-6736(01)06723-X; KILPATRICK L, 1997, FETAL NEONATAL PHYSL, P1967; Schultz C, 2002, PEDIATR RES, V51, P317, DOI 10.1203/00006450-200203000-00009; Zupan V, 1996, DEV MED CHILD NEUROL, V38, P1061	5	4	4	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1522	1523		10.1016/S0140-6736(02)08447-7	http://dx.doi.org/10.1016/S0140-6736(02)08447-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988277	Bronze			2022-12-28	WOS:000175279100040
J	Ewing, RC; Macfarlane, A				Ewing, RC; Macfarlane, A			Nuclear waste - Yucca Mountain	SCIENCE			English	Editorial Material									Univ Michigan, Dept Nucl Engn & Radiol Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Geol Sci & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Engn, Ann Arbor, MI 48109 USA; MIT, Secur Studies Program, Cambridge, MA 02139 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Massachusetts Institute of Technology (MIT)	Ewing, RC (corresponding author), Univ Michigan, Dept Nucl Engn & Radiol Sci, Ann Arbor, MI 48109 USA.		Dublyansky, Yuri/AAM-6110-2020	Dublyansky, Yuri/0000-0003-1433-9999; Ewing, Rodney/0000-0001-9472-4031				ABRAHAM S, 2002, COMMUNICATION   0214; BUSH GW, 2002, COMMUNICATION   0214; CAMPBELL K, IN PRESS J CONTAM HY; Connor CB, 2000, J GEOPHYS RES-SOL EA, V105, P417, DOI 10.1029/1999JB900353; Government Accountability Office, 2001, GAO02191; Jensen KA, 2001, GEOL SOC AM BULL, V113, P32; JOHNSON LH, 1994, MRS BULL, V19, P24, DOI 10.1557/S088376940004865X; Kersting AB, 1999, NATURE, V397, P56, DOI 10.1038/16231; MESERVE RA, 2001, COMMUNICATION   0918; Metlay D., 2000, PREDICTION SCI DECIS; SAGUES AA, 1999, MAT RES SOC P, V845, P845; Vaniman DT, 2001, GEOCHIM COSMOCHIM AC, V65, P3409, DOI 10.1016/S0016-7037(01)00682-2; WRONKIEWICZ DJ, 1992, J NUCL MATER, V190, P107, DOI 10.1016/0022-3115(92)90081-U	13	25	27	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					659	660		10.1126/science.1071886	http://dx.doi.org/10.1126/science.1071886			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976429				2022-12-28	WOS:000175281700027
J	Strohman, R				Strohman, R			Maneuvering in the complex path from genotype to phenotype	SCIENCE			English	Editorial Material							ALZHEIMERS; DISEASE	Human disease phenotypes are controlled not only by genes but by [awful self-organizing networks that display system-wide dynamics. These networks range from metabolic pathways to signaling pathways that regulate hormone action. When perturbed, networks alter their output of matter and energy which, depending on the environmental context, can produce either a pathological or a normal phenotype. Study of the dynamics of these networks by approaches such as metabolic control analysis may provide new insights into the pathogenesis and treatment of complex diseases.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Strohman, R (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall 3206, Berkeley, CA 94720 USA.							Cahill G F Jr, 1970, N Engl J Med, V282, P668, DOI 10.1056/NEJM197003052821026; Chong L, 2002, SCIENCE, V295, P1661, DOI 10.1126/science.295.5560.1661; Fell D., 1997, UNDERSTANDING CONTRO; FOXKELLER E, 2001, CENTURY GENE; Garber K, 2002, NAT BIOTECHNOL, V20, P207, DOI 10.1038/nbt0302-207b; HORROBIN D, 2002, NAT BIOTECHNOL, V19, P1099; Hoshi M, 1997, J BIOL CHEM, V272, P2038, DOI 10.1074/jbc.272.4.2038; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; KASHIWAYA Y, 1994, J BIOL CHEM, V269, P25502; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; KUHN TS, 1996, STRUCTURE SCI REVOLU, pCH8; LARDY HA, 1945, ARCH BIOCHEM, V6, P41; Lewontin R, 2000, TRIPLE HELIX; PATTEE HH, 2000, DOWNWARD CAUSATION, P63; POLANYI M, 1968, SCIENCE, V160, P1308, DOI 10.1126/science.160.3834.1308; Riddihough G, 2001, SCIENCE, V293, P1063, DOI 10.1126/science.293.5532.1063; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SATO K, 1995, FASEB J, V9, P651, DOI 10.1096/fasebj.9.8.7768357; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194; VEECH R, COMMUNICATION; Veech RL, 2001, IUBMB LIFE, V51, P241; Weatherall DJ, 2001, NAT REV GENET, V2, P245, DOI 10.1038/35066048; Zhang QH, 2002, SCIENCE, V295, P1895	23	143	146	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					701	703		10.1126/science.1070534	http://dx.doi.org/10.1126/science.1070534			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976445				2022-12-28	WOS:000175281700044
J	Yaffe, K; Fox, P; Newcomer, R; Sands, L; Lindquist, K; Dane, K; Covinsky, KE				Yaffe, K; Fox, P; Newcomer, R; Sands, L; Lindquist, K; Dane, K; Covinsky, KE			Patient and Caregiver characteristics and nursing home placement in patients with dementia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ALZHEIMERS-DISEASE DEMONSTRATION; INSTITUTIONALIZATION; PREDICTORS; CARE; TIME; INTERVENTION; ETHNICITY; ADMISSION; BURDEN; DEATH	Context The decision to institutionalize a patient with dementia is complex and is based on patient and caregiver characteristics and the sociocultural context of patients and caregivers. Most studies have determined predictors of nursing home placement primarily according to patient or caregiver characteristics alone. Objective To develop and validate a prognostic model to determine the comprehensive predictors of placement among an ethnically diverse population of patients with dementia. Design, Setting, and Participants The Medicare Alzheimer's Disease Demonstration and Evaluation study, a prospective study at 8 sites in the United States, with enrollment between December 1989 and December 1994 of 5788 community-living persons with advanced dementia. Main Outcome Measures Time to nursing home placement throughout a 36-month follow-up period, assessed by interview and review of Medicare records, and its association with patient and caregiver characteristics, obtained by interview at enrollment. Results Patients were divided into a development (n=3859) and validation (n=1929) cohort. In the development cohort, the Kaplan-Meier estimates of nursing home placement throughout 1, 2, and 3 years were 22%, 40%, and 52%, respectively. After multivariate adjustment, patient characteristics that were associated with nursing home placement were as follows: black ethnicity (hazard ratio, 0.60; 95% confidence interval [CI], 0.48-0.74), Hispanic ethnicity (HR, 0.40; 95% Cl, 0.28-0.56) (both ethnicities were inversely associated with placement), living alone (HR, 1.74; 95% Cl, 1.49-2.02), 1 or more dependencies in activities of daily living (HR, 1.38; 95% Cl, 1.20-1.60), high cognitive impairment (for Mini-Mental Status Examination score less than or equal to20: HR, 1.52; 95% Cl, 1.33-1.73), and 1 or more difficult behaviors (HR, 1.30; 95% Cl, 1.11-1.52). Caregiver characteristics associated with patient placement were age 65 to 74 years (HR, 1.17; 95% Cl, 1.01-1.37), age 75 years or older (HR, 1.55; 95% Cl, 1.31-1.84), and high Zarit Burden Scale score (for highest quartile: HR, 1.73; 95% Cl, 1.49-2.00). Patients were assigned to quartiles of risk based on this model. In the development cohort, patients in the first, second, third, and fourth quartile had a 25%, 42%, 64%, and 91% rate of nursing home placement at 3 years, respectively. In the validation cohort, the respective rates were 21%, 50%, 64%, and 89%. The C statistic for 3-year nursing home placement was 0.66 in the development cohort and 0.63 in the validation cohort. Conclusions Patient and caregiver characteristics are both important determinants of long-term care placement for patients with dementia. Interventions directed at delaying placement, such as reduction of caregiver burden or difficult patient behaviors, need to take into account the patient and caregiver as a unit.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94121 USA; Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA 94121 USA; San Francisco VA Med Ctr, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center	Yaffe, K (corresponding author), Univ Calif San Francisco, Dept Psychiat, Box 111G,4150 Clement St, San Francisco, CA 94121 USA.	kyaffe@itsa.ucsf.edu	Sands, Laura P/E-8919-2015	Sands, Laura P/0000-0003-2446-4486; Lindquist, Karla/0000-0002-1971-2273	NATIONAL INSTITUTE ON AGING [K23AG000888] Funding Source: NIH RePORTER; NIA NIH HHS [K23-AG00888] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BRODATY H, 1989, BMJ-BRIT MED J, V299, P1375, DOI 10.1136/bmj.299.6712.1375; Butler R, 1995, ADAPTATIONS AGING, P289; COLERICK EJ, 1986, J AM GERIATR SOC, V34, P493, DOI 10.1111/j.1532-5415.1986.tb04239.x; Covinsky KE, 2001, J GERONTOL A-BIOL, V56, pM707, DOI 10.1093/gerona/56.11.M707; Cummings JL, 1999, NEUROLOGY, V53, P899, DOI 10.1212/WNL.53.5.899; FALCONE D, 1994, J HEALTH POLIT POLIC, V19, P583, DOI 10.1215/03616878-19-3-583; Fisher L, 1999, GERONTOLOGIST, V39, P677, DOI 10.1093/geront/39.6.677; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fox P, 2000, ALZ DIS ASSOC DIS, V14, P87, DOI 10.1097/00002093-200004000-00006; Heyman A, 1997, NEUROLOGY, V48, P1304, DOI 10.1212/WNL.48.5.1304; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; KEMPER P, 1992, HEALTH SERV RES, V27, P421; Knopman D, 1996, NEUROLOGY, V47, P166, DOI 10.1212/WNL.47.1.166; Knopman DS, 1999, NEUROLOGY, V52, P714, DOI 10.1212/WNL.52.4.714; KNOPMAN DS, 1988, J AM GERIATR SOC, V36, P108, DOI 10.1111/j.1532-5415.1988.tb01778.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Leon J, 1998, HEALTH AFFAIR, V17, P206, DOI 10.1377/hlthaff.17.6.206; Michel JP, 2001, AGING CLIN EXP RES, V13, P255, DOI 10.1007/BF03351484; Miller SC, 1998, J GERONTOL B-PSYCHOL, V53, pS341, DOI 10.1093/geronb/53B.6.S341; MITTELMAN MS, 1993, GERONTOLOGIST, V33, P730, DOI 10.1093/geront/33.6.730; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; MorrowHowell N, 1996, HEALTH SOC WORK, V21, P131, DOI 10.1093/hsw/21.2.131; Newcomer R, 1999, HEALTH SERV RES, V34, P669; Newcomer R, 1999, HEALTH SERV RES, V34, P645; RICE DP, 1993, HEALTH AFFAIR, V12, P164, DOI 10.1377/hlthaff.12.2.164; SALIVE ME, 1993, AM J PUBLIC HEALTH, V83, P1765, DOI 10.2105/AJPH.83.12.1765; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SEVERSON MA, 1994, J AM GERIATR SOC, V42, P181; SHEIKH J I, 1986, Clinical Gerontologist, V5, P165; Smith GE, 2000, J AM GERIATR SOC, V48, P519, DOI 10.1111/j.1532-5415.2000.tb04998.x; STEELE C, 1990, AM J PSYCHIAT, V147, P1049; Stern Y, 1997, JAMA-J AM MED ASSOC, V277, P806, DOI 10.1001/jama.277.10.806; Wallace SP, 1998, J GERONTOL B-PSYCHOL, V53, pS104, DOI 10.1093/geronb/53B.2.S104; Walter LC, 2001, JAMA-J AM MED ASSOC, V285, P2987, DOI 10.1001/jama.285.23.2987; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	36	589	603	1	43	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2002	287	16					2090	2097		10.1001/jama.287.16.2090	http://dx.doi.org/10.1001/jama.287.16.2090			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	542ZK	11966383				2022-12-28	WOS:000175075700026
J	Sharma, DC				Sharma, DC			Indian groups demand ban on asbestos	LANCET			English	News Item																			0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1414	1414		10.1016/S0140-6736(02)08400-3	http://dx.doi.org/10.1016/S0140-6736(02)08400-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978351				2022-12-28	WOS:000175076200026
J	Struthers, AD; Morris, AD				Struthers, AD; Morris, AD			Screening for and treating left-ventricular abnormalities in diabetes mellitus: a new way of reducing cardiac deaths	LANCET			English	Editorial Material							ESSENTIAL-HYPERTENSION; MYOCARDIAL-INFARCTION; NATRIURETIC PEPTIDES; HEART-DISEASE; CARDIOMYOPATHY; FRAMINGHAM; SURVIVAL; FAILURE; IMPACT; MASS		Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Med, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Struthers, AD (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Dundee DD1 9SY, Scotland.		Morris, Andrew D/C-2837-2009	Struthers, Allan/0000-0002-2926-2528				ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; Butler R, 1998, EUR HEART J, V19, P1617, DOI 10.1053/euhj.1998.1284; Cowie MR, 1997, LANCET, V350, P1349, DOI 10.1016/S0140-6736(97)06031-5; Devereux RB, 2000, CIRCULATION, V101, P2271, DOI 10.1161/01.CIR.101.19.2271; DORTIMER AC, 1978, CIRCULATION, V57, P133, DOI 10.1161/01.CIR.57.1.133; Francis G, 2001, HEART, V85, P247, DOI 10.1136/heart.85.3.247; Fruhwald FM, 1999, EUR HEART J, V20, P1415, DOI 10.1053/euhj.1999.1633; GALDERISI M, 1991, AM J CARDIOL, V68, P85, DOI 10.1016/0002-9149(91)90716-X; GARCIA MJ, 1974, DIABETES, V23, P105, DOI 10.2337/diab.23.2.105; Gerstein HC, 2000, LANCET, V355, P253; KANNEL WB, 1974, AM J CARDIOL, V34, P29, DOI 10.1016/0002-9149(74)90089-7; KOHNO M, 1992, AM J MED, V92, P29, DOI 10.1016/0002-9343(92)90011-Y; Lindholm LH, 2002, LANCET, V359, P1004, DOI 10.1016/S0140-6736(02)08090-X; Mak KH, 2000, J AM COLL CARDIOL, V35, P563, DOI 10.1016/S0735-1097(99)00628-2; Nishikimi T, 1996, HYPERTENSION, V28, P22, DOI 10.1161/01.HYP.28.1.22; Phillips RA, 1998, J CLIN ENDOCR METAB, V83, P4284, DOI 10.1210/jc.83.12.4284; RUTLER S, 1972, AM J CARDIOL, V30, P595; Sandler D.A., 2000, BR J CARDIOL, V7, P94; VANHOEVEN KH, 1989, CLIN CARDIOL, V12, P600, DOI 10.1002/clc.4960121009; Verdecchia P, 1998, CIRCULATION, V97, P48, DOI 10.1161/01.CIR.97.1.48; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44	21	116	118	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1430	1432		10.1016/S0140-6736(02)08358-7	http://dx.doi.org/10.1016/S0140-6736(02)08358-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978359				2022-12-28	WOS:000175076200033
J	Yazdanbakhsh, M; Kremsner, PG; van Ree, R				Yazdanbakhsh, M; Kremsner, PG; van Ree, R			Immunology - Allergy, parasites, and the hygiene hypothesis	SCIENCE			English	Review							GROWTH-FACTOR-BETA; ANTHELMINTIC TREATMENT; INVERSE ASSOCIATION; HELMINTH INFECTION; DENDRITIC CELLS; HAY-FEVER; IGE; ATOPY; ASTHMA; RESPONSES	The increase of allergic diseases in the industrialized world has often been explained by a decline in infections during childhood. The immunological explanation has been put into the context of the functional T cell subsets known as T helper 1 (T(H)1) and T helper 2 (T(H)2) that display polarized cytokine profiles. It has been argued that bacterial, and viral infections during early life direct the maturing immune system toward T(H)1, which counterbalance proallergic responses of T(H)2 cells. Thus, a reduction in the overall microbial burden will result in weak T(H)1 imprinting and unrestrained T(H)2 responses that allow an increase in allergy. This notion is contradicted by observations that the prevalence of T(H)1-autoimmune diseases is also increasing and that T(H)2-skewed parasitic worm (helminth) infections are not associated with allergy. More recently, elevations of anti-inflammatory cytokines, such as interieukin-10, that occur during tong-term helminth infections have been shown to be inversely correlated with allergy. The induction of a robust anti-inflammatory regulatory network by persistent immune challenge offers a unifying explanation for the observed inverse association of many infections with allergic disorders.	Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands; Univ Tubingen, Inst Trop Med, Dept Parasitol, D-72074 Tubingen, Germany; Albert Schweitzer Hosp, Res Unit, Lambarene, Gabon; CLB, Immunopathol, Sanquin Res, Dept Allergy, Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Eberhard Karls University of Tubingen	Yazdanbakhsh, M (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, Leiden, Netherlands.	M.Yazdanbakhsh@LUMC.NL	Yazdanbakhsh, Maria/AAI-3996-2020	Yazdanbakhsh, Maria/0000-0002-7666-1441				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; [Anonymous], 1976, LANCET, V1, P894; Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Buijs J, 1997, EUR RESPIR J, V10, P1467, DOI 10.1183/09031936.97.10071467; Cooper PJ, 1998, J INFECT DIS, V178, P1133, DOI 10.1086/515661; Dai WJ, 1999, IMMUNOLOGY, V97, P107, DOI 10.1046/j.1365-2567.1999.00723.x; de Jong EC, 2002, J IMMUNOL, V168, P1704, DOI 10.4049/jimmunol.168.4.1704; Doetze A, 2000, INT IMMUNOL, V12, P623, DOI 10.1093/intimm/12.5.623; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Elias D, 2001, CLIN EXP IMMUNOL, V123, P219, DOI 10.1046/j.1365-2249.2001.01446.x; Faniran AO, 1999, THORAX, V54, P606, DOI 10.1136/thx.54.7.606; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GREENWOOD BM, 1972, LANCET, V1, P169; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Herfarth H, 2002, GUT, V50, P146, DOI 10.1136/gut.50.2.146; Hirsch CS, 1996, P NATL ACAD SCI USA, V93, P3193, DOI 10.1073/pnas.93.8.3193; Holt PG, 1999, NATURE, V402, pB12; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; JARRETT E, 1980, NATURE, V283, P302, DOI 10.1038/283302a0; Jeannin P, 1998, J IMMUNOL, V160, P3555; King CL, 1996, J IMMUNOL, V156, P4715; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; LARRICK JW, 1983, J ALLERGY CLIN IMMUN, V71, P184, DOI 10.1016/0091-6749(83)90097-0; Lell B, 2001, WIEN KLIN WOCHENSCHR, V113, P927; Loveless MH, 1943, J IMMUNOL, V47, P165; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50, DOI 10.1164/ajrccm.156.1.9606081; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MAHANTY S, 1995, PARASITE IMMUNOL, V17, P385, DOI 10.1111/j.1365-3024.1995.tb00906.x; Malhotra I, 1999, J IMMUNOL, V162, P6843; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; MASTERS S, 1985, EPIDEMIOL REV, V7, P49, DOI 10.1093/oxfordjournals.epirev.a036285; Matricardi PM, 2000, BMJ-BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PRENNER C, 1992, BIOCHEM J, V284, P377, DOI 10.1042/bj2840377; Redpath S, 2001, TRENDS MICROBIOL, V9, P86, DOI 10.1016/S0966-842X(00)01919-3; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rook GAW, 2000, IMMUNOL TODAY, V21, P503, DOI 10.1016/S0167-5699(00)01700-X; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; TURTON JA, 1976, LANCET, V2, P686; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van Die I, 1999, FEBS LETT, V463, P189, DOI 10.1016/S0014-5793(99)01508-2; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; van Ree R, 1999, J ALLERGY CLIN IMMUN, V103, P1000, DOI 10.1016/S0091-6749(99)70169-7; VANDENBIGGELAAR AH, UNPUB; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187, DOI 10.1046/j.1365-2222.2000.00801.x; Wakkach A, 2000, EUR CYTOKINE NETW, V11, P153; Wohlleben G, 2001, TRENDS IMMUNOL, V22, P618, DOI 10.1016/S1471-4906(01)02055-5; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	67	1076	1131	3	404	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	2002	296	5567					490	494		10.1126/science.296.5567.490	http://dx.doi.org/10.1126/science.296.5567.490			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964470				2022-12-28	WOS:000175179400035
J	Herzinger, T; Schorling, S; Rocken, J; Rocken, M				Herzinger, T; Schorling, S; Rocken, J; Rocken, M			A hoarse voice	LANCET			English	Article							DERMATOMYOSITIS		Univ Munich, Dept Dermatol & Allergol, D-80337 Munich, Germany; Municipal Hosp Schwabing, Dept Otolaryngol, Munich, Germany	University of Munich	Rocken, M (corresponding author), Univ Munich, Dept Dermatol & Allergol, D-80337 Munich, Germany.			Rocken, Martin/0000-0003-3795-7001				Callen JP, 2000, LANCET, V355, P53, DOI 10.1016/S0140-6736(99)05157-0; Marie I, 1999, J RHEUMATOL, V26, P2706; Messer G, 1997, STRATEGIES FOR IMMUNOINTERVENTIONS IN DERMATOLOGY, P147; Pachman LM, 1998, J RHEUMATOL, V25, P1198; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484	5	3	3	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1308	1308		10.1016/S0140-6736(02)08271-5	http://dx.doi.org/10.1016/S0140-6736(02)08271-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965277				2022-12-28	WOS:000174989700014
J	Lewis, JA; Jonsson, B; Kreutz, G; Sampaio, C; van Zwieten-Boot, B				Lewis, JA; Jonsson, B; Kreutz, G; Sampaio, C; van Zwieten-Boot, B			Placebo-control led trials and the Declaration of Helsinki	LANCET			English	Article								A revised version of the Declaration of Helsinki, issued in October, 2000, remains a vital expression of medical ethics, and deserves unanimous support. A strict interpretation of the declaration seems to rule out clinical trials that use a placebo control group whenever licensed therapeutic methods already exist, preferring active controls. Although the efficacy of some new medicines can be satisfactorily established without the use of a placebo, for others the judicious use of placebo remains essential to establish their effectiveness.	Hatch Green Cottage, Canterbury CT4 7LP, Kent, England; Med Prod Agcy, Uppsala, Sweden; Bundesinst Arzneimettel & Med Prod, Bonn, Germany; Hosp Santa Maria, Lisbon Sch Med, Lisbon, Portugal; Med Evaluat Board, The Hague, Netherlands	Medical Products Agency; Universidade de Lisboa; Hospital Santa Maria	Lewis, JA (corresponding author), Hatch Green Cottage, Chartham Hatch, Canterbury CT4 7LP, Kent, England.	johnlewis@clinitrial.co.uk						Christie B, 2000, BRIT MED J, V321, P913, DOI 10.1136/bmj.321.7266.913; *COMM PROPR MED PR, 2002, EMEA CPMP POS STAT U; Committee for Proprietary Medicinal Products, 2000, POINTS CONS SWITCH S; Ellenberg SS, 2000, ANN INTERN MED, V133, P464, DOI 10.7326/0003-4819-133-6-200009190-00015; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Koski G, 2001, NEW ENGL J MED, V345, P136, DOI 10.1056/NEJM200107123450211; Moreno JD, 2001, ANN NEUROL, V49, P558; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Shapiro HT, 2001, NEW ENGL J MED, V345, P139, DOI 10.1056/NEJM200107123450212; Siegel JP, 2000, AM HEART J, V139, pS166, DOI 10.1016/S0002-8703(00)90066-8; Storosum JG, 2001, EUR NEUROPSYCHOPHARM, V11, P173, DOI 10.1016/S0924-977X(01)00083-9; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1997, E6 ICH EMEA; 1998, E9 ICH EMEA; 2000, E10 ICH EMEA	16	54	57	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	2002	359	9314					1337	1340		10.1016/S0140-6736(02)08277-6	http://dx.doi.org/10.1016/S0140-6736(02)08277-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965296				2022-12-28	WOS:000174989700032
J	Padture, NP; Gell, M; Jordan, EH				Padture, NP; Gell, M; Jordan, EH			Materials science - Thermal barrier coatings for gas-turbine engine applications	SCIENCE			English	Review							FAILURE MECHANISMS; OXIDE SCALES; STRESS; OXIDATION; LIFE; SPALLATION; CONDUCTIVITY; DURABILITY; STRAIN; MODEL	Hundreds of different types of coatings are used to protect a variety of structural engineering materials from corrosion, wear, and erosion, and to provide Lubrication and thermal insulation. Of all these, thermal barrier coatings (TBCs) have the most complex structure and must operate in the most demanding high-temperature environment of aircraft and Industrial gas-turbine engines. TBCs, which comprise metal and ceramic multilayers, insulate turbine and combustor engine components from the hot gas stream, and improve the durability and energy efficiency of these engines. Improvements in TBCs will require a better understanding of the complex changes In their structure and properties that occur under operating conditions that lead to their failure. The structure, properties, and failure mechanisms of TBCs are herein reviewed, together with a discussion of current Limitations and future opportunities.	Univ Connecticut, Dept Met & Mat Engn, Storrs, CT 06269 USA; Univ Connecticut, Inst Mat Sci, Dept Mech Engn, Storrs, CT 06269 USA	University of Connecticut; University of Connecticut	Padture, NP (corresponding author), Univ Connecticut, Dept Met & Mat Engn, Storrs, CT 06269 USA.	nitin.padture@uconn.edu	Padture, Nitin P/A-9746-2009	Padture, Nitin P/0000-0001-6622-8559				Ambrico JM, 2001, ACTA MATER, V49, P1577, DOI 10.1016/S1359-6454(01)00059-3; BRINDLEY WJ, 1990, SURF COAT TECH, V43-4, P446, DOI 10.1016/0257-8972(90)90096-U; CHANG GC, 1987, SURF COAT TECH, V30, P13, DOI 10.1016/0257-8972(87)90004-1; Cheng J, 1998, ACTA MATER, V46, P5839, DOI 10.1016/S1359-6454(98)00230-4; Clarke DR, 1999, ACTA MATER, V47, P1749, DOI 10.1016/S1359-6454(99)00078-6; CRUSE TA, 1988, J ENG GAS TURB POWER, V110, P610, DOI 10.1115/1.3240179; Dorvaux J.-M., 1998, P 85 M ADV GROUP AER, P13; Evans AG, 2001, PROG MATER SCI, V46, P505, DOI 10.1016/S0079-6425(00)00020-7; EVANS AG, 1984, INT J SOLIDS STRUCT, V20, P455, DOI 10.1016/0020-7683(84)90012-X; Evans AG, 2001, PROG MATER SCI, V46, P249, DOI 10.1016/S0079-6425(00)00007-4; Fox AC, 1998, THERMAL SPRAY, VOLS 1 AND 2, P1589; Freborg AM, 1998, MAT SCI ENG A-STRUCT, V245, P182, DOI 10.1016/S0921-5093(97)00849-6; Gell M, 1999, SURF COAT TECH, V120, P53, DOI 10.1016/S0257-8972(99)00338-2; GELL M, 1987, JOM-J MIN MET MAT S, V39, P11, DOI 10.1007/BF03258033; Gong XY, 1998, OXID MET, V50, P355, DOI 10.1023/A:1018848607100; GRAY DM, 2001, Patent No. 6180184; HASSELMAN DPH, 1987, AM CERAM SOC BULL, V66, P799; Hsueh C. H., 1999, Materials Science Forum, V308-311, P442, DOI 10.4028/www.scientific.net/MSF.308-311.442; Hsueh CH, 2000, SCRIPTA MATER, V42, P781, DOI 10.1016/S1359-6462(99)00430-3; Jones R, 1996, METALLURGICAL CERAMI, P194; Kaden U, 1999, ELEVATED TEMPERATURE COATINGS: SCIENCE AND TECHNOLOGY III, P27; Karlsson AM, 2001, ACTA MATER, V49, P1793, DOI 10.1016/S1359-6454(01)00073-8; Kofstad P., 1988, HIGH TEMPERATURE COR, DOI DOI 10.1002/CRAT.2170240408; LEE EY, 1989, MAT SCI ENG A-STRUCT, V120, P467, DOI 10.1016/0921-5093(89)90803-4; Leyens C, 2001, Z METALLKD, V92, P762; Lipkin DM, 1996, OXID MET, V45, P267, DOI 10.1007/BF01046985; Maloney M., 2000, US Pat., Patent No. 6117560; MEIER SM, 1991, JOM-J MIN MET MAT S, V43, P50, DOI 10.1007/BF03220164; MEIER SM, 1992, J ENG GAS TURB POWER, V114, P521; MILLER RA, 1987, SURF COAT TECH, V30, P1, DOI 10.1016/0257-8972(87)90003-X; MILLER RA, 1987, J ENG GAS TURB POWER, V109, P448, DOI 10.1115/1.3240062; MILLER RA, 1982, THIN SOLID FILMS, V95, P265, DOI 10.1016/0040-6090(82)90019-0; Mumm DR, 2000, ACTA MATER, V48, P1815, DOI 10.1016/S1359-6454(99)00473-5; Padture NP, 2001, ACTA MATER, V49, P2251, DOI 10.1016/S1359-6454(01)00130-6; PADTURE NP, 2000, Patent No. 6015630; Peters M, 1997, MATERIALWISS WERKST, V28, P357, DOI 10.1002/mawe.19970280807; Pint BA, 2000, SUPERALLOYS 2000, P629; Rabiei A, 2000, ACTA MATER, V48, P3963, DOI 10.1016/S1359-6454(00)00171-3; Schlichting KW, 2001, J MATER SCI, V36, P3003, DOI 10.1023/A:1017970924312; Schlichting KW, 2000, MAT SCI ENG A-STRUCT, V291, P68, DOI 10.1016/S0921-5093(00)00973-4; SCHLICHTING KW, UNPUB MAT SCI ENG A; Schumann E, 2000, OXID MET, V53, P259, DOI 10.1023/A:1004585003083; SMEGGIL JG, 1987, MATER SCI ENG, V87, P261, DOI 10.1016/0025-5416(87)90387-9; SMIALEK JL, 1994, THIN SOLID FILMS, V253, P285, DOI 10.1016/0040-6090(94)90335-2; Sohn YH, 2001, SURF COAT TECH, V146, P70, DOI 10.1016/S0257-8972(01)01478-5; Stiger MJ, 1999, Z METALLKD, V90, P1069; STOTT FH, 1987, MATER SCI ENG, V87, P267, DOI 10.1016/0025-5416(87)90388-0; STRANGMAN TE, 1985, THIN SOLID FILMS, V127, P93, DOI 10.1016/0040-6090(85)90215-9; STRANGMAN TE, 1988, Patent No. 4743514; SUBBARAO EC, 1984, SCI TECHNOLOGY ZIRCO, V3, P1; SUBRAMANIAN R, 2001, Patent No. 6258467; Vaidyanathan K, 2000, SURF COAT TECH, V133, P28, DOI 10.1016/S0257-8972(00)00891-4; Wright PK, 1998, MAT SCI ENG A-STRUCT, V245, P191, DOI 10.1016/S0921-5093(97)00850-2; Zhu DM, 1998, SURF COAT TECH, V108, P114, DOI 10.1016/S0257-8972(98)00669-0; [No title captured]; [No title captured]	56	3129	3388	82	1942	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	2002	296	5566					280	284		10.1126/science.1068609	http://dx.doi.org/10.1126/science.1068609			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951028				2022-12-28	WOS:000175000300039
J	Venis, S; Horton, R				Venis, S; Horton, R			Violence against women: a global burden	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Venis, S (corresponding author), Lancet, London NW1 7BY, England.							ASHRAF N, 2002, GULF NEWS       0318; Cloutier S, 2002, J EPIDEMIOL COMMUN H, V56, P265, DOI 10.1136/jech.56.4.265; Kanji N., 2001, WHAT DOES FEMINISATI; Schuler S R, 1998, Dev Pract, V8, P148, DOI 10.1080/09614529853774; *WHO DEP IND VIOL, 1997, WHO VIOL WOM INF PAC; *WORLD BANK, 1993, WORLD DEV REP 1993 I	6	15	15	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1172	1172		10.1016/S0140-6736(02)08251-X	http://dx.doi.org/10.1016/S0140-6736(02)08251-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955533				2022-12-28	WOS:000174846300005
J	Wright, JR				Wright, JR			From ugly fish to conquer death: J J R Macleod's fish insulin research, 1922-24	LANCET			English	Review								Fish insulin research had a very short heyday. Throughout most of 1922, production of insulin from livestock was difficult, erratic, and expensive. Although fish insulin was easy to extract and seemed to be a brilliant and logical solution to the shortage of insulin, collection of fish islets was a logistical nightmare. By the end of 1922, a scientist at the pharmaceutical company Ell Lilly in Indianapolis, IN, USA had developed a way to concentrate and purify insulin by isoelectric precipitation. As a result of this breakthrough, the scales began to tip heavily in favour of livestock insulin. Nevertheless, research on commercial production of fish insulin continued for another 18 months but was finally abandoned.	IWK Hlth Ctr, Dept Pathol, Halifax, NS B3H 1V7, Canada; IWK Hlth Ctr, Dept Surg, Halifax, NS B3H 1V7, Canada; IWK Hlth Ctr, Dept Biomed Engn, Halifax, NS B3H 1V7, Canada; Dalhousie Univ, Halifax, NS, Canada	Dalhousie University; Dalhousie University; Dalhousie University; Dalhousie University	Wright, JR (corresponding author), IWK Hlth Ctr, Dept Pathol, 5850 Univ Ave, Halifax, NS B3H 1V7, Canada.							BANTING FG, 1925, Patent No. 209766; BLISS M, 1989, Q J EXP PHYSIOL CMS, V74, P87, DOI 10.1113/expphysiol.1989.sp003266; Bliss M., 1982, DISCOVERY INSULIN; Dale HH, 1923, LANCET, V1, P989; Diamare V, 1899, INT MONATSSCHR ANAT, V16, P155; Dudley HW, 1924, BIOCHEM J, V18, P665, DOI 10.1042/bj0180665; GIFFEN PJ, 1923, HALIFAX SUNDAY  0805; HACHEY HB, 1965, MANUSCRIPT REPORT SE, V843; Jackson S., 1922, Journal of Metabolic Research Morristown, V2, P141; Johnstone Kenneth, 1977, AQUATIC EXPLORERS HI; KROGH, 1922, COMMUNICATION   1216; LAGUESSE E, 1895, REV BIOL NORD FRANCE, V7, P343; LAGUESSE E, 1893, COMPT REND SOC BIOL, V45, P819; MACLEAN, 1961, COMMUNICATION   0705; MACLEAN, 1961, COMMUNICATION   0420; MACLEOD JJR, 2002, NOB LECT MAY 26 1925; Macleod JJR, 1922, J METAB RES, V2, P149; MASSARI G, 1898, REND R ACAD LINCEI R, V7, P134; McCormick NA, 1925, P R SOC LOND B-CONTA, V98, P1, DOI 10.1098/rspb.1925.0020; MCCORMICK NA, 1924, B BIOL BOARD CANADA, P3; MCCORMICK NA, 1923, P AM SOC BIOL CHEM, V18, P29; MCCORMICK NA, 1924, CONTRIBUTIONS CANADI, V2, P117; MURNAGHAN JH, 1992, B HIST MED, V66, P440; NAGASAWA K, 1968, J ASSOC OFF ANA CHEM, V51, P326; NOBLE, 1961, COMMUNICATION   0413; Rennie J, 1904, Q J MICROSC SCI, V48, P379; Rennie J, 1907, BIOCHEM J, V2, P7, DOI 10.1042/bj0020007; Rennie J, 1903, J ANAT PHYSIOL, V37, P375; RIGBY MS, 1958, MANUSCRIPT REPORT SE, V660; Trippel EA, 1999, CAN J FISH AQUAT SCI, V56, P2495, DOI 10.1139/cjfas-56-12-2495; WILLS MR, 1993, ANN CLIN LAB SCI, V23, P1; WITTERS LA, 1977, AM J MED, V63, P703, DOI 10.1016/0002-9343(77)90155-3; 1937, NOVA SCOTIA MED B, V16, P30	33	13	14	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1238	1242		10.1016/S0140-6736(02)08222-3	http://dx.doi.org/10.1016/S0140-6736(02)08222-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955558				2022-12-28	WOS:000174846300030
J	Schlissel, MS				Schlissel, MS			Does Artemis end the hunt for the hairpin-opening activity in V(D)J recombination?	CELL			English	Review							RAG PROTEINS; DNA; CLEAVAGE; MUTANT; CELLS	When complexed with the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs), the recently discovered dsDNA break repair protein named Artemis acquires the ability to open hairpin DNA molecules in vitro. Both genetic and biochemical data point toward a physiological role for this complex as the elusive hairpin-opening activity in V(D)J recombination.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Schlissel, MS (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Immunol, Berkeley, CA 94720 USA.	mss@uclink4.berkeley.edu						Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Leu TMJ, 1997, IMMUNITY, V7, P303, DOI 10.1016/S1074-7613(00)80532-4; Lin JM, 1999, MOL IMMUNOL, V36, P1263, DOI 10.1016/S0161-5890(99)00099-1; Livak F, 1997, J MOL BIOL, V267, P1, DOI 10.1006/jmbi.1996.0834; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Qiu JX, 2001, MOL CELL, V7, P77, DOI 10.1016/S1097-2765(01)00156-3; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; Schlissel MS, 1998, MOL CELL BIOL, V18, P2029, DOI 10.1128/MCB.18.4.2029; Schultz HY, 2001, MOL CELL, V7, P65, DOI 10.1016/S1097-2765(01)00155-1; Sekiguchi J, 2001, MOL CELL, V8, P1383, DOI 10.1016/S1097-2765(01)00423-3; Shockett PE, 1999, MOL CELL BIOL, V19, P4159; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; WeisGarcia F, 1997, MOL CELL BIOL, V17, P6379, DOI 10.1128/MCB.17.11.6379	21	32	32	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	2002	109	1					1	4		10.1016/S0092-8674(02)00694-3	http://dx.doi.org/10.1016/S0092-8674(02)00694-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955439	Bronze			2022-12-28	WOS:000174888300001
J	Papavasiliou, FN; Schatz, DG				Papavasiliou, FN; Schatz, DG			Somatic hypermutation of immunoglobulin genes: Merging mechanisms for genetic diversity	CELL			English	Review							CLASS-SWITCH RECOMBINATION; CYTIDINE DEAMINASE AID; STRAND-BREAK REPAIR; LIGHT-CHAIN GENES; MISMATCH REPAIR; CELL-CYCLE; B-CELLS; SACCHAROMYCES-CEREVISIAE; INTRON ENHANCER; VARIABLE GENES	Somatic hypermutation is critical for the generation of high-affinity antibodies and effective immune responses, but its molecular mechanism remains poorly understood. Recent studies have identified DNA strand lesions associated with the hypermutation process and suggested the involvement of specific repair molecules and pathways. Particularly exciting has been the discovery of a putative RNA editing enzyme, the activation-induced cytidine deaminase (AID), that is required for all immunoglobulin gene-specific modification reactions (somatic hypermutation, class switch recombination, and gene conversion). Parallels between these three reactions are considered in light of recent advances.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Rockefeller Univ, Lab Lymphocyte Biol, New York, NY 10021 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Rockefeller University; Yale University	Schatz, DG (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 310 Cedar St, New Haven, CT 06510 USA.		Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176				Arakawa H, 2002, SCIENCE, V295, P1301, DOI 10.1126/science.1067308; Bachl J, 1998, P NATL ACAD SCI USA, V95, P2396, DOI 10.1073/pnas.95.5.2396; Bachl J, 2001, J IMMUNOL, V166, P5051, DOI 10.4049/jimmunol.166.8.5051; Bemark M, 2000, J EXP MED, V192, P1509, DOI 10.1084/jem.192.10.1509; Bemark M, 2000, ONCOGENE, V19, P3404, DOI 10.1038/sj.onc.1203686; BERNARD O, 1978, CELL, V15, P1133, DOI 10.1016/0092-8674(78)90041-7; BETZ AG, 1994, CELL, V77, P239, DOI 10.1016/0092-8674(94)90316-6; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; Bross L, 2000, IMMUNITY, V13, P589, DOI 10.1016/S1074-7613(00)00059-5; BURNET F. M., 1957, AUSTRALIAN JOUR SCI, V20, P67; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Diaz M, 1998, IMMUNOL REV, V162, P13, DOI 10.1111/j.1600-065X.1998.tb01425.x; DUNNICK W, 1989, MOL CELL BIOL, V9, P1850, DOI 10.1128/MCB.9.5.1850; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; Ehrenstein MR, 1999, EMBO J, V18, P3484, DOI 10.1093/emboj/18.12.3484; Ehrenstein MR, 2001, P NATL ACAD SCI USA, V98, P14553, DOI 10.1073/pnas.241525998; Frey S, 1998, IMMUNITY, V9, P127, DOI 10.1016/S1074-7613(00)80594-4; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; Gearhart PJ, 2001, NAT REV IMMUNOL, V1, P187, DOI 10.1038/35105009; GOLDING GB, 1987, GENETICS, V115, P169; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; Goyenechea B, 1997, EMBO J, V16, P3987, DOI 10.1093/emboj/16.13.3987; GRIFFITHS GM, 1984, NATURE, V312, P271, DOI 10.1038/312271a0; Haber JE, 2001, NAT IMMUNOL, V2, P902, DOI 10.1038/ni1001-902; Harris RS, 2002, CURR BIOL, V12, P435, DOI 10.1016/S0960-9822(02)00717-0; Hendrickson EA, 1997, AM J HUM GENET, V61, P795, DOI 10.1086/514895; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Huang JR, 2002, NUCLEIC ACIDS RES, V30, P667, DOI 10.1093/nar/30.3.667; Jacobs H, 2001, CURR OPIN IMMUNOL, V13, P208, DOI 10.1016/S0952-7915(00)00206-5; Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1; Klix N, 1998, EUR J IMMUNOL, V28, P317, DOI 10.1002/(SICI)1521-4141(199801)28:01&lt;317::AID-IMMU317&gt;3.0.CO;2-S; Klotz EL, 1998, J IMMUNOL, V161, P782; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kong QZ, 1998, J IMMUNOL, V161, P294; Kong QZ, 2001, GENETICS, V158, P369; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Landsteiner K, 1936, SPECIFICITY SEROLOGI; LEBECQUE SG, 1990, J EXP MED, V172, P1717, DOI 10.1084/jem.172.6.1717; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LIN WC, 1995, IMMUNOL TODAY, V16, P279, DOI 10.1016/0167-5699(95)80182-0; MAIZELS N, 1995, CELL, V83, P9, DOI 10.1016/0092-8674(95)90227-9; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; MANIS JP, 2002, IN PRESS IMMUNITY, V16; Martin A, 2002, NATURE, V415, P802, DOI 10.1038/nature714; Michael N, 2002, IMMUNITY, V16, P123, DOI 10.1016/S1074-7613(02)00261-3; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; OBRIEN RL, 1987, NATURE, V326, P405, DOI 10.1038/326405a0; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; Oprea M, 2001, J IMMUNOL, V166, P892, DOI 10.4049/jimmunol.166.2.892; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; PAPAVASILIOU FN, 2002, IN PRESS J EXP MED; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Pinaud E, 2001, IMMUNITY, V15, P187, DOI 10.1016/S1074-7613(01)00181-9; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Rada C, 2001, EMBO J, V20, P4570, DOI 10.1093/emboj/20.16.4570; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Reynaud CA, 1999, IMMUNOL TODAY, V20, P522, DOI 10.1016/S0167-5699(99)01540-6; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; Rolink A, 1996, IMMUNITY, V5, P319, DOI 10.1016/S1074-7613(00)80258-7; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; Sale JE, 2001, NATURE, V412, P921, DOI 10.1038/35091100; Schrader CE, 2002, J EXP MED, V195, P367, DOI 10.1084/jem.20011877; Selsing E, 1996, Semin Immunol, V8, P151, DOI 10.1006/smim.1996.0019; Shapiro GS, 1999, J IMMUNOL, V163, P259; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Shen HM, 2001, INT IMMUNOL, V13, P665, DOI 10.1093/intimm/13.5.665; Siskind G W, 1969, Adv Immunol, V10, P1, DOI 10.1016/S0065-2776(08)60414-9; SISKIND GREGORY W., 1965, J IMMUNOL, V95, P436; Stavnezer J, 1996, ADV IMMUNOL, V61, P79, DOI 10.1016/S0065-2776(08)60866-4; Storb U, 1998, J EXP MED, V188, P689, DOI 10.1084/jem.188.4.689; Storb U, 1998, IMMUNOL REV, V162, P153; Sugawara N, 1997, P NATL ACAD SCI USA, V94, P9214, DOI 10.1073/pnas.94.17.9214; TALMAGE DW, 1957, ANNU REV MED, V8, P239, DOI 10.1146/annurev.me.08.020157.001323; Tian M, 2000, J BIOL CHEM, V275, P24163, DOI 10.1074/jbc.M003343200; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TumasBrundage K, 1997, J EXP MED, V185, P239, DOI 10.1084/jem.185.2.239; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0; Wiesendanger M, 2000, J EXP MED, V191, P579, DOI 10.1084/jem.191.3.579; Wilson PC, 1998, J EXP MED, V187, P59, DOI 10.1084/jem.187.1.59; Winter DB, 1998, IMMUNOL REV, V162, P89, DOI 10.1111/j.1600-065X.1998.tb01432.x; Winter DB, 1998, CURR TOP MICROBIOL, V229, P1; Wood RD, 1998, CURR BIOL, V8, pR757, DOI 10.1016/S0960-9822(07)00479-4; WU HY, 1995, SCAND J IMMUNOL, V42, P52, DOI 10.1111/j.1365-3083.1995.tb03625.x; YELAMOS J, 1995, NATURE, V376, P225	89	143	154	1	11	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR	2002	109			S			S35	S44		10.1016/S0092-8674(02)00706-7	http://dx.doi.org/10.1016/S0092-8674(02)00706-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	544UY	11983151	Bronze			2022-12-28	WOS:000175181100004
J	Oakeshott, P; Hay, P				Oakeshott, P; Hay, P			10-minute consultation - Genital herpes	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Sch Med, Dept Gen Practice, London SW17 0RE, England; St George Hosp, Sch Med, Dept Genitourinary Med, London SW17 0RE, England	St Georges University London; St Georges University London	Oakeshott, P (corresponding author), St George Hosp, Sch Med, Dept Gen Practice, London SW17 0RE, England.			Oakeshott, Pippa/0000-0003-2568-8211					0	0	0	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 4	2002	324	7345					1076	1076		10.1136/bmj.324.7345.1076	http://dx.doi.org/10.1136/bmj.324.7345.1076			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YY	11991914	Green Published			2022-12-28	WOS:000175476500022
J	Setou, M; Seog, DH; Tanaka, Y; Kanai, Y; Takei, Y; Kawagishi, M; Hirokawa, N				Setou, M; Seog, DH; Tanaka, Y; Kanai, Y; Takei, Y; Kawagishi, M; Hirokawa, N			Glutamate-receptor-interacting protein GRIP1 directly steers kinesin to dendrites	NATURE			English	Article							HEAVY-CHAIN; CONVENTIONAL KINESIN; HIPPOCAMPAL-NEURONS; BINDING PROTEIN; AMPA RECEPTORS; TRANSPORT; SUPPRESSION; DOMAIN	In cells, molecular motors operate in polarized sorting of molecules, although the steering mechanisms of motors remain elusive(1). In neurons, the kinesin motor(2) conducts vesicular transport such as the transport of synaptic vesicle components to axons(3) and of neurotransmitter receptors to dendrites(4), indicating that vesicles may have to drive the motor for the direction to be correct. Here we show that an AMPA (alpha-amino-3-hydroxy-5- methylisoxazole-4-propionate) receptor subunit-GluR2-interacting protein (GRIP1)-can directly interact and steer kinesin heavy chains to dendrites as a motor for AMPA receptors. As would be expected if this complex is functional, both gene targeting and dominant negative experiments of heavy chains of mouse kinesin showed abnormal localization of GRIP1. Moreover, expression of the kinesin-binding domain of GRIP1 resulted in accumulation of the endogenous kinesin predominantly in the somatodendritic area. This pattern was different from that generated by the overexpression of the kinesin-binding scaffold protein JSAP1 (JNK/SAPK-associated protein-1, also known as Mapk8ip3), which occurred predominantly in the somatoaxon area. These results indicate that directly binding proteins can determine the traffic direction of a motor protein.	Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Bunkyo Ku, Tokyo 1130033, Japan; Inje Univ, Coll Med, Dept Microbiol, Jingu 633165, Busan, South Korea	University of Tokyo; Inje University	Hirokawa, N (corresponding author), Univ Tokyo, Grad Sch Med, Dept Cell Biol & Anat, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		Takei, Yosuke/I-1828-2015; Kanai, Yoshimitsu/W-3486-2019	Takei, Yosuke/0000-0002-5026-8027; , Masahiko/0000-0001-7416-4938; Kanai, Yoshimitsu/0000-0002-0375-6853; Tanaka, Yosuke/0000-0001-5376-5726				BAAS PW, 1988, P NATL ACAD SCI USA, V85, P8335, DOI 10.1073/pnas.85.21.8335; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Burack MA, 2000, NEURON, V26, P465, DOI 10.1016/S0896-6273(00)81178-2; Burette A, 2001, J NEUROSCI, V21, P495, DOI 10.1523/JNEUROSCI.21-02-00495.2001; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Ito M, 1999, MOL CELL BIOL, V19, P7539; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kanai Y, 2000, J NEUROSCI, V20, P6374, DOI 10.1523/JNEUROSCI.20-17-06374.2000; Kim CH, 2001, J NEUROSCI, V21, P4188, DOI 10.1523/JNEUROSCI.21-12-04188.2001; Lee SH, 2001, NEUROPHARMACOLOGY, V41, P680, DOI 10.1016/S0028-3908(01)00124-1; Marszalek JR, 1999, J CELL BIOL, V145, P469, DOI 10.1083/jcb.145.3.469; NICLAS J, 1994, NEURON, V12, P1059, DOI 10.1016/0896-6273(94)90314-X; Rahman A, 1999, J CELL BIOL, V146, P1277, DOI 10.1083/jcb.146.6.1277; Rubio ME, 1999, J NEUROSCI, V19, P5549; Seiler S, 2000, NAT CELL BIOL, V2, P333, DOI 10.1038/35014022; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Severt WL, 1999, J CELL SCI, V112, P3691; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8	29	379	393	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	2002	417	6884					83	87		10.1038/nature743	http://dx.doi.org/10.1038/nature743			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986669				2022-12-28	WOS:000175307200042
J	Talwar, SK; Xu, SH; Hawley, ES; Weiss, SA; Moxon, KA; Chapin, JK				Talwar, SK; Xu, SH; Hawley, ES; Weiss, SA; Moxon, KA; Chapin, JK			Behavioural neuroscience: Rat navigation guided by remote control - Free animals can be 'virtually' trained by microstimulating key areas of their brains.	NATURE			English	Article							SELF-STIMULATION		Suny Downstate Med Ctr, Dept Physiol & Pharmacol, Brooklyn, NY 11203 USA; Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19104 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Drexel University	Talwar, SK (corresponding author), Suny Downstate Med Ctr, Dept Physiol & Pharmacol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.		Moxon, Karen/K-7407-2012	Moxon, Karen/0000-0002-5790-097X; Weiss, Shennan/0000-0003-0825-8439				DEUTSCH JA, 1963, J THEOR BIOL, V4, P193, DOI 10.1016/0022-5193(63)90028-6; Doty R W, 1969, Annu Rev Psychol, V20, P289, DOI 10.1146/annurev.ps.20.020169.001445; FUKUDA M, 1992, J NEUROSCI METH, V44, P121, DOI 10.1016/0165-0270(92)90005-X; GALLISTEL CR, 1969, J COMP PHYSIOL PSYCH, V69, P713, DOI 10.1037/h0028232; HAWLEY ES, IN PRESS HIPPOCAMPUS; Loucks RB, 1933, J COMP PSYCHOL, V16, P439, DOI 10.1037/h0073424; OLDS J, 1954, J COMP PHYSIOL PSYCH, V47, P419, DOI 10.1037/h0058775; OLDS ME, 1981, ANNU REV PSYCHOL, V32, P523, DOI 10.1146/annurev.ps.32.020181.002515; Romo R, 2000, NEURON, V26, P273, DOI 10.1016/S0896-6273(00)81156-3; Skinner B.F., 1938, BEHAV ORG EXPT ANAL	10	236	281	4	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	2002	417	6884					37	38		10.1038/417037a	http://dx.doi.org/10.1038/417037a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986657				2022-12-28	WOS:000175307200029
J	Pollock, AM; Price, D				Pollock, AM; Price, D			Market forces in public health	LANCET			English	Editorial Material									UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9QU, England; Northumbria Univ, Social Welf Res Unit, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England	University of London; University College London; Northumbria University	Pollock, AM (corresponding author), UCL, Sch Publ Policy, Hlth Policy & Hlth Serv Res Unit, London WC1H 9QU, England.	allyson.pollock@ucl.ac.uk		pollock, allyson/0000-0002-7388-3110				BILAL S, 2002, TRADE NEGOTIATIONS I, V1, P5; Braveman P, 2001, BRIT MED J, V323, P678, DOI 10.1136/bmj.323.7314.678; Buse K, 1998, LANCET, V351, P665, DOI 10.1016/S0140-6736(97)11453-2; MATTOO A, 2002, GLOBAL EC PROSPECTS, pCH3; Price D, 1999, LANCET, V354, P1889, DOI 10.1016/S0140-6736(99)11060-2; *WHO, 2002, DOH DEV AG; World Health Organization, 2000, HLTH SYST IMPR PERF	7	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1363	1364		10.1016/S0140-6736(02)08390-3	http://dx.doi.org/10.1016/S0140-6736(02)08390-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978330				2022-12-28	WOS:000175076200005
J	Zheng, N; Schulman, BA; Song, LZ; Miller, JJ; Jeffrey, PD; Wang, P; Chu, C; Koepp, DM; Elledge, SJ; Pagano, M; Conaway, RC; Conaway, JW; Harper, JW; Pavletich, NP				Zheng, N; Schulman, BA; Song, LZ; Miller, JJ; Jeffrey, PD; Wang, P; Chu, C; Koepp, DM; Elledge, SJ; Pagano, M; Conaway, RC; Conaway, JW; Harper, JW; Pavletich, NP			Structure of the Cul1-Rbx1-Skp1-F box(Skp2) SCF ubiquitin ligase complex	NATURE			English	Article							ANAPHASE-PROMOTING COMPLEX; CYCLIN-E; CRYSTAL-STRUCTURE; PROTEIN; SUBUNIT; IDENTIFICATION; DEGRADATION; PROTEOLYSIS; MECHANISMS; P27(KIP1)	SCF complexes are the largest family of E3 ubiquitin-protein ligases and mediate the ubiquitination of diverse regulatory and signalling proteins. Here we present the crystal structure of the Cul1-Rbx1-Skp1-F box(Skp2) SCF complex, which shows that Cul1 is an elongated protein that consists of a long stalk and a globular domain. The globular domain binds the RING finger protein Rbx1 through an intermolecular beta-sheet, forming a two-subunit catalytic core that recruits the ubiquitin-conjugating enzyme. The long stalk, which consists of three repeats of a novel five-helix motif, binds the Skp1-F box(Skp2) protein substrate-recognition complex at its tip. Cul1 serves as a rigid scaffold that organizes the Skp1-F box(Skp2) and Rbx1 subunits, holding them over 100 Angstrom apart. The structure suggests that Cul1 may contribute to catalysis through the positioning of the substrate and the ubiquitin-conjugating enzyme, and this model is supported by Cul1 mutations designed to eliminate the rigidity of the scaffold.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; NYU, Med Ctr, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA; Stowers Inst Med Res, Kansas City, MO 64110 USA	Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; New York University; New York University; Stowers Institute for Medical Research	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA.	nikola@xray2.mskcc.org		pagano, michele/0000-0003-3210-2442; Conaway, Joan/0000-0002-2786-0663; Miller, Julie/0000-0002-1288-593X; Jeffrey, Philip/0000-0002-4351-5341	NIA NIH HHS [R01 AG011085] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG011085] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Grossberger R, 1999, J BIOL CHEM, V274, P14500, DOI 10.1074/jbc.274.20.14500; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kipreos ET, 2000, GENOME BIOL, V1, DOI 10.1186/gb-2000-1-5-reviews3002; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Morimoto M, 2000, BIOCHEM BIOPH RES CO, V270, P1093, DOI 10.1006/bbrc.2000.2576; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Polakis P, 2000, GENE DEV, V14, P1837; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Rice LM, 1999, MOL CELL, V4, P85, DOI 10.1016/S1097-2765(00)80190-2; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Shirane M, 1999, J BIOL CHEM, V274, P13886, DOI 10.1074/jbc.274.20.13886; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Stroschein SL, 2001, GENE DEV, V15, P2822; Wu K, 2002, J BIOL CHEM, V277, P516, DOI 10.1074/jbc.M108008200; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	50	1120	1170	9	136	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	2002	416	6882					703	709		10.1038/416703a	http://dx.doi.org/10.1038/416703a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961546				2022-12-28	WOS:000175033500033
J	Bassing, CH; Swat, W; Alt, FW				Bassing, CH; Swat, W; Alt, FW			The mechanism and regulation of chromosomal V(D)J recombination	CELL			English	Review							STRAND BREAK REPAIR; DNA-LIGASE IV; DEPENDENT PROTEIN-KINASE; TCR-BETA LOCUS; SEVERE COMBINED IMMUNODEFICIENCY; VARIABLE REGION GENES; ANTIGEN-RECEPTOR; CATALYTIC SUBUNIT; ALLELIC EXCLUSION; RAG2 PROTEINS	V(D)J recombination is of fundamental importance to the generation of diverse antigen receptor repertoires. We review our current understanding of the V(D)J recombination reaction and how it is regulated during lymphocyte development. We also discuss how defects in the mechanism or regulation of V(D)J recombination can lead to human disease.	Childrens Hosp, Ctr Blood Res, Howard Hughes Med Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Howard Hughes Medical Institute	Alt, FW (corresponding author), Childrens Hosp, Ctr Blood Res, Howard Hughes Med Inst, 300 Longwood Ave, Boston, MA 02115 USA.	alt@rascal.med.harvard.edu						Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; ALT FW, 1980, CELL, V21, P1, DOI 10.1016/0092-8674(80)90109-9; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; Baker JE, 1998, IMMUNITY, V9, P159, DOI 10.1016/S1074-7613(00)80598-1; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Barreto V, 2000, J IMMUNOL, V164, P893, DOI 10.4049/jimmunol.164.2.893; Bassing CH, 2000, NATURE, V405, P583, DOI 10.1038/35014635; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bories JC, 1996, P NATL ACAD SCI USA, V93, P7871, DOI 10.1073/pnas.93.15.7871; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Bouvier G, 1996, P NATL ACAD SCI USA, V93, P7877, DOI 10.1073/pnas.93.15.7877; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Constantinescu A, 1997, J EXP MED, V185, P609, DOI 10.1084/jem.185.4.609; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Doherty AJ, 2001, CURR BIOL, V11, pR920, DOI 10.1016/S0960-9822(01)00555-3; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Frank KM, 2000, MOL CELL, V5, P993, DOI 10.1016/S1097-2765(00)80264-6; Fugmann SD, 2000, MOL CELL, V5, P97, DOI 10.1016/S1097-2765(00)80406-2; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gartner F, 1999, IMMUNITY, V10, P537, DOI 10.1016/S1074-7613(00)80053-9; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; Golding A, 1999, EMBO J, V18, P3712, DOI 10.1093/emboj/18.13.3712; Gorman JR, 1998, ADV IMMUNOL, V69, P113, DOI 10.1016/S0065-2776(08)60607-0; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NATURE, V388, P492, DOI 10.1038/41358; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Hempel WM, 1998, GENE DEV, V12, P2305, DOI 10.1101/gad.12.15.2305; Hesslein DGT, 2001, ADV IMMUNOL, V78, P169, DOI 10.1016/S0065-2776(01)78004-2; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Iritani BM, 1999, IMMUNITY, V10, P713, DOI 10.1016/S1074-7613(00)80070-9; Jacobs H, 2001, CURR OPIN IMMUNOL, V13, P208, DOI 10.1016/S0952-7915(00)00206-5; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim DR, 1999, GENE DEV, V13, P3070, DOI 10.1101/gad.13.23.3070; Kirch SA, 1998, EMBO J, V17, P4881, DOI 10.1093/emboj/17.16.4881; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; Krangel MS, 1998, IMMUNOL REV, V165, P131, DOI 10.1111/j.1600-065X.1998.tb01236.x; Kurimasa A, 1999, P NATL ACAD SCI USA, V96, P1403, DOI 10.1073/pnas.96.4.1403; Kwon J, 2000, MOL CELL, V6, P1037, DOI 10.1016/S1097-2765(00)00102-7; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; Landree MA, 1999, GENE DEV, V13, P3059, DOI 10.1101/gad.13.23.3059; Lee J, 1999, IMMUNITY, V11, P771, DOI 10.1016/S1074-7613(00)80151-X; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; Li ZY, 1995, CELL, V83, P1079, DOI 10.1016/0092-8674(95)90135-3; Liao MJ, 1999, GENE DEV, V13, P1246, DOI 10.1101/gad.13.10.1246; Livak F, 2000, J EXP MED, V192, P1191, DOI 10.1084/jem.192.8.1191; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Mathieu N, 2000, J EXP MED, V192, P625, DOI 10.1084/jem.192.5.625; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; McMurry MT, 2000, SCIENCE, V287, P495, DOI 10.1126/science.287.5452.495; Melek M, 2000, CELL, V101, P625, DOI 10.1016/S0092-8674(00)80874-0; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Monroe RJ, 1999, IMMUNITY, V11, P201, DOI 10.1016/S1074-7613(00)80095-3; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Mostoslavsky R, 1998, GENE DEV, V12, P1801, DOI 10.1101/gad.12.12.1801; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; Nemazee D, 2000, J EXP MED, V191, P1813, DOI 10.1084/jem.191.11.1813; Notarangelo LD, 1999, CURR OPIN IMMUNOL, V11, P435, DOI 10.1016/S0952-7915(99)80073-9; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Paull TT, 2001, CELL, V107, P563, DOI 10.1016/S0092-8674(01)00591-8; Raghavan SC, 2001, J BIOL CHEM, V276, P29126, DOI 10.1074/jbc.M103797200; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Sakai E, 1999, P NATL ACAD SCI USA, V96, P1526, DOI 10.1073/pnas.96.4.1526; Santagata S, 2000, IMMUNOL REV, V178, P64, DOI 10.1034/j.1600-065X.2000.17818.x; Scheuermann RH, 1999, CRIT REV EUKAR GENE, V9, P295, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.140; Schultz HY, 2001, MOL CELL, V7, P65, DOI 10.1016/S1097-2765(01)00155-1; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; Sekiguchi J, 2001, MOL CELL, V8, P1383, DOI 10.1016/S1097-2765(01)00423-3; Senoo M, 2001, INT IMMUNOL, V13, P1405, DOI 10.1093/intimm/13.11.1405; Skok JA, 2001, NAT IMMUNOL, V2, P848, DOI 10.1038/ni0901-848; Sleckman BP, 2000, P NATL ACAD SCI USA, V97, P7975, DOI 10.1073/pnas.130190597; Sleckman BP, 1998, J EXP MED, V188, P1465, DOI 10.1084/jem.188.8.1465; Sleckman BP, 1997, IMMUNITY, V7, P505, DOI 10.1016/S1074-7613(00)80372-6; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; StanhopeBaker P, 1996, CELL, V85, P887, DOI 10.1016/S0092-8674(00)81272-6; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Tourigny MR, 1997, J EXP MED, V185, P1549, DOI 10.1084/jem.185.9.1549; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villey I, 1996, IMMUNITY, V5, P331, DOI 10.1016/S1074-7613(00)80259-9; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Whitehurst CE, 1999, IMMUNITY, V10, P313, DOI 10.1016/S1074-7613(00)80031-X; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2; Yi M, 1999, J IMMUNOL, V162, P6029; Yu W, 1999, NATURE, V400, P682, DOI 10.1038/23287; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	108	662	683	4	68	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR	2002	109			S			S45	S55		10.1016/S0092-8674(02)00675-X	http://dx.doi.org/10.1016/S0092-8674(02)00675-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	544UY	11983152	Bronze			2022-12-28	WOS:000175181100005
J	Ting, JPY; Trowsdale, J				Ting, JPY; Trowsdale, J			Genetic control of MHC class II expression	CELL			English	Review							MAJOR HISTOCOMPATIBILITY COMPLEX; BARE LYMPHOCYTE SYNDROME; CREB-BINDING-PROTEIN; INTERFERON REGULATORY FACTOR-1; MELANOMA CELL-LINES; HLA-DM; TRANSCRIPTION FACTOR; TRANSACTIVATOR CIITA; SELF-ASSOCIATION; DENDRITIC CELLS	The presentation of peptides to T cells by MHC class II molecules is of critical importance in specific recognition by the immune system. Expression of class II molecules is exquisitely controlled at the transcriptional level. A large set of proteins interact with the promoters of class II genes. The most important of these is CIITA, a master controller that orchestrates expression but does not bind directly to the promoter. The transcriptosome complex formed at class II promoters is a model for induction of gene expression.	Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Cambridge, Dept Pathol, Div Immunol, Cambridge CB2 1QP, England; Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Cambridge; University of Cambridge	Ting, JPY (corresponding author), Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA.							Accolla RS, 2001, TRENDS IMMUNOL, V22, P560, DOI 10.1016/S1471-4906(01)02003-8; Alfonso C, 2000, ANNU REV IMMUNOL, V18, P113, DOI 10.1146/annurev.immunol.18.1.113; Allcock RJN, 2000, IMMUNOL TODAY, V21, P328, DOI 10.1016/S0167-5699(00)01654-6; ANDERSEN LC, 1991, J EXP MED, V173, P181, DOI 10.1084/jem.173.1.181; Armstrong TD, 1997, P NATL ACAD SCI USA, V94, P6886, DOI 10.1073/pnas.94.13.6886; Baumgart M, 1998, P NATL ACAD SCI USA, V95, P6936, DOI 10.1073/pnas.95.12.6936; Beck S, 1999, IMMUNOL REV, V167, P201, DOI 10.1111/j.1600-065X.1999.tb01393.x; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Brickey WJ, 1999, J IMMUNOL, V163, P6622; Caretti G, 1999, MOL CELL BIOL, V19, P8591; CHIN KC, 1994, IMMUNITY, V1, P687, DOI 10.1016/1074-7613(94)90039-6; Chou CL, 2000, J EXP MED, V192, P1697, DOI 10.1084/jem.192.12.1697; Clausen BE, 1998, IMMUNITY, V8, P143, DOI 10.1016/S1074-7613(00)80467-7; Copier J, 1996, J IMMUNOL, V157, P1017; Cressman DE, 1999, IMMUNITY, V10, P163, DOI 10.1016/S1074-7613(00)80017-5; Cressman DE, 2001, J IMMUNOL, V167, P3626, DOI 10.4049/jimmunol.167.7.3626; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; Cullen M, 1997, AM J HUM GENET, V60, P397; Dawkins R, 1999, IMMUNOL REV, V167, P275, DOI 10.1111/j.1600-065X.1999.tb01399.x; Deffrennes V, 2001, J IMMUNOL, V167, P98, DOI 10.4049/jimmunol.167.1.98; DeSandro A, 1999, AM J HUM GENET, V65, P279, DOI 10.1086/302519; Doebele RC, 2000, IMMUNITY, V13, P517, DOI 10.1016/S1074-7613(00)00051-0; Dong YS, 2001, J IMMUNOL, V167, P311, DOI 10.4049/jimmunol.167.1.311; Douhan J, 1996, J EXP MED, V183, P1063, DOI 10.1084/jem.183.3.1063; Durand B, 1997, EMBO J, V16, P1045, DOI 10.1093/emboj/16.5.1045; Fontes JD, 1999, MOL CELL BIOL, V19, P941; Gao J, 2001, J VIROL, V75, P1124, DOI 10.1128/JVI.75.3.1124-1131.2001; Ghosh N, 1999, J BIOL CHEM, V274, P32342, DOI 10.1074/jbc.274.45.32342; Ghosh N, 2001, J BIOL CHEM, V276, P15264, DOI 10.1074/jbc.M100862200; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Goodwin BL, 2001, CELL GROWTH DIFFER, V12, P327; Gourley TS, 2001, J IMMUNOL, V166, P2917, DOI 10.4049/jimmunol.166.5.2917; Grahovac B, 1998, HUM GENET, V102, P27, DOI 10.1007/s004390050650; Gunther E, 2001, IMMUNOGENETICS, V53, P520, DOI 10.1007/s002510100361; HAAS DA, 1987, IMMUNOGENETICS, V25, P15, DOI 10.1007/BF00768828; Hake SB, 2000, MOL CELL BIOL, V20, P7716, DOI 10.1128/MCB.20.20.7716-7725.2000; Hammond C, 1998, J IMMUNOL, V161, P3282; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Harton JA, 2001, J BIOL CHEM, V276, P38715, DOI 10.1074/jbc.M106652200; HAUBER I, 1995, J EXP MED, V181, P1411, DOI 10.1084/jem.181.4.1411; HIRAYAMA K, 1987, NATURE, V327, P426, DOI 10.1038/327426a0; Itoh-Lindstrom Y, 1999, J IMMUNOL, V163, P2425; JabraneFerrat N, 1996, MOL CELL BIOL, V16, P4683; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; KAMBHU S, 1990, P NATL ACAD SCI USA, V87, P4927, DOI 10.1073/pnas.87.13.4927; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; Koonin EV, 2000, TRENDS BIOCHEM SCI, V25, P223, DOI 10.1016/S0968-0004(00)01577-2; Kretsovali A, 2001, J BIOL CHEM, V276, P32191, DOI 10.1074/jbc.M103164200; Kretsovali A, 1998, MOL CELL BIOL, V18, P6777, DOI 10.1128/MCB.18.11.6777; Kropshofer H, 1999, IMMUNOL REV, V172, P267, DOI 10.1111/j.1600-065X.1999.tb01371.x; Kwak B, 2000, NAT MED, V6, P1399, DOI 10.1038/82219; Landmann S, 2001, J EXP MED, V194, P379, DOI 10.1084/jem.194.4.379; Li GX, 2001, MOL CELL BIOL, V21, P4626, DOI 10.1128/MCB.21.14.4626-4635.2001; Linhoff MW, 2001, MOL CELL BIOL, V21, P3001, DOI 10.1128/MCB.21.9.3001-3011.2001; Magner WJ, 2000, J IMMUNOL, V165, P7017, DOI 10.4049/jimmunol.165.12.7017; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Marten A, 2001, CANCER GENE THER, V8, P211, DOI 10.1038/sj.cgt.7700292; Martin BK, 1999, J IMMUNOL, V162, P6663; Masternak K, 2000, GENE DEV, V14, P1156; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Mora C, 1999, J IMMUNOL, V162, P4576; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Moreno CS, 1997, J IMMUNOL, V158, P5841; Morris AC, 2000, J IMMUNOL, V164, P4143, DOI 10.4049/jimmunol.164.8.4143; Morrison TE, 2001, IMMUNITY, V15, P787, DOI 10.1016/S1074-7613(01)00226-6; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Nagarajan UM, 2002, J IMMUNOL, V168, P1780, DOI 10.4049/jimmunol.168.4.1780; Nagarajan UM, 1999, IMMUNITY, V10, P153, DOI 10.1016/S1074-7613(00)80016-3; Nekrep N, 2001, MOL CELL BIOL, V21, P5566, DOI 10.1128/MCB.21.16.5566-5576.2001; Nelson C A, 1999, Rev Immunogenet, V1, P47; Nickerson K, 2001, J BIOL CHEM, V276, P19089, DOI 10.1074/jbc.M101295200; Osborne A, 2001, MOL CELL BIOL, V21, P6495, DOI 10.1128/MCB.21.19.6495-6506.2001; Peretti M, 2001, MOL CELL BIOL, V21, P5699, DOI 10.1128/MCB.21.17.5699-5709.2001; Piskurich JF, 1999, MOL CELL BIOL, V19, P431; Piskurich JF, 2000, NAT IMMUNOL, V1, P526, DOI 10.1038/82788; Rakoff-Nahoum S, 2001, J IMMUNOL, V167, P2331, DOI 10.4049/jimmunol.167.4.2331; Rasmussen HB, 2001, HUM IMMUNOL, V62, P371, DOI 10.1016/S0198-8859(01)00215-4; Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; Riegert P, 1996, P NATL ACAD SCI USA, V93, P1243, DOI 10.1073/pnas.93.3.1243; Sanderson F, 1995, CURR BIOL, V5, P1372, DOI 10.1016/S0960-9822(95)00274-0; Sartoris S, 1998, J IMMUNOL, V161, P814; Schafer P H, 1995, Semin Immunol, V7, P389, DOI 10.1006/smim.1995.0043; SIEGRIST CA, 1995, J EXP MED, V182, P1793, DOI 10.1084/jem.182.6.1793; Sims TN, 1999, MICROBES INFECT, V1, P903, DOI 10.1016/S1286-4579(99)00227-0; Sisk TJ, 2001, MOL CELL BIOL, V21, P4919, DOI 10.1128/MCB.21.15.4919-4928.2001; Sisk TJ, 2000, J IMMUNOL, V165, P2511, DOI 10.4049/jimmunol.165.5.2511; Spilianakis C, 2000, MOL CELL BIOL, V20, P8489, DOI 10.1128/MCB.20.22.8489-8498.2000; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; Taxman DJ, 2000, J IMMUNOL, V165, P1410, DOI 10.4049/jimmunol.165.3.1410; TONNELLE C, 1985, EMBO J, V4, P2839, DOI 10.1002/j.1460-2075.1985.tb04012.x; van den Elsen PJ, 1999, MICROBES INFECT, V1, P887, DOI 10.1016/S1286-4579(99)80532-2; Waldburger JM, 2001, J EXP MED, V194, P393, DOI 10.1084/jem.194.4.393; Westerheide SD, 1999, NUCLEIC ACIDS RES, V27, P1635, DOI 10.1093/nar/27.7.1635; Williams GS, 1998, INT IMMUNOL, V10, P1957, DOI 10.1093/intimm/10.12.1957; Wiszniewski W, 2001, J IMMUNOL, V167, P1787, DOI 10.4049/jimmunol.167.3.1787; Xi HK, 1999, ONCOGENE, V18, P5889, DOI 10.1038/sj.onc.1202969; Zhu XS, 2000, MOL CELL BIOL, V20, P6051, DOI 10.1128/MCB.20.16.6051-6061.2000; Zhu XS, 2001, MOL CELL BIOL, V21, P7078, DOI 10.1128/MCB.21.20.7078-7088.2001	105	418	438	1	24	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR	2002	109			S			S21	S33		10.1016/S0092-8674(02)00696-7	http://dx.doi.org/10.1016/S0092-8674(02)00696-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	544UY	11983150	Bronze			2022-12-28	WOS:000175181100003
J	Traver, D; Zon, LI				Traver, D; Zon, LI			Walking the walk: Migration and other common themes in blood and vascular development	CELL			English	Review							AVIAN EMBRYO; HEMATOPOIESIS; DROSOPHILA; ONTOGENY; MOUSE	In this issue of Cell, a study by N. Cho and coworkers provides insight into the role of vascular endothelial growth factor (VEGF) signaling in Drosophila hematopoiesis (Cho et al., 2002). Their work suggests that an ancestral function of VEGF was to guide blood cell migration and highlights the conservation of at least one aspect of VEGF signaling during evolution.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute	Zon, LI (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp, Boston, MA 02115 USA.							Bennett CM, 2001, BLOOD, V98, P643, DOI 10.1182/blood.V98.3.643; Cumano A, 2001, CURR OPIN IMMUNOL, V13, P166, DOI 10.1016/S0952-7915(00)00200-4; DieterlenLievre F, 1996, CURR TOP MICROBIOL, V212, P119; Duchek P, 2001, CELL, V107, P17, DOI 10.1016/S0092-8674(01)00502-5; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Heino TI, 2001, MECH DEVELOP, V109, P69, DOI 10.1016/S0925-4773(01)00510-X; Herbomel P, 1999, DEVELOPMENT, V126, P3735; Jaffredo T, 2000, DEV BIOL, V224, P204, DOI 10.1006/dbio.2000.9799; Keller G, 1999, EXP HEMATOL, V27, P777, DOI 10.1016/S0301-472X(99)00024-7; Lanot R, 2001, DEV BIOL, V230, P243, DOI 10.1006/dbio.2000.0123; Lebestky T, 2000, SCIENCE, V288, P146, DOI 10.1126/science.288.5463.146; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Nishikawa SI, 2001, CURR OPIN CELL BIOL, V13, P673, DOI 10.1016/S0955-0674(00)00270-2; Palis J, 2001, EXP HEMATOL, V29, P927, DOI 10.1016/S0301-472X(01)00669-5; Rehorn KP, 1996, DEVELOPMENT, V122, P4023; ROUSSET D, 1995, J MOL EVOL, V41, P421, DOI 10.1007/BF00160313; TEPASS U, 1994, DEVELOPMENT, V120, P1829; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; ZON LI, 1995, BLOOD, V86, P2876	19	48	59	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 22	2002	108	6					731	734		10.1016/S0092-8674(02)00686-4	http://dx.doi.org/10.1016/S0092-8674(02)00686-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955426	Bronze			2022-12-28	WOS:000174563000002
J	Huber, H; Hohn, MJ; Rachel, R; Fuchs, T; Wimmer, VC; Stetter, KO				Huber, H; Hohn, MJ; Rachel, R; Fuchs, T; Wimmer, VC; Stetter, KO			A new phylum of Archaea represented by a nanosized hyperthermophilic symbiont	NATURE			English	Article							RNA; VISUALIZATION; DIVERSITY; SEQUENCES; BACTERIA	According to small subunit ribosomal RNA (ss rRNA) sequence comparisons all known Archaea belong to the phyla Crenarchaeota, Euryarchaeota, and-indicated only by environmental DNA sequences-to the 'Korarchaeota'(1,2). Here we report the cultivation of a new nanosized hyperthermophilic archaeon from a submarine hot vent. This archaeon cannot be attached to one of these groups and therefore must represent an unknown phylum which we name 'Nanoarchaeota' and species, which we name 'Nanoarchaeum equitans'. Cells of 'N. equitans' are spherical, and only about 400 nm in diameter. They grow attached to the surface of a specific archaeal host, a new member of the genus Ignicoccus(3) . The distribution of the 'Nanoarchaeota' is so far unknown. Owing to their unusual ss rRNA sequence, members remained undetectable by commonly used ecological studies based on the polymerase chain reaction(4). 'N. equitans' harbours the smallest archaeal genome; it is only 0.5 megabases in size. This organism will provide insight into the evolution of thermophily, of tiny genomes and of interspecies communication.	Univ Regensburg, Lehrstuhl Mikrobiol & Archaeenzentrum, D-93053 Regensburg, Germany; Max Planck Inst Med Res, Dept Cell Physiol, D-69120 Heidelberg, Germany	University of Regensburg; Max Planck Society	Stetter, KO (corresponding author), Univ Regensburg, Lehrstuhl Mikrobiol & Archaeenzentrum, Univ Str 31, D-93053 Regensburg, Germany.			Wimmer, Verena/0000-0002-9931-8179				ASHKIN A, 1987, NATURE, V330, P769, DOI 10.1038/330769a0; Barns SM, 1996, P NATL ACAD SCI USA, V93, P9188, DOI 10.1073/pnas.93.17.9188; BARNS SM, 1994, P NATL ACAD SCI USA, V91, P1609, DOI 10.1073/pnas.91.5.1609; Baumann C, 1998, EXTREMOPHILES, V2, P101, DOI 10.1007/s007920050048; Boetius A, 2000, NATURE, V407, P623, DOI 10.1038/35036572; BROSIUS J, 1981, J MOL BIOL, V148, P107, DOI 10.1016/0022-2836(81)90508-8; BURGGRAF S, 1994, APPL ENVIRON MICROB, V60, P3112, DOI 10.1128/AEM.60.9.3112-3119.1994; Burggraf S, 1997, INT J SYST BACTERIOL, V47, P657, DOI 10.1099/00207713-47-3-657; Burggraf S, 1997, NATURE, V385, P780, DOI 10.1038/385780a0; DeRijk P, 1997, NUCLEIC ACIDS RES, V25, P4679, DOI 10.1093/nar/25.22.4679; Eder W, 1999, ARCH MICROBIOL, V172, P213, DOI 10.1007/s002030050762; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FRICKE H, 1989, MAR BIOL, V102, P425, DOI 10.1007/BF00428495; HUBER H, 1985, SYST APPL MICROBIOL, V6, P105, DOI 10.1016/S0723-2020(85)80021-7; Huber H, 2000, INT J SYST EVOL MICR, V50, P2093, DOI 10.1099/00207713-50-6-2093; HUBER R, 1995, NATURE, V376, P57, DOI 10.1038/376057a0; Hutchison CA, 1999, SCIENCE, V286, P2165, DOI 10.1126/science.286.5447.2165; Ludwig W, 1998, ELECTROPHORESIS, V19, P554, DOI 10.1002/elps.1150190416; Ochman H, 2001, SCIENCE, V292, P1096, DOI 10.1126/science.1058543; Preston CM, 1996, P NATL ACAD SCI USA, V93, P6241, DOI 10.1073/pnas.93.13.6241; ROHOZINSKI J, 1989, VIROLOGY, V168, P363, DOI 10.1016/0042-6822(89)90277-8; Stahl D.A., 1991, NUCL ACID TECHNIQUES, P205; STETTER KO, 1995, ASM NEWS, V61, P285; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; [No title captured]	26	491	545	2	129	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	2002	417	6884					63	67		10.1038/417063a	http://dx.doi.org/10.1038/417063a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986665				2022-12-28	WOS:000175307200037
J	Storch, KF; Lipan, O; Leykin, I; Viswanathan, N; Davis, FC; Wong, WH; Weitz, CJ				Storch, KF; Lipan, O; Leykin, I; Viswanathan, N; Davis, FC; Wong, WH; Weitz, CJ			Extensive and divergent circadian gene expression in liver and heart	NATURE			English	Article							TRANSCRIPTION; TISSUES; CLOCK; ALPHA	Many mammalian peripheral tissues have circadian clocks(1-4); endogenous oscillators that generate transcriptional rhythms thought to be important for the daily timing of physiological processes(5,6). The extent of circadian gene regulation in peripheral tissues is unclear, and to what degree circadian regulation in different tissues involves common or specialized pathways is unknown. Here we report a comparative analysis of circadian gene expression in vivo in mouse liver and heart using oligonucleotide arrays representing 12,488 genes. We find that peripheral circadian gene regulation is extensive (greater than or equal to8-10% of the genes expressed in each tissue), that the distributions of circadian phases in the two tissues are markedly different, and that very few genes show circadian regulation in both tissues. This specificity of circadian regulation cannot be accounted for by tissue-specific gene expression. Despite this divergence, the clock-regulated genes in liver and heart participate in overlapping, extremely diverse processes. A core set of 37 genes with similar circadian regulation in both tissues includes candidates for new clock genes and output genes, and it contains genes responsive to circulating factors with circadian or diurnal rhythms.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA; Harvard Univ, Dept Stat, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Northeastern University; Harvard University	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.		Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BUCHAN P, 1994, J AM ACAD DERMATOL, V30, P428, DOI 10.1016/S0190-9622(94)70051-6; Chen JY, 2001, BIOCHEM BIOPH RES CO, V281, P475, DOI 10.1006/bbrc.2001.4362; Claridge-Chang A, 2001, NEURON, V32, P657, DOI 10.1016/S0896-6273(01)00515-3; Claverie JM, 2001, SCIENCE, V291, P1255, DOI 10.1126/science.1058969; Cooper P, 2001, AM J PHYSIOL-LUNG C, V280, pL841, DOI 10.1152/ajplung.2001.280.5.L841; Grundschober C, 2001, J BIOL CHEM, V276, P46751, DOI 10.1074/jbc.M107499200; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; Harris HJ, 2001, ENDOCRINOLOGY, V142, P114, DOI 10.1210/en.142.1.114; Kalsbeek A, 2000, ENDOCRINOLOGY, V141, P3832, DOI 10.1210/en.141.10.3832; KLEIND C, 1991, SUPRACHIASMATIC NUCL; Kornmann B, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.11.e51; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1; McNamara P, 2001, CELL, V105, P877, DOI 10.1016/S0092-8674(01)00401-9; MURPHY WJ, 2001, GENOME BIOL REV, V2; PANDA SJ, 2002, CELL; Petrovsky N, 1998, Int Rev Immunol, V16, P635, DOI 10.3109/08830189809043012; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Ripperger JA, 2001, CURR OPIN CELL BIOL, V13, P357, DOI 10.1016/S0955-0674(00)00220-9; Ripperger JA, 2000, GENE DEV, V14, P679; TATA JR, 1993, J STEROID BIOCHEM, V46, P105, DOI 10.1016/0960-0760(93)90286-6; Torra IP, 2000, ENDOCRINOLOGY, V141, P3799, DOI 10.1210/en.141.10.3799; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; WOLF FW, 1994, J BIOL CHEM, V269, P3633; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	30	1144	1175	1	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	2002	417	6884					78	83		10.1038/nature744	http://dx.doi.org/10.1038/nature744			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11967526				2022-12-28	WOS:000175307200041
J	Radomskij, P; Schmidt, MA; Heron, CW; Prasher, D				Radomskij, P; Schmidt, MA; Heron, CW; Prasher, D			Effect of MRI noise on cochlear function	LANCET			English	Article								A disadvantage of magnetic resonance Imaging (MRI) Is the high level of noise produced (peaking between 122 dB and 131 dB). We used otoacoustic emissions (OAEs) as a method to quantify the effect of MRI-generated noise on the cochlea. OAEs were measured In 16 patients before and after MRI and in 16 controls. OAEs decreased In patients after MRI, but the controls, who were not exposed to MRI noise, showed no decrease over the same period. The change in OAEs shows a clear effect of MRI noise on cochlear function, despite use of earplugs. The importance of correctly fitted earplugs cannot be underestimated.	UCL, Inst Laryngol & Otol, London WC1X 8EE, England; Univ London St Georges Hosp, Dept Audiol, London, England; Univ London St Georges Hosp, Magnet Resonance Unit, London, England	University of London; University College London; St Georges University London; St Georges University London	Radomskij, P (corresponding author), UCL, Inst Laryngol & Otol, London WC1X 8EE, England.	p.radomskij@ucl.ac.uk		Schmidt, Maria/0000-0001-8993-5301				Desai Anjali, 1999, Noise Health, V1, P58; PRASHER D, 1998, BIOL EFFECTS NOISE, P125; Ulmer JL, 1998, J COMPUT ASSIST TOMO, V22, P480, DOI 10.1097/00004728-199805000-00022	3	44	45	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1485	1486		10.1016/S0140-6736(02)08423-4	http://dx.doi.org/10.1016/S0140-6736(02)08423-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988249				2022-12-28	WOS:000175279100013
J	Sharma, GK; Osti, B; Sharma, B				Sharma, GK; Osti, B; Sharma, B			Physicians persecuted for ethical practice in Nepal	LANCET			English	Editorial Material									Ctr Victims Torture, Kathmandu, Nepal		Sharma, B (corresponding author), Ctr Victims Torture, Nepal GPO Box 5839, Kathmandu, Nepal.							*AMN INT, 2002, URG APP BEH J MAH; Stevenson PC, 2001, LANCET, V358, P752, DOI 10.1016/S0140-6736(01)05844-5; 2001, RISING NEPAL    1201; 2001, KATHMANDU POST  1201	4	8	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1519	1519		10.1016/S0140-6736(02)08422-2	http://dx.doi.org/10.1016/S0140-6736(02)08422-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	546NA	11988269				2022-12-28	WOS:000175279100032
J	Levinson, DF; Holmans, PA; Laurent, C; Riley, B; Pulver, AE; Gejman, PV; Schwab, SG; Williams, NM; Owen, MJ; Wildenauer, DB; Sanders, AR; Nestadt, G; Mowry, BJ; Wormley, B; Bauche, S; Soubigou, S; Ribble, R; Nertney, DA; Liang, KY; Martinolich, L; Maier, W; Norton, N; Williams, H; Albus, M; Carpenter, EB; deMarchi, N; Ewen-White, KR; Walsh, D; Jay, M; Deleuze, JF; O'Neill, FA; Papadimitriou, G; Weilbaecher, A; Lerer, B; O'Donovan, MC; Dikeos, D; Silverman, JM; Kendler, KS; Mallet, J; Crowe, RR; Walters, M				Levinson, DF; Holmans, PA; Laurent, C; Riley, B; Pulver, AE; Gejman, PV; Schwab, SG; Williams, NM; Owen, MJ; Wildenauer, DB; Sanders, AR; Nestadt, G; Mowry, BJ; Wormley, B; Bauche, S; Soubigou, S; Ribble, R; Nertney, DA; Liang, KY; Martinolich, L; Maier, W; Norton, N; Williams, H; Albus, M; Carpenter, EB; deMarchi, N; Ewen-White, KR; Walsh, D; Jay, M; Deleuze, JF; O'Neill, FA; Papadimitriou, G; Weilbaecher, A; Lerer, B; O'Donovan, MC; Dikeos, D; Silverman, JM; Kendler, KS; Mallet, J; Crowe, RR; Walters, M			No major schizophrenia locus detected on chromosome 1q in a large multicenter sample	SCIENCE			English	Article							SUSCEPTIBILITY LOCI; LINKAGE ANALYSIS; GENOME SCAN; GENES; 6Q	Reports of substantial evidence for genetic linkage of schizophrenia to chromosome 1q were evaluated by genotyping 16 DNA markers across 107 centimorgans of this chromosome in a multicenter sample of 779 informative schizophrenia pedigrees. No significant evidence was observed for such linkage, nor for heterogeneity in allele sharing among the eight individual samples. Separate analyses of European-origin families, recessive models of inheritance, and families with larger numbers of affected cases also failed to produce significant evidence for linkage. If schizophrenia susceptibility genes are present on chromosome 1q, their population-wide genetic effects are likely to be small.	Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; MRC, Biostat Unit, Cambridge CB2 2SR, England; Hop La Pitie Salpetriere, CNRS, Lab Genet Mol Neurotransmiss & Proc Neurodegenera, F-75013 Paris, France; Virginia Commonwealth Univ, Dept Psychiat, Virginia Inst Psychiat & Behav Genet, Richmond, VA 23298 USA; Johns Hopkins Univ, Dept Psychiat, Baltimore, MD 21231 USA; Univ Chicago, Dept Psychiat, Chicago, IL 60637 USA; Univ Bonn, Dept Psychiat, D-53105 Bonn, Germany; Univ Wales Coll Med, Dept Psychol Med, Cardiff CF14 4XN, S Glam, Wales; Wolston Pk Hosp, Queensland Ctr Schizophrenia Res, Wacol, Qld 4076, Australia; Univ Queensland, Dept Psychiat, Brisbane, Qld 4029, Australia; Aventis Pharma SA, F-91006 Evry, France; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21231 USA; State Mental Hosp, D-85529 Haar, Germany; Univ Naples 2, Psychiat Clin, I-80138 Naples, Italy; Walter & Eliza Hall Inst Med Res, Australian Genome Res Facil, Melbourne, Vic 3050, Australia; Hlth Res Board, Dublin 2, Ireland; Queens Univ Belfast, Dept Psychiat, Belfast BT7 1NN, Antrim, North Ireland; Univ Athens, Sch Med, Dept Psychiat, Athens 11526, Greece; Hadassah Hebrew Univ Med Ctr, Dept Psychiat, IL-91120 Jerusalem, Israel; Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; Univ Iowa, Coll Med, Mental Hlth Clin Res Ctr, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; Queensland Inst Med Res, Herston, Qld 4006, Australia	University of Pennsylvania; MRC Biostatistics Unit; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Virginia Commonwealth University; Johns Hopkins University; University of Chicago; University of Bonn; Cardiff University; University of Queensland; Sanofi-Aventis; Sanofi France; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Universita della Campania Vanvitelli; Walter & Eliza Hall Institute; Health Research Board - Ireland; Queens University Belfast; Athens Medical School; National & Kapodistrian University of Athens; Hebrew University of Jerusalem; Icahn School of Medicine at Mount Sinai; University of Iowa; University of Iowa; QIMR Berghofer Medical Research Institute	Levinson, DF (corresponding author), Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.		Kendler, Kenneth/AAF-2876-2019; O'Donovan, Michael C/P-7005-2018; Liang, Kung-Yee/F-8299-2011; Silverman, Jeremy M./AAO-4268-2020; Carpenter, Everett/A-2797-2010; Williams, Hywel/AAL-2440-2021; Holmans, Peter/F-4518-2015; O'Neill, Francis A/C-5582-2008; Mowry, Bryan/G-5046-2010	O'Donovan, Michael C/0000-0001-7073-2379; Carpenter, Everett/0000-0002-3497-0318; Williams, Hywel/0000-0001-7758-0312; Holmans, Peter/0000-0003-0870-9412; O'Neill, Francis A/0000-0002-7531-7657; Mowry, Bryan/0000-0002-4115-5645; Bauche, Stephanie/0000-0002-6926-339X	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052537, R01MH057314, R01MH045390, U01MH046318, R01MH041953, U01MH046289, K24MH064197] Funding Source: NIH RePORTER; Medical Research Council [G9810900, G9309834] Funding Source: Medline; NIMH NIH HHS [MH 52537, K24-MH64197, MH 45390, U01 MH46318, MH61602, MH 41953, R01-MH57314, U01 MH46289] Funding Source: Medline; PHS HHS [KO2-01207] Funding Source: Medline; MRC [G9309834, G9810900] Funding Source: UKRI	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Blackwood DHR, 2001, AM J HUM GENET, V69, P428, DOI 10.1086/321969; Blouin JL, 1998, NAT GENET, V20, P70, DOI 10.1038/1734; Bonnet-Brilhault F, 1999, EUR J HUM GENET, V7, P247, DOI 10.1038/sj.ejhg.5200278; Bray NJ, 2001, TRENDS MOL MED, V7, P169, DOI 10.1016/S1471-4914(01)01950-5; Brzustowicz LM, 2000, SCIENCE, V288, P678, DOI 10.1126/science.288.5466.678; CAMPION D, 1994, PSYCHIAT RES, V51, P215, DOI 10.1016/0165-1781(94)90010-8; Cao QH, 1997, GENOMICS, V43, P1, DOI 10.1006/geno.1997.4815; CAVALLIFORZA L, 1994, HIST GEOGRAPHY HUMAN, P268; Cloninger CR, 1998, AM J MED GENET, V81, P275, DOI 10.1002/(SICI)1096-8628(19980710)81:4<275::AID-AJMG1>3.3.CO;2-U; Dorr DA, 1997, GENET EPIDEMIOL, V14, P617, DOI 10.1002/(SICI)1098-2272(1997)14:6<617::AID-GEPI11>3.0.CO;2-T; Ekelund J, 2001, HUM MOL GENET, V10, P1611, DOI 10.1093/hmg/10.15.1611; Ewen KR, 2000, AM J HUM GENET, V67, P727, DOI 10.1086/303048; Goring HHH, 2001, AM J HUM GENET, V69, P1357, DOI 10.1086/324471; Gurling HMD, 2001, AM J HUM GENET, V68, P661, DOI 10.1086/318788; Hauser ER, 1996, GENET EPIDEMIOL, V13, P117, DOI 10.1002/(SICI)1098-2272(1996)13:2<117::AID-GEPI1>3.0.CO;2-5; HOLMANS P, 1993, AM J HUM GENET, V52, P362; JAMES JW, 1971, ANN HUM GENET, V35, P47, DOI 10.1111/j.1469-1809.1956.tb01377.x; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Levinson DF, 1996, AM J MED GENET, V67, P580; Levinson DF, 2000, AM J HUM GENET, V67, P652, DOI 10.1086/303041; Levinson DF, 1998, AM J PSYCHIAT, V155, P741; Millar JK, 2000, HUM MOL GENET, V9, P1415, DOI 10.1093/hmg/9.9.1415; Schwab SG, 2000, MOL PSYCHIATR, V5, P638, DOI 10.1038/sj.mp.4000791; STRAUB RE, 1995, NAT GENET, V11, P287, DOI 10.1038/ng1195-287; Straub RE, 1998, AM J MED GENET, V81, P296, DOI 10.1002/(SICI)1096-8628(19980710)81:4<296::AID-AJMG4>3.0.CO;2-S; Terwilliger JD, 1998, CURR OPIN BIOTECH, V9, P578, DOI 10.1016/S0958-1669(98)80135-3; Tsuang MT, 2001, BRIT J PSYCHIAT, V178, pS18, DOI 10.1192/bjp.178.40.s18; Williams NM, 1999, HUM MOL GENET, V8, P1729, DOI 10.1093/hmg/8.9.1729	28	71	72	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					739	741		10.1126/science.1069914	http://dx.doi.org/10.1126/science.1069914			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976456				2022-12-28	WOS:000175281700056
J	Soden, BJ; Wetherald, RT; Stenchikov, GL; Robock, A				Soden, BJ; Wetherald, RT; Stenchikov, GL; Robock, A			Global cooling after the eruption of Mount Pinatubo: A test of climate feedback by water vapor	SCIENCE			English	Article							UPPER-TROPOSPHERE; SURFACE-TEMPERATURE; VOLCANIC-ERUPTION; RELATIVE-HUMIDITY; CLOUD FEEDBACK; SATELLITE DATA; VARIABILITY; RADIATION; AEROSOL; IMPACT	The sensitivity of Earth's climate to an external radiative forcing depends critically on the response of water vapor. We use the global cooling and drying of the atmosphere that was observed after the eruption of Mount Pinatubo to test model predictions of the climate feedback from water vapor. Here, we first highlight the success of the model in reproducing the observed drying after the volcanic eruption. Then, by comparing model simulations with and without water vapor feedback, we demonstrate the importance of the atmospheric drying in amplifying the temperature change and show that, without the strong positive feedback from water vapor, the model is unable to reproduce the observed cooling. These results provide quantitative evidence of the reliability of water vapor feedback in current climate models, which is crucial to their use for global warming projections.	Princeton Univ, NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA; Rutgers State Univ, Dept Environm Sci, New Brunswick, NJ 08901 USA	National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University; Rutgers State University New Brunswick	Soden, BJ (corresponding author), Princeton Univ, NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA.		Robock, Alan/B-6385-2016; Georgiy, Stenchikov/J-8569-2013; Soden, Brian/ABC-3659-2021; Stenchikov, Georgiy/AAA-4371-2022	Robock, Alan/0000-0002-6319-5656; Stenchikov, Georgiy Lvovich/0000-0001-9033-4925; Soden, Brian/0000-0001-9693-8236				Bates JJ, 1996, J CLIMATE, V9, P427, DOI 10.1175/1520-0442(1996)009<0427:IVOUTW>2.0.CO;2; BONY S, 1995, CLIM DYNAM, V11, P307, DOI 10.1007/BF00211682; CESS R, 1989, J GEOPHYS RES, V95, P16601; Chen JY, 2002, SCIENCE, V295, P838, DOI 10.1126/science.1065835; Christy JR, 2000, J ATMOS OCEAN TECH, V17, P1153, DOI 10.1175/1520-0426(2000)017<1153:MTTDCA>2.0.CO;2; DELGENIO AD, 1994, GEOPHYS RES LETT, V21, P2701, DOI 10.1029/94GL02658; DICKINSON RE, 1996, CLIMATE CHANGE 1995; FRANKLIN B, 1784, MANCHESTER LIT PHILO, V2, P122; Hall A, 1999, J CLIMATE, V12, P2327, DOI 10.1175/1520-0442(1999)012<2327:TROWVF>2.0.CO;2; HANSEN J, 1992, GEOPHYS RES LETT, V19, P215, DOI 10.1029/91GL02788; HEID I, 2000, ANNU REV ENERG ENV, V25, P441; Inamdar AK, 1998, J GEOPHYS RES-ATMOS, V103, P32177, DOI 10.1029/1998JD900007; Kiehl JT, 1997, B AM METEOROL SOC, V78, P197, DOI 10.1175/1520-0477(1997)078<0197:EAGMEB>2.0.CO;2; Kirchner I, 1999, J GEOPHYS RES-ATMOS, V104, P19039, DOI 10.1029/1999JD900213; Lau KM, 1996, GEOPHYS RES LETT, V23, P2971, DOI 10.1029/96GL02414; Levitus S., 1982, 13 NOAA; LINDZEN RS, 1990, B AM METEOROL SOC, V71, P288, DOI 10.1175/1520-0477(1990)071<0288:SCCGW>2.0.CO;2; MINNIS P, 1993, SCIENCE, V259, P1411, DOI 10.1126/science.259.5100.1411; MOLLER F, 1963, PLANET SPACE SCI, V5, P202; Parker DE, 1996, INT J CLIMATOL, V16, P487, DOI 10.1002/(SICI)1097-0088(199605)16:5<487::AID-JOC39>3.0.CO;2-J; Randel DL, 1996, B AM METEOROL SOC, V77, P1233, DOI 10.1175/1520-0477(1996)077<1233:ANGWVD>2.0.CO;2; RAVAL A, 1989, NATURE, V342, P758, DOI 10.1038/342758a0; RIND D, 1991, NATURE, V349, P500, DOI 10.1038/349500a0; ROBOCK A, 1995, J CLIMATE, V8, P1086, DOI 10.1175/1520-0442(1995)008<1086:TVSIST>2.0.CO;2; Robock A, 2000, REV GEOPHYS, V38, P191, DOI 10.1029/1998RG000054; RODGERS CD, 1976, REV GEOPHYS, V14, P609, DOI 10.1029/RG014i004p00609; Santer BD, 1999, J GEOPHYS RES-ATMOS, V104, P6305, DOI 10.1029/1998JD200096; Santer BD, 2001, J GEOPHYS RES-ATMOS, V106, P28033, DOI 10.1029/2000JD000189; Soden B, 2000, B AM METEOROL SOC, V81, P797, DOI 10.1175/1520-0477(2000)081<0797:AIORCF>2.3.CO;2; Soden BJ, 1997, J CLIMATE, V10, P1050, DOI 10.1175/1520-0442(1997)010<1050:VITTGE>2.0.CO;2; SODEN BJ, 1993, J GEOPHYS RES-ATMOS, V98, P16669, DOI 10.1029/93JD01283; Stenchikov GL, 1998, J GEOPHYS RES-ATMOS, V103, P13837, DOI 10.1029/98JD00693; STOWE LL, 1992, GEOPHYS RES LETT, V19, P159, DOI 10.1029/91GL02958; Susskind J, 1997, B AM METEOROL SOC, V78, P1449, DOI 10.1175/1520-0477(1997)078<1449:COTTPP>2.0.CO;2; TREPTE CR, 1993, J GEOPHYS RES-ATMOS, V98, P18563, DOI 10.1029/93JD01362; UDELHOFEN PM, 1995, J GEOPHYS RES-ATMOS, V100, P7423, DOI 10.1029/94JD02826; Wentz FJ, 2000, NATURE, V403, P414, DOI 10.1038/35000184; WETHERALD RT, 1988, J ATMOS SCI, V45, P1397, DOI 10.1175/1520-0469(1988)045<1397:CFPIAG>2.0.CO;2; Wielicki BA, 2002, SCIENCE, V295, P841, DOI 10.1126/science.1065837; [No title captured]	40	314	322	5	105	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					727	730		10.1126/science.296.5568.727	http://dx.doi.org/10.1126/science.296.5568.727			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976452				2022-12-28	WOS:000175281700052
J	Barnes, DKA				Barnes, DKA			Biodiversity - Invasions by marine life on plastic debris	NATURE			English	Article							DISPERSAL; ISLAND		British Antarctic Survey, Nat Environm Res Council, Cambridge CB3 OET, England; Univ Coll Cork, Dept Zool & Anim Ecol, Cork, Ireland	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Antarctic Survey; University College Cork	Barnes, DKA (corresponding author), British Antarctic Survey, Nat Environm Res Council, High Cross,Madingley Rd, Cambridge CB3 OET, England.	dkab@bas.ac.uk						Barnes DK, 2000, P 11 INT BRYOZ ASS C, P154; Bonner W.N., 1982, BRIT ANTARCT SURV B, V57, P73; DUNTON K, 1992, TRENDS ECOL EVOL, V7, P183, DOI 10.1016/0169-5347(92)90070-R; Goldberg E.D., 1995, CHEM ECOL, V10, P3, DOI [DOI 10.1080/02757549508035325, 10.1080/02757549508035325]; Gregory MR, 1999, OCEAN COAST MANAGE, V42, P603, DOI 10.1016/S0964-5691(99)00036-8; HIGHSMITH RC, 1985, MAR ECOL PROG SER, V25, P169, DOI 10.3354/meps025169; JOKIEL PL, 1990, ENDEAVOUR, V14, P66, DOI 10.1016/0160-9327(90)90074-2; MURPHY JM, 1995, J CLIMATE, V8, P496, DOI 10.1175/1520-0442(1995)008<0496:TROTHC>2.0.CO;2; Quayle WC, 2002, SCIENCE, V295, P645, DOI 10.1126/science.1064074; THRESHER RE, 1985, EVOLUTION, V39, P878, DOI 10.1111/j.1558-5646.1985.tb00429.x; Walker TR, 1997, MAR POLLUT BULL, V34, P61, DOI 10.1016/S0025-326X(96)00053-7; Winston Judith E., 1997, P81; 1999, BRIT ECOLOGICAL SOC	13	463	482	12	337	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	2002	416	6883					808	809		10.1038/416808a	http://dx.doi.org/10.1038/416808a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976671				2022-12-28	WOS:000175163800039
J	Dean, B; Schachter, M; Vincent, C; Barber, N				Dean, B; Schachter, M; Vincent, C; Barber, N			Causes of prescribing errors in hospital inpatients: a prospective study	LANCET			English	Article							ADVERSE DRUG EVENTS; INTENSIVE-CARE; UNITED-KINGDOM; MEDICATION; RISK; SAFETY	Background To prevent errors made during the prescription of drugs, we need to know why they arise. Theories of human error used to understand the causes of mistakes made in high-risk industries are being used in health-care. They have not, however, been applied to prescribing errors, which are a great cause of patient harm. Our aim was to use this approach to investigate the causes of such errors. Methods Pharmacists at a UK teaching hospital prospectively identified 88 potentially serious prescribing errors. We interviewed the prescribers who made 44 of these, and analysed our findings with human error theory. Findings Our results suggest that most mistakes were made because of slips in attention, or because prescribers did not apply relevant rules. Doctors identified many risk factors-work environment, workload, whether or not they were prescribing for their own patient, communication within their team, physical and mental well-being, and lack of knowledge. Organisational factors were also identified, and included inadequate training, low perceived importance of prescribing, a hierarchical medical team, and an absence of self-awareness of errors. Interpretation To reduce prescribing errors, hospitals should train junior doctors in the principles of drug dosing before they start prescribing, and enforce good practice in documentation. They should also create a culture in which prescription writing is seen as important, and formally review interventions made by pharmacists, locum arrangements, and the workload of junior doctors, and make doctors aware of situations in which they are likely to commit errors.	Univ London, Sch Pharm, Ctr Practice & Policy, London WC1N 1AX, England; Imperial Coll Sch Med, London, England; UCL, Clin Risk Univ, London, England	University of London; University College London; University of London School of Pharmacy; Imperial College London; University of London; University College London	Dean, B (corresponding author), Hammersmith Hosp NHS Trust, Dept Pharm, Acad Pharm Unit, London W12 0HS, England.	bdean@hhnt.org	Dean, Brian/M-3558-2019; Vincent, Charles A/D-1134-2010	Dean, Brian/0000-0001-7773-4473; Vincent, Charles A/0000-0003-0270-0222; Franklin, Bryony/0000-0002-2892-1245				ADAMS JGU, 1988, ERGONOMICS, V31, P407, DOI 10.1080/00140138808966688; Barber N, 1993, INT J PHARM PRACT, V2, P152; Barber ND, 1997, AM J HEALTH-SYST PH, V54, P397, DOI 10.1093/ajhp/54.4.397; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Battles JB, 1998, ARCH PATHOL LAB MED, V122, P231; BLEYER WA, 1979, AM J DIS CHILD, V133, P366, DOI 10.1001/archpedi.1979.02130040020002; COTTER SM, 1994, AM J HOSP PHARM, V51, P2676, DOI 10.1093/ajhp/51.21.2676; Dean B, 2000, QUAL HEALTH CARE, V9, P232, DOI 10.1136/qhc.9.4.232; DEAN BS, IN PRESS QUAL HLTH C; *DEP HLTH SOC SERV, 1970, HM7036 DHHS DEP HLTH; Department of Health, 2000, EXP GROUP LEARN ADV; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; Jacklin A, 2001, PHARM PRACT, V11, P100; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; LESAR TS, 1992, ANN INTERN MED, V117, P537, DOI 10.7326/0003-4819-117-6-537_2; Lesar TS, 1997, ARCH INTERN MED, V157, P1569, DOI 10.1001/archinte.157.14.1569; Lesar TS, 1998, ARCH PEDIAT ADOL MED, V152, P340; MCEWAN D, 1999, THESIS U LONDON; NEALE G, 1995, CLIN RISK MANAGEMENT, P253; PERLSTEIN PH, 1979, AM J DIS CHILD, V133, P376, DOI 10.1001/archpedi.1979.02130040030006; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; Rowe C, 1998, ARCH DIS CHILD, V79, P56, DOI 10.1136/adc.79.1.56; Vincent C, 2000, BRIT MED J, V320, P777, DOI 10.1136/bmj.320.7237.777; Vincent C, 1998, BRIT MED J, V316, P1154, DOI 10.1136/bmj.316.7138.1154; VITILLO JA, 1991, DICP ANN PHARMAC, V25, P1388, DOI 10.1177/106002809102501221	27	389	404	0	51	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	2002	359	9315					1373	1378		10.1016/S0140-6736(02)08350-2	http://dx.doi.org/10.1016/S0140-6736(02)08350-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978334				2022-12-28	WOS:000175076200009
J	Jewkes, R				Jewkes, R			Intimate partner violence: causes and prevention	LANCET			English	Article							DOMESTIC VIOLENCE; WIFE ABUSE; WOMEN; SAMPLE	Unlike many health problems, there are few social and demographic characteristics that define risk groups for intimate partner violence. Poverty is the exception and increases risk through effects on conflict, women's power; and male identity. Violence is used as a strategy in conflict. Relationships full of conflict, and especially those in which conflicts occur about finances, jealousy, and women's gender role transgressions are more violent than peaceful relationships. Heavy alcohol consumption also increases risk of violence. Women who are more empowered educationally, economically, and socially are most protected, but below this high level the relation between empowerment and risk of violence is non-linear. Violence is frequently used to resolve a crisis of male identity, at times caused by poverty or an inability to control women. Risk of violence is greatest in societies where the use of violence in many situations is a socially-accepted norm. Primary preventive interventions should focus on improving the status of women and reducing norms of violence, poverty, and alcohol consumption.	MRC, Gender & Hlth Grp, ZA-0001 Pretoria, South Africa		Jewkes, R (corresponding author), MRC, Gender & Hlth Grp, Private Bag X385, ZA-0001 Pretoria, South Africa.	rjewkes@mrc.ac.za		Jewkes, Rachel/0000-0002-4330-6267				ABBY A, 1995, DRUG ALCOHOL REV, V5; ABRAHAMS N, 1999, I DONT BELIEVE DEMOC; Bachman R., 1995, BUREAU JUSTICE STAT; Bourgois P, 1996, BRIT J CRIMINOL, V36, P412; Bourgois Philippe, 1996, SEARCH RESPECT SELLI; COSNER LA, 1967, CONTINUITIES STUDY S; Counts DA, 2019, SANCTIONS SANCTUARY, P1, DOI 10.4324/9780429305306; Dearwater SR, 1998, JAMA-J AM MED ASSOC, V280, P433, DOI 10.1001/jama.280.5.433; *DEP HLTH, IN PRESS S AFR DEM H; EDWARDS JN, 1992, J MARRIAGE FAM, V54, P59, DOI 10.2307/353275; Ellsberg M, 2001, STUD FAMILY PLANN, V32, P1, DOI 10.1111/j.1728-4465.2001.00001.x; Ellsberg MC, 1999, AM J PUBLIC HEALTH, V89, P241, DOI 10.2105/AJPH.89.2.241; FARRINGTON DP, 1998, CRIME JUSTICE, V0024; Gelles R.J., 1974, VIOLENT HOME; GELLES RJ, 1987, FAMILY VIOLENCE; GELLES RJ, 1998, INTIMATE VIOLENCE CA; Harvey P., 1994, SEX VIOLENCE ISSUES, ppp66; HEISE L, 1999, POPULATION REPORTS, V27; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; HOFFMAN KL, 1994, J MARRIAGE FAM, V56, P131, DOI 10.2307/352709; Hotaling G T, 1986, Violence Vict, V1, P101; *INT CLIN EP NETW, 2000, DOM VIOL IND SUMM RE; Jewkes R, 2000, REPROD HEALTH MATTER, V8, P93, DOI 10.1016/S0968-8080(00)90010-7; Jewkes R, 1998, SOC SCI MED, V47, P1781, DOI 10.1016/S0277-9536(98)00240-8; JEWKES R, IN PRESS SOC SCI MED; Johnson H, 1996, DANGEROUS DOMAINS VI, P252; Jones AS, 1999, WOMEN HEALTH ISS, V9, P295; Kandiyoti D., 1994, DISLOCATING MASCULIN, P196; KANTOR GK, 1993, ALCOHOL INTERPERSONA, P281; Kawachi I, 1997, BMJ-BRIT MED J, V314, P1037, DOI 10.1136/bmj.314.7086.1037; LEVINS D, 1989, VIOLENCE CROSS CULTU; Mager A, 1999, GENDER MAKING S AFRI; Martin SL, 1999, AM J EPIDEMIOL, V150, P417, DOI 10.1093/oxfordjournals.aje.a010021; MCCALL GJ, 1986, VIOLENCE HOME INTERD; MCDONALD M, 1994, GENDER DRINK DRUGS, P14; MCFARLANE J, IN PRESS AM J PUBLIC; Mechanic M B, 2000, Violence Vict, V15, P443; MICZEK KA, 1994, UNDERSTANDING PREVEN, V3, P377; MOORE H, 1994, PASSION DIFFERENCE S; Morrell R, 2001, CHANGING MEN SO AFRI; O'Muircheartaigh C, 1998, J ROY STAT SOC A STA, V161, P63, DOI 10.1111/1467-985X.00090; OBRIEN JE, 1971, J MARRIAGE FAM, V33, P692, DOI 10.2307/349443; OKUN L, 1986, WOMEN ABUSE FACTS RE; Pagelow M., 1984, FAMILY VIOLENCE; Rao V, 1997, SOC SCI MED, V44, P1169, DOI 10.1016/S0277-9536(96)00252-3; RATNER PA, 1993, CAN J PUBLIC HEALTH, V84, P246; Rodman H., 1972, J COMP FAM STUD, V3, P50, DOI [10.3138/jcfs.3.1.50, DOI 10.3138/JCFS.3.1.50]; Schuler SR, 1996, SOC SCI MED, V43, P1729, DOI 10.1016/S0277-9536(96)00068-8; Skinner C.J., 1989, ANAL COMPLEX SURVEYS; STEINMETZ SK, 1987, HDB MARRIAGE FAMILY, P725; STETS JE, 1990, J MARRIAGE FAM, V52, P501, DOI 10.2307/353043; Straus M.M.A., 1980, CLOSED DOORS VIOLENC; Sugarman DB, 1996, J FAM VIOLENCE, V11, P13, DOI 10.1007/BF02333338; TJADEN P, 2000, VIOLENCE WOMEN, V0006; WIKSTROM PH, 1985, EVERYDAY VIOLENCE CO; Wood K, 2001, CHANGING MEN SO AFRI; YLLO K, 1998, FEMINIST PERSPECTIVE; 1997, SOUL CITY 1997 VIOLE	58	1038	1052	6	186	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	2002	359	9315					1423	1429		10.1016/S0140-6736(02)08357-5	http://dx.doi.org/10.1016/S0140-6736(02)08357-5			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	542ZQ	11978358				2022-12-28	WOS:000175076200032
J	Coombs, R; Georghiou, L				Coombs, R; Georghiou, L			Research and development - New "industrial ecology"	SCIENCE			English	Article									UMIST, Manchester Sch Management, Manchester M60 1QD, Lancs, England; Univ Manchester, Ctr Res Innovat & Competit, Manchester M60 1QD, Lancs, England	University of Manchester; University of Manchester	Coombs, R (corresponding author), UMIST, Manchester Sch Management, Manchester M60 1QD, Lancs, England.		Georghiou, Luke/J-1345-2014	Georghiou, Luke/0000-0002-3324-4955				COOMBS R, 2001, GENERATION SELECTION; GIBBONS M., 1994, NEW PRODUCTION KNOWL; HOWARDSPINK S, POWER PROTEINS; HOWELLS J, 1997, 6 U MANCH CTR RES IN; LARSEN CF, 2000, R D IND 1999, P6; SHEEHAN J, 2001, DSTPSTP200129 OECD O	6	32	32	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					471	471		10.1126/science.1068350	http://dx.doi.org/10.1126/science.1068350			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964461				2022-12-28	WOS:000175179400023
J	Rodondi, N; Darioli, R; Ramelet, AA; Hohl, D; Lenain, V; Perdrix, J; Wietlisbach, V; Riesen, WF; Walther, T; Medinger, L; Nicod, P; Desvergne, A; Mooser, V				Rodondi, N; Darioli, R; Ramelet, AA; Hohl, D; Lenain, V; Perdrix, J; Wietlisbach, V; Riesen, WF; Walther, T; Medinger, L; Nicod, P; Desvergne, A; Mooser, V			High risk for hyperlipidemia and the metabolic syndrome after an episode of hypertriglyceridemia during 13-cis retinoic acid therapy for acne: A pharmacogenetic study	ANNALS OF INTERNAL MEDICINE			English	Article							FAMILIAL COMBINED HYPERLIPIDEMIA; INSULIN-RESISTANCE; ISOTRETINOIN THERAPY; DISEASE; DYSLIPIDEMIA; CHOLESTEROL; LINKAGE; LIPIDS	Background: Administration of 13-cis retinoic acid (isotretinoin) for acne is occasionally accompanied by hyperlipidemia. It is not known why some persons develop this side effect. Objective: To determine whether isotretinoin triggers a familial susceptibility to hyperlipidemia and the metabolic syndrome. Design: cross-sectional comparison. Setting: University hospital in Lausanne, Switzerland. Participants: 102 persons in whom triglyceride levels increased at least 1.0 mmol/L (greater than or equal to89 mg/dL) (hyperresponders) and 100 persons in whom triglyceride levels changed 0.1 mmol/L (less than or equal to9 mg/dL) or less (nonresponders) during isotretinoin therapy for acne. Parents of 71 hyperresponders and 60 nonresponders were also evaluated. Measurements: Waist-to-hip ratio; fasting glucose, insulin, and lipid levels; and apoE genotype. Results: Hyperresponders and nonresponders had similar pre-treatment body weight and plasma lipid levels. When reevaluated approximately 4 years after completion of isotretinoin therapy, hyperresponders were more likely to have hypertriglyceridemia (triglyceride level > 2.0 mmol/L [>177 mg/dL]; odds ratio [OR], 4.8 [95% Cl, 1.6 to 13.81), hypercholesterolemia (cholesterol level > 6.5 mmol/L [>252 mg/dL]; OR, 9.1 [Cl, 1.9 to 43)), truncal obesity (waist-to-hip ratio > 0.90 [OR, 11.0 (Cl, 2.0 to 59]), and hyperinsulinemia (insulin-glucose ratio > 7.2; OR, 3.0 [Cl, 1.6 to 5.71). In addition, more hyperresponders had at least one parent with hypertriglyceridemia (OR, 2.6 [Cl, 1.2 to 5.7]) or a ratio of total to high-density lipoprotein cholesterol that exceeded 4.0 (OR, 3.5 (Cl, 1.5 to 8.0]). Lipid response to isotretinoin was closely associated with the apoE gene. Conclusion: Persons who develop hypertriglyceridemia during isotretinoin therapy for acne, as well as their parents, are at increased risk for future hyperlipidemia and the metabolic syndrome.	CHUV Univ Hosp, Dept Med, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Mooser, V (corresponding author), CHUV Univ Hosp, Dept Med, CH-1011 Lausanne, Switzerland.	vincent.mooser@chuv.hospvd.ch	Hohl, Daniel M/N-7554-2016; Desvergne, Beatrice/C-8892-2016	Desvergne, Beatrice/0000-0001-5483-288X; Rodondi, Nicolas/0000-0001-9083-6896				Aitman TJ, 1997, ARTERIOSCL THROM VAS, V17, P748, DOI 10.1161/01.ATV.17.4.748; Ascaso JF, 1997, AM J CARDIOL, V80, P1484, DOI 10.1016/S0002-9149(97)00737-6; BERSHAD S, 1985, NEW ENGL J MED, V313, P981, DOI 10.1056/NEJM198510173131604; DallingaThie GM, 1997, J CLIN INVEST, V99, P953, DOI 10.1172/JCI119260; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; DEFRONZO RA, 1991, DIABETES CARE, V14, P173, DOI 10.2337/diacare.14.3.173; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; Grundy SM, 1999, AM J CARDIOL, V83, p25F; HIXSON JE, 1990, J LIPID RES, V31, P545; JAMES RW, 1987, SCHWEIZ MED WSCHR, V117, P2021; Liese AD, 1997, DIABETOLOGIA, V40, P963, DOI 10.1007/s001250050775; MCCARTER TL, 1992, AM J GASTROENTEROL, V87, P1855; Periard D, 1999, CIRCULATION, V100, P700, DOI 10.1161/01.CIR.100.7.700; Pichard C, 1997, NUTRITION, V13, P952, DOI 10.1016/S0899-9007(97)00336-5; REAVEN GM, 1995, PHYSIOL REV, V75, P473, DOI 10.1152/physrev.1995.75.3.473; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Wang JP, 1998, J CLIN INVEST, V101, P1283, DOI 10.1172/JCI1343; ZECH LA, 1983, ARCH DERMATOL, V119, P987, DOI 10.1001/archderm.119.12.987	18	60	67	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2002	136	8					582	589		10.7326/0003-4819-136-8-200204160-00007	http://dx.doi.org/10.7326/0003-4819-136-8-200204160-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	543WY	11955026				2022-12-28	WOS:000175125800003
J	Double, D				Double, D			The limits of psychiatry	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DSM-III		Norfolk Mental Hlth Care NHS Trust, Norwich NR6 5BE, Norfolk, England		Double, D (corresponding author), Norfolk Mental Hlth Care NHS Trust, Norwich NR6 5BE, Norfolk, England.	dbdouble@dbdouble.co.uk						American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BEISER M, 1978, TODAYS PRIORITIES ME; Bracken P, 2001, BMJ-BRIT MED J, V322, P724, DOI 10.1136/bmj.322.7288.724; Bracken Patrick., 1998, RETHINKING TRAUMA WA; *BRIT ROYAL INF, 2001, CM5207; Charlton BG, 1998, J ROY SOC MED, V91, P599, DOI 10.1177/014107689809101117; Illich I, 1995, LIMITS MED MED NEMES, VEnl; Jellinek EM., 1960, DIS CONCEPT ALCOHOLI; Kennedy I, 1983, UNMASKING MED; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Klerman G., 1978, SCHIZOPHRENIA SCI PR; Lord J, 2000, CLIN EFFECTIVENESS C; MELTZER H, 1995, PREVALENCE PSYCHIAT; MUNRO R, 1999, COLUMBIA J ASIAN LAW, P13; RICHMAN A, 1985, BRIT J PSYCHIAT, V146, P164, DOI 10.1192/bjp.146.2.164; ROSENHAN DL, 1973, SCIENCE, V179, P250, DOI 10.1126/science.179.4070.250; Singleton N., 1998, PSYCHIAT MORBIDITY P; Stein MB, 2001, J PSYCHIATR NEUROSCI, V26, P185; TANTUM D, 1991, 150 YEARS BRIT PSYCH; Wender PH, 1998, PSYCHIAT CLIN N AM, V21, P761, DOI 10.1016/S0193-953X(05)70039-3; WILSON M, 1993, AM J PSYCHIAT, V150, P399; WINTERS E, 1951, COLLECTED PAPERS A M, V1; Zito JM, 2000, JAMA-J AM MED ASSOC, V283, P1025, DOI 10.1001/jama.283.8.1025	23	61	67	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 13	2002	324	7342					900	904		10.1136/bmj.324.7342.900	http://dx.doi.org/10.1136/bmj.324.7342.900			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950743	Green Published			2022-12-28	WOS:000175052200029
J	Moynihan, R; Heath, I; Henry, D				Moynihan, R; Heath, I; Henry, D			Selling sickness: the pharmaceutical industry and disease mongering	BRITISH MEDICAL JOURNAL			English	Article							ERECTILE DYSFUNCTION; VERTEBRAL FRACTURES; MEDICALIZATION; ALENDRONATE; PREVALENCE; MEDICINE; LIMITS; TRIAL; WOMEN; RISK		Australian Financial Review, Sydney, NSW 2201, Australia; Caversham Grp, London NW5 2UP, England; Univ Newcastle, Fac Hlth, Sch med Practice & Populat Hlth, Newcastle, NSW 2308, Australia	University of Newcastle	Moynihan, R (corresponding author), Australian Financial Review, GPO Box 506, Sydney, NSW 2201, Australia.		Henry, David/AAU-4650-2020; Henry, David/AAJ-4332-2020; Moynihan, Ray/ABC-3010-2020	Henry, David/0000-0001-7169-7704; Henry, David/0000-0003-2934-2242; 				Bentall Richard, 1999, J MENTAL HLTH, V8, P261, DOI DOI 10.1080/09638239917427; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Chew KK, 2000, INT J IMPOT RES, V12, P41, DOI 10.1038/sj.ijir.3900457; Cook J., 2001, PHARM MARKETING, V6, P1422; CRAWFORD R, 1980, INT J HEALTH SERV, V10, P365, DOI 10.2190/3H2H-3XJN-3KAY-G9NY; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Gilbert D, 2000, BRIT MED J, V321, P1341, DOI 10.1136/bmj.321.7272.1341; GREEN CJ, 1997, BONE MINERAL DENSITY; Heath I, 1999, BRIT MED J, V318, P439; HEATH S, 1998, AGE             0330, P16; HICKMAN B, 1998, AUSTRALIAN      0521, P4; ILLICH I, 1990, LIMITS MED; Moynihan R, 2000, NEW ENGL J MED, V342, P1645, DOI 10.1056/NEJM200006013422206; MOYNIHAN R, 1998, TOO MUCH MED, P137; MOYNIHAN R, 2000, AUSTR FINANCIAL 1113, P29; Payer Lynn, 1992, DIS MONGERS; Pinnock CB, 1999, MED J AUSTRALIA, V171, P353, DOI 10.5694/j.1326-5377.1999.tb123691.x; *US FDA, 2002, GLAX WELLC DEC WITHD; Wade JP, 2001, CAN MED ASSOC J, V165, P45; Wilkin TJ, 1999, BRIT MED J, V318, P862, DOI 10.1136/bmj.318.7187.862; Williams SJ, 1996, SOC SCI MED, V42, P1609, DOI 10.1016/0277-9536(95)00313-4; 2002, LOTRONEX INFORMATION; 2000, SYDNEY MORNING  1021, P76	23	540	560	0	64	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					886	890		10.1136/bmj.324.7342.886	http://dx.doi.org/10.1136/bmj.324.7342.886			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950740	Green Published			2022-12-28	WOS:000175052200025
J	Brock, DW				Brock, DW			Human cloning and our sense of self	SCIENCE			English	Article								This Viewpoint formulates and responds to three Lines of argument concerning human reproductive cloning's potential to undermine our sense of self or identity. First, cloning would undermine our sense of individuality or uniqueness. But it could only undermine our genetic uniqueness, not our full individuality. Second, cloning would undermine the value or worth of human beings. But it would not make individuals replaceable or of any Less moral worth. Third, a clone's freedom or autonomy to construct his or her own life would be undermined by the presence of an earlier twin. But only a mistaken belief in genetic determinism supports this feared loss of freedom.	Brown Univ, Dept Philosophy, Providence, RI 02912 USA	Brown University	Brock, DW (corresponding author), Brown Univ, Dept Philosophy, Providence, RI 02912 USA.							Aiken W., 1980, WHOSE CHILD, P124; Baker L.R, 2000, PERSONS BODIES CONST; Brock D. W., 1997, CLONING HUMAN BEINGS; KASS L, 1997, NEW REPUBLIC    0602; Macklin Ruth, 1994, Kennedy Institute of Ethics Journal, V4, P209; Murphy J. F., 1974, CONCEPTS LEISURE PHI; Schechtman M., 1996, CONSTITUTION SELVES	7	22	22	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					314	316		10.1126/science.1070371	http://dx.doi.org/10.1126/science.1070371			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951036				2022-12-28	WOS:000175000300047
J	Hanotte, O; Bradley, DG; Ochieng, JW; Verjee, Y; Hill, EW; Rege, JEO				Hanotte, O; Bradley, DG; Ochieng, JW; Verjee, Y; Hill, EW; Rege, JEO			African pastoralism: Genetic imprints of origins and migrations	SCIENCE			English	Article							BOS-TAURUS; CATTLE; TAURINE	The genetic history of African cattle pastoralism is controversial and poorly understood. We reveal the genetic signatures of its origins, secondary movements, and differentiation through the study of 15 microsatellite Loci in 50 indigenous cattle breeds spanning the present cattle distribution in Africa. The earliest cattle originated within the African continent, but Near East and European genetic influences are also identified. The initial expansion of African Bos taurus was Likely from a single region of origin. It reached the southern part of the continent by following an eastern route rather than a western one. The B. indicus genetic influence shows a major entry point through the Horn and the East Coast of Africa and two modes of introgression into the continent.	Int Livestock Res Inst, Nairobi, Kenya; Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Dublin 2, Ireland; Int Livestock Res Inst, Addis Ababa, Ethiopia	CGIAR; International Livestock Research Institute (ILRI); Trinity College Dublin; CGIAR; International Livestock Research Institute (ILRI)	Hanotte, O (corresponding author), Int Livestock Res Inst, POB 30709, Nairobi, Kenya.	o.hanotte@cgiar.org	Bradley, Daniel G/A-3240-2012; Hanotte, Olivier/B-4669-2013	Hanotte, Olivier/0000-0002-2877-4767; Hill, Emmeline/0000-0002-1805-2250; Bradley, Daniel G/0000-0001-7335-7092				BARBUJANI G, 1995, AM J PHYS ANTHROPOL, V96, P109, DOI 10.1002/ajpa.1330960202; Bradley DG, 1996, P NATL ACAD SCI USA, V93, P5131, DOI 10.1073/pnas.93.10.5131; BRADLEY DG, 2000, ORIGINS DEV AFRICAN, P244; Clutton-Brock J., 1993, ARCHAEOLOGY AFRICA F, V20, P61; Denbow J, 1990, AFR ARCHAEOL REV, V8, P139, DOI DOI 10.1007/BF01116874; Epstein H, 1971, ORIGINS DOMESTIC ANI, V1; Fix AG, 1997, HUM BIOL, V69, P663; Gifford-Gonzalez D., 2000, ARCHAEL REV, V17, P95, DOI DOI 10.1023/A:1006601020217; Grigson C., 1989, BAR International Series, P77; Hanotte O, 2000, MOL ECOL, V9, P387, DOI 10.1046/j.1365-294x.2000.00858.x; Harlan J. R, 1993, ARCHAEOLOGY AFRICA F, P53; Hassan F.A., 2000, ORIGINS DEV AFRICAN, P61; Loftus RT, 1999, MOL ECOL, V8, P2015, DOI 10.1046/j.1365-294x.1999.00805.x; MacDonald K., 2000, ORIGINS DEV AFRICAN; MacHugh DE, 1997, GENETICS, V146, P1071; Marshall F., 2000, ORIGIN DEV AFRICAN L, P191; MUZZOLINI A, 1983, THESIS U PROVENCE AI; NDERITO PC, 1976, AFRICAN DISTRIBUTION; Newman JL., 1995, PEOPLING AFRICA GEOG; REGE JEO, 1996, P 2 AFR C AN AGR PRE; ROBERTS DF, 1965, HUM BIOL, V37, P38; SMITH AB, 1992, ANNU REV ANTHROPOL, V21, P125; TROY C, 2000, THESIS TRINITY COLL; WADE MJ, 1988, EVOLUTION, V42, P995, DOI 10.1111/j.1558-5646.1988.tb02518.x; Wendorf F, 1998, J ANTHROPOL ARCHAEOL, V17, P97, DOI 10.1006/jaar.1998.0319	25	337	349	2	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	2002	296	5566					336	339		10.1126/science.1069878	http://dx.doi.org/10.1126/science.1069878			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951043				2022-12-28	WOS:000175000300055
J	Nathanson, N; Fine, P				Nathanson, N; Fine, P			Virology: Poliomyelitis eradication - a dangerous endgame	SCIENCE			English	Editorial Material									Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA; Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England	University of Pennsylvania; University of Pennsylvania; University of London; London School of Hygiene & Tropical Medicine	Nathanson, N (corresponding author), Univ Penn, Dept Microbiol, Philadelphia, PA 19104 USA.	nathansn@mail.med.upenn.edu; paul.fine@lshtm.ac.uk						ABRAHAM R, 1993, J INFECT DIS, V168, P1105, DOI 10.1093/infdis/168.5.1105; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P874; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P41; DUNN G, 1990, J MED VIROL, V32, P92, DOI 10.1002/jmv.1890320205; Fine PEM, 1999, AM J EPIDEMIOL, V150, P1001, DOI 10.1093/oxfordjournals.aje.a009924; Greenwood BM, 1997, J INFECT DIS, V175, pS215; Henderson DA, 2002, CLIN INFECT DIS, V34, P79, DOI 10.1086/323897; Kew O, 2002, SCIENCE, V296, P356, DOI 10.1126/science.1068284; MINOR PD, 1992, J GEN VIROL, V73, P3065, DOI 10.1099/0022-1317-73-12-3065; Orenstein W, 2002, CLIN INFECT DIS, V34, P72, DOI 10.1086/338262	10	25	28	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	2002	296	5566					269	270		10.1126/science.1071207	http://dx.doi.org/10.1126/science.1071207			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951020				2022-12-28	WOS:000175000300031
J	Kyba, M; Perlingeiro, RCR; Daley, GQ				Kyba, M; Perlingeiro, RCR; Daley, GQ			HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors	CELL			English	Article							IN-VITRO; HOMEOBOX GENES; MOUSE EMBRYO; BONE-MARROW; EXPRESSION; OVEREXPRESSION; DIFFERENTIATION; SUBPOPULATIONS; ACTIVATION; CULTURE	The extent to which primitive embryonic blood progenitors contribute to definitive lymphoid-myeloid hematopoiesis In the adult remains uncertain. In an effort to characterize factors that distinguish the definitive adult hematopoietic stem cell (HSC) and primitive progenitors derived from yolk sac or embryonic stem (ES) cells, we examined the effect of ectopic expression of HoxB4, a homeotic selector gene implicated in self-renewal of definitive HSCs. Expression of HoxB4 in primitive progenitors combined with culture on hematopoietic stroma induces a switch to the definitive HSC phenotype. These progenitors engraft lethally irradiated adults and contribute to long-term, multilineage hematopoiesis in primary and secondary recipients. Our results suggest that primitive HSCs are poised to become definitive HSCs and that this transition can be promoted by HoxB4 expression. This strategy for blood engraftment enables modeling of hematopoietic transplantation from ES cells.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol Oncol, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital	Daley, GQ (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.			Kyba, Michael/0000-0002-5579-7534	NATIONAL CANCER INSTITUTE [R01CA086991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059279] Funding Source: NIH RePORTER; NCI NIH HHS [CA86991] Funding Source: Medline; NIDDK NIH HHS [DK59279] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bronson SK, 1996, P NATL ACAD SCI USA, V93, P9067, DOI 10.1073/pnas.93.17.9067; Brun A, 2001, BLOOD, V98, p66A; Buske C, 2001, BLOOD, V97, P2286, DOI 10.1182/blood.V97.8.2286; Cumano A, 1996, CELL, V86, P907, DOI 10.1016/S0092-8674(00)80166-X; Cumano A, 2001, IMMUNITY, V15, P477, DOI 10.1016/S1074-7613(01)00190-X; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Gould A, 1997, GENE DEV, V11, P900, DOI 10.1101/gad.11.7.900; Helgason CD, 1996, BLOOD, V87, P2740, DOI 10.1182/blood.V87.7.2740.bloodjournal8772740; Hole N, 1996, BLOOD, V88, P1266, DOI 10.1182/blood.V88.4.1266.bloodjournal8841266; Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; Matsuoka S, 2001, BLOOD, V98, P6, DOI 10.1182/blood.V98.1.6; McGrath KE, 1997, MOL REPROD DEV, V48, P145, DOI 10.1002/(SICI)1098-2795(199710)48:2&lt;145::AID-MRD1&gt;3.0.CO;2-S; Medvinsky A, 1996, CELL, V86, P897, DOI 10.1016/S0092-8674(00)80165-8; MULLER AM, 1993, DEVELOPMENT, V118, P1343; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; North T, 1999, DEVELOPMENT, V126, P2563; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Perlingeiro RCR, 2001, DEVELOPMENT, V128, P4597; Potocnik AJ, 1997, P NATL ACAD SCI USA, V94, P10295, DOI 10.1073/pnas.94.19.10295; Rideout WM, 2002, CELL, V109, P17, DOI 10.1016/S0092-8674(02)00681-5; Sanchez MJ, 1996, IMMUNITY, V5, P513, DOI 10.1016/S1074-7613(00)80267-8; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Weissman I, 1978, DIFFERENTIATION NORM, V5, P33; Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820; Yoder MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6; Yoder MC, 2001, BLOOD, V98, P3, DOI 10.1182/blood.V98.1.3; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789	35	589	629	1	26	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	2002	109	1					29	37		10.1016/S0092-8674(02)00680-3	http://dx.doi.org/10.1016/S0092-8674(02)00680-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955444	Bronze			2022-12-28	WOS:000174888300006
J	Lu, QR; Sun, T; Zhu, ZM; Ma, N; Garcia, M; Stiles, CD; Rowitch, DH				Lu, QR; Sun, T; Zhu, ZM; Ma, N; Garcia, M; Stiles, CD; Rowitch, DH			Common developmental requirement for Olig function indicates a motor neuron/oligodendrocyte connection	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; VENTRAL NEURAL-TUBE; OLIGODENDROCYTE LINEAGE; SPINAL-CORD; CEREBRAL-CORTEX; CELL LINEAGE; ASTROCYTES; EXPRESSION; GENES; DIFFERENTIATION	The oligodendrocyte lineage genes Olig1 and Olig2 encode related bHLH proteins that are coexpressed in neural progenitors. Targeted disruption of these two genes sheds light on the ontogeny of oligodendroglia and genetic requirements for their development from multipotent CNS progenitors. Olig2 is required for oligodendrocyte and motor neuron specification in the spinal cord. Olig1 has roles in development and maturation of oligodendrocytes, evident especially within the brain. Both Olig genes contribute to neural pattern formation. Neither Olig gene is required for astrocytes. These findings, together with fate mapping analysis of Olig-expressing cells, indicate that oligodendrocytes are derived from Olig-specified progenitors that give rise also to neurons.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Stiles, CD (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.			Rowitch, David/0000-0002-0079-0060	NICHD NIH HHS [HD24296] Funding Source: Medline; NINDS NIH HHS [NS4051] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alberta JA, 2001, MOL CELL NEUROSCI, V18, P434, DOI 10.1006/mcne.2001.1026; Arber S, 1999, NEURON, V23, P659, DOI 10.1016/S0896-6273(01)80026-X; Barres BA, 2000, CURR OPIN NEUROBIOL, V10, P642, DOI 10.1016/S0959-4388(00)00134-3; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; Franco D, 2001, EUR J MORPHOL, V39, P3, DOI 10.1076/ejom.39.1.3.7982; Hardy RJ, 1997, J NEUROSCI RES, V50, P139, DOI 10.1002/(SICI)1097-4547(19971015)50:2<139::AID-JNR3>3.0.CO;2-G; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kandel E R, 2000, PRINCIPLES NEURAL SC, P19; Lee JC, 2000, GLIA, V30, P105, DOI 10.1002/(SICI)1098-1136(200004)30:2<105::AID-GLIA1>3.0.CO;2-H; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; LEVISON SW, 1993, NEURON, V10, P201, DOI 10.1016/0896-6273(93)90311-E; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; Lu QR, 2001, NAT NEUROSCI, V4, P973, DOI 10.1038/nn718; Lu QR, 2001, P NATL ACAD SCI USA, V98, P10851, DOI 10.1073/pnas.181340798; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; Marie Y, 2001, LANCET, V358, P298, DOI 10.1016/S0140-6736(01)05499-X; McMahon AP, 2000, GENE DEV, V14, P2261, DOI 10.1101/gad.840800; Mizuguchi R, 2001, NEURON, V31, P757, DOI 10.1016/S0896-6273(01)00413-5; Nery S, 2001, DEVELOPMENT, V128, P527; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Orentas DM, 1999, DEVELOPMENT, V126, P2419; Park SK, 2001, J CELL BIOL, V154, P1245, DOI 10.1083/jcb.200104025; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; PRICE J, 1988, DEVELOPMENT, V104, P473; Pringle NP, 1998, NEURON, V20, P883, DOI 10.1016/S0896-6273(00)80470-5; PRINGLE NP, 1993, DEVELOPMENT, V117, P525; Qi YC, 2001, DEVELOPMENT, V128, P2723; Richardson WD, 2000, GLIA, V29, P136, DOI 10.1002/(SICI)1098-1136(20000115)29:2<136::AID-GLIA6>3.0.CO;2-G; Scardigli R, 2001, NEURON, V31, P203, DOI 10.1016/S0896-6273(01)00358-0; SKOFF RP, 1990, DEV BIOL, V139, P149, DOI 10.1016/0012-1606(90)90285-Q; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Spassky N, 2001, DEVELOPMENT, V128, P4993; Sun T, 2001, CURR BIOL, V11, P1413, DOI 10.1016/S0960-9822(01)00441-9; Sun T, 1998, MOL CELL NEUROSCI, V12, P228, DOI 10.1006/mcne.1998.0711; Takebayashi H, 2000, MECH DEVELOP, V99, P143, DOI 10.1016/S0925-4773(00)00466-4; Tekki-Kessaris N, 2001, DEVELOPMENT, V128, P2545; TIMSIT S, 1995, J NEUROSCI, V15, P1012; Zhou Q, 2001, NEURON, V31, P791, DOI 10.1016/S0896-6273(01)00414-7; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	41	803	832	0	27	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	2002	109	1					75	86		10.1016/S0092-8674(02)00678-5	http://dx.doi.org/10.1016/S0092-8674(02)00678-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955448	Bronze			2022-12-28	WOS:000174888300010
J	El-Husseini, AE; Schnell, E; Dakoji, S; Sweeney, N; Zhou, Q; Prange, O; Gauthier-Campbell, C; Aguilera-Moreno, A; Nicoll, RA; Bredt, DS				El-Husseini, AE; Schnell, E; Dakoji, S; Sweeney, N; Zhou, Q; Prange, O; Gauthier-Campbell, C; Aguilera-Moreno, A; Nicoll, RA; Bredt, DS			Synaptic strength regulated by palmitate cycling on PSD-95	CELL			English	Article							DENSITY PROTEIN PSD-95; NITRIC-OXIDE SYNTHASE; LONG-TERM POTENTIATION; KINASE-LIKE DOMAIN; POSTSYNAPTIC DENSITY; AMPA RECEPTORS; K+ CHANNELS; INTRAMOLECULAR INTERACTION; DISTINCT MECHANISMS; SIGNAL-TRANSDUCTION	Dynamic regulation of AMPA-type glutamate receptors represents a primary mechanism for controlling synaptic strength, though mechanisms for this process are poorly understood. The palmitoylated postsynaptic density protein, PSD-95, regulates synaptic plasticity and associates with the AMPA receptor trafficking protein, stargazin. Here, we identify palmitate cycling on PSD-95 at the synapse and find that palmitate turnover on PSD-95 is regulated by glutamate receptor activity. Acutely blocking palmitoylation disperses synaptic clusters of PSD-95 and causes a selective loss of synaptic AMPA receptors. We also find that rapid glutamate-mediated AMPA receptor internalization requires depalmitoylation of PSD-95. In a nonneuronal model system, clustering of PSD-95 stargazin, and AMPA receptors is also regulated by ongoing palmitoylation of PSD-95 at the plasma membrane. These studies suggest that palmitate cycling on PSD-95 can regulate synaptic strength and regulates aspects of activity-dependent plasticity.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ British Columbia, Dept Psychiat, Kinsmen Lab, Vancouver, BC, Canada; Univ British Columbia, Brain Res Ctr, Vancouver, BC, Canada	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of British Columbia; University of British Columbia	El-Husseini, AE (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.			Schnell, Eric/0000-0002-5623-5015				ALALUF S, 1995, J NEUROCHEM, V64, P1548; ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; BERTHIAUME L, 1995, METHOD ENZYMOL, V250, P454; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Burke NA, 1999, J GEN PHYSIOL, V113, P71, DOI 10.1085/jgp.113.1.71; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Craven SE, 1999, NEURON, V22, P497, DOI 10.1016/S0896-6273(00)80705-9; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dunphy JT, 1998, BBA-MOL CELL BIOL L, V1436, P245, DOI 10.1016/S0005-2760(98)00130-1; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; El-Hussein AE, 2000, SCIENCE, V290, P1364; El-Husseini AE, 2000, J BIOL CHEM, V275, P23904, DOI 10.1074/jbc.M909919199; El-Husseini AE, 2000, J CELL BIOL, V148, P159, DOI 10.1083/jcb.148.1.159; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KISTNER U, 1993, J BIOL CHEM, V268, P4580; Koh YH, 1999, CELL, V98, P353, DOI 10.1016/S0092-8674(00)81964-9; KOMAU HC, 1997, CURR OPIN NEUROBIOL, V7, P368; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Lee SH, 2000, CURR OPIN NEUROBIOL, V10, P125, DOI 10.1016/S0959-4388(99)00046-X; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; McGee AW, 1999, J BIOL CHEM, V274, P17431, DOI 10.1074/jbc.274.25.17431; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; Mumby SM, 1997, CURR OPIN CELL BIOL, V9, P148, DOI 10.1016/S0955-0674(97)80056-7; Passafaro M, 1999, NAT NEUROSCI, V2, P1063, DOI 10.1038/15990; Pickering DS, 1995, P NATL ACAD SCI USA, V92, P12090, DOI 10.1073/pnas.92.26.12090; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Resh MD, 1996, CELL SIGNAL, V8, P403, DOI 10.1016/S0898-6568(96)00088-5; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Tomita S, 2001, J CELL BIOL, V153, pF19, DOI 10.1083/jcb.153.5.F19; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; Tu YP, 1997, SCIENCE, V278, P1132, DOI 10.1126/science.278.5340.1132; WALTERS BB, 1975, BIOCHEM SOC T, V3, P109, DOI 10.1042/bst0030109; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; Yamazaki M, 2001, NEUROSCI LETT, V304, P81, DOI 10.1016/S0304-3940(01)01766-9; Zhou Q, 2001, P NATL ACAD SCI USA, V98, P1261, DOI 10.1073/pnas.031573798	57	365	374	0	11	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 22	2002	108	6					849	863		10.1016/S0092-8674(02)00683-9	http://dx.doi.org/10.1016/S0092-8674(02)00683-9			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955437	Bronze			2022-12-28	WOS:000174563000013
J	Vion, D; Aassime, A; Cottet, A; Joyez, P; Pothier, H; Urbina, C; Esteve, D; Devoret, MH				Vion, D; Aassime, A; Cottet, A; Joyez, P; Pothier, H; Urbina, C; Esteve, D; Devoret, MH			Manipulating the quantum state of an electrical circuit	SCIENCE			English	Article							CHARGE; QUANTIZATION; DECOHERENCE; NOISE	We have designed and operated a superconducting tunnel junction circuit that behaves as a two-level atom: the "quantronium." An arbitrary evolution of its quantum state can be programmed with a series of microwave pulses, and a projective measurement of the state can be performed by a pulsed readout subcircuit. The measured quality factor of quantum coherence Q(phi) congruent to 25,000 is sufficiently high that a solid-state quantum processor based on this type of circuit can be envisioned.	CEA Saclay, Direct Sci Mat, Serv Phys Etat Condense, Quantron Grp, F-91191 Gif Sur Yvette, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Vion, D (corresponding author), CEA Saclay, Direct Sci Mat, Serv Phys Etat Condense, Quantron Grp, F-91191 Gif Sur Yvette, France.	vion@drecam.saclay.cea.fr	Pothier, Hugues/D-1151-2014; Cottet, Audrey/F-7769-2011; Urbina, Cristian/M-6412-2015	Pothier, Hugues/0000-0002-0601-6885; Cottet, Audrey/0000-0003-2044-7718; Urbina, Cristian/0000-0001-9145-8081				Aassime A, 2001, PHYS REV LETT, V86, P3376, DOI 10.1103/PhysRevLett.86.3376; Averin D. V., 1991, MESOSCOPIC PHENOMENA; Bouchiat V, 1998, PHYS SCRIPTA, VT76, P165, DOI 10.1238/Physica.Topical.076a00165; Braginsky V. B., 1992, QUANTUM MEASUREMENT; Cottet A, 2002, PHYSICA C, V367, P197, DOI 10.1016/S0921-4534(01)01014-0; DEVORET MH, 1992, QUANTUM TUNNELING CO; EKERT A, 2000, PHYSICS QUANTUM INFO; Friedman JR, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.050403; Han SY, 2000, PHYS REV LETT, V84, P1300, DOI 10.1103/PhysRevLett.84.1300; Han SY, 2001, SCIENCE, V293, P1457, DOI 10.1126/science.1062266; Hekking FWJ, 2001, ELECTRONIC CORRELATIONS: FROM MESO- TO NANO-PHYSICS, P515; LAFARGE P, 1993, NATURE, V365, P422, DOI 10.1038/365422a0; Makhlin Y, 2001, REV MOD PHYS, V73, P357, DOI 10.1103/RevModPhys.73.357; MARTINIS JM, UNPUB; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Preskill J, 1998, P ROY SOC A-MATH PHY, V454, P385, DOI 10.1098/rspa.1998.0167; Rabi II, 1937, PHYS REV, V51, P0652, DOI 10.1103/PhysRev.51.652; SHOR PW, 1995, PHYS REV A, V52, pR2493, DOI 10.1103/PhysRevA.52.R2493; Steane AM, 1996, PHYS REV LETT, V77, P793, DOI 10.1103/PhysRevLett.77.793; TUOMINEN MT, 1992, PHYS REV LETT, V69, P1997, DOI 10.1103/PhysRevLett.69.1997; van der Wal CH, 2000, SCIENCE, V290, P773, DOI 10.1126/science.290.5492.773; WELLSTOOD FC, 1987, APPL PHYS LETT, V50, P772, DOI 10.1063/1.98041; Wolf H, 1997, IEEE T INSTRUM MEAS, V46, P303, DOI 10.1109/19.571840; Zorin AB, 2002, PHYSICA C, V368, P284, DOI 10.1016/S0921-4534(01)01182-0; ZUREK WH, 2000, COHERENT ATOMIC MATT; [No title captured]	29	1326	1359	6	131	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	2002	296	5569					886	889		10.1126/science.1069372	http://dx.doi.org/10.1126/science.1069372			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988568	Green Submitted			2022-12-28	WOS:000175442500037
J	Namouni, F; Porco, C				Namouni, F; Porco, C			The confinement of Neptune's ring arcs by the moon Galatea	NATURE			English	Article							MODEL	Neptune has five narrow ring arcs, spanning about 40 degrees in longitude, which are apparently confined against the rapid azimuthal and radial spreading that normally results from inter-particle collisions. A gravitational resonance based on the vertical motion of the nearby neptunian moon Galatea was proposed(1,2) to explain the trapping of the ring particles into a sequence of arcs. But recent observations(3,4) have indicated that the arcs are away from the resonance, leaving their stability again unexplained. Here we report that a resonance based on Galatea's eccentricity is responsible for the angular confinement of the arcs. The mass of the arcs affects the precession of Galatea's eccentric orbit, which will enable a mass estimate from future observations of Galatea's eccentricity.	SW Res Inst, Boulder, CO 80302 USA		Namouni, F (corresponding author), SW Res Inst, 1050 Walnut St, Boulder, CO 80302 USA.	fathi@ciclops.swri.edu						COLWELL JE, 1993, J GEOPHYS RES-PLANET, V98, P7387, DOI 10.1029/93JE00329; COLWELL JE, 1990, GEOPHYS RES LETT, V17, P1741, DOI 10.1029/GL017i010p01741; Dumas C, 1999, NATURE, V400, P733, DOI 10.1038/23414; DUMAS C, IN PRESS ASTRON J; GOLDREICH P, 1986, ASTRON J, V92, P490, DOI 10.1086/114178; GOLDSTEIN SJ, 1983, SURG NEUROL, V20, P249, DOI 10.1016/0090-3019(83)90062-9; Hanninen J, 1997, ICARUS, V126, P1, DOI 10.1006/icar.1996.5613; HORANYI M, 1993, ICARUS, V106, P525, DOI 10.1006/icar.1993.1190; LISSAUER JJ, 1985, NATURE, V318, P544, DOI 10.1038/318544a0; Namouni E, 1998, MON NOT R ASTRON SOC, V300, P915, DOI 10.1046/j.1365-8711.1998.01956.x; NICHOLSON PD, 1995, ICARUS, V113, P295, DOI 10.1006/icar.1995.1025; OWEN WM, 1991, ASTRON J, V101, P1511, DOI 10.1086/115783; PORCO C, 1991, SCIENCE, V400, P995; Porco CC, 1995, SPACE SCI S, P703; Sicardy B, 1999, NATURE, V400, P731, DOI 10.1038/23410; SMITH BA, 1989, SCIENCE, V246, P1422, DOI 10.1126/science.246.4936.1422	16	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	2002	417	6884					45	47		10.1038/417045a	http://dx.doi.org/10.1038/417045a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986660				2022-12-28	WOS:000175307200032
J	Oster, G				Oster, G			Brownian ratchets: Darwin's motors	NATURE			English	Editorial Material									Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Oster, G (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.							Boyer PD, 1998, ANGEW CHEM INT EDIT, V37, P2297, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2296::AID-ANIE2296>3.0.CO;2-W; Huxley AF, 1998, CURR BIOL, V8, pR485, DOI 10.1016/S0960-9822(98)70313-6; Simmons RM, 2000, PHILOS T ROY SOC B, V355, P415, DOI 10.1098/rstb.2000.0582; WALKER J, 2000, BIOCHIM BIOPHYS ACTA, V1458, P231	4	61	64	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	2002	417	6884					25	25		10.1038/417025a	http://dx.doi.org/10.1038/417025a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986647	Bronze			2022-12-28	WOS:000175307200021
J	Crawford, LM				Crawford, LM			Treatment for liver tumors	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Crawford, LM (corresponding author), US FDA, Rockville, MD 20857 USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2203	2203		10.1001/jama.287.17.2203	http://dx.doi.org/10.1001/jama.287.17.2203			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980508				2022-12-28	WOS:000175260600005
J	Kazim, SN; Wakil, SM; Khan, LA; Hasnain, SE; Sarin, SK				Kazim, SN; Wakil, SM; Khan, LA; Hasnain, SE; Sarin, SK			Vertical transmission of hepatitis B virus despite maternal lamivudine therapy	LANCET			English	Article								Lamivudine given during the last weeks of pregnancy in women with chronic hepatitis B has been reported to be safe. We report a case of chronic hepatitis B virus (HBV) infection in a newborn, despite suppression of HBV DNA to undetectable levels in the mother by prolonged lamivudine therapy. The newborn had raised alanine aminotransferase concentrations and was positive for HBV DNA at birth which persisted until 9 months of age, despite neonatal vaccination, treatment with hepatitis B immune globulin, and high concentrations of anti-HBs. On HBV DNA sequencing, complete sequence homology and a similar precore mutation was found in the mother and child, indicating vertical transmission. Lamivudine therapy might not prevent perinatal transmission of HBV infection in every newborn.	GB Pant Hosp, Dept Gastroenterol, New Delhi 110002, India; Jamia Millia Islamia, Dept Biosci, New Delhi 110025, India; Jamia Hamdard, Dept Toxicol & Med Elementol, New Delhi, India; Natl Inst Immunol, Eukaryot Gene Express Lab, New Delhi 110067, India; Ctr DNA Fingerprinting & Diagnost, Hyderabad, Andhra Pradesh, India	Govind Ballabh Pant Institute of Postgraduate Medical Education & Research; Jamia Millia Islamia; Jamia Hamdard University; Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting & Diagnostics (CDFD)	Sarin, SK (corresponding author), GB Pant Hosp, Dept Gastroenterol, New Delhi 110002, India.		Majid, Salma/AAT-6166-2020; HASNAIN, SEYED/C-1492-2009	Majid, Salma/0000-0002-7883-2515; Hasnain, Seyed/0000-0002-2967-0791				AKOREA US, 1994, HEPATOLOGY, V19, P1366; delCanho R, 1997, VACCINE, V15, P1624, DOI 10.1016/S0264-410X(97)00080-7; Moodley J, 1998, J INFECT DIS, V178, P1327, DOI 10.1086/314431; Ngui SL, 1998, CLIN INFECT DIS, V27, P100, DOI 10.1086/514610; van Nunen AB, 2000, J HEPATOL, V32, P1040	5	47	53	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1488	1489		10.1016/S0140-6736(02)08425-8	http://dx.doi.org/10.1016/S0140-6736(02)08425-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988251				2022-12-28	WOS:000175279100015
J	Smeeth, L; Fletcher, AE; Ng, ESW; Stirling, S; Nunes, M; Breeze, E; Bulpitt, CJ; Jones, D; Tulloch, A				Smeeth, L; Fletcher, AE; Ng, ESW; Stirling, S; Nunes, M; Breeze, E; Bulpitt, CJ; Jones, D; Tulloch, A			Reduced hearing, ownership, and use of hearing aids in elderly people in the UK - the MRC Trial of the Assessment and Management of Older People in the Community: a cross-sectional survey	LANCET			English	Article							SENSORY IMPAIRMENT; WHISPERED VOICE; SCREENING-TEST; QUALITY; ADULTS; LIFE	Background Reduced hearing in elderly people is important because it is disabling and potentially treatable. We aimed to assess the prevalence of reduced hearing in elderly people and levels of ownership of hearing aids and use. Methods We have done a cross-sectional survey of people aged at least 75 years in 106 family practices in the UK. We obtained self-reported data on hearing difficulties for 32 656 people and gave 14 877 a whispered voice test (response rate 78%). Findings 2537 (8%) of 32 656 participants reported a lot of difficulty hearing and 13 630 (42%) a little or a lot of difficulty. 3795 (26%) of 14 877 participants who completed the whispered voice test (95% CI 23-29) failed the test, the proportion rising sharply with age. Following wax removal, 343 passed a retest, leaving 3452 (23%, 20-26) who failed the test, even after wax removal if present. 998 (46%) of 2180 people wearing a hearing aid at the time of testing failed the whispered voice test. More than half the people who failed the test did not own a hearing aid. 2200 (60%) of 3846 people who owned a hearing aid said they used it regularly. Level of use was strongly related to perceived benefit. Interpretation Reduced hearing is common and provision of hearing aids inadequate in elderly people. Many people who own a hearing aid do not use it regularly, and even when wearing their aid many still have socially disabling levels of hearing loss. A major source of morbidity in elderly people could be alleviated by improvements in detection and management of reduced hearing.	Univ London London Sch Hyg & Trop Med, Ctr Ageing & Publ Hlth, London WC1E 7HT, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Sect Care Elderly, London, England; Univ Wales Coll Med, Univ Dept Geriatr Med, Cardiff CF4 4XN, S Glam, Wales; Univ Oxford, Inst Hlth Sci, Unit Hlth Care Epidemiol, Oxford, England	University of London; London School of Hygiene & Tropical Medicine; Imperial College London; Cardiff University; University of Oxford	Smeeth, L (corresponding author), Univ London London Sch Hyg & Trop Med, Ctr Ageing & Publ Hlth, Keppel St, London WC1E 7HT, England.		Breeze, Elizabeth/AAK-4927-2021; Ng, Edmond/L-5871-2019; Ng, Edmond/G-8788-2011; Smeeth, Liam/X-5862-2018	Smeeth, Liam/0000-0002-9168-6022				Arlinger S, 1999, BRIT J AUDIOL, V33, P223, DOI 10.3109/03005369909090103; Audit Commission, 2000, FULL EQ; BESS FH, 1989, J AM GERIATR SOC, V37, P123, DOI 10.1111/j.1532-5415.1989.tb05870.x; Bille M, 1999, SCAND AUDIOL, V28, P127, DOI 10.1080/010503999424851; Boymans M, 1999, AUDIOLOGY, V38, P99; BROWNING GG, 1989, J LARYNGOL OTOL, V103, P7, DOI 10.1017/S0022215100107923; CARABELLESE C, 1993, J AM GERIATR SOC, V41, P401, DOI 10.1111/j.1532-5415.1993.tb06948.x; DAVIS AC, 1989, INT J EPIDEMIOL, V18, P911, DOI 10.1093/ije/18.4.911; Davis AC, 1995, HEARING IN ADULTS; Department of Health, 2001, NAT SERV FRAM OLD PE; Department of Health, 2000, MOD NHS HEAR AID SER; Eekhof JAH, 1996, BRIT J GEN PRACT, V46, P473; Hanratty B, 2000, J PUBLIC HEALTH MED, V22, P512, DOI 10.1093/pubmed/22.4.512; Larkin M, 2000, LANCET, V356, P744, DOI 10.1016/S0140-6736(05)73651-5; MACPHEE GJA, 1988, AGE AGEING, V17, P347, DOI 10.1093/ageing/17.5.347; MULROW CD, 1990, J AM GERIATR SOC, V38, P45, DOI 10.1111/j.1532-5415.1990.tb01595.x; *NICE, 2000, GUID HEAR TECHN NICE; Reuben DB, 1999, J AM GERIATR SOC, V47, P930, DOI 10.1111/j.1532-5415.1999.tb01286.x; Smeeth L, 2001, BRIT MED J, V323, P1403, DOI 10.1136/bmj.323.7326.1403; Strawbridge WJ, 1996, AM J EPIDEMIOL, V144, P135, DOI 10.1093/oxfordjournals.aje.a008900; SWAN IRC, 1985, J ROY COLL GEN PRACT, V35, P197; UHLMANN RF, 1989, J GEN INTERN MED, V4, P90, DOI 10.1007/BF02602346; *WHO, 2001, PREV DEAFN HEAR IMP; *WHO, 1999, HEAR AIDS SERV NEEDS; 1987, LANCET, V1, P1181; 2000, LIVING BRITAIN RESUL	26	98	105	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1466	1470		10.1016/S0140-6736(02)08433-7	http://dx.doi.org/10.1016/S0140-6736(02)08433-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	546NA	11988245				2022-12-28	WOS:000175279100009
J	Annas, GJ				Annas, GJ			Bioterrorism, public health, and civil liberties	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BIOLOGICAL TERRORISM; LAW		Boston Univ, Sch Med, Hlth Law Dept, Boston, MA 02118 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Med, Hlth Law Dept, Boston, MA 02118 USA.			Annas, George/0000-0001-5836-7831				Albert MR, 2001, NEW ENGL J MED, V344, P375, DOI 10.1056/NEJM200102013440511; ALTMAN LK, 2002, NY TIMES        0106, P1; ANNAS GJ, 1993, NEW ENGL J MED, V328, P585, DOI 10.1056/NEJM199302253280825; Annas GJ, 1997, NEW ENGL J MED, V337, P1098, DOI 10.1056/NEJM199710093371523; Barbera J, 2001, JAMA-J AM MED ASSOC, V286, P2711, DOI 10.1001/jama.286.21.2711; Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357; Centers for Disease Control and Prevention, 2001, INT SMALLP RESP PLAN; Centers for Disease Control and Prevention, 2001, MOD STAT EM HLTH POW; Clancy Tom, 1996, EXECUTIVE ORDERS; Fidler DP, 2001, CLIN INFECT DIS, V33, P686, DOI 10.1086/322704; GAVIN R, 2002, WALL STREET J   0327, pB1; GILLIS J, 2001, WASHINTON POST  1119, pA1; Kellman B, 2001, HARVARD J LAW PUBL P, V24, P417; LIPTON E, 2001, NY TIMES        1226, pA1; Mann Jonathan M, 1994, Health Hum Rights, V1, P6; MARINER W, 2001, NATL LAW J      1217, P18; MARLANDS L, 2001, CHRISTIAN SCI M 1217, P1; Martinez B., 2001, WALL STR J, pB1; Miller J., 2001, GERMS BIOL WEAPONS A; Osterholm MT, 2000, LIVING TERRORS WHAT; Parmet WE, 2001, BOSTON GLOBE, pA15; PRESTON R, 1997, COBRA EVENT; Rosenberg Charles E., 1987, CARE STRANGERS RISE; Scharf MP, 1999, MICH J INT L, V20, P495; Stolberg S G, 2001, N Y Times Web, pA16; STOLBERG SG, 2001, NY TIMES        1004, pB7; Tucker JB, 2001, SCOURGE ONCE FUTURE; WING KR, 1999, LAW PUBLICS HLTH	28	83	85	5	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1337	1342		10.1056/NEJM200204253461722	http://dx.doi.org/10.1056/NEJM200204253461722			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544GX	11973377	Green Published			2022-12-28	WOS:000175150800033
J	Bach, PB; Schrag, D; Brawley, OW; Galaznik, A; Yakren, S; Begg, CB				Bach, PB; Schrag, D; Brawley, OW; Galaznik, A; Yakren, S; Begg, CB			Survival of blacks and whites after a cancer diagnosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							INDEPENDENT PROGNOSTIC FACTOR; SURGICAL ADJUVANT BREAST; ADVANCED PROSTATE-CANCER; THERAPY ONCOLOGY GROUP; LONG-TERM SURVIVAL; CELL LUNG-CANCER; RACIAL-DIFFERENCES; RADIATION-THERAPY; CLINICAL-TRIALS; AFRICAN-AMERICAN	Context In recent years a theory that cancer biology is different in blacks and whites has gained prominence in reaction to epidemiologic observations that blacks have poorer survival than whites, even when diagnosed with cancer of similar severity. Yet, few studies have evaluated whether lower-quality treatment and shorter overall life expectancy due to a greater burden of other illnesses may explain the survival discrepancy. Objective To estimate the magnitude of overall and cancer-specific survival differences between blacks and whites who receive comparable treatment for similar-stage cancer. Data Sources We searched MEDLINE for English-language articles published from 1966 to January 2002 that reported on overall survival for black and white patients treated similarly for cancer. Study Selection The abstracts or titles for 891 citations were independently examined by 2 authors. The full text was retrieved if the abstract mentioned both black and white patients, made some comment regarding either similarity of treatment received or presented an analysis based on the treatment received, and commented on survival. Studies were included if they included data for at least 10 black and 10 white patients; specified the cohort ascertainment method and what measures were undertaken to minimize loss to follow-up; summarized survival of both blacks and whites using actuarial measures; presented outcomes within stage, adjusted for stage, or based on cohorts with balanced stage distributions; and specified that blacks and whites in the study received similar treatment. We identified 89 unique cohorts in 54 articles that met our inclusion criteria. Data Extraction Overall survival rates and hazard ratios (HRs) for death for blacks relative to whites were calculated. These were subsequently adjusted for rates of death due to causes other than the cancer under study to determine cancer-specific survival and cancer-specific HRs. Data Synthesis Results represent 189 877 white and 32 004 black patients with 14 different cancers. Compared with whites, blacks had an overall excess risk of death (HR, 1.16; 95% confidence interval [CI], 1.12-1.20). After correction for deaths due to other causes, the cancer-specific HR was 1.07 (95% CI, 1.02-1.13). Of the 14 cancers, blacks were at a significantly higher risk of cancer-specific death only for cancer of the breast, uterus, or bladder. Conclusions Only modest cancer-specific survival differences are evident for blacks and whites treated comparably for similar-stage cancer. Therefore, differences in cancer biology between racial groups are unlikely to be responsible for a substantial portion of the survival discrepancy. Differences in treatment, stage at presentation, and mortality from other diseases should represent the primary targets of research and interventions designed to reduce disparities in cancer outcomes.	Mem Sloan Kettering Canc Ctr, Dept Epidemiol Biostat, Hlth Outcomes Res Grp, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY USA; Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Emory University	Bach, PB (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol Biostat, Hlth Outcomes Res Grp, 1275 York Ave,Box 221, New York, NY 10021 USA.			Schrag, Deborah/0000-0002-4334-5717				AKERLEY WL, 1993, ARCH INTERN MED, V153, P1681, DOI 10.1001/archinte.153.14.1681; AMENDOLA B, 1980, SOUTHERN MED J, V73, P1481, DOI 10.1097/00007611-198011000-00019; ANSELL D, 1993, CANCER, V72, P2974, DOI 10.1002/1097-0142(19931115)72:10<2974::AID-CNCR2820721019>3.0.CO;2-M; Arbes SJ, 1999, CANCER CAUSE CONTROL, V10, P513, DOI 10.1023/A:1008911300100; ARMSTRONG RJ, 1997, US DECENNIAL LIFE TA, P13; AUSTIN JP, 1993, AM J CLIN ONCOL-CANC, V16, P140, DOI 10.1097/00000421-199304000-00012; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Brawley OW, 1999, J NATL CANCER I, V91, P1908, DOI 10.1093/jnci/91.22.1908; BRAWN PN, 1993, CANCER, V71, P2569, DOI 10.1002/1097-0142(19930415)71:8<2569::AID-CNCR2820710822>3.0.CO;2-R; Breen N, 2001, J NATL CANCER I, V93, P1704, DOI 10.1093/jnci/93.22.1704; Breen Nancy, 1999, Ethnicity and Disease, V9, P111; BROWN BW, 1993, J NATL CANCER I, V85, P979, DOI 10.1093/jnci/85.12.979; Carethers J M, 1999, J Assoc Acad Minor Phys, V10, P59; CELLA DF, 1991, J CLIN ONCOL, V9, P1500, DOI 10.1200/JCO.1991.9.8.1500; CHEN VW, 1994, CANCER EPIDEM BIOMAR, V3, P127; COLLETT D, 1994, MODELLING SURVIVAL D, P1; CRAWFORD ED, 1990, CANCER-AM CANCER SOC, V66, P1039; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; Dignam JJ, 1999, JNCI-J NATL CANCER I, V91, P1933, DOI 10.1093/jnci/91.22.1933; Dignam JJ, 1997, CANCER-AM CANCER SOC, V80, P80, DOI 10.1002/(SICI)1097-0142(19970701)80:1<80::AID-CNCR11>3.0.CO;2-B; Dominitz JA, 1998, CANCER, V82, P2312, DOI 10.1002/(SICI)1097-0142(19980615)82:12<2312::AID-CNCR3>3.0.CO;2-U; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; EVANS LA, 1992, IN VIVO, V6, P429; Farley JH, 2001, CANCER, V91, P869, DOI 10.1002/1097-0142(20010215)91:4<869::AID-CNCR1075>3.0.CO;2-D; FEINSTEIN AR, 1985, NEW ENGL J MED, V312, P1604, DOI 10.1056/NEJM198506203122504; FIELDS JN, 1989, CANCER-AM CANCER SOC, V63, P1225, DOI 10.1002/1097-0142(19890315)63:6<1225::AID-CNCR2820630632>3.0.CO;2-5; Fowler JE, 2000, J UROLOGY, V163, P137, DOI 10.1016/S0022-5347(05)67989-X; Fowler JE, 1996, J UROLOGY, V156, P133, DOI 10.1016/S0022-5347(01)65966-4; FRANCO EL, 1993, J CLIN EPIDEMIOL, V46, P37, DOI 10.1016/0895-4356(93)90007-N; Franzini L, 1997, ANN SURG ONCOL, V4, P111, DOI 10.1007/BF02303792; FREEDMAN LS, 1995, CONTROL CLIN TRIALS, V16, P277, DOI 10.1016/0197-2456(95)00048-8; Freeman HP, 1998, CANCER, V82, P219, DOI 10.1002/(SICI)1097-0142(19980101)82:1<219::AID-CNCR27>3.0.CO;2-4; GRAHAM MV, 1992, J NATL CANCER I, V84, P1731, DOI 10.1093/jnci/84.22.1731; Greenwald HP, 1998, AM J PUBLIC HEALTH, V88, P1681, DOI 10.2105/AJPH.88.11.1681; GREGORIO DI, 1983, AM J PUBLIC HEALTH, V73, P590, DOI 10.2105/AJPH.73.5.590; Grigsby PW, 2000, GYNECOL ONCOL, V79, P357, DOI 10.1006/gyno.2000.5974; Hart K B, 1998, Semin Urol Oncol, V16, P227; HAYNES MA, 1999, UNEQUAL BURDEN CANC, P154; Heimann R, 1997, J CLIN ONCOL, V15, P2329, DOI 10.1200/JCO.1997.15.6.2329; Hicks ML, 1997, J NATL MED ASSOC, V89, P134; Hill HA, 1996, OBSTET GYNECOL, V88, P919; Hodgson DC, 2001, JNCI-J NATL CANCER I, V93, P501, DOI 10.1093/jnci/93.7.501; Howard D L, 1998, Fam Med, V30, P228; HOWARD J, 1992, CANCER, V69, P2349, DOI 10.1002/1097-0142(19920501)69:9&lt;2349::AID-CNCR2820690925&gt;3.0.CO;2-7; Howell EA, 1999, OBSTET GYNECOL, V94, P509, DOI 10.1016/S0029-7844(99)00334-8; HOYERT DL, 2001, DEATHS FINAL DATA 19, V49; HUNTER CP, 1993, J NATL CANCER I, V85, P1129, DOI 10.1093/jnci/85.14.1129; HUVOS AG, 1983, CANCER, V52, P1959, DOI 10.1002/1097-0142(19831115)52:10<1959::AID-CNCR2820521031>3.0.CO;2-2; JETTER A, 2000, NY TIMES        0222; KIM JA, 1995, RADIOLOGY, V194, P545, DOI 10.1148/radiology.194.2.7529936; KIMMICK G, 1991, CANCER, V67, P2850, DOI 10.1002/1097-0142(19910601)67:11<2850::AID-CNCR2820671124>3.0.CO;2-S; Klabunde CN, 1998, MED CARE, V36, P1337, DOI 10.1097/00005650-199809000-00006; Krongrad A, 1996, J UROLOGY, V156, P1084, DOI 10.1016/S0022-5347(01)65710-0; LAWTON CA, 1994, RADIOLOGY, V192, P37, DOI 10.1148/radiology.192.1.8208961; Lee AJ, 1997, MED CARE, V35, P1173, DOI 10.1097/00005650-199712000-00002; Light R.J., 1984, SUMMING SCI REV RES; Mancino AT, 2001, J SURG RES, V100, P161, DOI 10.1006/jsre.2001.6232; MANLEY C, 2001, UNIQUE STUDY AIMS WH; Manne U, 2000, INT J CANCER, V89, P423, DOI 10.1002/1097-0215(20000920)89:5<423::AID-IJC5>3.0.CO;2-T; Manne U, 2000, CLIN CANCER RES, V6, P4017; Marcella S, 2001, J CLIN EPIDEMIOL, V54, P359, DOI 10.1016/S0895-4356(00)00316-4; MAYBERRY RM, 1995, J NATL CANCER I, V87, P1686, DOI 10.1093/jnci/87.22.1686; McLeod DG, 1999, PROSTATE, V40, P218, DOI 10.1002/(SICI)1097-0045(19990901)40:4<218::AID-PROS2>3.0.CO;2-6; Modiano MR, 1996, J CLIN ONCOL, V14, P974, DOI 10.1200/JCO.1996.14.3.974; Moody-Ayers SY, 2000, ARCH INTERN MED, V160, P1109, DOI 10.1001/archinte.160.8.1109; Morgan MA, 1996, OBSTET GYNECOL, V88, P914; MUSS HB, 1992, CANCER-AM CANCER SOC, V70, P2460, DOI 10.1002/1097-0142(19921115)70:10<2460::AID-CNCR2820701012>3.0.CO;2-A; Nelson AR, 2002, UNEQUAL TREATMENT CO, DOI DOI 10.17226/12875; NEWMAN L, 2000, PROSTATE CANC DEV DI; OPTENBERG SA, 1995, JAMA-J AM MED ASSOC, V274, P1599, DOI 10.1001/jama.274.20.1599; PAGE WF, 1980, CANCER, V45, P1029, DOI 10.1002/1097-0142(19800301)45:5<1029::AID-CNCR2820450533>3.0.CO;2-3; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Perkins P, 1996, CANCER, V78, P1241, DOI 10.1002/(SICI)1097-0142(19960915)78:6<1241::AID-CNCR11>3.0.CO;2-0; Pettaway CA, 1999, J NATL MED ASSOC, V91, P653; PIERCE L, 1992, CANCER-AM CANCER SOC, V69, P2831, DOI 10.1002/1097-0142(19920601)69:11<2831::AID-CNCR2820691132>3.0.CO;2-J; POWELL IJ, 1995, UROLOGY, V46, P825, DOI 10.1016/S0090-4295(99)80352-5; RAGLAND KE, 1991, AM J EPIDEMIOL, V133, P672; Ries L, 2000, SEER CANC STAT REV 1; Ries LAG .M.K.C, 2001, SEER CANC STAT REV 1; ROACH M, 1992, INT J RADIAT ONCOL, V24, P441, DOI 10.1016/0360-3016(92)91058-U; Roach M, 1998, J NATL MED ASSOC, V90, pS713; Roach M, 1997, CANCER J SCI AM, V3, P107; ROACH M, 1992, J NATL MED ASSOC, V84, P668; ROACH M, 1995, J NATL MED ASSOC, V87, P214; Robbins AS, 1998, JNCI-J NATL CANCER I, V90, P986, DOI 10.1093/jnci/90.13.986; Roetzheim RG, 2000, CANCER-AM CANCER SOC, V89, P2202, DOI 10.1002/1097-0142(20001201)89:11<2202::AID-CNCR8>3.0.CO;2-L; SATARIANO WA, 1994, ANN INTERN MED, V120, P104, DOI 10.7326/0003-4819-120-2-199401150-00002; SAVAGE D, 1984, CANCER, V54, P3085, DOI 10.1002/1097-0142(19841215)54:12<3085::AID-CNCR2820541246>3.0.CO;2-Z; Shavers VL, 2002, JNCI-J NATL CANCER I, V94, P334; SHWARTZ M, 1980, CANCER, V46, P844, DOI 10.1002/1097-0142(19800815)46:4<844::AID-CNCR2820460434>3.0.CO;2-5; Simpson JR, 1996, AM J CLIN ONCOL-CANC, V19, P114, DOI 10.1097/00000421-199604000-00005; Smith TJ, 1995, LUNG CANCER-J IASLC, V13, P235, DOI 10.1016/0169-5002(95)00496-3; STEINHORN SC, 1986, AM J EPIDEMIOL, V124, P85, DOI 10.1093/oxfordjournals.aje.a114373; SUTHERLAND CM, 1986, CANCER-AM CANCER SOC, V57, P622, DOI 10.1002/1097-0142(19860201)57:3<622::AID-CNCR2820570338>3.0.CO;2-C; Thompson IM, 2001, J NATL CANCER I, V93, P219, DOI 10.1093/jnci/93.3.219; THOMS WW, 1995, CANCER, V76, P2518, DOI 10.1002/1097-0142(19951215)76:12<2518::AID-CNCR2820761217>3.0.CO;2-#; Tudur C, 2001, J ROY STAT SOC A STA, V164, P357, DOI 10.1111/1467-985X.00207; *US DEP HHS, 2001, RFA PUBLICATION US D; West DW, 1996, ANN EPIDEMIOL, V6, P413, DOI 10.1016/S1047-2797(96)00096-8; Wojcik BE, 1998, CANCER, V82, P1310, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1310::AID-CNCR14>3.0.CO;2-9; Yood MU, 1999, J NATL CANCER I, V91, P1487, DOI 10.1093/jnci/91.17.1487; Zagars GK, 1998, INT J RADIAT ONCOL, V42, P517, DOI 10.1016/S0360-3016(98)00260-0	104	394	396	0	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2002	287	16					2106	2113		10.1001/jama.287.16.2106	http://dx.doi.org/10.1001/jama.287.16.2106			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZK	11966385				2022-12-28	WOS:000175075700028
J	Barbour, V				Barbour, V			Science and myth	LANCET			English	Editorial Material									Lancet, London NW1 7BY, England		Barbour, V (corresponding author), Lancet, London NW1 7BY, England.			Barbour, Virginia/0000-0002-2358-2440				2002, SCI CREATIONISM VIEW	1	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1364	1364		10.1016/S0140-6736(02)08391-5	http://dx.doi.org/10.1016/S0140-6736(02)08391-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978331				2022-12-28	WOS:000175076200006
J	Benitez, O; Devaux, D; Dausset, J				Benitez, O; Devaux, D; Dausset, J			Audiovisual documentation of oral consent: a new method of informed consent for illiterate populations	LANCET			English	Article								Informed consent Is a legal and ethical requirement of most research in human beings, but obtaining proof of consent in illiterate populations can prove problematic. We used audiovisual documentation of oral consent (video and audiotape recording and photography), a new method of Informed consent designed for illiterate populations, in the Guarani Indians Project, a genetic study In the Paraguayan Guarani Indians. We obtained consent from 42 of about 100 potential participants. We believe that our procedure allowed more than half the potential participants to exercise their freedom of refusal. We propose to include this new method as a standard procedure for clinical research in Illiterate populations as an alternative to written and signed consent.	Guarani Indians Project, F-75014 Paris, France; Ctr Etud Polymorphisme Humain, F-75010 Paris, France		Benitez, O (corresponding author), Guarani Indians Project, 45 Rue Alesia, F-75014 Paris, France.							CADOGAN L, 1970, DICCIONARIO MBYA GUA; Cadogan Leon, 1968, DICCIONARIO GUAYAKI; Joffe S, 2001, J NATL CANCER I, V93, P139, DOI 10.1093/jnci/93.2.139; SARDI MC, 1995, INDIOS PARAGUAY, P304; Shapiro HT, 2001, NEW ENGL J MED, V345, P139, DOI 10.1056/NEJM200107123450212	5	24	26	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1406	1407		10.1016/S0140-6736(02)08361-7	http://dx.doi.org/10.1016/S0140-6736(02)08361-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978341				2022-12-28	WOS:000175076200016
J	Wallace, S				Wallace, S			A new technique for identifying risk for type 2 diabetes?	LANCET			English	News Item																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1411	1411		10.1016/S0140-6736(02)08396-4	http://dx.doi.org/10.1016/S0140-6736(02)08396-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978347				2022-12-28	WOS:000175076200022
J	Carlson, RW				Carlson, RW			Geology: Osmium remembers	SCIENCE			English	Editorial Material							ISOTOPE SYSTEM; COSMOCHEMISTRY; GEOCHEMISTRY		Carnegie Inst Washington, Dept Terr Magnetism, Washington, DC 20015 USA	Carnegie Institution for Science	Carlson, RW (corresponding author), Carnegie Inst Washington, Dept Terr Magnetism, 5241 Broad Branch Rd NW, Washington, DC 20015 USA.							Brandon AD, 1998, SCIENCE, V280, P1570, DOI 10.1126/science.280.5369.1570; Meibom A, 2002, SCIENCE, V296, P516, DOI 10.1126/science.1069119; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; Walker RJ, 1997, GEOCHIM COSMOCHIM AC, V61, P4799, DOI 10.1016/S0016-7037(97)00270-6	4	5	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					475	+		10.1126/science.1070515	http://dx.doi.org/10.1126/science.1070515			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964463				2022-12-28	WOS:000175179400027
J	Gaietta, G; Deerinck, TJ; Adams, SR; Bouwer, J; Tour, O; Laird, DW; Sosinsky, GE; Tsien, RY; Ellisman, MH				Gaietta, G; Deerinck, TJ; Adams, SR; Bouwer, J; Tour, O; Laird, DW; Sosinsky, GE; Tsien, RY; Ellisman, MH			Multicolor and electron microscopic imaging of connexin trafficking	SCIENCE			English	Article							HIGH-RESOLUTION; GAP-JUNCTIONS; PROTEIN; PHOTOOXIDATION; LIGHT; TRANSPORT; MECHANISM; COLOR; EOSIN	Recombinant proteins containing tetracysteine tags can be successively labeled in living cells with different colors of blarsenicat fluorophores so that older and younger protein molecules can be sharply distinguished by both fluorescence and electron microscopy. Here we used this approach to show that newly synthesized connexin43 was transported predominantly in 100- to 150-nanometer vesicles to the plasma membrane and incorporated at the periphery of existing gap junctions, whereas older connexins were removed from the center of the plaques into pleiomorphic vesicles of widely varying sizes. Selective imaging by correlated optical and electron microscopy of protein molecules of known ages wilt clarify fundamental processes of protein trafficking in situ.	Univ Calif San Diego, Dept Neurosci, Natl Ctr Microscopy & Imaging Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Western University (University of Western Ontario); Howard Hughes Medical Institute; University of California System; University of California San Diego	Ellisman, MH (corresponding author), Univ Calif San Diego, Dept Neurosci, Natl Ctr Microscopy & Imaging Res, 0608,9500 Gilman Dr, La Jolla, CA 92093 USA.	mhellisman@ucsd.edu	Laird, Dale W/AAL-2407-2020; Laird, Dale w/E-4176-2015	Laird, Dale W/0000-0002-4568-3285; 	NCRR NIH HHS [RR04050] Funding Source: Medline; NIDCD NIH HHS [DC03192] Funding Source: Medline; NIDDK NIH HHS [P01 DK54441] Funding Source: Medline; NIGMS NIH HHS [R01 GM065937] Funding Source: Medline; NINDS NIH HHS [NS27177, NS14718] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR004050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK054441] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS014718, R37NS027177, R01NS027177] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003192] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADAMS SR, IN PRESS J AM CHEM S; Berthoud VM, 2000, METHODS, V20, P180, DOI 10.1006/meth.1999.0935; BEYER JG, 2000, GAP JUNCTIONS MOL BA, V49, P24; Capani F, 2001, J HISTOCHEM CYTOCHEM, V49, P1351, DOI 10.1177/002215540104901103; DEERINCK TJ, 1994, J CELL BIOL, V126, P901, DOI 10.1083/jcb.126.4.901; Falk MM, 2001, MICROSC RES TECHNIQ, V52, P251, DOI 10.1002/1097-0029(20010201)52:3<251::AID-JEMT1011>3.0.CO;2-#; Falk MM, 2000, J CELL SCI, V113, P4109; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; Griffin BA, 2000, METHOD ENZYMOL, V327, P565; Griffin BA, 1998, SCIENCE, V281, P269, DOI 10.1126/science.281.5374.269; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HUANG S, 1994, J CELL BIOL, V126, P877, DOI 10.1083/jcb.126.4.877; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Jordan K, 2001, J CELL SCI, V114, P763; Laird DW, 1996, J BIOENERG BIOMEMBR, V28, P311, DOI 10.1007/BF02110107; Laird DW, 2001, MICROSC RES TECHNIQ, V52, P263, DOI 10.1002/1097-0029(20010201)52:3<263::AID-JEMT1012>3.0.CO;2-Q; Lauf U, 2001, FEBS LETT, V498, P11, DOI 10.1016/S0014-5793(01)02462-0; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; MARANTO AR, 1982, SCIENCE, V217, P953, DOI 10.1126/science.7112109; Marchant JS, 2001, NAT BIOTECHNOL, V19, P645, DOI 10.1038/90249; Martin PE, 2000, BIOCHEM J, V350, P943, DOI 10.1042/0264-6021:3500943; Martone ME, 2000, J HISTOTECHNOL, V23, P261, DOI 10.1179/his.2000.23.3.261; Musil LS, 2000, J BIOL CHEM, V275, P25207, DOI 10.1074/jbc.275.33.25207; Sosinsky G, 2000, CURR TOP MEMBR, V49, P1; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; Terskikh A, 2000, SCIENCE, V290, P1585, DOI 10.1126/science.290.5496.1585; Yeager M, 1996, CURR OPIN STRUC BIOL, V6, P183, DOI 10.1016/S0959-440X(96)80073-X; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	28	732	769	4	102	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	2002	296	5567					503	507		10.1126/science.1068793	http://dx.doi.org/10.1126/science.1068793			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964472				2022-12-28	WOS:000175179400038
J	Meibom, A; Frei, R				Meibom, A; Frei, R			Evidence for an ancient osmium isotopic reservoir in Earth	SCIENCE			English	Article							CORE-MANTLE INTERACTION; IRON-METEORITES; SYSTEMATICS; GEOCHEMISTRY; COSMOCHEMISTRY; PT-190-OS-186; PERIDOTITES; INTRUSIONS	Iridosmine grains from placer deposits associated with peridotite-bearing ophiolites in the Klamath mountains have extremely radiogenic Os-186/Os-188 ratios and old Re-Os minimum ages, from 256 to 2644 million years. This indicates the existence of an ancient platinum group element reservoir with a supra-chondritic Pt/Os ratio. Such a ratio may be produced in the outer core as a result of inner core crystallization that fractionates Os from Pt. However, if the iridosmine Os isotopic compositions are a signature of the outer core, then the inner core must have formed very early, within several hundred million years after the accretion of Earth.	Stanford Univ, Stanford, CA 94305 USA; Univ Copenhagen, Inst Geol, DK-1350 Copenhagen, Denmark	Stanford University; University of Copenhagen	Meibom, A (corresponding author), Stanford Univ, 320 Lomita Mall, Stanford, CA 94305 USA.		Frei, Robert/N-6798-2014	Frei, Robert/0000-0001-7708-9881; Meibom, Anders/0000-0002-4542-2819				Brandon AD, 1999, EARTH PLANET SC LETT, V174, P25, DOI 10.1016/S0012-821X(99)00251-4; Brandon AD, 1998, SCIENCE, V280, P1570, DOI 10.1126/science.280.5369.1570; Brandon AD, 2000, EARTH PLANET SC LETT, V177, P319, DOI 10.1016/S0012-821X(00)00044-3; CLARK WB, 1970, PUB CALIF DIV MINES, V23, P115; Harper G.D., 1990, PALEOZOIC EARLY MESO, P379, DOI [10.1130/ SPE255-p379, DOI 10.1130/SPE255-P379]; HARPER GD, 1984, GEOL SOC AM BULL, V95, P1009, DOI 10.1130/0016-7606(1984)95<1009:TJONC>2.0.CO;2; HATTORI K, 1991, EARTH PLANET SC LETT, V107, P499, DOI 10.1016/0012-821X(91)90096-Z; Hirata T, 1998, CHEM GEOL, V144, P269, DOI 10.1016/S0009-2541(97)00138-1; JONES JH, 1994, EOS, V75, P694; MORGAN JW, 1995, GEOCHIM COSMOCHIM AC, V59, P2331, DOI 10.1016/0016-7037(95)00109-D; Parkinson IJ, 1998, SCIENCE, V281, P2011, DOI 10.1126/science.281.5385.2011; Puchtel I, 2000, GEOCHIM COSMOCHIM AC, V64, P4227, DOI 10.1016/S0016-7037(00)00492-0; REISWIG RD, 1964, T METALL SOC AIME, V230, P469; Shen JJ, 1996, GEOCHIM COSMOCHIM AC, V60, P2887, DOI 10.1016/0016-7037(96)00120-2; Shirey SB, 1998, ANNU REV EARTH PL SC, V26, P423, DOI 10.1146/annurev.earth.26.1.423; Smoliar MI, 1996, SCIENCE, V271, P1099, DOI 10.1126/science.271.5252.1099; Walker D, 2000, GEOCHIM COSMOCHIM AC, V64, P2897, DOI 10.1016/S0016-7037(00)00429-4; WALKER RJ, 1994, GEOCHIM COSMOCHIM AC, V58, P4179, DOI 10.1016/0016-7037(94)90272-0; Walker RJ, 1997, GEOCHIM COSMOCHIM AC, V61, P4799, DOI 10.1016/S0016-7037(97)00270-6; WALKER RJ, 1995, SCIENCE, V269, P819, DOI 10.1126/science.269.5225.819; WALKER RJ, 11 GOLDSCHM C HOT SP	21	65	66	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					516	518		10.1126/science.1069119	http://dx.doi.org/10.1126/science.1069119			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964475				2022-12-28	WOS:000175179400042
J	Aidoo, M; Terlouw, DJ; Kolczak, M; McElroy, PD; ter Kuile, FO; Kariuki, S; Nahlen, BL; Lal, AA; Udhayakumar, V				Aidoo, M; Terlouw, DJ; Kolczak, M; McElroy, PD; ter Kuile, FO; Kariuki, S; Nahlen, BL; Lal, AA; Udhayakumar, V			Protective effects of the sickle cell gene against malaria morbidity and mortality	LANCET			English	Article							CHILDREN; COHORT	The high frequency of the sickle-cell haemoglobin (HbS) gene in malaria endemic regions is believed to be due to a heterozygote (HbAS) advantage against fatal malaria. Data to prospectively confirm the protection associated with HbAS against mortality are lacking. We show that HbAS provides significant protection against all-cause mortality, severe malarial anaemia, and high-density parasitaemia. This significant reduction in mortality was detected between the ages of 2 and 16 months, the highest risk period for severe malarial anaemia in this area. These data are important in understanding the role of malaria In the selection and maintenance of the sickle cell gene.	Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Kenya Govt Med Res Ctr, Vector Biol & Control Res Ctr, Kisumu, Kenya; Amsterdam Med Ctr, Dept Infect Dis Trop Med & AIDS, Amsterdam, Netherlands	Centers for Disease Control & Prevention - USA; Kenya Medical Research Institute; University of Amsterdam; Academic Medical Center Amsterdam	Aidoo, M (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA.		Nahlen, Bernard/AAH-2051-2021; Kuile, Feiko ter/ABD-6681-2020	Kuile, Feiko ter/0000-0003-3663-5617; Terlouw, Anja/0000-0001-5327-8995				ALLISON AC, 1964, COLD SPRING HARB SYM, V29, P137, DOI 10.1101/SQB.1964.029.01.018; Bloland PB, 1999, AM J TROP MED HYG, V60, P641, DOI 10.4269/ajtmh.1999.60.641; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; McElroy PD, 2001, AM J TROP MED HYG, V64, P18, DOI 10.4269/ajtmh.2001.64.18; McElroy PD, 1999, AM J TROP MED HYG, V61, P932, DOI 10.4269/ajtmh.1999.61.932	5	388	395	7	238	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1311	1312		10.1016/S0140-6736(02)08273-9	http://dx.doi.org/10.1016/S0140-6736(02)08273-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965279				2022-12-28	WOS:000174989700016
J	Dargie, HJ; Ford, I; Fox, KM; Hillis, WS				Dargie, HJ; Ford, I; Fox, KM; Hillis, WS		IONA Study Grp	Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial	LANCET			English	Article							HEART-DISEASE; ISOSORBIDE DINITRATE; UNSTABLE ANGINA; DOUBLE-BLIND; ISCHEMIA; EPIDEMIOLOGY; ATENOLOL	Background In addition to its anti-ischaemic effects, the antianginal drug nicorandil is thought to have cardioprotective properties. We did a randomised trial to find out whether nicorandil could reduce the frequency of coronary events in men and women with stable angina and additional risk factors. Methods 5126 patients were randomly assigned 20 mg nicorandil twice daily (n=2565) or identical placebo (n=2561) in addition to standard antianginal therapy. The primary composite endpoint was coronary heart disease death, nonfatal myocardial infarction, or unplanned hospital admission for cardiac chest pain. The secondary endpoint was the combined outcome of coronary heart disease death or nonfatal myocardial infarction. Other outcomes reported include all-cause mortality, all cardiovascular events, and acute coronary syndromes. Mean follow-up was 1.6 years (SD 0.5). Analysis was by intention to treat. Findings There were 398 (15.5%) primary endpoint events in the placebo group and 337 (13.1%) in the nicorandil group (hazard ratio 0.83, 95% Cl 0.72-0.97; p=0.014). The frequency of the secondary endpoint was not significantly different between the groups (134 events [5.2%] vs 107 events [4.2%]; 0.79, 0.61-1.02; p=0.068). The rate of acute coronary syndromes was 195 (7.6%) in the placebo group and 156 (6.1%) in the nicorandil group (0.79, 0.64-0.98; p=0.028), and the corresponding rates for all cardiovascular events were 436 (17.0%) and 378 (14.7%; 0.86, 0.75-0.98; p=0.027). Interpretation We showed a significant improvement in outcome due to a reduction in major coronary events by antianginal therapy with nicorandil in patients with stable angina.	Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; Royal Brompton Hosp, London SW3 6LY, England	University of Glasgow; University of Glasgow; Royal Brompton Hospital	Dargie, HJ (corresponding author), Univ Glasgow, Western Infirm, Glasgow G11 6NT, Lanark, Scotland.	h.dargie@bio.gla.ac.uk	Ford, Ian/ABE-6145-2020					*ANT TRIAL COLL, 1994, COLL OV RAND TRIALS, P81; AUCHAMPACH JA, 1992, J CARDIOVASC PHARM, V20, P765, DOI 10.1097/00005344-199220050-00012; Braunwald E, 1998, CIRCULATION, V98, P2219, DOI 10.1161/01.CIR.98.21.2219; CE M, 1986, CIRCULATION, V74, P1124; CHIBANA T, 1991, ARZNEIMITTEL-FORSCH, V41-1, P591; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; Dargie HJ, 1996, EUR HEART J, V17, P104; DISOMMA S, 1993, CARDIOVASC DRUG THER, V7, P119, DOI 10.1007/BF00878320; DORING G, 1992, J CARDIOVASC PHARM, V20, pS74; Gandhi MM, 1997, BRIT J HOSP MED, V58, P23; GROSS GJ, 1992, CARDIOVASC RES, V26, P1011, DOI 10.1093/cvr/26.11.1011; *IONA STUD GROUP, 2001, HEART, V85, pE9; Jenkins DP, 1997, HEART, V77, P314, DOI 10.1136/hrt.77.4.314; Matsubara T, 2000, J AM COLL CARDIOL, V35, P345, DOI 10.1016/S0735-1097(99)00539-2; Patel DJ, 1999, EUR HEART J, V20, P51, DOI 10.1053/euhj.1998.1354; PEDERSEN TR, 1994, LANCET, V344, P1383; PEPINE CJ, 1994, J AM COLL CARDIOL, V24, P1, DOI 10.1016/0735-1097(94)90534-7; PEPINE CJ, 1994, CIRCULATION, V90, P762, DOI 10.1161/01.CIR.90.2.762; Rehnqvist N, 1996, EUR HEART J, V17, P483; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; SAITO S, 1998, CARDIOVASC PHARM, V31, P74; Sato T, 2000, J AM COLL CARDIOL, V35, P514, DOI 10.1016/S0735-1097(99)00552-5; TAIRA N, 1987, J CARDIOVASC PHARM, V10, pS1, DOI 10.1097/00005344-198700108-00002; TAIRA N, 1989, AM J CARDIOL, V63, pJ18, DOI 10.1016/0002-9149(89)90200-2; The SWAN study group, 1999, J CLIN BASIC CARDIOL, V2, P213; TOMAI F, 1993, J AM COLL CARDIOL, V22, P1892, DOI 10.1016/0735-1097(93)90775-V; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; TREESE N, 1992, J CARDIOVASC PHARM, V20, pS52, DOI 10.1097/00005344-199206203-00010; TUNSTALLPEDOE H, 1985, EUR HEART J, V6, P1; Yellon DM, 1996, LANCET, V347, P1159, DOI 10.1016/S0140-6736(96)90613-3; YELLON DM, 1993, LANCET, V342, P276, DOI 10.1016/0140-6736(93)91819-8; Yusuf S, 2000, NEW ENGL J MED, V342, P145	32	462	481	1	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	2002	359	9314					1269	1275		10.1016/s0140-6736(02)08265-x	http://dx.doi.org/10.1016/s0140-6736(02)08265-x			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965271				2022-12-28	WOS:000174989700008
J	Borst, P				Borst, P			Antigenic variation and allelic exclusion	CELL			English	Review							TRYPANOSOMA-BRUCEI; PLASMODIUM-FALCIPARUM; EXPRESSION; TRANSCRIPTION; GENES	Cells often express only one gene from a set of two or more. African trypanosomes appear to accomplish this monoallelic expression by segregating the selected gene into a specific nuclear body. The possibility that such a structure might explain monoallelic expression in other multigene systems is discussed here.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.							Barry JD, 2001, ADV PARASIT, V49, P1, DOI 10.1016/S0065-308X(01)49037-3; Bitter W, 1998, NATURE, V391, P499, DOI 10.1038/35166; Borst P, 2001, MOL BIOCHEM PARASIT, V114, P17, DOI 10.1016/S0166-6851(01)00243-2; BORST P, 2002, ANTIGENIC VARIATION, V2, P953; Chaves I, 1999, EMBO J, V18, P4846, DOI 10.1093/emboj/18.17.4846; Chess A, 1998, SCIENCE, V279, P2067, DOI 10.1126/science.279.5359.2067; Cross GAM, 1998, MOL BIOCHEM PARASIT, V91, P77, DOI 10.1016/S0166-6851(97)00186-2; Deitsch KW, 2001, NATURE, V412, P875, DOI 10.1038/35091146; Freitas-Junior LH, 2000, NATURE, V407, P1018, DOI 10.1038/35039531; Grosveld F, 1999, CURR OPIN GENET DEV, V9, P152, DOI 10.1016/S0959-437X(99)80023-9; Kratz E, 2002, TRENDS GENET, V18, P29, DOI 10.1016/S0168-9525(01)02579-3; Lane RP, 2001, P NATL ACAD SCI USA, V98, P7390, DOI 10.1073/pnas.131215398; Navarro M, 2001, NATURE, V414, P759, DOI 10.1038/414759a; Ohlsson R, 1998, TRENDS GENET, V14, P435, DOI 10.1016/S0168-9525(98)01583-2; Pays E, 2001, MOL BIOCHEM PARASIT, V114, P1, DOI 10.1016/S0166-6851(01)00242-0; Scherf A, 1998, EMBO J, V17, P5418, DOI 10.1093/emboj/17.18.5418; Serizawa S, 2000, NAT NEUROSCI, V3, P687, DOI 10.1038/76641; Sleutels F, 2002, ADV GENET, V46, P119; Stringer JR, 2001, INFECT IMMUN, V69, P627, DOI 10.1128/IAI.69.2.627-639.2001; Zhang XM, 2002, NAT NEUROSCI, V5, P124, DOI 10.1038/nn800	20	134	135	0	8	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	2002	109	1					5	8		10.1016/S0092-8674(02)00711-0	http://dx.doi.org/10.1016/S0092-8674(02)00711-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955440	Bronze			2022-12-28	WOS:000174888300002
J	Keverne, EB				Keverne, EB			Pheromones, vomeronasal function, and gender-specific behavior	CELL			English	Review							ACCESSORY OLFACTORY-BULB; FEMALE MICE; RESPONSES; ORGAN; NEURONS	The striking behavioral phenotypes of mice lacking the TRP2 ion channel have highlighted the importance of the vomeronasal organ in gender-specific sexual behavior.	Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England	University of Cambridge	Keverne, EB (corresponding author), Univ Cambridge, Subdept Anim Behav, Cambridge CB3 8AA, England.							Brennan PA, 1999, NEUROSCIENCE, V90, P1463, DOI 10.1016/S0306-4522(98)00556-9; CAMPENHAUSEN H, 2000, EUR J NEUROSCI, V12, P33; Curtis JT, 2001, BRAIN RES, V901, P167, DOI 10.1016/S0006-8993(01)02343-5; Halem HA, 1999, J NEUROBIOL, V39, P249, DOI 10.1002/(SICI)1097-4695(199905)39:2<249::AID-NEU9>3.3.CO;2-I; HERBERT J, 1993, PROG NEUROBIOL, V41, P723, DOI 10.1016/0301-0082(93)90033-O; Holy TE, 2000, SCIENCE, V289, P1569, DOI 10.1126/science.289.5484.1569; HUDSON R, 1986, PHYSIOL BEHAV, V37, P123, DOI 10.1016/0031-9384(86)90394-X; KEVERNE EB, 1986, CHEM SENSES, V11, P119, DOI 10.1093/chemse/11.1.119; Leinders-Zufall T, 2000, NATURE, V405, P792, DOI 10.1038/35015572; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; NOVOTNY M, 1985, P NATL ACAD SCI USA, V82, P2059, DOI 10.1073/pnas.82.7.2059; Savic I, 2000, NEURON, V26, P735, DOI 10.1016/S0896-6273(00)81209-X; Segovia S, 1996, HORM BEHAV, V30, P618, DOI 10.1006/hbeh.1996.0065; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Sugai T, 2000, NEUROSCIENCE, V95, P23; Tirindelli R, 1998, TRENDS NEUROSCI, V21, P482, DOI 10.1016/S0166-2236(98)01274-0; Trotier D, 2000, CHEM SENSES, V25, P369, DOI 10.1093/chemse/25.4.369; WYSOCKI CJ, 1991, J STEROID BIOCHEM, V39, P661, DOI 10.1016/0960-0760(91)90265-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607	19	58	60	0	11	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	MAR 22	2002	108	6					735	738		10.1016/S0092-8674(02)00687-6	http://dx.doi.org/10.1016/S0092-8674(02)00687-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955427	Bronze			2022-12-28	WOS:000174563000003
J	de Boer, J; Andressoo, JO; de Wit, J; Huijmans, J; Beems, RB; van Steeg, H; Weeda, G; van der Horst, GTJ; van Leeuwen, W; Themmen, APN; Meradji, M; Hoeijmakers, JHJ				de Boer, J; Andressoo, JO; de Wit, J; Huijmans, J; Beems, RB; van Steeg, H; Weeda, G; van der Horst, GTJ; van Leeuwen, W; Themmen, APN; Meradji, M; Hoeijmakers, JHJ			Premature aging in mice deficient in DNA repair and transcription	SCIENCE			English	Article							NUCLEOTIDE EXCISION-REPAIR; COCKAYNE-SYNDROME; COUPLED REPAIR; CANCER PREDISPOSITION; PREFERENTIAL REPAIR; INDUCED APOPTOSIS; WERNER-SYNDROME; RNA-POLYMERASE; ULTRAVIOLET-B; SYNDROME GENE	One of the factors postulated to drive the aging process is the accumulation of DNA damage. Here, we provide strong support for this hypothesis by describing studies of mice with a mutation in XPD, a gene encoding a DNA helicase that functions In both repair and transcription and that is mutated in the human disorder trichothiodystrophy (TTD). TTD mice were found to exhibit many symptoms of premature aging, Including osteoporosis and kyphosis, osteosclerosis, early greying, cachexia, infertility, and reduced life-span. TTD mice carrying an additional mutation in XPA, which enhances the DNA repair defect, showed a greatly accelerated aging phenotype, which correlated with an increased cellular sensitivity to oxidative DNA damage. We hypothesize that aging in TTD mice is caused by unrepaired DNA damage that compromises transcription, leading to functional inactivation of critical genes and enhanced apoptosis.	Erasmus Univ, Med Genet Ctr, Dept Cell Biol & Genet, Ctr Biomed Genet, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, MGC, Dept Clin Genet, CBG, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Expt Radiol, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Dept Endocrinol & Reprod, NL-3000 DR Rotterdam, Netherlands; Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; Sophia Childrens Univ Hosp, Dept Radiol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Netherlands National Institute for Public Health & the Environment; Erasmus University Rotterdam; Erasmus MC - Sophia Children's Hospital	Hoeijmakers, JHJ (corresponding author), Erasmus Univ, Med Genet Ctr, Dept Cell Biol & Genet, Ctr Biomed Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Andressoo, Jaan-Olle/AAA-1216-2021; van der Horst, Gijsbertus TJ/E-3661-2015; Hoeijmakers, Jan/AAX-6972-2021	van der Horst, Gijsbertus TJ/0000-0002-7773-6396; Andressoo, Jaan-Olle/0000-0002-0271-3157; de Boer, Jan/0000-0001-9188-9324	NATIONAL INSTITUTE ON AGING [P01AG017242] Funding Source: NIH RePORTER; NIA NIH HHS [AG 17242-02] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1761, UNPUB; Bootsma D., 1998, GENETIC BASIS HUMAN, P245; Botta E, 1998, AM J HUM GENET, V63, P1036, DOI 10.1086/302063; Bremer HJ, 1981, DISTURBANCES AMINO A, P80; Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Campisi J, 2000, IN VIVO, V14, P183; Citterio E, 2000, CELL, V101, P447, DOI 10.1016/S0092-8674(00)80854-5; Conforti G, 2000, ONCOGENE, V19, P2714, DOI 10.1038/sj.onc.1203583; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Day BJ, 1996, TOXICOL APPL PHARM, V140, P94, DOI 10.1006/taap.1996.0201; de Boer J, 1999, CANCER RES, V59, P3489; de Boer J, 1998, MOL CELL, V1, P981, DOI 10.1016/S1097-2765(00)80098-2; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Dolle MET, 1997, NAT GENET, V17, P431, DOI 10.1038/ng1297-431; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Evans E, 1997, EMBO J, V16, P6559, DOI 10.1093/emboj/16.21.6559; GOSDEN RG, 1983, BIOL REPROD, V28, P255, DOI 10.1095/biolreprod28.2.255; Goyns MH, 2000, MECH AGEING DEV, V114, P69, DOI 10.1016/S0047-6374(00)00095-6; Hanawalt PC, 2000, NATURE, V405, P415, DOI 10.1038/35013197; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Holstege FCP, 1996, EMBO J, V15, P1666, DOI 10.1002/j.1460-2075.1996.tb00512.x; ITIN PH, 1990, J AM ACAD DERMATOL, V22, P705, DOI 10.1016/0190-9622(90)70096-Z; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; KUMAR P, 1988, BRIT J DERMATOL, V118, P397, DOI 10.1111/j.1365-2133.1988.tb02434.x; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Ljungman M, 1996, ONCOGENE, V13, P823; Martin GM, 2000, NATURE, V408, P263, DOI 10.1038/35041705; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MCCUAIG C, 1993, J AM ACAD DERMATOL, V28, P820, DOI 10.1016/0190-9622(93)70109-7; MURAKAMI M, 1995, MUTAT RES-DNA REPAIR, V336, P215, DOI 10.1016/0921-8777(94)00059-F; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; Nehlin JO, 2000, ANN NY ACAD SCI, V908, P167; Oshima J, 2000, IN VIVO, V14, P165; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; STEFANINI M, 1986, HUM GENET, V74, P107, DOI 10.1007/BF00282072; Toelle SP, 2001, EUR J PEDIATR, V160, P728, DOI 10.1007/s004310100845; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a; vanderHorst GTJ, 1997, CELL, V89, P425, DOI 10.1016/S0092-8674(00)80223-8; VERMEULEN W, 1994, AM J HUM GENET, V54, P191; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; Vijg J, 2000, MUTAT RES-FUND MOL M, V447, P117, DOI 10.1016/S0027-5107(99)00202-X; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; YU EE, 1996, SCIENCE, V272, P258	54	415	428	2	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 17	2002	296	5571					1276	1279		10.1126/science.1070174	http://dx.doi.org/10.1126/science.1070174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	554BL	11950998				2022-12-28	WOS:000175713000043
J	Cummings, JL; Cole, G				Cummings, JL; Cole, G			Alzheimer disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; QUALITY STANDARDS SUBCOMMITTEE; ACADEMY-OF-NEUROLOGY; DOUBLE-BLIND; PRACTICE PARAMETER; COGNITIVE IMPAIRMENT; RISK-FACTORS; DEMENTIA; POPULATION; INHIBITORS		Univ Calif Los Angeles, Sch Med, Reed Neurol Res Ctr, Dept Neurol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90095 USA; Vet Affairs Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Cummings, JL (corresponding author), Univ Calif Los Angeles, Sch Med, Reed Neurol Res Ctr, Dept Neurol, 710 Westwood Plaza, Los Angeles, CA 90095 USA.	cummings@ucla.edu			NATIONAL INSTITUTE ON AGING [P50AG016570] Funding Source: NIH RePORTER; NIA NIH HHS [AG16570] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arnold SE, 1991, CEREB CORTEX, V1, P103, DOI 10.1093/cercor/1.1.103; Ball M, 1997, NEUROBIOL AGING, V18, pS1, DOI 10.1016/s0197-4580(97)00057-2; Beard CM, 1996, ANN EPIDEMIOL, V6, P195, DOI 10.1016/1047-2797(95)00068-2; BRACCO L, 1994, ARCH NEUROL-CHICAGO, V51, P1213, DOI 10.1001/archneur.1994.00540240057016; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; COREYBLOOM J, 1998, INT J GERIATR PSYCHO, V1, P55; Costa P T, 1996, RECOGNITION INITIAL; Cummings JL, 2000, AM J PSYCHIAT, V157, P4, DOI 10.1176/ajp.157.1.4; Cummings JL, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.1_Suppl_1.S2; Cummings JL, 1992, DEMENTIA CLIN APPROA; Doody RS, 2001, NEUROLOGY, V56, P1154, DOI 10.1212/WNL.56.9.1154; ERNST RL, 1994, AM J PUBLIC HEALTH, V84, P1261, DOI 10.2105/AJPH.84.8.1261; Evans DA, 1997, ARCH NEUROL-CHICAGO, V54, P1399, DOI 10.1001/archneur.1997.00550230066019; FARRER LA, 1995, JAMA-J AM MED ASSOC, V274, P1627, DOI 10.1001/jama.1995.03530200063039; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Gao S, 1998, ARCH GEN PSYCHIAT, V55, P809, DOI 10.1001/archpsyc.55.9.809; Gotz J, 2001, SCIENCE, V293, P1491, DOI 10.1126/science.1062097; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Henderson VW, 2000, NEUROLOGY, V54, P295, DOI 10.1212/WNL.54.2.295; Hendrie HC, 2001, JAMA-J AM MED ASSOC, V285, P739, DOI 10.1001/jama.285.6.739; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Katz IR, 1999, J CLIN PSYCHIAT, V60, P107, DOI 10.4088/JCP.v60n0207; Knopman DS, 2001, NEUROLOGY, V56, P1143, DOI 10.1212/WNL.56.9.1143; LANTOS P, 2000, DEMENTIA, P443; Launer LJ, 1999, NEUROLOGY, V52, P78, DOI 10.1212/WNL.52.1.78; Launer LJ, 1997, NEUROBIOL AGING, V18, P257, DOI 10.1016/S0197-4580(97)00010-9; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P1686, DOI 10.1176/appi.ajp.157.10.1686; MAX W, 1993, NEUROLOGY, V43, pS6; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mega MS, 1999, ARCH NEUROL-CHICAGO, V56, P1388, DOI 10.1001/archneur.56.11.1388; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Orgogozo JM, 1997, REV NEUROL-FRANCE, V153, P185; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Selkoe DJ, 2001, CLIN NEUROSCI RES, V1, P91, DOI 10.1016/S1566-2772(00)00016-5; SESHADRI S, 1995, ARCH NEUROL-CHICAGO, V52, P1074, DOI 10.1001/archneur.1995.00540350068018; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Taragano FE, 1997, PSYCHOSOMATICS, V38, P246, DOI 10.1016/S0033-3182(97)71461-0; Tariot PN, 1998, AM J PSYCHIAT, V155, P54, DOI 10.1176/ajp.155.1.54; Tariot PN, 2000, NEUROLOGY, V54, P2269, DOI 10.1212/WNL.54.12.2269; von Strauss E, 1999, ARCH NEUROL-CHICAGO, V56, P587, DOI 10.1001/archneur.56.5.587; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439	49	309	326	2	28	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	2002	287	18					2335	2338		10.1001/jama.287.18.2335	http://dx.doi.org/10.1001/jama.287.18.2335			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548PF	11988038				2022-12-28	WOS:000175397000002
J	Ferguson-Avery, B				Ferguson-Avery, B			Body English	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	2002	287	18					2331	2332		10.1001/jama.287.18.2331	http://dx.doi.org/10.1001/jama.287.18.2331			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548PF	11988037				2022-12-28	WOS:000175397000001
J	Sulkowski, MS; Ray, SC; Thomas, DL				Sulkowski, MS; Ray, SC; Thomas, DL			Needlestick transmission of hepatitis C	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NON-B-HEPATITIS; HUMAN-IMMUNODEFICIENCY-VIRUS; RANDOMIZED CONTROLLED TRIAL; POLYMERASE CHAIN-REACTION; HEALTH-CARE WORKERS; INTERFERON-ALPHA-2B PLUS RIBAVIRIN; CYTOTOXIC T-LYMPHOCYTES; INJECTING DRUG-USERS; TERM FOLLOW-UP; NON-A	Hepatitis C virus (HCV) transmission following a needlestick is an important threat to health care workers. We present the case of a 29-year-old medical intern who sustained a needlestick injury from a source patient known to be infected with both human immunodeficiency virus and HCV. The case patient subsequently developed acute HCV infection. The optimal strategy for diagnosing HCV infection after occupational exposures has not been defined. At a minimum, HCV antibody and alanine aminotransferase testing should be done within several days of exposure (to assess if the health care worker is already infected with HCV) and 6 months after percutaneous, mucosal, or nonintact skin exposure to blood or infectious body fluids from an HCV-infected patient. Currently, it is not possible to prevent HCV infection after exposure. However, recent data suggest that early treatment of acute HCV infection with interferon (x may be highly effective in preventing chronic HCV infection. These data underscore the importance of identifying persons with acute HCV infection and promptly referring them to experienced clinicians who can provide updated counseling and treatment.	Johns Hopkins Sch Med, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Thomas, DL (corresponding author), Johns Hopkins Sch Med, 424 N Bond St, Baltimore, MD 21231 USA.		Ray, Stuart C./B-7527-2008	Ray, Stuart C./0000-0002-1051-7260	NIAID NIH HHS [U19AI40035, R01 AI47364, U19 AI040035] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047364, U19AI040035] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABE K, 1992, HEPATOLOGY, V15, P690, DOI 10.1002/hep.1840150423; Adams G, 1997, PEDIATR INFECT DIS J, V16, P533, DOI 10.1097/00006454-199705000-00021; Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; ALTER HJ, 1978, LANCET, V1, P459; [Anonymous], 2001, MMWR Recomm Rep, V50, P1; BARRERA JM, 1995, VOX SANG, V68, P15, DOI 10.1111/j.1423-0410.1995.tb02538.x; Beld M, 1999, BLOOD, V94, P1183, DOI 10.1182/blood.V94.4.1183.416k15_1183_1191; Beld M, 1998, J CLIN MICROBIOL, V36, P872, DOI 10.1128/JCM.36.4.872-877.1998; BOGARD M, 1995, CELL MOL BIOL, V41, P725; Bresee JS, 1996, JAMA-J AM MED ASSOC, V276, P1563, DOI 10.1001/jama.276.19.1563; Bronowicki JP, 1997, J INFECT DIS, V176, P518, DOI 10.1086/517279; BUKH J, 1993, J INFECT DIS, V168, P1343, DOI 10.1093/infdis/168.6.1343; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; CHAMOT E, 1990, AIDS, V4, P1275, DOI 10.1097/00002030-199012000-00016; Chang KM, 1997, J CLIN INVEST, V100, P2376, DOI 10.1172/JCI119778; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; COUROUCE AM, 1994, TRANSFUSION, V34, P790, DOI 10.1046/j.1537-2995.1994.34994378281.x; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; Department of Labor, 1991, FED REG, V56, P64004; Diepolder HM, 1997, J VIROL, V71, P6011, DOI 10.1128/JVI.71.8.6011-6019.1997; DIEPOLDER HM, 1995, LANCET, V346, P1006, DOI 10.1016/S0140-6736(95)91691-1; Dore GJ, 1997, BRIT MED J, V315, P333; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; Farci P, 1996, P NATL ACAD SCI USA, V93, P15394, DOI 10.1073/pnas.93.26.15394; FARCI P, 1994, P NATL ACAD SCI USA, V91, P7792, DOI 10.1073/pnas.91.16.7792; Farci P, 1996, NEW ENGL J MED, V335, P631, DOI 10.1056/NEJM199608293350904; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FERRARI C, 1994, HEPATOLOGY, V19, P286; Fried MW, 2001, GASTROENTEROLOGY, V120, pA55, DOI 10.1016/S0016-5085(08)80271-5; GENESCA J, 1993, GUT, V34, pS62, DOI 10.1136/gut.34.2_Suppl.S62; GERBERDING JL, 1994, J INFECT DIS, V170, P1410, DOI 10.1093/infdis/170.6.1410; GRADY GF, 1978, J INFECT DIS, V138, P625, DOI 10.1093/infdis/138.5.625; Gursoy M, 2001, J VIRAL HEPATITIS, V8, P70, DOI 10.1046/j.1365-2893.2001.00268.x; Hasan F, 1999, HEPATO-GASTROENTEROL, V46, P1678; HERNANDEZ ME, 1992, J HEPATOL, V16, P56, DOI 10.1016/S0168-8278(05)80094-7; Houghton M, 2000, CURR TOP MICROBIOL, V242, P327; HWANG SJ, 1994, J HEPATOL, V21, P831, DOI 10.1016/S0168-8278(94)80246-7; Inglesby TV, 1999, HEPATOLOGY, V29, P590, DOI 10.1002/hep.510290219; Ippolito G, 1998, JAMA-J AM MED ASSOC, V280, P28, DOI 10.1001/jama.280.1.28; Jaeckel E, 2001, NEW ENGL J MED, V345, P1452, DOI 10.1056/NEJMoa011232; JAGGER J, 1988, NEW ENGL J MED, V319, P284, DOI 10.1056/NEJM198808043190506; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KNODELL RG, 1976, LANCET, V1, P557; Koziel MJ, 1997, J INFECT DIS, V176, P859, DOI 10.1086/516546; KOZIEL MJ, 1993, J VIROL, V67, P7522, DOI 10.1128/JVI.67.12.7522-7532.1993; Krawczynski K, 1996, J INFECT DIS, V173, P822, DOI 10.1093/infdis/173.4.822; LAMPERTICO P, 1994, HEPATOLOGY, V19, P19, DOI 10.1016/0270-9139(94)90047-7; LANPHEAR BP, 1994, INFECT CONT HOSP EP, V15, P745; Lechmann M, 1996, HEPATOLOGY, V24, P790; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; LIN HH, 1994, J INFECT DIS, V169, P638, DOI 10.1093/infdis/169.3.638; Major ME, 1999, J VIROL, V73, P3317, DOI 10.1128/JVI.73.4.3317-3325.1999; Manns MP, 2001, LANCET, V358, P958, DOI 10.1016/S0140-6736(01)06102-5; MARCELLIN P, 1994, J INFECT DIS, V170, P433, DOI 10.1093/infdis/170.2.433; MATSUBARA T, 1995, EUR J PEDIATR, V154, P973, DOI 10.1007/BF01958640; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Missale G, 1996, J CLIN INVEST, V98, P706, DOI 10.1172/JCI118842; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; Morand P, 2001, CLIN INFECT DIS, V33, P727, DOI 10.1086/322619; NAKANO Y, 1995, J GASTROEN HEPATOL, V10, P609, DOI 10.1111/j.1440-1746.1995.tb01355.x; Nelson DR, 1997, J IMMUNOL, V158, P1473; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; Okamoto M, 2000, J INFECT DIS, V182, P1511, DOI 10.1086/315883; OMATA M, 1991, LANCET, V338, P914, DOI 10.1016/0140-6736(91)91774-O; PALMOVIC D, 1994, INFECTION, V22, P222, DOI 10.1007/BF01716714; PEREZTRALLERO E, 1994, LANCET, V344, P548, DOI 10.1016/S0140-6736(94)91943-7; PETROSILLO N, 1994, LANCET, V344, P339; Piazza M, 1997, ARCH INTERN MED, V157, P1537, DOI 10.1001/archinte.157.14.1537; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Piton A, 1998, HEPATOLOGY, V27, P1213, DOI 10.1002/hep.510270505; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; PRINCE AM, 1993, J INFECT DIS, V167, P1296, DOI 10.1093/infdis/167.6.1296; PURO V, 1995, INFECT CONT HOSP EP, V16, P324; RAGNI MV, 1993, BLOOD, V82, P1010, DOI 10.1182/blood.V82.3.1010.bloodjournal8231010; Ray SC, 2000, J VIROL, V74, P3058, DOI 10.1128/JVI.74.7.3058-3066.2000; Rehermann B, 1996, J CLIN INVEST, V98, P1432, DOI 10.1172/JCI118931; SANCHEZQUIJANO A, 1988, LANCET, V1, P1245; SHIMIZU YK, 1990, P NATL ACAD SCI USA, V87, P6441, DOI 10.1073/pnas.87.16.6441; SHIMIZU YK, 1994, J VIROL, V68, P1494, DOI 10.1128/JVI.68.3.1494-1500.1994; SODEYAMA T, 1993, ARCH INTERN MED, V153, P1565, DOI 10.1001/archinte.153.13.1565; TABOR E, 1978, LANCET, V1, P463, DOI 10.1016/s0140-6736(78)90132-0; Takaki A, 2000, NAT MED, V6, P578, DOI 10.1038/75063; TAKANO S, 1994, GASTROENTEROLOGY, V107, P805, DOI 10.1016/0016-5085(94)90130-9; TASSOPOULOS NC, 1993, GUT, V34, pS130, DOI 10.1136/gut.34.2_Suppl.S130; Thio CL, 2000, HEPATOLOGY, V31, P819, DOI 10.1053/he.2000.4316; Thio CL, 2001, J INFECT DIS, V184, P16, DOI 10.1086/321005; Thomas DL, 1998, J INFECT DIS, V177, P1480, DOI 10.1086/515315; Thomas DL, 2000, JAMA-J AM MED ASSOC, V284, P450, DOI 10.1001/jama.284.4.450; Thursz M, 1999, LANCET, V354, P2119, DOI 10.1016/S0140-6736(99)91443-5; Tsai SL, 1997, HEPATOLOGY, V25, P449; Tsai SL, 1998, GASTROENTEROLOGY, V115, P954, DOI 10.1016/S0016-5085(98)70268-9; VILADOMIU L, 1992, HEPATOLOGY, V15, P767, DOI 10.1002/hep.1840150504; Villano SA, 1999, HEPATOLOGY, V29, P908, DOI 10.1002/hep.510290311; Vogel W, 1996, DIGEST DIS SCI, V41, pS81, DOI 10.1007/BF02087880; WEINER A, 1995, P NATL ACAD SCI USA, V92, P2755, DOI 10.1073/pnas.92.7.2755; WEINER AJ, 1992, P NATL ACAD SCI USA, V89, P3468, DOI 10.1073/pnas.89.8.3468; Widell A, 1996, VOX SANG, V71, P55, DOI 10.1046/j.1423-0410.1996.7110055.x; ZAAIJER HL, 1993, LANCET, V341, P722, DOI 10.1016/0140-6736(93)90488-3; 1997, MMWR MORB MORTAL WKL, V46, P21	101	84	93	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	2002	287	18					2406	2413		10.1001/jama.287.18.2406	http://dx.doi.org/10.1001/jama.287.18.2406			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548PF	11988061				2022-12-28	WOS:000175397000029
J	Leggett, AJ				Leggett, AJ			Physics - Superconducting qubits - a major roadblock dissolved?	SCIENCE			English	Editorial Material							QUANTUM SUPERPOSITION; STATES		Univ Illinois, Dept Phys, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Leggett, AJ (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.							Friedman JR, 2000, NATURE, V406, P43, DOI 10.1038/35017505; LEGGETT AJ, 1985, PHYS REV LETT, V54, P857, DOI 10.1103/PhysRevLett.54.857; Makhlin Y, 2001, REV MOD PHYS, V73, P357, DOI 10.1103/RevModPhys.73.357; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Nielsen Michael A., 2002, QUANTUM COMPUTATION; van der Wal CH, 2000, SCIENCE, V290, P773, DOI 10.1126/science.290.5492.773; Vion D, 2002, SCIENCE, V296, P886, DOI 10.1126/science.1069372; Yu Y, 2002, SCIENCE, V296, P889, DOI 10.1126/science.1069452	9	27	29	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					861	862		10.1126/science.1071703	http://dx.doi.org/10.1126/science.1071703			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988560				2022-12-28	WOS:000175442500029
J	Gifford, AL; Cunningham, WE; Heslin, KC; Andersen, RM; Nakazono, T; Lieu, DK; Shapiro, MF; Bozzette, SA				Gifford, AL; Cunningham, WE; Heslin, KC; Andersen, RM; Nakazono, T; Lieu, DK; Shapiro, MF; Bozzette, SA		HIV Cost Services Utilization Stud	Participation in research and access to experimental treatments by HIV-infected patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATIONAL PROBABILITY SAMPLES; LOW-PREVALENCE DISEASES; AIDS CLINICAL-TRIALS; SERVICES UTILIZATION; AFRICAN-AMERICANS; INFORMED CONSENT; UNITED-STATES; HEALTH-CARE; DRUG; COST	Background: Although there is concern that minority groups and women are underrepresented in research involving patients with human immunodeficiency virus (HIV) infection, the available data are inconclusive. Methods: We used nationally representative data from the HIV Cost and Services Utilization Study to determine the characteristics of the participants and nonparticipants in trials of medications for HIV infection and whether or not patients had access to experimental treatments. A probability sample of 2864 persons, representing all 231,400 adults with known HIV infection who are cared for in the contiguous United States, were interviewed on three occasions between 1996 and 1998. They were asked about participation in clinical research studies of medications and past receipt of experimental medications for HIV. Results: We estimate that 14 percent of adults receiving care for HIV infection participated in a medication trial or study; 24 percent had received experimental medications; and 8 percent had tried and failed to obtain experimental treatments. According to multivariate models, non-Hispanic blacks and Hispanics were less likely to be participating in trials than non-Hispanic whites (odds ratio for participation among non-Hispanic blacks, 0.50 [95 percent confidence interval, 0.28 to 0.91]; odds ratio among Hispanics, 0.58 [95 percent confidence interval, 0.37 to 0.93]) and to have received experimental medications (odds ratios, 0.41 [95 percent confidence interval, 0.32 to 0.54] and 0.56 [95 percent confidence interval, 0.41 to 0.78], respectively). Patients who were cared for in private health maintenance organizations were less likely to participate in trials than those with fee-for-service insurance (odds ratio, 0.43 [95 percent confidence interval, 0.21 to 0.88]). Women were not underrepresented in research trials and had a similar likelihood of receiving experimental treatments. Conclusions: Among patients with HIV infection, participation in research trials and access to experimental treatment is influenced by race or ethnic group and type of health insurance.	Vet Affairs San Diego Healthcare Syst, Ctr Res Patient Oriented Care & Qual Enhancement, San Diego, CA 92161 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; RAND Hlth, Santa Monica, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; University of California System; University of California San Diego; RAND Corporation	Gifford, AL (corresponding author), Vet Affairs San Diego Healthcare Syst, Ctr Res Patient Oriented Care & Qual Enhancement, 3350 La Jolla Village Dr 111N-1, San Diego, CA 92161 USA.		Young, Alexander/A-1523-2009; Gifford, Allen L/D-9329-2016	Young, Alexander/0000-0002-9367-9213; Gifford, Allen L/0000-0001-6442-1128	AHRQ HHS [HS08578] Funding Source: Medline; NIAID NIH HHS [AI027670, AI038858] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U01HS008578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI038858, U01AI027670] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1993, KEYST NAT POL DIAL E; BELTANGADY M, 1993, BIOMETRIC B, V10, P7; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Brown J. A., 2002, HCSUS PATIENT QUESTI; CARTER SK, 1995, J ACQ IMMUN DEF SYND, V10, pS107; *CDCP, 1999, HIV AIDS SURVEILLANC, V11, P16; *CDCP, 2000, HIV AIDS SURV REP US, V12, P40; *CDCP, 2000, HIV AIDS SURVEILLANC, V12, P1; Corbie-Smith G, 1999, J GEN INTERN MED, V14, P537, DOI 10.1046/j.1525-1497.1999.07048.x; DIAZ T, 1995, J ACQ IMMUN DEF SYND, V10, P562; ELSADR W, 1992, JAMA-J AM MED ASSOC, V267, P954, DOI 10.1001/jama.267.7.954; Falloon J, 2000, AIDS, V14, pS209; FAUCI AS, 1989, ACAD MED, V64, P115, DOI 10.1097/00001888-198903000-00002; Frankel MR, 1999, HEALTH SERV RES, V34, P969; Fureman I, 1997, AIDS EDUC PREV, V9, P330; Gesensway D, 2001, ANN INTERN MED, V135, P935, DOI 10.7326/0003-4819-135-10-200111200-00032; Gorkin L, 1996, CONTROL CLIN TRIALS, V17, P46, DOI 10.1016/0197-2456(95)00089-5; Hader SL, 2001, JAMA-J AM MED ASSOC, V285, P1186, DOI 10.1001/jama.285.9.1186; Hankins C, 1998, CAN MED ASSOC J, V159, P1359; Jacobson MA, 1996, J ACQ IMMUN DEF SYND, V11, P45, DOI 10.1097/00042560-199601010-00006; Johnson JA, 1997, J PHARM SCI, V86, P1328, DOI 10.1021/js9702168; KALTON G, 1983, COMPENSATING MISSING; Kao AC, 1998, JAMA-J AM MED ASSOC, V280, P1708, DOI 10.1001/jama.280.19.1708; KISH L, 1974, J ROY STAT SOC B MET, V36, P1; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; Klonoff EA, 1999, PREV MED, V28, P451, DOI 10.1006/pmed.1999.0463; KRANTZ DS, 1980, J PERS SOC PSYCHOL, V39, P977, DOI 10.1037/0022-3514.39.5.977; Longford NT, 1999, STAT MED, V18, P1467, DOI 10.1002/(SICI)1097-0258(19990630)18:12<1467::AID-SIM149>3.0.CO;2-H; MAHLER HIM, 1991, HEALTH PSYCHOL, V10, P399, DOI 10.1037/0278-6133.10.6.399; *NAT I ALL INF DIS, 2000, DIV AIDS RES MAT DEM; National Institutes of Health, 1994, FED REGISTER, V59, P1408; *NIH, 1994, OUTR NOTCB NIH GUID; PIKE IM, 1994, CLIN INFECT DIS, V19, P1071, DOI 10.1093/clinids/19.6.1071; PIKE IM, 1993, CLIN INFECT DIS, V16, pS63, DOI 10.1093/clinids/16.Supplement_1.S63; Robinson D, 1996, J CLIN PSYCHOPHARM, V16, P170, DOI 10.1097/00004714-199604000-00009; Rossi P. H., 1983, HDB SURVEY RES; Sengupta S, 2000, J ACQ IMMUN DEF SYND, V24, P275; Shapiro MF, 1999, HEALTH SERV RES, V34, P951; Shapiro MF, 1999, JAMA-J AM MED ASSOC, V281, P2305, DOI 10.1001/jama.281.24.2305; SMITH MD, 1991, JAMA-J AM MED ASSOC, V266, P2750, DOI 10.1001/jama.266.19.2750; Stone VE, 1997, J GEN INTERN MED, V12, P150, DOI 10.1046/j.1525-1497.1997.012003150.x; Stone VE, 1998, J ACQ IMMUN DEF SYND, V19, P245, DOI 10.1097/00042560-199811010-00006; SVENSSON CK, 1989, JAMA-J AM MED ASSOC, V261, P263, DOI 10.1001/jama.261.2.263; Tejeda HA, 1996, J NATL CANCER I, V88, P812, DOI 10.1093/jnci/88.12.812; TINDALL B, 1994, PATIENT EDUC COUNS, V24, P261, DOI 10.1016/0738-3991(94)90069-8; *US BUR CENS, 2002, ANN POPULATION ESTIM; Wizemann TM, 2001, EXPLORING BIOL CONTR, P173, DOI [10.17226/10028, DOI 10.17226/10028]	47	192	192	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					1373	1382		10.1056/NEJMsa011565	http://dx.doi.org/10.1056/NEJMsa011565			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	546MZ	11986412	Bronze			2022-12-28	WOS:000175279000007
J	Penterman, R; Klink, SL; de Koning, H; Nisato, G; Broer, DJ				Penterman, R; Klink, SL; de Koning, H; Nisato, G; Broer, DJ			Single-substrate liquid-crystal displays by photo-enforced stratification	NATURE			English	Article							SEPARATED COMPOSITE FILMS; POLYMER	Data visualization plays a crucial role in our society, as illustrated by the many displays that surround us. In the future, displays may become even more pervasive, ranging from individually addressable image-rendering wall hangings to data displays integrated in clothes(1). Liquid-crystal displays (LCDs) provide most of the flat-panel displays currently used. To keep pace with the ever-increasing possibilities afforded by developments in information technology, we need to develop manufacturing processes that will make LCDs cheaper and larger, with more freedom in design. Existing batch processes for making and filling LCD cells(2,3) are relatively expensive, with size and shape limitations. Here we report a cost-effective, single-substrate technique in which a coated film is transformed into a polymer-covered liquid-crystal layer. This approach is based on photo-enforced stratification: a two-step photopolymerization-induced phase separation of a liquid-crystal blend and a polymer precursor. The process leads to the formation of micrometre-sized containers filled with a switchable liquid-crystal phase. In this way, displays can be produced on a variety of substrates using current coating technology. The developed process may be an important step towards new technologies such as 'display-on-anything' and 'paintable displays'.	Philips Res Labs, NL-5656 AA Eindhoven, Netherlands; Eindhoven Univ Technol, Dept Polymer Chem & Technol, NL-5600 MB Eindhoven, Netherlands	Philips; Philips Research; Eindhoven University of Technology	Broer, DJ (corresponding author), Philips Res Labs, Prof Holstlaan 4, NL-5656 AA Eindhoven, Netherlands.		Broer, Dirk J/J-2614-2014	Broer, Dirk J/0000-0001-6136-3276; Nisato, Giovanni/0000-0002-5824-0061				Bobrov YA, 1998, MATER RES SOC SYMP P, V508, P225, DOI 10.1557/PROC-508-225; Bowley CC, 1999, MOL CRYST LIQ CRYS A, V331, P2069; BROER DJ, 1995, NATURE, V378, P467, DOI 10.1038/378467a0; DOANE JW, 1986, APPL PHYS LETT, V48, P269, DOI 10.1063/1.96577; FARRINGDON J, 1999, P 3 INT S WEAR COMP, P107; HIRAI Y, 1990, P SOC PHOTO-OPT INS, V1257, P2, DOI 10.1117/12.19921; Kamiya H., 2001, SID INT SYMP DIG, V32, P1354; Kiefer R., 1992, P 12 INT DISPL RES C, P547; Morozumi S, 1990, LIQUID CRYSTALS APPL, V1, P181; OHE M, 1995, P 15 INT DISPL RES C, P577; Park E. Y., 2000, SID 00 DIG TECHN PAP, V31, P782; Qian TZ, 2000, PHYS REV E, V61, P4007, DOI 10.1103/PhysRevE.61.4007; VAZ NA, 1987, MOL CRYST LIQ CRYST, V146, P1, DOI 10.1080/00268948708071798; Vorflusev V, 1999, SCIENCE, V283, P1903, DOI 10.1126/science.283.5409.1903; Yamamoto T, 1995, J Glaucoma, V4, P158	15	147	148	1	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	2002	417	6884					55	58		10.1038/417055a	http://dx.doi.org/10.1038/417055a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986663				2022-12-28	WOS:000175307200035
J	Finsterer, J				Finsterer, J			Earl Grey tea intoxication	LANCET			English	Editorial Material							POTASSIUM		Neurol Krankenhaus Rosenhugel, A-1130 Vienna, Austria		Finsterer, J (corresponding author), Neurol Krankenhaus Rosenhugel, Riedelgasse 5, A-1130 Vienna, Austria.							BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; During T, 2000, GEN PHYSIOL BIOPHYS, V19, P345; Kaddu S, 2001, J AM ACAD DERMATOL, V45, P458, DOI 10.1067/mjd.2001.116226; Newsom-Davis J, 1997, ANN NY ACAD SCI, V835, P111, DOI 10.1111/j.1749-6632.1997.tb48622.x; Wulff H, 1998, J MED CHEM, V41, P4542, DOI 10.1021/jm981032o	5	12	12	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1484	1484		10.1016/S0140-6736(02)08436-2	http://dx.doi.org/10.1016/S0140-6736(02)08436-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988248				2022-12-28	WOS:000175279100012
J	Grady, D; Reynolds				Grady, D; Reynolds			A 60-year-old woman trying to discontinue hormone replacement therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							SURGICAL ADJUVANT BREAST; ESTROGEN PLUS PROGESTIN; POSTMENOPAUSAL WOMEN; HOT FLASHES; NONVERTEBRAL FRACTURES; VASOMOTOR SYMPTOMS; ENDOMETRIAL CANCER; TAMOXIFEN THERAPY; RANDOMIZED-TRIAL; CLINICAL-TRIAL		Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94105 USA	University of California System; University of California San Francisco	Grady, D (corresponding author), Univ Calif San Francisco, Dept Epidemiol, 74 New Montgomery St,Suite 600, San Francisco, CA 94105 USA.	dgrady@itsa.ucsf.edu						ADAMS MR, 1990, ARTERIOSCLEROSIS, V10, P1051, DOI 10.1161/01.ATV.10.6.1051; Barrett-Connor E, 2002, JAMA-J AM MED ASSOC, V287, P847, DOI 10.1001/jama.287.7.847; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; BERG G, 1988, MATURITAS, V10, P193, DOI 10.1016/0378-5122(88)90022-9; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bone HG, 2000, J CLIN ENDOCR METAB, V85, P720, DOI 10.1210/jc.85.2.720; Bush TL, 1996, JAMA-J AM MED ASSOC, V276, P1389, DOI 10.1001/jama.276.17.1389; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; Cauley JA, 2001, AM J MED, V110, P442, DOI 10.1016/S0002-9343(01)00647-7; Cauley JA, 1999, ANN INTERN MED, V130, P270, DOI 10.7326/0003-4819-130-4_Part_1-199902160-00004; Clarke M, 1998, LANCET, V351, P1451; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Cummings SR, 1998, JAMA-J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077; Davies GC, 1999, OBSTET GYNECOL, V93, P558, DOI 10.1016/S0029-7844(98)00476-1; Davis SR, 2001, BRIT MED J, V323, P354, DOI 10.1136/bmj.323.7309.354; Ettinger B, 1998, AM J MANAG CARE, V4, P1377; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fisher B, 1996, JNCI-J NATL CANCER I, V88, P1529, DOI 10.1093/jnci/88.21.1529; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FUCHSYOUNG R, 1995, ANN NY ACAD SCI, V761, P355, DOI 10.1111/j.1749-6632.1995.tb31392.x; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GALLAGHER EJ, 1993, JAMA-J AM MED ASSOC, V270, P742, DOI 10.1001/jama.270.6.742; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; GRADY D, 1991, AM J EPIDEMIOL, V134, P1396, DOI 10.1093/oxfordjournals.aje.a116043; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; Greendale GA, 1998, OBSTET GYNECOL, V92, P982, DOI 10.1016/S0029-7844(98)00305-6; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Harris ST, 1999, JAMA-J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344; Heinemann DF, 2000, GERIATRICS, V55, P31; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hlatky MA, 2002, JAMA-J AM MED ASSOC, V287, P591, DOI 10.1001/jama.287.5.591; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; *INT AG RES CANC, 1979, IARC MON EV CARC RIS, V21; KRONENBERG F, 1990, ANN NY ACAD SCI, V592, P52; LENFANT C, 2000, PRELIMINARY TRENDS W; Loprinzi CL, 2000, LANCET, V356, P2059, DOI 10.1016/S0140-6736(00)03403-6; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; MacLennan A, 2001, Climacteric, V4, P58, DOI 10.1080/713605036; Manson JE, 2001, NEW ENGL J MED, V345, P34, DOI 10.1056/NEJM200107053450106; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Mosca L, 2001, CIRCULATION, V104, P499, DOI 10.1161/hc2901.092200; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; Pandya KJ, 2000, ANN INTERN MED, V132, P788, DOI 10.7326/0003-4819-132-10-200005160-00004; Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068; Ries LAG .M.K.C, 2001, SEER CANC STAT REV 1; Saletu B, 1995, PSYCHOPHARMACOLOGY, V122, P321, DOI 10.1007/BF02246261; Santen RJ, 1996, J CLIN ENDOCR METAB, V81, P2027, DOI 10.1210/jc.81.6.2027; SHERWIN BB, 1985, PSYCHONEUROENDOCRINO, V10, P325, DOI 10.1016/0306-4530(85)90009-5; Simon JA, 2001, CIRCULATION, V103, P638, DOI 10.1161/01.cir.103.5.638; Simon JA, 2001, ANN INTERN MED, V135, P493, DOI 10.7326/0003-4819-135-7-200110020-00008; Stearns V, 2000, ANN ONCOL, V11, P17, DOI 10.1023/A:1008382706068; Torgerson DJ, 2001, JAMA-J AM MED ASSOC, V285, P2891, DOI 10.1001/jama.285.22.2891; UTIAN WH, 1994, MENOPAUSE, V1, P39; Utian WH, 1999, AM J OBSTET GYNECOL, V181, P71, DOI 10.1016/S0002-9378(99)70438-2; Utian WH, 2001, FERTIL STERIL, V75, P1065, DOI 10.1016/S0015-0282(01)01791-5; Viscoli CM, 2001, NEW ENGL J MED, V345, P1243, DOI 10.1056/NEJMoa010534; Willis DB, 1996, CANCER CAUSE CONTROL, V7, P449, DOI 10.1007/BF00052671; YUEN J, 1993, CANCER CAUSE CONTROL, V4, P369, DOI 10.1007/BF00051340	70	24	24	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2002	287	16					2130	2137		10.1001/jama.287.16.2130	http://dx.doi.org/10.1001/jama.287.16.2130			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZK	11966388				2022-12-28	WOS:000175075700031
J	Pereira, MA; Jacobs, DR; Van Horn, L; Slattery, ML; Kartashov, AI; Ludwig, DS				Pereira, MA; Jacobs, DR; Van Horn, L; Slattery, ML; Kartashov, AI; Ludwig, DS			Dairy consumption, obesity, and the insulin resistance syndrome in young adults - The CARDIA study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; DEPENDENT DIABETES-MELLITUS; HIGH-CARBOHYDRATE DIETS; CARDIOVASCULAR-DISEASE; SYNDROME-X; POSTMENOPAUSAL WOMEN; NUTRITIONAL FACTORS; HDL-CHOLESTEROL; BLOOD-PRESSURE; UNITED-STATES	Context Components of the insulin resistance syndrome (IRS), including obesity, glucose intolerance, hypertension, and dyslipidemia, are major risk factors for type 2 diabetes and heart disease. Although diet has been postulated to influence IRS, the independent effects of dairy consumption on development of this syndrome have not been investigated. Objective To examine associations between dairy intake and incidence of IRS, adjusting for confounding lifestyle and dietary factors, Design The Coronary Artery Risk Development in Young Adults (CARDIA) study, a population-based prospective study. S etting and Participants General community sample from 4 US metropolitan areas of 3157 black and white adults aged 18 to 30 years who were followed up from 1985-1986 to 1995-1996. Main Outcome Measure Ten-year cumulative incidence of IRS and its association with dairy consumption, measured by diet history interview. Results Dairy consumption was inversely associated with the incidence of all IRS components among individuals who were overweight (body mass index greater than or equal to25 kg/m(2)) at baseline but not among leaner individuals (body mass index <25 kg/m(2)). The adjusted odds of developing IRS (2 or more components) were 72% lower (odds ratio, 0.28; 95% confidence interval, 0.14-0.58) among overweight individuals in the highest (&GE;35 times per week, 24/102 individuals) compared with the lowest (<10 times per week, 85/190 individuals) category of dairy consumption. Each daily occasion of dairy consumption was associated with a 21% lower odds of IRS (odds ratio, 0.79; 95% confidence interval, 0.70-0.88). These associations were similar for blacks and whites and for men and women. Other dietary factors, including macronutrients and micronutrients, did not explain the association between dairy intake and IRS. Conclusions Dietary patterns characterized by increased dairy consumption have a strong inverse association with IRS among overweight adults and may reduce risk of type 2 diabetes and cardiovascular disease.	Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Clin Res Program, Boston, MA 02115 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Univ Oslo, Inst Nutr Res, Oslo, Norway; Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL USA; Univ Utah, Sch Med, Salt Lake City, UT USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; University of Minnesota System; University of Minnesota Twin Cities; University of Oslo; Northwestern University; Utah System of Higher Education; University of Utah	Pereira, MA (corresponding author), Childrens Hosp, Dept Med, 300 Longwood Ave, Boston, MA 02115 USA.			Pereira, Mark/0000-0002-6704-5276; Jacobs, David/0000-0002-7232-0543; Ludwig, David/0000-0003-3307-8544	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC095095, N01HC048050, N01HC048048, N01HC048047, N01HC048049] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002440] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-95095, N01-HC-48050, N01-HC-48049, N01-HC-48048, N01-HC-48047] Funding Source: Medline; NIDDK NIH HHS [K08DK02440] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbasi F, 2000, AM J CARDIOL, V85, P45, DOI 10.1016/S0002-9149(99)00604-9; Abbott RD, 1996, STROKE, V27, P813, DOI 10.1161/01.STR.27.5.813; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Arslanian S, 1996, J CLIN ENDOCR METAB, V81, P1058, DOI 10.1210/jc.81.3.1058; Ascherio A, 1996, HYPERTENSION, V27, P1065, DOI 10.1161/01.HYP.27.5.1065; Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; BAO WH, 1994, ARCH INTERN MED, V154, P1842; Barr SI, 2000, J AM DIET ASSOC, V100, P810, DOI 10.1016/S0002-8223(00)00236-4; Black HR, 1997, ARCH INTERN MED, V157, P2413; BLADES B, 1995, AM J CLIN NUTR, V62, P996, DOI 10.1093/ajcn/62.5.996; Bostick RM, 1999, AM J EPIDEMIOL, V149, P151, DOI 10.1093/oxfordjournals.aje.a009781; Burke JP, 1999, ARCH INTERN MED, V159, P1450, DOI 10.1001/archinte.159.13.1450; Carruth BR, 2001, INT J OBESITY, V25, P559, DOI 10.1038/sj.ijo.0801562; Cavadini C, 2000, ARCH DIS CHILD, V83, P18, DOI 10.1136/adc.83.1.18; Davies KM, 2000, J CLIN ENDOCR METAB, V85, P4635, DOI 10.1210/jc.85.12.4635; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FRIEDMAN GD, 1988, J CLIN EPIDEMIOL, V41, P1105, DOI 10.1016/0895-4356(88)90080-7; Frost G, 1999, LANCET, V353, P1045, DOI 10.1016/S0140-6736(98)07164-5; FUKAGAWA NK, 1990, AM J CLIN NUTR, V52, P524, DOI 10.1093/ajcn/52.3.524; Harnack L, 1999, J AM DIET ASSOC, V99, P436, DOI 10.1016/S0002-8223(99)00106-6; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Iso H, 1999, STROKE, V30, P1772, DOI 10.1161/01.STR.30.9.1772; Jacobs David R Jr, 1989, J Cardiopulm Rehabil, V9, P448, DOI 10.1097/00008483-198911000-00003; Jahns L, 2001, J PEDIATR-US, V138, P493, DOI 10.1067/mpd.2001.112162; Jeppesen J, 1997, ARTERIOSCL THROM VAS, V17, P1114, DOI 10.1161/01.ATV.17.6.1114; Jeppesen J, 1997, AM J CLIN NUTR, V65, P1027, DOI 10.1093/ajcn/65.4.1027; Kleinbaum D, 1988, APPL REGRESSION ANAL; KOROTKOV NS, 1956, CLASSICS ARTERIAL HY, P127; Krauss RM, 2000, CIRCULATION, V102, P2284; Lin PY, 2000, PEDIATR INFECT DIS J, V19, P754, DOI 10.1097/00006454-200008000-00016; Liu Kiang, 1994, Ethnicity and Disease, V4, P15; Liu SM, 2000, AM J CLIN NUTR, V71, P1455; Ludwig DS, 1999, JAMA-J AM MED ASSOC, V282, P1539, DOI 10.1001/jama.282.16.1539; Ludwig DS, 2001, JAMA-J AM MED ASSOC, V286, P1427, DOI 10.1001/jama.286.12.1427; MA J, 1995, J CLIN EPIDEMIOL, V48, P927, DOI 10.1016/0895-4356(94)00200-A; MCDONALD A, 1991, J AM DIET ASSOC, V91, P1104; Mennen LI, 1999, THROMB RES, V94, P381, DOI 10.1016/S0049-3848(99)00027-4; Mennen LI, 2000, NUTR RES, V20, P335, DOI 10.1016/S0271-5317(00)00127-5; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; NELSON GJ, 1995, LIPIDS, V30, P969, DOI 10.1007/BF02536280; Ness AR, 2001, J EPIDEMIOL COMMUN H, V55, P379, DOI 10.1136/jech.55.6.379; POPKIN BM, 1992, AM J CLIN NUTR, V55, P823, DOI 10.1093/ajcn/55.4.823; Reaven G M, 2000, Curr Atheroscler Rep, V2, P503, DOI 10.1007/s11883-000-0050-z; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rosamond WD, 1998, NEW ENGL J MED, V339, P861, DOI 10.1056/NEJM199809243391301; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472; STERN MP, 1995, DIABETES, V44, P369, DOI 10.2337/diabetes.44.4.369; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085, DOI 10.1001/archpedi.1995.02170230039005; *U MINN NCC NUTR C, 1984, NCC NUTR DAT TAP 10; *U MINN NCC NUTR C, 1991, NCC NUTR DAT TAP 20; WARRICK GR, 1982, CLIN CHEM, V28, P1379; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; Young-Hyman D, 2001, DIABETES CARE, V24, P1359, DOI 10.2337/diacare.24.8.1359; Zemel MB, 2000, FASEB J, V14, P1132, DOI 10.1096/fasebj.14.9.1132; 1997, MMWR MORB MORTAL WKL, V46, P1014	56	806	839	1	58	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2002	287	16					2081	2089		10.1001/jama.287.16.2081	http://dx.doi.org/10.1001/jama.287.16.2081			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZK	11966382	Bronze			2022-12-28	WOS:000175075700025
J	Black, GF; Weir, RE; Floyd, S; Bliss, L; Warndorff, DK; Crampin, AC; Ngwira, B; Sichali, L; Nazareth, B; Blackwell, JM; Branson, K; Chaguluka, SD; Donovan, L; Jarman, E; King, E; Fine, PEM; Dockrell, HM				Black, GF; Weir, RE; Floyd, S; Bliss, L; Warndorff, DK; Crampin, AC; Ngwira, B; Sichali, L; Nazareth, B; Blackwell, JM; Branson, K; Chaguluka, SD; Donovan, L; Jarman, E; King, E; Fine, PEM; Dockrell, HM			BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies	LANCET			English	Article							T-CELL RESPONSES; WHOLE-BLOOD ASSAY; PROTECTIVE IMMUNITY; ENVIRONMENTAL MYCOBACTERIA; TUBERCULOSIS; IDENTIFICATION; CONVERSIONS; INFECTION; HEALTHY; LEPROSY	Background The efficacy of BCG vaccines against pulmonary tuberculosis varies between populations, showing no protection in Malawi but 50-80% protection in the UK. To investigate the mechanism underlying these differences, randomised controlled studies were set up to measure vaccine-induced immune responsiveness to mycobacterial antigens in both populations. Methods 483 adolescents and young adults in Malawi and 180 adolescents in the UK were tested for interferon-gamma (IFN-gamma) response to M tuberculosis purified protein derivative (PPD) in a whole blood assay, and for delayed type hypersensitivity (DTH) skin test response to tuberculin PPD, before and 1 year after receiving BCG (Glaxo 1077) vaccination or placebo or no vaccine. Findings The percentages of the randomised individuals who showed IFN-gamma and DTH responses were higher in Malawi than in the UK pre-vaccination-ie, 61% (331/546) versus 22% (47/213) for IFN-gamma and 46% (236/517) versus 13% (27/211) for DTH. IFN-gamma responses increased more in the UK than in Malawi, with 83% (101/122) and 78% (251/321) respectively of the vaccinated groups responding, with similar distributions in the two populations 1 year post-vaccination. The DTH response increased following vaccination in both locations, but to a greater extent in the UK than Malawi. The IFN-gamma and DTH responses were strongly associated, except among vaccines in Malawi. Interpretation The magnitude of the BCG-attributable increase in IFN-gamma responsiveness to M tuberculosis PPD, from before to 1 year post-vaccination, correlates better with the known levels of protection induced by immunisation with BCG than does the absolute value of the IFN-gamma or DTH response after vaccination. It is likely that differential sensitisation due to exposure to environmental mycobacteria is the most important determinant of the observed differences in protection by BCG between populations.	Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Immunol Unit, London WC1E 7HT, England; Karonga Prevent Study, Chilumba, Malawi; Redbridge & Waltham Forest Hlth Author, Ilford, England; Wellcome Trust Ctr Mol Mech Dis, Cambridge, England	University of London; London School of Hygiene & Tropical Medicine; Malawi Epidemiology and Intervention Research Unit; University of Cambridge	Dockrell, HM (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Infect & Trop Med, Immunol Unit, Keppel St, London WC1E 7HT, England.	Hazel.Dockrell@lshtm.ac.uk	Blackwell, Jenefer M/H-3015-2015	Crampin, Amelia/0000-0002-1513-4330; Black, Gillian/0000-0002-5081-274X; Dockrell, Hazel/0000-0003-1869-9107				Black GF, 2001, J INFECT DIS, V184, P322, DOI 10.1086/322042; Black GF, 2001, INT J TUBERC LUNG D, V5, P664; Brandt L, 2002, INFECT IMMUN, V70, P672, DOI 10.1128/IAI.70.2.672-678.2002; *BRIT THOR ASS, 1980, BR J DIS CHEST, V74, P215; CHENG SH, 1993, INFECT IMMUN, V61, P4501, DOI 10.1128/IAI.61.10.4501-4503.1993; COMSTOCK GW, 1988, AM REV RESPIR DIS, V138, P479, DOI 10.1164/ajrccm/138.2.479; COMSTOCK GW, 1978, AM REV RESPIR DIS, V118, P215; COOPER AM, 1993, J EXP MED, V178, P2243, DOI 10.1084/jem.178.6.2243; Das SD, 1998, INT J TUBERC LUNG D, V2, P836; EDWARDS LB, 1973, AM REV RESPIR DIS, V108, P1334; Ellner JJ, 2000, CLIN INFECT DIS, V30, pS279, DOI 10.1086/313874; Fine PEM, 1996, LANCET, V348, P17, DOI 10.1016/S0140-6736(96)02166-6; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; Fine PEM, 2001, EPIDEMIOL INFECT, V126, P379, DOI 10.1017/S0950268801005532; Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962; FLYNN JL, 1993, J EXP MED, V178, P2249, DOI 10.1084/jem.178.6.2249; HART P. D'A., 1967, Tubercle, V48, P201, DOI 10.1016/S0041-3879(67)80024-2; HernandezPando R, 1997, INFECT IMMUN, V65, P3317, DOI 10.1128/IAI.65.8.3317-3327.1997; Marchant A, 1999, J IMMUNOL, V163, P2249; Menzies D, 1999, AM J RESP CRIT CARE, V159, P15, DOI 10.1164/ajrccm.159.1.9801120; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; ORME IM, 1984, CELL IMMUNOL, V84, P113, DOI 10.1016/0008-8749(84)90082-0; PALMER CE, 1966, AM REV RESPIR DIS, V94, P553; Ravn P, 1997, J IMMUNOL, V158, P1949; SUTHERLAND I, 1987, TUBERCLE, V68, P81, DOI 10.1016/0041-3879(87)90023-7; Weir RE, 1999, CLIN EXP IMMUNOL, V116, P263; WEIR RE, 1994, J IMMUNOL METHODS, V176, P93, DOI 10.1016/0022-1759(94)90353-0; ZHANG M, 1995, INFECT IMMUN, V63, P3231, DOI 10.1128/IAI.63.8.3231-3234.1995	28	247	256	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	2002	359	9315					1393	1401		10.1016/S0140-6736(02)08353-8	http://dx.doi.org/10.1016/S0140-6736(02)08353-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978337				2022-12-28	WOS:000175076200012
J	Gonzalez, F; Delahodde, A; Kodadek, T; Johnston, SA				Gonzalez, F; Delahodde, A; Kodadek, T; Johnston, SA			Recruitment of a 19S proteasome subcomplex to an activated promoter	SCIENCE			English	Article							UBIQUITIN-MEDIATED PROTEOLYSIS; REGULATORY PARTICLE; BINDING PROTEIN; 26S PROTEASOME; GAL4; COMPLEX; TRANSCRIPTION; DEGRADATION; RECOGNITION; SEQUENCES	The 19S proteasome regulatory particle plays a critical role in cellular proteolysis. However, recent reports have demonstrated that 19S proteins play a nonproteolytic role in nucleotide excision repair and transcription elongation. We show by chromatin immunoprecipitation assays that proteins comprising the 19S complex are recruited to the GAL1-10 promoter by the Gal4 transactivator upon induction with galactose. This recruited complex does not contain proteins from the 20S proteolytic particle and includes a subset of the 19S proteins. This subset is also specifically retained from an extract by the Gal4 activation domain. These data indicate that in vivo, the base of the 19S complex functions independently of the larger complex and plays a direct, nonproteolytic role in RNA polymerase II transcription.	Univ Texas, SW Med Ctr, Ctr Biomed Invent, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Johnston, SA (corresponding author), Univ Texas, SW Med Ctr, Ctr Biomed Invent, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Kodadek, Thomas/0000-0003-1930-4795				Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; CARRINGTON JC, 1987, NUCLEIC ACIDS RES, V15, P10066, DOI 10.1093/nar/15.23.10066; Chang C, 2001, J BIOL CHEM, V276, P30956, DOI 10.1074/jbc.M102254200; CONFALONIERI F, 1995, BIOESSAYS, V17, P639, DOI 10.1002/bies.950170710; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Gonzalez F., UNPUB; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; LOHR D, 1995, FASEB J, V9, P777, DOI 10.1096/fasebj.9.9.7601342; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Orphanides G, 1999, NATURE, V400, P284, DOI 10.1038/22350; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Saeki Y, 2000, BIOCHEM BIOPH RES CO, V273, P509, DOI 10.1006/bbrc.2000.2980; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94	25	283	290	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					548	550		10.1126/science.1069490	http://dx.doi.org/10.1126/science.1069490			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964484				2022-12-28	WOS:000175179400051
J	Tran, H; Brunet, A; Grenier, JM; Datta, SR; Fornace, AJ; DiStefano, PS; Chiang, LW; Greenberg, ME				Tran, H; Brunet, A; Grenier, JM; Datta, SR; Fornace, AJ; DiStefano, PS; Chiang, LW; Greenberg, ME			DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; DAMAGING AGENTS; GROWTH ARREST; LIFE-SPAN; EXPRESSION; INDUCTION; RESISTANCE; SIGNALS; DAF-16; FAMILY	The signaling pathway from phosphoinositide 3-kinase to the protein kinase Akt controls organismal life-span in invertebrates and cell survival and proliferation in mammals by inhibiting the activity of members of the FOXO family of transcription factors. We show that mammalian FOXO3a also functions at the G(2) to M checkpoint in the cell cycle and triggers the repair of damaged DNA. By gene array analysis, FOXO3a was found to modulate the expression of several genes that regulate the cellular response to stress at the G(2)-M checkpoint. The growth arrest and DNA damage response gene Gadd45a appeared to be a direct target of FOXO3a that mediates part of FOXO3a's effects on DNA repair. These findings indicate that in mammals FOXO3a regulates the resistance of cells to stress by inducing DNA repair and thereby may also affect organismal life-span.	Harvard Univ, Childrens Hosp, Sch Med, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA; NCI, NIH, Bethesda, MD 20892 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Greenberg, ME (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Div Neurosci, Boston, MA 02115 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD024926] Funding Source: NIH RePORTER; NICHD NIH HHS [P01-HD24926, NIHP30-HD18655] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BRUNET A, UNPUB; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; KIRKWOOD TBL, 1989, MUTAT RES, V219, P1, DOI 10.1016/0921-8734(89)90035-0; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Smith ML, 1996, ONCOGENE, V13, P2255; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	23	679	706	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					530	534		10.1126/science.1068712	http://dx.doi.org/10.1126/science.1068712			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964479				2022-12-28	WOS:000175179400046
J	Shaheen, N; Ransohoff, DF				Shaheen, N; Ransohoff, DF			Gastroesophageal reflux, Barrett esophagus, and esophageal cancer - Scientific review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HIGH-GRADE DYSPLASIA; ARGON PLASMA COAGULATION; ENDOSCOPIC SURVEILLANCE; GASTROINTESTINAL ENDOSCOPY; SQUAMOUS REEPITHILIALIZATION; PHOTODYNAMIC THERAPY; GASTRIC CARDIA; UNITED-STATES; RISK FACTOR; ADENOCARCINOMA	Context Gastroesophageal reflux disease (GERD) is a risk factor for adenocarcinoma of the esophagus, a rare cancer whose incidence is increasing. Adenocarcinoma may develop from Barrett esophagus, a metaplastic change of the esophageal epithelium from squamous to intestinalized columnar mucosa, which is associated with chronic reflux. Some have recommended that patients with chronic reflux symptoms undergo upper endoscopy to assess for Barrett esophagus and to screen for cancer. Objectives To review the evidence linking GERD and Barrett esophagus to esophageal adenocarcinoma and to examine the utility of upper endoscopy as a screening tool in adenocarcinoma of the esophagus among individuals with GERD. Data Sources A MEDLINE search was performed to identify all pertinent English-language reports about GERD, adenocarcinoma, and Barrett esophagus from 1968 through 2001. Reports were of randomized controlled clinical trials if available, case-control data if trials were unavailable, and cohort studies if case-control data were unavailable, Pertinent bibliographies were also reviewed to find reports not otherwise identified. Study Selection and Data Extraction Studies were selected by using the search terms gastroesophageal reflux, adenocarcinoma, and Barrett's esophagus, with subheadings for classification, complications, drug therapy, economics, epidemiology, mortality, surgery, and prevention and control. Clinical guidelines for the care of subjects with GERD and Barrett esophagus were retrieved and abstracted. Data Synthesis Cohort studies demonstrate that symptoms of GERD occur monthly in almost 50% of US adults and weekly in almost 20%. Three large case-control studies demonstrate a positive association between reflux symptoms and risk of adenocarcinoma of the esophagus, with more prolonged and severe symptoms accentuating this risk. However, because of the low incidence of adenocarcinoma of the esophagus and the ubiquity of reflux symptoms, the risk of cancer in any given individual with reflux symptoms is low. No randomized trial data are available to demonstrate either decreased cancer incidence or increased life expectancy in subjects with GERD who undergo screening endoscopy. Conclusions Strong evidence supports the association of GERD and adenocarcinoma of the esophagus; however, the risk of cancer in any given individual with GERD is low. Barrett esophagus appears to be a common precursor lesion to this cancer. Given the low absolute risk of cancer in those with GERD and the lack of demonstrated efficacy of endoscopic screening, insufficient evidence exists to endorse routine endoscopic screening of patients with chronic GERD symptoms.	Univ N Carolina, Ctr Esophageal Dis & Swallowing, Div Digest Dis & Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Shaheen, N (corresponding author), Univ N Carolina, Ctr Esophageal Dis & Swallowing, Div Digest Dis & Nutr, CB 7080, Chapel Hill, NC 27599 USA.	nshaheen@med.unc.edu	Shaheen, Nicholas J/A-1898-2013		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK059311] Funding Source: NIH RePORTER; NIDDK NIH HHS [K23 DK59311-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHKAR E, 1988, AM J GASTROENTEROL, V83, P291; ADANG RP, 1995, GASTROINTEST ENDOSC, V42, P390, DOI 10.1016/S0016-5107(95)70037-4; American Cancer Society, 2002, CANC FACTS FIG 2002; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; Barham CP, 1997, GUT, V41, P281, DOI 10.1136/gut.41.3.281; Bartlesman J F, 1992, Eur J Cancer Prev, V1, P323, DOI 10.1097/00008469-199206000-00008; BEHAR J, 1976, GASTROENTEROLOGY, V71, P9; Boch JA, 1997, GASTROENTEROLOGY, V112, P760, DOI 10.1053/gast.1997.v112.pm9041237; BREMNER CG, 1970, SURGERY, V68, P209; Bytzer P, 1999, AM J GASTROENTEROL, V94, P86; CALDWELL MTP, 1995, BRIT J SURG, V82, P657, DOI 10.1002/bjs.1800820528; CAMERON AJ, 1995, GASTROENTEROLOGY, V109, P1541, DOI 10.1016/0016-5085(95)90642-8; Cameron AJ, 1997, AM J GASTROENTEROL, V92, P586; CAMERON AJ, 1985, NEW ENGL J MED, V313, P857, DOI 10.1056/NEJM198510033131404; CAMERON AJ, 1990, GASTROENTEROLOGY, V99, P918, DOI 10.1016/0016-5085(90)90607-3; Campos GMR, 2001, ARCH SURG-CHICAGO, V136, P1267, DOI 10.1001/archsurg.136.11.1267; CEDERQVIST C, 1978, ACTA CHIR SCAND, V144, P233; Chan M F, 1996, Gastrointest Endosc Clin N Am, V6, P287; CHOW WH, 1995, JAMA-J AM MED ASSOC, V274, P474, DOI 10.1001/jama.274.6.474; Chow WH, 1998, JNCI-J NATL CANCER I, V90, P150, DOI 10.1093/jnci/90.2.150; Coenraad M, 1998, AM J GASTROENTEROL, V93, P1068; COOPER BT, 1987, Q J MED, V62, P97; Cooper BT, 1998, ALIMENT PHARM THERAP, V12, P893, DOI 10.1046/j.1365-2036.1998.00389.x; Corder AP, 1996, BRIT J CLIN PRACT, V50, P245; COSTANTINI M, 1993, SURGERY, V114, P780; Csendes A, 2000, DIS ESOPHAGUS, V13, P5, DOI 10.1046/j.1442-2050.2000.00065.x; Csendes A, 1998, SURGERY, V123, P645, DOI 10.1067/msy.1998.87452; Daly JM, 1996, CANCER, V78, P1820, DOI 10.1002/(SICI)1097-0142(19961015)78:8<1820::AID-CNCR25>3.0.CO;2-Z; DEMEESTER TR, 1988, J THORAC CARDIOV SUR, V95, P42; DeVault KR, 1999, AM J GASTROENTEROL, V94, P1434; Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2; DODDS WJ, 1982, NEW ENGL J MED, V307, P1547, DOI 10.1056/NEJM198212163072503; Drewitz DJ, 1997, AM J GASTROENTEROL, V92, P212; Dulai GS, 2002, GASTROENTEROLOGY, V122, P26, DOI 10.1053/gast.2002.30297; Dumoulin FL, 1997, ENDOSCOPY, V29, P751, DOI 10.1055/s-2007-1004302; Eckardt VF, 2001, AM J MED, V111, P33, DOI 10.1016/S0002-9343(01)00745-8; Edwards MJ, 1996, ANN SURG, V223, P585, DOI 10.1097/00000658-199605000-00014; Eisen GM, 1997, AM J GASTROENTEROL, V92, P27; ELLIS FH, 1983, ANN SURG, V198, P531, DOI 10.1097/00000658-198310000-00013; ElSerag HB, 1997, GUT, V41, P594, DOI 10.1136/gut.41.5.594; Falk GW, 1999, GASTROINTEST ENDOSC, V49, P170, DOI 10.1016/S0016-5107(99)70482-7; Farrow DC, 2000, CANCER CAUSE CONTROL, V11, P231, DOI 10.1023/A:1008913828105; Fennerty MB, 2001, AM J GASTROENTEROL, V96, P2302; Ferraris R, 1997, EUR J GASTROEN HEPAT, V9, P881, DOI 10.1097/00042737-199709000-00011; GALANDIUK S, 1986, ANN SURG, V203, P101, DOI 10.1097/00000658-198601000-00016; *GALL ORG, 1988, GALL ORG NAT SURV HE; GILLEN P, 1988, BRIT J SURG, V75, P113, DOI 10.1002/bjs.1800750208; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; HAMILTON SR, 1987, AM J CLIN PATHOL, V87, P301, DOI 10.1093/ajcp/87.3.301; HART R, 1990, ENDOSCOPY, V22, P229, DOI 10.1055/s-2007-1010734; Heitmiller RF, 1996, ANN SURG, V224, P66, DOI 10.1097/00000658-199607000-00010; Hennekens C.H., 1987, EPIDEMIOLOGY MED; IFTIKHAR SY, 1992, GUT, V33, P1155, DOI 10.1136/gut.33.9.1155; JOHANSSON KE, 1986, SCAND J GASTROENTERO, V21, P837, DOI 10.3109/00365528609011128; KASAPIDIS P, 1993, AM J GASTROENTEROL, V88, P1893; Katz D, 1998, AM J GASTROENTEROL, V93, P536; Kavic SM, 2001, AM J SURG, V181, P319, DOI 10.1016/S0002-9610(01)00589-X; KLAUSER AG, 1990, LANCET, V335, P205, DOI 10.1016/0140-6736(90)90287-F; Kuo W H, 1998, Gastrointest Endosc Clin N Am, V8, P273; Lagergren J, 2000, JAMA-J AM MED ASSOC, V284, P961, DOI 10.1001/jama.284.8.961; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Lagergren J, 1999, ANN INTERN MED, V130, P883, DOI 10.7326/0003-4819-130-11-199906010-00003; Locke GR, 1997, GASTROENTEROLOGY, V112, P1448, DOI 10.1016/S0016-5085(97)70025-8; Macey N, 2001, GASTROEN CLIN BIOL, V25, P204; MATTIOLI S, 1989, DIGEST DIS SCI, V34, P71, DOI 10.1007/BF01536157; McCarthy M, 1999, Gastrointest Endosc, V49, P129; McDonald ML, 1996, J THORAC CARDIOV SUR, V111, P1135, DOI 10.1016/S0022-5223(96)70214-3; Menges M, 2001, AM J GASTROENTEROL, V96, P331; MIROS M, 1991, GUT, V32, P1441, DOI 10.1136/gut.32.12.1441; MOGHISSI K, 1993, EUR J CARDIO-THORAC, V7, P126, DOI 10.1016/1010-7940(93)90034-9; NAEF AP, 1975, J THORAC CARDIOV SUR, V70, P826; Nigro JJ, 1999, ANN SURG, V230, P433, DOI 10.1097/00000658-199909000-00015; O'Connor JB, 1999, AM J GASTROENTEROL, V94, P2037; Ortiz A, 1996, BRIT J SURG, V83, P274; OVASKA J, 1989, DIGEST DIS SCI, V34, P1336, DOI 10.1007/BF01538065; Overholt BF, 1999, GASTROINTEST ENDOSC, V49, P1, DOI 10.1016/S0016-5107(99)70437-2; Panjehpour M, 2000, AM J GASTROENTEROL, V95, P2177; Patti MG, 2001, DIGEST DIS SCI, V46, P597, DOI 10.1023/A:1005611602100; PERA M, 1992, ANN THORAC SURG, V54, P199, DOI 10.1016/0003-4975(92)91370-O; Peters FTM, 1999, GUT, V45, P489, DOI 10.1136/gut.45.4.489; Provenzale D, 1999, AM J GASTROENTEROL, V94, P2043; Rader AE, 2001, DIGEST DIS SCI, V46, P2681, DOI 10.1023/A:1012771328187; Rana PS, 2000, DIS ESOPHAGUS, V13, P28, DOI 10.1046/j.1442-2050.2000.00069.x; Reid BJ, 2000, AM J GASTROENTEROL, V95, P1669, DOI 10.1111/j.1572-0241.2000.02196.x; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; RICE TW, 1993, AM J GASTROENTEROL, V88, P1832; Richter JE, 2000, DIGEST DIS, V18, P208, DOI 10.1159/000051401; ROBERTSON CS, 1988, BRIT J SURG, V75, P760, DOI 10.1002/bjs.1800750813; Rudolph RE, 2000, ANN INTERN MED, V132, P612, DOI 10.7326/0003-4819-132-8-200004180-00003; Sampliner RE, 1998, AM J GASTROENTEROL, V93, P1028; Sampliner RE, 2001, GASTROINTEST ENDOSC, V53, P554, DOI 10.1067/mge.2001.114418; Sampliner RE, 1996, GASTROINTEST ENDOSC, V44, P532, DOI 10.1016/S0016-5107(96)70004-4; SAVARY M, 1984, DIS ESOPHAGUS, P529; Sawhney RA, 1996, DIGEST DIS SCI, V41, P1088, DOI 10.1007/BF02088224; Schnell TG, 2001, GASTROENTEROLOGY, V120, P1607, DOI 10.1053/gast.2001.25065; Schulz H, 2000, GASTROINTEST ENDOSC, V51, P659, DOI 10.1016/S0016-5107(00)33002-4; Shaheen NJ, 2000, GASTROENTEROLOGY, V119, P333, DOI 10.1053/gast.2000.9302; Shand A, 2001, GUT, V48, P580; Sharma P, 1997, AM J GASTROENTEROL, V92, P582; SHIELDS HM, 1993, DIGEST DIS SCI, V38, P97, DOI 10.1007/BF01296780; SINGH P, 1994, AM J GASTROENTEROL, V89, P349; SKINNER DB, 1983, J THORAC CARDIOV SUR, V85, P59; SKINNER DB, 1989, BENIGN LESIONS ESOPH, P764; Soni A, 2000, AM J GASTROENTEROL, V95, P2086; Spechler SJ, 2000, GASTROENTEROLOGY, V119, P587, DOI 10.1053/gast.2000.9849; SPECHLER SJ, 1984, GASTROENTEROLOGY, V87, P927; Spechler SJ, 2001, JAMA-J AM MED ASSOC, V285, P2331, DOI 10.1001/jama.285.18.2331; Stal P, 1999, SCAND J GASTROENTERO, V34, P121; Streitz JM, 1998, AM J GASTROENTEROL, V93, P911; STREITZ JM, 1993, J THORAC CARDIOV SUR, V105, P383; Tefera L, 1997, AM SURGEON, V63, P933; Vaezi MF, 1996, GASTROENTEROLOGY, V111, P1192, DOI 10.1053/gast.1996.v111.pm8898632; Valle C, 1999, DIGEST DIS SCI, V44, P1848, DOI 10.1023/A:1018846807296; Van Laethem JL, 2000, GUT, V46, P574, DOI 10.1136/gut.46.4.574; vanderBurgh A, 1996, GUT, V39, P5, DOI 10.1136/gut.39.1.5; Voutilainen M, 2000, DIGESTION, V61, P6, DOI 10.1159/000007730; WATSON RGP, 1991, EUR J GASTROEN HEPAT, V3, P159; Weston AP, 1997, DIGEST DIS SCI, V42, P597, DOI 10.1023/A:1018811512939; WILLIAMSON WA, 1991, ARCH INTERN MED, V151, P2212, DOI 10.1001/archinte.151.11.2212; Winters C, 1987, GASTROENTEROLOGY, V92, P118, DOI 10.1016/0016-5085(87)90847-X; Zaman A, 1998, AM J GASTROENTEROL, V93, P1260; 1976, AM J DIG DIS, V21, P953	122	359	372	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2002	287	15					1972	1981		10.1001/jama.287.15.1972	http://dx.doi.org/10.1001/jama.287.15.1972			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NC	11960540	Bronze			2022-12-28	WOS:000174989800026
J	Neuman, M; Bitton, A; Glantz, S				Neuman, M; Bitton, A; Glantz, S			Tobacco industry strategies for influencing European Community tobacco advertising legislation	LANCET			English	Article							SMOKING CESSATION; BENEFITS; HEALTH	Restrictions on tobacco company advertising and sponsorship are effective parts of tobacco control programmes worldwide. Through Council Directive 98/43/EC, the European Community (EC) sought to end all tobacco advertising and sponsorship in EC member states by 2006. Initially proposed in 1989, the directive was adopted in 1998, and was annulled by the European Court of Justice In 2000 following a protracted lobbying campaign against the directive by a number of interested organisations including European tobacco companies. A new advertising directive was proposed in May, 2001. We reviewed online collections of tobacco industry documents from US tobacco companies made public under the US Master Settlement Agreement of 1998. Documents reviewed dated from 1978 to 1994 and came from Philip Morris, R J Reynolds, and Brown and Williamson (British American Tobacco) collections. We also obtained approximately 15 000 pages of paper records related to British American Tobacco from its documents' depository in Guildford, UK. This Information was supplemented with information In the published literature and consultations with European tobacco control experts. The tobacco industry lobbied against Directive 98/43/EC at the level of EC member state governments as well as on a pan-European level. The industry sought to prevent passage of the directive within the EC legislature, to substitute industry-authored proposals in place of the original directive, and If necessary to use litigation to prevent implementation of the directive after its passage. The tobacco industry sought to delay, and eventually defeat, the EC directive on tobacco advertising and sponsorship by seeking to enlist the aid of figures at the highest levels of European politics while at times attempting to conceal the Industry's role. An understanding of these proposed strategies can help European health advocates to pass and Implement effective future tobacco control legislation.	Univ Calif San Francisco, Sch Med, Cardiovasc Res Inst,Inst Hlth Policy Studies, Ctr Tobacco Control Res & Educ, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Glantz, S (corresponding author), Univ Calif San Francisco, Sch Med, Cardiovasc Res Inst,Inst Hlth Policy Studies, Ctr Tobacco Control Res & Educ, Box 0130, San Francisco, CA 94143 USA.				NCI NIH HHS [CA-84742] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGUINAGA Stella, 1995, TOB CONTROL, V4, P222, DOI DOI 10.1136/tc.4.3.222; BANGEMANN M, 1991, COMMUNICATION   1106; BARBAERLITZ T, 1994, CORPORATE AFFAIRS WE; Bialous SA, 2001, AM J PUBLIC HEALTH, V91, P62; Bitton A., 2002, TOBACCO IND ATTEMPTS; CAMPBELL D, 2001, GUARDIAN        0822; CLARKE K, 1992, COMMUNICATION   0501; *COMM EUR COMM, 2001, PROP DIR EUR PARL CO; DOYLE L, 1995, GUARDIAN        1129; Fichtenberg C, 2001, NEW ENGL J MED, V344, P1798; Fichtenberg CM, 2000, NEW ENGL J MED, V343, P1772, DOI 10.1056/NEJM200012143432406; GABARA I, 1996, WALL STREET J E 1010; GIROD L, 1993, CORPORATE AFFAIRS WE; Glantz SA, 2000, BRIT MED J, V321, P313, DOI 10.1136/bmj.321.7257.313; Glantz SA, 2000, TOBACCO WAR INSIDE C; GODFREY F, 2000, CENTRAL EUR J PUBLIC, V2, P128; HARE D, 1991, BASP REPORT GIVE CHI; HARTOGH JM, 1980, EAAA M EUR COMM TOB; HERBISON D, 1991, COMMUNICATION   0605; HERBISON D, 1990, ADVERTISING TOBACCO; HERVEY TK, 2001, EUROPEAN LAW REV, V26, P101; HORST M, 1992, COMMUNICATION   0424; Jha P., 1999, CURBING EPIDEMIC GOV; JOOSENS L, 1995, 5 WHO SEM TOB FREE E; JOOSSENS L, 1991, GIVE CHILDEN CHANCE; KAPLAN R, 1991, INT MARK TRAIN C AUG; KOHL H, 1978, COMMUNICATION   0526; LEE G, 2001, TOBACCO IND SUCCESSF; LEPERE J, 1992, COMMUNICATION   0423; LEPERE J, 1992, TOBACCO ADVERTISING; LEPERE J, 1991, POSSIBLE BASIS NEW E; Lightwood JM, 1999, PEDIATRICS, V104, P1312, DOI 10.1542/peds.104.6.1312; Lightwood JM, 1997, CIRCULATION, V96, P1089, DOI 10.1161/01.CIR.96.4.1089; MAGLIONE P, 1992, COMMUNICATION   0218; MILES MA, 1992, COMMUNICATION   0720; NAETT C, 1992, TOB CONTROL, V1, P57; *NAT ASS ATT GEN, 2002, MAST SETTL AGR; Nugent N., 2017, GOVT POLITICS EUROPE; Ong EK, 2000, LANCET, V355, P1253, DOI 10.1016/S0140-6736(00)02098-5; *PHIL MORR, 1993, EEC REGION 3 YEAR PL; *PRIMA EUR, 1992, UK GOV TOB ADV SIT R; Richards J W Jr, 1996, Tob Control, V5, P295, DOI 10.1136/tc.5.4.295; RUFFORD N, 1992, SUNDAY TIMES    0719; SAMUELS B, 1991, JAMA-J AM MED ASSOC, V266, P2110, DOI 10.1001/jama.266.15.2110; SARGEANT I, 1992, CECCM PROPOSAL ADVER; SARGEANT I, 1992, COMMUNICATION   0226; TRAYNOR MP, 1993, JAMA-J AM MED ASSOC, V270, P479, DOI 10.1001/jama.270.4.479; US Department of Health and Human Services [Internet], 1990, HLTH BEN SMOK CESS R; VONSPECHT D, 1978, COMMUNICATION   0608; YACH D, 2000, TOBACCO EPIDEMIC GLO; Zeltner T., 2000, TOBACCO CO STRATEGIE	51	101	103	1	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1323	1330		10.1016/S0140-6736(02)08275-2	http://dx.doi.org/10.1016/S0140-6736(02)08275-2			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	541NB	11965294				2022-12-28	WOS:000174989700030
J	Khush, RS; Leulier, F; Lemaitre, B				Khush, RS; Leulier, F; Lemaitre, B			Immunology: Pathogen surveillance - the flies have it	SCIENCE			English	Editorial Material							PEPTIDOGLYCAN RECOGNITION PROTEIN; INNATE IMMUNITY		Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA; CNRS, Ctr Genet Mol, F-91198 Gif Sur Yvette, France	Stanford University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Khush, RS (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA.		Lemaitre, Bruno/T-8146-2019	Lemaitre, Bruno/0000-0001-7970-1667				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Choe KM, 2002, SCIENCE, V296, P359, DOI 10.1126/science.1070216; GOTTAR M, 2002, NATURE          0324; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; RAMET M, 2002, NATURE          0324; Tzou P, 2002, CURR OPIN MICROBIOL, V5, P102, DOI 10.1016/S1369-5274(02)00294-1; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854	12	34	35	2	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					273	275		10.1126/science.1071208	http://dx.doi.org/10.1126/science.1071208			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951023	Green Submitted			2022-12-28	WOS:000175000300034
J	Choi, HK; Hernan, MA; Seeger, JD; Robins, JM; Wolfe, F				Choi, HK; Hernan, MA; Seeger, JD; Robins, JM; Wolfe, F			Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study	LANCET			English	Article							LONG-TERM MORTALITY; CLINICAL-TRIALS; ATHEROSCLEROSIS; ASSOCIATION; DISEASE	Background Methotrexate is the most frequent choice of disease-modifying antirheumatic therapy for rheumatoid arthritis. Although results of studies have shown the efficacy of such drugs, including methotrexate, on rheumatoid arthritis morbidity measures, their effect on mortality in patients with the disease remains unknown. Our aim was to prospectively assess the effect on mortality of methotrexate in a cohort of patients with rheumatoid arthritis. Methods Our cohort included 1240 patients with rheumatoid arthritis seen at the Wichita Arthritis Center, an outpatient rheumatology facility. Patients' details were entered into a computerised database at the time of their first clinic visit. We also obtained and recorded demographic, clinical, laboratory, and self-reported data at each follow-up visit (average interval 3.5 months). We estimated the mortality hazard ratio of methotrexate with a marginal structural Cox proportional hazards model. Findings 191 individuals died during follow-up. Patients who began treatment with methotrexate (n=588) had worse prognostic factors for mortality. After adjustment for this confounding by indication, the mortality hazard ratio for methotrexate use compared with no methotrexate use was 0.4 (95% Cl 0.2-0.8). Other conventional disease-modifying antirheumatic drugs did not have a significant effect on mortality. The hazard ratio of methotrexate use for cardiovascular death was 0.3 (0.2-0.7), whereas that for non-cardiovascular deaths was 0.6 (0.2-1.2). Interpretation Our data indicate that methotrexate may provide a substantial survival benefit, largely by reducing cardiovascular mortality. This survival benefit of methotrexate would set a standard against which new disease-modifying antirheumatic drugs could be compared.	Univ Kansas, Sch Med, Arthrit Res Ctr Fdn, Natl Data Bank Rheumat Dis, Wichita, KS 67214 USA; Harvard Univ, Sch Publ Hlth, Harvard Sch Med,Massachusetts Gen Hosp, Dept Med,Arthrit Unit, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Igenix Epidemiol, Newton, MA USA	National Data Bank for Rheumatic Diseases; University of Kansas; University of Kansas Medical Center; Harvard University; Harvard Medical School; Harvard T.H. Chan School of Public Health; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Wolfe, F (corresponding author), Univ Kansas, Sch Med, Arthrit Res Ctr Fdn, Natl Data Bank Rheumat Dis, 1035 N Emporia,Suite 230, Wichita, KS 67214 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032457, K08AI049392] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49392, R01-AI32457] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201; ERHARDT CC, 1989, ANN RHEUM DIS, V48, P7, DOI 10.1136/ard.48.1.7; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; Firestein GS, 1999, J CLIN INVEST, V103, P3, DOI 10.1172/JCI5929; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hernan MA, 2001, J AM STAT ASSOC, V96, P440, DOI 10.1198/016214501753168154; Kremer JM, 1998, RHEUM DIS CLIN N AM, V24, P651, DOI 10.1016/S0889-857X(05)70032-6; Kremer JM, 1997, ARTHRITIS RHEUM, V40, P984, DOI 10.1002/art.1780400533; Landewe RBM, 2000, LANCET, V355, P1616, DOI 10.1016/S0140-6736(00)02222-4; LEIGH JP, 1991, J RHEUMATOL, V18, P1307; Liuzzo G, 2000, CIRCULATION, V101, P2883, DOI 10.1161/01.CIR.101.25.2883; MEENAN RF, 1980, ARTHRITIS RHEUM, V23, P146, DOI 10.1002/art.1780230203; MUTRU O, 1989, CARDIOLOGY, V76, P71, DOI 10.1159/000174474; Oppenheimer-Marks N, 1998, SPRINGER SEMIN IMMUN, V20, P95, DOI 10.1007/BF00832001; Pasceri V, 1999, CIRCULATION, V100, P2124, DOI 10.1161/01.CIR.100.21.2124; PINCUS T, 1994, ANN INTERN MED, V120, P26, DOI 10.7326/0003-4819-120-1-199401010-00005; Pincus T, 2001, ARTHRITIS RHEUM-US, V44, P1234, DOI 10.1002/1529-0131(200106)44:6<1234::AID-ART213>3.0.CO;2-R; PRIOR P, 1984, BRIT J RHEUMATOL, V23, P92; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Symmons DPM, 1998, J RHEUMATOL, V25, P1072; THOMPSON PW, 1991, J RHEUMATOL, V18, P661; VANDERWAL AC, 1994, CIRCULATION, V89, P36, DOI 10.1161/01.CIR.89.1.36; WallbergJonsson S, 1997, J RHEUMATOL, V24, P445; Ward MM, 2001, ARTHRITIS RHEUM-US, V44, P1467, DOI 10.1002/1529-0131(200106)44:6<1467::AID-ART243>3.0.CO;2-6; WEINBLATT ME, 1990, ARTHRITIS RHEUM, V33, P330, DOI 10.1002/art.1780330305; WOLFE F, 1991, J RHEUMATOL, V18, P672; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408; Zonana-Nacach A, 2000, ARTHRITIS RHEUM, V43, P1801, DOI 10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O	30	872	909	1	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1173	1177		10.1016/S0140-6736(02)08213-2	http://dx.doi.org/10.1016/S0140-6736(02)08213-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955534				2022-12-28	WOS:000174846300006
J	Latronico, N; Fassini, P; Antonini, B; Gasparotti, R				Latronico, N; Fassini, P; Antonini, B; Gasparotti, R			A pain in the neck	LANCET			English	Editorial Material									Univ Brescia, Inst Anesthesiol Intens Care, I-25125 Brescia, Italy; Univ Brescia, Inst Radiol, I-25125 Brescia, Italy	University of Brescia; University of Brescia	Latronico, N (corresponding author), Univ Brescia, Inst Anesthesiol Intens Care, I-25125 Brescia, Italy.		Latronico, Nicola/F-1557-2010; Gasparotti, Roberto/K-5165-2018	Latronico, Nicola/0000-0002-2521-5871; Gasparotti, Roberto/0000-0002-2591-2415				DUNN DW, 1981, ARCH NEUROL-CHICAGO, V38, P263, DOI 10.1001/archneur.1981.00510040089020; Greer IA, 1999, LANCET, V353, P1258, DOI 10.1016/S0140-6736(98)10265-9; Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9; PIGMAN EC, 1991, AM J EMERG MED, V9, P452, DOI 10.1016/0735-6757(91)90213-4; Spiller WG, 1909, J NERV MENT DIS, V36, P0601, DOI 10.1097/00005053-190910000-00003	5	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1206	1206		10.1016/S0140-6736(02)08219-3	http://dx.doi.org/10.1016/S0140-6736(02)08219-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955540				2022-12-28	WOS:000174846300012
J	Allman, D; Punt, JA; Izon, DJ; Aster, JC; Pear, WS				Allman, D; Punt, JA; Izon, DJ; Aster, JC; Pear, WS			An invitation to T and more: Notch signaling in lymphopoiesis	CELL			English	Review							NF-KAPPA-B; HEMATOPOIETIC STEM-CELLS; GENE-EXPRESSION; CAENORHABDITIS-ELEGANS; V(D)J RECOMBINATION; LIN-12 ACTIVITY; CYCLE ARREST; ALPHA-BETA; LINEAGE; LIGAND	Cell fate decisions in metazoans are regulated by Notch signals. During lymphoid development, Notch influences a series of cell fate decisions involving multipotent progenitors. This review focuses on current views and lingering uncertainties about Notch function in lymphoid cells.	Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Inst Med & Engn, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Haverford Coll, Dept Biol, Haverford, PA 19041 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Haverford College; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Pear, WS (corresponding author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.	wpear@mail.med.upenn.edu	Aster, Jon C/B-6857-2009					AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; Allen RD, 2001, MOL CELL BIOL, V21, P3071, DOI 10.1128/MCB.21.9.3071-3082.2001; Allman D, 2001, J EXP MED, V194, P99, DOI 10.1084/jem.194.1.99; Anderson AC, 2001, CURR OPIN GENET DEV, V11, P554, DOI 10.1016/S0959-437X(00)00232-X; Anderson G, 2001, EUR J IMMUNOL, V31, P3349, DOI 10.1002/1521-4141(200111)31:11<3349::AID-IMMU3349>3.0.CO;2-S; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2001, CURR OPIN HEMATOL, V8, P237, DOI 10.1097/00062752-200107000-00010; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Barolo S, 2000, CELL, V103, P957, DOI 10.1016/S0092-8674(00)00198-7; Bash J, 1999, EMBO J, V18, P2803, DOI 10.1093/emboj/18.10.2803; Berry LW, 1997, DEVELOPMENT, V124, P925; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; Bertrand FE, 2000, LEUKEMIA, V14, P2095, DOI 10.1038/sj.leu.2401942; Bray S, 2001, CURR BIOL, V11, pR217, DOI 10.1016/S0960-9822(01)00109-9; Bush G, 2001, DEV BIOL, V229, P494, DOI 10.1006/dbio.2000.9992; Cheng PY, 2001, J IMMUNOL, V167, P4458, DOI 10.4049/jimmunol.167.8.4458; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; Deftos ML, 2000, IMMUNITY, V13, P73, DOI 10.1016/S1074-7613(00)00009-1; Deftos ML, 2000, CURR OPIN IMMUNOL, V12, P166, DOI 10.1016/S0952-7915(99)00067-9; Doerfler P, 2001, P NATL ACAD SCI USA, V98, P9312, DOI 10.1073/pnas.161102498; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Fares H, 1999, GENETICS, V153, P1641; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hadland BK, 2001, P NATL ACAD SCI USA, V98, P7487, DOI 10.1073/pnas.131202798; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; Hettmann T, 2000, J IMMUNOL, V165, P5004, DOI 10.4049/jimmunol.165.9.5004; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Hoyne GF, 2000, INT IMMUNOL, V12, P177, DOI 10.1093/intimm/12.2.177; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Innes KM, 1999, EXP HEMATOL, V27, P75, DOI 10.1016/S0301-472X(98)00015-0; Izon DJ, 2002, IMMUNITY, V16, P231, DOI 10.1016/S1074-7613(02)00271-6; Izon DJ, 2001, IMMUNITY, V14, P253, DOI 10.1016/S1074-7613(01)00107-8; Jaleco AC, 2001, J EXP MED, V194, P991, DOI 10.1084/jem.194.7.991; Jehn BM, 1999, J IMMUNOL, V162, P635; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Johnston LA, 1998, NATURE, V394, P82, DOI 10.1038/27925; Kaneta M, 2000, J IMMUNOL, V164, P256, DOI 10.4049/jimmunol.164.1.256; Karanu FN, 2000, J EXP MED, V192, P1365, DOI 10.1084/jem.192.9.1365; Koch U, 2001, IMMUNITY, V15, P225, DOI 10.1016/S1074-7613(01)00189-3; Kondo M, 2001, CURR OPIN GENET DEV, V11, P520, DOI 10.1016/S0959-437X(00)00227-6; Kopan R, 2000, GENE DEV, V14, P2799, DOI 10.1101/gad.836900; Kramer H, 2001, DEV CELL, V1, P725, DOI 10.1016/S1534-5807(01)00095-8; Kurooka K, 2000, J BIOL CHEM, V275, P17211, DOI 10.1074/jbc.M000909200; Legname G, 2000, IMMUNITY, V12, P537, DOI 10.1016/S1074-7613(00)80205-8; Liao MJ, 1998, MOL CELL BIOL, V18, P3495, DOI 10.1128/MCB.18.6.3495; Liao MJ, 1999, GENE DEV, V13, P1246, DOI 10.1101/gad.13.10.1246; MATSUNO K, 1995, DEVELOPMENT, V121, P2633; Miller DT, 1998, DEVELOPMENT, V125, P2327; Milner LA, 1999, BLOOD, V93, P2431, DOI 10.1182/blood.V93.8.2431.408k33_2431_2448; Mizutani T, 2001, P NATL ACAD SCI USA, V98, P9026, DOI 10.1073/pnas.161269998; Mohr OL, 1919, GENETICS, V4, P275; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Morimura T, 2001, J IMMUNOL, V166, P3277, DOI 10.4049/jimmunol.166.5.3277; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Nie J, 2002, EMBO J, V21, P93, DOI 10.1093/emboj/21.1.93; Osborne B, 1999, IMMUNITY, V11, P653, DOI 10.1016/S1074-7613(00)80140-5; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Reizis B, 2002, GENE DEV, V16, P295, DOI 10.1101/gad.960702; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Simpson P, 1998, SEMIN CELL DEV BIOL, V9, P581, DOI 10.1006/scdb.1998.0265; Strobl LJ, 2000, J VIROL, V74, P1727, DOI 10.1128/JVI.74.4.1727-1735.2000; Tomita K, 1999, GENE DEV, V13, P1203, DOI 10.1101/gad.13.9.1203; Vamum-Finney B, 1998, BLOOD, V91, P4084; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Wang JH, 2001, J IMMUNOL, V167, P289, DOI 10.4049/jimmunol.167.1.289; Washburn T, 1997, CELL, V88, P833, DOI 10.1016/S0092-8674(00)81929-7; Wilson A, 2001, J EXP MED, V194, P1003, DOI 10.1084/jem.194.7.1003; Winandy S, 1999, J EXP MED, V190, P1039, DOI 10.1084/jem.190.8.1039; Wolfer A, 2001, NAT IMMUNOL, V2, P235, DOI 10.1038/85294; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yasutomo K, 2000, NATURE, V404, P506, DOI 10.1038/35006664; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zecchini V, 1999, CURR BIOL, V9, P460, DOI 10.1016/S0960-9822(99)80211-5; Zimber-Strobl U, 2001, SEMIN CANCER BIOL, V11, P423, DOI 10.1006/scbi.2001.0409	82	117	124	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR	2002	109			S			S1	S11		10.1016/S0092-8674(02)00689-X	http://dx.doi.org/10.1016/S0092-8674(02)00689-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	544UY	11983148	Bronze			2022-12-28	WOS:000175181100001
J	Ho, IC; Glimcher, LH				Ho, IC; Glimcher, LH			Transcription: Tantalizing times for T cells	CELL			English	Review							CYTOKINE GENE-EXPRESSION; GERMINAL-CENTER FORMATION; TH2 CELLS; FACTOR GATA-3; IN-VIVO; C-MAF; REGULATORY ELEMENTS; TH2-SPECIFIC EXPRESSION; COORDINATE REGULATOR; IL-12-DEFICIENT MICE	The T helper lymphocyte is responsible for orchestrating an appropriate immune response to pathogens. To do so, it has evolved into two specialized subsets that direct type 1 and type 2 immunity. Here, we discuss the genetic programs that control lineage commitment of progenitor T helper cells along each of these pathways.	Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Glimcher, LH (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, 651 Huntington Ave,FXB-2, Boston, MA 02115 USA.							Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Agarwal S, 2000, IMMUNITY, V12, P643, DOI 10.1016/S1074-7613(00)80215-0; Aronica MA, 1999, J IMMUNOL, V163, P5116; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Balamuth F, 2001, IMMUNITY, V15, P729, DOI 10.1016/S1074-7613(01)00223-0; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Dent AL, 1998, P NATL ACAD SCI USA, V95, P13823, DOI 10.1073/pnas.95.23.13823; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DONG C, 2000, SCI STKE; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; Farrar JD, 2001, J EXP MED, V193, P643, DOI 10.1084/jem.193.5.643; Finkelman FD, 2000, J IMMUNOL, V164, P2303, DOI 10.4049/jimmunol.164.5.2303; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Gessner A, 2000, IMMUNOBIOLOGY, V201, P285, DOI 10.1016/S0171-2985(00)80084-4; Glimcher LH, 2000, GENE DEV, V14, P1693; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Hendriks RW, 1999, EUR J IMMUNOL, V29, P1912, DOI 10.1002/(SICI)1521-4141(199906)29:06<1912::AID-IMMU1912>3.3.CO;2-4; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; Ho IC, 1998, J EXP MED, V188, P1859, DOI 10.1084/jem.188.10.1859; Ho IC, 1996, CELL, V85, P973, DOI 10.1016/S0092-8674(00)81299-4; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; HODGE MR, 1996, IMMUNITY, V4, P1; Hu-Li J, 2001, IMMUNITY, V14, P1, DOI 10.1016/S1074-7613(01)00084-X; Jankovic D, 2000, J IMMUNOL, V164, P3047, DOI 10.4049/jimmunol.164.6.3047; KAMOGAWA Y, 1993, CELL, V75, P985, DOI 10.1016/0092-8674(93)90542-X; Kaplan MH, 1998, J EXP MED, V188, P1191, DOI 10.1084/jem.188.6.1191; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kim JI, 1999, IMMUNITY, V10, P745, DOI 10.1016/S1074-7613(00)80073-4; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Kishikawa H, 2001, J IMMUNOL, V167, P4414, DOI 10.4049/jimmunol.167.8.4414; Kurata H, 1999, IMMUNITY, V11, P677, DOI 10.1016/S1074-7613(00)80142-9; Lakshmanan G, 1999, MOL CELL BIOL, V19, P1558; Lane P, 2000, J EXP MED, V191, P201, DOI 10.1084/jem.191.2.201; Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lee HJ, 1998, J IMMUNOL, V160, P2343; Lieberson R, 2001, J EXP MED, V194, P89, DOI 10.1084/jem.194.1.89; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; McAdam AJ, 2000, J IMMUNOL, V165, P5035, DOI 10.4049/jimmunol.165.9.5035; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; Mohrs M, 2001, NAT IMMUNOL, V2, P842, DOI 10.1038/ni0901-842; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; MUNOZ E, 1990, J EXP MED, V172, P95, DOI 10.1084/jem.172.1.95; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; NEURATH MF, 2002, IN PRESS J EXP MED; Noben-Trauth N, 2000, J IMMUNOL, V165, P3620, DOI 10.4049/jimmunol.165.7.3620; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Pauza ME, 2001, DIABETES, V50, P39, DOI 10.2337/diabetes.50.1.39; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Peritt D, 1998, J IMMUNOL, V161, P5821; Piccotti JR, 1998, J IMMUNOL, V160, P1132; Range LM, 1998, J PERS INTERPERS LOS, V3, P161, DOI 10.1080/10811449808414438; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rengarajan J, 2002, NAT IMMUNOL, V3, P48, DOI 10.1038/ni744; Riviere I, 1998, IMMUNITY, V9, P217, DOI 10.1016/S1074-7613(00)80604-4; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Salomon B, 2001, ANNU REV IMMUNOL, V19, P225, DOI 10.1146/annurev.immunol.19.1.225; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; Sperling AI, 2001, NAT IMMUNOL, V2, P573, DOI 10.1038/89709; Staudt L M, 1999, Int Rev Immunol, V18, P381, DOI 10.3109/08830189909088490; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749; van Lohuizen M, 1999, CURR OPIN GENET DEV, V9, P355, DOI 10.1016/S0959-437X(99)80053-7; Wurster AL, 2000, ONCOGENE, V19, P2577, DOI 10.1038/sj.onc.1203485; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787; Yamagata T, 2000, EMBO J, V19, P4676, DOI 10.1093/emboj/19.17.4676; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Yin ZN, 2002, J IMMUNOL, V168, P1566, DOI 10.4049/jimmunol.168.4.1566; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; YOUNG HA, 1994, J IMMUNOL, V153, P3603; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zhang YK, 2001, J EXP MED, V194, P165, DOI 10.1084/jem.194.2.165; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou MX, 2001, J EXP MED, V194, P1461, DOI 10.1084/jem.194.10.1461	107	201	211	0	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR	2002	109			S			S109	S120		10.1016/S0092-8674(02)00705-5	http://dx.doi.org/10.1016/S0092-8674(02)00705-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	544UY	11983157	Bronze			2022-12-28	WOS:000175181100010
J	Goldacre, MJ; Griffith, M; Gill, L; Mackintosh, A				Goldacre, MJ; Griffith, M; Gill, L; Mackintosh, A			In-hospital deaths as fraction of all deaths within 30 days of hospital admission for surgery: analysis of routine statistics	BRITISH MEDICAL JOURNAL			English	Article									Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England	University of Oxford	Goldacre, MJ (corresponding author), Univ Oxford, Dept Publ Hlth, Unit Hlth Care Epidemiol, Oxford OX3 7LF, England.							Acheson E.D., 1967, MED RECORD LINKAGE; Callum KG, 2000, THEN NOW 2000 REPORT; *DEP HLTH SOC SEC, 1969, HOSP ACT AN; HENDERSON J, 1992, J EPIDEMIOL COMMUNIT, V42, P297; *STEER GROUP HLTH, 1982, 1 STEER GROUP HLTH S	5	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 4	2002	324	7345					1069	1070		10.1136/bmj.324.7345.1069	http://dx.doi.org/10.1136/bmj.324.7345.1069			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YY	11991911	Green Published, Bronze			2022-12-28	WOS:000175476500019
J	Klironomos, JN				Klironomos, JN			Feedback with soil biota contributes to plant rarity and invasiveness in communities	NATURE			English	Article							DIVERSITY; PATHOGENS; VEGETATION; ECOSYSTEM; MOSAICS	Understanding the relative abundance of species in plant communities is an unsolved problem(1-10). Mechanisms such as competition, resource partitioning(5), dispersal ability(10) and predation tolerance(6-9) do not adequately explain relative abundance under field conditions(11,12). Recent work suggests that interactions between plants and soil microbes is important(13-21). Here I show that such interaction explains a significant proportion of the variance in the relative abundance of species in plant communities. Rare plants exhibited a relative decrease in growth on 'home' soil in which pathogens had had a chance to accumulate, whereas invasive plants benefited from interactions with mycorrhizal fungi. Some plant species accumulate pathogens quickly and maintain low densities as a result of the accumulation of species-specific pathogens, whereas others accumulate species-specific pathogens more slowly and do not experience negative feedback until plant densities reach high levels(13,15,21). These results indicate that plants have different abilities to influence their abundance by changing the structure of their soil communities, and that this is an important regulator of plant community structure.	Univ Guelph, Dept Bot, Guelph, ON N1G 2W1, Canada	University of Guelph	Klironomos, JN (corresponding author), Univ Guelph, Dept Bot, Guelph, ON N1G 2W1, Canada.							Anderson TH., 1980, COMPENDIUM SOIL FUNG, V1; Bazzaz F.A., 1990, PERSPECTIVES PLANT C, P240; BELSKY JA, 1992, J VEG SCI, V3, P187, DOI 10.2307/3235679; Bever JD, 1997, J ECOL, V85, P561, DOI 10.2307/2960528; BEVER JD, 1994, ECOLOGY, V75, P1965, DOI 10.2307/1941601; Blomqvist MM, 2000, OIKOS, V90, P582, DOI 10.1034/j.1600-0706.2000.900316.x; BRAGULAT MR, 1991, APPL ENVIRON MICROB, V57, P2777, DOI 10.1128/AEM.57.9.2777-2780.1991; BURDON JJ, 1987, CAMBRIDGE STUDIES EC; Callaway RM, 2000, SCIENCE, V290, P521, DOI 10.1126/science.290.5491.521; Gaston K.J., 1994, RARITY, P1; GRIME JP, 1987, NATURE, V328, P420, DOI 10.1038/328420a0; Huston M. A., 1994, BIOL DIVERSITY; KLIRONOMOS JN, 1993, CAN J BOT, V71, P1472, DOI 10.1139/b93-178; Mills KE, 1998, ECOLOGY, V79, P1595, DOI 10.1890/0012-9658(1998)079[1595:MODWPC]2.0.CO;2; Milton WEJ, 1940, J ECOL, V28, P326, DOI 10.2307/2256233; Olff H, 2000, OECOLOGIA, V125, P45, DOI 10.1007/PL00008890; Packer A, 2000, NATURE, V404, P278, DOI 10.1038/35005072; PYSEK P, 1995, PLANT INVASIONS GEN; RABINOWITZ D, 1989, AM NAT, V134, P525, DOI 10.1086/284995; Reader RJ, 1998, PLANT ECOL, V134, P43, DOI 10.1023/A:1009700100343; Ricklefs R.E., 1993, J EVOLUTION BIOL, DOI DOI 10.1046/J.1420-9101.1993.6020171.X; TILMAN D, 1994, BIODIVERSITY ECOSYST, P327; Tokeshi M., 1999, SPECIES COEXISTENCE; van der Heijden MGA, 1998, NATURE, V396, P69, DOI 10.1038/23932; van der Putten WH, 2000, NATURE, V404, P232, DOI 10.1038/35005188; VANDERPUTTEN WH, 1993, NATURE, V362, P53; [No title captured]	27	1248	1335	34	883	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	2002	417	6884					67	70		10.1038/417067a	http://dx.doi.org/10.1038/417067a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986666				2022-12-28	WOS:000175307200038
J	Winthrop, KL; Abrams, M; Yakrus, M; Schwartz, I; Ely, J; Gillies, D; Vugia, DJ				Winthrop, KL; Abrams, M; Yakrus, M; Schwartz, I; Ely, J; Gillies, D; Vugia, DJ			An outbreak of mycobacterial furunculosis associated with footbaths at a nail salon	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRINKING-WATER SAMPLES; NONTUBERCULOUS MYCOBACTERIA; NOSOCOMIAL OUTBREAKS; ELECTROPHORESIS; PATTERNS; DNA	Background: In September 2000, a physician in northern California described four patients with persistent, culture-negative boils on the lower extremities. The patients had received pedicures at the same nail salon. We identified and investigated an outbreak of Mycobacterium fortuitum furunculosis among customers of this nail salon. Methods: Patients were defined as salon customers with persistent skin infections below the knee. A case-control study was conducted that included the first 48 patients identified, and 56 unaffected friends and family members who had had a pedicure at the same salon served as controls. Selected M. fortuitum isolates, cultured from patients and the salon environment, were compared by pulsed-field gel electrophoresis. Results: We identified 110 customers of the nail salon who had furunculosis. Cultures from 34 were positive for rapidly growing mycobacteria (32 M. fortuitum and 2 unidentified). Most of the affected patients had more than 1 boil (median, 2; range, 1 to 37). All patients and controls had had whirlpool footbaths. Shaving the legs with a razor before pedicure was a risk factor for infection (70 percent of patients vs. 31 percent of controls; adjusted odds ratio, 4.8; 95 percent confidence interval, 2.1 to 11.1). Cultures from all 10 footbaths at the salon yielded M. fortuitum. The M. fortuitum isolates from three footbaths and 14 patients were indistinguishable by electrophoresis. Conclusions: We identified a large outbreak of rapidly growing mycobacterial infections among persons who had had footbaths and pedicures at one nail salon. Physicians should suspect this cause in patients with persistent furunculosis after exposure to whirlpool footbaths.	Calif Dept Hlth Serv, Div Communicable Dis Control, Berkeley, CA 94704 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA USA; Ctr Dis Control & Prevent, Div AIDS Sexually Transmitted Dis & TB Lab Res, TB Mycobacterial Branch, Atlanta, GA USA; Santa Cruz Cty Dept Hlth, Santa Cruz, CA USA	California Department of Health Care Services; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Winthrop, KL (corresponding author), Calif Dept Hlth Serv, Div Communicable Dis Control, Rm 708,2151 Berkeley Way, Berkeley, CA 94704 USA.							AUBUCHON C, 1986, J BONE JOINT SURG AM, V68A, P766, DOI 10.2106/00004623-198668050-00021; BROWN BA, 2000, MANDELL DOUGLAS BENN, V2, P2630; Butler WR, 2001, CLIN MICROBIOL REV, V14, P704, DOI 10.1128/CMR.14.4.704-726.2001; CARSON LA, 1978, APPL ENVIRON MICROB, V36, P839, DOI 10.1128/AEM.36.6.839-846.1978; COLLINS CH, 1984, J APPL BACTERIOL, V57, P193, DOI 10.1111/j.1365-2672.1984.tb01384.x; Covert TC, 1999, APPL ENVIRON MICROB, V65, P2492; Da Costa Cruz JC, 1938, ACTA MED RIO DE JANE, V1, P297; FISCHEDER R, 1991, ZBL HYG UMWELTMED, V192, P154; HECTOR JSR, 1992, J CLIN MICROBIOL, V30, P1250, DOI 10.1128/JCM.30.5.1250-1255.1992; JONES RJ, 1965, CAN J MICROBIOL, V11, P127, DOI 10.1139/m65-018; Kent P. T., 1985, PUBLIC HLTH MYCOBACT, P31; Kent PT, 1985, PUBLIC HLTH MYCOBACT, P57; Lee W J, 2000, J Dermatol, V27, P264; Nolte N.F., 1999, MANUAL CLIN MICROBIO, P399; SCHULZEROBBECKE R, 1991, J MICROBIOL METH, V14, P177, DOI 10.1016/0167-7012(91)90021-H; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; WALLACE RJ, 1983, REV INFECT DIS, V5, P657; Wallace RJ, 1998, ANNU REV MICROBIOL, V52, P453, DOI 10.1146/annurev.micro.52.1.453; WOLINSKY E, 1968, AM REV RESPIR DIS, V97, P1032; YAKRUS MA, 1992, J CLIN MICROBIOL, V30, P1474, DOI 10.1128/JCM.30.6.1474-1478.1992; 2001, NAILS MAGAZINE, V18, P33	21	143	148	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					1366	1371		10.1056/NEJMoa012643	http://dx.doi.org/10.1056/NEJMoa012643			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546MZ	11986410				2022-12-28	WOS:000175279000004
J	Ferguson, TB; Coombs, LP; Peterson, ED				Ferguson, TB; Coombs, LP; Peterson, ED		Soc Thoracic Surg Natl Adult Cardi	Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY BYPASS; STS NATIONAL DATABASE; ELDERLY-PATIENTS; HEART-FAILURE; OFF-PUMP; THERAPY; RISK; PREDICTORS; INTERVENTION	Context beta-Blockade therapy has recently been shown to convey a survival benefit in preoperative noncardiac vascular surgical settings. The effect of preoperative beta-blocker therapy on coronary artery bypass graft surgery (CABG) outcomes has not been assessed. Objectives To examine patterns of use of preoperative beta-blockers in patients undergoing isolated CABG and to determine whether use of beta-blockers is associated with lower operative mortality and morbidity. Design, Setting, and Patients Observational study using the Society of Thoracic Surgeons National Adult Cardiac Surgery Database (NCD) to assess beta-blocker use and outcomes among 629877 patients undergoing isolated CABG between 1996 and 1999 at 497 US and Canadian sites. Main Outcome Measure influence of beta-blockers on operative mortality, examined using both direct risk adjustment and a matched-pairs analysis based on propensity for preoperative beta-blocker therapy. Results From 1996 to 1999, overall use of preoperative beta-blockers increased from 50% to 60% in the NCD (P<.001 for time trend). Major predictors of use included recent myocardial infarction; hypertension; worse angina; younger age; better left ventricular systolic function; and absence of congestive heart failure, chronic lung disease, and diabetes. Patients who received beta-blockers had lower mortality than those who did not (unadjusted 30-day mortality, 2.8% vs 3.4%; odds ratio [OR], 0.80; 95% confidence interval [CI], 0.78-0.82). Preoperative beta-blocker use remained associated with slightly lower mortality after adjusting for patient risk and center effects using both risk adjustment (OR, 0.94; 95% CI, 0.91-0.97) and treatment propensity matching (OR, 0.97; 95% CI, 0.93-1.00). Procedural complications also tended to be lower among treated patients. This treatment advantage was seen among the majority of patient subgroups, including women; elderly persons; and those with chronic lung disease, diabetes, or moderately depressed ventricular function. Among patients with a left ventricular ejection fraction of less than 30%, however, preoperative beta-blocker therapy was associated with a trend toward a higher mortality rate (OR, 1.13; 95% CI, 0,96-1,33; P=.23). Conclusions In this large North American observational analysis, preoperative beta-blocker therapy was associated with a small but consistent survival benefit for patients undergoing CABG, except among patients with a left ventricular ejection fraction of less than 30%. This analysis further suggests that preoperative beta-blocker therapy may be a useful process measure for CABG quality improvement assessment.	Soc Thorac Surgeons, Natl Database Comm, Chicago, IL USA; Duke Clin Res Inst, Durham, NC USA	Society of Thoracic Surgeons; Duke University	Ferguson, TB (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Surg, 1542 Tulane Ave,7th Floor, New Orleans, LA 70012 USA.	tbruceferg732@pol.net	Peterson, Eric David/ABF-5033-2021		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010403] Funding Source: NIH RePORTER; AHRQ HHS [R01-HS 10403] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*1 INT STUD INF SU, 1988, LANCET, V1, P921; Berlin JA, 1999, BIOMETRICS, V55, P470, DOI 10.1111/j.0006-341X.1999.00470.x; Boersma E, 2001, JAMA-J AM MED ASSOC, V285, P1865, DOI 10.1001/jama.285.14.1865; Chen J, 2000, ARCH INTERN MED, V160, P947, DOI 10.1001/archinte.160.7.947; Farrell MH, 2002, JAMA-J AM MED ASSOC, V287, P890, DOI 10.1001/jama.287.7.890; FENNINGER M, 2001, ANESTHESIOLOGY, V95, pA250; Ferguson TB, 2002, ANN THORAC SURG, V73, P480, DOI 10.1016/S0003-4975(01)03339-2; Ferguson TB, 2001, ANN THORAC SURG, V72, P697, DOI 10.1016/S0003-4975(01)02955-1; Ferguson TB, 2000, ANN THORAC SURG, V69, P680, DOI 10.1016/S0003-4975(99)01538-6; Foody JM, 2002, JAMA-J AM MED ASSOC, V287, P883, DOI 10.1001/jama.287.7.883; Gheorghiade Mihai, 2001, American Journal of Medicine, V110, p68S; GIBBONS RJ, IN PRESS J AM COLL C; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; GRIGORE AM, 1999, ANESTH ANALG, V88; Grover FL, 2000, ANN THORAC SURG, V70, P1143, DOI 10.1016/S0003-4975(00)02168-8; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; Neuhaus JM, 1998, BIOMETRICS, V54, P638, DOI 10.2307/3109770; Normand SLT, 2001, J CLIN EPIDEMIOL, V54, P387, DOI 10.1016/S0895-4356(00)00321-8; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Peterson ED, 2000, J AM COLL CARDIOL, V36, P2174, DOI 10.1016/S0735-1097(00)01022-6; Plomondon ME, 2001, ANN THORAC SURG, V72, P114, DOI 10.1016/S0003-4975(01)02670-4; Radford MJ, 2001, JAMA-J AM MED ASSOC, V286, P1228, DOI 10.1001/jama.286.10.1228; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Ryan TJ, 1999, J AM COLL CARDIOL, V34, P890, DOI 10.1016/S0735-1097(99)00351-4; Sharma SK, 2000, CIRCULATION, V102, P166, DOI 10.1161/01.CIR.102.2.166; SHROYER AL, IN PRESS ANN THORAC; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; SWEDBERG K, 1979, LANCET, V1, P1374; van Dijk D, 2001, CIRCULATION, V104, P1761, DOI 10.1161/hc4001.097036; Vetrovec GW, 2000, CIRCULATION, V102, P147, DOI 10.1161/01.CIR.102.2.147; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005; Wang TJ, 1998, ARCH INTERN MED, V158, P1901, DOI 10.1001/archinte.158.17.1901; Weightman WM, 1999, ANESTH ANALG, V88, P286, DOI 10.1097/00000539-199902000-00011; Whorlow SL, 2000, AM J CARDIOL, V86, P886, DOI 10.1016/S0002-9149(00)01114-0; 2001, N ENGL J MED, V334, P1659	37	190	200	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2221	2227		10.1001/jama.287.17.2221	http://dx.doi.org/10.1001/jama.287.17.2221			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980522	Bronze			2022-12-28	WOS:000175260600022
J	Duncan, B				Duncan, B			Health policy in the European Union: how it's made and how to influence it	BRITISH MEDICAL JOURNAL			English	Article									BMA, B-1000 Brussels, Belgium		Duncan, B (corresponding author), BMA, 31 Rue Montoyer, B-1000 Brussels, Belgium.							*EUR HLTH MAN ASS, 2001, IMP EUR UN INT MARK; GRANT S, 2001, HOSP DOCTOR     0707; Lang T., 2001, Eurohealth, V7, P34; Mossialos E, 2001, BRIT MED J, V323, P248, DOI 10.1136/bmj.323.7307.248; MOSSIALOS E, 1996, J EUR SOC POLICY, V6, P268; RAYNER M, 1995, BRIT MED J, V311, P1180, DOI 10.1136/bmj.311.7014.1180; RICHARDS T, 1994, BRIT MED J, V309, P116, DOI 10.1136/bmj.309.6947.116; Watson R, 2000, BRIT MED J, V321, P915, DOI 10.1136/bmj.321.7266.915; WATSON R, 2001, BRIT MED J, V323, P128; *WORK GROUP SPEC M, 1993, HOSP DOCT TRAIN FUT	10	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 27	2002	324	7344					1027	1030		10.1136/bmj.324.7344.1027	http://dx.doi.org/10.1136/bmj.324.7344.1027			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547UP	11976248	Green Published			2022-12-28	WOS:000175350900026
J	Hey, E				Hey, E			Clinical trials: when to start and when to stop	LANCET			English	Editorial Material							PATENT DUCTUS-ARTERIOSUS; PRETERM INFANTS; IBUPROFEN; INDOMETHACIN; THERAPY											Aranda JV, 1997, ACTA PAEDIATR, V86, P289, DOI 10.1111/j.1651-2227.1997.tb08892.x; Bourke B, 2002, ARCH DIS CHILD, V86, P71, DOI 10.1136/adc.86.2.71; Clyman RI, 2000, NEW ENGL J MED, V343, P728, DOI 10.1056/NEJM200009073431009; Dani C, 2000, ACTA PAEDIATR, V89, P1369, DOI 10.1080/080352500300002598; De Carolis MP, 2000, EUR J PEDIATR, V159, P364, DOI 10.1007/s004310051288; Doll R, 2002, CLIN TRIALS, P97; Feinglos MN, 1999, AM HEART J, V138, pS346; Horbar Jeffrey D., 1992, P562; Kluckow M, 1999, ARCH DIS CHILD-FETAL, V80, pF34, DOI 10.1136/fn.80.1.F34; Ment LR, 2000, PEDIATRICS, V105, P485, DOI 10.1542/peds.105.3.485; Patel J, 2000, PEDIATR RES, V47, P36, DOI 10.1203/00006450-200001000-00009; Schmidt B, 2001, NEW ENGL J MED, V344, P1966, DOI 10.1056/NEJM200106283442602; Van Overmeire B, 2000, NEW ENGL J MED, V343, P674, DOI 10.1056/NEJM200009073431001; Varvarigou A, 1996, JAMA-J AM MED ASSOC, V275, P539, DOI 10.1001/jama.275.7.539	14	2	2	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1449	1449		10.1016/S0140-6736(02)08463-5	http://dx.doi.org/10.1016/S0140-6736(02)08463-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988238				2022-12-28	WOS:000175279100002
J	Ben-Shahar, Y; Robichon, A; Sokolowski, MB; Robinson, GE				Ben-Shahar, Y; Robichon, A; Sokolowski, MB; Robinson, GE			Influence of gene action across different time scales on behavior	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; DIVISION-OF-LABOR; NITRIC-OXIDE; DROSOPHILA; BRAIN	Genes can affect natural behavioral variation in different ways. Allelic variation causes alternative behavioral phenotypes, whereas changes in gene expression can influence the initiation of behavior at different ages. We show that the age-related transition by honey bees from hive work to foraging is associated with an increase in the expression of the foraging (for) gene, which encodes a guanosine 3',5'-monophosphate (cGMP)-dependent protein kinase (PKG). cGMP treatment elevated PKG activity and caused foraging behavior. Previous research showed that allelic differences in PKG expression result in two Drosophila foraging variants. The same gene can thus exert different types of influence on a behavior.	Univ Illinois, Dept Entomol, Urbana, IL 61801 USA; Univ Illinois, Program Neurosci, Urbana, IL 61801 USA; Univ Bourgogne, CNRS, CESG, F-21000 Dijon, France; Univ Toronto, Dept Zool, Mississauga, ON L5L 1C6, Canada	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Centre National de la Recherche Scientifique (CNRS); Universite de Bourgogne; University of Toronto; University Toronto Mississauga	Robinson, GE (corresponding author), Univ Illinois, Dept Entomol, 320 Morrill Hall,505 S Goodwin Ave, Urbana, IL 61801 USA.			Sokolowski, Marla/0000-0002-7462-8007; robichon, alain/0000-0003-1075-9646				Ben-Shahar Y, 2001, J COMP PHYSIOL A, V187, P891, DOI 10.1007/s00359-001-0260-z; Bloch G, 2001, J BIOL RHYTHM, V16, P444, DOI 10.1177/074873001129002123; COX DR, 1972, J R STAT SOC B, V34, P187; DELLAFERA MA, 1981, PHYSIOL BEHAV, V26, P799, DOI 10.1016/0031-9384(81)90102-5; Ding YC, 2002, P NATL ACAD SCI USA, V99, P309, DOI 10.1073/pnas.012464099; FRANCIS SH, 1988, MOL PHARMACOL, V34, P506; Gilad Y, 2002, P NATL ACAD SCI USA, V99, P862, DOI 10.1073/pnas.022614799; Gronenberg W, 2001, J COMP NEUROL, V435, P474, DOI 10.1002/cne.1045; Heisenberg M, 1998, LEARN MEMORY, V5, P1; HUANG ZY, 1992, P NATL ACAD SCI USA, V89, P11726, DOI 10.1073/pnas.89.24.11726; Krieger MJB, 2002, SCIENCE, V295, P328, DOI 10.1126/science.1065247; MORLEY JE, 1995, PHARMACOL BIOCHEM BE, V50, P369, DOI 10.1016/0091-3057(94)00276-O; Moroz LL, 2000, J COMP NEUROL, V427, P274; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Page RE, 2002, GENETICS, V160, P375; ROBINSON GE, IN PRESS AM NAT; SEELEY TD, 1997, WISDOM HIVE; Sokolowski MB, 1997, P NATL ACAD SCI USA, V94, P7373, DOI 10.1073/pnas.94.14.7373; Toma DP, 2000, P NATL ACAD SCI USA, V97, P6914, DOI 10.1073/pnas.97.12.6914; WILSON EO, 1975, SOCIOBIOLOGY; Young LJ, 2001, HORM BEHAV, V40, P133, DOI 10.1006/hbeh.2001.1691	21	368	390	1	127	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					741	744		10.1126/science.1069911	http://dx.doi.org/10.1126/science.1069911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976457				2022-12-28	WOS:000175281700057
J	Boss, PK; Thomas, MR				Boss, PK; Thomas, MR			Association of dwarfism and floral induction with a grape 'green revolution' mutation	NATURE			English	Article							GIBBERELLIN RESPONSES; ARABIDOPSIS-THALIANA; GENES; EXPRESSION; PATHWAY; MUTANT	The transition from vegetative to reproductive growth is an essential process in the life cycle of plants. Plant floral induction pathways respond to both environmental and endogenous cues and much has been learnt about these genetic pathways by studying mutants of Arabidopsis(1,2). Gibberellins (GAs) are plant growth regulators important in many aspects of plant growth and in Arabidopsis they promote flowering(3-5). Here we provide genetic evidence that GAs inhibit flowering in grapevine. A grapevine dwarf mutant derived from the L1 cell layer of the champagne cultivar Pinot Meunier produces inflorescences along the length of the shoot where tendrils are normally formed. The mutated gene associated with the phenotype is a homologue of the wheat 'green revolution' gene Reduced height-1 (ref. 6) and the Arabidopsis gene GA insensitive (GAI)(7). The conversion of tendrils to inflorescences in the mutant demonstrates that the grapevine tendril is a modified inflorescence inhibited from completing floral development by GAs.	CSIRO, Plant Ind & Cooperat Res Ctr Viticulture, Glen Osmond, SA 5064, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Thomas, MR (corresponding author), CSIRO, Plant Ind & Cooperat Res Ctr Viticulture, POB 350, Glen Osmond, SA 5064, Australia.		Boss, Paul K/A-1292-2010; Thomas, Mark/A-3117-2010	Boss, Paul K/0000-0003-0356-9342; 				Araki T, 2001, CURR OPIN PLANT BIOL, V4, P63, DOI 10.1016/S1369-5266(00)00137-0; Blazquez MA, 1998, PLANT CELL, V10, P791, DOI 10.1105/tpc.10.5.791; Blazquez MA, 2000, NATURE, V404, P889, DOI 10.1038/35009125; Boss P. K., 2000, Australian Journal of Grape and Wine Research, V6, P168, DOI 10.1111/j.1755-0238.2000.tb00176.x; Boss PK, 1996, PLANT PHYSIOL, V111, P1059, DOI 10.1104/pp.111.4.1059; Buttrose M. S., 1974, Horticultural Abstracts, V44, P319; ELLIS RH, 1983, VITIS, V22, P211; Franks T, 2002, THEOR APPL GENET, V104, P192, DOI 10.1007/s001220100683; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Hempel FD, 2000, TRENDS PLANT SCI, V5, P17, DOI 10.1016/S1360-1385(99)01511-3; KOORNNEEF M, 1985, PHYSIOL PLANTARUM, V65, P33, DOI 10.1111/j.1399-3054.1985.tb02355.x; LANGRIDGE J, 1957, NATURE, V180, P36, DOI 10.1038/180036a0; MULLINS MG, 1968, J EXP BOT, V19, P532, DOI 10.1093/jxb/19.3.532; Neff MM, 1998, PLANT J, V14, P387, DOI 10.1046/j.1365-313X.1998.00124.x; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Peng JR, 1999, NATURE, V400, P256, DOI 10.1038/22307; Peng JR, 1999, PLANT PHYSIOL, V119, P1199, DOI 10.1104/pp.119.4.1199; Peng JR, 1997, PLANT SCI, V130, P181, DOI 10.1016/S0168-9452(97)00216-1; PRATT C, 1971, AM J ENOL VITICULT, V22, P92; Pysh LD, 1999, PLANT J, V18, P111, DOI 10.1046/j.1365-313X.1999.00431.x; Rives M, 2000, AGRONOMIE, V20, P79, DOI 10.1051/agro:2000109; Simpson GG, 1999, ANNU REV CELL DEV BI, V15, P519, DOI 10.1146/annurev.cellbio.15.1.519; SKENE KGM, 1983, J EXP BOT, V34, P1271, DOI 10.1093/jxb/34.10.1271; THOMAS MR, 1993, THEOR APPL GENET, V86, P173, DOI 10.1007/BF00222076; THOMPSON MM, 1963, AM J BOT, V50, P901, DOI 10.2307/2439777; UTSUNOMIYA N, 1978, J JPN SOC HORTIC SCI, V47, P151, DOI 10.2503/jjshs.47.151; VIALA P, 2001, AMPELOGRAPHIE, V2	27	301	354	4	105	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					847	850		10.1038/416847a	http://dx.doi.org/10.1038/416847a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976683				2022-12-28	WOS:000175163800051
J	Pelkmans, L; Puntener, D; Helenius, A				Pelkmans, L; Puntener, D; Helenius, A			Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; SIMIAN VIRUS-40; MEMBRANE; SIGNAL; ENDOTHELIUM; MOTILITY; VACCINIA; VESICLES; COMPLEX	Simian virus 40 (SV40) utilizes endocytosis through caveolae for infectious entry into host cells. We found that after binding to caveolae, virus particles induced transient breakdown of actin stress fibers. Actin was then recruited to virus-loaded caveolae as actin patches that served as sites for actin "tail" formation. Dynamin II was also transiently recruited. These events depended on the presence of cholesterol and on the activation of tyrosine kinases that phosphorylated proteins in caveolae. They were necessary for formation of caveolae-derived endocytic vesicles and for infection of the cell. Thus, caveolar endocytosis is ligand-triggered and involves extensive rearrangement of the actin cytoskeleton.	ETH Honggerberg, Swiss Fed Inst Technol ETHZ, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Helenius, A (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol ETHZ, HPM1 Bldg, CH-8093 Zurich, Switzerland.			Pelkmans, Lucas/0000-0002-6754-9730				Anderson HA, 1996, MOL BIOL CELL, V7, P1825, DOI 10.1091/mbc.7.11.1825; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Aoki T, 1999, EXP CELL RES, V253, P629, DOI 10.1006/excr.1999.4652; Benmerah A, 1999, J CELL SCI, V112, P1303; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Chen YZ, 1999, EXP CELL RES, V246, P83, DOI 10.1006/excr.1998.4301; Dramsi S, 1998, ANNU REV CELL DEV BI, V14, P137, DOI 10.1146/annurev.cellbio.14.1.137; Fish KN, 2000, J CELL BIOL, V150, P145, DOI 10.1083/jcb.150.1.145; Frischknecht F, 1999, CURR BIOL, V9, P89, DOI 10.1016/S0960-9822(99)80020-7; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Kang YS, 2000, EXP CELL RES, V255, P221, DOI 10.1006/excr.1999.4792; KARTENBECK J, 1989, J CELL BIOL, V109, P2721, DOI 10.1083/jcb.109.6.2721; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Marjomaki V, 2002, J VIROL, V76, P1856, DOI 10.1128/JVI.76.4.1856-1865.2002; May RC, 2001, J CELL SCI, V114, P1061; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; PALADE GE, 1953, J APPL PHYS, V24, P1424; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; PELKMANS L, UNPUB; Richterova Z, 2001, J VIROL, V75, P10880, DOI 10.1128/JVI.75.22.10880-10891.2001; Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Shin JS, 2001, MICROBES INFECT, V3, P755, DOI 10.1016/S1286-4579(01)01423-X; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stang E, 1997, MOL BIOL CELL, V8, P47, DOI 10.1091/mbc.8.1.47; Thomsen P, 2002, MOL BIOL CELL, V13, P238, DOI 10.1091/mbc.01-06-0317; Ward BM, 2001, J VIROL, V75, P11651, DOI 10.1128/JVI.75.23.11651-11663.2001; YAMADA M, 1993, J VIROL, V67, P119, DOI 10.1128/JVI.67.1.119-130.1993	33	558	579	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					535	539		10.1126/science.1069784	http://dx.doi.org/10.1126/science.1069784			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964480				2022-12-28	WOS:000175179400047
J	Chandrappa, GT; Steunou, N; Livage, J				Chandrappa, GT; Steunou, N; Livage, J			Materials chemistry - Macroporous crystalline vanadium oxide foam	NATURE			English	Editorial Material									Univ Paris 06, F-75252 Paris, France	UDICE-French Research Universities; Sorbonne Universite	Chandrappa, GT (corresponding author), Bangalore Univ, Dept Chem, Bangalore 560001, Karnataka, India.	livage@ccr.jussieu.fr	STEUNOU, Nathalie/O-2636-2018; STEUNOU, Nathalie/AAD-2778-2019	STEUNOU, Nathalie/0000-0002-7049-7388; STEUNOU, Nathalie/0000-0002-7049-7388				Alonso B, 1999, J SOLID STATE CHEM, V148, P16, DOI 10.1006/jssc.1999.8283; KRESGE CT, 1992, NATURE, V359, P710, DOI 10.1038/359710a0; Liu P, 1997, CHEM MATER, V9, P2513, DOI 10.1021/cm970067u; LIVAGE J, 1991, CHEM MATER, V3, P578, DOI 10.1021/cm00016a006; Mann S, 2000, ANGEW CHEM INT EDIT, V39, P3393; Mann S, 1996, NATURE, V382, P313, DOI 10.1038/382313a0; Williams RJP., 1989, BIOMINERALISATION, P1; Yang PD, 1998, NATURE, V396, P152	8	147	150	3	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	2002	416	6882					702	702		10.1038/416702a	http://dx.doi.org/10.1038/416702a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961545	Bronze			2022-12-28	WOS:000175033500032
J	Cadieux, P; Burton, J; Gardiner, G; Braunstein, I; Bruce, AW; Kang, CY; Reid, G				Cadieux, P; Burton, J; Gardiner, G; Braunstein, I; Bruce, AW; Kang, CY; Reid, G			Lactobacillus strains and vaginal ecology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									Canadian Res & Dev Ctr Probiot, Lawson Hlth Res Inst, London, ON N6A 3K7, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada; Univ Western Ontario, Dept Surg, London, ON N6A 3K7, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Cadieux, P (corresponding author), Canadian Res & Dev Ctr Probiot, Lawson Hlth Res Inst, London, ON N6A 3K7, Canada.		Reid, Gregor/ABE-8327-2020; Burton, Jeremy/AAR-8902-2020	Reid, Gregor/0000-0001-9658-5696; Burton, Jeremy/0000-0002-3591-6436				Gardiner GE, 2002, CLIN DIAGN LAB IMMUN, V9, P92, DOI 10.1128/CDLI.9.1.92-96.2002; Keane FEA, 1997, INT J STD AIDS, V8, P489, DOI 10.1258/0956462971920631; Kontiokari T, 2001, BMJ-BRIT MED J, V322, P1571, DOI 10.1136/bmj.322.7302.1571; Reid G, 2001, AM J CLIN NUTR, V73, p437S, DOI 10.1093/ajcn/73.2.437s; REID G, 1987, J UROLOGY, V138, P330, DOI 10.1016/S0022-5347(17)43137-5; Reid G, 2001, J INFECT DIS, V183, pS77, DOI 10.1086/318841; SEWANKAMBO N, 1997, LANCET, V350, P530	7	82	93	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2002	287	15					1940	1941		10.1001/jama.287.15.1940	http://dx.doi.org/10.1001/jama.287.15.1940			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NC	11960535				2022-12-28	WOS:000174989800021
J	Vrebalov, J; Ruezinsky, D; Padmanabhan, V; White, R; Medrano, D; Drake, R; Schuch, W; Giovannoni, J				Vrebalov, J; Ruezinsky, D; Padmanabhan, V; White, R; Medrano, D; Drake, R; Schuch, W; Giovannoni, J			A MADS-box gene necessary for fruit ripening at the tomato ripening-inhibitor (Rin) locus	SCIENCE			English	Article							EXPRESSION; ETHYLENE	Tomato plants harboring the ripening-inhibitor (rin) mutation yield fruits that fail to ripen. Additionally, rin plants display enlarged sepals and loss of inflorescence determinacy. Positional cloning of the rin locus revealed two tandem MADS-box genes (LeMADS-RIN and LeMADS-MC), whose expression patterns suggested roles in fruit ripening and sepal development, respectively. The rin mutation alters expression of both genes. Gene repression and mutant complementation demonstrate that LeMADS-RIN regulates ripening, whereas LeMADS-MC affects sepal development and inflorescence determinacy. LeMADS-RIN demonstrates an agriculturally important function of plant MADS-box genes and provides molecular insight into nonhormonal (developmental) regulation of ripening.	ARS, USDA, Plant Soil & Nutr Lab, Ithaca, NY 14853 USA; Cornell Univ, Boyce Thompson Inst Plant Res, Ithaca, NY 14853 USA; Texas A&M Univ, Dept Hort Sci, College Stn, TX 77843 USA; Zeneca Plant Sci Syngenta, Jeallots Hill Res Stn, Bracknell RG12 6EY, Berks, England	United States Department of Agriculture (USDA); Cornell University; Boyce Thompson Institute for Plant Research; Texas A&M University System; Texas A&M University College Station; Syngenta	Giovannoni, J (corresponding author), ARS, USDA, Plant Soil & Nutr Lab, Ithaca, NY 14853 USA.							Alvarez-Buylla ER, 2000, PLANT J, V24, P457, DOI 10.1046/j.1365-313x.2000.00891.x; [Anonymous], 1993, BIOCH FRUIT RIPENING; Fillatti J. J., 1987, Tomato biotechnology. Proceedings of a symposium held at the University of California, Davis, California, August 20-22, 1986, P199; Giovannoni J, 2001, ANNU REV PLANT PHYS, V52, P725, DOI 10.1146/annurev.arplant.52.1.725; GIOVANNONI JJ, 1995, MOL GEN GENET, V248, P195, DOI 10.1007/BF02190801; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; HUANG H, 1995, PLANT MOL BIOL, V28, P549, DOI 10.1007/BF00020401; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; LINCOLN JE, 1988, PLANT PHYSIOL, V88, P370, DOI 10.1104/pp.88.2.370; Ng M, 2001, NAT REV GENET, V2, P186, DOI 10.1038/35056041; Pelaz S, 2000, NATURE, V405, P200, DOI 10.1038/35012103; PNUELI L, 1994, PLANT CELL, V6, P163, DOI 10.1105/tpc.6.2.163; REICHMANN JL, 1997, BIOL CHEM, V378, P1079; REICHMANN JL, 1996, P NATL ACAD SCI USA, V93, P4793; Rhodes M. J. C., 1980, Senescence in plants., P157; Robinson R., 1968, REP TOMATO GENET COO, V18, P36; Theissen G, 2001, CURR OPIN PLANT BIOL, V4, P75, DOI 10.1016/S1369-5266(00)00139-4; Theissen G, 1996, J MOL EVOL, V43, P484, DOI 10.1007/BF02337521; TIGCHELAAR EC, 1978, HORTSCIENCE, V13, P508; VREBALOV J, UNPUB; YEN HC, 1995, PLANT PHYSIOL, V107, P1343, DOI 10.1104/pp.107.4.1343	21	809	912	11	258	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					343	346		10.1126/science.1068181	http://dx.doi.org/10.1126/science.1068181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951045				2022-12-28	WOS:000175000300057
J	Kramps, T; Peter, O; Brunner, E; Nellen, D; Froesch, B; Chatterjee, S; Murone, M; Zullig, S; Basler, K				Kramps, T; Peter, O; Brunner, E; Nellen, D; Froesch, B; Chatterjee, S; Murone, M; Zullig, S; Basler, K			Wnt/Wingless signaling requires BCL9/legless-mediated recruitment of pygopus to the nuclear beta-catenin-TCF complex	CELL			English	Article							E-CADHERIN; GENE; ARMADILLO; INTERACTS; POLARITY; ACTIVATION; PATHWAY; PROTEIN	Wnt/Wingless signaling controls many fundamental processes during animal development. Wnt transduction is mediated by the association of beta-catenin with nuclear TCF DNA binding factors. Here we report the identification of two segment polarity genes in Drosophila, legless (lgs), and pygopus (pygo), and we show that their products are required for Wnt signal transduction at the level of nuclear beta-catenin. Lgs encodes the homolog of human BCL9, and we provide genetic and molecular evidence that these proteins exert their function by physically linking Pygo to beta-catenin. Our results suggest that the recruitment of Pygo permits beta-catenin to transcriptionally activate Wnt target genes and raise the possibility that a deregulation of these events may play a causal role in the development of B cell malignancies.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Genet Co Inc, CH-8952 Schlieren, Switzerland	University of Zurich	Basler, K (corresponding author), Univ Zurich, Inst Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	basler@molbio.unizh.ch		Basler, Konrad/0000-0003-3534-1529; Peter, Oliver/0000-0001-7091-6653				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Ahmad K, 1998, GENETICS, V148, P775; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Bauer A, 1998, P NATL ACAD SCI USA, V95, P14787, DOI 10.1073/pnas.95.25.14787; BRIDGES C. B., 1935, Biol. Z., V4, P401; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Collins RT, 2000, GENE DEV, V14, P3140, DOI 10.1101/gad.854300; Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464; MULLER HJ, 1957, DROSOPHILA INFORM, V31, P140; Ng M, 1996, NATURE, V381, P316, DOI 10.1038/381316a0; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; Pai LM, 1996, J BIOL CHEM, V271, P32411, DOI 10.1074/jbc.271.50.32411; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; PEIFER M, 1991, DEVELOPMENT, V111, P1029; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polakis P, 2000, GENE DEV, V14, P1837; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Sambrook J., 2001, MOL CLONING LAB MANU; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521-4141(200101)31:1<285::AID-IMMU285>3.3.CO;2-4; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Willis TG, 1998, BLOOD, V91, P1873, DOI 10.1182/blood.V91.6.1873.1873_1873_1881; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	41	476	508	0	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	2002	109	1					47	60		10.1016/S0092-8674(02)00679-7	http://dx.doi.org/10.1016/S0092-8674(02)00679-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955446	Bronze, Green Accepted			2022-12-28	WOS:000174888300008
J	Welch, HCE; Coadwell, WJ; Ellson, CD; Ferguson, GJ; Andrews, SR; Erdjument-Bromage, H; Tempst, P; Hawkins, PT; Stephens, LR				Welch, HCE; Coadwell, WJ; Ellson, CD; Ferguson, GJ; Andrews, SR; Erdjument-Bromage, H; Tempst, P; Hawkins, PT; Stephens, LR			P-Rex1, a PtdIns(3,4,5)P-3- and G beta gamma-regulated guanine-nucleotide exchange factor for Rac	CELL			English	Article							PROTEIN-KINASE B; RHO FAMILY; GUANOSINE TRIPHOSPHATASES; PLECKSTRIN HOMOLOGY; CRYSTAL-STRUCTURE; FACTOR TIAM1; GTPASE RAC2; ACTIVATION; BINDING; VAV	Rac, a member of the Rho family of monomeric GTPases, is an integrator of intracellular signaling in a wide range of cellular processes. We have purified a PtdIns(3,4,5)P-3-sensitive activator of Rac from neutrophil cytosol. It is an abundant, 185 kDa guanine-nucleotide exchange factor (GEF), which we cloned and named P-Rex1. The recombinant enzyme has Rac-GEF activity that is directly, substantially, and synergistically activated by PtdIns(3,4,5)P-3 and Gbetagammas both in vitro and in vivo. P-Rex1 antisense oligonucleotides reduced endogenous P-Rex1 expression and C5a-stimulated reactive oxygen species formation in a neutrophil-like cell line. P-Rex1 appears to be a coincidence detector in PtdIns(3,4,5)P3 and Gbetagamma signaling pathways that is particularly adapted to function downstream of heterotrimeric G proteins in neutrophils.	Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England; Babraham Inst, Bioinformat Grp Signalling, Cambridge CB2 4AT, England; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Memorial Sloan Kettering Cancer Center	Stephens, LR (corresponding author), Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England.	len.stephens@bbsrc.ac.uk		Hawkins, Phillip/0000-0002-6979-0464; Welch, Heidi/0000-0001-7865-7000; stephens, len/0000-0002-2771-3487; Tempst, Paul/0000-0002-6680-3987; Erdjument-Bromage, Hediye/0000-0003-0224-3594				Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; Arcaro A, 1998, J BIOL CHEM, V273, P805, DOI 10.1074/jbc.273.2.805; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; Buchanan FG, 2000, J BIOL CHEM, V275, P9742, DOI 10.1074/jbc.275.13.9742; Condliffe AM, 2000, NATURE, V404, P135, DOI 10.1038/35004693; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Gaffney PRJ, 1997, BIOORG MED CHEM LETT, V7, P3171, DOI 10.1016/S0960-894X(97)10166-4; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Geiszt M, 2001, BIOCHEM J, V355, P851, DOI 10.1042/bj3550851; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Kiyono M, 1999, P NATL ACAD SCI USA, V96, P4826, DOI 10.1073/pnas.96.9.4826; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; LANOTTE M, 1991, BLOOD, V77, P1080; Lemmon MA, 2000, FR MOLEC B, V27, P131; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3; Painter GF, 1999, J CHEM SOC PERK T 1, P923, DOI 10.1039/a900278b; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STERNWEIS PC, 1992, TRENDS BIOCHEM SCI, V17, P502, DOI 10.1016/0968-0004(92)90340-F; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1990, RECEPTOR EFFECTOR CO, P1; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; van der Kaay J, 1998, Methods Mol Biol, V105, P109; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yoshii S, 1999, ONCOGENE, V18, P5680, DOI 10.1038/sj.onc.1202936	48	403	411	1	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	2002	108	6					809	821		10.1016/S0092-8674(02)00663-3	http://dx.doi.org/10.1016/S0092-8674(02)00663-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955434	Bronze			2022-12-28	WOS:000174563000010
J	Strasser, K; Masuda, S; Mason, P; Pfannstiel, J; Oppizzi, M; Rodriguez-Navarro, S; Rondon, AG; Aguilera, A; Struhl, K; Reed, R; Hurt, E				Strasser, K; Masuda, S; Mason, P; Pfannstiel, J; Oppizzi, M; Rodriguez-Navarro, S; Rondon, AG; Aguilera, A; Struhl, K; Reed, R; Hurt, E			TREX is a conserved complex coupling transcription with messenger RNA export	NATURE			English	Article							NUCLEAR EXPORT; SACCHAROMYCES-CEREVISIAE; PROTEIN COMPLEX; YEAST HOMOLOG; IN-VIVO; GENE; ELONGATION; SUB2P; THO2; IDENTIFICATION	The essential yeast proteins Yra1 and Sub2 are messenger RNA export factors that have conserved counterparts in metazoans, designated Aly and UAP56, respectively(1-7). These factors couple the machineries that function in splicing and export of mRNA(1-7). Here we show that both Yra1 and Sub2 are stoichiometrically associated with the heterotetrameric THO complex(8),which functions in transcription in yeast(8-11). We also show that Sub2 and Yra1 interact genetically with all four components of the THO complex (Tho2, Hpr1, Mft1 and Thp2). Moreover, these components operate in the export of bulk poly(A)(+) RNA as well as of mRNA derived from intronless genes. Both Aly and UAP56 associate with human counterparts of the THO complex. Together, these data define a conserved complex, designated the TREX ('transcription/export') complex. The TREX complex is specifically recruited to activated genes during transcription and travels the entire length of the gene with RNA polymerase II. Our data indicate that the TREX complex has a conserved role in coupling transcription to mRNA export.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Heidelberg Univ, BZH, D-69120 Heidelberg, Germany; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Seville, Dept Genet, E-41012 Seville, Spain	Harvard University; Harvard Medical School; Ruprecht Karls University Heidelberg; Harvard University; Harvard Medical School; University of Sevilla	Reed, R (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	Kevin@hms.harvard.edu; rreed@hms.harvard.edu; cg5@ix.urz.uni-heidelberg.de	Aguilera, Andres/L-1825-2014; Rodríguez-Navarro, Susana/B-5182-2014; Ed Hurt, Dr./AAE-8874-2019; Rondon, Ana G/C-2102-2017	Aguilera, Andres/0000-0003-4782-1714; Rodríguez-Navarro, Susana/0000-0001-7472-3111; Ed Hurt, Dr./0000-0002-4535-8255; , Ana/0000-0002-9481-1255; Strasser, Katja/0000-0003-3533-5516				Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Chang MP, 1999, MOL CELL BIOL, V19, P1056; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; Chavez S, 1997, GENE DEV, V11, P3459, DOI 10.1101/gad.11.24.3459; Fan HY, 2001, MOL CELL BIOL, V21, P5459, DOI 10.1128/MCB.21.16.5459-5470.2001; Fleckner J, 1997, GENE DEV, V11, P1864, DOI 10.1101/gad.11.14.1864; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; Kulish D, 2001, MOL CELL BIOL, V21, P4162, DOI 10.1128/MCB.21.13.4162-4168.2001; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Piruat JI, 1998, EMBO J, V17, P4859, DOI 10.1093/emboj/17.16.4859; Piruat JI, 1997, GENETICS, V147, P1585; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Schneiter R, 1999, MOL CELL BIOL, V19, P3415; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; West RW, 2000, GENE, V243, P195, DOI 10.1016/S0378-1119(99)00510-7; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160	25	632	653	1	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 16	2002	417	6886					304	308		10.1038/nature746	http://dx.doi.org/10.1038/nature746			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	551YT	11979277				2022-12-28	WOS:000175592100051
J	Benner, SA; Caraco, MD; Thomson, JM; Gaucher, EA				Benner, SA; Caraco, MD; Thomson, JM; Gaucher, EA			Evolution - Planetary biology - Paleontological, geological, and molecular histories of life	SCIENCE			English	Review							PROTEIN-PROTEIN INTERACTION; HOMOLOGOUS PROTEINS; FUNCTIONAL GENOMICS; DIVERGENCE; PREDICTION; DATABASE; DEHYDROGENASE; DROSOPHILA; INDICATORS; LIKELIHOOD	The history of life on Earth is chronicled in the geological strata, the fossil record, and the genomes of contemporary organisms. When examined together, these records help identify metabolic and regulatory pathways, annotate protein sequences, and identify animal models to develop new drugs, among other features of scientific and biomedical interest. Together, planetary analysis of genome and proteome databases is providing an enhanced understanding of how life interacts with the biosphere and adapts to global change.	Univ Florida, Dept Chem, Gainesville, FL 32611 USA; Univ Florida, Dept Anat & Cell Biol, Gainesville, FL 32611 USA; Univ Florida, Dept Chem, NASA, Astrobiol Inst, Gainesville, FL 32611 USA; Fdn Appl Mol Evolut, Gainesville, FL 32604 USA; ETH Honggerberg, Dept Chem, CH-8093 Zurich, Switzerland	State University System of Florida; University of Florida; State University System of Florida; University of Florida; National Aeronautics & Space Administration (NASA); State University System of Florida; University of Florida; Swiss Federal Institutes of Technology Domain; ETH Zurich	Benner, SA (corresponding author), Univ Florida, Dept Chem, Gainesville, FL 32611 USA.	benner@chem.ufl.edu	Gaucher, Eric/I-7313-2013		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054075] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54075, R01 GM054075-02, R01 GM054075] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M, 1998, BIOESSAYS, V20, P949, DOI 10.1002/(SICI)1521-1878(199811)20:11&lt;949::AID-BIES10&gt;3.0.CO;2-0; AUDETAT SV, 2001, THESIS ETH ZURICH ZU; Ayala FJ, 1999, BIOESSAYS, V21, P71, DOI 10.1002/(SICI)1521-1878(199901)21:1<71::AID-BIES9>3.0.CO;2-B; BAKKER RT, 1978, NATURE, V274, P661, DOI 10.1038/274661a0; BARNARD EA, 1969, NATURE, V221, P340, DOI 10.1038/221340a0; Barrett PM, 2001, BIOL REV, V76, P411, DOI 10.1017/S1464793101005735; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BENNER S, 1988, CRC CR REV BIOCH MOL, V23, P369, DOI 10.3109/10409238809082549; Benner SA, 2000, RES MICROBIOL, V151, P97, DOI 10.1016/S0923-2508(00)00123-6; Benner SA, 1998, ADV ENZYME REGUL, V38, P155, DOI 10.1016/S0065-2571(97)00019-8; BENNER SA, 1991, ADV ENZYME REGUL, V31, P121, DOI 10.1016/0065-2571(91)90012-B; BENNER SA, 1989, ADV ENZYME REGUL, V28, P219, DOI 10.1016/0065-2571(89)90073-3; Benner SA, 2001, TRENDS GENET, V17, P414, DOI 10.1016/S0168-9525(01)02320-4; BERBEE ML, 1993, CAN J BOT, V71, P1114, DOI 10.1139/b93-131; BOWRING SA, 1993, SCIENCE, V261, P1293, DOI 10.1126/science.11539488; CARACO MD, 2001, THESIS ETH ZURICH ZU; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; Chicurel M, 2000, NATURE, V404, P538, DOI 10.1038/35007253; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Dean AM, 1997, P NATL ACAD SCI USA, V94, P3104, DOI 10.1073/pnas.94.7.3104; Dilcher D, 2000, P NATL ACAD SCI USA, V97, P7030, DOI 10.1073/pnas.97.13.7030; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; DORIT RL, 1990, SCIENCE, V250, P1377, DOI 10.1126/science.2255907; Fetrow JS, 1998, J MOL BIOL, V281, P949, DOI 10.1006/jmbi.1998.1993; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gaucher EA, 2001, P NATL ACAD SCI USA, V98, P548, DOI 10.1073/pnas.98.2.548; GAUCHER EA, 2001, THESIS U FLORIDA GAI; GAUCHER EA, IN PRESS TRENDS BIOC; GONNET GH, 1992, SCIENCE, V256, P1443, DOI 10.1126/science.1604319; GRADDY LG, 1999, THESIS U FLORIDA GAI; Hedges SB, 2001, P NATL ACAD SCI USA, V98, P1, DOI 10.1073/pnas.98.1.1; Hegyi H, 2001, GENOME RES, V11, P1632, DOI 10.1101/gr. 183801; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; JERMANN TM, 1995, NATURE, V374, P57, DOI 10.1038/374057a0; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; LEHMAN WP, 1973, HIST LINGUISTICS; LI WH, 1985, MOL BIOL EVOL, V2, P150; Liberles D A, 2001, GENOME BIOL, V2; Liu FGR, 2001, SCIENCE, V291, P1786, DOI 10.1126/science.1056346; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; Marcotte EM, 1999, NATURE, V402, P83, DOI 10.1038/47048; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; MARGULIS L, 1986, ORIGINS LIFE EVOL B, V16, P205, DOI 10.1007/BF02421982; Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; PAULING L, 1963, ACTA CHEM SCAND, V17, P9, DOI 10.3891/acta.chem.scand.17s-0009; Pazos F, 2001, PROTEIN ENG, V14, P609, DOI 10.1093/protein/14.9.609; PEREIRA HS, 1995, GENETICS, V141, P263; Prothero D.R., 1994, EOCENE OLIGOCENE TRA; Riley M, 1997, J MOL BIOL, V268, P857, DOI 10.1006/jmbi.1997.1003; Swofford DL, 1998, PHYLOGENETIC ANAL US; THORNE JL, 1992, J MOL EVOL, V34, P3, DOI 10.1007/BF00163848; Wallis M, 2001, J MOL EVOL, V53, P10, DOI 10.1007/s002390010187; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; Wolfe JA, 1992, EOCENE OLIGOCENE CLI, P421, DOI DOI 10.1515/9781400862924.421; Yang ZH, 1997, COMPUT APPL BIOSCI, V13, P555; Zachos J, 2001, SCIENCE, V292, P686, DOI 10.1126/science.1059412; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	58	77	81	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	2002	296	5569					864	868		10.1126/science.1069863	http://dx.doi.org/10.1126/science.1069863			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988562				2022-12-28	WOS:000175442500031
J	Raff, MC; Whitmore, AV; Finn, JT				Raff, MC; Whitmore, AV; Finn, JT			Neuroscience - Axonal self-destruction and neurodegeneration	SCIENCE			English	Review							SLOW WALLERIAN DEGENERATION; AMYOTROPHIC-LATERAL-SCLEROSIS; PERIPHERAL-NERVE DISEASE; DYING-BACK PROCESS; CELL-DEATH; CYTOSKELETAL PROTEINS; ALZHEIMERS-DISEASE; TRANSECTED NERVES; C57BL/OLA MICE; LOCAL-CONTROL	Neurons seem to have at least two self-destruct programs. Like other cell types, they have an intracellular death program for undergoing apoptosis when they are injured, infected, or not needed. In addition, they apparently have a second, molecularly distinct self-destruct program in their axon. This program is activated when the axon is severed and leads to the rapid degeneration of the isolated part of the cut axon. Do neurons also use this second program to prune their axonal tree during development and to conserve resources in response to chronic insults?.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Cell Biol Unit, London WC1E 6BT, England; UCL, Dept Biol, London WC1E 6BT, England	University of London; University College London; University of London; University College London; University of London; University College London	Raff, MC (corresponding author), UCL, MRC, Mol Cell Biol Lab, Mortimer St, London WC1E 6BT, England.	m.raff@ucl.ac.uk						Azzouz M, 1997, MUSCLE NERVE, V20, P45, DOI 10.1002/(SICI)1097-4598(199701)20:1<45::AID-MUS6>3.0.CO;2-H; Behl C, 2000, J NEURAL TRANSM, V107, P1325, DOI 10.1007/s007020070021; Bergeron L, 1998, CURR OPIN NEUROBIOL, V8, P55, DOI 10.1016/S0959-4388(98)80008-1; Bjartmar C, 2001, CURR OPIN NEUROL, V14, P271, DOI 10.1097/00019052-200106000-00003; Braak H, 1999, NEUROSCI LETT, V265, P67, DOI 10.1016/S0304-3940(99)00208-6; Buki A, 2000, J NEUROSCI, V20, P2825; Burne JF, 1996, J NEUROSCI, V16, P2064; CAMPENOT RB, 1982, DEV BIOL, V93, P13, DOI 10.1016/0012-1606(82)90233-0; CAMPENOT RB, 1994, J NEUROBIOL, V25, P599, DOI 10.1002/neu.480250603; CAVANAGH JB, 1964, INT REV EXP PATHOL, V3, P219; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Coleman MP, 1998, P NATL ACAD SCI USA, V95, P9985, DOI 10.1073/pnas.95.17.9985; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; DECKWERTH TL, 1994, DEV BIOL, V165, P63, DOI 10.1006/dbio.1994.1234; DELAMONTE SM, 1988, ANN NEUROL, V23, P485, DOI 10.1002/ana.410230510; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; FERRI A, COMMUNICATION; Finn JT, 2000, J NEUROSCI, V20, P1333; Gan WB, 1998, SCIENCE, V282, P1508, DOI 10.1126/science.282.5393.1508; GEORGE EB, 1995, J NEUROSCI, V15, P6445; Gibson RM, 2001, BRIT MED J, V322, P1539, DOI 10.1136/bmj.322.7301.1539; Gillingwater TH, 2001, J PHYSIOL-LONDON, V534, P627, DOI 10.1111/j.1469-7793.2001.00627.x; GLASS JD, 1994, J NEUROSCI, V14, P3915; GLASS JD, 1993, J NEUROCYTOL, V22, P311, DOI 10.1007/BF01195555; GLASS JD, 1991, J NEUROSCI, V11, P3146; Griffin JW, 1996, BAILLIERE CLIN NEUR, V5, P65; Heintz N, 2000, ANNU REV PHYSIOL, V62, P779, DOI 10.1146/annurev.physiol.62.1.779; HIRANO A, 1984, J NEUROPATH EXP NEUR, V43, P461, DOI 10.1097/00005072-198409000-00001; Iseki E, 2001, J NEUROL SCI, V185, P129, DOI 10.1016/S0022-510X(01)00481-6; Lee T, 2000, NEURON, V28, P807, DOI 10.1016/S0896-6273(00)00155-0; Li H, 2001, J NEUROSCI, V21, P8473, DOI 10.1523/JNEUROSCI.21-21-08473.2001; Lichtman JW, 2000, NEURON, V25, P269, DOI 10.1016/S0896-6273(00)80893-4; LUNN ER, 1989, EUR J NEUROSCI, V1, P27, DOI 10.1111/j.1460-9568.1989.tb00771.x; LYON MF, 1993, P NATL ACAD SCI USA, V90, P9717, DOI 10.1073/pnas.90.20.9717; Mandelkow EM, 1998, TRENDS CELL BIOL, V8, P425, DOI 10.1016/S0962-8924(98)01368-3; Martin LJ, 2001, INT J MOL MED, V7, P455; NAKAMURA H, 1989, J NEUROSCI, V9, P3776; OLEARY DD, COMMUNICATION; OLEARY DDM, 1993, NEURON, V10, P991, DOI 10.1016/0896-6273(93)90049-W; Osborne NN, 1999, BRIT J OPHTHALMOL, V83, P980, DOI 10.1136/bjo.83.8.980; Pardo CA, 2001, J PERIPHER NERV SYST, V6, P21, DOI 10.1046/j.1529-8027.2001.006001021.x; Parson SH, 1997, EUR J NEUROSCI, V9, P1586, DOI 10.1111/j.1460-9568.1997.tb01516.x; PERRY VH, 1990, EUR J NEUROSCI, V2, P802, DOI 10.1111/j.1460-9568.1990.tb00472.x; Phelan JK, 2000, MOL VIS, V6, P116; Rich T, 1999, NAT CELL BIOL, V1, pE69, DOI 10.1038/11038; SAGOT Y, 1995, J NEUROSCI, V15, P7727; SCHAUMBURG HH, 1974, J NEUROPATH EXP NEUR, V33, P260, DOI 10.1097/00005072-197404000-00006; SCHMALBRUCH H, 1991, J NEUROPATH EXP NEUR, V50, P192, DOI 10.1097/00005072-199105000-00002; SIMA AAF, 1983, ANN NEUROL, V13, P264, DOI 10.1002/ana.410130307; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; TILL GA, 2001, NAT NEUROSCI, V4, P12; TRUMAN JW, 1990, J NEUROBIOL, V21, P1072, DOI 10.1002/neu.480210711; TSAO JW, 1994, EUR J NEUROSCI, V6, P516, DOI 10.1111/j.1460-9568.1994.tb00295.x; Waller A., 1850, PHIL T R SOC, V140, P423, DOI DOI 10.1098/RSTL.1850.0021; WALSH J C, 1970, Proceedings of the Australian Association of Neurologists, V7, P77; Wang NS, 2001, NEUROBIOL DIS, V8, P155; WATSON DF, 1993, J NEUROSCI, V13, P4354	57	515	536	2	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	2002	296	5569					868	871		10.1126/science.1068613	http://dx.doi.org/10.1126/science.1068613			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988563				2022-12-28	WOS:000175442500032
J	Allada, RK; Navrotsky, A; Berbeco, HT; Casey, WH				Allada, RK; Navrotsky, A; Berbeco, HT; Casey, WH			Thermochemistry and aqueous solubilities of hydrotalcite-like solids	SCIENCE			English	Article							PRECIPITATION; IMPREGNATION; CALORIMETRY; SORPTION; PHASES	Hydrotalcites are used in technology as catalysts and anion exchangers and are important sinks for environmental contaminants. Their compositional variability makes it important, but difficult, to estimate their aqueous solubility. We report calorimetric measurements of the heats of formation of cobalt-aluminum hydrotalcite phases. The heat and free energy of formation from the elements are equal to those of mechanical mixtures of binary compounds, namely hydroxides and carbonates. The interlayer anion is much more important than the cation in determining the solubility of the hydrotalcite phase and its ability to contain or release heavy metals to the environment. Because hydrotalcites do not have an unreactive polymer as a structural core, their aqueous stability will change dramatically with composition, particularly with anion content. This simple mechanical mixture model allows prediction of aqueous solubilities and trace metal retention in a variety of geochemical settings.	Univ Calif Davis, Dept Chem Engn & Mat Sci, Thermochem Facil, Davis, CA 95616 USA; Franklin W Olin Coll Engn, Needham, MA 02492 USA; Univ Calif Davis, Dept Geol, Davis, CA 95616 USA; Univ Calif Davis, Dept Land Air & Water Resources, Davis, CA 95616 USA	University of California System; University of California Davis; Franklin W. Olin College of Engineering; University of California System; University of California Davis; University of California System; University of California Davis	Navrotsky, A (corresponding author), Univ Calif Davis, Dept Chem Engn & Mat Sci, Thermochem Facil, Davis, CA 95616 USA.		VIEILLARD, Philippe/B-8544-2008	VIEILLARD, Philippe/0000-0003-0394-7999				Baes C.F., 1976, HYDROLYSIS CATIONS, DOI 10.1002/bbpc.19770810252; Bellotto M, 1996, J PHYS CHEM-US, V100, P8527, DOI 10.1021/jp960039j; Casey WH, 1996, GEOCHIM COSMOCHIM AC, V60, P933, DOI 10.1016/0016-7037(96)00441-3; Cavani F, 1991, CATAL TODAY, V11, P173, DOI 10.1016/0920-5861(91)80068-K; DELACAILLERIE JBD, 1995, J PHYS CHEM-US, V99, P17273; DELACAILLERIE JBD, 1995, J AM CHEM SOC, V117, P11471; KITTRICK J. A., 1971, Proceedings. Soil Science Society of America, V35, P450; KOUD JM, 1990, SCI GEOL, V43, P29; Navrotsky A, 1997, PHYS CHEM MINER, V24, P222, DOI 10.1007/s002690050035; NAVROTSKY A, 1994, AM MINERAL, V79, P1099; ORESKES N, 1994, SCIENCE, V263, P641, DOI 10.1126/science.263.5147.641; ROBIE RA, 1995, USGS B, V2131; Scheidegger AM, 1998, GEOCHIM COSMOCHIM AC, V62, P2233, DOI 10.1016/S0016-7037(98)00136-7; Scheidegger AM, 1997, J COLLOID INTERF SCI, V186, P118, DOI 10.1006/jcis.1996.4624; Thompson HA, 1999, CLAY CLAY MINER, V47, P425, DOI 10.1346/CCMN.1999.0470405; Thompson HA, 1999, GEOCHIM COSMOCHIM AC, V63, P1767, DOI 10.1016/S0016-7037(99)00125-8; Thompson HA, 2000, J COLLOID INTERF SCI, V222, P241, DOI 10.1006/jcis.1999.6631; THOMPSON HA, 1998, THESIS STANFORD U; Towle SN, 1997, J COLLOID INTERF SCI, V187, P62, DOI 10.1006/jcis.1996.4539; Woods TL, 1987, THERMODYNAMIC VALUES	20	112	124	4	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					721	723		10.1126/science.1069797	http://dx.doi.org/10.1126/science.1069797			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976450				2022-12-28	WOS:000175281700050
J	Sawa, A; Snyder, SH				Sawa, A; Snyder, SH			Schizophrenia: Diverse approaches to a complex disease	SCIENCE			English	Review							PREFRONTAL CORTEX; T102C POLYMORPHISM; BIPOLAR DISORDER; GENE-EXPRESSION; SIZE; HIPPOCAMPUS; ASSOCIATION; REELIN; LOCUS	Schizophrenia is a debilitating mental illness that affects 1% of the population, Despite intensive study, its molecular etiology remains enigmatic, Like many common diseases, schizophrenia is multifactorial in origin, with both genetic and environmental contributions likely playing an important rote in the manifestation of symptoms. Recent advances based on pharmacological studies, brain imaging analyses, and genetic research are now converging on tantalizing leads that point to a central role for several neurotransmitters, including dopamine, glutamate, and serotonin, that may interface with neurodevelopmental defects reflecting disease-related genetic aberrations. Here, we provide a brief overview of the parallel approaches being used to identify the molecular causes of schizophrenia and discuss possible directions for future research.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Snyder, SH (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA.				NIDA NIH HHS [DA-00266, DA-00074] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AKBARIAN S, 1995, ARCH GEN PSYCHIAT, V52, P258, DOI 10.1001/archpsyc.1995.03950160008002; Andreasen NC, 1996, NEURON, V16, P697, DOI 10.1016/S0896-6273(00)80090-2; ARNOLD SE, 1995, AM J PSYCHIAT, V152, P738; Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; Bassett AS, 1999, BIOL PSYCHIAT, V46, P882, DOI 10.1016/S0006-3223(99)00114-6; BENES FM, 1991, SCHIZOPHRENIA BULL, V17, P597, DOI 10.1093/schbul/17.4.597; Berrettini WH, 2000, BIOL PSYCHIAT, V48, P531, DOI 10.1016/S0006-3223(00)00883-0; Blouin JL, 1998, NAT GENET, V20, P70, DOI 10.1038/1734; Brzustowicz LM, 2000, SCIENCE, V288, P678, DOI 10.1126/science.288.5466.678; CARLSSON A, 1988, NEUROPSYCHOPHARMACOL, V1, P179, DOI 10.1016/0893-133X(88)90012-7; CREESE I, 1976, SCIENCE, V192, P481, DOI 10.1126/science.3854; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Ekelund J, 2001, HUM MOL GENET, V10, P1611, DOI 10.1093/hmg/10.15.1611; Fatemi SH, 2000, MOL PSYCHIATR, V5, P654, DOI 10.1038/sj.mp.4000783; Goff DC, 2001, AM J PSYCHIAT, V158, P1367, DOI 10.1176/appi.ajp.158.9.1367; GOGOS JA, 1998, P NATL ACAD SCI USA, V95, P1991; Gorelick David A., 1995, P1767; GOTTESMAN II, 1991, SCHIZOPHRENIA GENETI; Guidotti A, 2000, ARCH GEN PSYCHIAT, V57, P1061, DOI 10.1001/archpsyc.57.11.1061; Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593; JOHNSTONE EC, 1976, LANCET, V2, P924; Karlsson H, 2001, P NATL ACAD SCI USA, V98, P4634, DOI 10.1073/pnas.061021998; Levinson DF, 2002, SCIENCE, V296, P739, DOI 10.1126/science.1069914; Meltzer Herbert Y., 1995, P1277; Millar JK, 2000, HUM MOL GENET, V9, P1415, DOI 10.1093/hmg/9.9.1415; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Mohn AR, 1999, CELL, V98, P427, DOI 10.1016/S0092-8674(00)81972-8; MURPHY KC, 1999, ARCH GEN PSYCHIAT, V56, P9940; Rajkowska G, 1998, ARCH GEN PSYCHIAT, V55, P215, DOI 10.1001/archpsyc.55.3.215; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; STRAUB RE, 1995, NAT GENET, V11, P287, DOI 10.1038/ng1195-287; WEINBERGER DR, 1979, ARCH GEN PSYCHIAT, V36, P735; Williams J, 1996, LANCET, V347, P1294, DOI 10.1016/S0140-6736(96)90939-3; Williams J, 1997, LANCET, V349, P1221, DOI 10.1016/S0140-6736(05)62413-0	34	423	444	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					692	695		10.1126/science.1070532	http://dx.doi.org/10.1126/science.1070532			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976442				2022-12-28	WOS:000175281700041
J	Ji, Q; Luo, ZX; Yuan, CX; Wible, JR; Zhang, JP; Georgi, JA				Ji, Q; Luo, ZX; Yuan, CX; Wible, JR; Zhang, JP; Georgi, JA			The earliest known eutherian mammal	NATURE			English	Article							MONGOLIA; EVOLUTION; PHYLOGENY; TREE	The skeleton of a eutherian (placental) mammal has been discovered from the Lower Cretaceous Yixian Formation of northeastern China. We estimate its age to be about 125 million years (Myr), extending the date of the oldest eutherian records with skull and skeleton by about 40-50 Myr. Our analyses place the new fossil at the root of the eutherian tree and among the four other known Early Cretaceous eutherians, and suggest an earlier and greater diversification of stem eutherians that occurred well before the molecular estimate for the diversification of extant placental superorders (104-64 Myr). The new eutherian has limb and foot features that are known only from scansorial (climbing) and arboreal (tree-living) extant mammals, in contrast to the terrestrial or cursorial (running) features of other Cretaceous eutherians. This suggests that the earliest eutherian lineages developed different locomotory adaptations, facilitating their spread to diverse niches in the Cretaceous.	Carnegie Museum Nat Hist, Pittsburgh, PA 15213 USA; Chinese Acad Geol Sci, Beijing 100037, Peoples R China; Geosci Univ China, Beijing 100083, Peoples R China	Chinese Academy of Geological Sciences; China University of Geosciences	Luo, ZX (corresponding author), Carnegie Museum Nat Hist, 4400 Forbes Ave, Pittsburgh, PA 15213 USA.		Luo, Zhe-XI/AAU-2263-2021					Archibald JD, 2001, NATURE, V414, P62, DOI 10.1038/35102048; Argot C, 2001, J MORPHOL, V247, P51, DOI 10.1002/1097-4687(200101)247:1<51::AID-JMOR1003>3.0.CO;2-#; Averianov A, 2000, LETHAIA, V33, P330, DOI 10.1080/002411600750053899; Averianov AO, 2001, ACTA PALAEONTOL POL, V46, P431; BEARD KC, 1992, PRIMATES THEIR RELAT, P63; Cifelli Richard L., 1997, Journal of Mammalian Evolution, V4, P241, DOI 10.1023/A:1027394430433; Cifelli RL, 1999, NATURE, V401, P363, DOI 10.1038/43861; de Muizon Christian, 1998, Geodiversitas, V20, P19; Eizirik E, 2001, J HERED, V92, P212, DOI 10.1093/jhered/92.2.212; Foote M, 1999, SCIENCE, V283, P1310, DOI 10.1126/science.283.5406.1310; GEE H, 2001, RISE DRAGON READINGS, P1; GRADSTEIN FM, 1995, SEPM SPEC PUBL, V54, P95; Horovitz I, 2000, J VERTEBR PALEONTOL, V20, P547, DOI 10.1671/0272-4634(2000)020[0547:TTOUNE]2.0.CO;2; Hu YM, 1997, NATURE, V390, P137, DOI 10.1038/36505; HU YM, 1998, VERT PALASIATIC, V38, P102; Jenkins F.A. Jr., 1974, P85; Ji Q, 1999, NATURE, V398, P326; Kielan-Jaworowska Z., 1977, Palaeontologia Polonica, V37, P65; Kielan-Jaworowska Z., 1978, PALAEONTOLOGICA POLO, V38, P5; Kielan-Jaworowska Z, 1981, PALAEONTOLOGIA POLON, V42, P25; Kielan-Jaworowska Zofia, 1994, Fossils and Strata, V36, P1; KIELANJAWOROWSKA Z, 1989, ZOOL SCR, V18, P347, DOI 10.1111/j.1463-6409.1989.tb00460.x; KRAUSE D W, 1983, Bulletin of the Museum of Comparative Zoology, V150, P199; Krebs B., 1991, Berliner Geowissenschaftliche Abhandlungen Reihe A Geologie und Palaeontologie, V133, P1; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Loope DB, 1998, GEOLOGY, V26, P27, DOI 10.1130/0091-7613(1998)026<0027:LADIAL>2.3.CO;2; Luo ZX, 2002, ACTA PALAEONTOL POL, V47, P1; Luo ZX, 2001, NATURE, V409, P53, DOI 10.1038/35051023; McKenna M.C., 1997, CLASSIFICATION MAMMA, P1; McKenna MC, 2000, ACTA PALAEONTOL POL, V45, P1; MCLEOD N, 1993, AM J SCI, V293, P300; Meng J, 1997, NATURE, V385, P712, DOI 10.1038/385712a0; Murphy WJ, 2001, SCIENCE, V294, P2348, DOI 10.1126/science.1067179; Nessov Lev A., 1998, Bulletin of Carnegie Museum of Natural History, V34, P40; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Novacek MJ, 1997, NATURE, V389, P483, DOI 10.1038/39020; Rich TH, 1997, SCIENCE, V278, P1438, DOI 10.1126/science.278.5342.1438; Rich Thomas H., 2001, Records of the Queen Victoria Museum, V110, P1; Rougier GW, 1998, NATURE, V396, P459, DOI 10.1038/24856; ROUGIER GW, 1993, THESIS U NAC BUENOS; Rowe T., 1988, Journal of Vertebrate Paleontology, V8, P241; Schilling N, 1999, Z SAUGETIERKD, V64, P129; SIGOGNEAURUSSELL D, 1992, ZOOL SCR, V21, P205, DOI 10.1111/j.1463-6409.1992.tb00322.x; Swisher CC, 1999, NATURE, V400, P58, DOI 10.1038/21872; Szalay FS, 1996, J VERTEBR PALEONTOL, V16, P474, DOI 10.1080/02724634.1996.10011335; Szalay FS, 1994, EVOLUTIONARY HIST MA, P1; Szalay FS., 1996, NEW MEX MUS NAT HIST, V7, P1; Wang YQ, 2001, SCIENCE, V294, P357, DOI 10.1126/science.1063830; [No title captured]; [No title captured]	50	345	393	7	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					816	822		10.1038/416816a	http://dx.doi.org/10.1038/416816a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976675				2022-12-28	WOS:000175163800043
J	Tu, HT; Reschovsky, JD				Tu, HT; Reschovsky, JD			Assessments of medical care by enrollees in for-profit and nonprofit health maintenance organizations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PEOPLE	Background: It is uncertain how assessments of medical care differ between enrollees in for-profit and nonprofit health maintenance organizations (HMOs). Methods: We analyzed the relation between the profit status of HMOs and enrollees' assessments of their care. We used data from two national surveys from the Community Tracking Study: the Household Survey, 1996-1997, and the 1997-1998 Insurance Followback Survey. The final sample included 13,271 persons under 65 years of age (10,654 adults and 2617 children) with employer-sponsored insurance who obtained health care through an HMO. A total of 12,445 enrollees who reported their health status as excellent, very good, or good were considered to be healthy; 826 with self-reported fair or poor health were considered to be sick. Results: In the sample as a whole, enrollees in nonprofit plans were more likely to be very satisfied with their overall care than enrollees in for-profit plans (adjusted means, 64.0 percent and 58.1 percent, respectively; P=0.01). Among enrollees in for-profit HMOs, sick enrollees were more likely than healthy enrollees to report unmet need or delayed care (17.4 percent vs. 13.1 percent, P=0.004) and organizational or administrative barriers to care (12.9 percent vs. 9.0 percent, P<0.001); they also reported higher out-of-pocket spending during the previous year ($731 vs. $480, P=0.002). For nonprofit HMOs, there was only one significant difference between the ratings of healthy and sick enrollees; sick enrollees expressed more trust in doctors to refer when needed. Conclusions: Although there are few overall differences in assessments of medical care between enrollees in for-profit and nonprofit HMOs, for-profit HMOs are rated less favorably than nonprofit HMOs by patients who have self-reported fair or poor health.	Ctr Studying Hlth Syst Change, Washington, DC 20024 USA		Tu, HT (corresponding author), Ctr Studying Hlth Syst Change, 600 Maryland Ave SW,Ste 550, Washington, DC 20024 USA.							Born P, 1998, J Health Care Finance, V24, P65; Born PH, 2001, HEALTH AFFAIR, V20, P167, DOI 10.1377/hlthaff.20.2.167; Cox BG, 1980, P SURV RES METH SECT, P721; *CTR STUD HLTH SYS, 1999, TECHN PUBL CTR STUD, V17; Cunningham PJ, 2001, HEALTH AFFAIR, V20, P159, DOI 10.1377/hlthaff.20.2.159; DONELAN K, 2000, MED GEN MED, P2; DUAN N, 1983, J AM STAT ASSOC, V78, P605, DOI 10.2307/2288126; Fein R, 1999, J HEALTH POLIT POLIC, V24, P985; Garfinkel S A, 1988, Health Care Financ Rev, V9, P41; Hasan MM, 1996, NEW ENGL J MED, V334, P1055, DOI 10.1056/NEJM199604183341610; Himmelstein DU, 1999, JAMA-J AM MED ASSOC, V282, P159, DOI 10.1001/jama.282.2.159; *INT, 1998, INT COMP EDG 8 1 1; *INT HMO, 1998, INT HMO TREND REP 19; Kemper P, 1996, INQUIRY-J HEALTH CAR, V33, P195; Kuttner R, 1998, NEW ENGL J MED, V338, P1558, DOI 10.1056/NEJM199805213382123; Landon BE, 2001, HEALTH AFFAIR, V20, P274, DOI 10.1377/hlthaff.20.2.274; METCALF CE, 1996, SITE DEFINITION SAMP; Nelson DE, 2000, AM J PUBLIC HEALTH, V90, P924, DOI 10.2105/AJPH.90.6.924; NELSON H, 1997, NONPROFIT FOR PROFIT; Nudelman PM, 1996, NEW ENGL J MED, V334, P1057, DOI 10.1056/NEJM199604183341611; Reschovsky JD, 1999, INQUIRY-J HEALTH CAR, V36, P378; RESCHOVSKY JD, 2000, LTH CARE PERCEPTIONS; Shah BV, 1996, SUDAAN USERS MANUAL; STROUSE R, 1998, 8519940 MPR; Thorpe KE, 1999, J HEALTH POLIT POLIC, V24, P949; WARE JE, 1995, SF 12 HOW SCORE SF 1; Wynn P, 1996, Manag Care, V5, P23	27	28	28	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1288	1293		10.1056/NEJMsa011250	http://dx.doi.org/10.1056/NEJMsa011250			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	544GX	11973366				2022-12-28	WOS:000175150800006
J	Tinetti, ME; Baker, D; Gallo, WT; Nanda, A; Charpentier, P; O'Leary, J				Tinetti, ME; Baker, D; Gallo, WT; Nanda, A; Charpentier, P; O'Leary, J			Evaluation of restorative care vs usual care for older adults receiving an acute episode of home care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MINIMUM DATA SET; ELDERLY-PATIENTS; FUNCTIONAL DECLINE; BRAIN-INJURY; HEALTH-CARE; INTERVENTION; MANAGEMENT; PROGRAM; PEOPLE; HOSPITALIZATION	Context Illness and hospitalization often trigger functional decline among older persons. Home care services implemented for functional decline provide an opportunity, to intervene to improve outcomes. Objective To compare functional status and the likelihood of remaining at home for persons receiving restorative care vs usual home care. Design and Setting Intervention using prospective individual matching conducted between November 1, 1998, and April 30, 2000. Six offices of a home care agency in Connecticut were used. One branch office served as the restorative care unit and the other 5 served as usual care offices. Participants Patients receiving home care through the restorative care office who were 65 years or older; in receipt of Medicare-covered home care lasting at beast 7 days; with absence of severe cognitive impairment; and not terminal, bedridden, or requiring total care were matched with patients from 1 of the usual care offices. The matching factors included age, sex, race, baseline self-care function, cognitive status, whether hospitalization preceded the home care episode, and date of the home care episode. Of the 712 eligible restorative care patients, 691 (97%) were matched with a usual care patient. Intervention Restorative care, provided by the home care agency nursing, therapy, and home health aide staff, was based on principles from geriatric medicine., nursing, rehabilitation, and goal attainment. Main Outcome Measures Remaining at home, functional status at completion of the home care episode, and duration and intensity of home care episode. Results Compared with usual care, and after adjusting for baseline characteristics and other factors, restorative care was associated with a greater likelihood of remaining at home (82% vs 71%; odds ratio [OR], 1.99; 95% confidence interval [CI], 1.47-2.69) and a reduced likelihood of visiting an emergency department (10% vs 20%; OR, 0.44; 95% CI, 0.32-0.61). Home care episodes were shorter (mean [SD], 24.8 [26.8] days vs 34.3 [44.2] days; S = -17821; P<.001). Restorative care patients had better mean (SD) scores than usual care patients in self-care (11.0 [2.1] vs 10.7 [2.5]; P=.07 after adjustment), home management (9.5 [2.9] vs 9.2 [3.0]; P=.05 after adjustment), and mobility (3.3 [0.8] vs 3.2 [0.9]; P=.02 after adjustment). Conclusions This trial suggests that reorganizing the structure and goals of home care can enhance health outcomes of older patients without increasing health care utilization.	Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Yale University; Yale University	Tinetti, ME (corresponding author), 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	mary.tinetti@yale.edu		Nanda, Aman/0000-0002-3860-3267	NIA NIH HHS [AG10469] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P60AG010469] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMS CE, 1995, J NURS ADMIN, V25, P27, DOI 10.1097/00005110-199509000-00007; Baker DI, 2001, GERONTOLOGIST, V41, P257, DOI 10.1093/geront/41.2.257; Bernabei R, 1998, JAMA-J AM MED ASSOC, V279, P1877, DOI 10.1001/jama.279.23.1877; Bradley EH, 1999, SOC SCI MED, V49, P267, DOI 10.1016/S0277-9536(99)00107-0; Burrows AB, 2000, AGE AGEING, V29, P165, DOI 10.1093/ageing/29.2.165; CRISLER KS, 1994, STUDY DEV OUTCOME BA, V1; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; Eng C, 1997, J AM GERIATR SOC, V45, P223, DOI 10.1111/j.1532-5415.1997.tb04513.x; FEINSTEIN AR, 2002, PRINCIPLES MED STAT, P417; Ferrucci L, 1997, JAMA-J AM MED ASSOC, V277, P728; Fried LP, 1997, J AM GERIATR SOC, V45, P92, DOI 10.1111/j.1532-5415.1997.tb00986.x; Gill TM, 1999, J GERONTOL A-BIOL, V54, pM377, DOI 10.1093/gerona/54.7.M377; GILLICK MR, 1982, SOC SCI MED, V16, P1033, DOI 10.1016/0277-9536(82)90175-7; Graney MJ, 2000, GERONTOLOGIST, V40, P582, DOI 10.1093/geront/40.5.582; Gruber-Baldini AL, 2000, J AM GERIATR SOC, V48, P1601, DOI 10.1111/j.1532-5415.2000.tb03870.x; HOLFORD TR, 1989, AM J EPIDEMIOL, V130, P1247, DOI 10.1093/oxfordjournals.aje.a115453; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; JOYCE BM, 1994, AM J PHYS MED REHAB, V73, P10, DOI 10.1097/00002060-199473010-00003; KANE RL, 1994, HEALTH CARE FINANC R, V16, P131; KOCH M, 1994, PHYS THER, V74, P286, DOI 10.1093/ptj/74.4.286; KRAVITZ RL, 1994, J AM GERIATR SOC, V42, P1229, DOI 10.1111/j.1532-5415.1994.tb06502.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Leff B, 1999, J AM GERIATR SOC, V47, P697, DOI 10.1111/j.1532-5415.1999.tb01592.x; Lorig K, 1993, GENERATIONS, V3, P11; Madigan E A, 2000, Home Health Care Serv Q, V18, P49; Makuch RW, 1998, STAT MED, V17, P1517, DOI 10.1002/(SICI)1097-0258(19980715)17:13<1517::AID-SIM859>3.0.CO;2-0; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; McCurren C, 1999, APPL NURS RES, V12, P185, DOI 10.1016/S0897-1897(99)80249-3; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; PROCHASKA JO, 1991, CANCER-AM CANCER SOC, V67, P805, DOI 10.1002/1097-0142(19910201)67:3+<805::AID-CNCR2820671409>3.0.CO;2-4; PRYOR GA, 1988, LANCET, V1, P401; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; ROCKWOOD K, 1993, J CLIN EPIDEMIOL, V46, P1113, DOI 10.1016/0895-4356(93)90110-M; Sager MA, 1996, J AM GERIATR SOC, V44, P251, DOI 10.1111/j.1532-5415.1996.tb00910.x; Shaughnessy PW, 1997, MED CARE, V35, P1225, DOI 10.1097/00005650-199712000-00007; Siu AL, 1996, ARCH INTERN MED, V156, P76, DOI 10.1001/archinte.156.1.76; SOLOMON DH, 1993, J AM GERIATR SOC, V41, P961, DOI 10.1111/j.1532-5415.1993.tb06762.x; Stessman J, 1996, J AM GERIATR SOC, V44, P591; Stinemann MG, 2000, J AM GERIATR SOC, V48, P1734, DOI 10.1111/j.1532-5415.2000.tb03893.x; Tinetti ME, 1999, ARCH PHYS MED REHAB, V80, P916, DOI 10.1016/S0003-9993(99)90083-7; Tinetti ME, 1997, ARCH PHYS MED REHAB, V78, P1237, DOI 10.1016/S0003-9993(97)90338-5; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; VLADECK BC, 1994, HEALTH CARE FINANC R, V16, P7; Von Korff M, 1997, ANN INTERN MED, V127, P1097, DOI 10.7326/0003-4819-127-12-199712150-00008	45	99	99	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2002	287	16					2098	2105		10.1001/jama.287.16.2098	http://dx.doi.org/10.1001/jama.287.16.2098			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	542ZK	11966384	Bronze			2022-12-28	WOS:000175075700027
J	Young, JM; Glasziou, P; Ward, JE				Young, JM; Glasziou, P; Ward, JE			General practitioners' self ratings of skills in evidence based medicine: validation study	BRITISH MEDICAL JOURNAL			English	Article								To practise evidence based medicine, clinicians need to understand and use terms such as "relative risk reduction," "absolute risk reduction," and "number needed to treat:" Self ratings represent one method of assessing competence ill these skills. About a third of clinicians claim to understand such terms.(2) We evaluated the validity of self ratings and conducted a blinded validation in general practice.	Cent Sydney Area Hlth Serv, Needs Assessment & Hlth Outcomes Unit, Camperdown, NSW 2050, Australia; Univ Queensland, Sch Populat Hlth, Brisbane, Qld 4006, Australia; S Western Sydney Area Hlth Serv, Div Populat Hlth, Liverpool, NSW 2170, Australia	University of Queensland	Young, JM (corresponding author), Cent Sydney Area Hlth Serv, Needs Assessment & Hlth Outcomes Unit, Camperdown, NSW 2050, Australia.		Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X				AHMED T, 1995, MED J AUSTRALIA, V163, P60, DOI 10.5694/j.1326-5377.1995.tb126112.x; Cranney M, 1996, BRIT J GEN PRACT, V46, P661; Hyde C, 2000, SYSTEMATIC REV EFFEC; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; Sackett D. L., 1998, EVIDENCE BASED MED P	5	99	101	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 20	2002	324	7343					950	+		10.1136/bmj.324.7343.950	http://dx.doi.org/10.1136/bmj.324.7343.950			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544UF	11964341	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000175179500018
J	Pennisi, E				Pennisi, E			Primate evolution - Gene activity clocks brain's fast evolution	SCIENCE			English	News Item																			0	8	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					233	+		10.1126/science.296.5566.233	http://dx.doi.org/10.1126/science.296.5566.233			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951006				2022-12-28	WOS:000175000300006
J	Reich, JG				Reich, JG			Embryonic stem cells - The debate in Germany	SCIENCE			English	Editorial Material									Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Reich, JG (corresponding author), Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany.								0	4	4	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					265	265		10.1126/science.1070574	http://dx.doi.org/10.1126/science.1070574			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951019				2022-12-28	WOS:000175000300028
J	Fitze, G; Cramer, J; Ziegler, A; Schierz, M; Schreiber, M; Kuhlisch, E; Roesner, D; Schackert, HK				Fitze, G; Cramer, J; Ziegler, A; Schierz, M; Schreiber, M; Kuhlisch, E; Roesner, D; Schackert, HK			Association between c135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease	LANCET			English	Article							TOTAL COLONIC AGANGLIONOSIS; MULTIGENIC INHERITANCE; MISSENSE MUTATION; LONG ARM; PROTOONCOGENE; GENE; HETEROZYGOSITY; POLYMORPHISMS; CHROMOSOME-10; EXPRESSION	Background Several genes, including the major susceptibility gene RET, have roles in development of Hirschsprung's disease. Results of genetic-linkage analysis of patients with familial disease with both long-segment and short-segment phenotypes have shown close linkage with the RET locus. We aimed to investigate whether both RET mutations and polymorphisms contribute to phenotype of Hirschsprung's disease. Methods We looked at the coding region of all 21 exons of the RET proto-oncogene, including the flanking intronic sequences, by direct DNA sequencing in 76 caucasians from Germany with Hirschsprung's disease. Findings 20 different mutations were detected in 18 patients. Mutations were under-represented in patients with a homozygous RET c135A/A genotype in association with short-segment phenotype. Short-segment phenotype also arose if the RET mutation was on the c135A allele; conversely, a RET germline mutation on the c135G allele resulted in long-segment phenotype, particularly in heterozygous c135G/A patients. Interpretation These observations lend support to the idea that both RET alleles have a role in pathogenesis of Hirschsprung's disease, in a dose-dependent fashion. We also showed that the c135G/A polymorphism modifies the phenotype by a within-gene interaction between the c135A variant and a mutation.	Dresden Univ Technol, Dept Paediat Surg, D-01307 Dresden, Germany; Med Univ Lubeck, Inst Med Biometry & Stat, D-23538 Lubeck, Germany; Univ Erlangen Nurnberg, Dept Paediat Surg, Erlangen, Germany; Dresden Univ Technol, Dept Surg Res, D-8027 Dresden, Germany; Dresden Univ Technol, Inst Med Informat & Biometry, D-8027 Dresden, Germany	Technische Universitat Dresden; University of Lubeck; University of Erlangen Nuremberg; Technische Universitat Dresden; Technische Universitat Dresden	Fitze, G (corresponding author), Dresden Univ Technol, Dept Paediat Surg, Fetscherstr 74, D-01307 Dresden, Germany.		Ziegler, Andreas/G-4246-2012	Ziegler, Andreas/0000-0002-8386-5397				Amiel J, 1996, HUM MOL GENET, V5, P355, DOI 10.1093/hmg/5.3.355; Angrist M, 1996, NAT GENET, V14, P341, DOI 10.1038/ng1196-341; ATTIE T, 1995, HUM MOL GENET, V4, P1381, DOI 10.1093/hmg/4.8.1381; Auricchio A, 1999, AM J HUM GENET, V64, P1216, DOI 10.1086/302329; BADNER JA, 1990, AM J HUM GENET, V46, P568; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; Bolk S, 2000, P NATL ACAD SCI USA, V97, P268, DOI 10.1073/pnas.97.1.268; Borrego S, 1998, J CLIN ENDOCR METAB, V83, P3361, DOI 10.1210/jc.83.9.3361; Borrego S, 1999, J MED GENET, V36, P771, DOI 10.1136/jmg.36.10.771; Borrego S, 2000, J MED GENET, V37, P572, DOI 10.1136/jmg.37.8.572; BUCHIN PJ, 1986, J CLIN GASTROENTEROL, V8, P111, DOI 10.1097/00004836-198604000-00002; CECCHERINI I, 1994, ONCOGENE, V9, P3025; Cosma MP, 1998, MOL CELL BIOL, V18, P3321, DOI 10.1128/MCB.18.6.3321; Doray B, 1998, HUM MOL GENET, V7, P1449, DOI 10.1093/hmg/7.9.1449; Fitze G, 1999, AM J HUM GENET, V65, P1469, DOI 10.1086/302618; Geneste O, 1999, HUM MOL GENET, V8, P1989, DOI 10.1093/hmg/8.11.1989; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Inoue K, 2000, AM J MED GENET, V93, P278, DOI 10.1002/1096-8628(20000814)93:4<278::AID-AJMG5>3.0.CO;2-Q; LYONNET S, 1993, NAT GENET, V4, P346, DOI 10.1038/ng0893-346; MARTUCCIELLO G, 1992, PEDIATR SURG INT, V7, P308; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, HUM MOL GENET, V3, P2163, DOI 10.1093/hmg/3.12.2163; Onochie CI, 2000, J MED GENET, V37, P674, DOI 10.1136/jmg.37.9.674; PASINI B, 1995, NAT GENET, V10, P35, DOI 10.1038/ng0595-35; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Seri M, 1997, HUM MUTAT, V9, P243; Svensson PJ, 1998, CLIN GENET, V54, P39; Vladutiu GD, 2001, MOL GENET METAB, V74, P51, DOI 10.1006/mgme.2001.3240; Vockley J, 2000, MOL GENET METAB, V71, P10, DOI 10.1006/mgme.2000.3066; Wakamatsu N, 2001, NAT GENET, V27, P369, DOI 10.1038/86860	35	88	100	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1200	1205		10.1016/S0140-6736(02)08218-1	http://dx.doi.org/10.1016/S0140-6736(02)08218-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955539				2022-12-28	WOS:000174846300011
J	van de Wetering, M; de Lau, W; Clevers, H				van de Wetering, M; de Lau, W; Clevers, H			WNT signaling and lymphocyte development	CELL			English	Review							TCR-ALPHA ENHANCER; TRANSCRIPTION FACTOR LEF-1; T-CELL DEVELOPMENT; BETA-CATENIN; HMG-BOX; THYMOCYTE DEVELOPMENT; FACTOR-I; FUNCTIONAL INTERACTION; NUCLEAR-LOCALIZATION; NEGATIVE REGULATOR	Developmental studies in model organisms have revealed that cell fate decisions are governed by only a handful of highly conserved signal transduction cascades. Recent data indicate that at least two of these, the Wnt and the Notch cascades, have been recruited by the vertebrate immune system to control early lymphopoiesis.	UMC Utrecht, Dept Immunol, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Clevers, H (corresponding author), UMC Utrecht, Dept Immunol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Barker N, 2000, ADV CANCER RES, V77, P1; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brannon M, 1999, DEVELOPMENT, V126, P3159; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; DOOIJES D, 1993, J BIOL CHEM, V268, P24813; Galceran J, 2000, DEVELOPMENT, V127, P469; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Graham TA, 2001, NAT STRUCT BIOL, V8, P1048, DOI 10.1038/nsb718; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Hattori N, 1996, J EXP MED, V184, P1137, DOI 10.1084/jem.184.3.1137; Held W, 1999, IMMUNITY, V11, P433, DOI 10.1016/S1074-7613(00)80118-1; Hovanes K, 2000, NUCLEIC ACIDS RES, V28, P1994, DOI 10.1093/nar/28.9.1994; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; LAUDET V, 1993, NUCLEIC ACIDS RES, V21, P2493, DOI 10.1093/nar/21.10.2493; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; OOSTERWEGEL M, 1991, J EXP MED, V173, P1133, DOI 10.1084/jem.173.5.1133; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Poy F, 2001, NAT STRUCT BIOL, V8, P1053, DOI 10.1038/nsb720; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Schilham MW, 1998, J IMMUNOL, V161, P3984; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; Smalley MJ, 1999, EMBO J, V18, P2823, DOI 10.1093/emboj/18.10.2823; Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521-4141(200101)31:1<285::AID-IMMU285>3.3.CO;2-4; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; van Beest M, 2000, J BIOL CHEM, V275, P27266; VANDEWETERING M, 1992, J BIOL CHEM, V267, P8530; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110	65	106	110	1	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR	2002	109			S			S13	S19		10.1016/S0092-8674(02)00709-2	http://dx.doi.org/10.1016/S0092-8674(02)00709-2			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	544UY	11983149	Bronze			2022-12-28	WOS:000175181100002
J	Urizar, NL; Liverman, AB; Dodds, DT; Silva, FV; Ordentlich, P; Yan, YZ; Gonzalez, FJ; Heyman, RA; Mangelsdorf, DJ; Moore, DD				Urizar, NL; Liverman, AB; Dodds, DT; Silva, FV; Ordentlich, P; Yan, YZ; Gonzalez, FJ; Heyman, RA; Mangelsdorf, DJ; Moore, DD			A natural product that lowers cholesterol as an antagonist ligand for FXR	SCIENCE			English	Article							ST JOHNS WORT; NUCLEAR RECEPTOR; BILE-ACID; COMMIPHORA-MUKUL; TARGETED DISRUPTION; ENZYME-INDUCTION; PROTEIN GENE; IDENTIFICATION; ACTIVATION; MICE	Extracts of the resin of the guggul tree (Commiphora mukul) tower LDL (low-density lipoprotein) cholesterol levels in humans. The plant sterol guggul-sterone [4,17(20)-pregnadiene-3,16-dione] is the active agent in this extract. We show that guggulsterone is a highly efficacious antagonist of the farnesoid X receptor (FXR), a nuclear hormone receptor that is activated by bile acids. Guggulsterone treatment decreases hepatic cholesterol in wild-type mice fed a high-cholesterol diet but is not effective in FXR-null mice. Thus, we propose that inhibition of FXR activation is the basis for the cholesterol-lowering activity of guggulsterone. Other natural products with specific biologic effects may modulate the activity of FXR or other relatively promiscuous nuclear hormone receptors.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; X Ceptor Therapeut Inc, San Diego, CA 92121 USA; NCI, Lab Metab, Ctr Canc Res, Bethesda, MD 20892 USA	Baylor College of Medicine; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Moore, DD (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	moore@bcm.tmc.edu		Mangelsdorf, David/0000-0002-4355-0796; Valentin, Frank/0000-0003-3502-7097				ALLAIN CC, 1974, CLIN CHEM, V20, P470; BACHS L, 1992, GASTROENTEROLOGY, V102, P2077, DOI 10.1016/0016-5085(92)90335-V; CARLSON SE, 1977, CLIN CHIM ACTA, V79, P575, DOI 10.1016/0009-8981(77)90178-4; Chander R, 1996, PHYTOTHER RES, V10, P508, DOI 10.1002/(SICI)1099-1573(199609)10:6&lt;508::AID-PTR895&gt;3.0.CO;2-P; Cheema SK, 2000, J BIOL CHEM, V275, P12530, DOI 10.1074/jbc.275.17.12530; Crestani M, 1996, BIOCHEM BIOPH RES CO, V225, P585, DOI 10.1006/bbrc.1996.1215; Cummings DE, 1996, NATURE, V382, P622, DOI 10.1038/382622a0; Dev S, 1999, ENVIRON HEALTH PERSP, V107, P783, DOI 10.2307/3454574; ENAT R, 1984, P NATL ACAD SCI-BIOL, V81, P1411, DOI 10.1073/pnas.81.5.1411; FEELY J, 1983, BRIT J CLIN PHARMACO, V16, P195, DOI 10.1111/j.1365-2125.1983.tb04986.x; FOLCH J, 1957, J BIOL CHEM, V226, P497; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Howard WR, 2000, TOXICOL APPL PHARM, V163, P195, DOI 10.1006/taap.1999.8869; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Nityanand S, 1989, J Assoc Physicians India, V37, P323; OHNHAUS EE, 1979, CLIN PHARMACOL THER, V25, P591; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; SATYAVATI GV, 1988, INDIAN J MED RES, V87, P327; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; SINGH RB, 1994, CARDIOVASC DRUG THER, V8, P659, DOI 10.1007/BF00877420; Staudinger J, 2001, DRUG METAB DISPOS, V29, P1467; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Urizar NL, 2000, J BIOL CHEM, V275, P39313, DOI 10.1074/jbc.M007998200; VONBERGMANN K, 1981, ANTIMICROB AGENTS CH, V19, P342, DOI 10.1128/AAC.19.2.342; Wang DP, 1996, J LIPID RES, V37, P1831; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wentworth JM, 2000, J ENDOCRINOL, V166, pR11, DOI 10.1677/joe.0.166R011; WILLIAMS GM, 1982, MUTAT RES, V97, P359, DOI 10.1016/0165-1161(82)90003-6; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	39	385	441	2	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 31	2002	296	5573					1703	1706		10.1126/science.1072891	http://dx.doi.org/10.1126/science.1072891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	558PR	11988537				2022-12-28	WOS:000175976200064
J	Steinhardt, PJ; Turok, N				Steinhardt, PJ; Turok, N			A cyclic model of the universe	SCIENCE			English	Article							INFLATIONARY UNIVERSE; STATE; PERTURBATIONS; SUPERNOVAE; COSMOLOGY; EQUATION; FLATNESS; DYNAMICS; SCENARIO; HORIZON	We propose a cosmological model in which the universe undergoes an endless sequence of cosmic epochs that begin with a "bang" and end in a "crunch." Temperature and density at the transition remain finite. Instead of having an inflationary epoch, each cycle includes a period of slow accelerated expansion (as recently observed) followed by contraction that produces the homogeneity, flatness, and energy needed to begin the next cycle.	Princeton Univ, Joseph Henry Labs, Princeton, NJ 08544 USA; Ctr Math Sci, Dept Appl Math & Theoret Phys, Cambridge CB3 0WA, England	Princeton University; University of Cambridge	Steinhardt, PJ (corresponding author), Princeton Univ, Joseph Henry Labs, Princeton, NJ 08544 USA.	steinh@princeton.edu		Steinhardt, Paul/0000-0003-3488-1603				ALBRECHT A, 1982, PHYS REV LETT, V48, P1220, DOI 10.1103/PhysRevLett.48.1220; Bahcall NA, 1999, SCIENCE, V284, P1481, DOI 10.1126/science.284.5419.1481; BARDEEN JM, 1983, PHYS REV D, V28, P679, DOI 10.1103/PhysRevD.28.679; CALDWELL R, 2001, SCI AM           JAN, P46; Caldwell RR, 1998, PHYS REV LETT, V80, P1582, DOI 10.1103/PhysRevLett.80.1582; DAI J, 1989, MOD PHYS LETT A, V4, P2073, DOI 10.1142/S0217732389002331; DAMOUR T, 1994, NUCL PHYS B, V423, P532, DOI 10.1016/0550-3213(94)90143-0; DARNOUR T, IN PRESS C R ACAD SC; Dicke R.H., 1979, GEN RELATIVITY EINST; Garnavich PM, 1998, ASTROPHYS J, V509, P74, DOI 10.1086/306495; GUTH AH, 1981, PHYS REV D, V23, P347, DOI 10.1103/PhysRevD.23.347; GUTH AH, 1982, PHYS REV LETT, V49, P1110, DOI 10.1103/PhysRevLett.49.1110; HAWKING SW, 1982, PHYS LETT B, V115, P295, DOI 10.1016/0370-2693(82)90373-2; Horava P, 1996, NUCL PHYS B, V475, P94, DOI 10.1016/0550-3213(96)00308-2; Horava P, 1996, NUCL PHYS B, V460, P506, DOI 10.1016/0550-3213(95)00621-4; Kallosh R, 2001, PHYS REV D, V64, DOI 10.1103/PhysRevD.64.123523; Khoury J, 2001, PHYS REV D, V64, DOI 10.1103/PhysRevD.64.123522; Khoury J, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.086007; KHOURY J, IN PRESS PHYS REV D; Lewis A, 2002, PHYS REV D, V65, DOI 10.1103/PhysRevD.65.023505; LINDE AD, 1982, PHYS LETT B, V108, P389, DOI 10.1016/0370-2693(82)91219-9; LIU H, IN PRESS HIGH ENERGY; Ostriker JP, 2001, SCI AM, V284, P46, DOI 10.1038/scientificamerican0101-46; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; Polchinski J., 2007, STRING THEORY, V2, DOI [DOI 10.1017/CBO9780511816079, 10.1017/CBO9780511816079]; Polchinski J., 1998, STRING THEORY, V1; Riess AG, 1998, ASTRON J, V116, P1009, DOI 10.1086/300499; STAROBINSKY AA, 1982, PHYS LETT B, V117, P175, DOI 10.1016/0370-2693(82)90541-X; STEINHARDT PJ, IN PRESS PHYS REV D; TOLLEY AJ, IN PRESS HIGH ENERGY; Tolman R., 1934, RELATIVITY THERMODYN	31	341	345	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 24	2002	296	5572					1436	1439		10.1126/science.1070462	http://dx.doi.org/10.1126/science.1070462			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	557LP	11976408	Green Submitted			2022-12-28	WOS:000175910300039
J	Ming, GL; Wong, ST; Henley, J; Yuan, XB; Song, HJ; Spitzer, NC; Poo, MM				Ming, GL; Wong, ST; Henley, J; Yuan, XB; Song, HJ; Spitzer, NC; Poo, MM			Adaptation in the chemotactic guidance of nerve growth cones	NATURE			English	Article							PROTEIN-SYNTHESIS; SIGNAL-TRANSDUCTION; DNA FRAGMENTATION; MESSENGER-RNA; AXONS; NEUROTROPHINS; GRADIENTS; PROLIFERATION; INHIBITION; MECHANISM	Pathfinding by growing axons in the developing nervous system may be guided by gradients of extracellular guidance factors. Analogous to the process of chemotaxis in microorganisms, we found that axonal growth cones of cultured Xenopus spinal neurons exhibit adaptation during chemotactic migration, undergoing consecutive phases of desensitization and resensitization in the presence of increasing basal concentrations of the guidance factor netrin-1 or brain-derived neurotrophic factor. The desensitization is specific to the guidance factor and is accompanied by a reduction of Ca2+ signalling, whereas resensitization requires activation of mitogen-associated protein kinase and local protein synthesis. Such adaptive behaviour allows the growth cone to re-adjust its sensitivity over a wide range of concentrations of the guidance factor, an essential feature for long-range chemotaxis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA; Univ Calif San Diego, Div Biol, Neurobiol Sect, La Jolla, CA 92093 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA	University of California System; University of California Berkeley; University of California System; University of California San Diego; Salk Institute	Poo, MM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Neurobiol, Berkeley, CA 94720 USA.	gming@biomail.ucsd.edu	Henley, John/D-7171-2011; Ming, Guo-li/J-7880-2013	Spitzer, Nicholas/0000-0002-3523-1103; Henley, John/0000-0003-1846-5941; Yuan, Xiaobing/0000-0002-1632-8460; Ming, Guo-li/0000-0002-2517-6075				Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; BAIER H, 1992, SCIENCE, V255, P472, DOI 10.1126/science.1734526; BURHANS WC, 1991, EMBO J, V10, P4351, DOI 10.1002/j.1460-2075.1991.tb05013.x; CAJAL SRY, 1995, HISTOLOGY NERVOUS SY, V1, P532; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; DeSilva DR, 1998, J IMMUNOL, V160, P4175; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Falke JJ, 1997, ANNU REV CELL DEV BI, V13, P457, DOI 10.1146/annurev.cellbio.13.1.457; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Gomez TM, 2001, SCIENCE, V291, P1983, DOI 10.1126/science.1056490; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Job C, 2001, NAT REV NEUROSCI, V2, P889, DOI 10.1038/35104069; KATER SB, 1988, TRENDS NEUROSCI, V11, P315, DOI 10.1016/0166-2236(88)90094-X; Keynes R, 1997, NEURON, V18, P889, DOI 10.1016/S0896-6273(00)80329-3; KOCHI SK, 1993, EXP CELL RES, V208, P296, DOI 10.1006/excr.1993.1249; LOHOF AM, 1992, J NEUROSCI, V12, P1253; Loschinger J, 2000, PHILOS T ROY SOC B, V355, P971, DOI 10.1098/rstb.2000.0633; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Ming GI, 1999, NEURON, V23, P139, DOI 10.1016/S0896-6273(00)80760-6; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Ming GL, 1997, J NEUROSCI, V17, P7860; Ming GL, 2001, NEURON, V29, P441, DOI 10.1016/S0896-6273(01)00217-3; MITTLEMAN B, 1983, J MOL BIOL, V165, P461, DOI 10.1016/S0022-2836(83)80213-7; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; PIERCEALL WE, 1994, DEV BIOL, V166, P654, DOI 10.1006/dbio.1994.1345; PINI A, 1993, SCIENCE, V261, P95, DOI 10.1126/science.8316861; Rosentreter SM, 1998, J NEUROBIOL, V37, P541, DOI 10.1002/(SICI)1097-4695(199812)37:4<541::AID-NEU4>3.3.CO;2-C; SEGER R, 1994, J BIOL CHEM, V269, P25699; Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6; Song HJ, 1999, CURR OPIN NEUROBIOL, V9, P355, DOI 10.1016/S0959-4388(99)80052-X; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SPITZER NC, 1976, P NATL ACAD SCI USA, V73, P1641, DOI 10.1073/pnas.73.5.1641; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; Takei N, 2001, J BIOL CHEM, V276, P42818, DOI 10.1074/jbc.M103237200; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tucker KL, 2001, NAT NEUROSCI, V4, P29, DOI 10.1038/82868; Wang YW, 1998, J CELL SCI, V111, P373; WARING P, 1990, J BIOL CHEM, V265, P14476; Yee KT, 1999, NEURON, V24, P607, DOI 10.1016/S0896-6273(00)81116-2; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	50	327	337	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 23	2002	417	6887					411	418		10.1038/nature745	http://dx.doi.org/10.1038/nature745			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	554HZ	11986620				2022-12-28	WOS:000175730900031
J	Arase, H; Mocarski, ES; Campbell, AE; Hill, AB; Lanier, LL				Arase, H; Mocarski, ES; Campbell, AE; Hill, AB; Lanier, LL			Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors	SCIENCE			English	Article							NATURAL-KILLER-CELLS; MURINE CYTOMEGALOVIRUS; MHC MOLECULES; GENE-COMPLEX; HLA-C; RESISTANCE; MECHANISMS; INFECTION; BINDING; CMV-1	Natural killer (NK) cells express inhibitory receptors for major histocompatibility complex (MHC) class I antigens, preventing attack against healthy cells. Mouse cytomegatovirus (MCMV) encodes an MHC-like protein (m157) that binds to an inhibitory NK cell receptor in certain MCMV-susceptible mice. In MCMV-resistant mice, this viral protein engages a related activating receptor (Ly49H) and confers host protection. These activating and inhibitory receptors are highly homologous, suggesting the possibility that one evolved from the other in response to selective pressure imposed by the pathogen.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; Stanford Univ, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23507 USA; Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Eastern Virginia Medical School; Oregon Health & Science University	Lanier, LL (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.	lanier@itsa.ucsf.edu	Mocarski, Edward/ABC-2893-2020; Arase, Hisashi/C-8442-2009; Lanier, Lewis L/E-2139-2014	Arase, Hisashi/0000-0002-1153-3166; Lanier, Lewis L/0000-0003-1308-3952	NATIONAL CANCER INSTITUTE [R01CA089294] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030363, R21AI030363] Funding Source: NIH RePORTER; NCI NIH HHS [CA89294] Funding Source: Medline; NIAID NIH HHS [AI30363] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alcami A, 2000, MOL MED TODAY, V6, P365, DOI 10.1016/S1357-4310(00)01775-5; Anderson SK, 2001, IMMUNOL REV, V181, P79, DOI 10.1034/j.1600-065X.2001.1810106.x; ARASE H, UNPUB; Bakker ABH, 2000, IMMUNITY, V13, P345, DOI 10.1016/S1074-7613(00)00034-0; Brown MG, 2001, IMMUNOGENETICS, V53, P584, DOI 10.1007/s002510100365; Brown MG, 2001, SCIENCE, V292, P934, DOI 10.1126/science.1060042; Cavanaugh VJ, 1996, J VIROL, V70, P1365, DOI 10.1128/JVI.70.3.1365-1374.1996; Cerwenka A, 2001, NAT REV IMMUNOL, V1, P41, DOI 10.1038/35095564; Chapman TL, 1998, J VIROL, V72, P460, DOI 10.1128/JVI.72.1.460-466.1998; Daniels KA, 2001, J EXP MED, V194, P29, DOI 10.1084/jem.194.1.29; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; GRUNDY JE, 1981, INFECT IMMUN, V32, P277, DOI 10.1128/IAI.32.1.277-286.1981; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Khakoo SI, 2000, IMMUNITY, V12, P687, DOI 10.1016/S1074-7613(00)80219-8; Kleijnen MF, 1997, EMBO J, V16, P685, DOI 10.1093/emboj/16.4.685; Lanier LL, 2001, CURR OPIN IMMUNOL, V13, P326, DOI 10.1016/S0952-7915(00)00222-3; Lee SH, 2001, NAT GENET, V28, P42, DOI 10.1038/ng0501-42; Lee SH, 2001, IMMUNOGENETICS, V53, P501, DOI 10.1007/s002510100359; Makrigiannis AP, 2001, J IMMUNOL, V166, P5034, DOI 10.4049/jimmunol.166.8.5034; MORETTA A, 1995, J EXP MED, V182, P875, DOI 10.1084/jem.182.3.875; Orange JS, 1996, J IMMUNOL, V156, P1138; SCALZO AA, 1992, J IMMUNOL, V149, P581; SCALZO AA, 1990, J EXP MED, V171, P1469, DOI 10.1084/jem.171.5.1469; Smith KM, 1998, J IMMUNOL, V161, P7; Tay CH, 1997, J VIROL, V71, P267, DOI 10.1128/JVI.71.1.267-275.1997; TAY CH, 1995, J IMMUNOL, V154, P780; THALE R, 1995, J VIROL, V69, P6098; Vales-Gomez M, 1998, P NATL ACAD SCI USA, V95, P14326, DOI 10.1073/pnas.95.24.14326; Vink C, 2000, J VIROL, V74, P7656, DOI 10.1128/JVI.74.16.7656-7665.2000; Wilson MJ, 2000, P NATL ACAD SCI USA, V97, P4778, DOI 10.1073/pnas.080588597	31	931	955	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 17	2002	296	5571					1323	1326		10.1126/science.1070884	http://dx.doi.org/10.1126/science.1070884			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	554BL	11950999				2022-12-28	WOS:000175713000057
J	Lasser, KE; Allen, PD; Woolhandler, SJ; Himmelstein, DU; Wolfe, SN; Bor, DH				Lasser, KE; Allen, PD; Woolhandler, SJ; Himmelstein, DU; Wolfe, SN; Bor, DH			Timing of new black box warnings and withdrawals for prescription medications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIANS DESK REFERENCE; ADVERSE DRUG-REACTIONS; UNITED-KINGDOM; SAFETY; DISCONTINUATIONS; INFORMATION; PROMOTION; STATES; FDA	Context Recently approved drugs may be more likely to have unrecognized adverse drug reactions (ADRs) than established drugs, but no recent studies have examined how frequently postmarketing surveillance identifies important ADRs. Objective To determine the frequency and timing of discovery of new ADRs described in black box warnings or necessitating withdrawal of the drug from the market. Design and Setting Examination of the Physicians' Desk Reference for all new chemical entities approved by the US Food and Drug Administration between 1975 and 1999, and all drugs withdrawn from the market between 1975 and 2000 (with or without a prior black box warning). Main Outcome Measures Frequency of and time to a new black box warning or drug withdrawal. Results A total of 548 new chemical entities were approved in 1975-1999; 56 (10.2%) acquired a new black box warning or were withdrawn. Forty-five drugs (8.2%) acquired 1 or more black box warnings and 16 (2.9%) were withdrawn from the market. In Kaplan-Meier analyses, the estimated probability of acquiring a new black box warning or being withdrawn from the market over 25 years was 20%. Eighty-one major changes to drug labeling in the Physicians' Desk Reference occurred including the addition of 1 or more black box warnings per drug, or drug withdrawal. In Kaplan-Meier analyses, half of these changes occurred within 7 years of drug introduction; half of the withdrawals occurred within 2 years. Conclusions Serious ADRs commonly emerge after Food and Drug Administration approval. The safety of new agents cannot be known with certainty until a drug has been on the market for many years.	Cambridge Hosp, Dept Med, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Publ Citizen Hlth Res Grp, Washington, DC USA	Harvard University; Cambridge Health Alliance; Cambridge Hospital; Harvard University	Lasser, KE (corresponding author), Cambridge Hosp, Dept Med, Macht 4th Floor,1493 Cambridge St, Cambridge, MA 02139 USA.			Lasser, Karen/0000-0003-3777-6075	BHP HRSA HHS [5T32PE11001-12] Funding Source: Medline; DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [T32PE011001] Funding Source: NIH RePORTER	BHP HRSA HHS; DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA))		[Anonymous], 1995, PHYS DESK REF; [Anonymous], 1991, PHYS DESK REF; [Anonymous], 1997, PHYS DESK REF; [Anonymous], 2000, PHYS DESK REF; [Anonymous], 1998, PHYS DESK REF; BAKKE OM, 1995, CLIN PHARMACOL THER, V58, P108, DOI 10.1016/0009-9236(95)90078-0; BAKKE OM, 1984, CLIN PHARMACOL THER, V35, P559, DOI 10.1038/clpt.1984.78; Basara L. R., 1996, DRUG INF J, V30, P715, DOI DOI 10.1177/009286159603000315; Beach JE, 1998, FOOD DRUG LAW J, V53, P403; Brewer T, 1999, JAMA-J AM MED ASSOC, V281, P824, DOI 10.1001/jama.281.9.824; *CDER, 1999, CDER REP NAT; *CDER, 2000, CDER REP NAT; Cohen JS, 2001, ARCH INTERN MED, V161, P880, DOI 10.1001/archinte.161.6.880; Cohen JS, 1996, ARCH INTERN MED, V156, P1375, DOI 10.1001/archinte.156.13.1375; Food and Drug Administration, 1998, FED REG, V63, P195; Hayes TA, 1998, CLIN PHARMACOL THER, V63, P607, DOI 10.1016/S0009-9236(98)90083-2; HURWITZ MA, 1988, J LAW ECON, V31, P299, DOI 10.1086/467158; Jones MI, 2001, BMJ-BRIT MED J, V323, P378, DOI 10.1136/bmj.323.7309.378; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; Lurie P, 1999, JAMA-J AM MED ASSOC, V282, P2297, DOI 10.1001/jama.282.24.2297; *MED EC CO, 1994, PHYS DESK REF; *MED EC CO, 1999, PHYS DESK REF; *MED EC CO, 1988, PHYS DESK REF; *MED EC CO, 1996, PHYS DESK REF; *MED EC CO, 1977, PHYS DESK REF; *MED EC CO, 1993, PHYS DESK REF; *MED EC CO, 1978, PHYS DESK REF; *MED EC CO, 1975, PHYS DESK REF; *MED EC CO, 1980, PHYS DESK REF; *MED EC CO, 1983, PHYS DESK REF; *MED EC CO, 1984, PHYS DESK REF; *MED EC CO, 1985, PHYS DESK REF; *MED EC CO, 1992, PHYS DESK REF; *MED EC CO, 1990, PHYS DESK REF; *MED EC CO, 1976, PHYS DESK REF; *MED EC CO, 1987, PHYS DESK REF; *MED EC CO, 1979, PHYS DESK REF; *MED EC CO, 1986, PHYS DESK REF; *MED EC CO, 1989, PHYS DESK REF; *MED EC CO, 1982, PHYS DESK REF; *MED EC CO, 1981, PHYS DESK REF; Merrill RA, 1999, HEALTH AFFAIR, V18, P96, DOI 10.1377/hlthaff.18.2.96; Mullen WH, 1997, ANN EMERG MED, V29, P255, DOI 10.1016/S0196-0644(97)70277-4; MURPHY MN, 1992, J DRUG ISSUES, V22, P305, DOI 10.1177/002204269202200210; PEAY MY, 1988, SOC SCI MED, V26, P1183, DOI 10.1016/0277-9536(88)90149-9; STROSS JK, 1987, J GEN INTERN MED, V2, P155, DOI 10.1007/BF02596142; Thase ME, 1999, J CLIN PSYCHIAT, V60, P23; *TUFTS CTR STUD DR, 2001, US APPR DRUGS DATA S; *US GEN ACC OFF, 1990, PUBL; Wood AJJ, 1999, JAMA-J AM MED ASSOC, V281, P1753, DOI 10.1001/jama.281.18.1753; Wood AJJ, 2000, NEW ENGL J MED, V342, P1824, DOI 10.1056/NEJM200006153422410; 2000, FED REG, V65, P81081; 2000, LOS ANGELES TIM 1220, pA1; 2000, NY TIMES        1005, pC1	54	713	752	0	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2215	2220		10.1001/jama.287.17.2215	http://dx.doi.org/10.1001/jama.287.17.2215			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	546EZ	11980521	Green Published, Bronze			2022-12-28	WOS:000175260600021
J	Markowitz, AJ; Rabow, MH				Markowitz, AJ; Rabow, MH			Management of Dyspnea in patients with far-advanced lung disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article														Markowitz, Amy/0000-0001-9314-2814				Luce JM, 2001, JAMA-J AM MED ASSOC, V285, P1331, DOI 10.1001/jama.285.10.1331	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2261	2261		10.1001/jama.287.17.2261	http://dx.doi.org/10.1001/jama.287.17.2261			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980526				2022-12-28	WOS:000175260600026
J	Haffty, BG; Harrold, E; Khan, AJ; Pathare, P; Smith, TE; Turner, BC; Glazer, PM; Ward, B; Carter, D; Matloff, E; Bale, AE; Alvarez-Franco, M				Haffty, BG; Harrold, E; Khan, AJ; Pathare, P; Smith, TE; Turner, BC; Glazer, PM; Ward, B; Carter, D; Matloff, E; Bale, AE; Alvarez-Franco, M			Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status	LANCET			English	Article							GERMLINE MUTATIONS; PROPHYLACTIC MASTECTOMY; JEWISH WOMEN; THERAPY; RISK; OOPHORECTOMY; RADIOTHERAPY; CARCINOMAS; PROGNOSIS; SURVIVAL	Background Management of early-stage breast cancer in young women with mutations in BRCA1 or BRCA2 remains controversial. This study assessed the long-term risks of ipsilateral and contralateral breast cancer in a cohort of young women who underwent breast-conserving surgery followed by radiotherapy. Methods Between 1975 and 1998, 290 women with breast cancer diagnosed at age 42 years or younger underwent lumpectomy followed by radiotherapy at our hospital. We recruited 127 of these women for complete sequencing of BRCA1 and BRCA2. Demographic, clinical, pathological, and outcome data were recorded. The primary endpoints were rates of ipsilateral and contralateral breast cancer, in relation to germline BRCA1/2 status. Findings 105 women were classified as having sporadic disease (94 with wild-type or known polymorphisms and 11 with variants of unclear significance) and 22 as having genetic predisposition (deleterious mutations in BRCA1 [15] or BRCA2 [seven]). At 12 years of follow-up, the genetic group had significantly higher rates of ipsilateral (49% vs 21%, p=0.007) and contralateral events (42% vs 9%, p=0.001) than the sporadic group. The majority of events were classified as second primary tumours. No patient in the genetic group had undergone oophorectomy or was taking prophylactic agents such as tamoxifen. Interpretation Patients with germline mutations in BRCA1 or BRCA2 have a high risk of developing late ipsilateral and contralateral second primary tumours. With breast-conserving therapy, chemoprophylaxis or other interventions to reduce the rate of second cancers may be valuable. Alternatively, bilateral mastectomy may be considered, to minimise the risk of second tumours in the breasts.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Haffty, BG (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, POB 208040, New Haven, CT 06520 USA.	bruce.haffty@yale.edu	Glazer, Peter/S-7651-2019	Glazer, Peter/0000-0003-4525-5560; Khan, Atif/0000-0001-8640-8530; Ratchford, Elizabeth/0000-0002-2244-5604				Blackwood MA, 1998, J CLIN ONCOL, V16, P1969, DOI 10.1200/JCO.1998.16.5.1969; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; DELAROCHEFORDIERE A, 1993, LANCET, V341, P1039, DOI 10.1016/0140-6736(93)92407-K; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Formenti SC, 2000, J CLIN ONCOL, V18, P1159, DOI 10.1200/JCO.2000.18.5.1159; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; Johannsson OT, 1998, J CLIN ONCOL, V16, P397, DOI 10.1200/JCO.1998.16.2.397; Kroman N, 2000, BRIT MED J, V320, P474, DOI 10.1136/bmj.320.7233.474; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X; *NAT HUM GEN RES I, 2002, OP ACC ON LIN BREAST; Offit K, 1996, LANCET, V347, P1643, DOI 10.1016/S0140-6736(96)91484-1; Phillips KA, 1999, J CLIN ONCOL, V17, P3653, DOI 10.1200/JCO.1999.17.11.3653; Pierce LJ, 2000, J CLIN ONCOL, V18, P3360, DOI 10.1200/JCO.2000.18.19.3360; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Robson M, 1998, J CLIN ONCOL, V16, P1642, DOI 10.1200/JCO.1998.16.5.1642; Robson M, 1999, JNCI-J NATL CANCER I, V91, P2112, DOI 10.1093/jnci/91.24.2112; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; SEYNAEVE C, 1998, P AN M AM SOC CLIN, V17, pA119; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Szabo C, 2000, HUM MUTAT, V16, P123, DOI 10.1002/1098-1004(200008)16:2<123::AID-HUMU4>3.0.CO;2-Y; Turner BC, 1999, J CLIN ONCOL, V17, P3017, DOI 10.1200/JCO.1999.17.10.3017; van Dongen JA, 2000, JNCI-J NATL CANCER I, V92, P1143, DOI 10.1093/jnci/92.14.1143; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102; Walker RA, 1996, BRIT J CANCER, V74, P1796, DOI 10.1038/bjc.1996.632; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	31	208	217	1	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	2002	359	9316					1471	1477		10.1016/S0140-6736(02)08434-9	http://dx.doi.org/10.1016/S0140-6736(02)08434-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988246				2022-12-28	WOS:000175279100010
J	Lernmark, A				Lernmark, A			Multiple sclerosis and type 1 diabetes: an unlikely alliance	LANCET			English	Editorial Material							ASSOCIATION; MELLITUS; DISEASES; ONSET; AGE		Univ Washington, Dept Med, RH Williams Lab, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Lernmark, A (corresponding author), Univ Washington, Dept Med, RH Williams Lab, Seattle, WA 98195 USA.		Lernmark, Åke/F-8140-2015	Lernmark, Åke/0000-0003-1735-0499				Coraddu F, 2001, EUR J HUM GENET, V9, P621, DOI 10.1038/sj.ejhg.5200680; CUCCA F, 1993, HUM IMMUNOL, V37, P85, DOI 10.1016/0198-8859(93)90146-R; Graham J, 1999, EUR J IMMUNOGENET, V26, P117, DOI 10.1046/j.1365-2370.1999.00127.x; Heino M, 2001, HUM MUTAT, V18, P205, DOI 10.1002/humu.1176; JAWORSKI MA, 1989, AM J MED GENET, V32, P158, DOI 10.1002/ajmg.1320320204; Leslie D, 2001, J CLIN INVEST, V108, P1417, DOI 10.1172/JCI14452; LINDEGARD B, 1985, ACTA NEUROL SCAND, V71, P267; Marrosu MG, 2001, HUM MOL GENET, V10, P2907, DOI 10.1093/hmg/10.25.2907; Notkins AL, 2001, J CLIN INVEST, V108, P1247, DOI 10.1172/JCI200114257; Tuomi T, 1996, J CLIN ENDOCR METAB, V81, P1488, DOI 10.1210/jc.81.4.1488; WARREN S, 1991, NEUROEPIDEMIOLOGY, V10, P9, DOI 10.1159/000110241; WERTMAN E, 1992, J NEUROL, V239, P43, DOI 10.1007/BF00839211	12	11	11	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1450	1451		10.1016/S0140-6736(02)08464-7	http://dx.doi.org/10.1016/S0140-6736(02)08464-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988239				2022-12-28	WOS:000175279100003
J	Pattenden, J; Watt, I; Lewin, RJP; Stanford, N				Pattenden, J; Watt, I; Lewin, RJP; Stanford, N			Decision making processes in people with symptoms of acute myocardial infarction: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEART-ATTACK SYMPTOMS; PATIENT DELAY; THROMBOLYTIC THERAPY; PREHOSPITAL DELAY; UNITED-STATES; CAMPAIGN; MEDIA; TIME	Objective To identify, the themes that influence decision making processes used by patients with symptoms of acute myocardial infarction. Design Qualitative study using semistructured interviews. Setting Two district hospitals in North Yorkshire. Participants 22 patients admitted to hospital with confirmed second, third, or fourth acute myocardial infarction. Main outcome measure Patients' perceptions of their experience between the onset of symptoms and the decision to seek medical help. Results Six main themes that influence the decision making process were identified: appraisal of In symptoms, perceived risk, previous experience, psychological and emotional factors, use of the NHS, and context of the event. Conclusions Knowledge of symptoms may not be enough to promote prompt action in the event of an acute myocardial infarction. Cognitive and emotional processes, individual beliefs and values, and the influence of the context of the event should also be considered in individual interventions designed to reduce delay in the event of symptoms of acute myocardial infarction.	Univ York, Dept Hlth Serv, York YO10 5DQ, N Yorkshire, England	University of York - UK	Pattenden, J (corresponding author), Univ York, Dept Hlth Serv, York YO10 5DQ, N Yorkshire, England.	jp30@york.ac.uk						[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BERGER PB, 1994, AM J CARDIOL, V73, P231, DOI 10.1016/0002-9149(94)90225-9; Blohm MB, 1996, HEART, V76, P430, DOI 10.1136/hrt.76.5.430; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Dracup K, 1997, HEART LUNG, V26, P253, DOI 10.1016/S0147-9563(97)90082-0; DRACUP K, 1995, SOC SCI MED, V40, P379, DOI 10.1016/0277-9536(94)00278-2; Gaspoz JM, 1996, HEART, V76, P150, DOI 10.1136/hrt.76.2.150; Goff DC, 1999, AM HEART J, V138, P1046, DOI 10.1016/S0002-8703(99)70069-4; Goff DC, 1998, ARCH INTERN MED, V158, P2329, DOI 10.1001/archinte.158.21.2329; GOLDBERG RJ, 1992, AM J CARDIOL, V70, P421, DOI 10.1016/0002-9149(92)91183-5; HERLITZ J, 1992, EUR HEART J, V13, P171, DOI 10.1093/oxfordjournals.eurheartj.a060142; HO MT, 1989, ANN EMERG MED, V18, P727, DOI 10.1016/S0196-0644(89)80004-6; Horne R, 2000, HEART, V83, P388, DOI 10.1136/heart.83.4.388; Luepker RV, 2000, JAMA-J AM MED ASSOC, V284, P60, DOI 10.1001/jama.284.1.60; McKinley S, 2000, HEART LUNG, V29, P237, DOI 10.1067/mhl.2000.106940; Meischke H, 1997, AM J PUBLIC HEALTH, V87, P1705, DOI 10.2105/AJPH.87.10.1705; Roupie E, 1998, PRESSE MED, V27, P1636; Rustige J, 1997, EUR HEART J, V18, P1438; Ruston A, 1998, BRIT MED J, V316, P1060; Strauss A., 1990, BASICS QUALITATIVE R	22	98	100	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 27	2002	324	7344					1006	1009		10.1136/bmj.324.7344.1006	http://dx.doi.org/10.1136/bmj.324.7344.1006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547UP	11976241	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000175350900019
J	Manolopoulos, DE				Manolopoulos, DE			Reaction dynamics - Bending or breaking the rules?	SCIENCE			English	Editorial Material							SCATTERING; F(P-2)		Phys & Theoret Chem Lab, Oxford OX1 3QZ, England	University of Oxford	Manolopoulos, DE (corresponding author), Phys & Theoret Chem Lab, S Parks Rd, Oxford OX1 3QZ, England.		Manolopoulos, David/AAV-1276-2021	Manolopoulos, David/0000-0002-7111-0763				Alexander MH, 2002, SCIENCE, V296, P715, DOI 10.1126/science.1070472; Alexander MH, 2000, J CHEM PHYS, V113, P11084, DOI 10.1063/1.1326850; ATKINS PW, 1997, MOL QUANTUM MECH, P379; Born M, 1927, ANN PHYS-BERLIN, V84, P0457; DAGDIGIAN PJ, 1987, CHEM REV, V87, P1, DOI 10.1021/cr00077a001; Dong F, 2001, J CHEM PHYS, V115, P1197, DOI 10.1063/1.1378834; DONOVAN RJ, 1970, CHEM REV, V70, P489, DOI 10.1021/cr60266a003; REBENTROST F, 1977, J CHEM PHYS, V67, P3367, DOI 10.1063/1.435283; SCHATZ GC, 1995, J PHYS CHEM-US, V99, P7522, DOI 10.1021/j100019a038; TANAKA K, 1981, J CHEM PHYS, V74, P5561, DOI 10.1063/1.440919; TULLY JC, 1974, J CHEM PHYS, V60, P3042, DOI 10.1063/1.1681488; Whiteley TWJ, 2000, PHYS CHEM CHEM PHYS, V2, P549, DOI 10.1039/a908614e	12	11	11	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					664	664		10.1126/science.1071814	http://dx.doi.org/10.1126/science.1071814			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976430				2022-12-28	WOS:000175281700030
J	Boettger, T; Hubner, CA; Maier, H; Rust, MB; Beck, FX; Jentsch, TJ				Boettger, T; Hubner, CA; Maier, H; Rust, MB; Beck, FX; Jentsch, TJ			Deafness and renal tubular acidosis in mice lacking the K-Cl co-transporter Kcc4	NATURE			English	Article							INNER-EAR; SENSORINEURAL DEAFNESS; DOMINANT DEAFNESS; HAIR-CELLS; POTASSIUM; GENE; COTRANSPORTER; MUTATIONS; CHANNEL; COCHLEA	Hearing depends on a high K+ concentration bathing the apical membranes of sensory hair cells. K+ that has entered hair cells through apical mechanosensitive channels is transported to the stria vascularis for re-secretion into the scala media(1). K+ probably exits outer hair cells by KCNQ4 K+ channels(2,3), and is then transported-by means of a gap junction system connecting supporting Deiters' cells and fibrocytes(4)-back to the stria vascularis. We show here that mice lacking the K+/Cl- (K-Cl) co-transporter Kcc4 (coded for by Slc12a7) are deaf because their hair cells degenerate rapidly after the beginning of hearing. In the mature organ of Corti, Kcc4 is restricted to supporting cells of outer and inner hair cells. Our data suggest that Kcc4 is important for K+ recycling(1,5) by siphoning K+ ions after their exit from outer hair cells into supporting Deiters' cells, where K+ enters the gap junction pathway. Similar to some human genetic syndromes(6), deafness in Kcc4-deficient mice is associated with renal tubular acidosis. It probably results from an impairment of Cl- recycling across the basolateral membrane of acid-secreting alpha-intercalated cells of the distal nephron.	Univ Hamburg, ZMNH, Zentrum Mol Neurobiol, D-20246 Hamburg, Germany; Univ Hamburg, ZMNH, HNO Klin, D-20246 Hamburg, Germany; Univ Munich, Inst Physiol, D-80336 Munich, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University of Munich	Jentsch, TJ (corresponding author), Univ Hamburg, ZMNH, Zentrum Mol Neurobiol, Falkenried 94, D-20246 Hamburg, Germany.		Hannes, Maier/AAE-5070-2020; Hübner, Christian/A-2950-2017; Hannes, Maier/A-9457-2012; Boettger, Thomas/E-3406-2012	Hannes, Maier/0000-0001-8457-5327; Hübner, Christian/0000-0002-1030-4943; Hannes, Maier/0000-0001-8457-5327; Boettger, Thomas/0000-0003-4280-8449; Jentsch, Thomas/0000-0002-3509-2553				BECK FX, 1988, KIDNEY INT, V34, P455, DOI 10.1038/ki.1988.202; BECK FX, 1992, AM J PHYSIOL, V262, pF849, DOI 10.1152/ajprenal.1992.262.5.F849; Bruce LJ, 1997, J CLIN INVEST, V100, P1693, DOI 10.1172/JCI119694; Delpire E, 1999, NAT GENET, V22, P192, DOI 10.1038/9713; Dixon MJ, 1999, HUM MOL GENET, V8, P1579, DOI 10.1093/hmg/8.8.1579; Estevez R, 2001, NATURE, V414, P558, DOI 10.1038/35107099; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; JOHNSTONE BM, 1989, J PHYSIOL-LONDON, V408, P77, DOI 10.1113/jphysiol.1989.sp017448; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kharkovets T, 2000, P NATL ACAD SCI USA, V97, P4333, DOI 10.1073/pnas.97.8.4333; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; Kikuchi T, 2000, BRAIN RES REV, V32, P163, DOI 10.1016/S0165-0173(99)00076-4; Kubisch C, 1999, CELL, V96, P437, DOI 10.1016/S0092-8674(00)80556-5; Lauf PK, 2000, CELL PHYSIOL BIOCHEM, V10, P341, DOI 10.1159/000016357; Lee MP, 2000, J CLIN INVEST, V106, P1447, DOI 10.1172/JCI10897; Mount DB, 1999, J BIOL CHEM, V274, P16355, DOI 10.1074/jbc.274.23.16355; Nenov AP, 1998, HEARING RES, V123, P168, DOI 10.1016/S0378-5955(98)00121-X; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P11663, DOI 10.1073/pnas.90.24.11663; Oliver D, 2001, SCIENCE, V292, P2340, DOI 10.1126/science.1060939; Payne JA, 1997, AM J PHYSIOL-CELL PH, V273, pC1516, DOI 10.1152/ajpcell.1997.273.5.C1516; Rodriguez-Soriano J, 2000, PEDIATR NEPHROL, V14, P1121, DOI 10.1007/s004670000407; Spicer SS, 1998, HEARING RES, V118, P1, DOI 10.1016/S0378-5955(98)00006-9; SPICER SS, 1992, J HISTOCHEM CYTOCHEM, V40, P185, DOI 10.1177/40.2.1313059; Steel KP, 2001, NAT GENET, V27, P143, DOI 10.1038/84758; Vetter DE, 1996, NEURON, V17, P1251, DOI 10.1016/S0896-6273(00)80255-X; Voss AK, 1997, EXP CELL RES, V230, P45, DOI 10.1006/excr.1996.3418; WADA J, 1979, ARCH OTO-RHINO-LARYN, V225, P79, DOI 10.1007/BF00455206; Weber PC, 2001, LARYNGOSCOPE, V111, P1156, DOI 10.1097/00005537-200107000-00006	30	295	308	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					874	878		10.1038/416874a	http://dx.doi.org/10.1038/416874a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976689				2022-12-28	WOS:000175163800057
J	Boylston, AW				Boylston, AW			Occasional notes - Clinical investigation of smallpox in 1767.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Leeds, Leeds LS9 7TF, W Yorkshire, England	University of Leeds	Boylston, AW (corresponding author), Univ Leeds, Leeds LS9 7TF, W Yorkshire, England.							Boylston Zabdiel, 1726, HIST ACCOUNT SMALL P; Jurin J., 1722, PHILOS T ROY SOC LON, V32, P213, DOI [10.1098/rstl.1722.0038, DOI 10.1098/RSTL.1722.0038]; Lind J, 1753, TREATISE SCURVY 3 PA; Watson William, 1768, ACCOUNT SERIES EXPT	4	13	14	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1326	1328		10.1056/NEJM200204253461714	http://dx.doi.org/10.1056/NEJM200204253461714			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544GX	11973370				2022-12-28	WOS:000175150800013
J	Wright, TC; Cox, JT; Massad, LS; Twiggs, LB; Wilkinson, EJ				Wright, TC; Cox, JT; Massad, LS; Twiggs, LB; Wilkinson, EJ			2001 consensus guidelines for the management of women with cervical cytological abnormalities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATYPICAL GLANDULAR CELLS; ADENOCARCINOMA IN-SITU; HUMAN-PAPILLOMAVIRUS DNA; UNDETERMINED SIGNIFICANCE AGUS; HUMAN-IMMUNODEFICIENCY-VIRUS; PATHOLOGISTS Q-PROBES; LARGE-LOOP EXCISION; HIGH-RISK HPV; PAPANICOLAOU SMEARS; FOLLOW-UP	Objective To provide evidence-based consensus guidelines for the management of women with cervical cytological abnormalities and cervical cancer precursors. Participants A panel of 121 experts in the diagnosis and management of cervical cancer precursors, including representatives from 29 professional organizations, federal agencies, and national and international health organizations, were invited to participate in a consensus conference sponsored by the American Society for Colposcopy and Cervical Pathology (ASCCP). Evidence and Consensus Process Guidelines for the management of women with cervical cytological abnormalities were developed through a multistep process. Starting 6 months before the conference, working groups developed draft management guidelines based on formal literature reviews of English-language articles published in 1988-2001, as well as input from the professional community at large, obtained using interactive Internet-based bulletin boards. On September 6-8, 2001, the ASCCP Consensus Conference was held in Bethesda, Md. Guidelines with supporting evidence were presented and underwent discussion, revision, and voting. Conclusions Management of women with atypical squamous cells (ASC) depends on whether the Papanicolaou test is subcategorized as of undetermined significance (ASCUS) or as cannot exclude high-grade squamous intraepithelial lesion (HSIL) (ASC-H). Women with ASC-US should be managed using a program of 2 repeat cytology tests, immediate colposcopy, or DNA testing for high-risk types of human papillomavirus (HPV). Testing for HPV DNA is the preferred approach when liquid-based cytology is used for screening. In most instances, women with ASC-H, low-grade squamous intraepithelial lesion, HSIL, and atypical glandular cells should be referred for immediate colposcopic evaluation.	Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA; Univ Calif Santa Barbara, Student Hlth Serv, Santa Barbara, CA 93106 USA; Amer Social Hlth Assoc, Durham, NC USA; Cook Cty Hosp, Dept Obstet & Gynecol, Chicago, IL 60612 USA; Univ Miami, Inst Womens Hlth, Miami, FL 33152 USA; Univ Florida, Coll Med, Dept Pathol, Gainesville, FL USA	Columbia University; University of California System; University of California Santa Barbara; John H Stroger Junior Hospital Cook County; University of Miami; State University System of Florida; University of Florida	Wright, TC (corresponding author), Columbia Univ Coll Phys & Surg, Dept Pathol, Room 16-404,P&S Bldg,630 W 168th St, New York, NY 10032 USA.		Harper, Diane M./I-2180-2014; , Leo/GRX-9887-2022	Harper, Diane M./0000-0001-7648-883X; 	NATIONAL CANCER INSTITUTE [R13CA096190] Funding Source: NIH RePORTER; NCI NIH HHS [1 R13 CA 96190-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM COLL OBST GYN, 1993, ACOG TECHN B, V183; Azodi M, 1999, GYNECOL ONCOL, V73, P348, DOI 10.1006/gyno.1999.5395; BENEDET JL, 1987, AM J OBSTET GYNECOL, V157, P932, DOI 10.1016/S0002-9378(87)80091-1; Bergeron C, 2000, OBSTET GYNECOL, V95, P821, DOI 10.1016/S0029-7844(00)00795-X; BIGRIGG A, 1994, LANCET, V343, P32, DOI 10.1016/S0140-6736(94)90881-8; BIGRIGG MA, 1990, LANCET, V336, P229, DOI 10.1016/0140-6736(90)91746-W; Brown FM, 1999, AM J CLIN PATHOL, V112, P765; CHAPPATTE OA, 1991, GYNECOL ONCOL, V43, P46, DOI 10.1016/0090-8258(91)90007-R; Chhieng DC, 2001, CANCER CYTOPATHOL, V93, P1; Chin AB, 2000, AM J OBSTET GYNECOL, V182, P1278, DOI 10.1067/mob.2000.106537; Cox J T, 1997, J Low Genit Tract Dis, V1, P41, DOI 10.1097/00128360-199701000-00060; COX JT, 1995, AM J OBSTET GYNECOL, V172, P946, DOI 10.1016/0002-9378(95)90026-8; COX JT, 2000, J LOW GENIT TRACT DI, V4, P99; Crum CP, 1999, AM J CLIN PATHOL, V112, P384; CULLIMORE JE, 1992, BRIT J OBSTET GYNAEC, V99, P314, DOI 10.1111/j.1471-0528.1992.tb13730.x; Denehy TR, 1997, OBSTET GYNECOL, V90, P1, DOI 10.1016/S0029-7844(97)00122-1; DENNY LA, 1995, BRIT J OBSTET GYNAEC, V102, P545, DOI 10.1111/j.1471-0528.1995.tb11358.x; Duska LR, 1998, OBSTET GYNECOL, V91, P278, DOI 10.1016/S0029-7844(97)00659-5; ECONOMOS K, 1993, OBSTET GYNECOL, V81, P915; Eddy GL, 1997, OBSTET GYNECOL, V90, P999, DOI 10.1016/S0029-7844(97)00548-6; Eskridge C, 1998, OBSTET GYNECOL, V92, P351, DOI 10.1016/S0029-7844(98)00199-9; Ferris DG, 1998, J FAM PRACTICE, V46, P125; Ferris DG, 1998, J FAM PRACTICE, V46, P136; Flynn K, 2001, DIAGN CYTOPATHOL, V24, P132, DOI 10.1002/1097-0339(200102)24:2<132::AID-DC1026>3.0.CO;2-N; Geier CS, 2001, AM J OBSTET GYNECOL, V184, P64, DOI 10.1067/mob.2001.108995; GOFF BA, 1992, OBSTET GYNECOL, V79, P101; Grenko RT, 2000, AM J CLIN PATHOL, V114, P735, DOI 10.1309/K7C9-X5P0-001B-2HK5; GROSS PA, 1994, CLIN INFECT DIS, V18, P421, DOI 10.1093/clinids/18.3.421; Holschneider CH, 1999, CANCER-AM CANCER SOC, V86, P2659, DOI 10.1002/(SICI)1097-0142(19991215)86:12<2659::AID-CNCR10>3.0.CO;2-S; Howells REJ, 2000, BRIT J OBSTET GYNAEC, V107, P1075, DOI 10.1111/j.1471-0528.2000.tb11103.x; Jones BA, 2000, ARCH PATHOL LAB MED, V124, P672; Jones BA, 2000, ARCH PATHOL LAB MED, V124, P665; Jones BA, 1996, ARCH PATHOL LAB MED, V120, P523; JONES HW, 1995, CANCER, V76, P1914, DOI 10.1002/1097-0142(19951115)76:10+<1914::AID-CNCR2820761307>3.0.CO;2-R; Joste NE, 1996, HUM PATHOL, V27, P581, DOI 10.1016/S0046-8177(96)90165-3; Keating JT, 2001, CANCER CYTOPATHOL, V93, P100, DOI 10.1002/cncr.9014; Kennedy AW, 1996, GYNECOL ONCOL, V63, P14, DOI 10.1006/gyno.1996.0270; Kim TJ, 1999, GYNECOL ONCOL, V73, P292, DOI 10.1006/gyno.1999.5360; Kinney WK, 1998, OBSTET GYNECOL, V91, P973, DOI 10.1016/S0029-7844(98)00080-5; KIRBY AJ, 1992, LANCET, V339, P828, DOI 10.1016/0140-6736(92)90278-B; Kish MA, 2001, CLIN INFECT DIS, V32, P851, DOI 10.1086/319366; Kobelin MH, 1998, OBSTET GYNECOL, V92, P356, DOI 10.1016/S0029-7844(98)00234-8; Koutsky LA, 2000, J NATL CANCER I, V92, P397, DOI 10.1093/jnci/92.5.397; Krane JF, 2001, CANCER CYTOPATHOL, V93, P8, DOI 10.1002/1097-0142(20010225)93:1<8::AID-CNCR9001>3.0.CO;2-K; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; LAVERTY CR, 1988, AUST NZ J OBSTET GYN, V28, P307, DOI 10.1111/j.1479-828X.1988.tb01688.x; Lee KR, 1997, AM J CLIN PATHOL, V107, P30; LEE KR, 1995, DIAGN CYTOPATHOL, V13, P202, DOI 10.1002/dc.2840130305; Lin CT, 2000, J REPROD MED, V45, P345; Lonky NM, 1999, AM J OBSTET GYNECOL, V181, P560, DOI 10.1016/S0002-9378(99)70493-X; LUESLEY DM, 1990, BRIT MED J, V300, P1690, DOI 10.1136/bmj.300.6741.1690; Malik SN, 1999, ACTA CYTOL, V43, P376, DOI 10.1159/000331084; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; Massad LS, 2001, GYNECOL ONCOL, V82, P516, DOI 10.1006/gyno.2001.6323; Milne DS, 1999, BRIT J OBSTET GYNAEC, V106, P38, DOI 10.1111/j.1471-0528.1999.tb08082.x; MITCHELL H, 1995, BRIT J CANCER, V71, P894, DOI 10.1038/bjc.1995.172; Mitchell MF, 1998, OBSTET GYNECOL, V91, P626, DOI 10.1016/S0029-7844(98)00006-4; MUNTZ HG, 1992, OBSTET GYNECOL, V80, P935; Ostor AG, 2000, GYNECOL ONCOL, V79, P207, DOI 10.1006/gyno.2000.5957; Quddus MR, 2001, CANCER CYTOPATHOL, V93, P16, DOI 10.1002/1097-0142(20010225)93:1<16::AID-CNCR9002>3.0.CO;2-A; ROBB JA, 1994, DIAGN CYTOPATHOL, V11, P319, DOI 10.1002/dc.2840110402; ROBERTSON JH, 1988, BRIT MED J, V297, P18, DOI 10.1136/bmj.297.6640.18; ROBERTSON JH, 1994, J CLIN PATHOL, V47, P278, DOI 10.1136/jcp.47.3.278; Ronnett BM, 1999, HUM PATHOL, V30, P816, DOI 10.1016/S0046-8177(99)90143-0; Santos C, 1996, GYNECOL ONCOL, V61, P11, DOI 10.1006/gyno.1996.0088; Schoolland M, 1998, CANCER CYTOPATHOL, V84, P208, DOI 10.1002/(SICI)1097-0142(19980825)84:4<208::AID-CNCR5>3.0.CO;2-I; Sherman ME, 2002, J NATL CANCER I, V94, P102, DOI 10.1093/jnci/94.2.102; SHERMAN ME, 1994, AM J CLIN PATHOL, V102, P182, DOI 10.1093/ajcp/102.2.182; SHERMAN ME, IN PRESS AM J CLIN P; Shlay JC, 2000, OBSTET GYNECOL, V96, P410, DOI 10.1016/S0029-7844(00)00907-8; SLAWSON DC, 1994, J FAM PRACTICE, V38, P387; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Soofer SB, 2000, CANCER CYTOPATHOL, V90, P207, DOI 10.1002/1097-0142(20000825)90:4<207::AID-CNCR2>3.0.CO;2-H; Spitzer M, 1998, AM J OBSTET GYNECOL, V178, P74, DOI 10.1016/S0002-9378(98)70630-1; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903; Takezawa K, 1998, J Low Genit Tract Dis, V2, P136, DOI 10.1097/00128360-199807000-00004; TAYLOR RR, 1993, J REPROD MED, V38, P443; US Public Health Service and Infectious Diseases Society of America, 1999, MMWR RECOMM REP, V48, P61; US Public Health Service and Infectious Diseases Society of America, 1999, MMWR-MORBID MORTAL W, V48, P1; Valdini A, 2001, J Am Board Fam Pract, V14, P172; Veljovich DS, 1998, AM J OBSTET GYNECOL, V179, P382, DOI 10.1016/S0002-9378(98)70368-0; Widrich T, 1996, GYNECOL ONCOL, V61, P304, DOI 10.1006/gyno.1996.0147; Wolf JK, 1996, OBSTET GYNECOL, V88, P82, DOI 10.1016/0029-7844(96)00083-X; Woodrow N, 1998, AUST NZ J OBSTET GYN, V38, P161, DOI 10.1111/j.1479-828X.1998.tb02992.x; Wright TC, 1998, AM J OBSTET GYNECOL, V178, P962, DOI 10.1016/S0002-9378(98)70531-9; Wright TC, 1996, OBSTET GYNECOL, V87, P515, DOI 10.1016/0029-7844(95)00472-6; Wright TC, 1994, BLAUSTEINS PATHOLOGY, P229; Zweizig S, 1997, GYNECOL ONCOL, V65, P314, DOI 10.1006/gyno.1997.4640	90	873	923	0	45	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2002	287	16					2120	2129		10.1001/jama.287.16.2120	http://dx.doi.org/10.1001/jama.287.16.2120			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZK	11966387				2022-12-28	WOS:000175075700030
J	Rosner, I				Rosner, I			Uses of error - Early and late	LANCET			English	Article																			0	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1422	1422		10.1016/S0140-6736(02)08356-3	http://dx.doi.org/10.1016/S0140-6736(02)08356-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978357				2022-12-28	WOS:000175076200031
J	Ottosen, S; Herrera, FJ; Triezenberg, SJ				Ottosen, S; Herrera, FJ; Triezenberg, SJ			Transcription: Proteasome parts at gene promoters	SCIENCE			English	Editorial Material							TATA-BINDING PROTEIN; GAL4; PROTEOLYSIS; ACTIVATION; SUG1		Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Ottosen, S (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.			Triezenberg, Steven/0000-0003-4184-5221				Chang C, 2001, J BIOL CHEM, V276, P30956, DOI 10.1074/jbc.M102254200; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; Makino Y, 1999, GENES CELLS, V4, P529, DOI 10.1046/j.1365-2443.1999.00277.x; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; Ostendorff HP, 2002, NATURE, V416, P99, DOI 10.1038/416099a; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Russell SJ, 1996, J BIOL CHEM, V271, P32810, DOI 10.1074/jbc.271.51.32810; Russell SJ, 2001, J BIOL CHEM, V276, P9825, DOI 10.1074/jbc.M010889200; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; Varshavsky A, 2000, BIOL CHEM, V381, P779, DOI 10.1515/BC.2000.101; XU QL, 1995, MOL CELL BIOL, V15, P6025	18	21	22	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					479	481		10.1126/science.1071270	http://dx.doi.org/10.1126/science.1071270			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964465				2022-12-28	WOS:000175179400030
J	Gundersen, L				Gundersen, L			Intimate-partner violence: The need for primary prevention in the community	ANNALS OF INTERNAL MEDICINE			English	Article													Duran, Bonnie m/A-3029-2009						0	9	9	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2002	136	8					637	640		10.7326/0003-4819-136-8-200204160-00026	http://dx.doi.org/10.7326/0003-4819-136-8-200204160-00026			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	543WY	11955043				2022-12-28	WOS:000175125800020
J	Boeckxstaens, GE; Tytgat, GNJ				Boeckxstaens, GE; Tytgat, GNJ			More pathophysiologically oriented treatment of GORD?	LANCET			English	Editorial Material							ESOPHAGEAL SPHINCTER RELAXATIONS; REFLUX; INVOLVEMENT		Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam	Boeckxstaens, GE (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Gastroenterol & Hepatol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Boeckxstaens, Guy/AAP-2502-2020					Blackshaw LA, 2001, AM J PHYSIOL-GASTR L, V281, pG311, DOI 10.1152/ajpgi.2001.281.2.G311; Boeckxstaens GE, 1998, AM J GASTROENTEROL, V93, P1823; Hirsch DP, 2002, ALIMENT PHARM THER, V16, P17, DOI 10.1046/j.1365-2036.2002.01153.x; Hirsch DP, 1998, GASTROENTEROLOGY, V115, P1374, DOI 10.1016/S0016-5085(98)70015-0; HIRSCH DP, IN PRESS DIG DIS SCI; Kuipers EJ, 1996, NEW ENGL J MED, V334, P1018, DOI 10.1056/NEJM199604183341603; Lehmann A, 1999, GASTROENTEROLOGY, V117, P1147, DOI 10.1016/S0016-5085(99)70400-2; Lidums I, 2000, GASTROENTEROLOGY, V118, P7, DOI 10.1016/S0016-5085(00)70408-2; McDermott CM, 2001, GASTROENTEROLOGY, V120, P1749, DOI 10.1053/gast.2001.24849; Mittal RK, 1997, NEW ENGL J MED, V336, P924, DOI 10.1056/NEJM199703273361306; MITTAL RK, 1995, GASTROENTEROLOGY, V109, P1547, DOI 10.1016/0016-5085(95)90643-6; Penagini R, 1997, GASTROENTEROLOGY, V113, P409, DOI 10.1053/gast.1997.v113.pm9247457; Vela MF, 2001, GASTROENTEROLOGY, V120, P1599, DOI 10.1053/gast.2001.24840; Zhang Q, 2002, GUT, V50, P19, DOI 10.1136/gut.50.1.19	14	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1267	1268		10.1016/S0140-6736(02)08285-5	http://dx.doi.org/10.1016/S0140-6736(02)08285-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965270				2022-12-28	WOS:000174989700007
J	Wu, H; Kanatous, SB; Thurmond, FA; Gallardo, T; Isotani, E; Bassel-Duby, R; Williams, RS				Wu, H; Kanatous, SB; Thurmond, FA; Gallardo, T; Isotani, E; Bassel-Duby, R; Williams, RS			Regulation of mitochondrial biogenesis in skeletal muscle by CaMK	SCIENCE			English	Article							PROTEIN-KINASE-I; GENE-EXPRESSION; FIBER-TYPE; CONTRACTILE ACTIVITY; COACTIVATOR PGC-1; ENZYME-ACTIVITY; CDNA CLONING; NUCLEAR; CALCINEURIN; PHOSPHORYLATION	Endurance exercise training promotes mitochondrial biogenesis in skeletal muscle and enhances muscle oxidative capacity, but the signaling mechanisms involved are poorly understood. To investigate this adaptive process, we generated transgenic mice that selectively express in skeletal muscle a constitutively active form of calcium/calmodulin-dependent protein kinase IV (CaMKIV*). Skeletal muscles from these mice showed augmented mitochondrial DNA replication and mitochondrial biogenesis, up-regulation of mitochondrial enzymes involved in fatty acid metabolism and electron transport, and reduced susceptibility to fatigue during repetitive contractions. CaMK induced expression of peroxisome proliferator-activated receptor gamma coactivator 1 (PGC-1), a master regulator of mitochondrial biogenesis in vivo, and activated the PGC-1 gene promoter in cultured myocytes. Thus, a calcium-regulated signaling pathway controls mitochondrial biogenesis in mammalian cells.	Duke Univ, Med Ctr, Sch Med, Durham, NC 27710 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA	Duke University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Williams, RS (corresponding author), Duke Univ, Med Ctr, Sch Med, Durham, NC 27710 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL006296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R56AR040849, R01AR040849] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06296] Funding Source: Medline; NIAMS NIH HHS [AR40849] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alevizopoulos A, 1997, J BIOL CHEM, V272, P23597, DOI 10.1074/jbc.272.38.23597; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Grange RW, 2001, AM J PHYSIOL-CELL PH, V281, pC1487, DOI 10.1152/ajpcell.2001.281.5.C1487; HARIBABU B, 1995, EMBO J, V14, P3679, DOI 10.1002/j.1460-2075.1995.tb00037.x; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; OGILVIE RW, 1990, STAIN TECHNOL, V65, P231, DOI 10.3109/10520299009105613; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PICCIOTTO MR, 1993, J BIOL CHEM, V268, P26512; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wang H, 1999, EUR J APPL PHYSIOL O, V80, P22, DOI 10.1007/s004210050553; WILLIAMS RS, 1986, J BIOL CHEM, V261, P376; WILLIAMS RS, 1986, J BIOL CHEM, V261, P2390; WILLIAMS RS, 1987, J BIOL CHEM, V262, P2764; Wu GY, 2001, P NATL ACAD SCI USA, V98, P2808, DOI 10.1073/pnas.051634198; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X	23	510	542	0	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					349	352		10.1126/science.1071163	http://dx.doi.org/10.1126/science.1071163			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951046				2022-12-28	WOS:000175000300059
J	Yamaguchi, A; Clayton, RN; Mayeda, TK; Ebihara, M; Oura, Y; Miura, YN; Haramura, H; Misawa, K; Kojima, H; Nagao, K				Yamaguchi, A; Clayton, RN; Mayeda, TK; Ebihara, M; Oura, Y; Miura, YN; Haramura, H; Misawa, K; Kojima, H; Nagao, K			A new source of basaltic meteorites inferred from Northwest Africa 011	SCIENCE			English	Article							PARENT BODY; NOBLE-GASES; EUCRITES; METAMORPHISM; ACHONDRITES; ELEMENTS; CRUST	Eucrites are a class of basaltic meteorites that share common mineralogical, isotopic, and chemical properties and are thought to have been derived from the same parent body, possibly asteroid 4 Vesta. The texture, mineralogy, and noble gas data of the recently recovered meteorite, Northwest Africa (NWA) 011, are similar to those of basaltic eucrites. However, the oxygen isotopic composition of NWA011 is different from that of other eucrites, indicating that NWA011 may be derived from a different parent body. The presence of basaltic meteorites with variable oxygen isotopic composition suggests the occurrence of multiple basaltic meteorite parent bodies, perhaps similar to 4 Vesta, in the early solar system.	Natl Inst Polar Res, Antarctic Meteorite Res Ctr, Tokyo 1738515, Japan; Grad Univ Adv Studies, Tokyo 1738515, Japan; Univ Chicago, Enrico Fermi Inst, Chicago, IL 60637 USA; Tokyo Metropolitan Univ, Dept Chem, Tokyo 1920397, Japan; Univ Tokyo, Earthquake Res Inst, Tokyo 1130032, Japan; Univ Tokyo, Earthquake Chem Lab, Tokyo 1130033, Japan	Research Organization of Information & Systems (ROIS); National Institute of Polar Research (NIPR) - Japan; Graduate University for Advanced Studies - Japan; University of Chicago; Tokyo Metropolitan University; University of Tokyo; University of Tokyo	Yamaguchi, A (corresponding author), Natl Inst Polar Res, Antarctic Meteorite Res Ctr, Tokyo 1738515, Japan.							Afanasiev SV, 2000, METEORIT PLANET SCI, V35, pA19; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BINZEL RP, 1993, SCIENCE, V260, P186, DOI 10.1126/science.260.5105.186; CLAYTON RN, 1993, ANNU REV EARTH PL SC, V21, P115, DOI 10.1146/annurev.earth.21.1.115; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; CLAYTON RN, 1983, EARTH PLANET SC LETT, V62, P2; Ebihara M, 1996, GEOCHIM COSMOCHIM AC, V60, P5133, DOI 10.1016/S0016-7037(96)00282-7; EBIHARA M, UNPUB; ELGORESY A, 1975, P LUN SCI C, V6, P729; EUGSTER O, 1995, GEOCHIM COSMOCHIM AC, V59, P177, DOI 10.1016/0016-7037(94)00327-I; Floss C., 2000, ANTARCT METEORITE RE, V13, P222; Gibson E. K.  Jr., 1978, Meteoritics, V13, P277, DOI 10.1111/j.1945-5100.1978.tb00467.x; Haramura H., 1983, MEM NATL I POLAR RES, V30, P109; HIROI T, UNPUB; IKEDA Y, 1985, P LUNAR PLANET SCI S, V15, pC649; KRETZ R, 1982, GEOCHIM COSMOCHIM AC, V46, P411, DOI 10.1016/0016-7037(82)90232-0; Latif SA, 1999, J RADIOANAL NUCL CH, V239, P577, DOI 10.1007/BF02349072; Lazzaro D, 2000, SCIENCE, V288, P2033, DOI 10.1126/science.288.5473.2033; Mason B., 1979, SMITHSON CONTRIB EAR, V22, P27; MITTLEFEHLDT DW, REV MINERALOGY, V36, P1; Miura YN, 1998, GEOCHIM COSMOCHIM AC, V62, P2369, DOI 10.1016/S0016-7037(98)00118-5; MIYAMOTO M, 1985, P LUNAR PLANET SCI C, V15, pC629; Shinotsuka K, 1997, ANAL CHIM ACTA, V338, P237, DOI 10.1016/S0003-2670(96)00528-4; TAKEDA H, 1991, METEORITICS, V26, P129, DOI 10.1111/j.1945-5100.1991.tb01028.x; Wasson J.T., 1979, ASTEROIDS, P926; WILLIS J, 1982, J GEOPHYS RES, V87, pA435, DOI 10.1029/JB087iS01p0A435; Yamaguchi A, 1996, ICARUS, V124, P97, DOI 10.1006/icar.1996.0192; Yamaguchi A, 1997, J GEOPHYS RES-PLANET, V102, P13381, DOI 10.1029/97JE00519; Yamaguchi A, 2001, GEOCHIM COSMOCHIM AC, V65, P3577, DOI 10.1016/S0016-7037(01)00681-0	29	117	119	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					334	336		10.1126/science.1069408	http://dx.doi.org/10.1126/science.1069408			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951042				2022-12-28	WOS:000175000300054
J	French, AL; Cohen, MH; Gange, SJ; Burger, H; Gao, W; Semba, RD; Meyer, WA; Robison, E; Anastos, K				French, AL; Cohen, MH; Gange, SJ; Burger, H; Gao, W; Semba, RD; Meyer, WA; Robison, E; Anastos, K			Vitamin A deficiency and genital viral burden in women infected with HIV-1	LANCET			English	Article							A-DEFICIENCY; TRANSMISSION; PREGNANCY	The relation between vitamin A (retinol) deficiency and perinatal transmission of HIV-1, If It exists, might be mediated through an increased viral load in the mother's genital tract. To ascertain whether or not such an association is present, we measured the serum concentration of retinol with high performance liquid chromatography, and correlated the results with concurrent quantified HIV-1 RNA concentrations In cervicovaginal lavage fluid In 301 women Infected with the virus. We noted no association between retinol status and genital HIV-1 load. Our findings lend support to those of studies that reported no association between retinol deficiency and perinatal HIV-1. transmission.	Cook Cty Hosp, Div Infect Dis, Chicago, IL 60612 USA; Rush Med Coll, Chicago, IL 60612 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; New York State Dept Hlth, Wadsworth Ctr, Albany, NY USA; Montefiore Med Ctr, Bronx, NY 10467 USA; Johns Hopkins Sch Med, Baltimore, MD USA; Queat Diagnost Inc, Baltimore, MD USA; Lincoln Med Ctr, Bronx, NY USA	John H Stroger Junior Hospital Cook County; Rush University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; State University of New York (SUNY) System; Wadsworth Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University; Johns Hopkins Medicine	French, AL (corresponding author), Cook Cty Hosp, Div Infect Dis, Durand 115,1835 W Harrison St, Chicago, IL 60612 USA.		Gange, Stephen/AGY-5004-2022	Gange, Stephen/0000-0001-7842-512X; French, Audrey/0000-0002-9776-8934	NIAID NIH HHS [U01-AI-35004, AI-34989, U01-AI-34994, U01-AI-42590, U01-AI-31834, U01-AI-34993] Funding Source: Medline; NICHD NIH HHS [U01-HD-32632] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U01HD032632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035004, U01AI034989, U01AI042590, U01AI034993, U01AI034994, U01AI031834] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Burns DN, 1999, CLIN INFECT DIS, V29, P328, DOI 10.1086/520210; Greenberg BL, 1997, AIDS, V11, P325, DOI 10.1097/00002030-199703110-00010; John GC, 1997, J INFECT DIS, V175, P57, DOI 10.1093/infdis/175.1.57; Mostad SB, 1997, LANCET, V350, P922, DOI 10.1016/S0140-6736(97)04240-2; SEMBA RD, 1994, LANCET, V343, P1593, DOI 10.1016/S0140-6736(94)93056-2	5	8	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1210	1212		10.1016/S0140-6736(02)08226-0	http://dx.doi.org/10.1016/S0140-6736(02)08226-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955543				2022-12-28	WOS:000174846300015
J	Ruitenberg, M; Kannt, A; Bamberg, E; Fendler, K; Michel, H				Ruitenberg, M; Kannt, A; Bamberg, E; Fendler, K; Michel, H			Reduction of cytochrome c oxidase by a second electron leads to proton translocation	NATURE			English	Article							BO UBIQUINOL OXIDASE; PARACOCCUS-DENITRIFICANS; ESCHERICHIA-COLI; SUBUNIT-I; SITE; STATE	Cytochrome c oxidase, the terminal enzyme of cellular respiration in mitochondria and many bacteria, reduces O-2 to water. This four-electron reduction process is coupled to translocation (pumping) of four protons across the mitochondrial or bacterial membrane(1); however, proton pumping is poorly understood. Proton pumping was thought to be linked exclusively to the oxidative phase, that is, to the transfer of the third and fourth electron(2). Upon re-evaluation of these data, however, this proposal has been questioned(3,4), and a transport mechanism including proton pumping in the reductive phase-that is, during the transfer of the first two electrons-was suggested. Subsequently, additional studies reported that proton pumping during the reductive phase can occur, but only when it is immediately preceded by an oxidative phase(5). To help clarify the issue we have measured the generation of the electric potential across the membrane, starting from a defined one-electron reduced state. Here we show that a second electron transfer into the enzyme leads to charge translocation corresponding to pumping of one proton without necessity for a preceding turnover.	Max Planck Inst Biophys, Dept Mol Membrane Biol, D-60528 Frankfurt, Germany; Max Planck Inst Biophys, Dept Biophys Chem, D-60596 Frankfurt, Germany	Max Planck Society; Max Planck Society	Michel, H (corresponding author), Max Planck Inst Biophys, Dept Mol Membrane Biol, Heinrich Hoffmann Str 7, D-60528 Frankfurt, Germany.	fendler@mpibp-frankfurt.mpg.de; michel@mpibp-frankfurt.mpg.de	Kannt, Aimo/AAZ-6898-2020	Kannt, Aimo/0000-0002-5197-2286; Fendler, Klaus/0000-0002-5699-7060				BRZEZINSKI P, 1985, FEBS LETT, V187, P111, DOI 10.1016/0014-5793(85)81224-2; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; GREENWOOD C, 1974, BIOCHEM J, V137, P205, DOI 10.1042/bj1370205; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Jasaitis A, 1999, BIOCHEMISTRY-US, V38, P2697, DOI 10.1021/bi982275l; Konstantinov AA, 1997, P NATL ACAD SCI USA, V94, P9085, DOI 10.1073/pnas.94.17.9085; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; Michel H, 1998, ANNU REV BIOPH BIOM, V27, P329, DOI 10.1146/annurev.biophys.27.1.329; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; MOODY AJ, 1991, BIOCHEM SOC T, V19, P617, DOI 10.1042/bst0190617; NILSSON T, 1992, P NATL ACAD SCI USA, V89, P6497, DOI 10.1073/pnas.89.14.6497; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P7053, DOI 10.1021/bi00243a003; Ruitenberg M, 2000, P NATL ACAD SCI USA, V97, P4632, DOI 10.1073/pnas.080079097; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P11173, DOI 10.1021/bi00092a029; THOMAS JW, 1993, BIOCHEMISTRY-US, V32, P10923, DOI 10.1021/bi00091a048; Verkhovsky MI, 1999, NATURE, V400, P480, DOI 10.1038/22813; Verkhovsky MI, 2001, BIOCHEMISTRY-US, V40, P7077, DOI 10.1021/bi010030u; VYGODINA TV, 1988, ANN NY ACAD SCI, V550, P124, DOI 10.1111/j.1749-6632.1988.tb35329.x; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; WITT SN, 1987, J BIOL CHEM, V262, P1446	22	98	100	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	2002	417	6884					99	102		10.1038/417099a	http://dx.doi.org/10.1038/417099a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986672				2022-12-28	WOS:000175307200046
J	Song, SH; Stevens, CF; Gage, FH				Song, SH; Stevens, CF; Gage, FH			Astroglia induce neurogenesis from adult neural stem cells	NATURE			English	Article							HIPPOCAMPAL-NEURONS; SPINAL-CORD; ASTROCYTES; GLIA; DIFFERENTIATION; PROLIFERATION; PROGENITORS; GENERATION; NICHE	During an investigation of the mechanisms through which the local environment controls the fate specification of adult neural stem cells, we discovered that adult astrocytes from hippocampus are capable of regulating neurogenesis by instructing the stem cells to adopt a neuronal fate. This role in fate specification was unexpected because, during development, neurons are generated before most of the astrocytes. Our findings, together with recent reports that astrocytes regulate synapse formation and synaptic transmission, reinforce the emerging view that astrocytes have an active regulatory role-rather than merely supportive roles traditionally assigned to them-in the mature central nervous system.	Salk Inst Biol Studies, Howard Hughes Med Inst, Mol Neurobiol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA	Howard Hughes Medical Institute; Salk Institute; Salk Institute	Stevens, CF (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Mol Neurobiol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	stevens@salk.edu; gage@salk.edu						BANKER GA, 1980, SCIENCE, V209, P809, DOI 10.1126/science.7403847; Barres BA, 1999, J CELL BIOL, V147, P1123, DOI 10.1083/jcb.147.6.1123; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Cowan W M, 1980, Curr Top Dev Biol, V15 Pt 1, P103; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Goslin K., 1998, CULTURING NERVE CELL, P339; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Horner PJ, 2000, J NEUROSCI, V20, P2218; Kandel E.R., 2000, PRINCIPLES NEURAL SC, V4a, P1414; Kehl LJ, 1997, SCIENCE, V276, P586, DOI 10.1126/science.276.5312.586; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kornack DR, 2001, SCIENCE, V294, P2127, DOI 10.1126/science.1065467; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Lim DA, 1999, P NATL ACAD SCI USA, V96, P7526, DOI 10.1073/pnas.96.13.7526; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; Lino M, 2001, SCIENCE, V292, P926, DOI 10.1126/science.1058827; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Miyata T, 2001, NEURON, V31, P727, DOI 10.1016/S0896-6273(01)00420-2; NICHOLLS JG, 1992, NEURON BRAIN, P149; NOBLE M, 1998, CULTURING NERVE CELL, P499; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; Palmer TD, 2000, J COMP NEUROL, V425, P479, DOI 10.1002/1096-9861(20001002)425:4<479::AID-CNE2>3.0.CO;2-3; PIXLEY SK, 1992, NEURON, V8, P1191, DOI 10.1016/0896-6273(92)90139-5; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SCHWARTZ JP, 1992, GLIA, V5, P75, DOI 10.1002/glia.440050111; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Shihabuddin LS, 1997, EXP NEUROL, V148, P577, DOI 10.1006/exnr.1997.6697; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Ullian EM, 2001, SCIENCE, V291, P657, DOI 10.1126/science.291.5504.657	42	1098	1215	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	2002	417	6884					39	44		10.1038/417039a	http://dx.doi.org/10.1038/417039a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986659				2022-12-28	WOS:000175307200031
J	Patz, JA; Khaliq, M				Patz, JA; Khaliq, M			Global climate change and health: Challenges for future practitioners	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NINO-SOUTHERN OSCILLATION; EL-NINO; MALARIA		Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Patz, JA (corresponding author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.							[Anonymous], CONTRIBUTION WORKING; Bouma MJ, 1997, TROP MED INT HEALTH, V2, P1122, DOI 10.1046/j.1365-3156.1997.d01-210.x; BRAUER M, 1998, WHO WORKSH HLTH IMP; Checkley W, 2000, LANCET, V355, P442, DOI 10.1016/S0140-6736(00)82010-3; Curriero FC, 2002, AM J EPIDEMIOL, V155, P80, DOI 10.1093/aje/155.1.80; Gaffen DJ, 1998, NATURE, V396, P529, DOI 10.1038/25030; GOBLER DJ, 2001, ENVIRON HEALTH PER S, V109, P223; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; KARL TR, 1995, NATURE, V377, P217, DOI 10.1038/377217a0; Kilboume E.M., 1997, PUBLIC HLTH CONSEQUE, P51; Kilian AHD, 1999, T ROY SOC TROP MED H, V93, P22, DOI 10.1016/S0035-9203(99)90165-7; Malilay JF, 1997, PUBLIC HLTH CONSEQUE, P287; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; MCMICHAEL AJ, 1996, CLIMAGE CHANGE HUMAN; Milly PCD, 2002, NATURE, V415, P514, DOI 10.1038/415514a; Myers N., 1995, ENV EXODUS EMERGENT; NICHOLLS R, 1995, CLIMATE CHANGES INT, P92; Noji EK, 1997, PUBLIC HLTH CONSEQUE, P3; Pascual M, 2000, SCIENCE, V289, P1766, DOI 10.1126/science.289.5485.1766; Patz JA, 2001, HUM ECOL RISK ASSESS, V7, P1317, DOI 10.1080/20018091095023; Patz JA, 2000, ANNU REV PUBL HEALTH, V21, P271, DOI 10.1146/annurev.publhealth.21.1.271; ROPELEWSKI CF, 1987, MON WEATHER REV, V115, P1606, DOI 10.1175/1520-0493(1987)115<1606:GARSPP>2.0.CO;2; Whitman S, 1997, AM J PUBLIC HEALTH, V87, P1515, DOI 10.2105/AJPH.87.9.1515	23	29	29	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2283	2284		10.1001/jama.287.17.2283	http://dx.doi.org/10.1001/jama.287.17.2283			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980532				2022-12-28	WOS:000175260600031
J	Merkel, TC; Freeman, BD; Spontak, RJ; He, Z; Pinnau, I; Meakin, P; Hill, AJ				Merkel, TC; Freeman, BD; Spontak, RJ; He, Z; Pinnau, I; Meakin, P; Hill, AJ			Ultrapermeable, reverse-selective nanocomposite membranes	SCIENCE			English	Article							POSITRON-ANNIHILATION; GAS PERMEATION; FREE-VOLUME; SEPARATION; PERMEABILITY; POLYMERS	Polymer nanocomposites continue to receive tremendous attention for application in areas such as microelectronics, organic batteries, optics, and catalysis. We have discovered that physical dispersion of nonporous, nanoscale, fumed silica particles in glassy amorphous poly(4-methyl-2-pentyne) simultaneously and surprisingly enhances both membrane permeability and selectivity for large organic molecules over small permanent gases. These highly unusual property enhancements, in contrast to results obtained in conventional filled polymer systems, reflect fumed silica-induced disruption of polymer chain packing and an accompanying subtle increase in the size of free volume elements through which molecular transport occurs, as discerned by positron annihilation lifetime spectroscopy. Such nanoscale hybridization represents an innovative means to tune the separation properties of glassy polymeric media through systematic manipulation of molecular packing.	Res Triangle Inst, Ctr Energy Technol, Res Triangle Pk, NC 27709 USA; Univ Texas, Ctr Energy & Environm Resources, Dept Chem Engn, Austin, TX 78758 USA; N Carolina State Univ, Dept Chem Engn, Raleigh, NC 27695 USA; Membrane Technol & Res, Menlo Pk, CA 94025 USA; CSIRO, Div Mfg Sci & Technol, Clayton, Vic 3168, Australia; Monash Univ, Sch Chem, Clayton, Vic 3800, Australia	Research Triangle Institute; University of Texas System; University of Texas Austin; University of North Carolina; North Carolina State University; Commonwealth Scientific & Industrial Research Organisation (CSIRO); Monash University	Merkel, TC (corresponding author), Res Triangle Inst, Ctr Energy Technol, POB 12194, Res Triangle Pk, NC 27709 USA.		Freeman, Benny/G-5405-2016; Yong, Ng Law/K-4556-2012; Hill, Anita J/B-9231-2011	Freeman, Benny/0000-0003-2779-7788; Yong, Ng Law/0000-0002-6868-4977; Hill, Anita J/0000-0003-1574-243X				BARRER RM, 1963, J POLYM SCI PART A, V1, P2565, DOI 10.1002/pol.1963.100010806; BARRER RM, 1968, DIFFUSION POLYM, P165; COHEN MH, 1959, J CHEM PHYS, V31, P1164, DOI 10.1063/1.1730566; Coronado E, 2000, NATURE, V408, P447, DOI 10.1038/35044035; Croce F, 1998, NATURE, V394, P456, DOI 10.1038/28818; Freeman B, 1997, TRENDS POLYM SCI, V5, P167; Freeman BD, 1999, MACROMOLECULES, V32, P375, DOI 10.1021/ma9814548; Graham T., 1866, PHILOS MAG 4, V32, P401; JIA MD, 1991, J MEMBRANE SCI, V57, P289, DOI 10.1016/S0376-7388(00)80684-5; KOBAYASHI Y, 1994, POLYMER, V35, P925, DOI 10.1016/0032-3861(94)90934-2; Kulprathipanja S., 1988, U.S. Patent, Patent No. [4,740,219 A, 4740219, 4,740,219]; Mahajan R., 1999, POLYM MEMBRANES GAS, P277; Maxwell JC., 1873, TREATISE ELECT MAGNE; Morisato A, 1996, J MEMBRANE SCI, V121, P243, DOI 10.1016/S0376-7388(96)00183-4; Pinnau I, 1996, J MEMBRANE SCI, V116, P199, DOI 10.1016/0376-7388(96)00041-5; Pinnau I., 2001, US Patent, Patent No. [6,316,684, 6316684]; PINNAVAIA TJ, 1983, SCIENCE, V220, P365, DOI 10.1126/science.220.4595.365; ROBESON LM, 1991, J MEMBRANE SCI, V62, P165, DOI 10.1016/0376-7388(91)80060-J; Schmid G., 1994, CLUSTERS COLLOIDS; Shantarovich VP, 2000, MACROMOLECULES, V33, P7453, DOI 10.1021/ma000551+; Shiflett MB, 1999, SCIENCE, V285, P1902, DOI 10.1126/science.285.5435.1902; Sidorov SN, 2001, J AM CHEM SOC, V123, P10502, DOI 10.1021/ja0107834; Wang Y, 1996, SCIENCE, V273, P632, DOI 10.1126/science.273.5275.632; Winiarz JG, 1999, J AM CHEM SOC, V121, P5287, DOI 10.1021/ja983559w	24	891	910	21	437	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					519	522		10.1126/science.1069580	http://dx.doi.org/10.1126/science.1069580			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964476				2022-12-28	WOS:000175179400043
J	Ross, AGP; Bartley, PB; Sleigh, AC; Olds, GR; Li, YS; Williams, GM; McManus, DP				Ross, AGP; Bartley, PB; Sleigh, AC; Olds, GR; Li, YS; Williams, GM; McManus, DP			Current concepts - Schistosomiasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FEMALE GENITAL SCHISTOSOMIASIS; DONGTING LAKE REGION; HEPATIC-FIBROSIS; JAPONICUM INFECTION; NUTRITIONAL-STATUS; MANSONI INFECTION; ORAL ARTEMETHER; WESTERN KENYA; PRAZIQUANTEL; HAEMATOBIUM		Queensland Inst Med Res, Australian Ctr Int & Trop Hlth & Nutr, 300 Herston Rd, Brisbane, Qld 4029, Australia; Med Univ Amer, Charlestown, MA USA; Univ Queensland, Brisbane, Qld, Australia; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA	QIMR Berghofer Medical Research Institute; University of Queensland; Medical College of Wisconsin	McManus, DP (corresponding author), Queensland Inst Med Res, Australian Ctr Int & Trop Hlth & Nutr, 300 Herston Rd, Brisbane, Qld 4029, Australia.	donm@qimr.edu.au	Bartley, Paul/ABE-6528-2020; McManus, Don/AAC-5394-2020; Torero, Rebeca/C-1703-2012; sleigh, adrian/J-4540-2019; Bartley, Paul/C-2178-2016; McManus, Donald P./G-2678-2013	Bartley, Paul/0000-0001-6748-1775; McManus, Don/0000-0001-6443-1449; sleigh, adrian/0000-0001-8443-7864; Bartley, Paul/0000-0001-6748-1775; Ross, Allen/0000-0002-2329-0907; Williams, Gail/0000-0002-4822-5263	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI039461] Funding Source: NIH RePORTER; NIAID NIH HHS [1 P50 AI39461] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Sherbiny MM, 1999, AM J TROP MED HYG, V60, P960, DOI 10.4269/ajtmh.1999.60.960; Aquino Renata Telles Rudge de, 2000, Revista do Instituto de Medicina Tropical de Sao Paulo, V42, P313; Badawi AF, 1999, ANTICANCER RES, V19, P4565; Bedwani R, 1998, BRIT J CANCER, V77, P1186, DOI 10.1038/bjc.1998.197; Bethlem E P, 1997, Curr Opin Pulm Med, V3, P361, DOI 10.1097/00063198-199709000-00008; BOROS DL, 1970, J EXP MED, V132, P488, DOI 10.1084/jem.132.3.488; BRINDLEY P J, 1987, Memorias do Instituto Oswaldo Cruz, V82, P157, DOI 10.1590/S0074-02761987000800027; BRINDLEY PJ, 1987, J IMMUNOL, V139, P215; Capron A, 2001, INT ARCH ALLERGY IMM, V124, P9, DOI 10.1159/000053656; Cetron MS, 1996, LANCET, V348, P1274, DOI 10.1016/S0140-6736(96)01511-5; CHEEVER AW, 1982, T ROY SOC TROP MED H, V76, P641, DOI 10.1016/0035-9203(82)90231-0; CHEEVER AW, 1978, JNCI-J NATL CANCER I, V61, P13, DOI 10.1093/jnci/61.1.13; CHEN M, 1978, CHINESE MED J-PEKING, V4, P371; Chen M, 1989, TROP DIS B, V85, pR1; CHEN MG, 1991, ACTA TROP, V48, P163, DOI 10.1016/0001-706X(91)90044-K; Chitsulo L, 2000, ACTA TROP, V77, P41, DOI 10.1016/S0001-706X(00)00122-4; Cooke GS, 1999, CLIN INFECT DIS, V29, P836, DOI 10.1086/520445; Dessein AJ, 1999, AM J HUM GENET, V65, P709, DOI 10.1086/302526; DOENHOFF MJ, 1981, T ROY SOC TROP MED H, V75, P41, DOI 10.1016/0035-9203(81)90012-2; DOENHOFF MJ, 1986, T ROY SOC TROP MED H, V80, P503, DOI 10.1016/0035-9203(86)90126-4; Doherty JF, 1996, BRIT MED J, V313, P1071, DOI 10.1136/bmj.313.7064.1071; ELSEBAI I, 1977, CA-CANCER J CLIN, V27, P100, DOI 10.3322/canjclin.27.2.100; FELDMEIER H, 1995, T ROY SOC TROP MED H, V89, P237, DOI 10.1016/0035-9203(95)90512-X; Fowler R, 1999, AM J TROP MED HYG, V61, P47, DOI 10.4269/ajtmh.1999.61.47; Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7; Frenzel K, 1999, AM J TROP MED HYG, V60, P927, DOI 10.4269/ajtmh.1999.60.927; Garcia LSSR, 1999, MANUAL CLIN MICROBIO, P1336; GOLDSMITH PC, 1993, BMJ-BRIT MED J, V307, P556, DOI 10.1136/bmj.307.6903.556; Hagan P, 2000, PARASITOL TODAY, V16, P322, DOI 10.1016/S0169-4758(00)01711-7; HARRIES AD, 1986, LANCET, V1, P86; HATZ C, 1992, ACTA TROP, V51, P15, DOI 10.1016/0001-706X(92)90017-R; HATZ C, 1992, ACTA TROP, V51, P29, DOI 10.1016/0001-706X(92)90018-S; Hatz CF, 1998, AM J TROP MED HYG, V59, P775, DOI 10.4269/ajtmh.1998.59.775; Hirayama K, 1999, TISSUE ANTIGENS, V53, P269, DOI 10.1034/j.1399-0039.1999.530307.x; HUSSEIN AMT, 1983, LANCET, V1, P673; Ismail M, 1999, AM J TROP MED HYG, V60, P932, DOI 10.4269/ajtmh.1999.60.932; Jordan P., 1993, HUMAN SCHISTOSOMIASI; KANE CA, 1948, ARCH NEURO PSYCHIATR, V59, P141, DOI 10.1001/archneurpsyc.1948.02300370003001; Karanja DHS, 1998, AM J TROP MED HYG, V59, P307, DOI 10.4269/ajtmh.1998.59.307; Karanja DMS, 1997, AM J TROP MED HYG, V56, P515, DOI 10.4269/ajtmh.1997.56.515; Kardorff R, 1997, TROP MED INT HEALTH, V2, P230, DOI 10.1046/j.1365-3156.1997.d01-269.x; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; King CH, 2000, EMERG INFECT DIS, V6, P585, DOI 10.3201/eid0606.000606; KING CH, 2001, SCHISTOSOMIASIS, P265; King CL, 2001, SCHISTOSOMIASIS, P218; Lawn SD, 2000, AIDS, V14, P2437, DOI 10.1097/00002030-200011100-00004; Li YS, 2000, T ROY SOC TROP MED H, V94, P191, DOI 10.1016/S0035-9203(00)90274-8; McGarvey ST, 1996, AM J TROP MED HYG, V54, P498, DOI 10.4269/ajtmh.1996.54.498; MCGARVEY ST, 1993, AM J TROP MED HYG, V48, P547, DOI 10.4269/ajtmh.1993.48.547; McManus DP, 1999, IMMUNOL REV, V171, P149; Morel CM, 2000, PARASITOL TODAY, V16, P522, DOI 10.1016/S0169-4758(00)01815-9; NEWMAN L, 2001, LANCET INFECT DIS, V1, P140; Nokes C, 1999, AM J TROP MED HYG, V60, P556, DOI 10.4269/ajtmh.1999.60.556; Ojo O S, 1992, Trop Gastroenterol, V13, P64; Olds GR, 1996, AM J TROP MED HYG, V55, P121; Patz JA, 2000, INT J PARASITOL, V30, P1395, DOI 10.1016/S0020-7519(00)00141-7; Poggensee G, 2001, ACTA TROP, V79, P193, DOI 10.1016/S0001-706X(01)00086-9; Poon RTP, 1999, WORLD J SURG, V23, P713, DOI 10.1007/PL00012374; Richter J, 2000, ACTA TROP, V77, P111, DOI 10.1016/S0001-706X(00)00125-X; Ross AGP, 1997, AM J TROP MED HYG, V57, P302, DOI 10.4269/ajtmh.1997.57.302; Ross AGP, 2001, CLIN MICROBIOL REV, V14, P270, DOI 10.1128/CMR.14.2.270-295.2001; Ross Allen G.P., 2001, Biologist (London), V48, P121; SASA M, 1972, RES FILARIASIS SCHIS, V2, P235; SHAHIN M, 1992, HEPATOLOGY, V15, P637, DOI 10.1002/hep.1840150414; SHUHUA X, 2000, INT J PARASITOL, V30, P1001; SLEIGH A, 1991, WHO REPORT SERIES, P21; THOMAS H, 1977, Z PARASITENKD, V52, P117, DOI 10.1007/BF00389898; Tsang VCW, 1997, IMMUNOL INVEST, V26, P175, DOI 10.3109/08820139709048925; Utzinger J, 2000, LANCET, V355, P1320, DOI 10.1016/S0140-6736(00)02114-0; Waine GJ, 1997, BIOESSAYS, V19, P435, DOI 10.1002/bies.950190511; Wang XZ, 1999, CHINESE MED J-PEKING, V112, P124; Warren K, 1973, HELM ABSTR SER A, V42, P590; Whitty CJM, 2000, T ROY SOC TROP MED H, V94, P531, DOI 10.1016/S0035-9203(00)90077-4; William S, 2001, PARASITOLOGY, V122, P63, DOI 10.1017/S0031182000007137; WISHAHI M, 1989, EUR UROL, V16, P138; Wyler DJ, 1997, AM J TROP MED HYG, V56, P66, DOI 10.4269/ajtmh.1997.56.66; Xiao SH, 2000, PARASITOL TODAY, V16, P122, DOI 10.1016/S0169-4758(99)01601-4; Xiao SH, 1996, CHINESE MED J-PEKING, V109, P272; Xiao SH, 2000, PARASITOL INT, V49, P25, DOI 10.1016/S1383-5769(00)00029-5; Ye XP, 1998, EPIDEMIOL INFECT, V121, P193, DOI 10.1017/S0950268898008917; YU XN, 1991, CHINESE MED J-PEKING, V104, P64; Zhou H, 1998, T ROY SOC TROP MED H, V92, P245, DOI 10.1016/S0035-9203(98)90997-X	83	642	672	2	68	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	2002	346	16					1212	1220		10.1056/NEJMra012396	http://dx.doi.org/10.1056/NEJMra012396			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542FT	11961151				2022-12-28	WOS:000175033400007
J	Veillet, C; Parker, JW; Griffin, I; Marsden, B; Doressoundiram, A; Buie, M; Tholen, DJ; Connelley, M; Holman, MJ				Veillet, C; Parker, JW; Griffin, I; Marsden, B; Doressoundiram, A; Buie, M; Tholen, DJ; Connelley, M; Holman, MJ			The binary Kuiper-belt object 1998 WW31	NATURE			English	Article							HUBBLE-SPACE-TELESCOPE; DISCOVERY	The recent discovery(1,2) of a binary asteroid during a spacecraft fly-by generated keen interest, because the orbital parameters of binaries can provide measures of the masses, and mutual eclipses could allow us to determine individual sizes and bulk densities. Several binary near-Earth(3-5), main-belt(6-10) and Trojan(11) asteroids have subsequently been discovered. The Kuiper belt-the region of space extending from Neptune (at 30 astronomical units) to well over 100 AU and believed to be the source of new short-period comets(12)-has become a fascinating new window onto the formation of our Solar System since the first member object, not counting Pluto, was discovered in 1992 (ref. 13). Here we report that the Kuiper-belt object 1998 WW31 is binary with a highly eccentric orbit (eccentricity e approximate to 0.8) and a long period (about 570 days), very different from the Pluto/Charon system, which was hitherto the only previously known binary in the Kuiper belt. Assuming a density in the range of 1 to 2 g cm(-3), the albedo of the binary components is between 0.05 and 0.08, close to the value of 0.04 generally assumed for Kuiper-belt objects.	Canada France Hawaii Telescope Corp, Kamuela, HI 96743 USA; SW Res Inst, Boulder, CO 80302 USA; Space Telescope Sci Inst, Baltimore, MD 21218 USA; Ctr Astrophys, Cambridge, MA 02138 USA; Observ Paris, F-92195 Meudon, France; Lowell Observ, Flagstaff, AZ USA; Inst Astron, Honolulu, HI 96822 USA	Canada France Hawaii Telescope; Space Telescope Science Institute; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Veillet, C (corresponding author), Canada France Hawaii Telescope Corp, POB 1597, Kamuela, HI 96743 USA.		Veillet, Christian/P-5301-2018	Veillet, Christian/0000-0003-0272-0418; Griffin, Ian/0000-0002-5367-7539; Connelley, Michael/0000-0002-8293-1428; Parker, Joel/0000-0002-3672-0603				Belton MJS, 1996, ICARUS, V120, P185, DOI 10.1006/icar.1996.0044; Benner L.A.M., 2001, 7632 IAU; Brown M. E., 2001, 7588 IAU; BROWN ME, 2001, 7807 IAU; CHAPMAN CR, 1995, NATURE, V374, P783, DOI 10.1038/374783a0; DUNCAN M, 1988, ASTROPHYS J, V328, pL69, DOI 10.1086/185162; ELLIOT JL, 2001, 7733 IAU; HOLTZMAN J, 1995, PUBL ASTRON SOC PAC, V107, P156, DOI 10.1086/133533; Jewitt D, 2001, NATURE, V411, P446, DOI 10.1038/35078008; KAVELAARS J, 2001, 7749 IAU; MARGOT JL, 2000, 7503 IAU; Merline W.J., 2001, IAU CIRC, V7703, P2; Merline W. J., 2001, 7703 IAU; Merline WJ, 1999, NATURE, V401, P565, DOI 10.1038/44089; MERLINE WJ, 2000, DPS M 32 AM ASTR SOC; MERLINE WJ, 2002, 7827 IAU; MILLIS RL, 2001, 1999B24 MIN PLAN EL; NOLAN MC, 2000, 7632 IAU; NOLL KS, 2002, 7857 IAU; NOLL KS, 2002, 7824 IAU; Tholen DJ, 1997, ICARUS, V125, P245, DOI 10.1006/icar.1996.5494; TRUJILLO CA, 2001, 7787 IAU; [No title captured]	23	76	78	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					711	713		10.1038/416711a	http://dx.doi.org/10.1038/416711a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961547				2022-12-28	WOS:000175033500034
J	Churchland, PS				Churchland, PS			Self-representation in nervous systems	SCIENCE			English	Article								The brain's earliest self-representational capacities arose as evolution found neural network solutions for coordinating and regulating inner-body signals, thereby improving behavioral strategies. Additional flexibility in organizing coherent behavioral options emerges from neural models that represent some of the brain's inner states as states of its body, while representing other signals as perceptions of the external world. Brains manipulate inner models to predict the distinct consequences in the external world of distinct behavioral options. The self thus turns out to be identifiable not with a nonphysical, soul, but rather with a set of representational capacities of the physical brain.	Univ Calif San Diego, Philosophy Dept 0119, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Churchland, PS (corresponding author), Univ Calif San Diego, Philosophy Dept 0119, La Jolla, CA 92093 USA.							Anderson SW, 1999, NAT NEUROSCI, V2, P1032, DOI 10.1038/14833; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; Churchland P. S., 1986, NEUROPHILOSOPHY; Churchland Paul M., 1988, MATTER CONSCIOUSNESS; CHURCHLAND PS, BRAIN WISE STUDIES N; CRICK F, IN PRESS PROBLEMS SY; Damasio A.R., 2000, FEELING WHAT HAPPENS; DAMASIO AR, 1994, DESCARTES ERROR; Dennett D.C., 1991, CONSCIOUSNESS EXPLAI; Fodor J., 1974, SYNTHESE, V28, P97, DOI DOI 10.1007/BF00485230; Frith CD., 1992, COGNITIVE NEUROSCIEN; Grush R, 1997, PHILOS PSYCHOL, V10, P5, DOI 10.1080/09515089708573201; HARTER S, 1999, CONSTRUCTION SELF DE; HOBSON AR, 1989, SLEEP; Hume David, 1952, TREATISE HUMAN NATUR, V2; Lakoff G., 1999, PHILOS FLESH; LeDoux J. E., 1996, EMOTIONAL BRAIN; LLINAS RR, 2001, I VORTEX; Meyer-Lindenberg A, 2002, NAT NEUROSCI, V5, P267, DOI 10.1038/nn804; Palmer S., 1999, VISION SCI; Panksepp J., 1998, AFFECTIVE NEUROSCIEN; Pinker S., 1997, MIND WORKS; SCHORE AN, 1994, AFFECT REGULATION OR; SPERRY R, 1982, SCIENCE, V217, P1223, DOI 10.1126/science.7112125; Squire LR., 1999, MEMORY MIND MOL; STEPHENS GL, 2000, WHEN SELF CONSCIOUSN; Tomasello M, 1997, PRIMATE COGNITION; VENDLER Z, 1994, MIND BODY PROBLEM GU; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931	30	91	95	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					308	310		10.1126/science.1070564	http://dx.doi.org/10.1126/science.1070564			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951034				2022-12-28	WOS:000175000300045
J	Meunier, B				Meunier, B			Chemistry: Catalytic degradation of chlorinated phenols	SCIENCE			English	Editorial Material									CNRS, Chim Coordinat Lab, F-31077 Toulouse 04, France	Centre National de la Recherche Scientifique (CNRS)	Meunier, B (corresponding author), CNRS, Chim Coordinat Lab, 205 Route Narbonne, F-31077 Toulouse 04, France.		MEUNIER, Bernard/J-4879-2013	MEUNIER, Bernard/0000-0003-2200-7142				Clark JH., 1995, CHEM WASTE MINIMIZAT; COLLINS TJ, 1994, ACCOUNTS CHEM RES, V27, P279, DOI 10.1021/ar00045a004; Matus V, 1996, ENVIRON SCI TECHNOL, V30, P1472, DOI 10.1021/es950381u; Meunier B, 1997, ACCOUNTS CHEM RES, V30, P470, DOI 10.1021/ar960275c; PAL N, 1995, BIOTECHNOL BIOENG, V46, P599, DOI 10.1002/bit.260460613; Sen Gupta S, 2002, SCIENCE, V296, P326, DOI 10.1126/science.1069297; TROST BM, 1995, ANGEW CHEM INT EDIT, V34, P259, DOI 10.1002/anie.199502591	7	105	112	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					270	271		10.1126/science.1070976	http://dx.doi.org/10.1126/science.1070976			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951021				2022-12-28	WOS:000175000300032
J	Tanaka, T; Washimi, H				Tanaka, T; Washimi, H			Formation of the three-ring structure around supernova 1987A	SCIENCE			English	Article							NEBULA	From a magnetohydrodynamic simulation, we reproduce a three-ring structure in the circumstellar space of the supernova (SN) 1987A observed by the Hubble Space Telescope. When a star develops from a red supergiant (RSG) to a blue supergiant (BSG) just before the SN explosion, a wind-wind interaction occurs between the slow stellar wind from the RSG and the subsequent fast stellar wind from the BSG. This process is simulated numerically under an assumption that the density and velocity distributions around the RSG are anisotropic owing to the existence of toroidal magnetic field and coronal holes. The three rings with observed size and position are reproduced by the magnetic pinch effect and amplification of initial density asymmetry through the dynamical interaction.	Commun Res Labs, Koganei, Tokyo 1848795, Japan; Shonan Inst Technol, Fujisawa, Kanagawa 2518511, Japan	National Institute of Information & Communications Technology (NICT) - Japan	Tanaka, T (corresponding author), Commun Res Labs, Koganei, Tokyo 1848795, Japan.							BLONDIN JM, 1993, ASTROPHYS J, V405, P337, DOI 10.1086/172366; BURROWS CJ, 1995, ASTROPHYS J, V452, P680, DOI 10.1086/176339; Crotts APS, 2000, ASTROPHYS J, V528, P426, DOI 10.1086/308141; KWOK S, 1982, ASTROPHYS J, V258, P280, DOI 10.1086/160078; Maran SP, 2000, ASTROPHYS J, V545, P390, DOI 10.1086/317809; PHILLIPS JL, 1995, GEOPHYS RES LETT, V22, P3301, DOI 10.1029/95GL03094; TANAKA T, 1994, J COMPUT PHYS, V111, P381, DOI 10.1006/jcph.1994.1071; Washimi H, 1996, PUBL ASTRON SOC JPN, V48, P23, DOI 10.1093/pasj/48.1.23	8	22	23	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					321	322		10.1126/science.1069425	http://dx.doi.org/10.1126/science.1069425			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951038				2022-12-28	WOS:000175000300049
J	Worobey, M; Rambaut, A; Pybus, OG; Robertson, DL				Worobey, M; Rambaut, A; Pybus, OG; Robertson, DL			Questioning the evidence for genetic recombination in the 1918 "Spanish flu" virus	SCIENCE			English	Editorial Material							INFLUENZA-VIRUS; EVOLUTION		Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Worobey, M (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.		Pybus, Oliver G/B-2640-2012; Rambaut, Andrew/B-2481-2009	Pybus, Oliver G/0000-0002-8797-2667; Rambaut, Andrew/0000-0003-4337-3707				Gibbs MJ, 2001, SCIENCE, V293, P1842, DOI 10.1126/science.1061662; Huson DH, 1998, BIOINFORMATICS, V14, P68, DOI 10.1093/bioinformatics/14.1.68; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Rambaut A, 1997, COMPUT APPL BIOSCI, V13, P235; Reid AH, 1999, P NATL ACAD SCI USA, V96, P1651, DOI 10.1073/pnas.96.4.1651; SWOFFORD DL, 2000, PAUP STAR VERSION 4; Taubenberger JK, 1997, SCIENCE, V275, P1793, DOI 10.1126/science.275.5307.1793	7	54	57	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566												2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951002				2022-12-28	WOS:000175000300001
J	Campbell, EA; Masuda, S; Sun, JL; Muzzin, O; Olson, CA; Wang, S; Darst, SA				Campbell, EA; Masuda, S; Sun, JL; Muzzin, O; Olson, CA; Wang, S; Darst, SA			Crystal structure of the Bacillus stearothermophilus anti-sigma factor SpoIIAB with the sporulation sigma factor sigma(F)	CELL			English	Article							TRANSCRIPTION FACTOR SIGMA(F); CELL-SPECIFIC TRANSCRIPTION; ANTISIGMA FACTOR SPOIIAB; CORE RNA-POLYMERASE; ESCHERICHIA-COLI; SUBTILIS SPORULATION; ATPASE REACTION; PROTEIN-KINASE; GENE; BINDING	Cell type-specific transcription during Bacillus sporulation is established by sigma(F). SpollAB is an anti-sigma that binds and negatively regulates sigma(F), as well as a serine kinase that phosphorylates and inactivates the anti-anti-sigma SpoIIAA. The crystal structure of sigma(F) bound to the SpollAB dimer in the low-affinity, ADP form has been determined at 2.9 Angstrom resolution. SpollAB adopts the GHKL superfamily fold of ATPases and histidine kinases. A domain of sigma(F) contacts both SpoIIAB monomers, while 80% of the sigma factor is disordered. The interaction occludes an RNA polymerase binding surface of sigma(F), explaining the SpollAB anti-sigma activity. The structure also explains the specificity of SpollAB for its target sigma factors and, in combination with genetic and biochemical data, provides insight into the mechanism of SpoIIAA anti-anti-sigma activity.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Darst, SA (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	darst@rockefeller.edu		Campbell, Elizabeth/0000-0002-1332-128X	NIGMS NIH HHS [GM53759, GM20470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053759] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; ALPER S, 1994, CELL, V77, P195, DOI 10.1016/0092-8674(94)90312-3; Arigoni F, 1996, P NATL ACAD SCI USA, V93, P3238, DOI 10.1073/pnas.93.8.3238; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; Bilwes AM, 1999, CELL, V96, P131, DOI 10.1016/S0092-8674(00)80966-6; Bilwes AM, 2001, NAT STRUCT BIOL, V8, P353, DOI 10.1038/86243; BOWN JA, 1997, NUCL ACIDS MOL BIOL, P41; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; BROWN KL, 1995, MOL MICROBIOL, V16, P397, DOI 10.1111/j.1365-2958.1995.tb02405.x; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; Campbell EA, 2000, J MOL BIOL, V300, P17, DOI 10.1006/jmbi.2000.3838; CAMPBELL EA, 2002, IN PRESS MOL CELL; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; Decatur AL, 1996, GENE DEV, V10, P2348, DOI 10.1101/gad.10.18.2348; DIEDERICH B, 1994, GENE DEV, V8, P2653, DOI 10.1101/gad.8.21.2653; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; DRIKS A, 1991, P NATL ACAD SCI USA, V88, P9934, DOI 10.1073/pnas.88.22.9934; DUNCAN L, 1993, P NATL ACAD SCI USA, V90, P2325, DOI 10.1073/pnas.90.6.2325; DUNCAN L, 1994, CURR OPIN GENET DEV, V4, P630, DOI 10.1016/0959-437X(94)90127-O; Duncan L, 1996, J MOL BIOL, V260, P147, DOI 10.1006/jmbi.1996.0389; DUNCAN L, 1995, SCIENCE, V270, P641, DOI 10.1126/science.270.5236.641; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; ERRINGTON J, 1993, MICROBIOL REV, V57, P1; Feucht A, 1996, GENE DEV, V10, P794, DOI 10.1101/gad.10.7.794; FOULGER D, 1993, J GEN MICROBIOL, V139, P3197, DOI 10.1099/00221287-139-12-3197; Garsin DA, 1998, J MOL BIOL, V284, P569, DOI 10.1006/jmbi.1998.2202; Garsin DA, 1998, J MOL BIOL, V284, P557, DOI 10.1006/jmbi.1998.2201; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; GROSS CA, 1992, TRANSCRIPTIONAL REGU; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hughes KT, 1998, ANNU REV MICROBIOL, V52, P231, DOI 10.1146/annurev.micro.52.1.231; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joo DM, 1998, J BACTERIOL, V180, P1095, DOI 10.1128/JB.180.5.1095-1102.1998; Kellner EM, 1996, MOL MICROBIOL, V21, P913, DOI 10.1046/j.1365-2958.1996.461408.x; Kennelly PJ, 1996, J BACTERIOL, V178, P4759, DOI 10.1128/jb.178.16.4759-4764.1996; KIRCHMAN PA, 1993, MOL MICROBIOL, V8, P663, DOI 10.1111/j.1365-2958.1993.tb01610.x; Kovacs H, 1998, P NATL ACAD SCI USA, V95, P5067, DOI 10.1073/pnas.95.9.5067; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; LOSICK R, 1981, CELL, V25, P582, DOI 10.1016/0092-8674(81)90164-1; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Magnin T, 1997, J BACTERIOL, V179, P3922, DOI 10.1128/jb.179.12.3922-3927.1997; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; MARGOLIS P, 1991, SCIENCE, V254, P562, DOI 10.1126/science.1948031; MIN KT, 1993, CELL, V74, P735, DOI 10.1016/0092-8674(93)90520-Z; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Park SG, 1997, GENE, V194, P25, DOI 10.1016/S0378-1119(97)00096-6; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Seavers PR, 2001, STRUCTURE, V9, P605, DOI 10.1016/S0969-2126(01)00623-2; Sharp MM, 1999, GENE DEV, V13, P3015, DOI 10.1101/gad.13.22.3015; Smith CV, 1998, BIOCHEMISTRY-US, V37, P9658, DOI 10.1021/bi9801309; Stock J. B., 1995, 2 COMPONENT SIGNAL T; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; STRAGIER P, 1985, FEBS LETT, V187, P11, DOI 10.1016/0014-5793(85)81203-5; Tanaka T, 1998, NATURE, V396, P88, DOI 10.1038/23968; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; YOON MY, 1987, BIOCHEMISTRY-US, V26, P4118, DOI 10.1021/bi00387a056; YUDKIN MD, 1987, J GEN MICROBIOL, V133, P475; Zhang CC, 1996, MOL MICROBIOL, V20, P9, DOI 10.1111/j.1365-2958.1996.tb02483.x; Zhou HJ, 1997, BIOCHEMISTRY-US, V36, P699, DOI 10.1021/bi961663p	73	91	93	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	2002	108	6					795	807		10.1016/S0092-8674(02)00662-1	http://dx.doi.org/10.1016/S0092-8674(02)00662-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955433	Bronze			2022-12-28	WOS:000174563000009
J	Boggon, TJ; Murray, J; Chappuis-Flament, S; Wong, E; Gumbiner, BM; Shapiro, L				Boggon, TJ; Murray, J; Chappuis-Flament, S; Wong, E; Gumbiner, BM; Shapiro, L			C-cadherin ectodomain structure and implications for cell adhesion mechanisms	SCIENCE			English	Article							EXTRACELLULAR DOMAIN; HOMOPHILIC ADHESION; BINDING; COMPLEX	Cadherins are transmembrane proteins that mediate adhesion between cells in the solid tissues of animals. Here we present the 3.1 angstrom resolution crystal structure of the whole, functional extracellular domain from C-cadherin, a representative "classical" cadherin. The structure suggests a molecular mechanism for adhesion between cells by classical cadherins, and it provides a new framework for understanding both cis (same cell) and trans (juxtaposed cell) cadherin interactions. The trans adhesive interface is a twofold symmetric interaction defined by a conserved tryptophan side chain at the membrane-distal end of a cadherin molecule from one cell, which inserts into a hydrophobic pocket at the membrane-distal end of a cadherin molecule from the opposing cell.	Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Naomi Berrie Diabet Ctr, New York, NY 10032 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Columbia University; Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center	Shapiro, L (corresponding author), Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biol, 630 W 168th St, New York, NY 10032 USA.	Shapiro@convex.hhmi.columbia.edu	Shapiro, Lawrence/AAE-7172-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062270, R01GM052717] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM52717, R01 GM062270] Funding Source: Medline; NCPDCID CDC HHS [NCI-P30-CA-08784] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCPDCID CDC HHS		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berx G, 1998, CELL ADHES COMMUN, V6, P171, DOI 10.3109/15419069809004474; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Kitagawa M, 2000, BIOCHEM BIOPH RES CO, V271, P358, DOI 10.1006/bbrc.2000.2636; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Koch AW, 1999, CURR OPIN STRUC BIOL, V9, P275, DOI 10.1016/S0959-440X(99)80038-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Miyaguchi K, 2000, J STRUCT BIOL, V132, P169, DOI 10.1006/jsbi.2000.4244; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niessen CM, 2002, J CELL BIOL, V156, P389, DOI 10.1083/jcb.200108040; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, J CELL BIOL, V111, P1645, DOI 10.1083/jcb.111.4.1645; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHAPIRO L, 1995, P NATL ACAD SCI USA, V92, P6793, DOI 10.1073/pnas.92.15.6793; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Takeichi M, 2000, PHILOS T ROY SOC B, V355, P885, DOI 10.1098/rstb.2000.0624; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Troyanovsky RB, 1999, J CELL SCI, V112, P4379; Troyanovsky SM, 1999, CURR OPIN CELL BIOL, V11, P561, DOI 10.1016/S0955-0674(99)00021-6; Yap AS, 1998, J CELL BIOL, V141, P779, DOI 10.1083/jcb.141.3.779; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0	36	504	516	3	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 17	2002	296	5571					1308	1313		10.1126/science.1071559	http://dx.doi.org/10.1126/science.1071559			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	554BL	11964443				2022-12-28	WOS:000175713000052
J	Mortensen, EL; Michaelsen, KF; Sanders, SA; Reinisch, JM				Mortensen, EL; Michaelsen, KF; Sanders, SA; Reinisch, JM			The association between duration of breastfeeding and adult intelligence	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYUNSATURATED FATTY-ACIDS; COGNITIVE-DEVELOPMENT; PRETERM INFANTS; METAANALYSIS; TRIAL	Context A number of studies suggest a positive association between breastfeeding and cognitive development in early and middle childhood. However, the only previous study that investigated the relationship between breastfeeding and intelligence in adults had several methodological shortcomings. Objective To determine the association between duration of infant breastfeeding and intelligence in young adulthood. Design, Setting, and Participants Prospective longitudinal birth cohort study conducted in a sample of 973 men and women and a sample of 2280 men, all of whom were born in Copenhagen, Denmark, between October 1959 and December 1961, The samples were divided into 5 categories based on duration of breastfeeding, as assessed by physician interview with mothers at a 1-year examination. Main Outcome Measures Intelligence, assessed using the Wechsler Adult Intelligence Scale (WAIS) at a mean age of 27.2 years in the mixed-sex sample and the Borge Priens Prove (BPP) test at a mean age of 18.7 years in the all-male sample. Thirteen potential confounders were included as covariates: parental social status and education; single mother status; mother's height, age, and weight gain during pregnancy and cigarette consumption during the third trimester; number of pregnancies; estimated gestational age; birth weight; birth length; and indexes of pregnancy and delivery complications. Results Duration of breastfeeding was associated with significantly higher scores on the Verbal, Performance, and Full Scale WAIS IQs. With regression adjustment for potential confounding factors, the mean Full Scale WAIS IQs were 99.4, 101.7, 102.3, 106.0, and 104.0 for breastfeeding durations of less than 1 month, 2 to 3 months, 4 to 6 months, 7 to 9 months, and more than 9 months, respectively (P=.003 for overall F test). The corresponding mean scores on the BPP were 38.0, 39.2, 39.9, 40.1, and 40.1 (P=.01 for overall F test). Conclusion Independent of a wide range of possible confounding factors, a significant positive association between duration of breastfeeding and intelligence was observed in 2 independent samples of young adults, assessed with 2 different intelligence tests.	Copenhagen Univ Hosp, Inst Prevent Med, Danish Epidemiol Sci Ctr, Copenhagen, Denmark; Univ Copenhagen, Inst Publ Hlth, Dept Hlth Psychol, DK-1168 Copenhagen, Denmark; Royal Vet & Agr Univ, Res Dept Human Nutr, Frederiksberg, Denmark; Indiana Univ, Kinsey Inst Res Sex Gender & Reprod, Bloomington, IN USA	Aarhus University; University of Copenhagen; University of Copenhagen; University of Copenhagen; Indiana University System; Indiana University Bloomington	Mortensen, EL (corresponding author), Kommune Hosp Copenhagen, Inst Prevent Med, DK-1399 Copenhagen K, Denmark.	e.l.mortensen@pubhealth.ku.dk; rosenbl@downstate.edu		Michaelsen, Kim F/0000-0003-0449-0839; Mortensen, Erik Lykke/0000-0002-6985-451X	NICHD NIH HHS [HD20263, HD17655] Funding Source: Medline; NIDA NIH HHS [DA05056] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020263, R01HD017655] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Anderson JW, 1999, AM J CLIN NUTR, V70, P525; Angelsen NK, 2001, ARCH DIS CHILD, V85, P183, DOI 10.1136/adc.85.3.183; BAKER RL, 1984, INFLUENCES DEV LONGI, P3; Birch EE, 2000, DEV MED CHILD NEUROL, V42, P174, DOI 10.1017/S0012162200000311; Cohen J., 1983, APPL MULTIPLE REGRES; Feldman W, 1996, LANCET, V347, P1057, DOI 10.1016/S0140-6736(96)90270-6; FERGUSSON DM, 1982, SOC SCI MED, V16, P1705, DOI 10.1016/0277-9536(82)90096-X; Gale CR, 1996, LANCET, V347, P1072, DOI 10.1016/S0140-6736(96)90278-0; Golding J, 1997, EARLY HUM DEV, V49, pS175, DOI 10.1016/S0378-3782(97)00062-5; Horwood LJ, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.1.e9; JACOBSON SW, 1992, LANCET, V339, P926, DOI 10.1016/0140-6736(92)90962-3; Lauritzen L, 2001, PROG LIPID RES, V40, P1, DOI 10.1016/S0163-7827(00)00017-5; LUCAS A, 1994, ARCH DIS CHILD-FETAL, V70, pF141, DOI 10.1136/fn.70.2.F141; Lucas A, 1998, BRIT MED J, V317, P1481, DOI 10.1136/bmj.317.7171.1481; McGue M, 1993, NATURE NURTURE PSYCH, P59, DOI DOI 10.1037/10131-003; MORTENSEN EL, 1989, SCAND J PSYCHOL, V30, P315, DOI 10.1111/j.1467-9450.1989.tb01094.x; Mortensen EL, 2001, NEUROLOGY, V57, P89, DOI 10.1212/WNL.57.1.89; REINISCH JM, 1995, JAMA-J AM MED ASSOC, V274, P1518, DOI 10.1001/jama.274.19.1518; REINISCH JM, 1993, ACTA PSYCHIAT SCAND, V87, P54, DOI 10.1111/j.1600-0447.1993.tb05361.x; RODGERS B, 1978, DEV MED CHILD NEUROL, V20, P421, DOI 10.1111/j.1469-8749.1978.tb15242.x; Rogers IS, 1997, EARLY HUM DEV, V49, pS45, DOI 10.1016/S0378-3782(97)00053-4; Rogers IS, 1997, EARLY HUM DEV, V49, pS157, DOI 10.1016/S0378-3782(97)00061-3; SanGiovanni JP, 2000, PEDIATRICS, V105, P1292, DOI 10.1542/peds.105.6.1292; SCHUERGER JM, 1989, J CLIN PSYCHOL, V45, P294, DOI 10.1002/1097-4679(198903)45:2<294::AID-JCLP2270450218>3.0.CO;2-N; TEASDALE TW, 1987, NATURE, V325, P119, DOI 10.1038/325119a0; Wechsler D, 1958, MEASUREMENT APPRAISA; ZACHAUCHRISTIAN.B, 1975, BABIES HUMAN DEV 1 Y	27	268	281	0	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	2002	287	18					2365	2371		10.1001/jama.287.18.2365	http://dx.doi.org/10.1001/jama.287.18.2365			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548PF	11988057	Bronze			2022-12-28	WOS:000175397000025
J	Fleming, JG; Lin, SY; El-Kady, I; Biswas, R; Ho, KM				Fleming, JG; Lin, SY; El-Kady, I; Biswas, R; Ho, KM			All-metallic three-dimensional photonic crystals with a large infrared bandgap	NATURE			English	Article							TRANSMISSION; EMISSION; GAPS	Three-dimensional (3D) metallic crystals are promising photonic bandgap(1-3) structures: they can possess a large bandgap(4-6), new electromagnetic phenomena can be explored(7-9), and high-temperature (above 1,000 degreesC) applications may be possible. However, investigation of their photonic bandgap properties is challenging, especially in the infrared and visible spectrum, as metals are dispersive and absorbing in these regions(10). Studies of metallic photonic crystals have therefore mainly concentrated on microwave and millimetre wavelengths(8,11,12). Difficulties in fabricating 3D metallic crystals present another challenge, although emerging techniques such as self-assembly(13,14) may help to resolve these problems. Here we report measurements and simulations of a 3D tungsten crystal that has a large photonic bandgap at infrared wavelengths (from about 8 to 20 mum). A very strong attenuation exists in the bandgap similar to30 dB per unit cell at 12 mum. These structures also possess other interesting optical properties; a sharp absorption peak is present at the photonic band edge, and a surprisingly large transmission is observed in the allowed band, below 6 mum. We propose that these 3D metallic photonic crystals can be used to integrate various photonic transport phenomena, allowing applications in thermophotovoltaics and blackbody emission.	Sandia Natl Labs, Albuquerque, NM 87185 USA; Iowa State Univ, Dept Phys & Astron, Ames Lab, Ames, IA 50011 USA	United States Department of Energy (DOE); Sandia National Laboratories; Iowa State University; United States Department of Energy (DOE); Ames National Laboratory	Lin, SY (corresponding author), Sandia Natl Labs, MS 0603,POB 5800, Albuquerque, NM 87185 USA.	slin@sandia.gov	El-Kady, Ihab/D-2886-2013	El-Kady, Ihab/0000-0001-7417-9814				Bethe HA, 1944, PHYS REV, V66, P163, DOI 10.1103/PhysRev.66.163; DERENIAK EL, 1996, INFRARED DETECTORS S, P74; Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570; El-Kady I, 2000, PHYS REV B, V62, P15299, DOI 10.1103/PhysRevB.62.15299; Fan SH, 1996, PHYS REV B, V54, P11245, DOI 10.1103/PhysRevB.54.11245; GENACK AZ, 1991, PHYS REV LETT, V66, P2064, DOI 10.1103/PhysRevLett.66.2064; HO KM, 1994, SOLID STATE COMMUN, V89, P413, DOI 10.1016/0038-1098(94)90202-X; JOHN S, 1984, PHYS REV LETT, V53, P2169, DOI 10.1103/PhysRevLett.53.2169; Lin SY, 1998, NATURE, V394, P251, DOI 10.1038/28343; Lin SY, 2000, PHYS REV B, V62, pR2243, DOI 10.1103/PhysRevB.62.R2243; McIntosh KA, 1997, APPL PHYS LETT, V70, P2937, DOI 10.1063/1.118749; Moroz A, 1999, PHYS REV LETT, V83, P5274, DOI 10.1103/PhysRevLett.83.5274; ORDAL MA, 1983, APPL OPTICS, V22, P1099, DOI 10.1364/AO.22.001099; Ozbay E, 1996, APPL PHYS LETT, V69, P3797, DOI 10.1063/1.117002; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Porto JA, 1999, PHYS REV LETT, V83, P2845, DOI 10.1103/PhysRevLett.83.2845; Sievenpiper DF, 1998, PHYS REV LETT, V80, P2829, DOI 10.1103/PhysRevLett.80.2829; Sievenpiper DF, 1996, PHYS REV LETT, V76, P2480, DOI 10.1103/PhysRevLett.76.2480; SIGALAS MM, 1995, PHYS REV B, V52, P11744, DOI 10.1103/PhysRevB.52.11744; Velev OD, 2000, ADV MATER, V12, P531, DOI 10.1002/(SICI)1521-4095(200004)12:7<531::AID-ADMA531>3.0.CO;2-S; YABLONOVITCH E, 1987, PHYS REV LETT, V58, P2059, DOI 10.1103/PhysRevLett.58.2059; Zakhidov AA, 2001, SYNTHETIC MET, V116, P419, DOI 10.1016/S0379-6779(00)00407-0; Zenker M, 2001, IEEE T ELECTRON DEV, V48, P367, DOI 10.1109/16.902740; [No title captured]; [No title captured]	25	525	549	5	153	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	2002	417	6884					52	55		10.1038/417052a	http://dx.doi.org/10.1038/417052a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986662				2022-12-28	WOS:000175307200034
J	Chochinov, HM				Chochinov, HM			Dignity-conserving cre - A new model for palliative care - Helping the patient feel valued	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICIAN-ASSISTED SUICIDE; TERMINALLY-ILL PATIENTS; OF-LIFE; FIGHTING SPIRIT; END; EUTHANASIA; DEATH; CANCER; ATTITUDES; FAMILY	The basic tenets of palliative care may be summarized as the goal of helping patients to die with dignity. The term "dignity" provides an overarching framework that may guide the physician, patient, and family in defining the objectives and therapeutic considerations fundamental to end-of-life care. Dignity-conserving care is care that may conserve or bolster the dignity of dying patients. Using segments of interviews with a patient with advanced lung cancer, his wife, and his palliative care physician, this article illustrates and explores various aspects of dignity-conserving care and the model on which it is based. Dignity-conserving care offers an approach that clinicians can use to explicitly target the maintenance of dignity as a therapeutic objective and as a principle of bedside care for patients nearing death.	Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada; Canc Care, Winnipeg, MB, Canada	University of Manitoba	Chochinov, HM (corresponding author), FR CPC, PX246,771 Bannatyne Ave, Winnipeg, MB R3E 3N4, Canada.	chochin@cc.umanitoba.ca		Chochinov, Harvey/0000-0003-2656-4704				ABIVEN M, 1991, World Health Forum, V12, P375; Andershed B, 2001, J ADV NURS, V34, P554, DOI 10.1046/j.1365-2648.2001.01785.x; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Barthow C, 1997, Int J Nurs Pract, V3, P206, DOI 10.1111/j.1440-172X.1997.tb00103.x; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Block SD, 2001, JAMA-J AM MED ASSOC, V285, P2898, DOI 10.1001/jama.285.22.2898; Breitbart W, 2000, JAMA-J AM MED ASSOC, V284, P2907, DOI 10.1001/jama.284.22.2907; BREITBART W, 1998, TXB PSYCHOONCOLOGY, P437; Byock I R, 1994, J Palliat Care, V10, P8; Byock IR, 1996, CLIN GERIATR MED, V12, P237; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CASSEM NH, 1987, MASSACHUSETTS GEN HO, P332; Chater S, 1998, PALLIATIVE MED, V12, P255, DOI 10.1191/026921698671831786; Cherny N I, 1994, J Palliat Care, V10, P57; Chochinov HM, 1998, PSYCHOSOMATICS, V39, P366, DOI 10.1016/S0033-3182(98)71325-8; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; Chochinov HM, 2002, SOC SCI MED, V54, P433, DOI 10.1016/S0277-9536(01)00084-3; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; Cohen S R, 1992, J Palliat Care, V8, P40; Daaleman TP, 2000, JAMA-J AM MED ASSOC, V284, P2514, DOI 10.1001/jama.284.19.2514; Dobratz M C, 1993, West J Nurs Res, V15, P708, DOI 10.1177/019394599301500604; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; Field MJ, 1997, APPROACHING DEATH IM; Fisher BJ, 1995, INT J AGING HUM DEV, V41, P239, DOI 10.2190/HA9X-H48D-9GYB-85XW; FRANKL VE, 1963, MANS SEARCH MEANING, P171; Ganzini L, 1999, NEUROLOGY, V52, P1434, DOI 10.1212/WNL.52.7.1434; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Greer SS, 2000, LANCET, V355, P847, DOI 10.1016/S0140-6736(05)72464-8; HINTON J, 1981, J PSYCHOSOM RES, V25, P337, DOI 10.1016/0022-3999(81)90045-3; Hinton J, 1999, PALLIATIVE MED, V13, P19, DOI 10.1191/026921699672169546; Holland JC, 1999, PSYCHO-ONCOLOGY, V8, P14, DOI 10.1002/(SICI)1099-1611(199901/02)8:1<14::AID-PON321>3.0.CO;2-E; *I MED, 1997, APPR DEATH IMPR CAR; Kade W J, 2000, Ann Intern Med, V132, P504; Kagawa-Singer M, 2001, JAMA-J AM MED ASSOC, V286, P2993, DOI 10.1001/jama.286.23.2993; Kant Immanuel, 1987, FUNDAMENTAL PRINCIPL; Katz J S, 2001, Am J Hosp Palliat Care, V18, P321, DOI 10.1177/104990910101800507; Kinsella G, 1998, J PALLIATIVE CARE, V14, P37, DOI 10.1177/082585979801400206; Kristjanson LJ, 1996, J PALLIATIVE CARE, V12, P10, DOI 10.1177/082585979601200403; Lichter I, 1993, Palliat Med, V7, P133; LICHTER I, 1991, Palliative Medicine, V5, P138; Lynn J, 1997, J AM GERIATR SOC, V45, P526; MADAN TN, 1992, SOC SCI MED, V35, P425, DOI 10.1016/0277-9536(92)90335-N; Meier DE, 1998, NEW ENGL J MED, V338, P1193, DOI 10.1056/NEJM199804233381706; NELSON DV, 1989, J BEHAV MED, V12, P341, DOI 10.1007/BF00844928; NEMCEKOVA M, 1998, B MED ETHICS, P13; Payne SA, 1996, PALLIATIVE MED, V10, P307, DOI 10.1177/026921639601000406; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; Portenoy RK, 1997, PSYCHOSOMATICS, V38, P277, DOI 10.1016/S0033-3182(97)71465-8; Pullman D, 1996, Health Law J, V4, P197; PULLMAN D, IN PRESS THEOR MED B; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; Quill TE, 2000, JAMA-J AM MED ASSOC, V284, P2502, DOI 10.1001/jama.284.19.2502; SEALE C, 1994, SOC SCI MED, V39, P647, DOI 10.1016/0277-9536(94)90021-3; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Stewart AL, 1999, J PAIN SYMPTOM MANAG, V17, P93, DOI 10.1016/S0885-3924(98)00131-6; Sullivan AD, 2000, NEW ENGL J MED, V342, P598, DOI 10.1056/NEJM200002243420822; Sulmasy Daniel P, 1994, Linacre Q, V61, P27; TAYLOR SE, 1983, AM PSYCHOL, V38, P1161, DOI 10.1037/0003-066X.38.11.1161; TIGGES KN, 1999, OXFORD TXB PALLIATIV, P829; Turner K, 1996, J PALLIAT CARE, V12, P7, DOI 10.1177/082585979601200203; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1996, NEW ENGL J MED, V335, P1699, DOI 10.1056/NEJM199611283352227; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; Wilson KG, 2000, ARCH INTERN MED, V160, P2454, DOI 10.1001/archinte.160.16.2454; Wool M S, 1988, Adv Psychosom Med, V18, P37; 1946, WEBSTERS INT DICT, P730	69	386	393	0	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2253	2260		10.1001/jama.287.17.2253	http://dx.doi.org/10.1001/jama.287.17.2253			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	546EZ	11980525				2022-12-28	WOS:000175260600025
J	Hock, YL; Stewart, P; Livesley, E				Hock, YL; Stewart, P; Livesley, E			Prospective audit of records of deceased patients received in hospital mortuary	BRITISH MEDICAL JOURNAL			English	Article									Walsall Hosp NHS Trust, Walsall WS2 9PS, W Midlands, England; Walsall Hlth Author, Dept Publ Hlth, Walsall WS1 1TE, W Midlands, England		Hock, YL (corresponding author), Walsall Hosp NHS Trust, Walsall WS2 9PS, W Midlands, England.							CARVEL J, 2001, GUARDIAN        0119; *CLIN PATH ACCR UK, 2001, STAND MED LAB; Hunter M, 2001, BRIT MED J, V322, P255, DOI 10.1136/bmj.322.7281.255; LAWRENCE J, 2001, INDEPENDENT     0117	4	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 27	2002	324	7344					1009	1010		10.1136/bmj.324.7344.1009	http://dx.doi.org/10.1136/bmj.324.7344.1009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547UP	11976242	Green Published, Bronze			2022-12-28	WOS:000175350900020
J	Marrosu, MG; Cocco, E; Lai, M; Spinicci, G; Pischedda, MP; Contu, P				Marrosu, MG; Cocco, E; Lai, M; Spinicci, G; Pischedda, MP; Contu, P			Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study	LANCET			English	Article							AUTOIMMUNE-DISEASES; PATIENTS TARGET; SUSCEPTIBILITY; PREDISPOSITION; ENCEPHALITIS; ASSOCIATION; POPULATION; HAPLOTYPES; PREVALENCE; RELATIVES	Background Individuals from Sardinia, Italy, are at high risk of developing multiple sclerosis and type 1 diabetes mellitus. We attempted to assess the prevalence in this region of type 1 diabetes mellitus in individuals with multiple sclerosis, and to ascertain disease risk factors. Methods We did a cohort study to assess prevalence of type I diabetes in 1090 people with multiple sclerosis, and in their parents (n=2180) and siblings (n=3300), all born and living in Sardinia, All participants were patients at the multiple sclerosis clinic in Cagliari, and were judged representative of the total Sardinian outpatients and inpatients. We asked patients whether their parents or siblings had multiple sclerosis or diabetes, confirming replies by examining clinical records. We identified risk factors for diabetes with univariate and multivariate logistic regression analyses. Findings Diabetes prevalence in people with multiple sclerosis was, respectively, about three-fold and five-fold that in their healthy siblings (p=0.001) and in the general population (p<0.0001). Presence of other relatives with multiple sclerosis conferred increased risk of type 1 diabetes to healthy siblings of individuals with multiple sclerosis (odds ratio=3.41, p=0.0019). Diabetes risk was six-fold higher in patients with relatives having multiple sclerosis than in healthy siblings of multiple sclerosis patients without other relatives with the disease (p=0.0001). Interpretation In Sardinian families with genetic inheritance of multiple sclerosis type I diabetes is prevalent, both in multiple sclerosis patients and in healthy siblings. This finding indicates that common genes contribute to susceptibility to both diseases in this population.	Osped Binaghi, Ctr Sclerosi Multipla, Dipartimento Neurosci, I-09126 Cagliari, Italy; Univ Cagliari, Dipartimento Salute Pubbl, Cagliari, Italy	University of Cagliari	Marrosu, MG (corresponding author), Osped Binaghi, Ctr Sclerosi Multipla, Dipartimento Neurosci, Via Is Guadazzonis 2, I-09126 Cagliari, Italy.	gmarrosu@unica.it	Cocco, Eleonora/G-5064-2012; Contu, Paolo/I-2409-2019	Cocco, Eleonora/0000-0002-3878-8820; Contu, Paolo/0000-0002-5511-0923; Marrosu, Maria Giovanna/0000-0003-2334-2081				Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; Broadley SA, 2000, BRAIN, V123, P1102, DOI 10.1093/brain/123.6.1102; CLAYTON D, 1996, STAT MODELS EPIDEMIO, P227; CONGIA M, 1994, NATO ADV SCI INST SE, V270, P173; Coraddu F, 2001, EUR J HUM GENET, V9, P621, DOI 10.1038/sj.ejhg.5200680; CUCCA F, 1993, HUM IMMUNOL, V37, P85, DOI 10.1016/0198-8859(93)90146-R; CUCCA F, 1996, HLA MHC GENES MOL FU, P383; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; *EXP COMM DIAGN CL, 1997, DIABETES CARE, V20, P1193; Frongia O, 1997, ACTA DIABETOL, V34, P199, DOI 10.1007/s005920050074; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; Granieri E, 2000, NEUROLOGY, V55, P842, DOI 10.1212/WNL.55.6.842; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; Lampis R, 2000, HUM MOL GENET, V9, P2959, DOI 10.1093/hmg/9.20.2959; Lauer K, 1997, NEUROLOGY, V49, pS55, DOI 10.1212/WNL.49.2_Suppl_2.S55; Marrosu MG, 1997, AM J HUM GENET, V61, P454; Marrosu MG, 1998, HUM MOL GENET, V7, P1235, DOI 10.1093/hmg/7.8.1235; Merriman TR, 2001, DIABETES, V50, P184, DOI 10.2337/diabetes.50.1.184; OLERUP O, 1991, TISSUE ANTIGENS, V38, P1, DOI 10.1111/j.1399-0039.1991.tb02029.x; OLMOS P, 1988, DIABETOLOGIA, V31, P747, DOI 10.1007/BF00274777; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; Reed P, 1997, HUM MOL GENET, V6, P1011, DOI 10.1093/hmg/6.7.1011; SADOVNICK AD, 1993, CAN J NEUROL SCI, V20, P17, DOI 10.1017/S0317167100047351; SADOVNICK AD, 1988, AM J MED GENET, V29, P533, DOI 10.1002/ajmg.1320290310; Sadovnick AD, 1996, LANCET, V347, P1728, DOI 10.1016/S0140-6736(96)90807-7; THEOFILOPOULOS AN, 1995, IMMUNOL TODAY, V16, P150, DOI 10.1016/0167-5699(95)80133-2; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1; Winer S, 2001, J IMMUNOL, V166, P2831, DOI 10.4049/jimmunol.166.4.2831; Winer S, 2001, J IMMUNOL, V166, P4751, DOI 10.4049/jimmunol.166.7.4751; WITHAKER JN, 1997, MULTIPLE SCLEROSIS C, P3	30	96	97	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1461	1465		10.1016/S0140-6736(02)08431-3	http://dx.doi.org/10.1016/S0140-6736(02)08431-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988243				2022-12-28	WOS:000175279100007
J	Maxwell, SL; Ruiz, AL; Lappin, KJ; Cosgrove, AP				Maxwell, SL; Ruiz, AL; Lappin, KJ; Cosgrove, AP			Quality improvement report - Clinical screening for developmental dysplasia of the hip in Northern Ireland	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CONGENITAL DISLOCATION	Problem The incidence of late diagnosed developmental dysplasia of the hip requiring surgery in Northern Ireland is high. The reported incidence was 1.14 per 1000 children born during 1983-7. Design Comparative retrospective study. Background and setting Clinical screening programme in Northern Ireland. Key measure for improvement Reduced rate of operative intervention in children with developmental dysplasia of the hip detected after 6 months of age. Strategies for change Increased emphasis on staff training, introduction of a centralised nurse led clinic to improve access to orthopaedic surgeons, and increased use of ultrasonography. Effects of change The incidence of developmental dysplasia of the hip diagnosed after 6 months in children born between January 1991 and December 1997 fell to 0.59 per 1000, presumably due to improved early detection. Nevertheless, 29 (16%) of the affected hips were not diagnosed when the child was first referred in die first 3 months of life. In addition, for 27 affected hips in children diagnosed after the age of 6 months there was a known risk factor (family history or breech delivery). Lessons learnt Improvements to screening processes can reduce late incidence of developmental dysplasia of the hip. Further steps to improve detection in children with known risk factors mid rate of detection at first referral could reduce late presentation further.	Musgrave Pk Hosp, Musculoskeletal Educ & Res Unit, Belfast BT9 7JB, Antrim, North Ireland; Musgrave Pk Hosp, Dept Orthopaed, Belfast BT9 7JB, Antrim, North Ireland		Maxwell, SL (corresponding author), Musgrave Pk Hosp, Musculoskeletal Educ & Res Unit, Belfast BT9 7JB, Antrim, North Ireland.	lorrainemaxwell@hotmail.com						BARLOW TG, 1962, J BONE JOINT SURG BR, V44, P292, DOI 10.1302/0301-620X.44B2.292; CATTERALL A, 1994, J BONE JOINT SURG BR, V76B, P515, DOI 10.1302/0301-620X.76B4.8027129; DAVID TJ, 1983, LANCET, V2, P147; Dezateux C, 1995, J Med Screen, V2, P200; Godward S, 1998, LANCET, V351, P1149, DOI 10.1016/S0140-6736(97)10466-4; Jones D, 1998, J BONE JOINT SURG BR, V80B, P943, DOI 10.1302/0301-620X.80B6.0800943; Jones D, 2000, J BONE JOINT SURG BR, V82B, P160, DOI 10.1302/0301-620X.82B2 .10761; JONES D, 1977, J BONE JOINT SURG BR, V59, P318, DOI 10.1302/0301-620X.59B3.893510; KLISIC P, 1993, J PEDIATR ORTHOP B, V2, P108, DOI 10.1097/01202412-199302020-00003; MACNICOL MF, 1990, J BONE JOINT SURG BR, V72, P1057, DOI 10.1302/0301-620X.72B6.2246288; MANKEY MG, 1993, J BONE JOINT SURG AM, V75A, P1334, DOI 10.2106/00004623-199309000-00008; MARKS DS, 1994, J BONE JOINT SURG BR, V76B, P534, DOI 10.1302/0301-620X.76B4.8027134; MCKEE L, 1998, BRIT MED J, V346, pI265; Ortolani M., 1937, PEDIATRIA NAPOLI, V45, P129; PATTERSON CC, 1995, PAEDIATR PERINAT EP, V9, P90, DOI 10.1111/j.1365-3016.1995.tb00121.x; SANFRIDSON J, 1991, ACTA ORTHOP SCAND, V62, P87, DOI 10.3109/17453679108999228; Standing Medical Advisory Committee and the Standing Nursing and Midwifery Advisory Committee, 1986, SCREEN DET CONG DISL; WILLIAMSON J, 1972, Journal of Bone and Joint Surgery British Volume, V54, P13	18	22	27	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 27	2002	324	7344					1031	1033		10.1136/bmj.324.7344.1031	http://dx.doi.org/10.1136/bmj.324.7344.1031			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547UP	11976249	Green Published			2022-12-28	WOS:000175350900027
J	Grzybowski, BA; Whitesides, GM				Grzybowski, BA; Whitesides, GM			Dynamic aggregation of chiral spinners	SCIENCE			English	Article							DISSIPATION; BINDING	An object spinning at the surface of a Liquid creates a chiral vortex, If the spinning object is itself chiral, its shape modifies the characteristics of the vortex; interactions between that vortex and other vortices then depend on the chirality of the objects that produce them. This paper describes the aggregation of millimeter-sized, chiral magnetized plates floating at a liquid-air interface and rotating under the influence of a rotating external magnetic field. This external field confines all the plates at densities that cause the vortices they generate to interact strongly. For one set of plates investigated, plates of one chirality attract one another, and plates of the other chirality repel other plates of both chiralities.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Grzybowski, BA (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.		Grzybowski, Bartosz A/H-5741-2017	Grzybowski, Bartosz/0000-0001-6613-4261				CROSS MC, 1993, REV MOD PHYS, V65, P851, DOI 10.1103/RevModPhys.65.851; DRITSCHEL DG, 1985, J FLUID MECH, V157, P95, DOI 10.1017/S0022112085002324; Gladysz JA, 1997, ANGEW CHEM INT EDIT, V36, P551; Grzybowski BA, 2000, NATURE, V405, P1033, DOI 10.1038/35016528; Grzybowski BA, 2002, J PHYS CHEM B, V106, P1188, DOI 10.1021/jp012819k; Grzybowski BA, 2001, J PHYS CHEM B, V105, P404, DOI 10.1021/jp0026383; GRZYBOWSKI BA, 2001, PHYS REV E, V46, P11603; Havelock TH, 1931, PHILOS MAG, V11, P617; Islam MR, 1997, DRUG SAFETY, V17, P149, DOI 10.2165/00002018-199717030-00002; Lipkowitz KB, 2000, ACCOUNTS CHEM RES, V33, P555, DOI 10.1021/ar980115w; Noyori R, 2001, ANGEW CHEM INT EDIT, V40, P40, DOI 10.1002/1521-3773(20010105)40:1<40::AID-ANIE40>3.0.CO;2-5; Ribo JM, 2001, SCIENCE, V292, P2063, DOI 10.1126/science.1060835; Straskraba M, 1999, ECOL MODEL, V117, P3, DOI 10.1016/S0304-3800(98)00194-X; WINIWARTER P, 1992, SYST RES, V9, P9, DOI 10.1002/sres.3850090403; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G	15	73	73	3	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					718	721		10.1126/science.1068130	http://dx.doi.org/10.1126/science.1068130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976449				2022-12-28	WOS:000175281700049
J	Mecklenbrauker, I; Saijo, K; Zheng, NY; Leitges, M; Tarakhovsky, A				Mecklenbrauker, I; Saijo, K; Zheng, NY; Leitges, M; Tarakhovsky, A			Protein kinase C delta controls self-antigen-induced B-cell tolerance	NATURE			English	Article							REACTIVE LYMPHOCYTES-B; PROTEOLYTIC ACTIVATION; RECEPTOR; ANTIBODY; EXPRESSION; APOPTOSIS; DIVISION; LYSOZYME; MICE	Interaction of a B cell expressing self-specific B-cell antigen receptor (BCR) with an auto-antigen results in either clonal deletion or functional inactivation(1-3). Both of these processes lead to B-cell tolerance and are essential for the prevention of auto-immune diseases. Whereas clonal deletion results in the death of developing autoreactive B cells, functional inactivation of self-reactive B lymphocytes leads to complex changes in the phenotype of peripheral B cells, described collectively as anergy(1-3). Here we demonstrate that deficiency in protein kinase Cdelta (PKC-delta) prevents B-cell tolerance, and allows maturation and terminal differentiation of self-reactive B cells in the presence of the tolerizing antigen. The importance of PKC-delta in B-cell tolerance is further underscored by the appearance of autoreactive anti-DNA and anti-nuclear antibodies in the serum of PKC-delta-deficient mice. As deficiency of PKC-delta does not affect BCR-mediated B-cell activation in vitro and in vivo, our data suggest a selective and essential role of PKC-delta in tolerogenic, but not immunogenic, B-cell responses.	Rockefeller Univ, Lab Lymphocyte Signaling, New York, NY 10021 USA; Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany	Rockefeller University; Max Planck Society	Tarakhovsky, A (corresponding author), Rockefeller Univ, Lab Lymphocyte Signaling, 1230 York Ave, New York, NY 10021 USA.		Leitges, Michael/AAN-1953-2021					Chan VWF, 1998, J EXP MED, V188, P93, DOI 10.1084/jem.188.1.93; Doerre S, 1999, J IMMUNOL, V163, P269; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fulcher DA, 1996, J EXP MED, V183, P2313, DOI 10.1084/jem.183.5.2313; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Healy JI, 1997, IMMUNITY, V6, P419, DOI 10.1016/S1074-7613(00)80285-X; Hippen KL, 2000, J EXP MED, V191, P883, DOI 10.1084/jem.191.5.883; Kang SW, 2001, EMBO J, V20, P5692, DOI 10.1093/emboj/20.20.5692; Kozono Y, 1998, J IMMUNOL, V160, P1565; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Leitges M, 2001, J CLIN INVEST, V108, P1505; Lipford GB, 1997, EUR J IMMUNOL, V27, P2340, DOI 10.1002/eji.1830270931; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; METZGER DW, 1984, EUR J IMMUNOL, V14, P87, DOI 10.1002/eji.1830140116; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MIYAKE K, 1994, J EXP MED, V180, P1217, DOI 10.1084/jem.180.4.1217; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; Prodeus AP, 1998, IMMUNITY, V9, P721, DOI 10.1016/S1074-7613(00)80669-X; SMITHGILL SJ, 1982, J IMMUNOL, V128, P314; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; YAMAGATA T, 1995, ISSCC DIG TECH PAP I, V38, P248, DOI 10.1109/ISSCC.1995.535542	27	210	220	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					860	865		10.1038/416860a	http://dx.doi.org/10.1038/416860a			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976686				2022-12-28	WOS:000175163800054
J	Negro, JJ; Grande, JM; Tella, JL; Garrido, J; Hornero, D; Donazar, JA; Sanchez-Zapata, JA; Benitez, JR; Barcell, M				Negro, JJ; Grande, JM; Tella, JL; Garrido, J; Hornero, D; Donazar, JA; Sanchez-Zapata, JA; Benitez, JR; Barcell, M			Coprophagy: An unusual source of essential carotenoids - A yellow-faced vulture includes ungulate faeces in its diet for cosmetic purposes.	NATURE			English	Article							PLASMA CAROTENOIDS; PIGMENTS; BIRDS		CSIC, Estac Biol Donana, Dept Appl Biol, Seville 41013, Spain; CSIC, Inst Grasa, Food Biotechnol Dept, Seville 41012, Spain; Univ Miguel Hernandez, Dept Biol Aplicada, Area Ecol, Alicante 03312, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Biologica de Donana (EBD); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de la Grasa (IG); Universidad Miguel Hernandez de Elche	Negro, JJ (corresponding author), CSIC, Estac Biol Donana, Dept Appl Biol, Avda Maria Luisa S-N, Seville 41013, Spain.		Negro, Juan Jose/I-2653-2015; Sanchez-Zapata, Jose Antonio/H-1413-2015; Tella, José L/I-3707-2015	Negro, Juan Jose/0000-0002-8697-5647; Sanchez-Zapata, Jose Antonio/0000-0001-8230-4953; Tella, José L/0000-0002-3038-7424; Donazar, Jose Antonio/0000-0002-9433-9755; Grande, Juan Manuel/0000-0002-8183-0780				Britton G, 1995, FASEB J, V9, P1551, DOI 10.1096/fasebj.9.15.8529834; BRUSH AH, 1990, FASEB J, V4, P2969, DOI 10.1096/fasebj.4.12.2394316; Diaz-Delgado R, 2001, FOREST ECOL MANAG, V147, P67, DOI 10.1016/S0378-1127(00)00434-5; HILL GE, 1991, NATURE, V350, P337, DOI 10.1038/350337a0; Hurd PL, 1991, BEHAV ECOL, V2, P69, DOI 10.1093/beheco/2.1.69; Hutchings MR, 2001, ANIM BEHAV, V62, P955, DOI 10.1006/anbe.2001.1837; MINGUEZMOSQUERA MI, 1993, J AGR FOOD CHEM, V41, P1616, DOI 10.1021/jf00034a018; Mundy P., 1992, VULTURES AFRICA; Negro JJ, 2000, PHYSIOL BIOCHEM ZOOL, V73, P97, DOI 10.1086/316724; ROHWER S, 1975, EVOLUTION, V29, P593, DOI 10.1111/j.1558-5646.1975.tb00853.x; Tella JL, 1998, PHYSIOL ZOOL, V71, P708, DOI 10.1086/515991; Vogel A. I., 1957, ELEMENTARY PRACTICAL; Zahavi A., 1997, HANDICAP PRINCIPLE	13	85	89	6	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					807	808		10.1038/416807a	http://dx.doi.org/10.1038/416807a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976670	Green Submitted			2022-12-28	WOS:000175163800038
J	Nuckton, TJ; Alonso, JA; Kallet, RH; Daniel, BM; Pittet, JF; Eisner, MD; Matthay, MA				Nuckton, TJ; Alonso, JA; Kallet, RH; Daniel, BM; Pittet, JF; Eisner, MD; Matthay, MA			Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE LUNG INJURY; END-EXPIRATORY PRESSURE; CONSENSUS CONFERENCE; FACTOR ANTIGEN; TIDAL VOLUME; GAS-EXCHANGE; DEFINITIONS; VENTILATION; MECHANISMS; PHYSIOLOGY	Background: No single pulmonary-specific variable, including the severity of hypoxemia, has been found to predict the risk of death independently when measured early in the course of the acute respiratory distress syndrome. Because an increase in the pulmonary dead-space fraction has been described in observational studies of the syndrome, we systematically measured the dead-space fraction early in the course of the illness and evaluated its potential association with the risk of death. Methods: The dead-space fraction was prospectively measured in 179 intubated patients, a mean (+/-SD) of 10.9+/-7.4 hours after the acute respiratory distress syndrome had developed. Additional clinical and physiological variables were analyzed with the use of multiple logistic regression. The study outcome was mortality before hospital discharge. Results: The mean dead-space fraction was markedly elevated (0.58+/-0.09) early in the course of the acute respiratory distress syndrome and was higher among patients who died than among those who survived (0.63+/-0.10 vs. 0.54+/-0.09, P<0.001). The dead-space fraction was an independent risk factor for death: for every 0.05 increase, the odds of death increased by 45 percent (odds ratio, 1.45; 95 percent confidence interval, 1.15 to 1.83; P=0.002). The only other independent predictors of an increased risk of death were the Simplified Acute Physiology Score II, an indicator of the severity of illness (odds ratio, 1.06; 95 percent confidence interval, 1.03 to 1.08; P<0.001) and quasistatic respiratory compliance (odds ratio, 1.06; 95 percent confidence interval, 1.01 to 1.10; P=0.01). Conclusions: Increased dead-space fraction is a feature of the early phase of the acute respiratory distress syndrome. Elevated values are associated with an increased risk of death.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Nuckton, TJ (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, 505 Parnassus Ave,Box 0130, San Francisco, CA 94143 USA.	tomnuc@itsa.ucsf.edu			NHLBI NIH HHS [K23HL04201, R01 HL51856, HL51854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051854, R01HL051856, K23HL004201] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham E, 2000, CRIT CARE MED, V28, P232, DOI 10.1097/00003246-200001000-00039; *AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; BACHOFEN M, 1977, AM REV RESPIR DIS, V116, P589, DOI 10.1164/arrd.1977.116.4.589; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; BONE RC, 1989, CHEST, V96, P849, DOI 10.1378/chest.96.4.849; BRANDI LS, 1988, CRIT CARE MED, V16, P18, DOI 10.1097/00003246-198801000-00004; Cheifetz IM, 1998, CRIT CARE MED, V26, P710, DOI 10.1097/00003246-199804000-00020; CLARK JG, 1995, ANN INTERN MED, V122, P17, DOI 10.7326/0003-4819-122-1-199501010-00003; COFFEY RL, 1983, J APPL PHYSIOL, V55, P1550, DOI 10.1152/jappl.1983.55.5.1550; COMROE JH, 1955, LUNG CLIN PHYSL PULM; DANTZKER DR, 1979, AM REV RESPIR DIS, V120, P1039; DOYLE RL, 1995, AM J RESP CRIT CARE, V152, P1818, DOI 10.1164/ajrccm.152.6.8520742; Ely EW, 2002, ANN INTERN MED, V136, P25, DOI 10.7326/0003-4819-136-1-200201010-00007; Enghoff Henrik, 1938, UPSALA LAKAREFOREN FORHANDL, V44, P191; FALKE KJ, 1972, J CLIN INVEST, V51, P2315, DOI 10.1172/JCI107042; FERRANNINI E, 1988, METABOLISM, V37, P287, DOI 10.1016/0026-0495(88)90110-2; GATTINONI L, 1994, JAMA-J AM MED ASSOC, V271, P1772, DOI 10.1001/jama.271.22.1772; GREENE R, 1981, AM REV RESPIR DIS, V124, P593; HOSMER DW, 1989, APPL LOGISTIC REGRES; Idell S, 2001, AM J RESP CRIT CARE, V163, P578, DOI 10.1164/ajrccm.163.2.2005135; KIISKI R, 1992, AM REV RESPIR DIS, V146, P1131, DOI 10.1164/ajrccm/146.5_Pt_1.1131; LAMY M, 1976, AM REV RESPIR DIS, V114, P267; LEGALL JR, 1994, JAMA-J AM MED ASSOC, V271, P1321; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lichtwarck-Aschoff M, 2000, AM J RESP CRIT CARE, V162, P2125, DOI 10.1164/ajrccm.162.6.9910018; LUCE JM, 1982, AM REV RESPIR DIS, V125, P716; Lum L, 1998, CRIT CARE MED, V26, P760, DOI 10.1097/00003246-199804000-00029; MacKinnon JC, 1997, RESP CARE, V42, P761; Meade MO, 2000, AM J RESP CRIT CARE, V161, P85, DOI 10.1164/ajrccm.161.1.9809003; Monchi M, 1998, AM J RESP CRIT CARE, V158, P1076, DOI 10.1164/ajrccm.158.4.9802009; MONTGOMERY AB, 1989, AM REV RESPIR DIS, V139, P1548, DOI 10.1164/ajrccm/139.6.1548; MOSS M, 1995, CRIT CARE MED, V23, P1629, DOI 10.1097/00003246-199510000-00006; PETTY TL, 1971, CHEST, V60, P233, DOI 10.1378/chest.60.3.233; RALPH DD, 1985, AM REV RESPIR DIS, V131, P54; Rubenfeld GD, 1999, CHEST, V116, P1347, DOI 10.1378/chest.116.5.1347; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; Schuster DP, 1997, INTENS CARE MED, V23, P1197, DOI 10.1007/s001340050486; SEVERINGHAUS JW, 1957, J APPL PHYSIOL, V10, P335, DOI 10.1152/jappl.1957.10.3.335; SLOANE PJ, 1992, AM REV RESPIR DIS, V146, P419, DOI 10.1164/ajrccm/146.2.419; Smith ER, 1977, RESP CARE, V22(, P1341; TOMASHEFSKI JF, 1983, AM J PATHOL, V112, P112; Ware LB, 2001, CRIT CARE MED, V29, P2325, DOI 10.1097/00003246-200112000-00016; West JB, 2000, TXB RESP MED, V1, P55; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	44	535	560	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 25	2002	346	17					1281	1286		10.1056/NEJMoa012835	http://dx.doi.org/10.1056/NEJMoa012835			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544GX	11973365				2022-12-28	WOS:000175150800004
J	Solomon, D; Davey, D; Kurman, R; Moriary, A; O'Connor, D; Prey, M; Raab, S; Sherman, M; Wilbur, D; Wright, T; Young, N				Solomon, D; Davey, D; Kurman, R; Moriary, A; O'Connor, D; Prey, M; Raab, S; Sherman, M; Wilbur, D; Wright, T; Young, N			The 2001 Bethesda System - Terminology for reporting results of cervical cytology	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERLABORATORY COMPARISON PROGRAM; CERVICOVAGINAL CYTOLOGY; ADENOCARCINOMA INSITU; SPECIMEN ADEQUACY; ENDOMETRIAL CELLS; UTERINE CERVIX; FOLLOW-UP; FEATURES; LESIONS	Objectives The Bethesda 2001 Workshop was convened to evaluate and update the 1991 Bethesda System terminology for reporting the results of cervical cytology. A primary objective was to develop a new approach to broaden participation in the consensus process. Participants Forum groups composed of 6 to 10 individuals were responsible for developing recommendations for discussion at the workshop. Each forum group included at least 1 cytopathologist, cytotechnologist, clinician, and international representative to ensure a broad range of views and interests. More than 400 cytopathologists, cytotechnologists, histopathologists, family practitioners, gynecologists, public health physicians, epidemiologists, patient advocates, and attorneys participated in the workshop, which was convened by the National Cancer Institute and cosponsored by 44 professional societies. More than 20 countries were represented. Evidence Literature review, expert opinion, and input from an Internet bulletin board were all considered in developing recommendations. The strength of evidence of the scientific data was considered of paramount importance. Consensus Process Bethesda 2001 was a year-long iterative review process. An Internet bulletin board was used for discussion of issues and drafts of recommendations. More than 1000 comments were posted to the bulletin board over the course of 6 months. The Bethesda Workshop, held April 30-May 2, 2001, was open to the public. Postworkshop recommendations were posted on the bulletin board for a last round of critical review prior to finalizing the terminology. Conclusions Bethesda 2001 was developed with broad participation in the consensus process. The 2001 Bethesda System terminology reflects important advances in biological understanding of cervical neoplasia and cervical screening technology.	NCI, Div Canc Prevent, Bethesda, MD 20892 USA; Univ Kentucky, Med Ctr, Dept Pathol & Lab Med, Lexington, KY USA; Johns Hopkins Univ Hosp, Dept Gynecol & Obstet, Baltimore, MD 21287 USA; Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; AmeriPath Indiana, Indianapolis, IN USA; Clin Pathol Associates, Louisville, KY USA; Quest Diagnost Inc, St Louis, MO USA; Allegheny Hosp, Dept Pathol, Pittsburgh, PA USA; NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Columbia Univ, Dept Pathol, New York, NY USA; Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Kentucky; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Allegheny General Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Massachusetts General Hospital; Columbia University; Fox Chase Cancer Center	Solomon, D (corresponding author), EPN Room 2130,6130 Execut Blvd, Bethesda, MD 20892 USA.		Manzotti, Grazia/C-5985-2008					BETSILL WL, 1986, ACTA CYTOL, V30, P115; Biscotti CV, 1997, DIAGN CYTOPATHOL, V17, P326, DOI 10.1002/(SICI)1097-0339(199711)17:5<326::AID-DC4>3.3.CO;2-L; BRODER S, 1992, JAMA-J AM MED ASSOC, V267, P1892, DOI 10.1001/jama.267.14.1892; Davey DD, 2000, ARCH PATHOL LAB MED, V124, P203; DAVEY DD, 1992, ARCH PATHOL LAB MED, V116, P903; Eddy GL, 1997, AM J OBSTET GYNECOL, V177, P1188, DOI 10.1016/S0002-9378(97)70039-5; Einstein MH, 2001, PAPILLOMAVIRUS REP, V12, P119; FARNSWORTH A, 1989, INT J GYNECOL PATHOL, V8, P321, DOI 10.1097/00004347-198912000-00003; GONDOS B, 1977, ANN CLIN LAB SCI, V7, P486; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Jones BA, 2000, ARCH PATHOL LAB MED, V124, P665; Jones BA, 1996, ARCH PATHOL LAB MED, V120, P523; LEE KR, 1991, ACTA CYTOL, V35, P117; Montz FJ, 2001, GYNECOL ONCOL, V81, P33, DOI 10.1006/gyno.2000.6106; NG ABP, 1974, ACTA CYTOL, V18, P356; Park TW, 1996, J NATL CANCER I, V88, P355, DOI 10.1093/jnci/88.6.355; Quddus MR, 2001, CANCER CYTOPATHOL, V93, P16, DOI 10.1002/1097-0142(20010225)93:1<16::AID-CNCR9002>3.0.CO;2-A; Sherman ME, 2001, AM J CLIN PATHOL, V116, P386, DOI 10.1309/JM3V-U4HP-W8HJ-68XV; Sherman ME, 1999, MODERN PATHOL, V12, P335; Smith-McCune K, 2001, AM J OBSTET GYNECOL, V185, P551, DOI 10.1067/mob.2001.116725; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; Soofer SB, 2000, CANCER CYTOPATHOL, V90, P207, DOI 10.1002/1097-0142(20000825)90:4<207::AID-CNCR2>3.0.CO;2-H; WILBUR DC, 1997, GYNECOLOGIC CYTOPATH, P107; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120; Wright TC, 1994, PAPILLOMAVIRUS REPOR, V5, P175; YANCEY M, 1990, OBSTET GYNECOL, V76, P1000; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	28	2245	2436	2	60	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 24	2002	287	16					2114	2119		10.1001/jama.287.16.2114	http://dx.doi.org/10.1001/jama.287.16.2114			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZK	11966386				2022-12-28	WOS:000175075700029
J	van Tinteren, H; Hoekstra, OS; Smit, EF; van den Bergh, JHAM; Schreurs, AJM; Stallaert, RALM; van Velthoven, PCM; Comans, EFI; Diepenhorst, FW; Verboom, P; van Mourik, JC; Postmus, PE; Boers, M; Teule, GJJ				van Tinteren, H; Hoekstra, OS; Smit, EF; van den Bergh, JHAM; Schreurs, AJM; Stallaert, RALM; van Velthoven, PCM; Comans, EFI; Diepenhorst, FW; Verboom, P; van Mourik, JC; Postmus, PE; Boers, M; Teule, GJJ		PLUS study Gr	Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial	LANCET			English	Article							FDG-PET SCAN; EXTRATHORACIC METASTASES; DIAGNOSTIC-TESTS; SURGEONS; NODULES; CT	Background Up to 50% of curative surgery for suspected non-small-cell lung cancer is unsuccessful. Accuracy of positron emission tomography (PET) with 18-fluorodeoxyglucose ((18)FDG) is thought to be better than conventional staging for diagnosis of this malignancy. Up to now however, there has been no evidence that PET leads to improved management of patients in routine clinical practice. We did a randomised controlled trial in patients with suspected non-small-cell lung cancer, who were scheduled for surgery after conventional workup, to test whether PET with (18)FDG reduces number of futile thoracotomies. Methods Before surgery (mediastinoscopy or thoracotomy), 188 patients from nine hospitals were randomly assigned to either conventional workup (CWU) or conventional workup and PET (CWU+PET). Patients were followed up for 1 year. Thoracotomy was regarded as futile if the patient had benign disease, explorative thoracotomy, pathological stage IIIA-N2/IIIB, or postoperative relapse or death within 12 months of randomisation. The primary outcome measure was futile thoracotomy, Analysis was by intention to treat. Findings 96 patients were randomly assigned CWU and 92 CWU+PET. Two patients in the CWU+PET group did not undergo PET. 18 patients in the CWU group and 32 in the CWU+PET group did not have thoracotomy. In the CWU group, 39 (41%) patients had a futile thoracotomy, compared with 19 (21%) in the CWU+PET group (relative reduction 51%, 95% CI 32-80%; p=0.003). Interpretation Addition of PET to conventional workup prevented unnecessary surgery in one out of five patients with suspected non-small-cell lung cancer.	Comprehens Canc Ctr Amsterdam, IKA, NL-1066 CX Amsterdam, Netherlands; VU Univ Med Ctr, Dept Pulmonol, Amsterdam, Netherlands; Med Ctr Alkmaar, Alkmaar, Netherlands; Onze Lieve Vrouw Hosp, Dept Pulmonol, Amsterdam, Netherlands; Westfries Gasthuis Hoorn, Dept Pulmonol, Hoorn, Netherlands; VU Univ Med Ctr, Dept Nucl Med, Amsterdam, Netherlands; VU Univ Med Ctr, Dept Clin Epidemiol & Biostat, Amsterdam, Netherlands; VU Univ Med Ctr, Dept Surg, Amsterdam, Netherlands; Erasmus Univ, Inst Med Technol Assessment, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Medical Center Of Alkmaar; Onze Lieve Vrouwe Gasthuis Hospital; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Erasmus University Rotterdam	van Tinteren, H (corresponding author), Comprehens Canc Ctr Amsterdam, IKA, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.			van Tinteren, Harm/0000-0002-4626-8702; postmus, pieter/0000-0002-7774-2868; Smit, Egbert/0000-0002-7329-6995				ADAMS E, DESCRIPTIVE ANAL EXP; [Anonymous], 1997, AM J RESP CRIT CARE, V156, P320; BEGG CB, 1987, STAT MED, V6, P411, DOI 10.1002/sim.4780060402; Bury T, 1997, EUR RESPIR J, V10, P2529, DOI 10.1183/09031936.97.10112529; DeVita VT, 1997, CANC PRINCIPLES PRAC; Dwamena BA, 1999, RADIOLOGY, V213, P530, DOI 10.1148/radiology.213.2.r99nv46530; Fergusson RJ, 1996, THORAX, V51, P569, DOI 10.1136/thx.51.6.569; FLEISS JL, 1980, BIOMETRICS, V36, P343, DOI 10.2307/2529990; FREEDMAN LS, 1987, BRIT J RADIOL, V60, P1071, DOI 10.1259/0007-1285-60-719-1071; GOLDSTRAW P, 1994, LUNG CANCER-J IASLC, V11, pS1, DOI 10.1016/0169-5002(94)91856-2; GOLDSTRAW P, 1992, THORAX, V47, P1, DOI 10.1136/thx.47.1.1; Guyatt GH, 1999, ANN THORAC SURG, V68, P309, DOI 10.1016/S0003-4975(99)00324-0; GUYATT GH, 1995, ANN THORAC SURG, V60, P1382; HERDER GJM, 1999, EUR J RESPIR DIS, V14, P446; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; *INT UN CANC, 1987, TNM CLASS MAL TUM, P69; Kosuda S, 2000, CHEST, V117, P346, DOI 10.1378/chest.117.2.346; LEWIS P, 1994, LANCET, V344, P1265, DOI 10.1016/S0140-6736(94)90753-6; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; Lowe VJ, 1998, J CLIN ONCOL, V16, P1075, DOI 10.1200/JCO.1998.16.3.1075; NARUKE T, 1978, J THORAC CARDIOV SUR, V76, P832; *NAT COMPR CANC NE, 1996, ONCOLOGY S, V10, P81; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404; Spagnolo SV, 2000, CHEST, V117, P1219, DOI 10.1378/chest.117.5.1219; Valk PE, 1995, ANN THORAC SURG, V60, P1573, DOI 10.1016/0003-4975(95)00752-0; van Tinteren H, 2001, CONTROL CLIN TRIALS, V22, P89, DOI 10.1016/S0197-2456(00)00119-7; van Zandwijk N, 1991, Ned Tijdschr Geneeskd, V135, P1915; Vansteenkiste JF, 1998, J CLIN ONCOL, V16, P2142, DOI 10.1200/JCO.1998.16.6.2142; Vansteenkiste JF, 1998, EUR J NUCL MED, V25, P1495, DOI 10.1007/s002590050327; VISSER O, 2000, INCIDENCE CANC NETHE; WEBB WR, 1991, CLIN CHEST MED, V12, P133; Weder W, 1998, ANN THORAC SURG, V66, P886, DOI 10.1016/S0003-4975(98)00675-4; WEEDON D, REPORT COMMONWEALTH; WEISS NS, 1996, CLIN EPIDEMIOLOGY ST, V27, P27	34	600	615	0	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1388	1392		10.1016/S0140-6736(02)08352-6	http://dx.doi.org/10.1016/S0140-6736(02)08352-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978336				2022-12-28	WOS:000175076200011
J	Park, J; Levin, V				Park, J; Levin, V			Geophyics - Seismic anisotropy: Tracing plate dynamics in the mantle	SCIENCE			English	Review							SHEAR-WAVE ANISOTROPY; LATTICE PREFERRED ORIENTATION; AZIMUTHAL ANISOTROPY; PLASTIC-DEFORMATION; ELASTIC-ANISOTROPY; CRUSTAL ANISOTROPY; RECEIVER FUNCTIONS; NORTH-AMERICA; FLOW BENEATH; LITHOSPHERE	Elastic anisotropy is present where the speed of a seismic wave depends on its direction. In Earth's mantle, elastic anisotropy is induced by minerals that are preferentially oriented in a directional flow or deformation. Earthquakes generate two seismic wave types: compressional (P) and shear (S) waves, whose coupling in anisotropic rocks leads to scattering, birefringence, and waves with hybrid polarizations. This varied behavior is helping geophysicists explore rock textures within Earth's mantle and crust, map present-day upper-mantle convection, and study the formation of lithospheric plates and the accretion of continents in Earth history.	Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA	Yale University	Park, J (corresponding author), Yale Univ, Dept Geol & Geophys, POB 208109, New Haven, CT 06520 USA.							Amato A, 1998, PURE APPL GEOPHYS, V151, P479, DOI 10.1007/s000240050124; AMMON CJ, 1991, B SEISMOL SOC AM, V81, P2504; BABUSKA V, 1993, PHYS EARTH PLANET IN, V78, P167, DOI 10.1016/0031-9201(93)90154-2; BABUSKA V, 1991, SEISMIC ANISOTROPY E; BACKUS GE, 1962, J GEOPHYS RES, V67, P4427, DOI 10.1029/JZ067i011p04427; Barruol G, 1998, J GEOPHYS RES-SOL EA, V103, P30039, DOI 10.1029/98JB02790; Blackman DK, 1996, GEOPHYS J INT, V127, P415, DOI 10.1111/j.1365-246X.1996.tb04730.x; Bostock MG, 1998, J GEOPHYS RES-SOL EA, V103, P21183, DOI 10.1029/98JB01069; Buttles J, 1998, EARTH PLANET SC LETT, V164, P245, DOI 10.1016/S0012-821X(98)00211-8; CASSIDY JF, 1992, B SEISMOL SOC AM, V82, P1453; CHRISTENSEN NI, 1984, GEOPHYS J ROY ASTR S, V76, P89, DOI 10.1111/j.1365-246X.1984.tb05025.x; CRAMPIN S, 1984, GEOPHYS J ROY ASTR S, V76, P135, DOI 10.1111/j.1365-246X.1984.tb05029.x; Debayle E, 2000, EARTH PLANET SC LETT, V184, P339, DOI 10.1016/S0012-821X(00)00314-9; Ekstrom G, 1998, NATURE, V394, P168, DOI 10.1038/28148; Fischer KM, 1998, PURE APPL GEOPHYS, V151, P463, DOI 10.1007/s000240050123; Fouch MJ, 2000, J GEOPHYS RES-SOL EA, V105, P6255, DOI 10.1029/1999JB900372; Fouch MJ, 1996, J GEOPHYS RES-SOL EA, V101, P15987, DOI 10.1029/96JB00881; GAHERTY JB, 1995, SCIENCE, V268, P1468, DOI 10.1126/science.268.5216.1468; Griot DA, 1998, GEOPHYS RES LETT, V25, P1447, DOI 10.1029/98GL00991; Holt WE, 2000, GEOLOGY, V28, P67, DOI 10.1130/0091-7613(2000)28<67:CCAMSF>2.0.CO;2; Jung H, 2001, SCIENCE, V293, P1460, DOI 10.1126/science.1062235; Kaminski E, 2001, EARTH PLANET SC LETT, V189, P253, DOI 10.1016/S0012-821X(01)00356-9; KARATO S, 1992, GEOPHYS RES LETT, V19, P2255, DOI 10.1029/92GL02603; KELEMEN PB, 1995, J GEOPHYS RES-SOL EA, V100, P423, DOI 10.1029/94JB02063; Kobayashi R, 1998, GEOPHYS RES LETT, V25, P1067, DOI 10.1029/98GL00651; Kosarev G, 1999, SCIENCE, V283, P1306, DOI 10.1126/science.283.5406.1306; KUMAZAWA M, 1969, J GEOPHYS RES, V74, P5961, DOI 10.1029/JB074i025p05961; Laske G, 1998, GEOPHYS J INT, V132, P508, DOI 10.1046/j.1365-246X.1998.00450.x; Leveque JJ, 1998, GEOPHYS J INT, V133, P529, DOI 10.1046/j.1365-246X.1998.00504.x; Levin V, 2000, J GEOPHYS RES-SOL EA, V105, P19029, DOI 10.1029/2000JB900123; Levin V, 1998, PURE APPL GEOPHYS, V151, P669, DOI 10.1007/s000240050136; Levin V, 1998, J GEOPHYS RES-SOL EA, V103, P24321, DOI 10.1029/98JB02342; Levin V, 1997, GEOPHYS RES LETT, V24, P1283, DOI 10.1029/97GL51321; Levin V, 2000, TECTONOPHYSICS, V323, P131, DOI 10.1016/S0040-1951(00)00105-0; LI A, 1999, EOS T AGU S, V80, pF730; Margheriti L, 1996, GEOPHYS RES LETT, V23, P2721, DOI 10.1029/96GL02519; MASTERS TG, 1995, GLOBAL EARTH PHYS HD, P88; MCNAMARA DE, 1994, J GEOPHYS RES-SOL EA, V99, P13655, DOI 10.1029/93JB03406; Molnar P, 1999, SCIENCE, V286, P516, DOI 10.1126/science.286.5439.516; MONTAGNER JP, 1991, J GEOPHYS RES-SOL EA, V96, P20337, DOI 10.1029/91JB01890; Montagner JP, 1998, PURE APPL GEOPHYS, V151, P223, DOI 10.1007/s000240050113; MORRIS GB, 1969, J GEOPHYS RES, V74, P4300, DOI 10.1029/JB074i017p04300; NICOLAS A, 1973, AM J SCI, V273, P853, DOI 10.2475/ajs.273.10.853; *NSF, EAR9805206 NSF; Oda H, 2001, GEOPHYS J INT, V144, P247, DOI 10.1046/j.0956-540X.2000.01329.x; Oncken O, 1999, NATURE, V397, P341, DOI 10.1038/16909; Park J, 2000, B SEISMOL SOC AM, V90, P1507, DOI 10.1785/0119990122; PARK J, 1993, SCIENCE, V261, P1159, DOI 10.1126/science.261.5125.1159; PARK J, IN PRESS PLATE BOUND; Peacock SM, 1999, SCIENCE, V286, P937, DOI 10.1126/science.286.5441.937; Peyton V, 2001, GEOPHYS RES LETT, V28, P379, DOI 10.1029/2000GL012200; Plomerova J, 2001, TECTONOPHYSICS, V332, P1, DOI 10.1016/S0040-1951(00)00247-X; Plomerova J, 2000, STUD GEOPHYS GEOD, V44, P195, DOI 10.1023/A:1022110809240; Polet J, 2000, J GEOPHYS RES-SOL EA, V105, P6287, DOI 10.1029/1999JB900326; QUICK JE, 1995, GEOLOGY, V23, P739, DOI 10.1130/0091-7613(1995)023<0739:EOMPIT>2.3.CO;2; RIBE NM, 1994, J GEOPHYS RES-SOL EA, V99, P669, DOI 10.1029/93JB02386; RIBE NM, 1991, J GEOPHYS RES-SOLID, V96, P8325, DOI 10.1029/90JB02721; RIBE NM, 1989, GEOPHYS J INT, V97, P199, DOI 10.1111/j.1365-246X.1989.tb00496.x; Rondenay S, 2000, J GEOPHYS RES-SOL EA, V105, P13735, DOI 10.1029/2000JB900022; Rumpker G, 1998, GEOPHYS J INT, V135, P790, DOI 10.1046/j.1365-246X.1998.00660.x; RUSSO RM, 1994, SCIENCE, V263, P1105, DOI 10.1126/science.263.5150.1105; Saltzer RL, 2000, GEOPHYS J INT, V141, P374, DOI 10.1046/j.1365-246x.2000.00088.x; Savage MK, 1999, REV GEOPHYS, V37, P65, DOI 10.1029/98RG02075; Savage MK, 1998, J GEOPHYS RES-SOL EA, V103, P15069, DOI 10.1029/98JB00795; Schutt DL, 2001, GEOLOGY, V29, P291, DOI 10.1130/0091-7613(2001)029<0291:EFADAB>2.0.CO;2; SHEARER PM, 1986, GEOPHYS J ROY ASTR S, V87, P967, DOI 10.1111/j.1365-246X.1986.tb01979.x; SIEGESMUND S, 1991, GEODYNAMICS, V22, P291; Silveira G, 1998, PHYS EARTH PLANET IN, V106, P257, DOI 10.1016/S0031-9201(98)00079-X; SILVER PG, 1993, GEOPHYS RES LETT, V20, P1127, DOI 10.1029/93GL00775; SILVER PG, 1994, GEOPHYS J INT, V119, P949, DOI 10.1111/j.1365-246X.1994.tb04027.x; SILVER PG, 1988, NATURE, V335, P34, DOI 10.1038/335034a0; Silver PG, 1996, ANNU REV EARTH PL SC, V24, P385, DOI 10.1146/annurev.earth.24.1.385; Silver PG, 2001, GEOPHYS RES LETT, V28, P2493, DOI 10.1029/2000GL012696; Smith GP, 2001, SCIENCE, V292, P713, DOI 10.1126/science.1058763; SMITH ML, 1973, J GEOPHYS RES, V78, P3321, DOI 10.1029/JB078i017p03321; SU LQ, 1994, PHYS EARTH PLANET IN, V86, P263, DOI 10.1016/0031-9201(94)90125-2; Tommasi A, 1998, EARTH PLANET SC LETT, V160, P1, DOI 10.1016/S0012-821X(98)00081-8; TRAMPERT J, 1996, EUR GEOPHYS SOC NEWS, V58, P57; vanderLee S, 1997, J GEOPHYS RES-SOL EA, V102, P22815, DOI 10.1029/97JB01168; VINNIK LP, 1984, DOKL AKAD NAUK SSSR+, V278, P1335; WENK HR, 1991, J GEOPHYS RES-SOLID, V96, P8337, DOI 10.1029/91JB00117; Wiemer S, 1999, B SEISMOL SOC AM, V89, P1313; Wolfe CJ, 1998, SCIENCE, V280, P1230, DOI 10.1126/science.280.5367.1230; Wolfe CJ, 1999, GEOPHYS RES LETT, V26, P779, DOI 10.1029/1999GL900056; YU Y, 1994, J GEOPHYS RES-SOL EA, V99, P15399, DOI 10.1029/94JB00936; YU Y, 1995, PHYS EARTH PLANET IN, V87, P231, DOI 10.1016/0031-9201(94)02971-D; YUAN H, IN PRESS J GEOPHYS R; Zhang SQ, 2000, TECTONOPHYSICS, V316, P133, DOI 10.1016/S0040-1951(99)00229-2; ZHANG SQ, 1995, NATURE, V375, P774, DOI 10.1038/375774a0; Zhang YS, 1999, PHYS EARTH PLANET IN, V114, P71, DOI 10.1016/S0031-9201(99)00047-3	90	189	195	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	2002	296	5567					485	489		10.1126/science.1067319	http://dx.doi.org/10.1126/science.1067319			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964469				2022-12-28	WOS:000175179400034
J	Romanowicz, B; Gung, YC				Romanowicz, B; Gung, YC			Superplumes from the core-mantle boundary to the lithosphere: Implications for heat flux	SCIENCE			English	Article							SHEAR-VELOCITY MODEL; ATTENUATION; CONVECTION; HOTSPOTS; SURFACE; ANELASTICITY; TOMOGRAPHY; INVERSION; PATTERN; PLUMES	Three-dimensional modeling of upper-mantle anelastic structure reveals that thermal upwellings associated with the two superplumes, imaged by seismic elastic tomography at the base of the mantle, persist through the upper-mantle transition zone and are deflected horizontally beneath the lithosphere. This explains the unique transverse shear wave isotropy in the central Pacific. We infer that the two superplumes may play a major and stable role in supplying heat and horizontal flow to the low-viscosity asthenospheric channel, lubricating plate motions and feeding hot spots. We suggest that more heat may be carried through the core-mantle boundary than is accounted for by hot spot fluxes alone.	Univ Calif Berkeley, Seismol Lab, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Romanowicz, B (corresponding author), Univ Calif Berkeley, Seismol Lab, 215 McCone Hall, Berkeley, CA 94720 USA.	barbara@seismo.berkeley.edu	Romanowicz, barbara A/H-6726-2017	Romanowicz, barbara A/0000-0002-6208-6044; Gung, Yuancheng/0000-0001-7550-4025				Anderson DL, 2001, SCIENCE, V293, P2016, DOI 10.1126/science.1065448; Babuska V, 1998, PURE APPL GEOPHYS, V151, P257, DOI 10.1007/s000240050114; Bercovici D., 2000, GEOPHYS MONOGR SER, V121, P5; BURKE K, 2001, EOS T AM GEOPHYS UN, V82, pF1134; CASTILLO P, 1988, NATURE, V336, P667, DOI 10.1038/336667a0; Davaille A, 1999, NATURE, V402, P756, DOI 10.1038/45461; DAVIES GF, 1992, J GEOL, V100, P151, DOI 10.1086/629582; Durek JJ, 1996, B SEISMOL SOC AM, V86, P144; Ekstrom G, 1998, NATURE, V394, P168, DOI 10.1038/28148; Forte AM, 2001, NATURE, V410, P1049, DOI 10.1038/35074000; Foulger GR, 2001, GEOPHYS J INT, V145, pF1, DOI 10.1046/j.0956-540x.2001.01457.x; Fukao Y, 2001, REV GEOPHYS, V39, P291, DOI 10.1029/1999RG000068; GABORET C, 2001, EOS, V82, P47; Gu YJ, 2001, J GEOPHYS RES-SOL EA, V106, P11169, DOI 10.1029/2001JB000340; GUNG Y, UNPUB; HAGER BH, 1985, NATURE, V313, P541, DOI 10.1038/313541a0; HART SR, 1992, SCIENCE, V256, P517, DOI 10.1126/science.256.5056.517; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; Li XD, 1996, J GEOPHYS RES-SOL EA, V101, P22245, DOI 10.1029/96JB01306; Masters G, 1996, PHILOS T R SOC A, V354, P1385, DOI 10.1098/rsta.1996.0054; Megnin C, 2000, GEOPHYS J INT, V143, P709, DOI 10.1046/j.1365-246X.2000.00298.x; MINSTER JB, 1981, PHILOS T R SOC A, V299, P319, DOI 10.1098/rsta.1981.0025; Mitrovica JX, 1997, J GEOPHYS RES-SOL EA, V102, P2751, DOI 10.1029/96JB03175; MONTAGNER JP, 1991, J GEOPHYS RES-SOL EA, V96, P20337, DOI 10.1029/91JB01890; Mooney WD, 1998, J GEOPHYS RES-SOL EA, V103, P727, DOI 10.1029/97JB02122; MORGAN WJ, 1971, NATURE, V230, P42, DOI 10.1038/230042a0; Nolet G, 2000, J GEOPHYS RES-SOL EA, V105, P19043, DOI 10.1029/2000JB900161; NYBLADE AA, 1994, GEOPHYS RES LETT, V21, P765, DOI 10.1029/94GL00631; Reid FJL, 2001, GEOPHYS J INT, V145, P615, DOI 10.1046/j.1365-246x.2001.01395.x; RICHARDS MA, 1988, J GEOPHYS RES-SOLID, V93, P7690, DOI 10.1029/JB093iB07p07690; Ritsema J, 1999, SCIENCE, V286, P1925, DOI 10.1126/science.286.5446.1925; ROMANOWICZ B, 1995, J GEOPHYS RES-SOL EA, V100, P12375, DOI 10.1029/95JB00957; Roth EG, 1999, J GEOPHYS RES-SOL EA, V104, P4795, DOI 10.1029/1998JB900052; Selby ND, 2000, GEOPHYS J INT, V142, P933, DOI 10.1046/j.1365-246x.2000.00209.x; SLEEP NH, 1990, J GEOPHYS RES-SOLID, V95, P6715, DOI 10.1029/JB095iB05p06715; SUDA N, 1991, GEOPHYS RES LETT, V18, P1119, DOI 10.1029/91GL01337; Wolfe CJ, 1997, NATURE, V385, P245, DOI 10.1038/385245a0	37	183	192	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	2002	296	5567					513	516		10.1126/science.1069404	http://dx.doi.org/10.1126/science.1069404			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964474				2022-12-28	WOS:000175179400041
J	Sehgal, AR; Leon, JB; Siminoff, LA; Singer, ME; Bunosky, LM; Cebul, RD				Sehgal, AR; Leon, JB; Siminoff, LA; Singer, ME; Bunosky, LM; Cebul, RD			Improving the quality of hemodialysis treatment - A community-based randomized controlled trial to overcome patient-specific barriers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORE INDICATORS PROJECT; DIALYSIS; ADEQUACY; SURVIVAL; CLUSTER	Context Mortality rates among US hemodialysis patients are the highest in the industrialized world at 23% per year. Measures of dialysis dose (Kt/V) correspond strongly with survival and are inadequate in one sixth of patients. Inadequate dialysis is also associated with increased hospitalizations and high inpatient costs. Our previous work identified 3 barriers to adequate hemodialysis: dialysis underprescription, catheter use, and shortened treatment time. Objective To determine the effect of a tailored intervention on adequacy of hemodialysis. Design and Setting Community-based randomized controlled trial with recruitment from April 1999 to June 2000 at 29 hemodialysis facilities in northeast Ohio. Participants Forty-four nephrologists and their 169 randomly selected adult patients receiving inadequate hemodialysis. Intervention Nephrologists were randomly assigned to an intervention (n=21) or control (n=23) group. For patients in the intervention group (n=85), depending on the barrier(s) present, a study coordinator gave nephrologists recommendations about optimizing dialysis prescriptions, expedited conversion of catheters to surgically created grafts or fistulas, and educated patients about the importance of compliance with treatment time. Patients in the control group (n=84) continued to receive usual care. Main Outcome Measures Changes in Kt/V and specific barriers after 6 months. Results At baseline, intervention and control patients had similar Kt/V measurements, specific barriers, and demographic and medical characteristics. After 6 months, intervention patients had 2-fold larger increases in Kt/V compared with control patients (+0.20 vs +0.10; P<.001) and were more likely to achieve their facility Kt/V goal (62% vs 42%; P=.01). Intervention patients also had nearly 3-fold larger increases in dialysis prescription (+0.16 vs +0.06; P<.001) and were 4 times more likely to change from use of catheters to use of fistulas/grafts (28% vs 7%; P=.04). Conclusions An intervention tailored to patient-specific barriers resulted in increased hemodialysis dose. Extending this approach to the 33000 persons in the United States receiving inadequate hemodialysis may substantially enhance patient survival, diminish hospitalizations, and decrease inpatient expenditures.	Metrohlth Med Ctr, Div Nephrol, Cleveland, OH 44109 USA; Metrohlth Med Ctr, Ctr Hlth Care Res & Policy, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Biomed Eth, Cleveland, OH 44106 USA	MetroHealth System; MetroHealth System; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Sehgal, AR (corresponding author), Metrohlth Med Ctr, Div Nephrol, 2500 MetroHlth Dr, Cleveland, OH 44109 USA.		Siminoff, Laura A/H-6277-2012; Singer, Mendel/S-8775-2019	Singer, Mendel/0000-0002-3331-3340	NIDDK NIH HHS [DK54178, DK51472] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051472, P50DK054178] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRYK A, 1996, HIERARCHICAL LINEAR; Chertow GM, 1997, KIDNEY INT, V51, P1578, DOI 10.1038/ki.1997.216; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; Depner TA., 1991, PRESCRIBING HEMODIAL, V2nd Ed.; DONNER A, 1993, J CLIN EPIDEMIOL, V46, P123, DOI 10.1016/0895-4356(93)90050-B; DONNER A, 1981, AM J EPIDEMIOL, V114, P906, DOI 10.1093/oxfordjournals.aje.a113261; Frankenfield DL, 1999, AM J KIDNEY DIS, V34, P721, DOI 10.1016/S0272-6386(99)70399-9; Friedman L. M., 1998, FUNDAMENTALS CLIN TR; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; Hakim RM, 2001, HDB DIALYSIS, V3rd, P236; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; Helgerson SD, 1997, AM J KIDNEY DIS, V29, P851, DOI 10.1016/S0272-6386(97)90458-3; *HLTH CAR FIN ADM, 1998, PROF MED CHARTB 1998; *HLTH CAR FIN ADM, 2000, 2000 ANN REP ESRD CL; Hulley S. B., 1988, DESIGNING CLIN RES; Klar N, 2000, DESIGN ANAL CLUSTER, DOI [10.17843/rpmesp.2016.333.2293, DOI 10.17843/RPMESP.2016.333.2293]; Kloppenburg WD, 1999, KIDNEY INT, V55, P1961, DOI 10.1046/j.1523-1755.1999.00412.x; Leggat JE, 1998, AM J KIDNEY DIS, V32, P139, DOI 10.1053/ajkd.1998.v32.pm9669435; Leon JB, 2001, AM J NEPHROL, V21, P200, DOI 10.1159/000046248; Lowrie EG, 1999, KIDNEY INT, V56, P729, DOI 10.1046/j.1523-1755.1999.00584.x; McClellan WM, 1999, AM J KIDNEY DIS, V34, P1075, DOI 10.1016/S0272-6386(99)70013-2; McCullough K. P., 2000, Journal of the American Society of Nephrology, V11, p325A; MCLAUGHLIN CP, 1994, CONTINUOUS QUALITY I; *NAT KIDN FDN, 1997, AM J KIDNEY DIS S, V30, pS15; Owen WF, 1998, JAMA-J AM MED ASSOC, V280, P1764, DOI 10.1001/jama.280.20.1764; Sehgal AR, 2002, SEMIN DIALYSIS, V15, P35, DOI 10.1046/j.1525-139x.2002.00013.x; Sehgal AR, 1998, AM J KIDNEY DIS, V31, P593, DOI 10.1053/ajkd.1998.v31.pm9531174; Sehgal AR, 2001, AM J KIDNEY DIS, V37, P1223, DOI 10.1053/ajkd.2001.24526; Sehgal AR, 1997, AM J KIDNEY DIS, V30, P514, DOI 10.1016/S0272-6386(97)90310-3; *US REN DAT SYST, 2000, USRDS 2000 ANN DAT R; Wickstrom G, 2000, SCAND J WORK ENV HEA, V26, P363, DOI 10.5271/sjweh.555	32	47	53	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2002	287	15					1961	1967		10.1001/jama.287.15.1961	http://dx.doi.org/10.1001/jama.287.15.1961			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NC	11960538				2022-12-28	WOS:000174989800024
J	Hart, G; Wellings, K				Hart, G; Wellings, K			Sexual behaviour and its medicalisation: in sickness and in health	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DYSFUNCTION		Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland; Univ London London Sch Hyg & Trop Med, Ctr Sexual Hlth Res, Dept Publ Hlth & Policy, London WC1E 7HT, England	MRC/CSO SOCIAL AND PUBLIC HEALTH SCIENCES UNIT; University of Glasgow; University of London; London School of Hygiene & Tropical Medicine	Hart, G (corresponding author), Univ Glasgow, MRC, Social & Publ Hlth Sci Unit, Glasgow G12 8RZ, Lanark, Scotland.	g.hart@msoc.mrc.gla.ac.uk	Hart, Graham J/C-1591-2008	Hart, Graham/0000-0001-9676-6577				ACTON W, 1857, FUNCTIONS DISORDERS; ALTHOF SE, 1995, PSYCHIAT CLIN N AM, V18, P171, DOI 10.1016/S0193-953X(18)30078-9; Berridge V., 1987, OPIUM PEOPLE OPIATE; BOLOURI Y, 1996, SUN             1114, P1; *CHIEF MED OFF, 1998, MAIN REP CMOS EXP AD; Conrad P, 2001, HEALTH, V5, P373, DOI 10.1177/136345930100500306; Davidson Roger, 2001, SEX SIN SUFFERING VE; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Fenton KA, 2001, LANCET, V358, P1851, DOI 10.1016/S0140-6736(01)06886-6; Foucault Michel., 1978, HIST SEXUALITY INTRO; Hall L, 2001, SEX SIN SUFFERING VE; HALL L, 1991, HIDDEN ANXIETIES MAL; HALL LA, 1997, NEW SEXUAL AGENDAS; Hall Lesley, 1994, SEXUAL KNOWLEDGE SEX; Johnson AM, 2001, LANCET, V358, P1835, DOI 10.1016/S0140-6736(01)06883-0; Johnson AM, 1994, SEXUAL ATTITUDES LIF; JOWELL R, 2000, BRIT SOCIAL ATTITUDE; Kinsey A, 1948, SEXUAL BEHAV HUMAN M, DOI 10.1037/t17515-000; Kinsey A.C., 1998, SEXUAL BEHAV HUMAN F; Kutchins H, 1997, MAKING US CRAZY DSM; Larkin Philip, 1990, COLLECTED POEMS; Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537; Marcuse H., 1998, EROS CIVILIZATION; MARKS L V, 2001, SEXUAL CHEM HIST CON; Masters WH., 1966, HUMAN SEXUAL RESPONS; Porter Roy, 1995, FACTS LIFE CREATION; Sigerist HE., 1951, LASTRES HENRY SIGERI; Sim J., 1990, MED POWER PRISONS PR; Weeks J., 1985, SEXUALITY ITS DISCON; Wellings F, 2001, LANCET, V358, P1843, DOI 10.1016/S0140-6736(01)06885-4	30	65	65	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 13	2002	324	7342					896	900		10.1136/bmj.324.7342.896	http://dx.doi.org/10.1136/bmj.324.7342.896			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950742	Green Accepted, Green Published			2022-12-28	WOS:000175052200028
J	Johanson, R; Newburn, M; Macfarlane, A				Johanson, R; Newburn, M; Macfarlane, A			Has the medicalisation of childbirth gone too far?	BRITISH MEDICAL JOURNAL			English	Article							CARE; CONTINUITY; MIDWIFERY; BIRTH; TRIAL		Natl Childbirth Trust, London W3 6NH, England; N Staffordshire Matern Hosp, Acad Dept Obstet & Gynaecol, Stoke On Trent ST4 6QG, Staffs, England; City Univ London, St Bartholomew Sch Nursing & Midwifery, Dept Midwifery, London EC1A 7QN, England	University Hospital of North Staffordshire NHS Trust; City University London; University of London; Queen Mary University London	Newburn, M (corresponding author), Natl Childbirth Trust, Alexandra House,Oldham Terrace, London W3 6NH, England.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				ABOUZAHR C, 1998, GLOBAL BURDEN DIS IN, V3; [Anonymous], [No title captured]; Bosch X, 1998, BRIT MED J, V317, P1406, DOI 10.1136/bmj.317.7170.1406b; Chamberlain G, 1997, HOME BIRTHS REPORT 1; Donnison J., 1977, MIDWIVES MED MEN; *EXP ADV GROUP CAE, 2001, SCOTT PROGR CLIN EFF; FARQUHAR M, 1996, EVALUATION MIDWIFERY; Ferriman A, 2001, BRIT MED J, V322, P1081, DOI 10.1136/bmj.322.7294.1081; Flint C, 1989, Midwifery, V5, P11, DOI 10.1016/S0266-6138(89)80059-2; *GEN REG OFF, 1938, REG GEN DEC SUPPL A, V2; GLAZENER CMA, 1995, BRIT J OBSTET GYNAEC, V102, P282, DOI 10.1111/j.1471-0528.1995.tb09132.x; Homer CSE, 2001, BRIT J OBSTET GYNAEC, V108, P16, DOI 10.1016/S0306-5456(00)00022-X; Hopkins K, 2000, SOC SCI MED, V51, P725, DOI 10.1016/S0277-9536(99)00480-3; HOWELL CJ, 2002, COCHRANE DATABASE SY, DOI UNSP CD000331; KAUNITZ AM, 1984, AM J OBSTET GYNECOL, V150, P826, DOI 10.1016/0002-9378(84)90457-5; Kirkham M, 1999, J ADV NURS, V30, P732, DOI 10.1046/j.1365-2648.1999.01139.x; Lieberman E, 1997, PEDIATRICS, V99, P415, DOI 10.1542/peds.99.3.415; Loudon, 2000, TRAGEDY CHILDBED FEV; Loudon I., 1992, DEATH CHILDBIRTH; MCCOURT C, 1996, REPORT EVALUATION ON; MOULLA J, 2000, MIDW MOD EXC C 17 MA; NEWBURN M, 2002, MIDIRS MIDWIFERY DIG, V12, P122; Olsson P, 2000, MIDWIFERY, V16, P123, DOI 10.1054/midw.1999.0201; *ONT WOM HLTH COUN, 2000, ATT MAINT BEST PRACT; PARANJOTHY S, 2001, NATL SENTINEL CAESAR; ROWLEY MJ, 1995, MED J AUSTRALIA, V163, P289, DOI 10.5694/j.1326-5377.1995.tb124592.x; *ROYAL COLL MIDW R, 2001, MOD MAT CAR COMM TOO; Saunders D, 2000, EVALUATION EDGWARE B; THACKER SB, 2002, COCHRANE DB SYST REV; Turrentine MA, 1999, OBSTET GYNECOL, V94, P185, DOI 10.1016/S0029-7844(99)00315-4; Waldenstrom U, 1998, BRIT J OBSTET GYNAEC, V105, P1160, DOI 10.1111/j.1471-0528.1998.tb09969.x; Waldenstrom U, 1997, BRIT J OBSTET GYNAEC, V104, P410, DOI 10.1111/j.1471-0528.1997.tb11491.x; WILEY S, 2000, NOTTINGHAM EVEN 1019	33	228	232	1	31	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					892	895		10.1136/bmj.324.7342.892	http://dx.doi.org/10.1136/bmj.324.7342.892			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	542PA	11950741	Green Published			2022-12-28	WOS:000175052200027
J	Enard, W; Khaitovich, P; Klose, J; Zollner, S; Heissig, F; Giavalisco, P; Nieselt-Struwe, K; Muchmore, E; Varki, A; Ravid, R; Doxiadis, GM; Bontrop, RE; Paabo, S				Enard, W; Khaitovich, P; Klose, J; Zollner, S; Heissig, F; Giavalisco, P; Nieselt-Struwe, K; Muchmore, E; Varki, A; Ravid, R; Doxiadis, GM; Bontrop, RE; Paabo, S			Intra- and interspecific variation in primate gene expression patterns	SCIENCE			English	Article							GENOME	Although humans and their closest evolutionary relatives, the chimpanzees, are 98.7% identical in their genomic DNA sequences, they differ in many morphological, behavioral, and cognitive aspects. The underlying genetic basis of many of these differences may be altered gene expression. We have compared the transcriptome in blood leukocytes, liver, and brain of humans, chimpanzees, orangutans, and macaques using microarrays, as well as protein expression patterns of humans and chimpanzees using two-dimensional get electrophoresis. We also studied three mouse species that are approximately as related to each other as are humans, chimpanzees, and orangutans. We identified species-specific gene expression patterns indicating that changes in protein and gene expression have been particularly pronounced in the human brain.	Max Planck Inst Evolutionary Anthropol, D-04103 Leipzig, Germany; Inst Humangenet Charite, D-13353 Berlin, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Univ Calif San Diego, La Jolla, CA 92093 USA; Vet Adm Med Ctr, La Jolla, CA 92093 USA; Netherlands Brain Bank, Amsterdam, Netherlands; Biomed Primate Res Ctr, Rijswijk, Netherlands	Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Max Planck Society; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Paabo, S (corresponding author), Max Planck Inst Evolutionary Anthropol, Inselstr 22, D-04103 Leipzig, Germany.		Bontrop, Ronald E./D-4844-2011; Enard, Wolfgang/K-3483-2014; Khaitovich, Philipp/HGC-8520-2022; Bontrop, Ronald E/J-3628-2012	Bontrop, Ronald E/0000-0003-0874-6467				BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Chen FC, 2001, AM J HUM GENET, V68, P444, DOI 10.1086/318206; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; Fujiyama A, 2002, SCIENCE, V295, P131, DOI 10.1126/science.1065199; Gagneux P, 2001, AM J PHYS ANTHROPOL, V115, P99, DOI 10.1002/ajpa.1061; Gagneux P, 2001, MOL PHYLOGENET EVOL, V18, P2, DOI 10.1006/mpev.2000.0799; HELLMANN I, UNPUB; KING MC, 1975, SCIENCE, V188, P107, DOI 10.1126/science.1090005; KLEIN G, 1989, HUMAN CAREER HUMAN B; Klose J, 1999, METH MOL B, V112, P147; Klose J, 2002, NAT GENET, V30, P385, DOI 10.1038/ng861; Klose J, 1999, METH MOL B, V112, P67; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Varki A, 2000, GENOME RES, V10, P1065, DOI 10.1101/gr.10.8.1065; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	16	643	773	0	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					340	343		10.1126/science.1068996	http://dx.doi.org/10.1126/science.1068996			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951044				2022-12-28	WOS:000175000300056
J	Jacobs, HO; Tao, AR; Schwartz, A; Gracias, DH; Whitesides, GM				Jacobs, HO; Tao, AR; Schwartz, A; Gracias, DH; Whitesides, GM			Fabrication of a cylindrical display by patterned assembly	SCIENCE			English	Article							SURFACE-TENSION	We demonstrate the patterned assembly of integrated semiconductor devices onto planar, flexible, and curved substrates on the basis of capillary interactions involving liquid solder. The substrates presented patterned, solder-coated areas that acted both as receptors for the components of the device during its assembly and as electrical connections during its operation. The components were suspended in water and agitated gently. Minimization of the free energy of the solder-water interface provided the driving force for the assembly. One hundred and thirteen GaAlAs light-emitting diodes with a chip size of 280 micrometers were fabricated into a prototype cylindrical display. It was also possible to assemble 1500 silicon cubes, on an area of 5 square centimeters, in less than 3 minutes, with a defect rate of similar to2%.	Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Harvard University	Whitesides, GM (corresponding author), Harvard Univ, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA.		Gracias, David/A-1942-2010	Gracias, David/0000-0003-2735-4725				BOHRINGER KF, 2001, IEEE WORKSH MICR EL; BONCHEVA M, IN PRESS P NATL ACAD; Bowden N, 1997, SCIENCE, V276, P233, DOI 10.1126/science.276.5310.233; Bowden NB, 2001, ACCOUNTS CHEM RES, V34, P231, DOI 10.1021/ar0000760; Choi IS, 1999, ANGEW CHEM INT EDIT, V38, P3078, DOI 10.1002/(SICI)1521-3773(19991018)38:20<3078::AID-ANIE3078>3.0.CO;2-3; Cohn M. B., 1998, P SPIE MICR MICR SAN, P2; Dahlmann GW, 2000, ELECTRON LETT, V36, P1707, DOI 10.1049/el:20001190; Fearing R. S., 1995, P 1995 IEEE RSJ INT, V2, P212; Fung C. D., 1985, MICROMACHINING MICRO; Gracias DH, 2000, SCIENCE, V289, P1170, DOI 10.1126/science.289.5482.1170; Harsh KF, 1999, SENSOR ACTUAT A-PHYS, V77, P237, DOI 10.1016/S0924-4247(99)00220-4; Hosokawa K, 1996, SENSOR ACTUAT A-PHYS, V57, P117, DOI 10.1016/S0924-4247(97)80102-1; Lehn J.-M., 2000, NEW CHEM, P300; MILLER LF, 1969, IBM J RES DEV, V13, P239, DOI 10.1147/rd.133.0239; Rothemund PWK, 2000, P NATL ACAD SCI USA, V97, P984, DOI 10.1073/pnas.97.3.984; SLIWA JW, 1991, Patent No. 5075253; SMELA E, 1995, SCIENCE, V268, P1735, DOI 10.1126/science.268.5218.1735; Smith J. S., 1998, U.S. Patent, Patent No. [5 824 186 A, 5824186]; SMITH JS, 1999, Patent No. 5904545; Srinivasan U, 2001, J MICROELECTROMECH S, V10, P17, DOI 10.1109/84.911087; Syms RRA, 2001, SENSOR ACTUAT A-PHYS, V88, P273, DOI 10.1016/S0924-4247(00)00523-9; Syms RRA, 1998, SENSOR ACTUAT A-PHYS, V65, P238, DOI 10.1016/S0924-4247(97)01749-4; Weck M, 2000, J AM CHEM SOC, V122, P3546, DOI 10.1021/ja994099p; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; YEH HJJ, 1994, IEEE PHOTONIC TECH L, V6, P706, DOI 10.1109/68.300169	25	313	365	6	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					323	325		10.1126/science.1069153	http://dx.doi.org/10.1126/science.1069153			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951039	Green Submitted			2022-12-28	WOS:000175000300050
J	Shimoda, SL; Solomon, F				Shimoda, SL; Solomon, F			Integrating functions at the kinetochore	CELL			English	Review							BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; SPINDLE; CHECKPOINT; SEPARATION; MITOSIS	Kinetochore components have catalytic as well as structural activities. New evidence illustrates how these proteins integrate spindle morphogenesis with regulation of the timing and accuracy of chromosome segregation.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Canc Res Ctr, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Solomon, F (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; Goshima G, 2000, CELL, V100, P619, DOI 10.1016/S0092-8674(00)80699-6; He XW, 2000, CELL, V101, P763, DOI 10.1016/S0092-8674(00)80888-0; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Jones MH, 2001, P NATL ACAD SCI USA, V98, P13675, DOI 10.1073/pnas.241417098; Kang JS, 2001, J CELL BIOL, V155, P763, DOI 10.1083/jcb.200105029; King JM, 2000, J CELL BIOL, V151, P739, DOI 10.1083/jcb.151.4.739; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Li YM, 2002, GENE DEV, V16, P183, DOI 10.1101/gad.959402; Nicklas RB, 2001, J CELL SCI, V114, P4173; Pereira G, 2001, EMBO J, V20, P6359, DOI 10.1093/emboj/20.22.6359; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Stern BM, 2001, CURR BIOL, V11, P1462, DOI 10.1016/S0960-9822(01)00451-1; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5	19	8	8	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	2002	109	1					9	12		10.1016/S0092-8674(02)00712-2	http://dx.doi.org/10.1016/S0092-8674(02)00712-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955441	Bronze			2022-12-28	WOS:000174888300003
J	Rathmell, JC; Thompson, CB				Rathmell, JC; Thompson, CB			Pathways of apoptosis in lymphocyte development, homeostasis, and disease	CELL			English	Review							INDUCED CELL-DEATH; FAMILY-MEMBER BIM; FLICE-INHIBITORY PROTEIN; FAS-MEDIATED APOPTOSIS; MEMORY T-CELLS; SEE VOL. 30; NF-KAPPA-B; BCL-2 FAMILY; MITOCHONDRIAL DYSFUNCTION; BH3-ONLY PROTEINS	Apoptosis plays a critical role in lymphocyte development and homeostasis. Enhanced lymphocyte apoptosis can cause immunodeficiency through cell loss. Conversely, inhibition of apoptosis can lead to the development of autoimmunity or lymphoma. Two major pathways contribute to the regulation of lymphocyte cell death, death-by-neglect and death-by-instruction.	Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA; Univ Penn, Abramson Family Canc Res Inst, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Thompson, CB (corresponding author), Univ Penn, Abramson Family Canc Res Inst, Dept Canc Biol, Philadelphia, PA 19104 USA.	drt@mail.med.upenn.edu						Aubert S, 1996, J CELL BIOL, V133, P1251, DOI 10.1083/jcb.133.6.1251; Baird AM, 1999, CURR OPIN IMMUNOL, V11, P157, DOI 10.1016/S0952-7915(99)80027-2; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; Berard M, 1999, IMMUNOLOGY, V98, P47; Bouillet P, 2001, DEV CELL, V1, P645, DOI 10.1016/S1534-5807(01)00083-1; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Boussiotis VA, 1997, J IMMUNOL, V159, P3156; Brady HJM, 1996, EMBO J, V15, P6991, DOI 10.1002/j.1460-2075.1996.tb01091.x; Burr JS, 2001, J IMMUNOL, V166, P5331, DOI 10.4049/jimmunol.166.9.5331; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Chung DH, 2000, MOL CELLS, V10, P642, DOI 10.1007/s100590000024; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Conte D, 2001, P NATL ACAD SCI USA, V98, P5049, DOI 10.1073/pnas.081547998; DECKWERTH TL, 1993, J CELL BIOL, V123, P1207, DOI 10.1083/jcb.123.5.1207; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Fatenejad S, 1998, J IMMUNOL, V161, P6427; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Granziero L, 2001, BLOOD, V97, P2777, DOI 10.1182/blood.V97.9.2777; Griffith TS, 1996, IMMUNITY, V5, P7, DOI 10.1016/S1074-7613(00)80305-2; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hennino A, 2001, J EXP MED, V193, P447, DOI 10.1084/jem.193.4.447; Hennino A, 2000, J IMMUNOL, V165, P3023, DOI 10.4049/jimmunol.165.6.3023; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Jehn BM, 1999, J IMMUNOL, V162, P635; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Ku CC, 2000, SCIENCE, V288, P675, DOI 10.1126/science.288.5466.675; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Landowski TH, 2001, LEUKEMIA LYMPHOMA, V42, P835, DOI 10.3109/10428190109097702; Levine BL, 1997, J IMMUNOL, V159, P5921; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Melchers F, 2000, IMMUNOL REV, V175, P33, DOI 10.1111/j.1600-065X.2000.imr017510.x; MULLAUER L, 2000, MUTAT RES, V488, P211; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perkins DL, 1996, J IMMUNOL, V156, P4961; Polic B, 2001, P NATL ACAD SCI USA, V98, P8744, DOI 10.1073/pnas.141218898; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ranger AM, 2001, NAT GENET, V28, P113, DOI 10.1038/88815; Rathmell JC, 2001, J IMMUNOL, V167, P6869, DOI 10.4049/jimmunol.167.12.6869; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Refaeli Y, 1998, IMMUNITY, V8, P615, DOI 10.1016/S1074-7613(00)80566-X; ROTHSTEIN TL, 1995, NATURE, V374, P163, DOI 10.1038/374163a0; Rubio CF, 1996, J IMMUNOL, V157, P65; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schluns KS, 2000, NAT IMMUNOL, V1, P426, DOI 10.1038/80868; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Straus SE, 1999, ANN INTERN MED, V130, P591, DOI 10.7326/0003-4819-130-7-199904060-00020; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; TOUGH DF, 1995, IMMUNOL RES, V14, P1, DOI 10.1007/BF02918494; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; Van Parijs L, 1998, SCIENCE, V280, P243; Van Parijs L, 1999, IMMUNITY, V11, P763, DOI 10.1016/S1074-7613(00)80150-8; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vander Heiden MG, 1999, MOL CELL, V3, P159; Vanfleteren JR, 1999, NEUROBIOL AGING, V20, P487, DOI 10.1016/S0197-4580(99)00087-1; VanParijs L, 1996, IMMUNITY, V4, P321, DOI 10.1016/S1074-7613(00)80440-9; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang J, 2000, EUR J IMMUNOL, V30, P155, DOI 10.1002/1521-4141(200001)30:1<155::AID-IMMU155>3.3.CO;2-O; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WHETTON AD, 1983, NATURE, V303, P629, DOI 10.1038/303629a0; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xu XN, 2001, IMMUNITY, V15, P867, DOI 10.1016/S1074-7613(01)00255-2; Yamaguchi H, 2001, ONCOGENE, V20, P7779, DOI 10.1038/sj.onc.1204984; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	93	297	312	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR	2002	109			S			S97	S107		10.1016/S0092-8674(02)00704-3	http://dx.doi.org/10.1016/S0092-8674(02)00704-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	544UY	11983156	Bronze			2022-12-28	WOS:000175181100009
J	Dunah, AW; Jeong, H; Griffin, A; Kim, YM; Standaert, DG; Hersch, SM; Mouradian, MM; Young, AB; Tanese, N; Krainc, D				Dunah, AW; Jeong, H; Griffin, A; Kim, YM; Standaert, DG; Hersch, SM; Mouradian, MM; Young, AB; Tanese, N; Krainc, D			Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease	SCIENCE			English	Article							MEDIATED TRANSCRIPTION; GLUTAMINE REPEATS; GENE-EXPRESSION; TRANSGENIC MICE; MAMMALIAN-CELLS; BINDING PROTEIN; NERVOUS-SYSTEM; RECEPTOR GENE; TFIID SUBUNIT; HUMAN BRAIN	Huntington's disease (HD) is an inherited neurodegenerative disease caused by expansion of a polyglutamine tract in the huntingtin protein. Transcriptional dysregulation has been implicated in HD pathogenesis. Here, we report that huntingtin interacts with the transcriptional activator Sp1 and coactivator TAFII130. Coexpression of Sp1 and TAFII130 in cultured striatal cells from wild-type and HD transgenic mice reverses the transcriptional inhibition of the dopamine D2 receptor gene caused by mutant huntingtin, as well as protects neurons from huntingtin-induced cellular toxicity. Furthermore, soluble mutant huntingtin inhibits Sp1 binding to DNA in postmortem brain tissues of both presymptomatic and affected HD patients. Understanding these early molecular events in HD may provide an opportunity to interfere with the effects of mutant huntingtin before the development of disease symptoms.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Ctr Aging Genet & Neurodegenerat, Charlestown, MA 02129 USA; NINCDS, Genet Pharmacol Unit, Expt Therapeut Branch, NIH, Bethesda, MD 20892 USA; NYU, Sch Med, Dept Microbiol MSB258, New York, NY 10016 USA	Harvard University; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); New York University	Krainc, D (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Ctr Aging Genet & Neurodegenerat, Charlestown, MA 02129 USA.	krainc@helix.mgh.harvard.edu	Young, Anne/AAF-4283-2020	Mouradian, M. Maral/0000-0002-9937-412X; Standaert, David/0000-0003-2921-8348; Tanese, Naoko/0000-0002-1946-3211	NCCIH NIH HHS [AT00613] Funding Source: Medline; NIA NIH HHS [5R37AG13617] Funding Source: Medline; NINDS NIH HHS [NS35255, NS02174, NS34361] Funding Source: Medline; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000613] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [U01AT000613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS034361, Z01NS002826, R01NS034361, R01NS035255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG013617] Funding Source: NIH RePORTER	NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Augood SJ, 1997, ANN NEUROL, V42, P215, DOI 10.1002/ana.410420213; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; Dunah AW, 1998, MOL PHARMACOL, V53, P429, DOI 10.1124/mol.53.3.429; DUNAH AW, UNPUB; Furukawa T, 2000, J BIOL CHEM, V275, P29847, DOI 10.1074/jbc.M002989200; Gangloff YG, 2000, MOL CELL BIOL, V20, P340, DOI 10.1128/MCB.20.1.340-351.2000; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; HUANG CC, 1998, SOMAT CELL MOLEC GEN, V24, P971; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kegel KB, 2002, J BIOL CHEM, V277, P7466, DOI 10.1074/jbc.M103946200; Krainc D, 1998, J BIOL CHEM, V273, P26218, DOI 10.1074/jbc.273.40.26218; KRAINC D, UNPUB; Lahiri DK, 2000, BRAIN RES PROTOC, V5, P257, DOI 10.1016/S1385-299X(00)00021-0; Li H, 2000, NAT GENET, V25, P385, DOI 10.1038/78054; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; LI SH, 2002, MOL CELL BIOL, V22, P1722; Lunkes A, 1998, ESSAYS BIOCHEM, V33, P149, DOI 10.1042/bse0330149; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Mende-Mueller LM, 2001, J NEUROSCI, V21, P1830, DOI 10.1523/JNEUROSCI.21-06-01830.2001; Metsis M, 2001, EXP CELL RES, V269, P214, DOI 10.1006/excr.2001.5307; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; Rojo-Niersbach E, 1999, J BIOL CHEM, V274, P33778, DOI 10.1074/jbc.274.47.33778; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Surmeier DJ, 1996, J NEUROSCI, V16, P6579, DOI 10.1523/jneurosci.16-20-06579.1996; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; Weeks RA, 1996, ANN NEUROL, V40, P49, DOI 10.1002/ana.410400110; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Yajima S, 1998, DNA CELL BIOL, V17, P471, DOI 10.1089/dna.1998.17.471; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	42	545	567	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 21	2002	296	5576					2238	2243		10.1126/science.1072613	http://dx.doi.org/10.1126/science.1072613			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	565PQ	11988536				2022-12-28	WOS:000176379000064
J	Strecker, KE; Partridge, GB; Truscott, AG; Hulet, RG				Strecker, KE; Partridge, GB; Truscott, AG; Hulet, RG			Formation and propagation of matter-wave soliton trains	NATURE			English	Article							BOSE-EINSTEIN CONDENSATE; NONLINEAR SCHRODINGER-EQUATION; ATTRACTIVE INTERACTIONS; OPTICAL FIBERS; DARK SOLITONS; ATOMS; COLLISIONS; RESONANCE; DYNAMICS; COLLAPSE	Attraction between the atoms of a Bose-Einstein condensate renders it unstable to collapse, although a condensate with a limited number of atoms(1) can be stabilized(2) by confinement in an atom trap. However, beyond this number the condensate collapses(3-5). Condensates constrained to one-dimensional motion with attractive interactions are predicted to form stable solitons, in which the attractive forces exactly compensate for wave-packet dispersion(1). Here we report the formation of bright solitons of Li-7 atoms in a quasi-one-dimensional optical trap, by magnetically tuning the interactions in a stable Bose-Einstein condensate from repulsive to attractive. The solitons are set in motion by offsetting the optical potential, and are observed to propagate in the potential for many oscillatory cycles without spreading. We observe a soliton train, containing many solitons; repulsive interactions between neighbouring solitons are inferred from their motion.	Rice Univ, Dept Phys & Astron, Houston, TX 77251 USA; Rice Univ, Rice Quantum Inst, Houston, TX 77251 USA	Rice University; Rice University	Hulet, RG (corresponding author), Rice Univ, Dept Phys & Astron, Houston, TX 77251 USA.	randy@atomcool.rice.edu	Truscott, Andrew/A-8086-2011	Truscott, Andrew/0000-0003-2106-8613; Hulet, Randall/0000-0001-7045-8947				Anderson BP, 2001, PHYS REV LETT, V86, P2926, DOI 10.1103/PhysRevLett.86.2926; Bradley CC, 1997, PHYS REV LETT, V78, P985, DOI 10.1103/PhysRevLett.78.985; Burger S, 1999, PHYS REV LETT, V83, P5198, DOI 10.1103/PhysRevLett.83.5198; Carr LD, 2000, J PHYS B-AT MOL OPT, V33, P3983, DOI 10.1088/0953-4075/33/19/312; Carr LD, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.063611; Dalfovo F, 1999, REV MOD PHYS, V71, P463, DOI 10.1103/RevModPhys.71.463; Denschlag J, 2000, SCIENCE, V287, P97, DOI 10.1126/science.287.5450.97; Donley EA, 2001, NATURE, V412, P295, DOI 10.1038/35085500; Gerton JM, 2000, NATURE, V408, P692, DOI 10.1038/35047030; GORDON JP, 1983, OPT LETT, V8, P596, DOI 10.1364/OL.8.000596; Gorlitz A, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.130402; Hasegawa A., 1990, OPTICAL SOLITONS FIB; Inouye S, 1998, NATURE, V392, P151, DOI 10.1038/32354; Kasevich MA, 2001, CR ACAD SCI IV-PHYS, V2, P497, DOI 10.1016/S1296-2147(01)01181-7; LENZ G, 1993, PHYS REV LETT, V71, P3271, DOI 10.1103/PhysRevLett.71.3271; MCALEXANDER WI, 2000, THESIS RICE U, P33403; Muryshev AE, 1999, PHYS REV A, V60, pR2665, DOI 10.1103/PhysRevA.60.R2665; Perez-Garcia VM, 1998, PHYS REV A, V57, P3837, DOI 10.1103/PhysRevA.57.3837; Roberts JL, 2000, PHYS REV LETT, V85, P728, DOI 10.1103/PhysRevLett.85.728; RUPRECHT PA, 1995, PHYS REV A, V51, P4704, DOI 10.1103/PhysRevA.51.4704; Sackett CA, 1999, PHYS REV LETT, V82, P876, DOI 10.1103/PhysRevLett.82.876; Schreck F, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.080403; Stegeman GI, 1999, SCIENCE, V286, P1518, DOI 10.1126/science.286.5444.1518; TAI K, 1986, PHYS REV LETT, V56, P135, DOI 10.1103/PhysRevLett.56.135; TIESINGA E, 1993, PHYS REV A, V47, P4114, DOI 10.1103/PhysRevA.47.4114; Truscott AG, 2001, SCIENCE, V291, P2570, DOI 10.1126/science.1059318; ZAKHAROV VE, 1972, SOV PHYS JETP-USSR, V34, P62	28	1438	1462	5	131	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	2002	417	6885					150	153		10.1038/nature747	http://dx.doi.org/10.1038/nature747			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549RH	11986621	Green Submitted			2022-12-28	WOS:000175460200036
J	Drake, AJ; Howells, RJ; Shield, JPH; Prendiville, A; Ward, PS; Crowne, EC				Drake, AJ; Howells, RJ; Shield, JPH; Prendiville, A; Ward, PS; Crowne, EC			Symptomatic adrenal insufficiency presenting with hypoglycaemia in asthmatic children with asthma receiving high dose inhaled fluticasone propionate	BMJ-BRITISH MEDICAL JOURNAL			English	Review							SUPPRESSION; GROWTH		Bristol Royal Hosp Children, Dept Paediat Endocrinol & Diabet, Bristol BS2 8BJ, Avon, England; Southmead Gen Hosp, Bristol BS10 5NB, Avon, England; Royal Cornwall Hosp NHS Trust, Truro TR1 3LJ, Cornwall, England; Derriford Hosp, Plymouth PL6 8DH, Devon, England	Bristol Royal Hospital For Children; Southmead Hospital; Royal Cornwall Hospital; Derriford Hospital	Crowne, EC (corresponding author), Bristol Royal Hosp Children, Dept Paediat Endocrinol & Diabet, Bristol BS2 8BJ, Avon, England.	eccrowne@bch.u-net.com	Shield, Julian PH/D-6297-2014	Shield, Julian PH/0000-0003-2601-7575				Agwu JC, 1999, ARCH DIS CHILD, V80, P330, DOI 10.1136/adc.80.4.330; Clark DJ, 1996, THORAX, V51, P262, DOI 10.1136/thx.51.3.262; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715, DOI 10.1164/ajrccm.151.6.7767512; Duplantier JE, 1998, J ALLERGY CLIN IMMUN, V102, P699, DOI 10.1016/S0091-6749(98)70292-1; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Pearson MG, 1997, THORAX, V52, pS1; Pedersen S, 1997, ALLERGY, V52, P1, DOI 10.1111/j.1398-9995.1997.tb05047.x; Stewart PM, 1999, CLIN ENDOCRINOL, V51, P151, DOI 10.1046/j.1365-2265.1999.00801.x; Todd G, 1996, LANCET, V348, P27, DOI 10.1016/S0140-6736(96)03339-9; ZWAAN CM, 1992, LANCET, V340, P1289, DOI 10.1016/0140-6736(92)92991-N	11	106	108	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 4	2002	324	7345					1081	1082		10.1136/bmj.324.7345.1081	http://dx.doi.org/10.1136/bmj.324.7345.1081			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YY	11991916	Green Published			2022-12-28	WOS:000175476500024
J	Bose, HS; Lingappa, VR; Miller, WL				Bose, HS; Lingappa, VR; Miller, WL			Rapid regulation of steroidogenesis by mitochondrial protein import	NATURE			English	Article							CHAIN CLEAVAGE ENZYME; STAR; MECHANISM; EXPRESSION; MEMBRANE; SEQUENCE; BINDING; CLONING	Most mitochondrial proteins are synthesized on cytoplasmic ribosomes and imported into mitochondria(1-3). The imported proteins are directed to one of four submitochondrial compartments-the outer mitochondrial membrane, the inner mitochondrial membrane, the intramembraneous space, or the matrix-where the protein then functions. Here we show that the steroidogenic acute regulatory protein (StAR), a mitochondrial protein required for stress responses, reproduction, and sexual differentiation of male fetuses(4-7), exerts its activity transiently at the outer mitochondrial membrane rather than at its final resting place in the matrix. We also show that its residence time at this outer membrane and its activity are regulated by its speed of mitochondrial import. This may be the first example of a mitochondrial protein exerting its biological activity in a compartment other than that to which it is finally targeted. This system enables steroidogenic cells to initiate and terminate massive levels of steroidogenesis within a few minutes, permitting the rapid regulation of serum steroid hormone concentrations.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Miller, WL (corresponding author), Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA.	wlmlab@itsa.ucsf.edu	Miller, Walter L/J-3696-2012	Lingappa, Vishwanath R./0000-0003-0962-6571				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; Bauer MF, 2001, J INHERIT METAB DIS, V24, P166, DOI 10.1023/A:1010314900814; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Bose HS, 1998, BIOCHEMISTRY-US, V37, P9768, DOI 10.1021/bi980588a; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Christensen K, 2001, J BIOL CHEM, V276, P17044, DOI 10.1074/jbc.M100903200; CHUCK SL, 1992, NATURE, V356, P115, DOI 10.1038/356115b0; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HURT EC, 1985, EMBO J, V4, P2061, DOI 10.1002/j.1460-2075.1985.tb03892.x; JEFCOATE CR, 1974, EUR J BIOCHEM, V42, P539, DOI 10.1111/j.1432-1033.1974.tb03369.x; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; Meisinger C, 2001, MOL CELL BIOL, V21, P2337, DOI 10.1128/MCB.21.7.2337-2348.2001; Miller WL, 1999, J STEROID BIOCHEM, V69, P131, DOI 10.1016/S0960-0760(98)00153-8; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Song MS, 2001, BIOCHEM J, V356, P151, DOI 10.1042/0264-6021:3560151; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; TOAFF ME, 1982, ENDOCRINOLOGY, V111, P1785, DOI 10.1210/endo-111-6-1785; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408	30	267	274	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	2002	417	6884					87	91		10.1038/417087a	http://dx.doi.org/10.1038/417087a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986670				2022-12-28	WOS:000175307200043
J	Julian, DG; Norris, RM				Julian, DG; Norris, RM			Myocardial infarction: is evidence-based medicine the best?	LANCET			English	Editorial Material											Julian, DG (corresponding author), 7 Netherhall Gardens, London NW3 5RN, England.	djulian@dial.pipex.com						APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Boersma E, 1996, LANCET, V348, P771, DOI 10.1016/S0140-6736(96)02514-7; Mehta S, 2001, CLIN EVIDENCE, P8; Norris RM, 2001, HEART, V85, P395, DOI 10.1136/heart.85.4.395; Norris RM, 1998, HEART, V80, P114; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Woods KL, 1996, LANCET, V347, P1203, DOI 10.1016/S0140-6736(96)90732-1	7	16	18	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	2002	359	9316					1515	1516		10.1016/S0140-6736(02)08419-2	http://dx.doi.org/10.1016/S0140-6736(02)08419-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988265				2022-12-28	WOS:000175279100029
J	Cacchione, DA; Pratson, LF; Ogston, AS				Cacchione, DA; Pratson, LF; Ogston, AS			The shaping of continental slopes by internal tides	SCIENCE			English	Article							VARIABILITY	The angles of energy propagation of semidiurnal internal tides may determine the average gradient of continental slopes in ocean basins (similar to2 to 4 degrees). Intensification of near-bottom water velocities and bottom shear stresses caused by reflection of semi-diurnal internal tides affects sedimentation patterns and bottom gradients, as indicated by recent studies of continental slopes off northern California and New Jersey. Estimates of bottom shear velocities caused by semi-diurnal internal tides are high enough to inhibit deposition of fine-grained sediment onto the slopes.	US Geol Survey, Coastal & Marine Geol MS999, Menlo Pk, CA 94025 USA; Duke Univ, Nicholas Sch Environm & Earth Sci, Durham, NC 27708 USA; Univ Washington, Seattle, WA 98195 USA	United States Department of the Interior; United States Geological Survey; Duke University; University of Washington; University of Washington Seattle	Cacchione, DA (corresponding author), US Geol Survey, Coastal & Marine Geol MS999, 345 Middlefield Rd, Menlo Pk, CA 94025 USA.							Alexander CR, 1999, MAR GEOL, V154, P243, DOI 10.1016/S0025-3227(98)00116-9; CACCHIONE D, 1974, J FLUID MECH, V66, P223, DOI 10.1017/S0022112074000164; CACCHIONE DA, 2000, OC SCI M AM SOC LIMN; CONKRIGHT ME, 1999, NAT OCEAN DATA CTR I, V14; DICKSON RR, 1986, DEEP-SEA RES, V33, P791, DOI 10.1016/0198-0149(86)90089-0; HOTCHKISS FS, 1982, DEEP-SEA RES, V29, P415, DOI 10.1016/0198-0149(82)90068-1; Ivey GN, 2000, J FLUID MECH, V418, P59, DOI 10.1017/S0022112000008788; MCCAVE IN, 1972, SHELF SEDIMENT TRANS, pCH10; MCPHEE EE, 2000, THESIS U WASHINGTON; O'Grady DB, 2000, GEOLOGY, V28, P207, DOI 10.1130/0091-7613(2000)28<207:CTMVOS>2.0.CO;2; PARKER G, IN PRESS J SED RES; Phillips O.M., 1977, DYNAMICS UPPER OCEAN, V2nd ed.; PRATSON L, 1999, EOS, V80, P37; Pratson LF, 1996, GEOLOGY, V24, P3, DOI 10.1130/0091-7613(1996)024<0003:WITSOT>2.3.CO;2; PRINSENBERG SJ, 1974, DEEP-SEA RES, V16, P179; Ribbe J, 2001, CONT SHELF RES, V21, P395, DOI 10.1016/S0278-4343(00)00081-9; TURNER JS, 1973, BUOYANCY EFFECTS FLU, P128; WHITEHOUSE RJS, 1999, 527 SR HR WALL LTD; Zikanov O, 2001, J FLUID MECH, V445, P235, DOI 10.1017/S0022112001005560	19	258	263	4	63	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					724	727		10.1126/science.1069803	http://dx.doi.org/10.1126/science.1069803			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976451				2022-12-28	WOS:000175281700051
J	Fields, S; Johnston, M				Fields, S; Johnston, M			Genomics - A crisis in postgenomic nomenclature	SCIENCE			English	Editorial Material									Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Dept Med, Seattle, WA 98195 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Washington University (WUSTL)	Fields, S (corresponding author), Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.		Johnston, Mark/R-6156-2019; Johnston, Mark/K-3543-2019	Johnston, Mark/0000-0002-4932-7229				[Anonymous], 2002, OXFORD ENGLISH DICT	1	6	7	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					671	672		10.1126/science.1070208	http://dx.doi.org/10.1126/science.1070208			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976434				2022-12-28	WOS:000175281700034
J	Rind, D				Rind, D			Climatology - The sun's role in climate variations	SCIENCE			English	Review							NEOPROTEROZOIC SNOWBALL EARTH; GENERAL-CIRCULATION MODEL; 11-YEAR SOLAR-CYCLE; NORTHERN-HEMISPHERE; COSMIC-RAYS; GLOBAL CLIMATE; VARIABILITY; IRRADIANCE; TEMPERATURE; ATMOSPHERE	Is the Sun the controller of climate changes, only the instigator of changes that are mostly forced by the system feedbacks, or simply a convenient scapegoat for climate variations lacking any other obvious cause? This question is addressed for suggested solar forcing mechanisms operating on time scales from billions of years to decades. Each mechanism fails to generate the expected climate response in important respects, although some relations are found. The magnitude of the system feedbacks or variability appears as large or larger than that of the solar forcing, making the Sun's true role ambiguous. As the Sun provides an explicit external forcing, a better understanding of its cause and effect in climate change could help us evaluate the importance of other climate forcings (such as past and future greenhouse gas changes).	Columbia Univ, NASA, Goddard Inst Space Studies, New York, NY 10025 USA	Columbia University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Rind, D (corresponding author), Columbia Univ, NASA, Goddard Inst Space Studies, 2880 Broadway, New York, NY 10025 USA.							BALIUNAS S, 1990, NATURE, V348, P520, DOI 10.1038/348520a0; Bond G, 2001, SCIENCE, V294, P2130, DOI 10.1126/science.1065680; Bradley R, 2000, SCIENCE, V288, P1353, DOI 10.1126/science.288.5470.1353; CHANDLER M, 2001, EOS S, V20; Chandler MA, 2000, J GEOPHYS RES-ATMOS, V105, P20737, DOI 10.1029/2000JD900221; Charvatova I, 1997, SURV GEOPHYS, V18, P131, DOI 10.1023/A:1006527724221; CHYBA C, 1992, NATURE, V355, P125, DOI 10.1038/355125a0; Clark PU, 1999, SCIENCE, V286, P1104, DOI 10.1126/science.286.5442.1104; Cubasch U, 1997, CLIM DYNAM, V13, P757, DOI 10.1007/s003820050196; Fairbridge RW, 1995, EARTH MOON PLANETS, V70, P179, DOI 10.1007/BF00619462; Farrar PD, 2000, CLIMATIC CHANGE, V47, P7, DOI 10.1023/A:1005672825112; FRIISCHRISTENSEN E, 1991, SCIENCE, V254, P698, DOI 10.1126/science.254.5032.698; Frohlich C, 1998, GEOPHYS RES LETT, V25, P4377, DOI 10.1029/1998GL900157; Gallimore RG, 1996, NATURE, V381, P503, DOI 10.1038/381503a0; Gallup CD, 2002, SCIENCE, V295, P310, DOI 10.1126/science.1065494; GREENE A, 2001, THESIS COLUMBIA U; Haigh JD, 1996, SCIENCE, V272, P981, DOI 10.1126/science.272.5264.981; HALFMAN JD, 1988, GEOLOGY, V16, P496, DOI 10.1130/0091-7613(1988)016<0496:HRROCC>2.3.CO;2; Hare S. R., 1995, Canadian Special Publication of Fisheries and Aquatic Sciences, V121, P357; HAYES JD, 1976, SCIENCE, V194, P1121; Henderson GM, 2000, NATURE, V404, P61, DOI 10.1038/35003541; HERBERT TD, 1999, SOC SEDIMENT GEOL SP, V322, P105; HERMAN JR, 1985, SUN WEATHER CLIAMTE; Hodell DA, 2001, SCIENCE, V292, P1367, DOI 10.1126/science.1057759; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; HOYT DV, 1993, J GEOPHYS RES-SPACE, V98, P18895, DOI 10.1029/93JA01944; HUGHES MK, 1994, CLIMATIC CHANGE, V26, P109, DOI 10.1007/BF01092410; Hyde WT, 2000, NATURE, V405, P425, DOI 10.1038/35013005; Jenkins GS, 1999, GEOPHYS RES LETT, V26, P2263, DOI 10.1029/1999GL900538; JONES PD, 1992, CLIMATE AD 1500, P649; Karner DB, 2000, SCIENCE, V288, P2143, DOI 10.1126/science.288.5474.2143; Kerr RA, 2000, SCIENCE, V288, P1984, DOI 10.1126/science.288.5473.1984; KODERA K, 1995, J GEOPHYS RES-ATMOS, V100, P14077, DOI 10.1029/95JD01172; KUHN WR, 1979, ICARUS, V37, P207, DOI 10.1016/0019-1035(79)90126-X; LABITZKE K, 1992, J CLIMATE, V5, P240, DOI 10.1175/1520-0442(1992)005<0240:ABTYSC>2.0.CO;2; Lean J, 2000, GEOPHYS RES LETT, V27, P2425, DOI 10.1029/2000GL000043; LEAN J, 2000, GEOPHYS RES LETT, V27, P2423; LEVINE J, 2001, EOS S, V82; LUCKMAN BH, 1994, CLIMATIC VARIATIONS, P85; Luterbacher J, 1999, GEOPHYS RES LETT, V26, P2745, DOI 10.1029/1999GL900576; Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859; Marsh N, 2000, SPACE SCI REV, V94, P215, DOI 10.1023/A:1026723423896; MITCHELL JFB, 1993, PHILOS T R SOC B, V341, P267, DOI 10.1098/rstb.1993.0112; MITCHELL JM, 1979, SOLAR TERRESTRIAL IN, P125; PELTIER RW, 2001, EOS S, V82; Radick RR, 1998, ASTROPHYS J SUPPL S, V118, P239, DOI 10.1086/313135; RIND D, 1995, J CLIMATE, V8, P2080, DOI 10.1175/1520-0442(1995)008<2080:MTEOUV>2.0.CO;2; Rind D, 1999, J GEOPHYS RES-ATMOS, V104, P1973, DOI 10.1029/1998JD200020; RIND D, 1989, J GEOPHYS RES-ATMOS, V94, P12851, DOI 10.1029/JD094iD10p12851; RIND D, UNPUB; SCOTT PA, 2001, CLIM DYNAM, V17, P1; Shindell D, 1999, SCIENCE, V284, P305, DOI 10.1126/science.284.5412.305; Shindell DT, 2001, SCIENCE, V294, P2149, DOI 10.1126/science.1064363; Stuiver M., 1993, HOLOCENE, V3, P289, DOI DOI 10.1177/095968369300300401; Svensmark H, 1998, PHYS REV LETT, V81, P5027, DOI 10.1103/PhysRevLett.81.5027; THOMPSON LG, 1995, SCIENCE, V269, P46, DOI 10.1126/science.269.5220.46; Udelhofen PM, 2001, GEOPHYS RES LETT, V28, P2617, DOI 10.1029/2000GL012659; van Loon H, 1999, GEOPHYS RES LETT, V26, P2893, DOI 10.1029/1999GL900596; VERSCHUREN D, 2000, NATURE, V410, P403; White WB, 1997, J GEOPHYS RES-OCEANS, V102, P3255, DOI 10.1029/96JC03549; Williams DM, 1998, NATURE, V396, P453, DOI 10.1038/24845; WORSLEY TR, 1991, GEOLOGY, V19, P1161, DOI 10.1130/0091-7613(1991)019<1161:FOCOPA>2.3.CO;2; Zachos JC, 2001, SCIENCE, V292, P274, DOI 10.1126/science.1058288	64	200	240	3	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					673	677		10.1126/science.1069562	http://dx.doi.org/10.1126/science.1069562			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976436				2022-12-28	WOS:000175281700036
J	Bonaccorso, SN; Sturchio, JL				Bonaccorso, SN; Sturchio, JL			Direct to consumer advertising is medicalising normal human experience	BRITISH MEDICAL JOURNAL			English	Article							SOCIAL-CONTROL; HEALTH-CARE; QUALITY		Merck, Mkt & Med Serv, Whitehouse Stn, NJ 08889 USA; Merck, Publ Affairs Europe Middle E Africa, Whitehouse Stn, NJ 08889 USA	Merck & Company; Merck & Company	Bonaccorso, SN (corresponding author), Merck, Mkt & Med Serv, 1 Merck Dr, Whitehouse Stn, NJ 08889 USA.							Chassin MR, 1998, MILBANK Q, V76, P565, DOI 10.1111/1468-0009.00106; CONRAD P, 1992, ANNU REV SOCIOL, V18, P209, DOI 10.1146/annurev.so.18.080192.001233; Coulter A, 1999, BRIT MED J, V318, P318, DOI 10.1136/bmj.318.7179.318; Coulter A, 1999, BRIT MED J, V319, P719, DOI 10.1136/bmj.319.7212.719; DUNBAR-JACOB J, 1991, Annals of Behavioral Medicine, V13, P31; *EUR COMM, 2001, QUAL CRIT HLTH REL W; *EUR FED PHARM IND, 2001, GUID INT WEB SIT AV; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; HENRY J, 2001, KAISER FAMILY FDN PU, V3197; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; Rosenthal MB, 2002, NEW ENGL J MED, V346, P498, DOI 10.1056/NEJMsa012075; Royal Pharmaceutical Society of Great Britain, 1997, COMPL CONC ACH SHAR; Sackett DL, 1979, COMPLIANCE HLTH CARE; Schuster MA, 1998, MILBANK Q, V76, P517, DOI 10.1111/1468-0009.00105; SMITH M, 1985, IMPROVING MED COMPLI, P35; ZOLA IK, 1972, SOCIOL REV, V20, P487, DOI 10.1111/j.1467-954X.1972.tb00220.x; 1999, PREVENTION MAGAZINE; 2000, PREVENTION MAGAZINE	18	57	57	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					910	911		10.1136/bmj.324.7342.910	http://dx.doi.org/10.1136/bmj.324.7342.910			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	542PA	11950746	Green Published			2022-12-28	WOS:000175052200032
J	Ikehara, K; Suzuki, M; Tsuburai, T; Ishigatsubo, Y				Ikehara, K; Suzuki, M; Tsuburai, T; Ishigatsubo, Y			Lipoid pneumonia	LANCET			English	Editorial Material									Yokohama City Univ, Sch Med, Dept Internal Med 1, Kanagawa 2360004, Japan	Yokohama City University	Ikehara, K (corresponding author), Yokohama City Univ, Sch Med, Dept Internal Med 1, 3-9 Fukuura, Kanagawa 2360004, Japan.								0	8	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1300	1300		10.1016/S0140-6736(02)08269-7	http://dx.doi.org/10.1016/S0140-6736(02)08269-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965275	Bronze			2022-12-28	WOS:000174989700012
J	Abrams, RA				Abrams, RA			Communication	LANCET			English	Editorial Material									Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine	Abrams, RA (corresponding author), Johns Hopkins Oncol Ctr, Baltimore, MD 21231 USA.								0	0	0	2	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1245	1245		10.1016/S0140-6736(02)08252-1	http://dx.doi.org/10.1016/S0140-6736(02)08252-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955560				2022-12-28	WOS:000174846300032
J	Hill, J; Timmis, A				Hill, J; Timmis, A			ABC of clinical electrocardiography - Exercise tolerance testing	BRITISH MEDICAL JOURNAL			English	Article									Barts & London NHS Trust, London, England; London Chest Hosp, Barts & London NHS Trust, London, England	Barts Health NHS Trust; Barts Health NHS Trust; University of London; Queen Mary University London	Hill, J (corresponding author), Barts & London NHS Trust, London, England.								0	73	74	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 4	2002	324	7345					1084	1087		10.1136/bmj.324.7345.1084	http://dx.doi.org/10.1136/bmj.324.7345.1084			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YY	11991917	Green Published			2022-12-28	WOS:000175476500026
J	Butov, LV; Lai, CW; Ivanov, AL; Gossard, AC; Chemla, DS				Butov, LV; Lai, CW; Ivanov, AL; Gossard, AC; Chemla, DS			Towards Bose-Einstein condensation of excitons in potential traps	NATURE			English	Article							CU2O; STATISTICS; GAS	An exciton is an electron-hole bound pair in a semiconductor. In the low-density limit, it is a composite Bose quasi-particle, akin to the hydrogen atom(1). Just as in dilute atomic gases(2,3), reducing the temperature or increasing the exciton density increases the occupation numbers of the low-energy states leading to quantum degeneracy and eventually to Bose-Einstein condensation (BEC)(1). Because the exciton mass is small-even smaller than the free electron mass-exciton BEC should occur at temperatures of about 1 K, many orders of magnitude higher than for atoms. However, it is in practice difficult to reach BEC conditions, as the temperature of excitons can considerably exceed that of the semiconductor lattice. The search for exciton BEC has concentrated on long-lived excitons: the exciton lifetime against electron-hole recombination therefore should exceed the characteristic timescale for the cooling of initially hot photo-generated excitons(4-10). Until now, all experiments on atom condensation were performed on atomic gases confined in the potential traps. Inspired by these experiments, and using specially designed semiconductor nanostructures, we have collected quasi-two-dimensional excitons in an in-plane potential trap. Our photoluminescence measurements show that the quasi-two-dimensional excitons indeed condense at the bottom of the traps, giving rise to a statistically degenerate Bose gas.	Univ Calif Berkeley, EO Lawrence Berkeley Natl Lab, Div Sci Mat, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Cardiff Univ, Dept Phys & Astron, Cardiff CF24 3YB, S Glam, Wales; Univ Calif Santa Barbara, Dept Elect & Comp Engn, Santa Barbara, CA 93106 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Cardiff University; University of California System; University of California Santa Barbara	Butov, LV (corresponding author), Univ Calif Berkeley, EO Lawrence Berkeley Natl Lab, Div Sci Mat, Berkeley, CA 94720 USA.		Lai, Chih Wei/E-4945-2010	Lai, Chih Wei/0000-0003-3571-4671				ANDERSON MH, 1995, SCIENCE, V269, P198, DOI 10.1126/science.269.5221.198; Butov LV, 2000, PHYS REV B, V62, P1548, DOI 10.1103/PhysRevB.62.1548; Butov LV, 1998, PHYS REV B, V58, P1980, DOI 10.1103/PhysRevB.58.1980; Butov LV, 2001, PHYS REV LETT, V86, P5608, DOI 10.1103/PhysRevLett.86.5608; DAVIS KB, 1995, PHYS REV LETT, V75, P3969, DOI 10.1103/PhysRevLett.75.3969; Ivanov AL, 1999, PHYS REV B, V59, P5032, DOI 10.1103/PhysRevB.59.5032; Keldysh L. V., 1964, FIZ TVERD TELA, V6, P2791; Keldysh L. V., 1968, ZH EKSP TEOR FIZ, V54, P978; KELDYSH LV, 1965, FIZ TVERD TELA+, V6, P2219; KELDYSH LV, 1968, ZH EKSP TEOR FIZ, V27, P521; Ketterle W, 1996, PHYS REV A, V54, P656, DOI 10.1103/PhysRevA.54.656; Leggett AJ, 2001, REV MOD PHYS, V73, P307, DOI 10.1103/RevModPhys.73.307; LIN JL, 1993, PHYS REV LETT, V71, P1222, DOI 10.1103/PhysRevLett.71.1222; O'Hara KE, 1999, PHYS REV B, V60, P10565, DOI 10.1103/PhysRevB.60.10565; Popov V. N., 1983, Functional integrals in quantum field theory and statistical physics, DOI 10.1007/BF01028373; SNOKE D, 1987, PHYS REV LETT, V59, P827, DOI 10.1103/PhysRevLett.59.827; ZHU XJ, 1995, PHYS REV LETT, V74, P1633, DOI 10.1103/PhysRevLett.74.1633	17	350	360	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	2002	417	6884					47	52		10.1038/417047a	http://dx.doi.org/10.1038/417047a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546ZM	11986661				2022-12-28	WOS:000175307200033
J	Simes, RJ; Hunt, D; Kirby, A; Tonkin, A; Keech, A; Aylward, P; Colquhoun, D; Glasziou, P; Hague, W; MacMahon, S; Thompson, P; West, M; White, H; Tonkin, A; Avlward, P; Colquhoun, D; Glasziou, P; Harris, P; Hunt, D; Keech, A; McMahon, S; Sharpe, N; Simes, RJ; Thompson, P; Thomson, A; West, M; White, H				Simes, RJ; Hunt, D; Kirby, A; Tonkin, A; Keech, A; Aylward, P; Colquhoun, D; Glasziou, P; Hague, W; MacMahon, S; Thompson, P; West, M; White, H; Tonkin, A; Avlward, P; Colquhoun, D; Glasziou, P; Harris, P; Hunt, D; Keech, A; McMahon, S; Sharpe, N; Simes, RJ; Thompson, P; Thomson, A; West, M; White, H		LIPID Study Grp	Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up	LANCET			English	Article							MYOCARDIAL-INFARCTION; LOWERING MEDICATIONS; THERAPY; STATINS; EVENTS; RISK; INTERVENTION; PREVENTION; MORTALITY; CANCER	Background The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study showed that pravastatin therapy over 6 years reduced mortality and cardiovascular events in patients with previous acute coronary syndromes and average cholesterol concentrations. We assessed the longer-term effects of initial treatment with pravastatin on further cardiovascular events and mortality over a total follow-up period of 8 years. Methods In the main trial, 9014 patients with previous myocardial infarction or unstable angina and a baseline plasma cholesterol concentration of 4.0-7.0 mmol/L were randomly assigned pravastatin 40 mg daily or placebo and followed up for 6 years. Subsequently, all patients were offered open-label pravastatin for 2 more years. Major cardiovascular events and adverse events were compared according to initial treatment assignment. Findings 7680 (97% of those still alive) had 2 years of extended follow-up. 3766 (86%) of those assigned placebo and 3914 (88%) assigned pravastatin agreed to take open-label pravastatin. During this period, patients originally assigned pravastatin had almost identical cholesterol concentrations to those assigned placebo, but a lower risk of death from all causes (219 [5.6%] vs 255 [6.8%], p=0.029), coronary heart disease (CHID) death (108 [2.80] vs 137 [3.6%], p=0.026), and CHID death or non-fatal myocardial infarction (176 [4.5%] vs 196 [5.2%], p=0.08). Over the total 8-year period, all-cause mortality was 888 (19.7%) in the group originally assigned placebo and 717 (15.9%) in the group originally assigned pravastatin, CHID mortality was 510 (11.3%) versus 395 (8.8%), myocardial infarction was 570 (12.7%) versus 435 (9.6%; each p<0.0001), and stroke was 272 (6.0%) versus 224 (5.0%; p=0.015). Stronger evidence of separate treatment benefits than in the main trial was seen in important prespecified subgroups (women, patients aged,70 years, and those with total cholesterol <5.5 mmol/L). Pravastatin had no significant adverse effects. Interpretation The evidence of sustained treatment benefits and safety of long-term pravastatin treatment reinforces the importance of long-term cholesterol-lowering treatment for almost all patients with previous CHID events.	Univ Sydney, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia; Clin Trial Res Unit, Auckland, New Zealand	University of Sydney	Simes, RJ (corresponding author), Univ Sydney, NHMRC Clin Trials Ctr, Mallett St Campus, Sydney, NSW 2006, Australia.	enquiry@ctc.usyd.edu.au	west, malcolm J/C-9425-2009; Thompson, Peter L/P-1071-2014; Simes, Robert John/P-1497-2014; Glasziou, Paul/A-7832-2008; Htut, Thien/H-5144-2011; Colquhoun, David M/F-9078-2013	west, malcolm J/0000-0002-7629-5277; Glasziou, Paul/0000-0001-7564-073X; Aylward, Philip/0000-0002-5358-8552; Coupland, Lucy/0000-0002-8912-9534; MacMahon, Stephen/0000-0003-2064-7699				[Anonymous], 1997, Eur Heart J, V18, P1569; Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Bjerre LM, 2001, AM J MED, V110, P716, DOI 10.1016/S0002-9343(01)00705-7; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; Collins R, 2002, INT J CLIN PRACT, V56, P53; GLASZIOU P, IN PRESS MED J AUST; Keech A, 2000, ATHEROSCLEROSIS, V151, P83; Kotseva K, 2001, LANCET, V357, P995, DOI 10.1016/S0140-6736(00)04235-5; LAW MR, 1991, CANCER CAUSE CONTROL, V2, P253, DOI 10.1007/BF00052142; Marschner IC, 2001, J AM COLL CARDIOL, V38, P56, DOI 10.1016/S0735-1097(01)01360-2; McCormick D, 1999, ARCH INTERN MED, V159, P561, DOI 10.1001/archinte.159.6.561; MULDOON MF, 1990, LOWERING CHOLESTEROL, P309; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 2000, AM J CARDIOL, V86, P257, DOI 10.1016/S0002-9149(00)00910-3; Rauch U, 2000, ATHEROSCLEROSIS, V153, P181, DOI 10.1016/S0021-9150(00)00397-X; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Sacks FM, 2000, CIRCULATION, V102, P1893, DOI 10.1161/01.CIR.102.16.1893; Schwartz GG, 2001, JAMA-J AM MED ASSOC, V285, P1711, DOI 10.1001/jama.285.13.1711; Simes J, 2002, EUR HEART J, V23, P207, DOI 10.1053/euhj.2001.2775; Simes RJ, 2002, CIRCULATION, V105, P1162, DOI 10.1161/hc1002.105136; Simons LA, 1996, MED J AUSTRALIA, V164, P208, DOI 10.5694/j.1326-5377.1996.tb94138.x; TONKIN A, 1995, AM J CARDIOL, V76, P474; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; White HD, 2000, NEW ENGL J MED, V343, P317, DOI 10.1056/NEJM200008033430502; Yusuf S, 1996, CIRCULATION, V93, P1774, DOI 10.1161/01.CIR.93.10.1774	28	193	196	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	2002	359	9315					1379	1387						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978335				2022-12-28	WOS:000175076200010
J	Hart, SD; Maskaly, GR; Temelkuran, B; Prideaux, PH; Joannopoulos, JD; Fink, Y				Hart, SD; Maskaly, GR; Temelkuran, B; Prideaux, PH; Joannopoulos, JD; Fink, Y			External reflection from omnidirectional dielectric mirror fibers	SCIENCE			English	Article							CHALCOGENIDE GLASSES; LIGHT; AIR	We report the design and fabrication of a multilayered macroscopic fiber preform and the subsequent drawing and optical characterization of extended lengths of omnidirectional dielectric mirror fibers with submicrometer layer thickness. A pair of glassy materials with substantially different indices of refraction, but with similar thermomechanical properties, was used to construct 21 layers of alternating refractive index surrounding a tough polymer core. Large directional photonic band gaps and high reflection efficiencies comparable to those of the best metallic reflectors were obtained. Potential applications of these fibers include woven fabrics for radiation barriers, spectral authentication of cloth, and filters for telecommunications.	MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Elect Res Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Fink, Y (corresponding author), MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA.		Joannopoulos, John D/E-6401-2013	Temelkuran, Burak/0000-0003-2390-5091				Bass M, 1995, HDB OPTICS; Baumeister P., 1961, OPT ACTA, V8, P105, DOI 10.1080/713826378; Borisova Z. U., 1981, GLASSY SEMICONDUCTOR; Cregan RF, 1999, SCIENCE, V285, P1537, DOI 10.1126/science.285.5433.1537; Dai JW, 1997, APPL OPTICS, V36, P5072, DOI 10.1364/AO.36.005072; Fink Y, 1998, SCIENCE, V282, P1679, DOI 10.1126/science.282.5394.1679; Fink Y, 1999, J LIGHTWAVE TECHNOL, V17, P2039, DOI 10.1109/50.802992; Hilton A. R., 1970, Journal of Non-Crystalline Solids, V2, P28, DOI 10.1016/0022-3093(70)90118-3; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS MO; KING WA, 1995, J NON-CRYST SOLIDS, V181, P231, DOI 10.1016/S0022-3093(94)00512-5; KONG JA, 2000, ELECTROMAGNETIC WAVE, P370; Kucuk A, 1999, GLASS TECHNOL, V40, P149; MAHLEIN HF, 1974, J OPT SOC AM, V64, P647, DOI 10.1364/JOSA.64.000647; Mark J.E., 1999, POLYM DATA HDB; SARANTOS C, UNPUB; SEDDON AB, 1995, J NON-CRYST SOLIDS, V184, P44, DOI 10.1016/0022-3093(94)00686-5; Temelkuran B, 2001, OPT LETT, V26, P1370, DOI 10.1364/OL.26.001370; Van Krevelen D.W., 1990, PROPERTIES POLYM, Vthird; Varshneya AK, 2000, J NON-CRYST SOLIDS, V273, P1, DOI 10.1016/S0022-3093(00)00138-1; Varshneya AK, 1994, FUNDAMENTALS INORGAN; Weber MF, 2000, SCIENCE, V287, P2451, DOI 10.1126/science.287.5462.2451; Winn JN, 1998, OPT LETT, V23, P1573, DOI 10.1364/OL.23.001573; YEH P, 1977, J OPT SOC AM, V67, P423, DOI 10.1364/JOSA.67.000423; YEH P, 1978, J OPT SOC AM, V68, P1196, DOI 10.1364/JOSA.68.001196	24	275	300	3	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					510	513		10.1126/science.1070050	http://dx.doi.org/10.1126/science.1070050			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964473				2022-12-28	WOS:000175179400040
J	Tavare, S; Marshall, CR; Will, O; Soligo, C; Martin, RD				Tavare, S; Marshall, CR; Will, O; Soligo, C; Martin, RD			Using the fossil record to estimate the age of the last common ancestor of extant primates	NATURE			English	Article							MAMMALS; EVOLUTION; DIVERSITY; ORIGINS	Divergence times estimated from molecular data often considerably predate the earliest known fossil representatives of the groups studied. For the order Primates, molecular data calibrated with various external fossil dates uniformly suggest a mid-Cretaceous divergence from other placental mammals, some 90 million years (Myr) ago(1-9), whereas the oldest known fossil primates are from the basal Eocene epoch (54-55 Myr ago). The common ancestor of primates should be earlier than the oldest known fossils(10,11), but adequate quantification is needed to interpret possible discrepancies between molecular and palaeontological estimates. Here we present a new statistical method, based on an estimate of species preservation derived from a model of the diversification pattern, that suggests a Cretaceous last common ancestor of primates, approximately 81.5 Myr ago, close to the initial divergence time inferred from molecular data. It also suggests that no more than 7% of all primate species that have ever existed are known from fossils. The approach unites all the available palaeontological methods of timing evolutionary events: the fossil record, extant species and clade diversification models.	Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Dept Math, Los Angeles, CA 90089 USA; Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA; Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02138 USA; Univ Washington, Dept Stat, Seattle, WA 98195 USA; Univ Zurich Irchel, Inst Anthropol, CH-8057 Zurich, Switzerland; Univ Zurich Irchel, Museum, CH-8057 Zurich, Switzerland; Nat Hist Museum, Human Origins Grp, London SW7 5BD, England; Field Museum, Chicago, IL 60605 USA	University of Southern California; University of Southern California; University of Southern California; Harvard University; Harvard University; University of Washington; University of Washington Seattle; University of Zurich; University of Zurich; Natural History Museum London; Field Museum of Natural History (Chicago)	Tavare, S (corresponding author), Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA.							Alroy J, 1998, SCIENCE, V280, P731, DOI 10.1126/science.280.5364.731; Alroy J, 1998, BIODIVERSITY DYNAMICS, P232; ALROY J, 1994, THESIS U CHICAGO; Arnason U, 1998, J MOL EVOL, V47, P718, DOI 10.1007/PL00006431; Davison AC, 1997, BOOTSTRAP METHODS TH; Easteal S., 1995, MAMMALIAN MOL CLOCK; Eizirik E, 2001, J HERED, V92, P212, DOI 10.1093/jhered/92.2.212; Foote M, 1999, SCIENCE, V283, P1310, DOI 10.1126/science.283.5406.1310; Foote M, 1997, PALEOBIOLOGY, V23, P278, DOI 10.1017/S0094837300019692; Foote M, 1999, NATURE, V398, P415, DOI 10.1038/18872; GINGERICH PD, 1994, J HUM EVOL, V27, P443, DOI 10.1006/jhev.1994.1058; Harris T. E., 1963, THEORY BRANCHING PRO; Hedges SB, 1996, NATURE, V381, P226, DOI 10.1038/381226a0; Huelsenbeck JP, 2000, GENETICS, V154, P1879; JANKE A, 1994, GENETICS, V137, P243; MAC ARTHUR ROBERT H., 1967; MACARTHUR RH, 1963, EVOLUTION, V17, P373, DOI 10.2307/2407089; Madsen O, 2001, NATURE, V409, P610, DOI 10.1038/35054544; Marshall CR, 1998, ADEQUACY OF THE FOSSIL RECORD, P23; Martin R.D., 1986, P1; Martin R.D., 1990, PRIMATE ORIGINS EVOL; MARTIN RD, 1993, NATURE, V363, P223, DOI 10.1038/363223a0; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; NEE S, 1994, PHILOS T ROY SOC B, V344, P305, DOI 10.1098/rstb.1994.0068; RAUP DM, 1973, J GEOL, V81, P525, DOI 10.1086/627905; SEPKOSKI JJ, 1978, PALEOBIOLOGY, V4, P223, DOI 10.1017/S0094837300005972; Springer MS, 1997, NATURE, V388, P61, DOI 10.1038/40386; Wolfheim J, 1983, PRIMATES WORLD DISTR	28	189	194	1	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					726	729		10.1038/416726a	http://dx.doi.org/10.1038/416726a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961552				2022-12-28	WOS:000175033500039
J	Webster-Cyriaque, J				Webster-Cyriaque, J			Development of kaposi's sarcoma in a surgical wound	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KOEBNER PHENOMENON; HUMAN-HERPESVIRUS-8; HERPESVIRUS		Univ N Carolina, Sch Dent, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Webster-Cyriaque, J (corresponding author), Univ N Carolina, Sch Dent, Campus Box 7455, Chapel Hill, NC 27599 USA.	jennifer@med.unc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI050410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE011644] Funding Source: NIH RePORTER; NIAID NIH HHS [9P30 AIO50410] Funding Source: Medline; NIDCR NIH HHS [DE00460-01, DE11644-08] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Blasig C, 1997, J VIROL, V71, P7963, DOI 10.1128/JVI.71.10.7963-7968.1997; Cerimele F, 2001, J VIROL, V75, P2435, DOI 10.1128/JVI.75.5.2435-2443.2001; Ensoli B, 2001, EUR J CANCER, V37, P1251, DOI 10.1016/S0959-8049(01)00121-6; JANIER M, 1990, J AM ACAD DERMATOL, V22, P125, DOI 10.1016/S0190-9622(08)80011-4; Kieff E, 1998, J Natl Cancer Inst Monogr, P7; Maral T, 2000, ANN PLAS SURG, V44, P646, DOI 10.1097/00000637-200044060-00012; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Pauk J, 2000, NEW ENGL J MED, V343, P1369, DOI 10.1056/NEJM200011093431904; Polverini P J, 1997, EXS, V79, P11; WebsterCyriaque J, 1997, J INFECT DIS, V175, P1324, DOI 10.1086/516463	11	27	28	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	2002	346	16					1207	1210		10.1056/NEJMoa012125	http://dx.doi.org/10.1056/NEJMoa012125			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542FT	11961149				2022-12-28	WOS:000175033400005
J	Imrie, K; Esmail, R; Meyer, RM				Imrie, K; Esmail, R; Meyer, RM		Hematology Dis Site Grp Canc Care	The role of high-dose chemotherapy and stem-cell transplantation in patients with multiple myeloma: A practice care Ontario practice guidelines initiative	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MARROW-TRANSPLANTATION; PERIPHERAL-BLOOD; AUTOLOGOUS TRANSPLANTATION; RANDOMIZED-TRIAL; EUROPEAN GROUP; THERAPY; SINGLE; MELPHALAN; SURVIVAL; MM	The Hematology Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative has systematically reviewed the published literature and, through a consensus process, developed an evidence-based practice guideline assessing the role of stem-cell transplantation in patients with multiple myeloma. The conclusions were validated by solicited feedback from 221 practitioners across Ontario, Canada. The guideline comprises six recommendations: 1) Autologous transplantation is recommended for patients with stage 11 or III myeloma and good performance status. Evidence of benefit is strongest for patients who are younger than 55 years of age and have a serum creatinine level less than 150 mumol/L (<1.7 mg/dL). Physicians must use clinical judgment in recommending transplantation to other patients. 2) Allogeneic transplantation is not recommended as routine therapy. 3) Patients potentially eligible for transplantation should be referred for assessment early after diagnosis and should not be extensively exposed to alkylating agents before collection of stem cells. 4) Autologous peripheral blood stem cells should be harvested early in the patient's treatment course. The best available data suggest that transplantation is most advantageous when performed as part of initial therapy. 5) The comparative data addressing the specifics of the transplantation process are insufficient to allow definitive recommendations. In the absence of such data, a single transplant with high-dose melphalan, with or without total-body irradiation, is suggested for patients undergoing transplantation outside a clinical trial. 6) At this time, no conclusions can be reached about the role of interferon therapy after transplantation.	Hamilton Reg Canc Ctr, Hamilton, ON L8V 5C2, Canada	McMaster University	Meyer, RM (corresponding author), Hamilton Reg Canc Ctr, 699 Concess St, Hamilton, ON L8V 5C2, Canada.	ralph.meyer@hrcc.on.ca		Shehata, Nadine/0000-0002-9267-6256				[Anonymous], 1998, J Clin Oncol, V16, P3832; Attal M, 1999, BLOOD, V94, p714A; Attal M, 1996, NEW ENGL J MED, V335, P91, DOI 10.1056/NEJM199607113350204; Badros A, 1999, BLOOD, V94, p578A; Barlogie B, 1997, BLOOD, V89, P789, DOI 10.1182/blood.V89.3.789; Bataille R, 1997, NEW ENGL J MED, V336, P1657, DOI 10.1056/NEJM199706053362307; Bjorkstrand B, 1996, BLOOD, V88, P4711, DOI 10.1182/blood.V88.12.4711.bloodjournal88124711; Bjorkstrand BT, 1999, BLOOD, V94, p714A; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; Couban S, 1997, BONE MARROW TRANSPL, V19, P783, DOI 10.1038/sj.bmt.1700738; Cunningham D, 1998, BRIT J HAEMATOL, V102, P495, DOI 10.1046/j.1365-2141.1998.00795.x; Duncan N, 1996, BONE MARROW TRANSPL, V18, P1175; DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U; Fermand JP, 1998, BLOOD, V92, P3131, DOI 10.1182/blood.V92.9.3131.421k30_3131_3136; Fermand JP, 1999, BLOOD, V94, p396A; GREGORY WM, 1992, J CLIN ONCOL, V10, P334, DOI 10.1200/JCO.1992.10.2.334; HAAS R, 1994, BLOOD, V83, P3787; Harousseau JL, 1998, BLOOD, V92, p443A; Harousseau JLM, 1999, BLOOD, V94, p713A; Hartmann O, 1997, ANN INTERN MED, V126, P600, DOI 10.7326/0003-4819-126-8-199704150-00002; Henry JM, 1996, BRIT J HAEMATOL, V92, P614, DOI 10.1046/j.1365-2141.1996.00381.x; Larsson K, 1998, SUPPORT CARE CANCER, V6, P378, DOI 10.1007/s005200050180; Lenhoff S, 2000, BLOOD, V95, P7; Mahendra P, 1995, BONE MARROW TRANSPL, V16, P759; Mainwaring PN, 1998, BLOOD, V92, p662A; MARIT G, 1995, BONE MARROW TRANSPL, V15, P963; Mehta J., 1997, Blood, V90, p419A; Moreau P, 2002, BLOOD, V99, P731, DOI 10.1182/blood.V99.3.731; Musto P, 1999, BLOOD, V94, p576A; Palumbo A, 1999, BLOOD, V94, P1248, DOI 10.1182/blood.V94.4.1248.416k09_1248_1253; Powles R, 1996, LEUKEMIA LYMPHOMA, V21, P421, DOI 10.3109/10428199609093439; Prince HM, 1996, BRIT J HAEMATOL, V93, P142, DOI 10.1046/j.1365-2141.1996.448987.x; Raje N, 1997, BRIT J CANCER, V75, P1684, DOI 10.1038/bjc.1997.286; Siegel D. S., 1996, Blood, V88, p130A; Siegel DS, 1999, BLOOD, V93, P51, DOI 10.1182/blood.V93.1.51.401a01_51_54; Sirohi B, 1999, BLOOD, V94, p578A; Stewart AK, 1999, BLOOD, V94, p714A; Tosi P, 1999, BLOOD, V94, p715A; TRICOT G, 1995, BLOOD, V85, P588; Trippoli S, 1998, ONCOL REP, V5, P1475; Trippoli S, 1997, CLIN DRUG INVEST, V14, P392, DOI 10.2165/00044011-199714050-00008; Varterasian M, 1997, AM J CLIN ONCOL-CANC, V20, P462, DOI 10.1097/00000421-199710000-00005; VESOLE DH, 1994, P AN M AM SOC CLIN, V13, P410; WHEATLEY K, 1998, P AN M AM SOC CLIN, V17, pA8	44	23	23	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2002	136	8					619	629		10.7326/0003-4819-136-8-200204160-00012	http://dx.doi.org/10.7326/0003-4819-136-8-200204160-00012			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	543WY	11955031				2022-12-28	WOS:000175125800008
J	Nielsen, TO; West, RB; Linn, SC; Alter, O; Knowling, MA; O'Connell, JX; Zhu, S; Fero, M; Sherlock, G; Pollack, JR; Brown, PO; Botstein, D; van de Rijn, M				Nielsen, TO; West, RB; Linn, SC; Alter, O; Knowling, MA; O'Connell, JX; Zhu, S; Fero, M; Sherlock, G; Pollack, JR; Brown, PO; Botstein, D; van de Rijn, M			Molecular characterisation of soft tissue tumours: a gene expression study	LANCET			English	Article							GASTROINTESTINAL STROMAL TUMORS; CELLS; CLASSIFICATION	Background Soft-tissue tumours are derived from mesenchymal cells such as fibroblasts, muscle cells, or adipocytes, but for many such tumours the histogenesis is controversial. We aimed to start molecular characterisation of these rare neoplasms and to do a genome-wide search for new diagnostic markers. Methods We analysed gene-expression patterns of 41 soft-tissue tumours with spotted cDNA microarrays. After removal of errors introduced by use of different microarray batches, the expression patterns of 5520 genes that were well defined were used to separate tumours into discrete groups by hierarchical clustering and singular value decomposition. Findings Synovial sarcomas, gastrointestinal stromal tumours, neural tumours, and a subset of the leiomyosarcomas, showed strikingly distinct gene-expression patterns. Other tumour categories-malignant fibrous histiocytoma, liposarcoma, and the remaining leiomyosarcomas-shared molecular profiles that were not predicted by histological features or immunohistochemistry. Strong expression of known genes, such as KIT in gastrointestinal stromal tumours, was noted within gene sets that distinguished the different sarcomas. However, many uncharacterised genes also contributed to the distinction between tumour types. Interpretation These results suggest a new method for classification of soft-tissue tumours, which could improve on the method based on histological findings, Large numbers of uncharacterised genes contributed to distinctions between the tumours, and some of these could be useful markers for diagnosis, have prognostic significance, or prove possible targets for treatment.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	Stanford University; University of British Columbia; British Columbia Cancer Agency; Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	van de Rijn, M (corresponding author), Stanford Univ, Dept Pathol, Sch Med, Room L225,300 Pasteur Dr, Stanford, CA 94305 USA.		Sherlock, Gavin J/B-1831-2009; Sherlock, Gavin J/E-9110-2012	Sherlock, Gavin/0000-0002-1692-4983; Alter, Orly/0000-0002-0418-1078; van de Rijn, Matt/0000-0002-1909-9739; West, Robert/0000-0002-8330-8283	NCI NIH HHS [CA84967, CA85129] Funding Source: Medline; NHGRI NIH HHS [K01 HG000038, 1 K01 HG00038-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084967, U01CA085129] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [K01HG000038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; BLUMEJENSEN P, 1993, EMBO J, V12, P4199, DOI 10.1002/j.1460-2075.1993.tb06104.x; Brennan MF., 2001, CANC PRINCIPLES PRAC, P1841; Calamante F, 2000, MAGN RESON MED, V44, P466, DOI 10.1002/1522-2594(200009)44:3<466::AID-MRM18>3.0.CO;2-M; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; dos Santos NR, 2001, GENE CHROMOSOME CANC, V30, P1, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fletcher CDM, 2001, J CLIN ONCOL, V19, P3045, DOI 10.1200/JCO.2001.19.12.3045; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gomez-Skarmeta JL, 1998, EMBO J, V17, P181, DOI 10.1093/emboj/17.1.181; Hernandez MC, 1998, EXP CELL RES, V242, P470, DOI 10.1006/excr.1998.4109; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Kindblom LG, 1998, AM J PATHOL, V152, P1259; Klein I, 1999, BBA-BIOMEMBRANES, V1461, P237, DOI 10.1016/S0005-2736(99)00161-3; Miettinen M, 2000, MODERN PATHOL, V13, P1134, DOI 10.1038/modpathol.3880210; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Phimister B, 1999, NAT GENET, V21, P1, DOI 10.1038/4423; Plaat BEC, 2000, J CLIN ONCOL, V18, P3211, DOI 10.1200/JCO.2000.18.18.3211; Ryan PD, 2000, CLIN CANCER RES, V6, P4607; SHEARMAN MS, 1993, EMBO J, V12, P3817, DOI 10.1002/j.1460-2075.1993.tb06060.x; Shin DM, 2001, CLIN CANCER RES, V7, P1204; Suster S, 1998, AM J SURG PATHOL, V22, P863, DOI 10.1097/00000478-199807000-00008; Swinnen A, 2000, MED BIOL ENG COMPUT, V38, P297, DOI 10.1007/BF02347050; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; WEISS SW, 2001, SOFT TISSUE TUMORS; Zabel M, 2000, CIRCULATION, V102, P1252, DOI 10.1161/01.CIR.102.11.1252	32	423	460	0	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	2002	359	9314					1301	1307		10.1016/S0140-6736(02)08270-3	http://dx.doi.org/10.1016/S0140-6736(02)08270-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965276				2022-12-28	WOS:000174989700013
J	Freed, EO				Freed, EO			Virology: Rafting with Ebola	SCIENCE			English	Editorial Material							LIPID RAFTS; VIRUS; GLYCOPROTEINS		NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Freed, EO (corresponding author), NIAID, Mol Microbiol Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000772] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali A, 2000, J VIROL, V74, P8709, DOI 10.1128/JVI.74.18.8709-8719.2000; Bavari S, 2002, J EXP MED, V195, P593, DOI 10.1084/jem.20011500; FREED EO, IN PRESS J VIROL; Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690; Lindwasser OW, 2001, J VIROL, V75, P7913, DOI 10.1128/JVI.75.17.7913-7924.2001; Luban J, 2001, NAT MED, V7, P1278, DOI 10.1038/nm1201-1278; Nguyen DH, 2000, J VIROL, V74, P3264, DOI 10.1128/JVI.74.7.3264-3272.2000; Ono A, 2001, P NATL ACAD SCI USA, V98, P13925, DOI 10.1073/pnas.241320298; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Vincent S, 2000, J VIROL, V74, P9911, DOI 10.1128/JVI.74.21.9911-9915.2000; Zhang J, 2000, J VIROL, V74, P4634, DOI 10.1128/JVI.74.10.4634-4644.2000	11	12	13	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					279	279		10.1126/science.1070868	http://dx.doi.org/10.1126/science.1070868			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951027				2022-12-28	WOS:000175000300038
J	Medzhitov, R; Janeway, CA				Medzhitov, R; Janeway, CA			Decoding the patterns of self and nonself by the innate immune system	SCIENCE			English	Article							NKG2D RECEPTOR; CELL-DEATH; ACTIVATION; APOPTOSIS; FAMILY		Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Yale University	Medzhitov, R (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06520 USA.		Abrams, William R/A-5782-2008					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Austen K F, 1979, Adv Exp Med Biol, V120B, P3; Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(01)00095-4; Crocker PR, 2001, TRENDS IMMUNOL, V22, P337, DOI 10.1016/S1471-4906(01)01930-5; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2001, IMMUNOL REV, V181, P170, DOI 10.1034/j.1600-065X.2001.1810114.x; DOODY GM, 1995, SCIENCE, V269, P242, DOI 10.1126/science.7618087; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6	23	1538	1630	6	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					298	300		10.1126/science.1068883	http://dx.doi.org/10.1126/science.1068883			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951031	Green Submitted			2022-12-28	WOS:000175000300042
J	Schmid, B; Ribbe, MW; Einsle, O; Yoshida, M; Thomas, LM; Dean, DR; Rees, DC; Burgess, BK				Schmid, B; Ribbe, MW; Einsle, O; Yoshida, M; Thomas, LM; Dean, DR; Rees, DC; Burgess, BK			Structure of a cofactor-deficient nitrogenase MoFe protein	SCIENCE			English	Article							IRON-MOLYBDENUM COFACTOR; AZOTOBACTER-VINELANDII; BIOSYNTHESIS; RESOLUTION; COPPER	One of the most complex biosynthetic processes in metallobiochemistry is the assembly of nitrogenase, the key enzyme in biological nitrogen fixation. We describe here the crystal structure of an iron-molybdenum cofactor-deficient form of the nitrogenase MoFe protein, into which the cofactor is inserted in the final step of MoFe protein assembly. The MoFe protein folds as a heterotetramer containing two copies each of the homologous alpha and beta subunits. In this structure, one of the three alpha subunit domains exhibits a substantially changed conformation, whereas the rest of the protein remains essentially unchanged. A predominantly positively charged funnel is revealed; this funnel is of sufficient size to accommodate insertion of the negatively charged cofactor.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA; Virginia Polytech Inst & State Univ, Dept Biochem, Blacksburg, VA 24061 USA	California Institute of Technology; California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute; University of California System; University of California Irvine; Virginia Polytechnic Institute & State University	Rees, DC (corresponding author), CALTECH, Div Chem & Chem Engn, Mail Code 147-75ch, Pasadena, CA 91125 USA.	dcrees@caltech.edu		Einsle, Oliver/0000-0001-8722-2893				ALLEN RM, 1994, CRIT REV BIOTECHNOL, V14, P225, DOI 10.3109/07388554409079834; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; BURGESS BK, 1990, CHEM REV, V90, P1377, DOI 10.1021/cr00106a002; Christiansen J, 2001, ANNU REV PLANT PHYS, V52, P269, DOI 10.1146/annurev.arplant.52.1.269; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; Lee HI, 1997, J AM CHEM SOC, V119, P11395, DOI 10.1021/ja971508d; Mayer SM, 1999, J MOL BIOL, V292, P871, DOI 10.1006/jmbi.1999.3107; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Peters JW, 1997, BIOCHEMISTRY-US, V36, P1181, DOI 10.1021/bi9626665; Rangaraj P, 2001, J BIOL CHEM, V276, P15968, DOI 10.1074/jbc.M100907200; Rees DC, 2000, CURR OPIN CHEM BIOL, V4, P559, DOI 10.1016/S1367-5931(00)00132-0; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; SCHMID B, 2001, HDB METALLOPROTEINS, V2, P1025; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; Smith BE, 1999, ADV INORG CHEM, V47, P159, DOI 10.1016/S0898-8838(08)60078-1; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; Yoo SJ, 2000, J AM CHEM SOC, V122, P4926, DOI 10.1021/ja000254k	29	129	135	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	2002	296	5566					352	356		10.1126/science.1070010	http://dx.doi.org/10.1126/science.1070010			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951047				2022-12-28	WOS:000175000300060
J	Eastwood, PR; Szollosi, I; Platt, PR; Hillman, DR				Eastwood, PR; Szollosi, I; Platt, PR; Hillman, DR			Comparison of upper airway collapse during general anaesthesia and sleep	LANCET			English	Article							PRESSURE	Measurement of the collapsibility of the upper airway while a patient is awake is not a good guide to such collapsibility during sleep, presumably because of differences in respiratory drive, muscle tone, and sensitivity of reflexes. To assess whether a relation existed between general anaesthesia and sleep, we measured collapsibility of the upper airway during general anaesthesia and severity of sleep-disordered breathing in 25 people who were having minor surgery on their limbs. Anaesthetised patients who needed positive pressure to maintain airway patency had more severe sleep-disordered breathing than did those whose airways remained patent at or below atmospheric pressure. Such an association was strongest during rapid-eye-movement (REM) sleep. Our findings suggest that sleep-disordered breathing should be considered in all patients with a pronounced tendency for upper airway obstruction during anaesthesia or during recovery from it.	Sir Charles Gairdner Hosp, Dept Pulm Physiol, Nedlands, WA 6009, Australia; Sir Charles Gairdner Hosp, Dept Anaesthesia, Nedlands, WA 6009, Australia; Univ Western Australia, Dept Human Movement & Exercise Sci, Nedlands, WA 6009, Australia	University of Western Australia; University of Western Australia; University of Western Australia	Eastwood, PR (corresponding author), Sir Charles Gairdner Hosp, Dept Pulm Physiol, Hosp Ave, Nedlands, WA 6009, Australia.		Eastwood, Peter R/H-9129-2014	Eastwood, Peter R/0000-0002-4490-4138; Hillman, David/0000-0001-9987-539X				Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; HORNER RL, 1994, J PHYSIOL-LONDON, V476, P141; REMMERS JE, 1978, J APPL PHYSIOL, V44, P931, DOI 10.1152/jappl.1978.44.6.931; SMITH PL, 1988, J APPL PHYSIOL, V64, P789, DOI 10.1152/jappl.1988.64.2.789; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	5	122	128	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1207	1209		10.1016/S0140-6736(02)08224-7	http://dx.doi.org/10.1016/S0140-6736(02)08224-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955541				2022-12-28	WOS:000174846300013
J	Antonchuk, J; Sauvageau, G; Humphries, RK				Antonchuk, J; Sauvageau, G; Humphries, RK			HOXB4-induced expansion of adult hematopoietic stem cells ex vivo	CELL			English	Article							BONE-MARROW-CELLS; IN-VITRO; REPOPULATING ACTIVITY; QUANTITATIVE ASSAY; HOMEOBOX GENES; OVEREXPRESSION; PROLIFERATION; TRANSDUCTION; HOXB4	Hox transcription factors have emerged as important regulators of primitive hematopoietic cell proliferation and differentiation. In particular, HOXB4 appears to be a strong positive regulator of hernatopoietic stem cell (HSC) self-renewal. Here we demonstrate the potency of HOXB4 to enable high-level ex vivo HSC expansion. Cultures of nontransduced or GFP-transduced murine bone marrow cells experienced large HSC losses over 10-14 days. In sharp contrast, cultures of HOXB4-transduced cells achieved rapid, extensive, and highly polyclonal HSC expansions, resulting in over 1000-fold higher levels relative to controls and a 40-fold net HSC increase. Importantly, these HSCs retained full lympho-myeloid repopulating potential and enhanced in vivo regenerative potential, demonstrating the feasibility of achieving significant ex vivo expansion of HSCs without functional impairment.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Maisonneuve Rosemont Hosp, Dept Med, Div Hematol, Montreal, PQ H1T 2M2, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 1Z1, Canada	British Columbia Cancer Agency; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; University of British Columbia	Sauvageau, G (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	khumphri@bccancer.bc.ca; sauvagg@ircm.qc.ca		Humphries, Richard/0000-0003-0540-7005; Sauvageau, Guy/0000-0002-4333-7266	NHLBI NIH HHS [R01 HL65430] Funding Source: Medline; NIDDK NIH HHS [R01 DK48642] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048642] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonchuk J, 2001, EXP HEMATOL, V29, P1125, DOI 10.1016/S0301-472X(01)00681-6; Bhardwaj G, 2001, NAT IMMUNOL, V2, P172, DOI 10.1038/84282; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; Bunting KD, 2000, BLOOD, V96, P902, DOI 10.1182/blood.V96.3.902.015k40_902_909; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; Buske C, 2000, INT J HEMATOL, V71, P301; Conneally E, 1997, P NATL ACAD SCI USA, V94, P9836, DOI 10.1073/pnas.94.18.9836; Daga A, 2000, EXP HEMATOL, V28, P569, DOI 10.1016/S0301-472X(00)00135-1; DUBOULE D, 1995, CURR OPIN GENET DEV, V5, P525, DOI 10.1016/0959-437X(95)90058-O; Ema H, 2000, J EXP MED, V192, P1281, DOI 10.1084/jem.192.9.1281; FRASER CC, 1990, BLOOD, V76, P1071; Glimm H, 1999, BLOOD, V94, P2161, DOI 10.1182/blood.V94.7.2161.419k32_2161_2168; Krosl J, 2000, ONCOGENE, V19, P5134, DOI 10.1038/sj.onc.1203897; Kyba M, 2001, BLOOD, V98, p451A; Lawrence HJ, 1999, LEUKEMIA, V13, P1993, DOI 10.1038/sj.leu.2401578; Miller CL, 1997, P NATL ACAD SCI USA, V94, P13648, DOI 10.1073/pnas.94.25.13648; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Pawliuk R, 1996, BLOOD, V88, P2852, DOI 10.1182/blood.V88.8.2852.bloodjournal8882852; Purton LE, 2000, BLOOD, V95, P470, DOI 10.1182/blood.V95.2.470; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SZILVASSY SJ, 1990, P NATL ACAD SCI USA, V87, P8736, DOI 10.1073/pnas.87.22.8736; Thorsteinsdottir U, 1999, BLOOD, V94, P2605, DOI 10.1182/blood.V94.8.2605.420k19_2605_2612; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390	26	530	578	0	29	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	2002	109	1					39	45		10.1016/S0092-8674(02)00697-9	http://dx.doi.org/10.1016/S0092-8674(02)00697-9			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955445	Bronze			2022-12-28	WOS:000174888300007
J	Lowes, BD; Gilbert, EM; Abraham, WT; Minobe, WA; Larrabee, P; Ferguson, D; Wolfel, EE; Lindenfeld, J; Tsvetkova, T; Robertson, AD; Quaife, RA; Bristow, MR				Lowes, BD; Gilbert, EM; Abraham, WT; Minobe, WA; Larrabee, P; Ferguson, D; Wolfel, EE; Lindenfeld, J; Tsvetkova, T; Robertson, AD; Quaife, RA; Bristow, MR			Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC HEART-FAILURE; LEFT-VENTRICULAR PERFORMANCE; ISCHEMIC CARDIOMYOPATHY; EJECTION FRACTION; FAILING HEART; MESSENGER-RNA; CARVEDILOL; BLOCKADE; CHAIN; GEOMETRY	Background: Beta-blocker therapy may improve cardiac function in patients with idiopathic dilated cardiomyopathy. We tested the hypothesis that beta-blocker therapy produces favorable functional effects in dilated cardiomyopathy by altering the expression of myocardial genes that regulate contractility and pathologic hypertrophy. Methods: We randomly assigned 53 patients with idiopathic dilated cardiomyopathy to treatment with a beta-adrenergic-receptor blocking agent (metoprolol or carvedilol) or placebo. The amount of messenger RNA (mRNA) for contractility-regulating genes (those encoding beta(1)- and beta(2)-adrenergic receptors, calcium ATPase in the sarcoplasmic reticulum, and alpha- and beta-myosin heavy-chain isoforms) and of genes associated with pathologic hypertrophy (beta-myosin heavy chain and atrial natriuretic peptide) was measured with a quantitative reverse-transcription polymerase chain reaction in total RNA extracted from biopsy specimens of the right ventricular septal endomyocardium. Myocardial levels of beta-adrenergic receptors were also measured. Measurements were conducted at base line and after six months of treatment, and changes in gene expression were compared with changes in the left ventricular ejection fraction as measured by radionuclide ventriculography. Results: Twenty-six of 32 beta-blocker-treated patients (those with complete mRNA measurements) had an improvement in left ventricular ejection fraction of at least 5 ejection-fraction (EF) units (mean [+/-SE] increase, 18.8+/-1.8). As compared with the six beta-blocker-treated patients who did not have a response (mean change, a decrease of 2.5+/-1.8 EF units), those who did have a response had an increase in sarcoplasmic-reticulum calcium ATPase mRNA and alpha-myosin heavy chain mRNA and a decrease in beta-myosin heavy chain mRNA. The change in sarcoplasmic-reticulum calcium ATPase was not present in the patients in the placebo group who had a spontaneous response. There were no differences between those who had a response and those who did not in terms of the change in mRNA or protein expression of beta-adrenergic receptors. Conclusions: In idiopathic dilated cardiomyopathy, functional improvement related to treatment with beta-blockers is associated with changes in myocardial gene expression.	Univ Colorado, Hlth Sci Ctr, Div Cardiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Cardiovasc Inst, Denver, CO USA; Univ Utah, Hlth Sci Ctr, Div Cardiol, Salt Lake City, UT USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Utah System of Higher Education; University of Utah	Bristow, MR (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Cardiol, 4200 E 9th Ave,Campus Box B139, Denver, CO 80262 USA.		bristow, michael r/G-7850-2011; Lowes, Brian/M-9020-2017	Lowes, Brian/0000-0002-5919-2540	NCRR NIH HHS [M01-RR00064, M01-RR00051] Funding Source: Medline; NHLBI NIH HHS [1R01-HL48013] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064, M01RR000051] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048013] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOLUYT MO, 1995, AM J PHYSIOL-HEART C, V269, pH638; Bristow MR, 2000, CIRCULATION, V101, P558, DOI 10.1161/01.CIR.101.5.558; Bristow MR, 1996, CIRCULATION, V94, P2807, DOI 10.1161/01.CIR.94.11.2807; Bristow MR, 1997, AM J CARDIOL, V80, pL26, DOI 10.1016/S0002-9149(97)00846-1; BRISTOW MR, 1994, CIRCULATION, V89, P1632, DOI 10.1161/01.CIR.89.4.1632; Bristow MR, 2000, CIRCULATION, V102, P484; Bristow MR, 1998, LANCET, V352, P8; BRISTOW MR, 2001, HURSTS HEART, V2, P1947; BRISTOW MR, 2001, HEART DIS TXB CARDIO, V1, P635; CINTRON G, 1993, CIRCULATION, V87, P17; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; COHN JN, 1993, CIRCULATION, V87, P5; Colucci WS, 1997, AM J CARDIOL, V80, pL15, DOI 10.1016/S0002-9149(97)00845-X; Doughty RN, 1997, J AM COLL CARDIOL, V29, P1060, DOI 10.1016/S0735-1097(97)00012-0; Eichhorn EJ, 1996, CIRCULATION, V94, P2285, DOI 10.1161/01.CIR.94.9.2285; Engelhardt S, 1996, J AM COLL CARDIOL, V27, P146, DOI 10.1016/0735-1097(95)00425-4; FELDMAN AM, 1991, CIRCULATION, V83, P1866, DOI 10.1161/01.CIR.83.6.1866; Gilbert EM, 1996, CIRCULATION, V94, P2817, DOI 10.1161/01.CIR.94.11.2817; GILBERT EM, 1989, CIRCULATION S2, V80, P428; HALL SA, 1995, J AM COLL CARDIOL, V25, P1154, DOI 10.1016/0735-1097(94)00543-Y; LADENSON PW, 1992, P NATL ACAD SCI USA, V89, P8856; Linck B, 1998, J PHARMACOL EXP THER, V286, P531; Lowes BD, 1999, AM J CARDIOL, V83, P1201, DOI 10.1016/S0002-9149(99)00059-4; Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770; Metra M, 2000, CIRCULATION, V102, P546; Quaife RA, 1998, AM J CARDIOL, V81, P247, DOI 10.1016/S0002-9149(97)00874-6; Quaife RA, 1996, AM J CARDIOL, V78, P779, DOI 10.1016/S0002-9149(96)00420-1; RAHKO PS, 1994, J AM COLL CARDIOL, V23, P209, DOI 10.1016/0735-1097(94)90522-3; Schleman KA, 2001, J CARD FAIL, V7, P4, DOI 10.1054/jcaf.2001.22491; SCHWARTZ K, 1993, J AM COLL CARDIOL, V22, pA30, DOI 10.1016/0735-1097(93)90459-E; WOODLEY SL, 1991, CIRCULATION, V84, P2426, DOI 10.1161/01.CIR.84.6.2426; ZARET BL, 1991, CARDIAC NUCL MED	32	373	389	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					1357	1365		10.1056/NEJMoa012630	http://dx.doi.org/10.1056/NEJMoa012630			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546MZ	11986409	Bronze			2022-12-28	WOS:000175279000003
J	Burns, WCG				Burns, WCG			Climate change and human health: The critical policy agenda	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									Pacific Inst Studies Dev Environm & Secur, Oakland, CA USA		Burns, WCG (corresponding author), Pacific Inst Studies Dev Environm & Secur, Oakland, CA USA.							[Anonymous], 2002, CLEAN ENERGY JOBS; BURNS WCG, 2001, GEORGETOWN INT ENV L, V13, P335; CLAUSSEN E, 2002, CLIMATE CHANGE MOVIN; *HADL CTR, 1999, GREENH EFF CLIM CHAN; *INT PAN CLIM CHAN, 2002, CLIM CHANG 2001 SCI; Patz JA, 2000, ANNU REV PUBL HEALTH, V21, P271, DOI 10.1146/annurev.publhealth.21.1.271; *UNFCCC, 2001, C PART ITS 7 SESS MA; *UNFCCC, 1997, C PART ITS 3 SESS KY; [No title captured]	9	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2287	2287		10.1001/jama.287.17.2287	http://dx.doi.org/10.1001/jama.287.17.2287			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980535				2022-12-28	WOS:000175260600034
J	Ajayan, PM; Terrones, M; de la Guardia, A; Huc, V; Grobert, N; Wei, BQ; Lezec, H; Ramanath, G; Ebbesen, TW				Ajayan, PM; Terrones, M; de la Guardia, A; Huc, V; Grobert, N; Wei, BQ; Lezec, H; Ramanath, G; Ebbesen, TW			Nanotubes in a flash - Ignition and reconstruction	SCIENCE			English	Article							CARBON NANOTUBES		Rensselaer Polytech Inst, Dept Mat Sci & Engn, Troy, NY 12180 USA; IPICYT, San Luis Potosi 78210, Mexico; Univ Sussex, Fullerene Sci Ctr, Brighton BN1 9QJ, E Sussex, England; Univ Strasbourg 1, ISIS, Lab Nanostruct, UMR 7006, F-67000 Strasbourg, France	Rensselaer Polytechnic Institute; Instituto Potosino Investigacion Cientifica y Tecnologica; University of Sussex; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ajayan, PM (corresponding author), Rensselaer Polytech Inst, Dept Mat Sci & Engn, Troy, NY 12180 USA.		Terrones, Mauricio/B-3829-2014; Grobert, Nicole/D-6493-2016; Ramanath, Ganpati/C-1157-2011; Wei, Bingqing/A-4525-2008	Terrones, Mauricio/0000-0003-0010-2851; Grobert, Nicole/0000-0002-8499-8749; Ramanath, Ganpati/0000-0002-8718-9760; Wei, Bingqing/0000-0002-9416-1731				AJAYAN PM, 1993, NATURE, V362, P522, DOI 10.1038/362522a0; AJAYAN PM, UNPUB; Berber S, 2000, PHYS REV LETT, V84, P4613, DOI 10.1103/PhysRevLett.84.4613; CHEN HX, 1995, SCIENCE, V270, P963, DOI 10.1126/science.270.5238.963; Hone J, 2000, SCIENCE, V289, P1730, DOI 10.1126/science.289.5485.1730; Kim P, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.215502; Nikolaev P, 1997, CHEM PHYS LETT, V266, P422, DOI 10.1016/S0009-2614(97)00053-5; TSANG SC, 1993, NATURE, V362, P520, DOI 10.1038/362520a0	9	241	289	4	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					705	705		10.1126/science.296.5568.705	http://dx.doi.org/10.1126/science.296.5568.705			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976446				2022-12-28	WOS:000175281700045
J	Del Genio, AD				Del Genio, AD			Atmospheric science - The dust settles on water vapor feedback	SCIENCE			English	Editorial Material									NASA, Goddard Inst Space Studies, New York, NY 10025 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Del Genio, AD (corresponding author), NASA, Goddard Inst Space Studies, New York, NY 10025 USA.		Del Genio, Anthony/D-4663-2012	Del Genio, Anthony/0000-0001-7450-1359				Bates JJ, 1997, J GEOPHYS RES-ATMOS, V102, P21837, DOI 10.1029/97JD01769; Bauer M, 2002, J CLIMATE, V15, P203, DOI 10.1175/1520-0442(2002)015<0203:OASTHR>2.0.CO;2; Chen JY, 2002, SCIENCE, V295, P838, DOI 10.1126/science.1065835; CHOU MD, 1994, J CLIMATE, V7, P1684, DOI 10.1175/1520-0442(1994)007<1684:CITTPD>2.0.CO;2; Emanuel KA, 1999, J ATMOS SCI, V56, P1766, DOI 10.1175/1520-0469(1999)056<1766:DAEOAC>2.0.CO;2; Held IM, 2000, ANNU REV ENERG ENV, V25, P441, DOI 10.1146/annurev.energy.25.1.441; Lindzen RS, 2001, B AM METEOROL SOC, V82, P417, DOI 10.1175/1520-0477(2001)082<0417:DTEHAA>2.3.CO;2; Soden BJ, 2002, SCIENCE, V296, P727, DOI 10.1126/science.296.5568.727; Wielicki BA, 2002, SCIENCE, V295, P841, DOI 10.1126/science.1065837	9	12	13	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					665	666		10.1126/science.1071400	http://dx.doi.org/10.1126/science.1071400			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976431				2022-12-28	WOS:000175281700031
J	Novotny, V; Basset, Y; Miller, SE; Weiblen, GD; Bremer, B; Cizek, L; Drozd, P				Novotny, V; Basset, Y; Miller, SE; Weiblen, GD; Bremer, B; Cizek, L; Drozd, P			Low host specificity of herbivorous insects in a tropical forest	NATURE			English	Article							PHYLOGENETIC-RELATIONSHIPS; SEQUENCES; RBCL	Two decades of research(1-4) have not established whether tropical insect herbivores are dominated by specialists or generalists. This impedes our understanding of species coexistence in diverse rainforest communities. Host specificity and species richness of tropical insects are also key parameters in mapping global patterns of biodiversity(1,4,5). Here we analyse data for over 900 herbivorous species feeding on 51 plant species in New Guinea and show that most herbivorous species feed on several closely related plant species. Because species-rich genera are dominant in tropical floras, monophagous herbivores are probably rare in tropical forests. Furthermore, even between phylogenetically distant hosts, herbivore communities typically shared a third of their species. These results do not support the classical view that the coexistence of herbivorous species in the tropics is a consequence of finely divided plant resources; non-equilibrium models of tropical diversity(6) should instead be considered. Low host specificity of tropical herbivores reduces global estimates of arthropod diversity from 31 million (ref. 1) to 4-6 million species. This finding agrees with estimates based on taxonomic collections, reconciling an order of magnitude discrepancy between extrapolations of global diversity based on ecological samples of tropical communities with those based on sampling regional faunas (7,8).	Acad Sci Czech Republ, Inst Entomol, CR-37005 Ceske Budejovice, Czech Republic; Univ S Bohemia, Fac Biol, Ceske Budejovice 37005, Czech Republic; Smithsonian Trop Res Inst, Balboa, Ancon, Panama; Smithsonian Inst, Natl Museum Nat Hist, Dept Systemat Biol, Washington, DC 20560 USA; Univ Minnesota, Dept Plant Biol, Ctr Biol Sci 220, St Paul, MN 55108 USA; Royal Swedish Acad Sci, Bergius Fdn, SE-10405 Stockholm, Sweden; Univ Ostrava, Dept Biol, Ostrava, Czech Republic	Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences; University of South Bohemia Ceske Budejovice; Smithsonian Institution; Smithsonian Tropical Research Institute; Smithsonian Institution; Smithsonian National Museum of Natural History; University of Minnesota System; University of Minnesota Twin Cities; Royal Swedish Academy of Sciences; University of Ostrava	Novotny, V (corresponding author), Acad Sci Czech Republ, Inst Entomol, Branisovska 31, CR-37005 Ceske Budejovice, Czech Republic.	novotny@entu.cas.cz	Cizek, Lukas/K-7111-2015; Cizek, Lukas/G-7905-2014; Basset, Yves F/B-6642-2014; Drozd, Pavel/J-3943-2013; Novotny, Vojtech/G-9434-2014	Cizek, Lukas/0000-0002-6447-2002; Cizek, Lukas/0000-0002-6447-2002; Basset, Yves F/0000-0002-1942-5717; Drozd, Pavel/0000-0002-4602-8856; Novotny, Vojtech/0000-0001-7918-8023; Miller, Scott/0000-0002-4138-1378				Backlund M, 2000, AM J BOT, V87, P1029, DOI 10.2307/2657003; Barone JA, 1998, J ANIM ECOL, V67, P400, DOI 10.1046/j.1365-2656.1998.00197.x; Basset Y, 2000, BIOSCIENCE, V50, P899, DOI 10.1641/0006-3568(2000)050[0899:QBEWPA]2.0.CO;2; BASSET Y, 1992, BIOL J LINN SOC, V47, P115, DOI 10.1111/j.1095-8312.1992.tb00659.x; Basset Y, 1996, BIOL J LINN SOC, V59, P201, DOI 10.1111/j.1095-8312.1996.tb01461.x; Bremer B, 1999, SYST BIOL, V48, P413, DOI 10.1080/106351599260085; Bremer K, 1998, ANN MO BOT GARD, V85, P531, DOI 10.2307/2992015; Burger W., 1993, FIELDIANA BOT, V33, P1, DOI DOI 10.5962/BHL.TITLE.2550; ERWIN T L, 1982, Coleopterists Bulletin, V36, P74; GENTRY AH, 1990, 4 NEOTROPICAL FOREST; Hoft R., 1992, PLANTS NEW GUINEA SO; Hubbell Stephen P., 2001, V32, pi; JANZEN DH, 1988, BIOTROPICA, V20, P120, DOI 10.2307/2388184; JOLIVET P, 1995, HOST PLANTS CHRYSOME; Leps J, 2001, J ECOL, V89, P186, DOI 10.1046/j.1365-2745.2001.00540.x; Mabberley DJ, 1987, PLANT BOOK; Marquis R.J., 1991, P179; MAY RM, 1990, PHILOS T R SOC B, V330, P293, DOI 10.1098/rstb.1990.0200; May Robert M., 2000, P30; MILLER SE, IN PRESS FDN TROPICA; NIELSEN ES, 2000, NATURE HUMAN SOC QUE, P312; Odegaard F, 2000, BIOL J LINN SOC, V71, P583, DOI 10.1006/bijl.2000.0468; Parsons M., 1999, BUTTERFLIES PAPUA NE, DOI DOI 10.7717/peerj.2653; POWELL JA, 1998, LEPIDOPTERA MOTHS BU, V1, P403; Qiu YL, 1999, NATURE, V402, P404, DOI 10.1038/46536; Sekhran N., 1996, PAPUA NEW GUINEA COU; Soltis DE, 2000, BOT J LINN SOC, V133, P381, DOI [10.1111/j.1095-8339.2000.tb01588.x, 10.1006/bojl.2000.0380]; STORK NE, 1993, BIODIVERS CONSERV, V2, P215, DOI 10.1007/BF00056669; THOMAS CD, 1990, ECOLOGY, V71, P610, DOI 10.2307/1940314; Weiblen GD, 2000, AM J BOT, V87, P1342, DOI 10.2307/2656726	30	472	498	3	223	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	2002	416	6883					841	844		10.1038/416841a	http://dx.doi.org/10.1038/416841a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976681				2022-12-28	WOS:000175163800049
J	Jedema, FJ; Heersche, HB; Filip, AT; Baselmans, JJA; van Wees, BJ				Jedema, FJ; Heersche, HB; Filip, AT; Baselmans, JJA; van Wees, BJ			Electrical detection of spin precession in a metallic mesoscopic spin valve	NATURE			English	Article							INJECTION; ACCUMULATION; RELAXATION; COHERENCE; CHARGE	To study and control the behaviour of the spins of electrons that are moving through a metal or semiconductor is an outstanding challenge in the field of 'spintronics', where possibilities for new electronic applications based on the spin degree of freedom are currently being explored(1-5). Recently, electrical control of spin coherence(6) and coherent spin precession during transport(7) was studied by optical techniques in semiconductors. Here we report controlled spin precession of electrically injected and detected electrons in a diffusive metallic conductor, using tunnel barriers in combination with metallic ferromagnetic electrodes as spin injector and detector. The output voltage of our device is sensitive to the spin degree of freedom only, and its sign can be switched from positive to negative, depending on the relative magnetization of the ferromagnetic electrodes. We show that the spin direction can be controlled by inducing a coherent spin precession caused by an applied perpendicular magnetic field. By inducing an average precession angle of 180degrees, we are able to reverse the sign of the output voltage.	Univ Groningen, Dept Appl Phys, NL-9747 AG Groningen, Netherlands; Univ Groningen, Ctr Mat Sci, NL-9747 AG Groningen, Netherlands	University of Groningen; University of Groningen	Jedema, FJ (corresponding author), Univ Groningen, Dept Appl Phys, Nijenborgh 4-13, NL-9747 AG Groningen, Netherlands.	jedema@phys.rug.nl	van, bart/U-1770-2017; Baselmans, Jochem/A-4515-2017	Baselmans, Jochem/0000-0002-3385-7305				Fabian J, 1999, PHYS REV LETT, V83, P1211, DOI 10.1103/PhysRevLett.83.1211; Fert A, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.184420; Grimaldi C, 1996, PHYS REV LETT, V77, P2550, DOI 10.1103/PhysRevLett.77.2550; Huertas-Hernando D, 2000, PHYS REV B, V62, P5700, DOI 10.1103/PhysRevB.62.5700; JACKEL LD, 1981, APPL PHYS LETT, V39, P268, DOI 10.1063/1.92668; Jedema FJ, 2001, NATURE, V410, P345, DOI 10.1038/35066533; JEDEMA FJ, 2002, CONDMAT0111092; JEDEMA FJ, UNPUB PHYS REV B; JOHNSON M, 1993, PHYS REV LETT, V70, P2142, DOI 10.1103/PhysRevLett.70.2142; JOHNSON M, 1988, PHYS REV B, V37, P5326, DOI 10.1103/PhysRevB.37.5326; JOHNSON M, 1985, PHYS REV LETT, V55, P1790, DOI 10.1103/PhysRevLett.55.1790; JOHNSON M, 1988, PHYS REV B, V37, P5312, DOI 10.1103/PhysRevB.37.5312; JULLIERE M, 1975, PHYS LETT A, V54, P225, DOI 10.1016/0375-9601(75)90174-7; Kikkawa JM, 1999, NATURE, V397, P139, DOI 10.1038/16420; MESERVEY R, 1978, PHYS REV LETT, V41, P805, DOI 10.1103/PhysRevLett.41.805; MONOD P, 1979, PHYS REV B, V19, P911, DOI 10.1103/PhysRevB.19.911; Papaconstantopoulos D. A., 1986, HDB BAND STRUCTURE E; Prinz GA, 1998, SCIENCE, V282, P1660, DOI 10.1126/science.282.5394.1660; Rashba EI, 2000, PHYS REV B, V62, pR16267, DOI 10.1103/PhysRevB.62.R16267; RIJKS TGSM, 1995, PHYS REV B, V51, P283, DOI 10.1103/PhysRevB.51.283; Salis G, 2001, NATURE, V414, P619, DOI 10.1038/414619a; Schmidt G, 2000, PHYS REV B, V62, pR4790, DOI 10.1103/PhysRevB.62.R4790; VANSON PC, 1987, PHYS REV LETT, V58, P2271, DOI 10.1103/PhysRevLett.58.2271; Wolf SA, 2001, SCIENCE, V294, P1488, DOI 10.1126/science.1065389	24	582	597	8	155	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	2002	416	6882					713	716		10.1038/416713a	http://dx.doi.org/10.1038/416713a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961548				2022-12-28	WOS:000175033500035
J	MacLean, JD; Graeme-Cook, FM; Varghese, J				MacLean, JD; Graeme-Cook, FM; Varghese, J			A 50-year-old man with eosinophilia and fluctuating hepatic lesions - Infection with Fasciola hepatica	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							IMMUNODIAGNOSIS; ASPIRATION		Montreal Gen Hosp, McGill Ctr Trop Dis, Montreal, PQ, Canada; McGill Univ, Montreal, PQ, Canada	McGill University; McGill University	MacLean, JD (corresponding author), Montreal Gen Hosp, McGill Ctr Trop Dis, Montreal, PQ, Canada.							AKAHANE H, 1975, Japanese Journal of Parasitology, V24, P55; AMMANN R, 1985, ECHINOCOCCUS HYDATID, P411; [Anonymous], 1995, World Health Organ Tech Rep Ser, V849, P1; ARJONA R, 1995, MEDICINE, V74, P13, DOI 10.1097/00005792-199501000-00002; BEAVER PC, 1952, PEDIATRICS, V9, P7; Beaver PC, 1984, CLIN PARASITOLOGY, V9th; BENDEZU P, 1982, J PARASITOL, V68, P297, DOI 10.2307/3281190; BURROWS RB, 1965, MICROSCOPIC DIAGNOSI; Cerezo JG, 1998, CLIN INFECT DIS, V26, P1009, DOI 10.1086/517637; Chen MG, 1990, TROP DIS B, V87, pR1; CHILDS JE, 1985, AM J PUBLIC HEALTH, V75, P1092, DOI 10.2105/AJPH.75.9.1092; GLICKMAN L, 1978, AM J TROP MED HYG, V27, P492, DOI 10.4269/ajtmh.1978.27.492; GLICKMAN LT, 1987, AM J EPIDEMIOL, V125, P1019, DOI 10.1093/oxfordjournals.aje.a114618; GLICKMAN LT, 1981, EPIDEMIOL REV, V3, P230, DOI 10.1093/oxfordjournals.epirev.a036235; Han JK, 1996, TROP MED INT HEALTH, V1, P367, DOI 10.1046/j.1365-3156.1996.d01-43.x; JACQUIER P, 1991, J CLIN MICROBIOL, V29, P1831, DOI 10.1128/JCM.29.9.1831-1835.1991; Kabaalioglu A, 1999, EUR RADIOL, V9, P880, DOI 10.1007/s003300050759; Kazacos K.R., 1997, PATHOLOGY INFECT DIS, VII, P1459; KNOBLOCH J, 1985, TROP MED PARASITOL, V36, P88; MACLEAN JD, 1999, TROPICAL INFECT DIS, V2, P1039; Mas-Coma S, 1999, FASCIOLOSIS, P411; NORTON RA, 1961, GASTROENTEROLOGY, V41, P46; O'Neill SM, 1998, AM J TROP MED HYG, V58, P417, DOI 10.4269/ajtmh.1998.58.417; STURCHLER D, 1981, SCHWEIZ MED WSCHR, V111, P1578	24	23	25	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	2002	346	16					1232	1239		10.1056/NEJMcpc020012	http://dx.doi.org/10.1056/NEJMcpc020012			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542FT	11961153				2022-12-28	WOS:000175033400009
J	Shaheen, N; Ransohoff, DF				Shaheen, N; Ransohoff, DF			Gastroesophageal reflux, Barrett esophagus, and esophageal cancer - Clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							QUALITY-OF-LIFE; LAPAROSCOPIC NISSEN FUNDOPLICATION; GASTROINTESTINAL ENDOSCOPY; OMEPRAZOLE TEST; GASTRIC CARDIA; FOLLOW-UP; DISEASE; ADENOCARCINOMA; RISK; COMPLICATIONS	Gastroesophageal reflux disease (GERD), a condition commonly encountered in the primary care setting, is a risk factor for adenocarcinoma of the esophagus. Despite the ubiquity of the complaint, considerable uncertainty exists with respect to several basic questions, including when to perform endoscopy in patients with chronic reflux symptoms and how to address the cancer risk associated with GERD. These clinical vignettes illustrate common clinical questions encountered in caring for patients with GERD, especially as they relate to the issue of cancer risk. Applying data reviewed in the companion article, we propose practical answers to common clinical situations regarding care of patients with reflux. We also present an algorithm for treatment of patients with chronic GERD symptoms.	Univ N Carolina, Div Digest Dis & Nutr, Ctr Esophageal Dis & Swallowing, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Shaheen, N (corresponding author), Univ N Carolina, Div Digest Dis & Nutr, Ctr Esophageal Dis & Swallowing, CB 7080, Chapel Hill, NC 27599 USA.		Shaheen, Nicholas J/A-1898-2013		NIDDK NIH HHS [K23DK59311-01] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK059311] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADANG RP, 1995, GASTROINTEST ENDOSC, V42, P390, DOI 10.1016/S0016-5107(95)70037-4; ARROWSMITH JB, 1991, GASTROINTEST ENDOSC, V37, P421, DOI 10.1016/S0016-5107(91)70773-6; Bloomston M, 1998, AM SURGEON, V64, P509; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; Chan M F, 1996, Gastrointest Endosc Clin N Am, V6, P287; CHOW WH, 1995, JAMA-J AM MED ASSOC, V274, P474, DOI 10.1001/jama.274.6.474; Coelho JCU, 1999, J AM COLL SURGEONS, V189, P356, DOI 10.1016/S1072-7515(99)00182-9; DeVault KR, 1999, AM J GASTROENTEROL, V94, P1434; Eisen GM, 1997, AM J GASTROENTEROL, V92, P27; Farrow DC, 2000, CANCER CAUSE CONTROL, V11, P231, DOI 10.1023/A:1008913828105; Fass R, 1999, ARCH INTERN MED, V159, P2161, DOI 10.1001/archinte.159.18.2161; Fass R, 2000, ALIMENT PHARM THER, V14, P389; Havelund T, 1999, AM J GASTROENTEROL, V94, P1782; HETZEL DJ, 1988, GASTROENTEROLOGY, V95, P903, DOI 10.1016/0016-5085(88)90162-X; HINDER RA, 1994, ANN SURG, V220, P472, DOI 10.1097/00000658-199410000-00006; Isolauri J, 1997, AM J GASTROENTEROL, V92, P37; Kavic SM, 2001, AM J SURG, V181, P319, DOI 10.1016/S0002-9610(01)00589-X; Klinkenberg-Knol EC, 2000, GASTROENTEROLOGY, V118, P661, DOI 10.1016/S0016-5085(00)70135-1; KLINKENBERGKNOL EC, 1995, DRUGS, V49, P695, DOI 10.2165/00003495-199549050-00005; Koop H, 1996, EUR J GASTROEN HEPAT, V8, P915; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Locke GR, 1997, GASTROENTEROLOGY, V112, P1448, DOI 10.1016/S0016-5085(97)70025-8; MARKS RD, 1994, GASTROENTEROLOGY, V106, P907, DOI 10.1016/0016-5085(94)90749-8; MURPHY DW, 1988, AM J GASTROENTEROL, V83, P633; NEBEL OT, 1976, AM J DIG DIS, V21, P953, DOI 10.1007/BF01071906; O'Connor JB, 1999, AM J GASTROENTEROL, V94, P2037; PEHL C, 1993, DIGEST DIS SCI, V38, P93, DOI 10.1007/BF01296779; Pehl C, 1997, ALIMENT PHARM THER, V11, P483, DOI 10.1046/j.1365-2036.1997.00161.x; Perdikis G, 1997, SURG LAPAROSC ENDOSC, V7, P17, DOI 10.1097/00019509-199702000-00005; Revicki DA, 1999, ALIMENT PHARM THERAP, V13, P1621; Revicki DA, 1998, AM J MED, V104, P252, DOI 10.1016/S0002-9343(97)00354-9; Sampliner RE, 1998, AM J GASTROENTEROL, V93, P1028; SAMPLINER RE, 1994, AM J GASTROENTEROL, V89, P1844; SCHINDLBECK NE, 1992, GUT, V33, P1016, DOI 10.1136/gut.33.8.1016; Schnell TG, 2001, GASTROENTEROLOGY, V120, P1607, DOI 10.1053/gast.2001.25065; Shaheen NJ, 2000, GASTROENTEROLOGY, V119, P333, DOI 10.1053/gast.2000.9302; SMITH PM, 1994, GASTROENTEROLOGY, V107, P1312, DOI 10.1016/0016-5085(94)90532-0; SPECHLER SJ, 1984, GASTROENTEROLOGY, V87, P927; Spechler SJ, 2001, JAMA-J AM MED ASSOC, V285, P2331, DOI 10.1001/jama.285.18.2331; Valle C, 1999, DIGEST DIS SCI, V44, P1848, DOI 10.1023/A:1018846807296; Williams MP, 1998, ALIMENT PHARM THER, V12, P1079; Ye WM, 2001, GASTROENTEROLOGY, V121, P1286, DOI 10.1053/gast.2001.29569; Zubarik R, 1999, AM J GASTROENTEROL, V94, P1539	43	57	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2002	287	15					1982	1986		10.1001/jama.287.15.1982	http://dx.doi.org/10.1001/jama.287.15.1982			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NC	11960541	Bronze			2022-12-28	WOS:000174989800027
J	Singer, LT; Arendt, R; Minnes, S; Farkas, K; Salvator, A; Kirchner, HL; Kliegman, R				Singer, LT; Arendt, R; Minnes, S; Farkas, K; Salvator, A; Kirchner, HL; Kliegman, R			Cognitive and motor outcomes of cocaine-exposed infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG EXPOSURE; CHILDREN; ABUSE; BRAIN; MECHANISMS; MECONIUM; GROWTH; AGE	Context Maternal use of cocaine during pregnancy remains a significant public health problem, particularly in urban areas of the United States and among women of low socioeconomic status. Few longitudinal studies have examined cocaine-exposed infants, however, and findings are contradictory because of methodologic limitations. Objective To assess the effects of prenatal cocaine exposure on child developmental outcomes. Design Longitudinal, prospective, masked, comparison birth cohort study with recruitment in 1994-1996. Setting Obstetric unit of a large US urban teaching hospital. Participants Four hundred fifteen consecutively enrolled infants (218 cocaine-exposed and 197 unexposed) identified from a high-risk, low-socioeconomic status, primarily black (80%) population screened through clinical interview and urine and meconium samples for drug use. The retention rate was 94% at 2 years of age. Main Outcome Measures The Bayley Mental and Motor Scales of Infant Development, assessed at 6.5, 12, and 24 months of corrected age. Results Controlled for confounding variables, cocaine exposure had significant effects on cognitive development, accounting for a 6-point deficit in Bayley Mental and Motor Scales of Infant Development scores at 2 years, with cocaine-exposed children twice as likely to have significant delay (mental development index <80) (odds ratio, 1.98; 95% confidence interval, 1.21-3.24; P=.006). For motor outcomes, there were no significant cocaine effects. Conclusions Cocaine-exposed children had significant cognitive deficits and a doubling of the rate of developmental delay during the first 2 years of life. Because 2-year outcomes are predictive of later cognitive outcomes, it is possible that these children will continue to have learning difficulties at school age.	Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Mandel Sch Appl Social Sci, Cleveland, OH 44106 USA; Med Coll Wisconsin, Milwaukee, WI 53226 USA	Case Western Reserve University; Case Western Reserve University; Medical College of Wisconsin	Singer, LT (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pediat, Triangle Bldg,11400 Euclid Ave,Suite 250, Cleveland, OH 44106 USA.		Singer, Lynn/Q-2045-2019	Singer, Lynn/0000-0003-2950-9460	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007957] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00080] Funding Source: Medline; NIDA NIH HHS [R01 DA007957] Funding Source: Medline; PHS HHS [R01-07957] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Alessandri SM, 1998, DEV PSYCHOL, V34, P565, DOI 10.1037/0012-1649.34.3.565; Arendt R, 1999, PEDIATRICS, V103, P86, DOI 10.1542/peds.103.1.86; Arendt RE, 1999, J DRUG ISSUES, V29, P203, DOI 10.1177/002204269902900203; AZUMA SD, 1993, PEDIATRICS, V92, P396; Barron R. M., 1986, J PERS SOC PSYCHOL, V51, P1173, DOI DOI 10.1037/0022-3514.51.6.1173; Bayley N, 1993, BAYLEY SCALES INFANT; Bayley N., 1969, BAYLEY SCALES INFANT; CHOUTEAU M, 1988, OBSTET GYNECOL, V72, P351; CREGLER LL, 1986, NEW ENGL J MED, V315, P1495, DOI 10.1056/NEJM198612043152327; Derogatis LR., 1992, BRIEF SYMPTOM INVENT; Dunn L.M., 2007, PEABODY PICTURE VOCA; Fagan JF, 1983, ADV INFANCY RES, V2, P31; Frank DA, 2001, JAMA-J AM MED ASSOC, V285, P1613, DOI 10.1001/jama.285.12.1613; HOBEL CJ, 1973, AM J OBSTET GYNECOL, V117, P1; HURT H, 1995, J DEV BEHAV PEDIATR, V16, P29, DOI 10.1097/00004703-199502000-00005; JACOBSON SH, 1991, POLYM PREPR, V32, P390; Jacobson SW, 1996, J PEDIATR-US, V129, P581, DOI 10.1016/S0022-3476(96)70124-5; JOHNS JM, 1992, NEUROTOXICOL TERATOL, V14, P343, DOI 10.1016/0892-0362(92)90041-8; KANDEL DB, 1998, DRUG ADDICTION RES H, P105; Kosofsky BE, 1998, ANN NY ACAD SCI, V846, P248, DOI 10.1111/j.1749-6632.1998.tb09742.x; Lester BM, 1998, SCIENCE, V282, P633, DOI 10.1126/science.282.5389.633; LEWIS DE, 1994, J TOXICOL-CLIN TOXIC, V32, P697, DOI 10.3109/15563659409017976; LIDOW MS, 1995, SYNAPSE, V21, P332, DOI 10.1002/syn.890210408; LITTLE BB, 1991, OBSTET GYNECOL, V77, P361; Mayes LC, 1999, DEV PSYCHOPATHOL, V11, P685, DOI 10.1017/S0954579499002278; Molfese VJ, 1997, INT J BEHAV DEV, V20, P595, DOI 10.1080/016502597385072; *NAT I DRUG AB, 1992, PUBL NAT I DRUG AB; OSTREA EM, 1989, J PEDIATR-US, V115, P474, DOI 10.1016/S0022-3476(89)80860-1; Richardson GA, 1996, NEUROTOXICOL TERATOL, V18, P519, DOI 10.1016/0892-0362(96)00062-1; Richardson GA, 1996, NEUROTOXICOL TERATOL, V18, P627, DOI 10.1016/S0892-0362(96)00121-3; Singer L, 1997, DEV PSYCHOPATHOL, V9, P473, DOI 10.1017/S0954579497001259; SINGER L, 1994, ARCH PEDIAT ADOL MED, V148, P959, DOI 10.1001/archpedi.1994.02170090073014; Singer LT, 1999, INFANT BEHAV DEV, V22, P1, DOI 10.1016/S0163-6383(99)80002-2; Singer LT, 1999, J DRUG ISSUES, V29, P253, DOI 10.1177/002204269902900207; Singer LT, 2001, PEDIATRICS, V107, P1057, DOI 10.1542/peds.107.5.1057; SINGER LT, IN PRESS NEUROTOXICO; Singh VK, 2000, IMMUNOL RES, V22, P1, DOI 10.1385/IR:22:1:1; STREISSGUTH AP, 1986, BEHAV TERATOLOGY ALC; Strupp B. J., 1998, Neurotoxicology and Teratology, V20, P355, DOI 10.1016/S0892-0362(98)80587-4; VOLPE JJ, 1992, NEW ENGL J MED, V327, P399, DOI 10.1056/NEJM199208063270607; WECHSLER D, 1989, WESCHLER ADULT INTEL; Wilkins AS, 1998, NEUROTOXICOL TERATOL, V20, P239, DOI 10.1016/S0892-0362(97)00128-1; WOODS JR, 1987, JAMA-J AM MED ASSOC, V257, P957, DOI 10.1001/jama.257.7.957; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203	44	150	155	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2002	287	15					1952	1960		10.1001/jama.287.15.1952	http://dx.doi.org/10.1001/jama.287.15.1952			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	541NC	11960537	Bronze			2022-12-28	WOS:000174989800023
J	Gray, N				Gray, N			Tobacco industry and EC advertising ban	LANCET			English	Editorial Material							SMOKE		European Inst Oncol, I-20141 Milan, Italy	IRCCS European Institute of Oncology (IEO)	Gray, N (corresponding author), European Inst Oncol, I-20141 Milan, Italy.							Chapman S, 1999, AM J PUBLIC HEALTH, V89, P1018, DOI 10.2105/AJPH.89.7.1018; Gray N, 2000, ANN ONCOL, V11, P909, DOI 10.1023/A:1008313631233; Jha P., 1999, CURBING EPIDEMIC GOV; PERTSCHUK M, 2001, SMOKE THEIR EYES	4	1	1	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1264	1265		10.1016/S0140-6736(02)08282-X	http://dx.doi.org/10.1016/S0140-6736(02)08282-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965267				2022-12-28	WOS:000174989700004
J	O'Brien, A; Clapp, L; Singer, M				O'Brien, A; Clapp, L; Singer, M			Terlipressin for norepinephrine-resistant septic shock	LANCET			English	Article							LOW-DOSE VASOPRESSIN	Norepinephrine-resistant hypotension when associated with septic shock has a high rate of mortality, which might possibly be reduced by Infusion of low-dose vasopressin. However, rebound hypotension often arises after treatment is stopped, and the drug usually has to be administered for several days. We report use of terlipressin, a long-acting vasopressin analogue, in eight patients with septic shock who did not respond to corticosteroids and methylene blue. A significant rise in blood pressure that lasted for at least 5 h was seen in all patients after a single bolus, allowing reduction or cessation of norepinephrine administration in seven patients. We were able to discharge four patients from intensive care subsequently. Terlipressin seems to be an effective rescue therapy, which is able to restore blood pressure in patients with catecholamine-resistant septic shock, without obvious complication.	UCL, Royal Free & Univ Coll Med Sch, Dept Med, London, England	University of London; University College London	Singer, M (corresponding author), UCL, Wolfson Inst Biomed Res, Bloomsbury Inst Intens Care Med, Cruciform Bldg,Gower St, London WC1E 6BT, England.	m.singer@ucl.ac.uk	Singer, Mervyn/Q-6142-2019; Clapp, Lucie/B-1088-2008; Clapp, Lucie/L-4199-2019; Singer, Mervyn/J-4425-2012	Singer, Mervyn/0000-0002-1042-6350; Clapp, Lucie/0000-0001-7802-4481; Clapp, Lucie/0000-0001-7802-4481; Singer, Mervyn/0000-0002-1042-6350; O'Brien, Alastair/0000-0002-9168-7009				Hamu Y, 1999, ANESTH ANALG, V88, P542, DOI 10.1097/00000539-199903000-00015; Landry DW, 1997, CIRCULATION, V95, P1122; Malay MB, 1999, J TRAUMA, V47, P699, DOI 10.1097/00005373-199910000-00014; Noguera I, 1997, BRIT J PHARMACOL, V122, P431, DOI 10.1038/sj.bjp.0701397; Tsuneyoshi I, 2001, CRIT CARE MED, V29, P487, DOI 10.1097/00003246-200103000-00004	5	178	195	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1209	1210		10.1016/S0140-6736(02)08225-9	http://dx.doi.org/10.1016/S0140-6736(02)08225-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955542				2022-12-28	WOS:000174846300014
J	Watts, C; Zimmerman, C				Watts, C; Zimmerman, C			Violence against women: global scope and magnitude	LANCET			English	Article							EXCESS FEMALE MORTALITY; REPRODUCTIVE HEALTH; RAPE; CRIME; WAR	An increasing amount of research Is beginning to offer a global overview of the extent of violence against women. In this paper we discuss the magnitude of some of the most common and most severe forms of violence against women: intimate partner violence; sexual abuse by non-intimate partners; trafficking, forced prostitution, exploitation of labour, and debt bondage of women and girls; physical and sexual violence against prostitutes; sex selective abortion, female infanticide, and the deliberate neglect of girls; and rape in war. There are many potential perpetrators, including spouses and partners, parents, other family members, neighbours, and men in positions of power or influence. Most forms of violence are not unique incidents but are ongoing, and can even continue for decades. Because of the sensitivity of the subject, violence is almost universally under-reported. Nevertheless, the prevalence of such violence suggests that globally, millions of women are experiencing violence or living with its consequences.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Watts, C (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England.	charlotte.watts@lshtm.ac.uk						Bourgois P, 1996, BRIT J CRIMINOL, V36, P412; Buga GAB, 1996, S AFR MED J, V86, P523; Church S, 2001, BMJ-BRIT MED J, V322, P524, DOI 10.1136/bmj.322.7285.524; COALE AJ, 1991, POPUL DEV REV, V17, P517, DOI 10.2307/1971953; Cohen A, 2000, AM J PUBLIC HEALTH, V90, P1369, DOI 10.2105/AJPH.90.9.1369; Dickson N, 1998, BRIT MED J, V316, P29, DOI 10.1136/bmj.316.7124.29; Durham H, 2001, LANCET, V357, P302, DOI 10.1016/S0140-6736(00)03624-2; *E W CTR PROGR POP, 1995, 34 E W CTR PROGR POP; Ellsberg M, 2001, STUD FAMILY PLANN, V32, P1, DOI 10.1111/j.1728-4465.2001.00001.x; FINKELHOR D, 1994, CHILD ABUSE NEGLECT, V18, P409, DOI 10.1016/0145-2134(94)90026-4; Global Alliance Against Trafficked Women, 2001, HUM RIGHTS TRAFF PER; Hargreaves S, 2001, LANCET, V357, P737, DOI 10.1016/S0140-6736(00)04180-5; HEISE L, 1999, POPULATION REPORTS J, V27; *HUM RIGHTS WATCH, 1993, ASIA WATCH; *INT ORG MIGR IOM, 2001, NEW IOM FIG GLOB SCA; *IOM KOS COUNT TRA, 2001, RET REINT PROJ SIT R; JENKINS C, 1999, STRIV COMB VIOL INT; JENKINS C, 1993, WOMEN RISK AIDS STUD; Jennings PJ, 2001, LANCET, V357, P302, DOI 10.1016/S0140-6736(00)03625-4; JEWKES R, IN PRESS SOC SCI MED; KOSS MP, 1992, J SOC ISSUES, V48, P61, DOI 10.1111/j.1540-4560.1992.tb01157.x; Matasha E, 1998, AIDS CARE, V10, P571, DOI 10.1080/09540129848433; McNally RJ, 1998, J ABNORM PSYCHOL, V107, P596, DOI 10.1037/0021-843X.107.4.596; MIKO FT, 2000, 98649C US STAT DEP F; NARAYANA G, 1999, UNPUB FAMILY VIOLENC; O'Muircheartaigh C, 1998, J ROY STAT SOC A STA, V161, P63, DOI 10.1111/1467-985X.00090; ONEILL RA, 1999, INT TRAFFICKING US C; PHONGPAICHIT P, 1999, GUNS GIRLS GAMBLING; Saito Yutiko, 1999, JAPAN BACK THAI WOME; Salt J., 2000, MIGRANT TRAFFICKING; SEN A, 1992, BRIT MED J, V304, P587, DOI 10.1136/bmj.304.6827.587; Skrobanek S., 1997, TRAFFIC WOMEN HUMAN; SWISS S, 1993, JAMA-J AM MED ASSOC, V270, P612, DOI 10.1001/jama.270.5.612; *UN EC SOC COMM AS, 2000, SEX AB SEX EXPL CHIL; *UN GEN ASS, 2001, UN CONV TRANS ORG CR; *UN HIGH COMM REF, 1999, REPR HLTH REF SIT IN; *UNICEF, 1999, WOM TRANS MONEE PROJ; United Nations General Assembly, 1993, DECL EL VIOL WOM; WATTS C, 1998, REPROD HEALTH MATTER, V6, P57, DOI DOI 10.1016/S0968-8080(98)90008-8; *WHO, 1998, VIOL WOM; *WHO AD HOC COMM H, 1996, TDRGEN961 WHO AD HOC; Wijers M., 1999, TRAFFICKING WOMEN FO; World Health Organization, 2001, WHO MULT STUD WOM HL; ZWI AB, 1996, DEFINING VIOLENCE UN, P99	44	580	606	2	135	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	2002	359	9313					1232	1237		10.1016/S0140-6736(02)08221-1	http://dx.doi.org/10.1016/S0140-6736(02)08221-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	539AB	11955557				2022-12-28	WOS:000174846300029
J	Brophy, PJ				Brophy, PJ			Microbiology - Subversion of Schwann cells and the Leper's bell	SCIENCE			English	Editorial Material							MYCOBACTERIUM-LEPRAE; ALPHA-DYSTROGLYCAN; PERIPHERAL-NERVE; DYSTROPHIN; RECEPTOR; DISEASE		Univ Edinburgh, Dept Preclin Vet Sci, Edinburgh EH9 1QH, Midlothian, Scotland	University of Edinburgh	Brophy, PJ (corresponding author), Univ Edinburgh, Dept Preclin Vet Sci, Edinburgh EH9 1QH, Midlothian, Scotland.							Cao W, 1998, SCIENCE, V282, P2079, DOI 10.1126/science.282.5396.2079; Durbeej M, 1998, CURR OPIN CELL BIOL, V10, P594, DOI 10.1016/S0955-0674(98)80034-3; Guilbot A, 2001, HUM MOL GENET, V10, P415, DOI 10.1093/hmg/10.4.415; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; Mirsky R, 2002, J PHYSIOL-PARIS, V96, P17, DOI 10.1016/S0928-4257(01)00076-6; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Rambukkana A, 2002, SCIENCE, V296, P927, DOI 10.1126/science.1067631; Sherman DL, 2001, NEURON, V30, P677, DOI 10.1016/S0896-6273(01)00327-0; *WHO, 2002, WHO WKLY EP REC, V77	10	4	5	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					862	863		10.1126/science.1072444	http://dx.doi.org/10.1126/science.1072444			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988561				2022-12-28	WOS:000175442500030
J	Sun, LP; Song, KY; Hase, WL				Sun, LP; Song, KY; Hase, WL			A S(N)2 reaction that avoids its deep potential energy minimum	SCIENCE			English	Article							INITIO CLASSICAL TRAJECTORIES; HESSIAN-BASED INTEGRATORS; BORN-OPPENHEIMER SURFACE; PHASE IONIC REACTIONS; GAS-PHASE; NUCLEOPHILIC-SUBSTITUTION; REACTION DYNAMICS; KINETIC-ENERGY; RATE CONSTANTS; MODEL	Chemical dynamics trajectory simulations were used to study the atomic-level mechanisms of the OH- + CH3F --> CH3OH + F- S(N)2 nucleophilic substitution reaction. The reaction dynamics, from the [OH...CH3....F](-) central barrier to the reaction products, are simulated by ab initio direct dynamics. The reaction's potential energy surface has a deep minimum in the product exit channel arising from the CH3OH...F- hydrogen-bonded complex. Statistical theories of unimolecular reaction rates assume that the reactive system becomes trapped in this minimum and forms an intermediate, with random redistribution of its vibrational energy, but the majority of the trajectories (90%) avoided this potential energy minimum and instead dissociated directly to products. This finding is discussed in terms of intramolecular vibrational energy redistribution (IVR) and the relation between IVR and molecular structure. The finding of this study may be applicable to other reactive systems where there is a hierarchy of time scales for intramolecular motions and thus inefficient IVR.	Wayne State Univ, Dept Chem, Detroit, MI 48202 USA; Korea Natl Univ Educ, Dept Chem, Chongwon 363791, Chungbuk, South Korea	Wayne State University; Korea National University of Education	Hase, WL (corresponding author), Wayne State Univ, Dept Chem, Detroit, MI 48202 USA.		Sun, Lipeng/AAJ-7074-2020	Hase, William/0000-0002-0560-5100				Baer T., 1996, UNIMOLECULAR REACTIO; Bakken V, 1999, J CHEM PHYS, V111, P8773, DOI 10.1063/1.480224; Bolton K., 1998, MODERN METHODS MULTI, P143; Chabinyc ML, 1998, SCIENCE, V279, P1882, DOI 10.1126/science.279.5358.1882; Craig SL, 1997, J PHYS CHEM A, V101, P4745, DOI 10.1021/jp970602d; DEPUY CH, 1990, J AM CHEM SOC, V112, P8650, DOI 10.1021/ja00180a003; DeTuri VF, 1997, J PHYS CHEM A, V101, P5969, DOI 10.1021/jp971452+; Fersht A., 1985, ENZYME STRUCTURE MEC; Frisch M. J., 1998, GAUSSIAN 98; FUKUI K, 1970, J PHYS CHEM-US, V74, P4161, DOI 10.1021/j100717a029; Gonzales JM, 2001, J PHYS CHEM A, V105, P11327, DOI 10.1021/jp012892a; GRAUL ST, 1994, J AM CHEM SOC, V116, P3875, DOI 10.1021/ja00088a024; Hase W. L., 1996, QUANTUM CHEM PROGRAM, V16, P671; HASE WL, 1994, SCIENCE, V266, P998, DOI 10.1126/science.266.5187.998; Hase WL, 1998, ACCOUNTS CHEM RES, V31, P659, DOI 10.1021/ar970156c; HASE WL, 1979, CHEM PHYS LETT, V67, P263, DOI 10.1016/0009-2614(79)85159-3; HASE WL, 1983, J PHYS CHEM-US, V87, P2754, DOI 10.1021/j100238a014; Hernandez MI, 1999, PHYS CHEM CHEM PHYS, V1, P1197, DOI 10.1039/a808511k; HU XC, 1992, J PHYS CHEM-US, V96, P7535, DOI 10.1021/j100198a012; Kato S, 2001, INT J MASS SPECTROM, V210, P223, DOI 10.1016/S1387-3806(01)00398-0; KLOTS CE, 1977, J CHEM PHYS, V66, P5100, DOI 10.1063/1.433766; LARSON JW, 1983, J AM CHEM SOC, V105, P2944, DOI 10.1021/ja00348a003; LIM KF, 1991, J CHEM PHYS, V94, P7164, DOI 10.1063/1.460724; METZ RB, 1990, J PHYS CHEM-US, V94, P1377, DOI 10.1021/j100367a034; Millam JM, 1999, J CHEM PHYS, V111, P3800, DOI 10.1063/1.480037; Patai S., 1995, CHEM CYCLOPROPYL GRO, P469; Peslherbe GH, 1999, ADV CHEM PHYS, V105, P171, DOI 10.1002/9780470141649.ch6; Peslherbe GH, 1996, J CHEM PHYS, V105, P7432, DOI 10.1063/1.472571; QUACK M, 1974, BER BUNSEN PHYS CHEM, V78, P240, DOI 10.1002/bbpc.19740780306; Riveros JM, 1998, PURE APPL CHEM, V70, P1969, DOI 10.1351/pac199870101969; Schmatz S, 2001, J CHEM PHYS, V114, P5233, DOI 10.1063/1.1350902; SHI Z, 1990, J AM CHEM SOC, V112, P6789, DOI 10.1021/ja00175a008; Steinfeld J. I., 1999, CHEM KINETICS DYNAMI; Sun L, 2001, J AM CHEM SOC, V123, P5753, DOI 10.1021/ja004077z; Tonner DS, 2000, J AM CHEM SOC, V122, P8783, DOI 10.1021/ja000881+; UZER T, 1991, PHYS REP, V199, P73, DOI 10.1016/0370-1573(91)90140-H; VANDELINDE SR, 1990, J CHEM PHYS, V93, P7962, DOI 10.1063/1.459326; VIGGIANO AA, 1992, J AM CHEM SOC, V114, P10477, DOI 10.1021/ja00052a050; VIGGIANO AA, 1994, J AM CHEM SOC, V116, P2213, DOI 10.1021/ja00084a099; WANG HB, 1995, J AM CHEM SOC, V117, P9347, DOI 10.1021/ja00141a029; WOOLLEY RG, 1976, ADV PHYS, V25, P27, DOI 10.1080/00018737600101352; ZEWAIL AH, 1988, SCIENCE, V242, P1645, DOI 10.1126/science.242.4886.1645	43	317	316	4	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					875	878		10.1126/science.1068053	http://dx.doi.org/10.1126/science.1068053			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988565				2022-12-28	WOS:000175442500034
J	Yu, Y; Han, SY; Chu, X; Chu, SI; Wang, Z				Yu, Y; Han, SY; Chu, X; Chu, SI; Wang, Z			Coherent temporal oscillations of macroscopic quantum states in a Josephson junction	SCIENCE			English	Article							ZERO-VOLTAGE STATE; RABI OSCILLATIONS; 2-STATE SYSTEM; DISSIPATION; SUPERPOSITION; QUANTIZATION; TEMPERATURE; MECHANICS; DOT	We report the generation and observation of coherent temporal oscillations between the macroscopic quantum states of a Josephson tunnel junction by applying microwaves with frequencies close to the level separation. Coherent temporal oscillations of excited state populations were observed by monitoring the junction's tunneling probability as a function of time. From the data, the lower limit of phase decoherence time was estimated to be about 5 microseconds.	Univ Kansas, Dept Phys & Astron, Lawrence, KS 66045 USA; Univ Kansas, Dept Chem, Lawrence, KS 66045 USA; Minist Posts & Telecommun, Commun Res Lab, Kansai Adv Res Ctr, Nishi Ku, Kobe, Hyogo 65124, Japan	University of Kansas; University of Kansas; National Institute of Information & Communications Technology (NICT) - Japan	Han, SY (corresponding author), Univ Kansas, Dept Phys & Astron, Lawrence, KS 66045 USA.							Barone A., 1982, PHYS APPL JOSEPHSON, P1; Blick RH, 1998, PHYS REV LETT, V81, P689, DOI 10.1103/PhysRevLett.81.689; Bocko MF, 1997, IEEE T APPL SUPERCON, V7, P3638, DOI 10.1109/77.622206; CALDEIRA AO, 1981, PHYS REV LETT, V46, P211, DOI 10.1103/PhysRevLett.46.211; CLARKE J, 1988, SCIENCE, V239, P992, DOI 10.1126/science.239.4843.992; DEVORET MH, 1985, PHYS REV LETT, V55, P1908, DOI 10.1103/PhysRevLett.55.1908; Friedman JR, 2000, NATURE, V406, P43, DOI 10.1038/35017505; HAN S, 1991, PHYS REV LETT, V66, P810, DOI 10.1103/PhysRevLett.66.810; Han SY, 1996, PHYS REV LETT, V76, P3404, DOI 10.1103/PhysRevLett.76.3404; Han SY, 2000, PHYS REV LETT, V84, P1300, DOI 10.1103/PhysRevLett.84.1300; Han SY, 2001, SCIENCE, V293, P1457, DOI 10.1126/science.1062266; LEGGETT AJ, 1985, PHYS REV LETT, V54, P857, DOI 10.1103/PhysRevLett.54.857; LEGGETT AJ, 1987, REV MOD PHYS, V59, P1, DOI 10.1103/RevModPhys.59.1; LEGGETT AJ, 1992, MODERN PROBLEMS COND, V34, P1; LLOYD S, 1993, SCIENCE, V261, P1569, DOI 10.1126/science.261.5128.1569; Makhlin Y, 2001, REV MOD PHYS, V73, P357, DOI 10.1103/RevModPhys.73.357; MARTINIS JM, 1985, PHYS REV LETT, V55, P1543, DOI 10.1103/PhysRevLett.55.1543; Nakamura Y, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.246601; Rabi II, 1937, PHYS REV, V51, P0652, DOI 10.1103/PhysRev.51.652; ROUSE R, 1995, PHYS REV LETT, V75, P1614, DOI 10.1103/PhysRevLett.75.1614; Schrodinger E, 1935, NATURWISSENSCHAFTEN, V23, P844, DOI 10.1007/BF01491987; Schulzgen A, 1999, PHYS REV LETT, V82, P2346, DOI 10.1103/PhysRevLett.82.2346; SCHWARTZ DB, 1985, PHYS REV LETT, V55, P1547, DOI 10.1103/PhysRevLett.55.1547; Silvestrini P, 1997, PHYS REV LETT, V79, P3046, DOI 10.1103/PhysRevLett.79.3046; Stafford CA, 1996, PHYS REV LETT, V76, P1916, DOI 10.1103/PhysRevLett.76.1916; Stievater TH, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.133603; van der Wal CH, 2000, SCIENCE, V290, P773, DOI 10.1126/science.290.5492.773; VOSS RF, 1981, PHYS REV LETT, V47, P265, DOI 10.1103/PhysRevLett.47.265; WASHBURN S, 1985, PHYS REV LETT, V54, P2712, DOI 10.1103/PhysRevLett.54.2712	29	597	619	5	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					889	892		10.1126/science.1069452	http://dx.doi.org/10.1126/science.1069452			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988569				2022-12-28	WOS:000175442500038
J	Zhu, HW; Xu, CL; Wu, DH; Wei, BQ; Vajtai, R; Ajayan, PM				Zhu, HW; Xu, CL; Wu, DH; Wei, BQ; Vajtai, R; Ajayan, PM			Direct synthesis of long single-walled carbon nanotube strands	SCIENCE			English	Article							ROPES; HYDROCARBONS; STRENGTH	In the processes that are used to produce single-waited nanotubes (electric arc, laser ablation, and chemical vapor deposition), the typical lengths of tangled nanotube bundles reach several tens of micrometers. We report that long nanotube strands, up to several centimeters in length, consisting of aligned single-waited nanotubes can be synthesized by the catalytic pyrolysis of n-hexane with an enhanced vertical floating technique. The long strands of nanotubes assemble continuously from arrays of nanotubes, which are intrinsically long.	Tsing Hua Univ, Dept Engn Mech, Beijing 100084, Peoples R China; Rensselaer Polytech Inst, Dept Mat Sci & Engn, Troy, NY 12180 USA	Tsinghua University; Rensselaer Polytechnic Institute	Wu, DH (corresponding author), Tsing Hua Univ, Dept Engn Mech, Beijing 100084, Peoples R China.		Zhu, Hongwei/C-4655-2008; Wei, Bingqing/A-4525-2008; Vajtai, Robert/B-1029-2008	Zhu, Hongwei/0000-0001-6484-3371; Wei, Bingqing/0000-0002-9416-1731; Vajtai, Robert/0000-0002-3942-8827				Andrews R, 1999, CHEM PHYS LETT, V303, P467, DOI 10.1016/S0009-2614(99)00282-1; Baughman RH, 1999, SCIENCE, V284, P1340, DOI 10.1126/science.284.5418.1340; Cheng HM, 1998, CHEM PHYS LETT, V289, P602, DOI 10.1016/S0009-2614(98)00479-5; Cheng HM, 1998, APPL PHYS LETT, V72, P3282, DOI 10.1063/1.121624; Ci LJ, 2000, CARBON, V38, P1933, DOI 10.1016/S0008-6223(00)00030-0; ENDO M, 1993, J PHYS CHEM SOLIDS, V54, P1841, DOI 10.1016/0022-3697(93)90297-5; Fischer JE, 1997, PHYS REV B, V55, pR4921, DOI 10.1103/PhysRevB.55.R4921; Forro L, 2001, TOP APPL PHYS, V80, P329; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; Launois P, 2001, J NANOSCI NANOTECHNO, V1, P125, DOI 10.1166/jnn.2001.025; Li F, 2000, APPL PHYS LETT, V77, P3161, DOI 10.1063/1.1324984; Lu JP, 1997, PHYS REV LETT, V79, P1297, DOI 10.1103/PhysRevLett.79.1297; Pan ZW, 1998, NATURE, V394, P631, DOI 10.1038/29206; Rols S, 1999, EUR PHYS J B, V10, P263, DOI 10.1007/s100510050854; Thess A, 1996, SCIENCE, V273, P483, DOI 10.1126/science.273.5274.483; Treacy MMJ, 1996, NATURE, V381, P678, DOI 10.1038/381678a0; Vigolo B, 2000, SCIENCE, V290, P1331, DOI 10.1126/science.290.5495.1331; Wong EW, 1997, SCIENCE, V277, P1971, DOI 10.1126/science.277.5334.1971; Yu MF, 2000, PHYS REV LETT, V84, P5552, DOI 10.1103/PhysRevLett.84.5552; Zhang PH, 1998, PHYS REV LETT, V81, P5346, DOI 10.1103/PhysRevLett.81.5346	20	725	809	11	413	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					884	886		10.1126/science.1066996	http://dx.doi.org/10.1126/science.1066996			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988567				2022-12-28	WOS:000175442500036
J	Gorman, JD; Sack, KE; Davis, JC				Gorman, JD; Sack, KE; Davis, JC			Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							JUVENILE RHEUMATOID-ARTHRITIS; DISEASE-ACTIVITY; SERONEGATIVE SPONDYLARTHROPATHIES; FUNCTIONAL INDEX; CONTROLLED TRIAL; TNF-ALPHA; ETANERCEPT; PSORIASIS; METHOTREXATE; INFLIXIMAB	Background: There are few effective treatments for ankylosing spondylitis, which causes substantial morbidity. Because of the central role of tumor necrosis factor (alpha) in the spondyloarthritides, we performed a randomized, double-blind, placebo-controlled trial of etanercept, a recombinant human tumor necrosis factor receptor (p75):Fc fusion protein, in patients with ankylosing spondylitis. Methods: Forty patients with active, inflammatory ankylosing spondylitis were randomly assigned to receive twice-weekly subcutaneous injections of etanercept (25 mg) or placebo for four months. The primary end point was a composite of improvements in measures of morning stiffness, spinal pain, functioning, the patient's global assessment of disease activity, and joint swelling. Patients were allowed to continue taking nonsteroidal antiinflammatory drugs, oral corticosteriods (less than or equal to10 mg per day), and disease-modifying antirheumatic drugs at stable doses during the trial. Results: Treatment with etanercept resulted in significant and sustained improvement. At four months, 80 percent of the patients in the etanercept group had a treatment response, as compared with 30 percent of those in the placebo group (P=0.004). Improvements over base-line values for various measures of disease activity, including morning stiffness, spinal pain, functioning, quality of life, enthesitis, chest expansion, erythrocyte sedimentation rate, and C-reactive protein, were significantly greater in the etanercept group. Longitudinal analysis showed that the treatment response was rapid and did not diminish over time. Etanercept was well tolerated, with no significant differences in rates of adverse events between the two groups. Conclusions: Treatment with etanercept for four months resulted in rapid, significant, and sustained improvement in patients with ankylosing spondylitis.	Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Davis, JC (corresponding author), Univ Calif San Francisco, Div Rheumatol, 533 Parnassus Ave, San Francisco, CA 94143 USA.	jdavis@medicine.ucsf.edu			NIAMS NIH HHS [N01-AR-9-2244, AR07304] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007304, N01AR092244] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARBUCK SG, 2002, REV COMMON TOXICITY; Brandt J, 2000, ARTHRITIS RHEUM-US, V43, P1346, DOI 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E; BRANDT J, 2001, ANN RHEUM DIS S1, V1, P61; BRAUN J, 1995, ARTHRITIS RHEUM, V38, P499, DOI 10.1002/art.1780380407; Braun Juergen, 1996, Current Opinion in Rheumatology, V8, P275, DOI 10.1097/00002281-199607000-00003; CALIN A, 1994, J RHEUMATOL, V21, P2281; Canete JD, 1997, BRIT J RHEUMATOL, V36, P38; Clegg DO, 1996, ARTHRITIS RHEUM, V39, P2004, DOI 10.1002/art.1780391209; Conover WJ, 1980, PRACTICAL NONPARAMET, P493; CREEMERS MCW, 1994, SEMIN ARTHRITIS RHEU, V24, P71, DOI 10.1016/S0049-0172(05)80001-0; Crew MD, 1998, J INTERF CYTOK RES, V18, P219, DOI 10.1089/jir.1998.18.219; DEANDRADE J R, 1965, Arthritis Rheum, V8, P302; DOUGADOS M, 1988, J RHEUMATOL, V15, P302; Gonzalez Segundo, 1999, Current Opinion in Rheumatology, V11, P257, DOI 10.1097/00002281-199907000-00006; GOODACRE JA, 1991, BRIT J RHEUMATOL, V30, P336; Gran JT, 1997, BRIT J RHEUMATOL, V36, P766; GRATACOS J, 1994, BRIT J RHEUMATOL, V33, P927; Grom AA, 1996, ARTHRITIS RHEUM, V39, P1703, DOI 10.1002/art.1780391013; Helliwell PS, 1998, ANN RHEUM DIS, V57, P135, DOI 10.1136/ard.57.3.135; KENNEDY LG, 1993, J RHEUMATOL, V20, P688; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103; MANDER M, 1987, ANN RHEUM DIS, V46, P197, DOI 10.1136/ard.46.3.197; MCEWEN C, 1971, ARTHRITIS RHEUM, V14, P291, DOI 10.1002/art.1780140302; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; Mohan N, 2000, ARTHRITIS RHEUM, V43, pS228; MOLL JMH, 1972, ANN RHEUM DIS, V31, P1, DOI 10.1136/ard.31.1.1; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; RINGSDAL VS, 1989, ANN RHEUM DIS, V48, P924, DOI 10.1136/ard.48.11.924; Roussou E, 1997, J RHEUMATOL, V24, P908; STEVEN MM, 1985, J RHEUMATOL, V12, P735; Stone M, 2001, J RHEUMATOL, V28, P1605; Taylor AL, 1998, ARTHRITIS RHEUM, V41, P1119, DOI 10.1002/1529-0131(199806)41:6<1119::AID-ART20>3.0.CO;2-0; TOUSSIROT E, 1994, RHEUMATOL INT, V13, P175, DOI 10.1007/BF00390264; Toussirot E, 1998, DRUGS, V56, P225, DOI 10.2165/00003495-199856020-00006; van der Heijde D, 1999, J RHEUMATOL, V26, P951; VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361; Viitanen JV, 1998, BRIT J RHEUMATOL, V37, P377; Ward MM, 1999, ARTHRIT CARE RES, V12, P247, DOI 10.1002/1529-0131(199908)12:4<247::AID-ART3>3.0.CO;2-H; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; WILKINSON M, 1958, ANN RHEUM DIS, V17, P209, DOI 10.1136/ard.17.2.209; Zink A, 2000, J RHEUMATOL, V27, P613	44	595	645	1	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					1349	1356		10.1056/NEJMoa012664	http://dx.doi.org/10.1056/NEJMoa012664			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546MZ	11986408				2022-12-28	WOS:000175279000002
J	Stevenson, LW				Stevenson, LW			Perspective - Beta-blockers for stable heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Stevenson, LW (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.								0	13	13	0	1	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					1346	1347		10.1056/NEJM200205023461802	http://dx.doi.org/10.1056/NEJM200205023461802			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546MZ	11986407				2022-12-28	WOS:000175279000001
J	Liang, SY; Linthicum, KJ; Gaydos, JC				Liang, SY; Linthicum, KJ; Gaydos, JC			Climate change and the monitoring of vector-borne disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MALARIA TRANSMISSION; RISK; VILLAGES		Univ Maryland, Sch Med, Baltimore, MD 21201 USA; US Dept Def Global Emerging Infect Surveillance &, Silver Spring, MD 20910 USA	University System of Maryland; University of Maryland Baltimore; United States Department of Defense	Liang, SY (corresponding author), Univ Maryland, Sch Med, Baltimore, MD 21201 USA.							Beck LR, 1997, AM J TROP MED HYG, V56, P99, DOI 10.4269/ajtmh.1997.56.99; BECK LR, 1994, AM J TROP MED HYG, V51, P271, DOI 10.4269/ajtmh.1994.51.271; Dister SW, 1997, AM J TROP MED HYG, V57, P687, DOI 10.4269/ajtmh.1997.57.687; ENGLEMAN RC, 1975, 200 YEARS MILITARY M; Linthicum KJ, 1999, SCIENCE, V285, P397, DOI 10.1126/science.285.5426.397; *NAT RES COUNC, 2000, WEATH CLIM EC INF DI; Peters C. J., 1994, HDB ZOONOSES B, P125; Randolph SE, 2000, ADV PARASIT, V47, P217, DOI 10.1016/S0065-308X(00)47010-7; Woods CW, 2002, EMERG INFECT DIS, V8, P138, DOI 10.3201/eid0802.010023; Yoganathan D, 2001, AM J IND MED, V40, P199, DOI 10.1002/ajim.1088	10	8	10	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2286	2286		10.1001/jama.287.17.2286	http://dx.doi.org/10.1001/jama.287.17.2286			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980534	hybrid			2022-12-28	WOS:000175260600033
J	Siegel, DA; Doney, SC; Yoder, JA				Siegel, DA; Doney, SC; Yoder, JA			The North Atlantic spring phytoplankton bloom and Sverdrup's critical depth hypothesis	SCIENCE			English	Article							UPPER OCEAN; MODEL	More than 50 years ago, Harald Sverdrup developed a simple model for the necessary conditions leading to the spring bloom of phytoplankton. Although this model has been used extensively across a variety of aquatic ecosystems, its application requires knowledge of community compensation irradiance (I-C), the light [eve[ where photosynthetic and ecosystem community loss processes balance. However, reported I-C values have varied by an order of magnitude. Here, I-C estimates are determined using satellite and hydrographic data sets consistent with the assumptions in Sverdrup's 1953 critical depth hypothesis. Retrieved values of I-C are approximately uniform throughout much of the North Atlantic with a mean value of 1.3 mol photons meter(-2) day(-1). These community-based I-C determinations are roughly twice typical values found for phytoptankton alone indicating that phytoplankton account for approximately one-half of community ecosystem losses. This work also suggests that important aspects of heterotrophic community dynamics can be assessed using satellite observations.	Univ Calif Santa Barbara, Inst Computat Earth Syst Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Geog, Santa Barbara, CA 93106 USA; Natl Ctr Atmospher Res, Boulder, CO 80305 USA; Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; National Center Atmospheric Research (NCAR) - USA; University of Rhode Island	Siegel, DA (corresponding author), Univ Calif Santa Barbara, Inst Computat Earth Syst Sci, Santa Barbara, CA 93106 USA.		Siegel, David A/C-5587-2008; Doney, Scott C/F-9247-2010	Doney, Scott C/0000-0002-3683-2437				ANTONOV JI, 1998, 27 NOAA NESDIS; BANSE K, 1994, J GEOPHYS RES-OCEANS, V99, P7323, DOI 10.1029/93JC02155; Behrenfeld MJ, 2001, SCIENCE, V291, P2594, DOI 10.1126/science.1055071; Carton JA, 2000, J PHYS OCEANOGR, V30, P294, DOI 10.1175/1520-0485(2000)030<0294:ASODAA>2.0.CO;2; Doney SC, 1999, GLOBAL BIOGEOCHEM CY, V13, P705, DOI 10.1029/1999GB900039; DUCKLOW HW, 1993, DEEP-SEA RES PT II, V40, P1, DOI 10.1016/0967-0645(93)90003-6; Dutkiewicz S, 2001, DEEP-SEA RES PT II, V48, P2323, DOI 10.1016/S0967-0645(00)00178-8; Fromentin JM, 1996, MAR ECOL PROG SER, V134, P111, DOI 10.3354/meps134111; GIESKES W W C, 1975, Netherlands Journal of Sea Research, V9, P166, DOI 10.1016/0077-7579(75)90014-9; GRAN H. H., 1931, Conseil Perm. Internat. pour I'Explor. de la Mer. Rapp. et Proces-Verb., V75, P37; LANGDON C, 1988, J PLANKTON RES, V10, P1291, DOI 10.1093/plankt/10.6.1291; Longhurst A., 1988, ECOLOGICAL GEOGRAPHY; Lucas LV, 1998, J MAR RES, V56, P375, DOI 10.1357/002224098321822357; MCCLAIN CR, 1993, J GEOPHYS RES-OCEANS, V98, P12327, DOI 10.1029/93JC00868; MCCLAIN CR, 1990, J GEOPHYS RES-OCEANS, V95, P18027, DOI 10.1029/JC095iC10p18027; MCLAIN CR, 1988, SEA TECHNOL, V39, P10; MONTEREY GI, 1997, 14 NOAA NESDIS; MOREL A, 1988, J GEOPHYS RES-OCEANS, V93, P10749, DOI 10.1029/JC093iC09p10749; Najjar RG, 1997, J MAR RES, V55, P117, DOI 10.1357/0022240973224481; NELSON DM, 1991, LIMNOL OCEANOGR, V36, P1650, DOI 10.4319/lo.1991.36.8.1650; Obata A, 1996, J GEOPHYS RES-OCEANS, V101, P20657, DOI 10.1029/96JC01734; PLATT T, 1991, P ROY SOC B-BIOL SCI, V246, P205, DOI 10.1098/rspb.1991.0146; RILEY GA, 1957, LIMNOL OCEANOGR, V2, P252, DOI 10.1002/lno.1957.2.3.0252; SIEGEL DA, 1990, J MAR RES, V48, P379, DOI 10.1357/002224090784988791; SMETACEK V, 1990, LIMNOL OCEANOGR, V35, P228, DOI 10.4319/lo.1990.35.1.0228; Sverdrup H.U., 1953, J CONSEILCONSEIL PER, V18, P287, DOI [10.1093/icesjms/18.3.287, DOI 10.1093/ICESJMS/18.3.287]; TOWNSEND DW, 1992, NATURE, V360, P59, DOI 10.1038/360059a0; Williams RG, 1998, DEEP-SEA RES PT I, V45, P461, DOI 10.1016/S0967-0637(97)00094-0; Williams RG, 2000, GLOBAL BIOGEOCHEM CY, V14, P1299, DOI 10.1029/2000GB001260; YODER JA, 1993, GLOBAL BIOGEOCHEM CY, V7, P181, DOI 10.1029/93GB02358	30	391	407	3	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					730	733		10.1126/science.1069174	http://dx.doi.org/10.1126/science.1069174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976453				2022-12-28	WOS:000175281700053
J	Beldade, P; Koops, K; Brakefield, PM				Beldade, P; Koops, K; Brakefield, PM			Developmental constraints versus flexibility in morphological evolution	NATURE			English	Article							QUANTITATIVE GENETICS; EYESPOT PATTERNS; SELECTION; SPANDRELS	Evolutionary developmental biology has encouraged a change of research emphasis from the sorting of phenotypic variation by natural selection to the production of that variation through development(1). Some morphologies are more readily generated than others, and developmental mechanisms can limit or channel evolutionary change(2). Such biases determine how readily populations are able to respond to selection(3), and have been postulated to explain stasis in morphological evolution(4) and unexplored morphologies(5). There has been much discussion about evolutionary constraints(6-8) but empirical data testing them directly are sparse(9,10). The spectacular diversity in butterfly wing patterns(11) is suggestive of how little constrained morphological evolution can be. However, for wing patterns involving serial repeats of the same element, developmental properties suggest that some directions of evolutionary change might be restricted(12,13). Here we show that despite the developmental coupling between different eyespots in the butterfly Bicyclus anynana, there is great potential for independent changes. This flexibility is consistent with the diversity of wing patterns across species and argues for a dominant role of natural selection, rather than internal constraints, in shaping existing variation.	Leiden Univ, Inst Evolutionary & Ecol Sci, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University - Excl LUMC	Beldade, P (corresponding author), Leiden Univ, Inst Evolutionary & Ecol Sci, POB 9516, NL-2300 RA Leiden, Netherlands.	pbeldade@rulsfb.leidenuniv.nl; brakefield@rulsfb.leidenuniv.nl	Beldade, Patrícia/E-1970-2011; Rohlf, F J/A-8710-2008	Beldade, Patrícia/0000-0001-7831-979X; 				ANTONOVICS J, 1991, TRENDS ECOL EVOL, V6, P166, DOI 10.1016/0169-5347(91)90059-7; Barton N, 2000, BIOESSAYS, V22, P1075, DOI 10.1002/1521-1878(200012)22:12&lt;1075::AID-BIES5&gt;3.0.CO;2-M; Beldade P, 2002, NATURE, V415, P315, DOI 10.1038/415315a; Brakefield PM, 1998, HEREDITY, V80, P265, DOI 10.1038/sj.hdy.6883660; Brakefield PM, 1996, NATURE, V384, P236, DOI 10.1038/384236a0; Brakefield PM, 2001, J EXP ZOOL, V291, P93, DOI 10.1002/jez.1062; Brunetti CR, 2001, CURR BIOL, V11, P1578, DOI 10.1016/S0960-9822(01)00502-4; CHEVERUD JM, 1984, J THEOR BIOL, V110, P155, DOI 10.1016/S0022-5193(84)80050-8; Condamin M., 1973, MONOGRAPHIE GENRE BI; FRENCH V, 1995, DEV BIOL, V168, P112, DOI 10.1006/dbio.1995.1065; GOULD SJ, 1989, EVOLUTION, V43, P516, DOI 10.1111/j.1558-5646.1989.tb04249.x; GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/rspb.1979.0086; Monteiro A, 1997, EVOLUTION, V51, P1207, DOI 10.1111/j.1558-5646.1997.tb03968.x; MONTEIRO AF, 1994, EVOLUTION, V48, P1147, DOI [10.1111/j.1558-5646.1994.tb05301.x, 10.2307/2410374]; Nijhout H.F., 1991, DEV EVOLUTION BUTTER; NIJHOUT HF, 1994, DEVELOPMENT, P225; NIJHOUT HF, 1985, DEV BIOL, V108, P146, DOI 10.1016/0012-1606(85)90016-8; PAULSEN SM, 1993, EVOLUTION, V47, P593, DOI 10.1111/j.1558-5646.1993.tb02115.x; PAULSEN SM, 1994, DEV GENET, V15, P79, DOI 10.1002/dvg.1020150109; Pigliucci M, 2000, TRENDS ECOL EVOL, V15, P66, DOI 10.1016/S0169-5347(99)01762-0; ROFF D, 1999, EVOLUTIONARY QUANTIT; SCHARLOO W, 1983, ORG CONSTRAINTS DYNA, P197; SMITH JM, 1985, Q REV BIOL, V60, P265, DOI 10.1086/414425; Stern DL, 2000, EVOLUTION, V54, P1079, DOI 10.1554/0014-3820(2000)054[1079:PEDBAT]2.0.CO;2; Teotonio H, 2000, NATURE, V408, P463, DOI 10.1038/35044070; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610; WAGNER GP, 1988, J EVOLUTION BIOL, V1, P45, DOI 10.1046/j.1420-9101.1988.1010045.x; WEBER KE, 1992, GENETICS, V130, P345; WILLIAMSON PG, 1987, RATES EVOLUTION; Zar JH., 1999, BIOSTAT ANAL, V663rd	30	225	230	1	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	2002	416	6883					844	847		10.1038/416844a	http://dx.doi.org/10.1038/416844a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976682				2022-12-28	WOS:000175163800050
J	Gershon, D				Gershon, D			Diy or off-the-shelf?	NATURE			English	Article																			0	113	131	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					885	+		10.1038/416885a	http://dx.doi.org/10.1038/416885a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976691	Bronze			2022-12-28	WOS:000175163800061
J	Miyamoto, A; Nakayama, K; Imaki, H; Hirose, S; Jiang, Y; Abe, M; Tsukiyama, T; Nagahama, H; Ohno, S; Hatakeyama, S; Nakayama, KI				Miyamoto, A; Nakayama, K; Imaki, H; Hirose, S; Jiang, Y; Abe, M; Tsukiyama, T; Nagahama, H; Ohno, S; Hatakeyama, S; Nakayama, KI			Increased proliferation of B cells and auto-immunity in mice lacking protein kinase C delta	NATURE			English	Article							PHORBOL ESTER; PROTEOLYTIC ACTIVATION; TUMOR PROMOTION; TRANSGENIC MICE; EXPRESSION; GROWTH; ALPHA; DIFFERENTIATION; OVEREXPRESSION; INHIBITION	Protein kinase C (PKC), which comprises 11 closely related isoforms, has been implicated in a wide variety of cellular processes, such as growth, differentiation, secretion, apoptosis and tumour development(1-4). Among the PKC isotypes, PKC-delta is unique in that its overexpression results in inhibition of cell growth(5-11). Here we show that mice that lack PKC-delta exhibit expansion of the B-lymphocyte population with the formation of numerous germinal centres in the absence of stimulation. The rate of proliferation in response to stimulation was greater for B cells from PKC-delta-deficient mice than for those from wild-type mice. Adoptive transfer experiments suggested that the hyperproliferation phenotype is B-cell autonomous. Production of interleukin-6 was markedly increased in B cells of PKC-delta-null mice as a result of an increase in the DNA-binding activity of NF-IL6. Furthermore, the PKC-delta-deficient mice contain circulating autoreactive antibodies and display immune-complex-type glomerulonephritis, as well as lymphocyte infiltration in many organs. These results suggest that PKC-delta has an indispensable function in negative regulation of B-cell proliferation, and is particularly important for the establishment of B-cell tolerance.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi, Saitama 3320012, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Fukuoka 8128582, Japan; Juntendo Univ, Sch Med, Dept Pathol 2, Bunkyo Ku, Tokyo 1138421, Japan; Yokohama City Univ, Sch Med, Dept Biol Mol, Kanagawa 2360004, Japan	Kyushu University; Japan Science & Technology Agency (JST); Kyushu University; Juntendo University; Yokohama City University	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Fukuoka 8128582, Japan.		Ohno, Shigeo/B-1768-2010; Tsukiyama, Tadasuke/D-7589-2012; Hatakeyama, Shigetsugu/C-8333-2012	Ohno, Shigeo/0000-0002-1294-5269; Tsukiyama, Tadasuke/0000-0001-5205-8202; Hatakeyama, Shigetsugu/0000-0002-2150-9979				AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BURLINGAME RW, 1990, J IMMUNOL METHODS, V134, P187, DOI 10.1016/0022-1759(90)90380-E; Emoto Y, 1996, BLOOD, V87, P1990; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; LAPORTA CAM, 1995, CARCINOGENESIS, V16, P1233; Leitges M, 1996, SCIENCE, V273, P788, DOI 10.1126/science.273.5276.788; Li W, 1996, CURR TOP MICROBIOL, V211, P55; Li WQ, 1996, ONCOGENE, V13, P731; Livneh E, 1997, EUR J BIOCHEM, V248, P1, DOI 10.1111/j.1432-1033.1997.t01-4-00001.x; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHNO S, 1988, CELL, V53, P731, DOI 10.1016/0092-8674(88)90091-8; PESSINO A, 1995, BIOCHEM J, V312, P549, DOI 10.1042/bj3120549; Reddig PJ, 1999, CANCER RES, V59, P5710; SUEMATSU S, 1989, P NATL ACAD SCI USA, V86, P7547, DOI 10.1073/pnas.86.19.7547; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; Tsukiyama T, 2001, J IMMUNOL, V166, P304, DOI 10.4049/jimmunol.166.1.304; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	30	336	351	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					865	869		10.1038/416865a	http://dx.doi.org/10.1038/416865a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976687				2022-12-28	WOS:000175163800055
J	King, M; Davidson, O; Taylor, F; Haines, A; Sharp, D; Turner, R				King, M; Davidson, O; Taylor, F; Haines, A; Sharp, D; Turner, R			Effectiveness of teaching general practitioners skills in brief cognitive behaviour therapy to treat patients with depression: randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							HEALTH-SERVICE RESEARCH; PRIMARY-CARE; NEUROTIC DISORDERS; BRIEF INTERVENTION; HOSPITAL ANXIETY; QUESTIONNAIRE; MANAGEMENT; EDUCATION; DRINKERS; MODEL	Objective To assess the effectiveness of teaching general practitioners skills in brief cognitive behaviour therapy. Design Parallel group, cluster randomised, controlled trial of an educational package on cognitive behaviour therapy. Setting General practices in north London. Participants 84 general practitioner principals and 272 patients attending their practices who scored above the threshold for psychological distress on the hospital anxiety and depression scale. Intervention A training package of four half days on brief cognitive behaviour therapy. Main outcome measures Scores on the depression attitude questionnaire (general practitioners) and the Beck depression inventory (patients). Results Doctors' knowledge of depression and attitudes towards its treatment showed no major difference between intervention and control groups after 6 months. The training had no discernible impact on patients' outcomes. Conclusion General practitioners may require more training and support than a basic educational package on brief cognitive behaviour therapy to acquire skills to help patients with depression.	UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England; UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London NW3 2PF, England; Univ Bristol, Dept Clin Med, Div Primary Hlth Care, Bristol BS8 2PR, Avon, England; MRC, Clin Trials Unit, London NW1 2DA, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of Bristol; Medical Research Council Clinical Trials Unit	King, M (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, Royal Free Campus, London NW3 2PF, England.	m.king@rfc.ucl.ac.uk	Greiver, Michelle/N-8764-2015; King, Michael B/D-7477-2011	Greiver, Michelle/0000-0001-8957-0285; King, Michael B/0000-0003-4715-7171; Haines, Andy/0000-0002-8053-4605				Bashir K, 2000, BRIT J GEN PRACT, V50, P626; Bebbington PE, 2000, PSYCHOL MED, V30, P1359, DOI 10.1017/S0033291799002950; Bebbington PE, 2000, PSYCHOL MED, V30, P1369, DOI 10.1017/S0033291799002974; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Botega NJ., 1992, Int J Methods Psychiatr Res, V2, P169; Cape J, 2000, BRIT J GEN PRACT, V50, P396; Cordoba R, 1998, FAM PRACT, V15, P562, DOI 10.1093/fampra/15.6.562; DAVIDSON O, 1999, ED GEN PRACT, V10, P485; DUNN G, 1994, SOC PSYCH PSYCH EPID, V29, P198, DOI 10.1007/BF00796377; Fleming M, 1999, ALCOHOL RES HEALTH, V23, P128; Gedenk M, 1997, J Am Board Fam Pract, V10, P349; Goldberg DP., 1992, COMMON MENTAL DISORD; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; KERR M, 1995, BRIT J GEN PRACT, V45, P89; Lidbeck J, 1997, ACTA PSYCHIAT SCAND, V96, P14, DOI 10.1111/j.1600-0447.1997.tb09899.x; MYNORSWALLIS LM, 1995, BMJ-BRIT MED J, V310, P441, DOI 10.1136/bmj.310.6977.441; Omar RZ, 2000, STAT MED, V19, P2675, DOI 10.1002/1097-0258(20001015)19:19<2675::AID-SIM556>3.3.CO;2-1; Omar RZ, 1999, STAT MED, V18, P1587, DOI 10.1002/(SICI)1097-0258(19990715)18:13<1587::AID-SIM141>3.0.CO;2-Z; Paykel ES, 1999, ARCH GEN PSYCHIAT, V56, P829, DOI 10.1001/archpsyc.56.9.829; Ridgeway NA, 1999, SOUTHERN MED J, V92, P667, DOI 10.1097/00007611-199907000-00004; Robinson P, 1997, J FAM PRACTICE, V44, P562; Scott C, 1997, BRIT J PSYCHIAT, V171, P131, DOI 10.1192/bjp.171.2.131; SIBBALD B, 1993, BMJ-BRIT MED J, V306, P29, DOI 10.1136/bmj.306.6869.29; SMITH RC, 1974, PSYCHOL REP, V34, P519; Spiegelhalter DJ, 1999, BRIT MED J, V319, P508, DOI 10.1136/bmj.319.7208.508; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; Ukoumunne OC, 1999, BRIT MED J, V319, P376, DOI 10.1136/bmj.319.7206.376; Ward E, 2000, BRIT MED J, V321, P1383, DOI 10.1136/bmj.321.7273.1383; WILKINSON MJB, 1988, J ROY COLL GEN PRACT, V38, P311; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	112	113	1	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 20	2002	324	7343					947	951B		10.1136/bmj.324.7343.947	http://dx.doi.org/10.1136/bmj.324.7343.947			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544UF	11964340	Bronze, Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000175179500017
J	Li, ZX; Dullmann, J; Schiedlmeier, B; Schmidt, M; von Kalle, C; Meyer, J; Forster, M; Stocking, C; Wahlers, A; Frank, O; Ostertag, W; Kuhlcke, K; Eckert, HG; Fehse, B; Baum, C				Li, ZX; Dullmann, J; Schiedlmeier, B; Schmidt, M; von Kalle, C; Meyer, J; Forster, M; Stocking, C; Wahlers, A; Frank, O; Ostertag, W; Kuhlcke, K; Eckert, HG; Fehse, B; Baum, C			Murine leukemia induced by retroviral gene marking	SCIENCE			English	Article									Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Hannover Med Sch, D-30625 Hannover, Germany; Univ Hamburg, Hosp Eppendorf, D-20249 Hamburg, Germany; Univ Freiburg, D-79106 Freiburg, Germany; EUFETS AG, D-55743 Idar Oberstein, Germany	Heinrich Pette Institute; Hannover Medical School; University of Hamburg; University of Freiburg	Baum, C (corresponding author), Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany.		Fehse, Boris/HIR-6019-2022; Fehse, Boris/A-8721-2012	Fehse, Boris/0000-0001-9780-7211				Bonini C, 1997, SCIENCE, V276, P1719, DOI 10.1126/science.276.5319.1719; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; NUCIFORA G, 2001, TRANSCRIPTION FACTOR, P393; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Schmidt M, 2001, HUM GENE THER, V12, P743, DOI 10.1089/104303401750148649; STOCKING C, 1993, GROWTH FACTORS, V8, P197, DOI 10.3109/08977199309011023; Wahlers A, 2001, GENE THER, V8, P477, DOI 10.1038/sj.gt.3301426	9	517	558	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					497	497		10.1126/science.1068893	http://dx.doi.org/10.1126/science.1068893			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964471				2022-12-28	WOS:000175179400036
J	Vane, JR				Vane, JR			Biomedicine: Back to an aspirin a day?	SCIENCE			English	Editorial Material							PROSTACYCLIN; BIOSYNTHESIS; NAPROXEN; BALANCE		St Bartholomews Hosp, Coll Med, William Harvey Res Inst, London EC1M 6BQ, England	University of London; Queen Mary University London	Vane, JR (corresponding author), St Bartholomews Hosp, Coll Med, William Harvey Res Inst, London EC1M 6BQ, England.							Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; BUNTING S, 1983, BRIT MED BULL, V39, P271, DOI 10.1093/oxfordjournals.bmb.a071832; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; FITZGERALD GA, 1984, NEW ENGL J MED, V310, P1065, DOI 10.1056/NEJM198404263101701; Jick SS, 2000, PHARMACOTHERAPY, V20, P741, DOI 10.1592/phco.20.9.741.35209; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Ray WA, 2002, LANCET, V359, P118, DOI 10.1016/S0140-6736(02)07370-1; Reicin AS, 2002, AM J CARDIOL, V89, P204, DOI 10.1016/S0002-9149(01)02201-9; 2001, FDC REPORTS PINK SHE	13	72	81	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					474	475		10.1126/science.1071702	http://dx.doi.org/10.1126/science.1071702			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964462				2022-12-28	WOS:000175179400026
J	Knutti, R; Stocker, TF; Joos, F; Plattner, GK				Knutti, R; Stocker, TF; Joos, F; Plattner, GK			Constraints on radiative forcing and future climate change from observations and climate model ensembles	NATURE			English	Article							20TH-CENTURY TEMPERATURE-CHANGE; OCEAN-ATMOSPHERE MODEL; CARBON UPTAKE; ATTRIBUTION; SENSITIVITY	The assessment of uncertainties in global warming projections is often based on expert judgement, because a number of key variables in climate change are poorly quantified. In particular, the sensitivity of climate to changing greenhouse-gas concentrations in the atmosphere and the radiative forcing effects by aerosols are not well constrained, leading to large uncertainties in global warming simulations(1). Here we present a Monte Carlo approach to produce probabilistic climate projections, using a climate model of reduced complexity. The uncertainties in the input parameters and in the model itself are taken into account, and past observations of oceanic and atmospheric warming are used to constrain the range of realistic model responses. We obtain a probability density function for the present-day total radiative forcing, giving 1.4 to 2.4 W m(-2) for the 5-95 per cent confidence range, narrowing the global-mean indirect aerosol effect to the range of 0 to -1.2 W m(-2). Ensemble simulations for two illustrative emission scenarios suggest a 40 per cent probability that global-mean surface temperature increase will exceed the range predicted by the Intergovernmental Panel on Climate Change (IPCC), but only a 5 per cent probability that warming will fall below that range.	Univ Bern, Inst Phys, CH-3012 Bern, Switzerland	University of Bern	Stocker, TF (corresponding author), Univ Bern, Inst Phys, Sidlerstr 5, CH-3012 Bern, Switzerland.	stocker@climate.unibe.ch	Joos, Fortunat/B-4118-2018; Stocker, Thomas/B-1273-2013; Plattner, Gian-Kasper/A-5245-2016; Knutti, Reto/B-8763-2008	Joos, Fortunat/0000-0002-9483-6030; Plattner, Gian-Kasper/0000-0002-3765-0045; Knutti, Reto/0000-0001-8303-6700				Allen MR, 2000, NATURE, V407, P617, DOI 10.1038/35036559; ALLEN MR, IN PRESS SURV GEOPHY; Andronova NG, 2001, J GEOPHYS RES-ATMOS, V106, P22605, DOI 10.1029/2000JD000259; Barnett TP, 2001, SCIENCE, V292, P270, DOI 10.1126/science.1058304; Boucher O, 2001, CLIM DYNAM, V18, P297, DOI 10.1007/s003820100185; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; Forest CE, 2002, SCIENCE, V295, P113, DOI 10.1126/science.1064419; Forest CE, 2000, GEOPHYS RES LETT, V27, P569, DOI 10.1029/1999GL010859; GREGORY JM, UNPUB J CLIM; HANSEN J, 1985, SCIENCE, V229, P857, DOI 10.1126/science.229.4716.857; Hegerl GC, 2000, CLIM DYNAM, V16, P737, DOI 10.1007/s003820000071; Houghton J. T., 2001, CLIMATE CHANGE 2001; Jones PD, 1999, REV GEOPHYS, V37, P173, DOI 10.1029/1999RG900002; Joos F, 2001, GLOBAL BIOGEOCHEM CY, V15, P891, DOI 10.1029/2000GB001375; KATTENBERG A, 1996, IPCC 2 SCI ASSESSMEN, P285; Knutti R, 2000, J PHYS OCEANOGR, V30, P2738, DOI 10.1175/1520-0485(2000)030<2738:TEOSSP>2.0.CO;2; Levitus S, 2001, SCIENCE, V292, P267, DOI 10.1126/science.1058154; Levitus S, 2000, SCIENCE, V287, P2225, DOI 10.1126/science.287.5461.2225; Nakicenovic N., 2000, SPECIAL REPORT EMISS; Plattner GK, 2001, TELLUS B, V53, P564, DOI 10.1034/j.1600-0889.2001.530504.x; Santer BD, 1996, NATURE, V382, P39, DOI 10.1038/382039a0; Schmittner A, 1999, J CLIMATE, V12, P1117, DOI 10.1175/1520-0442(1999)012<1117:TSOTTC>2.0.CO;2; Schmittner A, 2001, J CLIMATE, V14, P1055, DOI 10.1175/1520-0442(2001)014<1055:ASFOAM>2.0.CO;2; Schneider SH, 2001, NATURE, V411, P17, DOI 10.1038/35075167; STOCKER TF, 1992, J CLIMATE, V5, P773, DOI 10.1175/1520-0442(1992)005<0773:AZACOA>2.0.CO;2; Stott PA, 2000, SCIENCE, V290, P2133, DOI 10.1126/science.290.5499.2133; Stott PA, 2001, CLIM DYNAM, V17, P1, DOI 10.1007/PL00007924; Tett SFB, 1999, NATURE, V399, P569, DOI 10.1038/21164; Wigley TML, 2001, SCIENCE, V293, P451, DOI 10.1126/science.1061604	29	264	270	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	2002	416	6882					719	723		10.1038/416719a	http://dx.doi.org/10.1038/416719a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961550				2022-12-28	WOS:000175033500037
J	Layde, PM; Maas, LA; Teret, SP; Brasel, KJ; Kuhn, EM; Mercy, JA; Hargarten, SW				Layde, PM; Maas, LA; Teret, SP; Brasel, KJ; Kuhn, EM; Mercy, JA; Hargarten, SW			Patient safety efforts should focus on medical injuries	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE EVENTS; HOSPITALIZED-PATIENTS; CARE; PREVENTION		Med Coll Wisconsin, Dept Family & Community Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Surg, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Injury Res Ctr, Milwaukee, WI 53226 USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin; Johns Hopkins University	Layde, PM (corresponding author), Med Coll Wisconsin, Dept Family & Community Med, 8701 Watertown Planck Rd, Milwaukee, WI 53226 USA.			Cortes, Leslie/0000-0001-6394-8534	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS011893] Funding Source: NIH RePORTER; AHRQ HHS [U18HS11893] Funding Source: Medline; ODCDC CDC HHS [R49/CCR519614-01] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); ODCDC CDC HHS		Andrews LB, 1997, LANCET, V349, P309, DOI 10.1016/S0140-6736(96)08268-2; Baker S P, 1981, J Public Health Policy, V2, P235, DOI 10.2307/3342369; BRANCH P, 2000, BRIT MED J, V320, P759; Brasel KJ, 2000, ACAD EMERG MED, V7, P1298, DOI 10.1111/j.1553-2712.2000.tb00479.x; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; Camacho LAB, 1998, MED CARE, V36, P748, DOI 10.1097/00005650-199805000-00014; Chorba T L, 1991, Int J Technol Assess Health Care, V7, P296; Cole T, 2000, JAMA-J AM MED ASSOC, V284, P2175, DOI 10.1001/jama.284.17.2175; HADDON W, 1972, J TRAUM, V12, P193, DOI 10.1097/00005373-197203000-00002; HADDON W, 1980, PUBLIC HEALTH REP, V95, P411; Haddon W., 1964, ACCIDENT RES METHODS; Jeffe DB, 1997, INFECT CONT HOSP EP, V18, P710; Kennedy HL, 1999, CLIN CARDIOL, V22, P6, DOI 10.1002/clc.4960220106; Kohn LT, 2000, ERR IS HUMAN BUILDIN; Leape LL, 1998, JAMA-J AM MED ASSOC, V280, P1444, DOI 10.1001/jama.280.16.1444; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; *QUAL INT COORD TA, 2002, REP PRES MED ERR; Robertson L, 1998, INJURY EPIDEMIOLOGY; Runyan CW, 2000, AM J PREV MED, V18, P116, DOI 10.1016/S0749-3797(00)00147-1; TRINKOFF A, 1993, PUBLIC HEALTH REP, V108, P784; Weiss NS, 1986, CLIN EPIDEMIOLOGY ST; [No title captured]	22	73	73	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2002	287	15					1993	1997		10.1001/jama.287.15.1993	http://dx.doi.org/10.1001/jama.287.15.1993			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NC	11960544				2022-12-28	WOS:000174989800030
J	Cohen, MH; Eisenberg, DM				Cohen, MH; Eisenberg, DM			Potential physician malpractice liability associated with complementary and integrative medical therapies	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-BACK-PAIN; ALTERNATIVE MEDICINE; GINKGO-BILOBA; UNITED-STATES; TRIAL; SURVIVAL; PLACEBO	Physicians are increasingly grappling with medical liability issues as complementary and integrative health care practices are made available in conventional medical settings. This article proposes a framework in which physicians can assess potential malpractice liability issues in counseling patients about complementary and integrative therapies. The framework classifies complementary and integrative therapies according to whether the evidence reported in the medical and scientific literature supports both safety and efficacy; supports safety, but evidence regarding efficacy is inconclusive; supports efficacy, but evidence regarding safety is inconclusive; or indicates either serious risk or inefficacy. Clinical examples in each category help guide the clinician on how to counsel patients regarding use of complementary and alternative medical therapies in a given clinical situation. Specific strategies to reduce the risk for potential malpractice liability include the following: 1) determine the clinical risk level; 2) document the literature supporting the therapeutic choice; 3) provide adequate informed consent; 4) continue to monitor the patient conventionally; and 5) for referrals, inquire about the competence of the complementary and alternative medicine provider. This framework provides a basis for clinical decisions involving complementary and integrative care.	Harvard Univ, Sch Med, Div Res & Educ Complementary & Integrat Med Thera, Landmark Ctr, Boston, MA 02215 USA	Harvard University; Harvard Medical School	Cohen, MH (corresponding author), Harvard Univ, Sch Med, Div Res & Educ Complementary & Integrat Med Thera, Landmark Ctr, 401 Pk Dr,Suite 22A, Boston, MA 02215 USA.							ADAMS KE, IN PRESS ANN INTERN; [Anonymous], 1991, CA-CANCER J CLIN, V41, P187; BIGOS SJ, 1994, LOW BACK PROBLEMS AD; Cardini F, 1998, JAMA-J AM MED ASSOC, V280, P1580, DOI 10.1001/jama.280.18.1580; CHLEBOWSKI RT, 1992, BREAST CANCER RES TR, V20, P73; COHEN M, 2000, COMPLEMENTARY MED LE; COHEN MH, 1999, CURR PRACT MED, V2, P87; COHEN MH, 2001, DESKTOP GUIDE COMPLE, P404; Cohen Michael, 1998, COMPLEMENTARY ALTERN; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; EISENBERG DM, IN PRESS CREDENTIALI; Ernst E, 1999, J PAIN SYMPTOM MANAG, V17, P65, DOI 10.1016/S0885-3924(98)00129-8; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; Ernst E, 2001, ARCH INTERN MED, V161, P2288, DOI 10.1001/archinte.161.19.2288; Ezzo J, 2000, PAIN, V86, P217, DOI 10.1016/S0304-3959(99)00304-8; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; FURROW BR, 1995, HLTH LAW CASES MAT P; GLOCK MH, 1995, NIH PUB; Goldman P, 2001, ANN INTERN MED, V135, P594, DOI 10.7326/0003-4819-135-8_Part_1-200110160-00010; Holmes MD, 1999, CANCER, V86, P826, DOI 10.1002/(SICI)1097-0142(19990901)86:5&lt;826::AID-CNCR19&gt;3.0.CO;2-0; KENT GP, 1988, AM J EPIDEMIOL, V127, P591, DOI 10.1093/oxfordjournals.aje.a114834; Koes BW, 1996, SPINE, V21, P2860, DOI 10.1097/00007632-199612150-00013; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; LEE MH, 1990, KRUSENS HDB PHYSICAL; Linde K, 1996, BRIT MED J, V313, P253, DOI 10.1136/bmj.313.7052.253; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; MOERTEL CG, 1982, NEW ENGL J MED, V306, P201, DOI 10.1056/NEJM198201283060403; Nahin RL, 2001, BRIT MED J, V322, P161, DOI 10.1136/bmj.322.7279.161; Norred C L, 2000, AANA J, V68, P13; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Sheikh NM, 1997, ARCH INTERN MED, V157, P913, DOI 10.1001/archinte.157.8.913; Spencer JW, 1999, COMPLEMENTARY ALTERN, P3; SPIEGEL D, 1989, LANCET, V2, P888; SPIEGEL D, 1983, PSYCHOSOM MED, V45, P333, DOI 10.1097/00006842-198308000-00007; Studdert DM, 1998, JAMA-J AM MED ASSOC, V280, P1610, DOI 10.1001/jama.280.18.1610; Taylor MA, 2000, BMJ-BRIT MED J, V321, P471, DOI 10.1136/bmj.321.7259.471; Wetzel MS, 1998, JAMA-J AM MED ASSOC, V280, P784, DOI 10.1001/jama.280.9.784; White A., 2001, DESKTOP GUIDE COMPLE; WILLMS D, 1991, WESTERN J MED, V154, P736; Wilt TJ, 1998, JAMA-J AM MED ASSOC, V280, P1604, DOI 10.1001/jama.280.18.1604; WRIGHT RS, 1991, WESTERN J MED, V154, P102; 2001, COCHRANE LIB	48	103	104	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2002	136	8					596	603		10.7326/0003-4819-136-8-200204160-00009	http://dx.doi.org/10.7326/0003-4819-136-8-200204160-00009			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	543WY	11955028				2022-12-28	WOS:000175125800005
J	Saaddine, JB; Engelgau, MM; Beckles, GL; Gregg, EW; Thompson, TJ; Narayan, KMV				Saaddine, JB; Engelgau, MM; Beckles, GL; Gregg, EW; Thompson, TJ; Narayan, KMV			A diabetes report card for the United States: Quality of care in the 1990s	ANNALS OF INTERNAL MEDICINE			English	Article							GLYCEMIC CONTROL; ETHNIC-DIFFERENCES; HEALTH-CARE; IMPROVEMENT PROJECT; COST-EFFECTIVENESS; MEDICAL-CARE; ADULTS; RISK; DISEASE; CHOLESTEROL	Background: Improving diabetes care in the United States is a topic of concern. Objective: To document the quality of diabetes care during 1988-1995. Design: National population-based cross-sectional surveys. Setting: Third U.S. National Health and Nutrition Examination Survey (NHANES 111) (1988-1994) and the Behavioral Risk Factors Surveillance System (BRFSS) (1995). Participants: Participants in NHANES III (n = 1026) or BRFSS (n = 3059) who were 18 to 75 years of age and reported a physician diagnosis of diabetes. Women with gestational diabetes were excluded. Measurements: Glycemic control, blood pressure, low-density lipoprotein (LDL) cholesterol level, biannual cholesterol monitoring, and annual foot and dilated eye examination, as defined by the Diabetes Quality Improvement Project. Results: 18.0% of participants (95% Cl, 15.7% to 22.3%) had poor glycemic control (hemoglobin A,, level > 9.5%), and 65.7% (Cl, 62.0% to 69.4%) had blood pressure less than 140/90 mm Hg. Cholesterol was monitored biannually in 85.3% (Cl, 83.1% to 88.6%) of participants, but only 42.0% (Cl, 34.9% to 49.1%) had LDL cholesterol levels less than 3.4 mmol/L (<130 mg/dL). During the previous year, 63.3% (Cl, 59.6% to 67.0%) had a dilated eye examination and 54.8% (Cl, 51.3% to 58.3%) had a foot examination. When researchers controlled for age, sex, ethnicity, education, health insurance, insulin use, and duration of diabetes, insured persons were more likely than uninsured persons to have a dilated eye examination (66.5% [Cl, 62.6% to 70.4%]) vs. 43.2% [Cl, 29.5% to 56.9%]) and were less likely to have a hemoglobin A, level greater than or equal to 9.5%. Persons taking insulin were more likely than those who were not to have annual dilated eye examination (72.2% [Cl, 66.3% to 78.1%] vs. 57.6% [Cl, 53.7% to 61.5%]) and foot examination (67.3% [Cl, 61.4% to 73.2%] vs. 47.1% [Cl, 43.2% to 51.0%]) but were also more likely to have poor glycemic control (24.2% [Cl, 18.3% to 30.1%] vs. 15.5% [Cl, 11.6% to 19.4%]). Conclusions: According to U.S. data collected during 1988-m1995, a gap exists between recommended diabetes care and the care patients actually receive. These data offer a benchmark for monitoring changes in diabetes care.	CDCP, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Saaddine, JB (corresponding author), CDCP, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,MS-K10, Atlanta, GA 30341 USA.	zna2@cdc.gov	Narayan, K.M. Venkat/J-9819-2012	Narayan, K.M. Venkat/0000-0001-8621-5405; Gregg, Edward/0000-0003-2381-6822				Acton KJ, 2001, DIABETES CARE, V24, P22, DOI 10.2337/diacare.24.1.22; Ayanian JZ, 2000, JAMA-J AM MED ASSOC, V284, P2061, DOI 10.1001/jama.284.16.2061; Beckles GLA, 1998, DIABETES CARE, V21, P1432, DOI 10.2337/diacare.21.9.1432; Bowlin SJ, 1996, J CLIN EPIDEMIOL, V49, P511, DOI 10.1016/0895-4356(96)00010-8; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; Bridges RB, 1996, J PERIODONTOL, V67, P1185, DOI 10.1902/jop.1996.67.11.1185; Cowie CC, 1997, DIABETES CARE, V20, P142, DOI 10.2337/diacare.20.2.142; Curb JD, 2002, DIABETES CARE, V25, P386; Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766; EBERHARDT MS, 1994, J CLIN EPIDEMIOL, V47, P1181, DOI 10.1016/0895-4356(94)90105-8; Engelgau MM, 1998, DIABETES CARE, V21, P2062, DOI 10.2337/diacare.21.12.2062; Fleming BB, 2001, DIABETES CARE, V24, P1815, DOI 10.2337/diacare.24.10.1815; Fowles JB, 1999, INT J QUAL HEALTH C, V11, P407, DOI 10.1093/intqhc/11.5.407; FRAZIER E, 1992, CHRONIC DIS DATA HDB; Gerstein HC, 2000, LANCET, V355, P253; Goldberg RB, 1998, CIRCULATION, V98, P2513, DOI 10.1161/01.CIR.98.23.2513; Gregg EW, 1999, DIABETES CARE, V22, P1734; Harris EL, 1999, DIABETES CARE, V22, P779, DOI 10.2337/diacare.22.5.779; Harris MI, 1996, ANN INTERN MED, V124, P117, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00007; Harris MI, 2000, DIABETES CARE, V23, P754, DOI 10.2337/diacare.23.6.754; Harris MI, 1999, DIABETES CARE, V22, P403, DOI 10.2337/diacare.22.3.403; Harris MI, 1999, DIABETES CARE, V22, P1679, DOI 10.2337/diacare.22.10.1679; Harris MI, 2001, DIABETES CARE, V24, P454, DOI 10.2337/diacare.24.3.454; Institute of Medicine, 2001, CROSSING QUALITY CHA; JAVITT JC, 1994, DIABETES CARE, V17, P909, DOI 10.2337/diacare.17.8.909; Jonsson B, 1999, DIABETOLOGIA, V42, P1293, DOI 10.1007/s001250051441; KENNY SJ, 1993, DIABETES CARE, V16, P1507, DOI 10.2337/diacare.16.11.1507; KORN EL, 1999, WILEY S PRO STAT SUR, P1; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; Martin WE, 1999, CLIN GERIATR MED, V15, P339; McCabe CJ, 1998, DIABETIC MED, V15, P80, DOI 10.1002/(SICI)1096-9136(199801)15:1<80::AID-DIA517>3.0.CO;2-K; Mealey B, 1999, J PERIODONTOL, V70, P935; Narayan KMV, 2000, DIABETES CARE, V23, P1794, DOI 10.2337/diacare.23.12.1794; Narayan KMV, 2000, DIABETES RES CLIN PR, V50, pS77; *NAT I DIAB DIG KI, 2001, TRANSL RES PREV CONT; Nathan DM, 1996, JAMA-J AM MED ASSOC, V276, P1409; National Center for Health Statistics, 1996, NHANES 3 REF MAN REP; Nichol KL, 1998, ARCH INTERN MED, V158, P1769, DOI 10.1001/archinte.158.16.1769; O'Connor PJ, 1998, J FAM PRACTICE, V47, P290; Pyorala K, 1997, DIABETES CARE, V20, P614, DOI 10.2337/diacare.20.4.614; Quickel KE, 1996, ANN INTERN MED, V124, P160, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00016; Ray NF, 1998, DIABETES CARE, V21, P296; *RES RRIANGL I, 2001, SUDAAN US MAN REL 8; SAS Institute, 1990, SAS PROC GUID VERS 6; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, pS111; Stearne MR, 1998, BMJ-BRIT MED J, V317, P720; Stearne MR, 1998, BRIT MED J, V317, P713; Stearne MR, 1998, BMJ-BRIT MED J, V317, P703; STEIN AD, 1995, AM J EPIDEMIOL, V141, P1097, DOI 10.1093/oxfordjournals.aje.a117375; STEIN AD, 1993, AM J PUBLIC HEALTH, V83, P1768, DOI 10.2105/AJPH.83.12.1768; Taylor GW, 1996, J PERIODONTOL, V67, P1085, DOI 10.1902/jop.1996.67.10s.1085; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; *US DEP HHS, 1997, DIAB SURV 1997; *US DEP HHS, 1997, NAT HLTH NUTR EX SUR; US Department of Health and Human Services, 1994, PLAN OP 3 NAT HLTH N; 1999, MMWR MORB MORTAL WKL, V48, P961	58	440	442	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2002	136	8					565	574		10.7326/0003-4819-136-8-200204160-00005	http://dx.doi.org/10.7326/0003-4819-136-8-200204160-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	543WY	11955024				2022-12-28	WOS:000175125800001
J	Tannock, IF				Tannock, IF			Eradication of a disease: how we cured symptomless prostate cancer	LANCET			English	Editorial Material							ACID-PHOSPHATASE; RECENT DECLINES; ANTIGEN; CARCINOMA; MORTALITY; SURVEILLANCE; HISTORY		Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Tannock, IF (corresponding author), Princess Margaret Hosp, Dept Med Oncol & Hematol, Toronto, ON M5G 2M9, Canada.	ian.tannock@uhn.on.ca						[Anonymous], 1997, Br J Urol, V79, P235; Brawley OW, 1997, CANCER-AM CANCER SOC, V80, P1857, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1857::AID-CNCR26>3.0.CO;2-3; COLEMAN CN, 1994, INT J RADIAT ONCOL, V28, P303, DOI 10.1016/0360-3016(94)90171-6; Etzioni R, 1998, AM J EPIDEMIOL, V148, P775; Etzioni R, 1999, J NATL CANCER I, V91, P1033, DOI 10.1093/jnci/91.12.1033; Hugosson J, 2000, BJU INT, V85, P1078, DOI 10.1046/j.1464-410x.2000.00679.x; Iselin CE, 1999, J UROLOGY, V161, P163, DOI 10.1016/S0022-5347(01)62088-3; Klotz LH, 1997, UROLOGY, V50, P831, DOI 10.1016/S0090-4295(97)00490-1; Pound CR, 1999, JAMA-J AM MED ASSOC, V281, P1591, DOI 10.1001/jama.281.17.1591; SEAMONDS B, 1986, UROLOGY, V28, P472, DOI 10.1016/0090-4295(86)90146-9; Shibata A, 1998, J NATL CANCER I, V90, P1230, DOI 10.1093/jnci/90.16.1230; SIDDALL JK, 1986, EUR UROL, V12, P123; Smart CR, 1997, CANCER, V80, P1835, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1835::AID-CNCR23>3.0.CO;2-5; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STEIN BS, 1982, AM J SURG PATHOL, V6, P553, DOI 10.1097/00000478-198209000-00007; Talcott JA, 1998, J CLIN ONCOL, V16, P275, DOI 10.1200/JCO.1998.16.1.275; Tarone RE, 2000, EPIDEMIOLOGY, V11, P167, DOI 10.1097/00001648-200003000-00014; WANG TY, 1986, ANN CLIN LAB SCI, V16, P461; YANTANI R, 1982, INT J CANCER, V29, P611; ZIETMAN AL, 1993, CANCER, V71, P959, DOI 10.1002/1097-0142(19930201)71:3+<959::AID-CNCR2820711411>3.0.CO;2-L	20	20	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	2002	359	9314					1341	1342		10.1016/S0140-6736(02)08278-8	http://dx.doi.org/10.1016/S0140-6736(02)08278-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965297				2022-12-28	WOS:000174989700033
J	McCabe, ERB				McCabe, ERB			Hirschsprung's disease: dissecting complexity in a pathogenetic network	LANCET			English	Editorial Material							SIMPLE MENDELIAN DISORDERS; TRAITS; GENES; RET		Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	McCabe, ERB (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Pediat, Los Angeles, CA 90095 USA.							Bolk S, 2000, P NATL ACAD SCI USA, V97, P268, DOI 10.1073/pnas.97.1.268; Borrego S, 1998, J CLIN ENDOCR METAB, V83, P3361, DOI 10.1210/jc.83.9.3361; Dipple KM, 2001, MOL GENET METAB, V74, P45, DOI 10.1006/mgme.2001.3227; Dipple KM, 2000, AM J HUM GENET, V66, P1729, DOI 10.1086/302938; Dipple KM, 2000, MOL GENET METAB, V71, P43, DOI 10.1006/mgme.2000.3052; Hofstra RMW, 1997, EUR J HUM GENET, V5, P180, DOI 10.1159/000484760; MAHAFFEY SM, 1990, J PEDIATR SURG, V25, P101, DOI 10.1016/S0022-3468(05)80172-1; Scriver CR, 1999, TRENDS GENET, V15, P267, DOI 10.1016/S0168-9525(99)01761-8; VERDY M, 1982, J PEDIATR GASTR NUTR, V1, P603, DOI 10.1097/00005176-198212000-00027; Vladutiu GD, 2001, MOL GENET METAB, V74, P51, DOI 10.1006/mgme.2001.3240; Vockley J, 2000, MOL GENET METAB, V71, P10, DOI 10.1006/mgme.2000.3066	11	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1169	1170		10.1016/S0140-6736(02)08249-1	http://dx.doi.org/10.1016/S0140-6736(02)08249-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955531				2022-12-28	WOS:000174846300003
J	Nishihama, R; Soyano, T; Ishikawa, M; Araki, S; Tanaka, H; Asada, T; Irie, K; Ito, M; Terada, M; Banno, H; Yamazaki, Y; Machida, Y				Nishihama, R; Soyano, T; Ishikawa, M; Araki, S; Tanaka, H; Asada, T; Irie, K; Ito, M; Terada, M; Banno, H; Yamazaki, Y; Machida, Y			Expansion of the cell plate in plant cytokinesis requires a kinesin-like protein/MAPKKK complex	CELL			English	Article							KINASE KINASE KINASE; TOBACCO BY-2 CELLS; MAP KINASE; CENP-E; SIGNAL-TRANSDUCTION; YEAST; ARABIDOPSIS; ACTIVATION; GENE; ENCODES	The tobacco mitogen-activated protein kinase kinase kinase NPK1 regulates lateral expansion of the cell plate at cytokinesis. Here, we show that the kinesin-like proteins NACK1 and NACK2 act as activators of NPK1. Biochemical analysis suggests that direct binding of NACK1 to NPK1 stimulates kinase activity. NACK1 is accumulated specifically in M phase and colocalized with NPK1 at the phragmoplast equator. Overexpression of a truncated NACK1 protein that lacks the motor domain disrupts NPK1 concentration at the phragmoplast equator and cell plate formation. Incomplete cytokinesis is also observed when expression of NACK1 and NACK2 is repressed by virus-induced gene silencing and in embryonic cells from Arabidopsis mutants in which a NACK1 ortholog is disrupted. Thus, we conclude that expansion of the cell plate requires NACK1/2 to regulate the activity and localization of NPK1.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Osaka Univ, Grad Sch Sci, Dept Biol, Toyonaka, Osaka 5600043, Japan	Nagoya University; Osaka University	Machida, Y (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.		Nishihama, Ryuichi/X-8623-2019; Ishikawa, Masaki/Q-7598-2018; Ishikawa, Masaki/AAC-8162-2022	Nishihama, Ryuichi/0000-0002-7032-732X; Ishikawa, Masaki/0000-0002-6491-5539; Ishikawa, Masaki/0000-0002-6491-5539; Tanaka, Hirokazu/0000-0003-4414-0649; Soyano, Takashi/0000-0002-0620-6734				Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Angell SM, 1999, PLANT J, V20, P357, DOI 10.1046/j.1365-313X.1999.t01-1-00597.x; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; ASADA T, 1994, J CELL SCI, V107, P2249; Asada T, 1997, J CELL SCI, V110, P179; Assaad FF, 2001, J CELL BIOL, V152, P531, DOI 10.1083/jcb.152.3.531; BANNO H, 1993, MOL CELL BIOL, V13, P4745, DOI 10.1128/MCB.13.8.4745; BAULCOMBE DC, 1995, PLANT J, V7, P1045, DOI 10.1046/j.1365-313X.1995.07061045.x; Bogre L, 1999, PLANT CELL, V11, P101, DOI 10.1105/tpc.11.1.101; Calderini O, 1998, J CELL SCI, V111, P3091; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; EMIARTI E, 2001, DEVELOPMENT, V128, P1771; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gunning B. E. S., 1982, CYTOSKELETON PLANT G, P229; Heese M, 1998, CURR OPIN PLANT BIOL, V1, P486, DOI 10.1016/S1369-5266(98)80040-X; Hunter AW, 2000, J CELL SCI, V113, P4379; Ingram R, 1999, PLANT CELL, V11, P1047, DOI 10.1105/tpc.11.6.1047; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Ito M, 1998, PLANT CELL, V10, P331; Ito M, 2001, PLANT CELL, V13, P1891, DOI 10.1105/tpc.13.8.1891; KAKIMOTO T, 1988, Protoplasma Supplementum, V2, P95; Kishimoto K, 2000, J BIOL CHEM, V275, P7359, DOI 10.1074/jbc.275.10.7359; Krysan PJ, 1999, PLANT CELL, V11, P2283, DOI 10.1105/tpc.11.12.2283; LEE KS, 1995, MOL CELL BIOL, V15, P7143; Lee YRJ, 2001, PLANT CELL, V13, P2427, DOI 10.1105/tpc.13.11.2427; Lloyd C, 2001, NAT REV MOL CELL BIO, V2, P40, DOI 10.1038/35048005; Lukowitz W, 1996, CELL, V84, P61, DOI 10.1016/S0092-8674(00)80993-9; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149; Nishihama R, 2001, CURR OPIN PLANT BIOL, V4, P507, DOI 10.1016/S1369-5266(00)00208-9; Nishihama R, 2001, GENE DEV, V15, P352, DOI 10.1101/gad.863701; Nishihama R, 1997, PLANT J, V12, P39, DOI 10.1046/j.1365-313X.1997.12010039.x; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Raich WB, 1998, MOL BIOL CELL, V9, P2037, DOI 10.1091/mbc.9.8.2037; Sakurai H, 2000, FEBS LETT, V474, P141, DOI 10.1016/S0014-5793(00)01588-X; SAMUELS AL, 1995, J CELL BIOL, V130, P1345, DOI 10.1083/jcb.130.6.1345; Severson AF, 2000, CURR BIOL, V10, P1162, DOI 10.1016/S0960-9822(00)00715-6; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Staehlin LA, 1996, CELL, V84, P821, DOI 10.1016/S0092-8674(00)81060-0; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Strompen G, 2002, CURR BIOL, V12, P153, DOI 10.1016/S0960-9822(01)00655-8; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tanaka H, 2001, DEVELOPMENT, V128, P4681; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; YASUHARA H, 1993, PLANT CELL PHYSIOL, V34, P21; Yasuhara H, 2000, PLANT CELL PHYSIOL, V41, P300, DOI 10.1093/pcp/41.3.300; YEN TJ, 1991, EMBO J, V10, P1245, DOI 10.1002/j.1460-2075.1991.tb08066.x; YEN TJ, 1992, NATURE, V359, P536, DOI 10.1038/359536a0; Zecevic M, 1998, J CELL BIOL, V142, P1547, DOI 10.1083/jcb.142.6.1547; Zuo JR, 2000, PLANT CELL, V12, P1137, DOI 10.1105/tpc.12.7.1137	54	176	194	2	15	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	APR 5	2002	109	1					87	99		10.1016/S0092-8674(02)00691-8	http://dx.doi.org/10.1016/S0092-8674(02)00691-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955449	Bronze			2022-12-28	WOS:000174888300011
J	Rideout, WM; Hochedlinger, K; Kyba, M; Daley, GQ; Jaenisch, R				Rideout, WM; Hochedlinger, K; Kyba, M; Daley, GQ; Jaenisch, R			Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy	CELL			English	Article							EMBRYONIC STEM-CELLS; IN-VITRO; HEMATOPOIETIC-CELLS; ES CELLS; MICE; DIFFERENTIATION; OVEREXPRESSION; ENGRAFTMENT; DERIVATION; GENERATION	Immune-deficient Rag2(-/-) mice were used as nuclear donors for transfer into enucleated oocytes, and the resulting blastocysts were cultured to isolate an isogenic embryonic stem cell line. One of the mutated alleles in the Rag2(-/-) ES cells was repaired by homologous recombination, thereby restoring normal Rag2 gene structure. Mutant mice were treated with the repaired ES cells in two ways. (1) Immune-competent mice were generated from the repaired ES cells by tetraploid embryo complementation and were used as bone marrow donors for transplantation. (2) Hematopoietic precursors were derived by in vitro differentiation from the repaired ES cells and engrafted into mutant mice. Mature myeloid and lymphoid cells as well as immunoglobulins became detectable 3-4 weeks after transplantation. Our results establish a paradigm for the treatment of a genetic disorder by combining therapeutic cloning with gene therapy.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Vienna, A-1010 Vienna, Austria; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Hematol Oncol, Boston, MA 02115 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Vienna; Harvard University; Harvard Medical School; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT)	Jaenisch, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	jaenisch@wi.mit.edu		Kyba, Michael/0000-0002-5579-7534	NATIONAL CANCER INSTITUTE [R01CA086991, R37CA084198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059279] Funding Source: NIH RePORTER; NCI NIH HHS [5-R37-CA84198, CA86991] Funding Source: Medline; NIDDK NIH HHS [DK59279] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; Brun A, 2001, BLOOD, V98, p66A; Burdon T, 1999, DEV BIOL, V210, P30, DOI 10.1006/dbio.1999.9265; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cibelli JB, 1998, NAT BIOTECHNOL, V16, P642, DOI 10.1038/nbt0798-642; Colman A, 2000, TRENDS BIOTECHNOL, V18, P192, DOI 10.1016/S0167-7799(00)01434-7; Cumano A, 2001, IMMUNITY, V15, P477, DOI 10.1016/S1074-7613(01)00190-X; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; Doevendans PA, 2000, J MOL CELL CARDIOL, V32, P839, DOI 10.1006/jmcc.2000.1128; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; Hochedlinger K, 2002, NATURE, V415, P1035, DOI 10.1038/nature718; Hole N, 1996, BLOOD, V88, P1266, DOI 10.1182/blood.V88.4.1266.bloodjournal8841266; HUANG H, 1993, P NATL ACAD SCI USA, V90, P10110, DOI 10.1073/pnas.90.21.10110; Kaufman DS, 2001, P NATL ACAD SCI USA, V98, P10716, DOI 10.1073/pnas.191362598; Kawase E, 2000, GENESIS, V28, P156, DOI 10.1002/1526-968X(200011/12)28:3/4<156::AID-GENE100>3.3.CO;2-K; Kehat I, 2001, J CLIN INVEST, V108, P407, DOI 10.1172/JCI12131; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KUNG SKP, 1995, J IMMUNOL, V154, P1624; Kyba M, 2002, CELL, V109, P29, DOI 10.1016/S0092-8674(02)00680-3; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Lee LA, 1996, TRANSPLANTATION, V61, P125, DOI 10.1097/00007890-199601150-00024; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Mazurier F, 1999, J INTERF CYTOK RES, V19, P533, DOI 10.1089/107999099313983; MULLER AM, 1993, DEVELOPMENT, V118, P1343; Munsie MJ, 2000, CURR BIOL, V10, P989, DOI 10.1016/S0960-9822(00)00648-5; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Notarangelo LD, 1999, CURR OPIN IMMUNOL, V11, P435, DOI 10.1016/S0952-7915(99)80073-9; Perlingeiro RCR, 2001, DEVELOPMENT, V128, P4597; Potocnik AJ, 1997, IMMUNOL LETT, V57, P131, DOI 10.1016/S0165-2478(97)00089-8; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Rideout WM, 2001, SCIENCE, V293, P1093, DOI 10.1126/science.1063206; Rozen S, 1998, PRIMER3; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; Taniguchi M, 1998, NUCLEIC ACIDS RES, V26, P679, DOI 10.1093/nar/26.2.679; Vogelstein B, 2002, SCIENCE, V295, P1237, DOI 10.1126/science.1070247; Wakayama T, 2001, SCIENCE, V292, P740, DOI 10.1126/science.1059399; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, P NATL ACAD SCI USA, V96, P14984, DOI 10.1073/pnas.96.26.14984; Wang ZQ, 1997, MECH DEVELOP, V62, P137, DOI 10.1016/S0925-4773(97)00655-2; Whitehurst CE, 1999, IMMUNITY, V10, P313, DOI 10.1016/S1074-7613(00)80031-X; WILES MV, 1991, DEVELOPMENT, V111, P259; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129	47	430	458	2	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 5	2002	109	1					17	27		10.1016/S0092-8674(02)00681-5	http://dx.doi.org/10.1016/S0092-8674(02)00681-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	539TY	11955443	Bronze			2022-12-28	WOS:000174888300005
J	Sakurai, T; Mihaliuk, E; Chirila, F; Showalter, K				Sakurai, T; Mihaliuk, E; Chirila, F; Showalter, K			Design and control of wave propagation patterns in excitable media	SCIENCE			English	Article							PHOTOSENSITIVITY; SENSITIVITY; DYNAMICS; FEEDBACK; MODEL	Intricate patterns of wave propagation are exhibited in a chemical reaction-diffusion system with spatiotemporal feedback, Wave behavior is controlled by feedback-regulated excitability gradients that guide propagation in specified directions. Waves interacting with boundaries and with other waves are observed when interaction terms are incorporated into the control algorithm. Spatiotemporal feedback offers wide flexibility for designing and controlling wave behavior in excitable media.	W Virginia Univ, Dept Chem, Morgantown, WV 26506 USA	West Virginia University	Showalter, K (corresponding author), W Virginia Univ, Dept Chem, Morgantown, WV 26506 USA.	kshowalt@wvu.edu	Showalter, Kenneth/P-3460-2015	Showalter, Kenneth/0000-0003-3443-9911				ARKIN A, 1995, J PHYS CHEM-US, V99, P970, DOI 10.1021/j100003a020; CHIRILA F, UNPUB; Eigen M., 1963, TECHNIQUES ORGANIC 2, P895; FIELD RJ, 1974, J CHEM PHYS, V60, P1877, DOI 10.1063/1.1681288; Gluckman BJ, 2001, J NEUROSCI, V21, P590, DOI 10.1523/JNEUROSCI.21-02-00590.2001; GRILL S, 1995, PHYS REV LETT, V75, P3368, DOI 10.1103/PhysRevLett.75.3368; HOOVERMAN RH, 1963, J APPL PHYS, V34, P3505, DOI 10.1063/1.1729248; Kadar S, 1997, J PHYS CHEM A, V101, P8200, DOI 10.1021/jp971937y; Kim M, 2001, SCIENCE, V292, P1357, DOI 10.1126/science.1059478; KRUG HJ, 1990, J PHYS CHEM-US, V94, P4862, DOI 10.1021/j100375a021; KUHNERT L, 1986, NATURE, V319, P393, DOI 10.1038/319393a0; Li G, 1996, PHYS REV LETT, V77, P2105, DOI 10.1103/PhysRevLett.77.2105; Lin AL, 2000, PHYS REV E, V62, P3790, DOI 10.1103/PhysRevE.62.3790; Mihaliuk E, 2001, FARADAY DISCUSS, V120, P383, DOI 10.1039/b103431f; Mihaliuk E, 1999, J PHYS CHEM A, V103, P8246, DOI 10.1021/jp991373t; NOSZTICZIUS Z, 1987, NATURE, V329, P619, DOI 10.1038/329619a0; Petrov V, 1997, NATURE, V388, P655, DOI 10.1038/41732; Sendina-Nadal I, 2001, PHYS REV LETT, V86, P1646, DOI 10.1103/PhysRevLett.86.1646; STEINBOCK O, 1993, NATURE, V366, P322, DOI 10.1038/366322a0; TYSON JJ, 1980, J CHEM PHYS, V73, P2224, DOI 10.1063/1.440418; Vanag VK, 2000, J PHYS CHEM A, V104, P8207, DOI 10.1021/jp001418m; Vanag VK, 2000, NATURE, V406, P389, DOI 10.1038/35019038; Wolff J, 2001, SCIENCE, V294, P134, DOI 10.1126/science.1063597; ZAIKIN AN, 1970, NATURE, V225, P535, DOI 10.1038/225535b0	24	166	173	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 14	2002	296	5575					2009	2012		10.1126/science.1071265	http://dx.doi.org/10.1126/science.1071265			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	563UD	11988535				2022-12-28	WOS:000176273300047
J	Rambukkana, A; Zanazzi, G; Tapinos, N; Salzer, JL				Rambukkana, A; Zanazzi, G; Tapinos, N; Salzer, JL			Contact-dependent demyelination by Mycobacterium leprae in the absence of immune cells	SCIENCE			English	Article							PERIPHERAL-NERVE PREDILECTION; LEPROUS NEUROPATHY; DAMAGE	Demyelination results in severe disability in many neurodegenerative diseases and nervous system infections, and it is typically mediated by inflammatory responses. Mycobacterium leprae, the causative organism of leprosy, induced rapid demyelination by a contact-dependent mechanism in the absence of immune cells in an in vitro nerve tissue culture model and in Rag1-knockout (Rag1(-/-)) mice, which tack mature B and T lymphocytes. Myelinated Schwann cells were resistant to M. leprae invasion but undergo demyelination upon bacterial attachment, whereas nonmyelinated Schwann cells harbor intracellular M. leprae in large numbers. During M. leprae-induced demyelination, Schwann cells proliferate significantly both in vitro and in vivo and generate a more nonmyelinated phenotype, thereby securing the intracellular niche for M. leprae.	Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, New York, NY 10021 USA; NYU, Med Ctr, Dept Cell Biol, New York, NY 10016 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA	Rockefeller University; New York University; New York University	Rambukkana, A (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis & Immunol, 1230 York Ave, New York, NY 10021 USA.			rambukkana, anura/0000-0002-6286-9145; Salzer, James/0000-0001-9126-7197				BRENNAN PJ, 1989, REV INFECT DIS, V11, P420; Cajal RS., 1928, DEGENERATION REGENER; Curtiss R, 2001, LEPROSY REV, V72, P8; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; HUNTER SW, 1981, J BACTERIOL, V147, P728, DOI 10.1128/JB.147.3.728-735.1981; JACOBS JM, 1987, J NEUROL SCI, V79, P301, DOI 10.1016/0022-510X(87)90237-1; JOB CK, 1989, INT J LEPROSY, V57, P532; JOHNSON PC, 1997, TXB NEUROPATHOLOGY, P1233; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; PLEASURE DE, 1972, ARCH NEUROL-CHICAGO, V26, P289, DOI 10.1001/archneur.1972.00490100019001; Rambukkana A, 1997, CELL, V88, P811, DOI 10.1016/S0092-8674(00)81927-3; Rambukkana A, 2001, CURR OPIN MICROBIOL, V4, P21, DOI 10.1016/S1369-5274(00)00159-4; RAMBUKKANA A, UNPUB; Scherer S.S., 1996, GLIAL CELL DEV, P165; Schmid CD, 2000, J NEUROSCI, V20, P729, DOI 10.1523/JNEUROSCI.20-02-00729.2000; Shetty V P, 1980, Lepr India, V52, P5; SHETTY VP, 1988, J NEUROL SCI, V88, P115, DOI 10.1016/0022-510X(88)90210-9; SHETTY VP, 1994, ACTA NEUROPATHOL, V88, P300; SHETTY VP, 1993, INT J LEPROSY, V61, P70; STONER GL, 1979, LANCET, V10, P994; Waxman SG, 1998, NEW ENGL J MED, V338, P323, DOI 10.1056/NEJM199801293380510; Wingerchuk DM, 2001, LAB INVEST, V81, P263, DOI 10.1038/labinvest.3780235	23	135	138	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					927	931		10.1126/science.1067631	http://dx.doi.org/10.1126/science.1067631			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988579				2022-12-28	WOS:000175442500049
J	Thompson, DWJ; Solomon, S				Thompson, DWJ; Solomon, S			Interpretation of recent Southern Hemisphere climate change	SCIENCE			English	Article							OZONE DEPLETION; GREENHOUSE-GAS; EXTRATROPICAL CIRCULATION; ANTARCTIC OZONE; ANNULAR MODES; TRENDS; OSCILLATION; TEMPERATURES; VARIABILITY; REANALYSIS	Climate variability in the high-latitude Southern Hemisphere (SH) is dominated by the SH annular mode, a large-scale pattern of variability characterized by fluctuations in the strength of the circumpolar vortex. We present evidence that recent trends in the SH tropospheric circulation can be interpreted as a bias toward the high-index polarity of this pattern, with stronger westerly flow encircling the polar cap. It is argued that the largest and most significant tropospheric trends can be traced to recent trends in the lower stratospheric polar vortex, which are due largely to photochemical ozone losses. During the summer-fall season, the trend toward stronger circumpolar flow has contributed substantially to the observed warming over the Antarctic Peninsula and Patagonia and to the cooling over eastern Antarctica and the Antarctic plateau.	Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA; NOAA, Aeron Lab, Boulder, CO 80305 USA	Colorado State University; National Oceanic Atmospheric Admin (NOAA) - USA	Thompson, DWJ (corresponding author), Colorado State Univ, Dept Atmospher Sci, Foothills Campus, Ft Collins, CO 80523 USA.	davet@atmos.colostate.edu	Thompson, David W J/F-9627-2012	Thompson, David W J/0000-0002-5413-4376				ANGELL JK, 2000, SO HEMISPHERE WINTER; [Anonymous], 1999, 44 WORLD MET ORG; Baldwin MP, 1999, J GEOPHYS RES-ATMOS, V104, P30937, DOI 10.1029/1999JD900445; Baldwin MP, 2001, SCIENCE, V294, P581, DOI 10.1126/science.1063315; CHARNEY JG, 1961, J GEOPHYS RES, V66, P83, DOI 10.1029/JZ066i001p00083; Forster PMD, 1999, GEOPHYS RES LETT, V26, P3309, DOI 10.1029/1999GL010487; Fyfe JC, 1999, GEOPHYS RES LETT, V26, P1601, DOI 10.1029/1999GL900317; Gong DY, 1999, GEOPHYS RES LETT, V26, P459, DOI 10.1029/1999GL900003; HANNA E, 1999, WEATHER, V54, P71; Hartmann DL, 1998, J ATMOS SCI, V55, P1303, DOI 10.1175/1520-0469(1998)055<1303:WDZFVI>2.0.CO;2; Hoerling MP, 2001, SCIENCE, V292, P90, DOI 10.1126/science.1058582; Hofmann DJ, 1997, J GEOPHYS RES-ATMOS, V102, P8931, DOI 10.1029/96JD03749; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; HURRELL JW, 1994, TELLUS A, V46, P325, DOI 10.1034/j.1600-0870.1994.t01-1-00007.x; Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 SCI; Jacobs SS, 1997, J CLIMATE, V10, P697, DOI 10.1175/1520-0442(1997)010<0697:CVITAA>2.0.CO;2; JONES AE, 1995, NATURE, V376, P409, DOI 10.1038/376409a0; JONES PD, 1994, J CLIMATE, V7, P1794, DOI 10.1175/1520-0442(1994)007<1794:HSATVA>2.0.CO;2; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Karoly D. J., 1990, Tellus, Series A (Dynamic Meteorology and Oceanography), V42A, P41, DOI 10.1034/j.1600-0870.1990.00005.x; Kidson JW, 1988, J CLIMATE, V1, P183, DOI 10.1175/1520-0442(1988)001<0183:IOTSHZ>2.0.CO;2; Kushner PJ, 2001, J CLIMATE, V14, P2238, DOI 10.1175/1520-0442(2001)014<0001:SHACRT>2.0.CO;2; Marshall GJ, 2002, J CLIMATE, V15, P659, DOI 10.1175/1520-0442(2002)015<0659:TIAGHA>2.0.CO;2; MARSHALL GJ, IN PRESS INT J CLIMA; Miller HL, 1999, J GEOPHYS RES-ATMOS, V104, P18769, DOI 10.1029/1999JD900301; PARKINSON C, IN PRESS ANN GLACIOL; PARKINSON CL, IN PRESS WEATHER; Randel WJ, 1999, J CLIMATE, V12, P1467, DOI 10.1175/1520-0442(1999)012<1467:COTAAA>2.0.CO;2; Roscoe HK, 1997, SCIENCE, V278, P93, DOI 10.1126/science.278.5335.93; Sexton DMH, 2001, GEOPHYS RES LETT, V28, P3697, DOI 10.1029/2001GL013376; Shindell DT, 2001, J GEOPHYS RES-ATMOS, V106, P7193, DOI 10.1029/2000JD900547; Shindell DT, 1998, NATURE, V392, P589, DOI 10.1038/33385; Shindell DT, 1999, NATURE, V399, P452, DOI 10.1038/20905; SHIOTANI M, 1990, J METEOROL SOC JPN, V68, P461, DOI 10.2151/jmsj1965.68.4_461; Stammerjohn SE, 1997, CLIMATIC CHANGE, V37, P617, DOI 10.1023/A:1005331731034; Thompson DWJ, 2000, J CLIMATE, V13, P1018, DOI 10.1175/1520-0442(2000)013<1018:AMITEC>2.0.CO;2; Thompson DWJ, 2000, J CLIMATE, V13, P1000, DOI 10.1175/1520-0442(2000)013<1018:AMITEC>2.0.CO;2; Thompson DWJ, 1998, GEOPHYS RES LETT, V25, P1297, DOI 10.1029/98GL00950; THOMPSON DWJ, IN PRESS J CLIMATE; TRENBERTH KE, 1989, J CLIMATE, V2, P1196, DOI 10.1175/1520-0442(1989)002<1196:TTATSP>2.0.CO;2; VANLOON H, 1978, MON WEATHER REV, V106, P296, DOI 10.1175/1520-0493(1978)106<0296:TSIWTB>2.0.CO;2; Vaughan DG, 1996, NATURE, V379, P328, DOI 10.1038/379328a0; Vaughan DG, 2001, SCIENCE, V293, P1777, DOI 10.1126/science.1065116; Waugh DW, 1999, J GEOPHYS RES-ATMOS, V104, P27191, DOI 10.1029/1999JD900795; Zhou ST, 2000, GEOPHYS RES LETT, V27, P1123, DOI 10.1029/1999GL011018	45	1331	1395	8	310	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	2002	296	5569					895	899		10.1126/science.1069270	http://dx.doi.org/10.1126/science.1069270			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988571				2022-12-28	WOS:000175442500040
J	Assaf, C; Geilen, CC; Tebbe, B; Schulze, K; Orfanos, CE				Assaf, C; Geilen, CC; Tebbe, B; Schulze, K; Orfanos, CE			Cutaneous mastocytosis	LANCET			English	Editorial Material									Free Univ Berlin, Univ Med Ctr Benjamin Franklin, Dept Dermatol, D-14195 Berlin, Germany; Free Univ Berlin, Univ Med Ctr Benjamin Franklin, Dept Internal Med, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Assaf, C (corresponding author), Free Univ Berlin, Univ Med Ctr Benjamin Franklin, Dept Dermatol, D-14195 Berlin, Germany.								0	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1465	1465		10.1016/S0140-6736(02)08432-5	http://dx.doi.org/10.1016/S0140-6736(02)08432-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988244				2022-12-28	WOS:000175279100008
J	Jodar, L; Feavers, IM; Salisbury, D; Granoff, DM				Jodar, L; Feavers, IM; Salisbury, D; Granoff, DM			Development of vaccines against meningococcal disease	LANCET			English	Review							B NEISSERIA-MENINGITIDIS; MEMBRANE-VESICLE VACCINE; INFLUENZAE TYPE-B; COMPLETE GENOME SEQUENCE; CONTROLLED FIELD TRIAL; GROUP-A; CONJUGATE VACCINE; POLYSACCHARIDE VACCINES; HAEMOPHILUS-INFLUENZAE; PROTECTIVE EFFICACY	Neisseria meningitidis is a major cause of bacterial meningitis and sepsis. Polysacchariwde-protein conjugate vaccines for prevention of group C disease have been licensed in Europe. Such vaccines for prevention of disease caused by groups A (which Is associated with the greatest disease burden worldwide), Y, and W135 are being developed. However, conventional approaches to develop a vaccine for group B strains, which are responsible for most cases in Europe and the USA, have been largely unsuccessful. Capsular polysaccharide-based vaccines can elicit autoantibodies to host polysialic acid, whereas the ability of most non-capsular antigens to elicit broad-based immunity is limited by their antigenic diversity. Many new membrane proteins have been discovered during analyses of genomic sequencing data. These antigens are highly conserved and, in mice, elicit serum bactericidal antibodies, which are the serological hallmark of protective immunity in man. Therefore, there are many promising new vaccine candidates, and improved prospects for development of a broadly protective vaccine for group B disease, and for control of all meningococcal disease.	WHO, Vaccine Dev & Qual & Safety Biol, CH-1211 Geneva, Switzerland; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England; Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA; Dept Hlth, London SE1 6TE, England	World Health Organization; National Institute for Biological Standards & Control; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	Jodar, L (corresponding author), WHO, Vaccine Dev & Qual & Safety Biol, CH-1211 Geneva, Switzerland.	jodar@who.ch			NIAID NIH HHS [AI46464, AI45642] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046464, R01AI045642] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Achtman M, 1995, MENINGOCOCCAL DIS, P159; ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; ANDERSEN BM, 1978, SCAND J INFECT DIS, V10, P277, DOI 10.3109/inf.1978.10.issue-4.04; ANDERSON EL, 1994, INFECT IMMUN, V62, P3391, DOI 10.1128/IAI.62.8.3391-3395.1994; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; [Anonymous], 2000, WORLD HLTH REP; Arhin FF, 1998, CAN J MICROBIOL, V44, P56, DOI 10.1139/cjm-44-1-56; ARTENSTEIN MS, 1970, NEW ENGL J MED, V282, P417, DOI 10.1056/NEJM197002192820803; ASHTON FE, 1989, MICROB PATHOGENESIS, V6, P455, DOI 10.1016/0882-4010(89)90087-9; BAKER M, 1999, NZ PUBLIC HLTH REP, V6, P57; BEGG N, 1995, MENINGOCOCCAL DIS, P285; BINKIN N, 1982, LANCET, V2, P315; BJUNE G, 1991, LANCET, V338, P1093, DOI 10.1016/0140-6736(91)91961-S; BOSMANS E, 1980, ANN SOC BELG MED TR, V60, P297; BOVRE K, 1977, J INFECT DIS, V135, P669, DOI 10.1093/infdis/135.4.669; BRANHAM SE, 1953, BACTERIOL REV, V17, P175, DOI 10.1128/MMBR.17.3.175-188.1953; BROOME CV, 1983, B WORLD HEALTH ORGAN, V61, P325; Bruce MG, 2001, JAMA-J AM MED ASSOC, V286, P688, DOI 10.1001/jama.286.6.688; Cadieux N, 1999, INFECT IMMUN, V67, P4955, DOI 10.1128/IAI.67.9.4955-4959.1999; Campagne G, 1999, B WORLD HEALTH ORGAN, V77, P499; Campagne G, 2000, PEDIATR INFECT DIS J, V19, P144, DOI 10.1097/00006454-200002000-00013; CANN KJ, 1989, J MED MICROBIOL, V30, P23, DOI 10.1099/00222615-30-1-23; Cartwright K, 1999, VACCINE, V17, P2612, DOI 10.1016/S0264-410X(99)00044-4; Cartwright K., 1995, MENINGOCOCCAL DIS, P115; CARTWRIGHT KAV, 1991, LANCET, V338, P554, DOI 10.1016/0140-6736(91)91112-8; Cartwright Keith, 2001, Vaccine, V19, P4347, DOI 10.1016/S0264-410X(01)00205-5; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; Chiang SL, 1999, ANNU REV MICROBIOL, V53, P129, DOI 10.1146/annurev.micro.53.1.129; Connolly M, 1999, EPIDEMIOL INFECT, V122, P41, DOI 10.1017/S0950268898001848; COSTA W, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P215; CRUZ C, 1990, EPIDEMIOL INFECT, V105, P119, DOI 10.1017/S0950268800047713; Dagan R, 1997, PEDIATR INFECT DIS J, V16, P1060, DOI 10.1097/00006454-199711000-00011; DANVE B, 1993, VACCINE, V11, P1214, DOI 10.1016/0264-410X(93)90045-Y; Danve B, 1998, 11 INT PATH NEISS C, P53; de Kleijn ED, 2000, VACCINE, V18, P1456, DOI 10.1016/S0264-410X(99)00423-5; DEMAEYER S, 1981, J INFECTION, V3, P63, DOI 10.1016/S0163-4453(81)80010-2; DEMORAES JC, 1992, LANCET, V340, P1074; Devi SJN, 1997, INFECT IMMUN, V65, P1045, DOI 10.1128/IAI.65.3.1045-1052.1997; DEWALS P, 1984, J INFECTION, V8, P264, DOI 10.1016/S0163-4453(84)94123-9; Diermayer M, 1999, JAMA-J AM MED ASSOC, V281, P1493, DOI 10.1001/jama.281.16.1493; EDWARDS MS, 1981, J PEDIATR-US, V99, P540, DOI 10.1016/S0022-3476(81)80250-8; ELLISON FC, 1983, SURG CLIN N AM, V63, P1313; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; Fairley CK, 1996, J INFECT DIS, V174, P1360, DOI 10.1093/infdis/174.6.1360; FARRANT JL, 1998, 11 INT PATH NEISS C, P208; Feavers IM, 1996, CLIN DIAGN LAB IMMUN, V3, P444, DOI 10.1128/CDLI.3.4.444-450.1996; FILICE GA, 1984, AM J PUBLIC HEALTH, V74, P253, DOI 10.2105/AJPH.74.3.253; FINNE J, 1983, LANCET, V2, P355; FINNE J, 1987, J IMMUNOL, V138, P4402; Frasch CE, 2001, METH MOLEC MED, V66, P81, DOI 10.1385/1-59259-148-5:81; Fusco PC, 1997, J INFECT DIS, V175, P364, DOI 10.1093/infdis/175.2.364; GOLD R, 1977, J INFECT DIS, V136, pS31, DOI 10.1093/infdis/136.Supplement.S31; GOLD R, 1978, J INFECT DIS, V138, P731, DOI 10.1093/infdis/138.6.731; GOLD R, 1975, J CLIN INVEST, V56, P1536, DOI 10.1172/JCI108235; GOLD R, 1979, J INFECT DIS, V140, P690, DOI 10.1093/infdis/140.5.690; Goldblatt D, 1998, Dev Biol Stand, V95, P125; GOTSCHLICH EC, 1969, J EXP MED, V129, P1367, DOI 10.1084/jem.129.6.1367; Grandi G, 2001, TRENDS BIOTECHNOL, V19, P181, DOI 10.1016/S0167-7799(01)01600-6; Granoff DM, 1998, J IMMUNOL, V160, P5028; Granoff DM, 1998, J INFECT DIS, V178, P870, DOI 10.1086/515346; Granoff DM, 2001, J IMMUNOL, V167, P6487, DOI 10.4049/jimmunol.167.11.6487; Greenwood B, 1999, T ROY SOC TROP MED H, V93, P341, DOI 10.1016/S0035-9203(99)90106-2; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P536, DOI 10.1016/0035-9203(87)90397-X; GREENWOOD BM, 1980, LANCET, V1, P729; Guibourdenche M, 1996, EPIDEMIOL INFECT, V116, P115, DOI 10.1017/S095026880005233X; HALSTENSEN A, 1987, SCAND J INFECT DIS, V19, P35, DOI 10.3109/00365548709032375; Harrison LH, 1999, JAMA-J AM MED ASSOC, V281, P1906, DOI 10.1001/jama.281.20.1906; Harrison LH, 2001, JAMA-J AM MED ASSOC, V286, P694, DOI 10.1001/jama.286.6.694; HASSANKING MKA, 1988, J INFECTION, V16, P55, DOI 10.1016/S0163-4453(88)96117-8; Hubert B, 1997, Euro Surveill, V2, P69; JACOBSON JA, 1977, J INFECT DIS, V136, P104, DOI 10.1093/infdis/136.1.104; Jelfs J, 2000, EPIDEMIOL INFECT, V125, P285, DOI 10.1017/S0950268899004471; JENNINGS HJ, 1987, J EXP MED, V165, P1207, DOI 10.1084/jem.165.4.1207; JENNINGS HJ, 1986, J IMMUNOL, V137, P1708; JONES DM, 1992, MICROB PATHOGENESIS, V13, P219, DOI 10.1016/0882-4010(92)90022-G; KIM JJ, 1989, INFECT IMMUN, V57, P602, DOI 10.1128/IAI.57.2.602-608.1989; Kirk R, 1950, SUDAN NOTES REC, V31, P43; Kirsch EA, 1996, PEDIATR INFECT DIS J, V15, P967, DOI 10.1097/00006454-199611000-00009; KRASINSKI K, 1987, AM J EPIDEMIOL, V125, P499, DOI 10.1093/oxfordjournals.aje.a114556; Kwara A, 1998, TROP MED INT HEALTH, V3, P742, DOI 10.1046/j.1365-3156.1998.00300.x; Landaverde M, 1999, Rev Panam Salud Publica, V5, P200, DOI 10.1590/S1020-49891999000300022; Laurichesse H, 1998, Commun Dis Public Health, V1, P22; LEPOW ML, 1977, PEDIATRICS, V60, P673; Lewis R, 2000, LANCET, V355, P1185, DOI 10.1016/S0140-6736(05)72265-0; Lieberman JM, 1996, JAMA-J AM MED ASSOC, V275, P1499, DOI 10.1001/jama.275.19.1499; Lipsitch M, 1999, EMERG INFECT DIS, V5, P336, DOI 10.3201/eid0503.990304; LIU TY, 1971, J BIOL CHEM, V246, P2849; LYSTAD A, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P57; MacDonald NE, 1998, JAMA-J AM MED ASSOC, V280, P1685, DOI 10.1001/jama.280.19.1685; MAIDEN MCJ, 1991, MOL MICROBIOL, V5, P727, DOI 10.1111/j.1365-2958.1991.tb00743.x; MAIDEN MCJ, 1995, SYMP SOC GEN MICROBI, V52, P269; Maiden MCJ, 1999, LANCET, V354, P615, DOI 10.1016/S0140-6736(99)00252-4; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; MAKELA PH, 1977, J INFECT DIS, V136, pS43; Martin D, 1997, J EXP MED, V185, P1173, DOI 10.1084/jem.185.7.1173; Martin DR, 1998, J INFECT DIS, V177, P497, DOI 10.1086/517385; MCGUINNESS B, 1990, J EXP MED, V171, P1871, DOI 10.1084/jem.171.6.1871; MERINO J, 1983, J INFECT DIS, V148, P331, DOI 10.1093/infdis/148.2.331; Miller MA, 1999, PEDIATR INFECT DIS J, V18, P1051, DOI 10.1097/00006454-199912000-00005; MOCCA LF, 1983, J INFECT DIS, V148, P249, DOI 10.1093/infdis/148.2.249; Moe GR, 1999, INFECT IMMUN, V67, P5664, DOI 10.1128/IAI.67.11.5664-5675.1999; Moe GR, 2001, INFECT IMMUN, V69, P3762, DOI 10.1128/IAI.69.6.3762-3771.2001; MOHAMMED I, 1981, LANCET, V2, P80; MURPHY TV, 1993, JAMA-J AM MED ASSOC, V269, P246, DOI 10.1001/jama.269.2.246; Neal KR, 1999, EPIDEMIOL INFECT, V122, P351, DOI 10.1017/S0950268899002368; NORONHA CP, 1995, INT J EPIDEMIOL, V24, P1050, DOI 10.1093/ije/24.5.1050; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; Peeters CCAM, 1996, VACCINE, V14, P1009, DOI 10.1016/0264-410X(96)00001-1; PELTOLA H, 1982, LANCET, V2, P595; Perkins BA, 1998, J INFECT DIS, V177, P683, DOI 10.1086/514232; Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816; Plested JS, 1999, INFECT IMMUN, V67, P5417, DOI 10.1128/IAI.67.10.5417-5426.1999; POOLMAN JT, 1986, LANCET, V2, P555; QUAGLIARELLO VJ, 1993, CLIN INFECT DIS, V17, P603, DOI 10.1093/clinids/17.4.603; Ramsay ME, 2001, LANCET, V357, P195, DOI 10.1016/S0140-6736(00)03594-7; Rappuoli R, 2001, VACCINE, V19, P2688, DOI 10.1016/S0264-410X(00)00554-5; Raymond NJ, 1997, J INFECT DIS, V176, P1277, DOI 10.1086/514123; REINGOLD AL, 1985, LANCET, V2, P114; RIEDO FX, 1995, PEDIATR INFECT DIS J, V14, P643, DOI 10.1097/00006454-199508000-00001; Robbins JB, 2000, PEDIATR INFECT DIS J, V19, P945, DOI 10.1097/00006454-200010000-00001; Robbins JB, 1997, LANCET, V350, P880, DOI 10.1016/S0140-6736(97)03227-3; ROBBINS JB, 1989, CURR TOP MICROBIOL, V146, P169; Rokbi B, 2000, INFECT IMMUN, V68, P4938, DOI 10.1128/IAI.68.9.4938-4947.2000; Rokbi B, 1997, CLIN DIAGN LAB IMMUN, V4, P522, DOI 10.1128/CDLI.4.5.522-529.1997; ROSENQVIST E, 1995, INFECT IMMUN, V63, P4642, DOI 10.1128/IAI.63.12.4642-4652.1995; Rosenstein NE, 2000, PEDIATR CLIN N AM, V47, P337, DOI 10.1016/S0031-3955(05)70210-8; Rosenstein NE, 1999, J INFECT DIS, V180, P1894, DOI 10.1086/315158; RYDER CS, 1987, ANN TROP PAEDIATR, V7, P47, DOI 10.1080/02724936.1987.11748473; SACCHI CT, 1992, J CLIN MICROBIOL, V30, P1734, DOI 10.1128/JCM.30.7.1734-1738.1992; SANBORN WR, 1972, PROGR IMMUNOBIOLOGIC, V5, P497; Saunders NJ, 2000, MOL MICROBIOL, V37, P207, DOI 10.1046/j.1365-2958.2000.02000.x; Shinefield HR, 2000, PEDIATR INFECT DIS J, V19, P394, DOI 10.1097/00006454-200004000-00036; SIERRA G V G, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P195; SMITH AW, 1988, T ROY SOC TROP MED H, V82, P312, DOI 10.1016/0035-9203(88)90459-2; Smith I, 1999, EPIDEMIOL INFECT, V123, P373, DOI 10.1017/S0950268899003143; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315, DOI 10.1017/S0950268800057733; Sun YH, 2000, NAT MED, V6, P1269, DOI 10.1038/81380; Swartley JS, 1997, P NATL ACAD SCI USA, V94, P271, DOI 10.1073/pnas.94.1.271; Taha MK, 2000, LANCET, V356, P2159, DOI 10.1016/S0140-6736(00)03502-9; Tappero JW, 1999, JAMA-J AM MED ASSOC, V281, P1520, DOI 10.1001/jama.281.16.1520; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Thomas K, 1999, LANCET, V353, P1216, DOI 10.1016/S0140-6736(98)07228-6; Tondella MLC, 2000, J CLIN MICROBIOL, V38, P3323, DOI 10.1128/JCM.38.9.3323-3328.2000; URIBE MLE, 1995, BOL OFIC SANIT PANAN, V118, P285; van der Voort ER, 2000, VACCINE, V18, P1334, DOI 10.1016/S0264-410X(99)00402-8; VANDERLEY P, 1992, INFECT IMMUN, V60, P3156, DOI 10.1128/IAI.60.8.3156-3161.1992; VANDERLEY P, 1991, INFECT IMMUN, V59, P2963, DOI 10.1128/IAI.59.9.2963-2971.1991; Varaine F, 1997, T ROY SOC TROP MED H, V91, P3, DOI 10.1016/S0035-9203(97)90371-0; Venetz I, 1998, INT J EPIDEMIOL, V27, P1101, DOI 10.1093/ije/27.6.1101; VERHEUL AFM, 1993, MICROBIOL REV, V57, P34, DOI 10.1128/MMBR.57.1.34-49.1993; Vogel U, 2000, NEW ENGL J MED, V342, P219, DOI 10.1056/NEJM200001203420319; WAHDAN MH, 1973, B WORLD HEALTH ORGAN, V48, P667; WAHDAN MH, 1977, B WORLD HEALTH ORGAN, V55, P645; WANG JF, 1993, J INFECT DIS, V167, P1320, DOI 10.1093/infdis/167.6.1320; WANG JF, 1992, INFECT IMMUN, V60, P5267, DOI 10.1128/IAI.60.12.5267-5282.1992; Wedege E, 1999, J INFECT DIS, V180, P242, DOI 10.1086/314856; WEI J, 1993, J CHINESE PREVENTIVE, V27, P160; Wenger J, 1997, LANCET, V350, P1709, DOI 10.1016/S0140-6736(05)64316-4; Wenger JD, 1999, VACCINE, V18, P736, DOI 10.1016/S0264-410X(99)00269-8; WENGER JD, 1997, NEW GENERATION VACCI, P489; West D, 2001, INFECT IMMUN, V69, P1561, DOI 10.1128/IAI.69.3.1561-1567.2001; WHITTLE HC, 1975, LANCET, V1, P1377; Yousuf M, 2000, J Pak Med Assoc, V50, P184; ZOLLINGER W D, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P211; Zollinger WD, 1997, INFECT IMMUN, V65, P1053, DOI 10.1128/IAI.65.3.1053-1060.1997	165	197	214	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	2002	359	9316					1499	1508		10.1016/S0140-6736(02)08416-7	http://dx.doi.org/10.1016/S0140-6736(02)08416-7			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988262				2022-12-28	WOS:000175279100026
J	Kramer, A; Rudolph, P; Kampf, G; Pittet, D				Kramer, A; Rudolph, P; Kampf, G; Pittet, D			Limited efficacy of alcohol-based hand gels	LANCET			English	Article								Alcohol-based gels have been introduced recently in many hospitals worldwide for hand antisepsis. We investigated the antimicrobial efficacy of ten gels and four rinses according to European standards (EN 1500). No gel met the EN 1500 requirements within 30 s of application, whereas all hand rinses did. The tested hand gels should be considered a retrograde step for hand hygiene because the application time in clinical practice is often shorter than 30 s; they should not replace alcohol-based liquid hand disinfectants currently used in hospitals or be implemented as first choice agents.	Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, CH-1211 Geneva 14, Switzerland; Univ Greifswald, Inst Hyg & Environm Med, Greifswald, Germany; Bode Chem GmbH, Sci Affairs, Hamburg, Germany	University of Geneva; Ernst Moritz Arndt Universitat Greifswald; BODE Chemie GmbH	Pittet, D (corresponding author), Univ Hosp Geneva, Dept Internal Med, Infect Control Programme, CH-1211 Geneva 14, Switzerland.		Kampf, Günter/ABB-8811-2021					CEN, 1997, 1500 CEN EN; *DTSCH I NORM, 1997, 1500 DTSCH I NORM; Pittet D, 2000, LANCET, V356, P1307, DOI 10.1016/S0140-6736(00)02814-2; Rotter Manfred L., 1999, P1339; *SOC FRANC HYG HOS, 2000, HYGIENE, V8, P73	5	127	132	2	44	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1489	1490		10.1016/S0140-6736(02)08426-X	http://dx.doi.org/10.1016/S0140-6736(02)08426-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988252				2022-12-28	WOS:000175279100016
J	Fraser, HB; Hirsh, AE; Steinmetz, LM; Scharfe, C; Feldman, MW				Fraser, HB; Hirsh, AE; Steinmetz, LM; Scharfe, C; Feldman, MW			Evolutionary rate in the protein interaction network	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; YEAST; GENES	High-throughput screens have begun to reveal the protein interaction network that underpins most cellular functions in the yeast Saccharomyces cerevisiae. How the organization of this network affects the evolution of the proteins that compose it is a fundamental question in molecular evolution. We show that the connectivity of welt-conserved proteins in the network is negatively correlated with their rate of evolution. Proteins with more interactors evolve more slowly not because they are more important to the organism, but because a greater proportion of the protein is directly involved in its function. At sites important for interaction between proteins, evolutionary changes may occur largely by coevolution, in which substitutions in one protein result in selection pressure for reciprocal changes in interacting partners. We confirm one predicted outcome of this process-namely, that interacting proteins evolve at similar rates.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Stanford Univ, Dept Biol Sci, Ctr Computat Genet & Biol Modeling, Stanford, CA 94305 USA; Stanford Genome Technol Ctr, Palo Alto, CA 94306 USA	University of California System; University of California Berkeley; Stanford University; Stanford University	Fraser, HB (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.			Steinmetz, Lars/0000-0002-3962-2865				Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Dickerson R E., 1971, Journal Molec Evol, V1, P26, DOI 10.1007/BF01659392; Feng DF, 1997, J MOL EVOL, V44, P361, DOI 10.1007/PL00006155; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GIBBONS JD, 1993, SAGE U PAPERS, P3; Grigoriev A, 2001, NUCLEIC ACIDS RES, V29, P3513, DOI 10.1093/nar/29.17.3513; GRISHIN NV, 1995, J MOL EVOL, V41, P675; Hirsh AE, 2001, NATURE, V411, P1046, DOI 10.1038/35082561; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; KAPLAN D, 2000, ADV QUANTITATIVE TEC, P13; Koretke KK, 2000, MOL BIOL EVOL, V17, P1956, DOI 10.1093/oxfordjournals.molbev.a026297; Rawson PD, 2000, GENE, V248, P15, DOI 10.1016/S0378-1119(00)00145-1; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; Schwikowski B, 2000, NAT BIOTECHNOL, V18, P1257, DOI 10.1038/82360; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; ZUCKERKANDL E, 1976, J MOL EVOL, V7, P167, DOI 10.1007/BF01731487	22	649	665	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					750	752		10.1126/science.1068696	http://dx.doi.org/10.1126/science.1068696			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976460	Green Submitted			2022-12-28	WOS:000175281700060
J	Hinnebusch, BJ; Rudolph, AE; Cherepanov, P; Dixon, JE; Schwan, TG; Forsberg, A				Hinnebusch, BJ; Rudolph, AE; Cherepanov, P; Dixon, JE; Schwan, TG; Forsberg, A			Role of Yersinia murine toxin in survival of Yersinia pestis in the midgut of the flea vector	SCIENCE			English	Article							PHOSPHOLIPID SYNTHASES; ESCHERICHIA-COLI; VIRULENCE; IDENTIFICATION; MUTAGENESIS; SUPERFAMILY; PLAGUE; FAMILY; MEMBER; LOCUS	Transmission by flea bite is a relatively recent adaptation that distinguishes Yersinia pestis, the plague bacillus, from closely related enteric bacteria. Here, a plasmid-encoded phospholipase D (PLD), previously characterized as Yersinia murine toxin (Ymt), was shown to be required for survival of Y, pestis in the midgut of its principal vector, the rat flea Xenopsylla cheopis. Intracellular PLD activity appeared to protect Y. pestis from a cytotoxic digestion product of blood plasma in the flea gut. By enabling colonization of the flea midgut, acquisition of this PLD may have precipitated the transition of Y. pestis to obligate arthropod-borne transmission.	NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden; Swedish Def Res Agcy, Dept Med Countermeasures, S-90182 Umea, Sweden	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of Michigan System; University of Michigan; Umea University; Saab Group	Hinnebusch, BJ (corresponding author), NIAID, Lab Human Bacterial Pathogenesis, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA.							Achtman M, 1999, P NATL ACAD SCI USA, V96, P14043, DOI 10.1073/pnas.96.24.14043; AJL SJ, 1955, J BACTERIOL, V70, P158, DOI 10.1128/JB.70.2.158-169.1955; Bacot A. W., 1914, Journal of Hygiene Cambridge Plague Suppl, V3; BROWN SD, 1977, INFECT IMMUN, V18, P85, DOI 10.1128/IAI.18.1.85-93.1977; BRUBAKER RR, 1991, CLIN MICROBIOL REV, V4, P309, DOI 10.1128/CMR.4.3.309-324.1991; Cherepanov P A, 1991, Mol Gen Mikrobiol Virusol, P19; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; DROZDOV IG, 1995, J MED MICROBIOL, V42, P264, DOI 10.1099/00222615-42-4-264; Du YD, 1995, CONTRIB TO MICROBIOL, V13, P321; ESKEY CR, 1940, PUBLIC HLTH B, V254; FORSBERG A, UNPUB; Heinrichs DE, 1998, J BIOL CHEM, V273, P29497, DOI 10.1074/jbc.273.45.29497; Hinnebusch BJ, 1998, J INFECT DIS, V178, P1406, DOI 10.1086/314456; Hinnebusch BJ, 1996, SCIENCE, V273, P367, DOI 10.1126/science.273.5273.367; Hinnebusch J, 2000, INT J MED MICROBIOL, V290, P483, DOI 10.1016/S1438-4221(00)80070-3; Hu P, 1998, J BACTERIOL, V180, P5192, DOI 10.1128/JB.180.19.5192-5202.1998; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Lindler LE, 1998, INFECT IMMUN, V66, P5731, DOI 10.1128/IAI.66.12.5731-5742.1998; MONTIE TC, 1970, MICROBIAL TOXINS, V3, P1; Ochman H, 2000, NATURE, V405, P299, DOI 10.1038/35012500; PERRY RD, 1990, J BACTERIOL, V172, P5929, DOI 10.1128/jb.172.10.5929-5937.1990; POLLITZER R, 1954, MONOGRAPH SERIES WHO, V22; Ponting CP, 1996, PROTEIN SCI, V5, P914; Rudolph AE, 1999, J BIOL CHEM, V274, P11824, DOI 10.1074/jbc.274.17.11824; SCHAR M, 1956, Schweiz Z Pathol Bakteriol, V19, P51; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; VAUGHAN JA, 1993, J MED ENTOMOL, V30, P214, DOI 10.1093/jmedent/30.1.214	27	225	244	1	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					733	735		10.1126/science.1069972	http://dx.doi.org/10.1126/science.1069972			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976454				2022-12-28	WOS:000175281700054
J	Roos, D; Winterbourn, CC				Roos, D; Winterbourn, CC			Immunology - Lethal weapons	SCIENCE			English	Editorial Material							SUPEROXIDE-DISMUTASE; POLYMORPHONUCLEAR NEUTROPHILS; NOCARDIA-ASTEROIDES; ESCHERICHIA-COLI; MYELOPEROXIDASE		Netherlands Blood Transfus Serv, Cent Lab, Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands; Christchurch Sch Med, Dept Pathol, Christchurch, New Zealand	University of Amsterdam; Academic Medical Center Amsterdam; University of Otago	Roos, D (corresponding author), Netherlands Blood Transfus Serv, Cent Lab, Amsterdam, Netherlands.							ALBRICH JM, 1982, FEBS LETT, V144, P157, DOI 10.1016/0014-5793(82)80591-7; BEAMAN BL, 1983, J BIOL CHEM, V258, P91; BEAMAN BL, 1985, INFECT IMMUN, V47, P135, DOI 10.1128/IAI.47.1.135-141.1985; BEAMAN L, 1990, INFECT IMMUN, V58, P3122, DOI 10.1128/IAI.58.9.3122-3128.1990; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; Chapman ALP, 2002, J BIOL CHEM, V277, P9757, DOI 10.1074/jbc.M106134200; Elsbach P, 1999, INFLAMMATION BASIC P, P801; Gaut JP, 2001, P NATL ACAD SCI USA, V98, P11961, DOI 10.1073/pnas.211190298; Gerber CE, 2001, BLOOD, V98, P3097, DOI 10.1182/blood.V98.10.3097; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hampton MB, 1996, INFECT IMMUN, V64, P3512, DOI 10.1128/IAI.64.9.3512-3517.1996; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; JOHNSTON RB, 1970, BLOOD-J HEMATOL, V35, P350, DOI 10.1182/blood.V35.3.350.350; Kettle AJ, 2001, BIOCHEMISTRY-US, V40, P10204, DOI 10.1021/bi010940b; Klebanoff S.J., 1999, INFLAMMATION BASIC P, P721; KLEBANOFF SJ, 1968, J BACTERIOL, V95, P2131, DOI 10.1128/JB.95.6.2131-2138.1968; KUSUNOSE E, 1976, J BIOCHEM, V80, P1343, DOI 10.1093/oxfordjournals.jbchem.a131407; Langford PR, 1996, INFECT IMMUN, V64, P5035, DOI 10.1128/IAI.64.12.5035-5041.1996; MANDELL GL, 1969, J BACTERIOL, V100, P531, DOI 10.1128/JB.100.1.531-532.1969; MANDELL GL, 1974, INFECT IMMUN, V9, P337, DOI 10.1128/IAI.9.2.337-341.1974; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; SEGAL AW, 1981, NATURE, V290, P406, DOI 10.1038/290406a0; SPIEGELHALDER C, 1993, INFECT IMMUN, V61, P5315, DOI 10.1128/IAI.61.12.5315-5325.1993; VOETMAN AA, 1981, J CLIN INVEST, V67, P1541, DOI 10.1172/JCI110185; WEISS J, 1982, J CLIN INVEST, V69, P959, DOI 10.1172/JCI110535	26	140	143	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					669	671		10.1126/science.1071271	http://dx.doi.org/10.1126/science.1071271			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976433				2022-12-28	WOS:000175281700033
J	Wagner, A				Wagner, A			Retrospective - Willibald Jentschke (1911-2002)	SCIENCE			English	Biographical-Item									DESY, D-22607 Hamburg, Germany	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Wagner, A (corresponding author), DESY, Notkestr 85, D-22607 Hamburg, Germany.								0	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					672	672		10.1126/science.1072237	http://dx.doi.org/10.1126/science.1072237			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976435				2022-12-28	WOS:000175281700035
J	Stott, PA; Kettleborough, JA				Stott, PA; Kettleborough, JA			Origins and estimates of uncertainty in predictions of twenty-first century temperature rise	NATURE			English	Article							CLIMATE-CHANGE; 20TH-CENTURY TEMPERATURE; MODEL	Predictions of temperature rise over the twenty-first century are necessarily uncertain, both because the sensitivity of the climate system to changing atmospheric greenhouse-gas concentrations, as well as the rate of ocean heat uptake, is poorly quantified(1,2) and because future influences on climate-of anthropogenic as well as natural origin-are difficult to predict(3). Past observations have been used to help constrain the range of uncertainties in future warming rates, but under the assumption of a particular scenario of future emissions(4). Here we investigate the relative importance of the uncertainty in climate response to a particular emissions scenario versus the uncertainty caused by the differences between future emissions scenarios for our estimates of future change. We present probabilistic forecasts of global-mean temperatures for four representative scenarios for future emissions(5), obtained with a comprehensive climate model. We find that, in the absence of policies to mitigate climate change, global-mean temperature rise is insensitive to the differences in the emissions scenarios over the next four decades. We also show that in the future, as the signal of climate change emerges further, the predictions will become better constrained.	Hadley Ctr Climate Predict & Res, Met Off, Bracknell RG12 2SY, Berks, England; Rutherford Appleton Lab, Space Sci & Technol Dept, Didcot OX11 0QX, Oxon, England	Met Office - UK; Hadley Centre; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); STFC Rutherford Appleton Laboratory	Stott, PA (corresponding author), Hadley Ctr Climate Predict & Res, Met Off, Bracknell RG12 2SY, Berks, England.		Stott, Peter/N-1228-2016; Scott, Peter/GYA-5335-2022	Stott, Peter/0000-0003-4853-7686; 				Allen M, 2001, SCIENCE, V293, P430; Allen M, 1999, NATURE, V401, P642, DOI 10.1038/44266; Allen MR, 2000, NATURE, V407, P617, DOI 10.1038/35036559; Allen MR, 1999, CLIM DYNAM, V15, P419, DOI 10.1007/s003820050291; ALLEN MR, UNPUB CLIM DYN; BOOTH BBB, 2002, RALTR2002005; Cox PM, 2000, NATURE, V408, P184, DOI 10.1038/35041539; Crowley TJ, 2000, SCIENCE, V289, P270, DOI 10.1126/science.289.5477.270; Cubasch U., 2001, PROJECTIONS FUTURE C, P525; Forest CE, 2002, SCIENCE, V295, P113, DOI 10.1126/science.1064419; Forest CE, 2000, GEOPHYS RES LETT, V27, P569, DOI 10.1029/1999GL010859; Gordon C, 2000, CLIM DYNAM, V16, P147, DOI 10.1007/s003820050010; Hasselmann K, 1997, CLIM DYNAM, V13, P601, DOI 10.1007/s003820050185; Hegerl GC, 2001, J CLIMATE, V14, P198, DOI 10.1175/1520-0442(2001)013<0198:EOOSEO>2.0.CO;2; Houghton J. T., 2001, CLIMATE CHANGE 2001; JOHNS TC, 2001, 22 HADL CTR CLIM PRE; Knutti R, 2002, NATURE, V416, P719, DOI 10.1038/416719a; LEAN J, 1995, GEOPHYS RES LETT, V22, P3195, DOI 10.1029/95GL03093; Nakicenovic N., 2000, SPECIAL REPORT EMISS; Pope VD, 2000, CLIM DYNAM, V16, P123, DOI 10.1007/s003820050009; Reilly J, 2001, SCIENCE, V293, P430; SATO M, 1993, J GEOPHYS RES-ATMOS, V98, P22987, DOI 10.1029/93JD02553; Stocker TF, 1997, NATURE, V388, P862, DOI 10.1038/42224; Stott PA, 2000, SCIENCE, V290, P2133, DOI 10.1126/science.290.5499.2133; Stott PA, 2001, CLIM DYNAM, V17, P1, DOI 10.1007/PL00007924; STOTT PA, 1998, J CLIMATOL, V11, P32892; Tett SFB, 1999, NATURE, V399, P569, DOI 10.1038/21164; TWOMEY S, 1974, ATMOS ENVIRON, V8, P1251, DOI 10.1016/0004-6981(74)90004-3; Wigley TML, 2001, SCIENCE, V293, P451, DOI 10.1126/science.1061604	29	255	263	11	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					723	726		10.1038/416723a	http://dx.doi.org/10.1038/416723a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961551				2022-12-28	WOS:000175033500038
J	Clancy, DJ; Gems, D; Hafen, E; Leevers, SJ; Partridge, L				Clancy, DJ; Gems, D; Hafen, E; Leevers, SJ; Partridge, L			Dietary restriction in long-lived dwarf flies	SCIENCE			English	Article							LIFE-SPAN; NUTRITION		UCL, Dept Biol, London WC1E 6BT, England; Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland; Imperial Canc Res Fund, Growth Regulat Lab, London WC2A 3PX, England	University of London; University College London; University of Zurich; Cancer Research UK	Partridge, L (corresponding author), UCL, Dept Biol, Gower ST, London WC1E 6BT, England.	l.partridge@ucl.ac.uk	Clancy, David J/F-4882-2011; Partridge, Linda/A-5501-2010; Partridge, Linda/E-7342-2015	Partridge, Linda/0000-0001-9615-0094; Clancy, David John/0000-0002-0299-7946; Gems, David/0000-0002-6653-4676	Biotechnology and Biological Sciences Research Council [SF19106] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bartke A, 2001, NATURE, V414, P412, DOI 10.1038/35106646; Chapman T, 1996, P ROY SOC B-BIOL SCI, V263, P755, DOI 10.1098/rspb.1996.0113; CHIPPINDALE AK, 1993, J EVOLUTION BIOL, V6, P171, DOI 10.1046/j.1420-9101.1993.6020171.x; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Lane MA, 1996, P NATL ACAD SCI USA, V93, P4159, DOI 10.1073/pnas.93.9.4159; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X	7	217	227	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					319	319		10.1126/science.1069366	http://dx.doi.org/10.1126/science.1069366			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951037	Green Accepted			2022-12-28	WOS:000175000300048
J	Welch, HG; Mogielnicki, J				Welch, HG; Mogielnicki, J			Presumed benefit: lessons from the American experience with marrow transplantation for breast cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HIGH-DOSE CHEMOTHERAPY; STEM-CELL TRANSPLANTATION		Dept Vet Affairs, VA Outcomes Grp 111B, White River Jct, VT 05009 USA; Brown Univ, Providence, RI 02912 USA	VA Outcomes Group; Brown University	Welch, HG (corresponding author), Dept Vet Affairs, VA Outcomes Grp 111B, White River Jct, VT 05009 USA.	h.gilbert.welch@dartmouth.edu						Altman LK, 1990, NY TIMES, V4, pA1; ANTMAN K, 1988, ANN INTERN MED, V108, P570, DOI 10.7326/0003-4819-108-4-570; Appelbaum FR, 1996, CA-CANCER J CLIN, V46, P142, DOI 10.3322/canjclin.46.3.142; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; CHESON B, 1994, US C SUBCOMITTEE COM; CHESON BD, 1989, ANN INTERN MED, V110, P51, DOI 10.7326/0003-4819-110-1-51; EDDY D, 1999, NY TIMES        0417, pA17; EDDY DM, 1992, J CLIN ONCOL, V10, P657, DOI 10.1200/JCO.1992.10.4.657; EDDY DM, 1992, JAMA-J AM MED ASSOC, V268, P1536; GORMAN T, 1993, LOS ANGELES TIM 1229, pA1; HILLNER BE, 1992, JAMA-J AM MED ASSOC, V267, P2055, DOI 10.1001/jama.267.15.2055; HOWE RF, 1990, WASHINGTON POST 0419, pC1; KOLATA G, 1988, NY TIMES        0406, V24, P42; KOLATA G, 2000, NY TIMES        1203, pA24; Kolata Gina, 1999, N Y Times Web, pC12; Kolata Gina, 1995, N Y Times Web, pC8; Lippman ME, 2000, NEW ENGL J MED, V342, P1119, DOI 10.1056/NEJM200004133421508; MAHANEY FX, 1989, J NATL CANCER I, V81, P1352, DOI 10.1093/jnci/81.18.1352; MAUGH TH, 1990, LOS ANGELES TIM 0514, V14, pB2; MCCRORY B, 1990, BOSTON GLOBE    0506, P44; MCGREAL C, 2000, GUARDIAN        0219, P18; PETERS WP, 1994, NEW ENGL J MED, V330, P473, DOI 10.1056/NEJM199402173300707; PETERS WP, 1993, J CLIN ONCOL, V11, P1132, DOI 10.1200/JCO.1993.11.6.1132; SQUIRES S, 1989, WASHINGTON POST 1226, V26, pZ5; Stadtmauer EA, 2000, NEW ENGL J MED, V342, P1069, DOI 10.1056/NEJM200004133421501; Stephenson J, 1997, JAMA-J AM MED ASSOC, V277, P1827, DOI 10.1001/jama.277.23.1827; Suplee C, 1990, WASH POST, pA1; Weiss RB, 2000, LANCET, V355, P999, DOI 10.1016/S0140-6736(00)90024-2; WINSLOW R, 1994, WALL STREET J   0906, pA1; 1992, CHICAGO SUN TIM 0430, pS4; [No title captured]	31	41	41	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 4	2002	324	7345					1088	1092		10.1136/bmj.324.7345.1088	http://dx.doi.org/10.1136/bmj.324.7345.1088			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YY	11991918	Green Published			2022-12-28	WOS:000175476500027
J	Ober, CK				Ober, CK			Self-assembly - Persistence pays off	SCIENCE			English	Editorial Material							BLOCK-COPOLYMER		Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14853 USA	Cornell University	Ober, CK (corresponding author), Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14853 USA.		Ober, Christopher/AAI-1568-2019	Ober, Christopher/0000-0002-3805-3314				CHEN JT, 1995, MACROMOLECULES, V28, P1688, DOI 10.1021/ma00109a048; Jeoung E, 2001, LANGMUIR, V17, P6396, DOI 10.1021/la010531g; Lee SW, 2002, SCIENCE, V296, P892, DOI 10.1126/science.1068054; Muthukumar M, 1997, SCIENCE, V277, P1225, DOI 10.1126/science.277.5330.1225; Park M, 2001, APPL PHYS LETT, V79, P257, DOI 10.1063/1.1378046; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; RADZILOWSKI LH, 1993, MACROMOLECULES, V26, P879, DOI 10.1021/ma00056a053; Welsh LC, 1996, MACROMOLECULES, V29, P7075, DOI 10.1021/ma9605614; Whaley SR, 2000, NATURE, V405, P665, DOI 10.1038/35015043; Yu SJM, 1997, NATURE, V389, P167, DOI 10.1038/38254	10	12	13	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					859	+		10.1126/science.1071399	http://dx.doi.org/10.1126/science.1071399			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988559				2022-12-28	WOS:000175442500028
J	Christian, MC; Goldberg, JL; Killen, J; Abrams, JS; McCabe, MS; Mauer, JK; Wittes, RE				Christian, MC; Goldberg, JL; Killen, J; Abrams, JS; McCabe, MS; Mauer, JK; Wittes, RE			Sounding board - A central institutional review board for multi-institutional trials.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NCI, Bethesda, MD 20892 USA; NIAID, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Christian, MC (corresponding author), NCI, Bethesda, MD 20892 USA.							Bankert E, 2000, IRB, V22, P9, DOI 10.2307/3563586; BROWN JG, 1998, OEI019700194 DHHS; Burman WJ, 2001, ANN INTERN MED, V134, P152, DOI 10.7326/0003-4819-134-2-200101160-00016; *DEP HHS, 1998, OEI019700193 DHHS; *DEP HHS, 1998, OEI019700190 DHHS; *DEP HHS, 1998, OEI019700192 DHHS; *DEP HHS, 1998, OEI019100191 DHHS; *GAO, 1996, GAOHEHS9672, P1; Gelijns AC, 2002, JAMA-J AM MED ASSOC, V287, P72, DOI 10.1001/jama.287.1.72; Gordon Bruce, 1999, IRB, V21, P10, DOI 10.2307/3564621; Heinrich J., 2001, GAO01959T, P1; *I MED, 2001, PRES PUBL TRUST ACCR, P1; Levin HS, 2000, J CLIN EXP NEUROPSYC, V22, P1, DOI 10.1076/1380-3395(200002)22:1;1-8;FT001; Levine RJ, 2001, ANN INTERN MED, V134, P161, DOI 10.7326/0003-4819-134-2-200101160-00018; *NAT BIOETH ADV CO, 2001, ETH POL ISS RES INV, V1; Phillips DF, 2000, JAMA-J AM MED ASSOC, V283, P729, DOI 10.1001/jama.283.6.729; Randal J, 2001, J NATL CANCER I, V93, P1440, DOI 10.1093/jnci/93.19.1440; Steinbrook R, 2002, NEW ENGL J MED, V346, P1425, DOI 10.1056/NEJM200205023461828	18	91	93	0	3	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					1405	1408		10.1056/NEJM200205023461814	http://dx.doi.org/10.1056/NEJM200205023461814			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546MZ	11986418				2022-12-28	WOS:000175279000013
J	Klompas, M				Klompas, M			Does this patient have an acute thoracic aortic dissection?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHEST PAIN; MARFAN-SYNDROME; DIAGNOSIS; EXPERIENCE; ECHOCARDIOGRAPHY; EMERGENCY; ISCHEMIA; FEATURES; ANEURYSM; DEATH	Context The diagnosis of acute thoracic aortic dissection is difficult to make and often missed. Objective To review the accuracy of clinical history taking, physical examination, and plain chest radiograph in the diagnosis of acute thoracic aortic dissection. Data Sources A comprehensive review of the English-language literature was conducted using MEDLINE for the years 1966 through 2000. Additional sources were identified from the references of retrieved articles. Study Selection The search revealed 274 potential sources, which were reviewed for pertinence and quality. Articles included were original investigations describing the clinical findings for 18 or more consecutive patients with confirmed thoracic aortic dissection. Twenty-one studies were identified that met selection criteria. Data Extraction Critical appraisal and data extraction were performed by the author. Data Synthesis Most patients with thoracic aortic dissection have severe pain (pooled sensitivity, 90%) of sudden onset (sensitivity, 84%). The absence of sudden pain onset lowers the likelihood of dissection (negative likelihood ratio [LR], 0.3; 95% confidence interval [CI], 0.2-0.5). On examination, 49% of patients have an elevated blood pressure, 28% have a diastolic murmur, 31% have pulse deficits or blood pressure differentials, and 17% have focal neurological deficits. Presence of a diastolic murmur does little to change the pretest probability of dissection (positive LR, 1.4; 95% CI, 1.0-2.0), whereas pulse or blood pressure differentials and neurological deficits increase the likelihood of disease (positive LRs, 5.7 and 6.6-33.0, respectively). The plain chest radiograph results are usually abnormal (sensitivity, 90%); hence, the presence of a normal aorta and mediastinum decreases the probability of dissection (negative LR, 0.3; 95% CI, 0.2-0.4). Combinations of findings increase the likelihood of disease. Conclusions The presence of pulse deficits or focal neurological deficits increases the likelihood of an acute thoracic aortic dissection in the appropriate clinical setting. Conversely, a completely normal chest radiograph result or the absence of pain of sudden onset lowers the likelihood. Overall, however, the clinical examination is insufficiently sensitive to rule out aortic dissection given the high morbidity of missed diagnosis.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Klompas, M (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	mklompas@partners.org	Klompas, Michael/Z-2415-2019					Armstrong WF, 1998, AM HEART J, V136, P1051, DOI 10.1016/S0002-8703(98)70162-0; BARBANT SD, 1992, AM HEART J, V124, P541, DOI 10.1016/0002-8703(92)90632-6; BEAN RB, 1961, W OSLER APHORISMS HI, P138; Burt CW, 1999, AM J EMERG MED, V17, P552, DOI 10.1016/S0735-6757(99)90195-X; CHAN KL, 1991, AM HEART J, V122, P495, DOI 10.1016/0002-8703(91)91007-A; Chan-Tack KM, 2000, NEW ENGL J MED, V343, P1199, DOI 10.1056/NEJM200010193431616; Choudhry NK, 1999, JAMA-J AM MED ASSOC, V281, P2231, DOI 10.1001/jama.281.23.2231; EAGLE KA, 1986, AM J CARDIOL, V57, P322, DOI 10.1016/0002-9149(86)90912-4; EARNEST F, 1979, MAYO CLIN PROC, V54, P43; Eddy DM, 1992, METAANALYSIS CONFIDE; ENIA F, 1989, CHEST, V95, P124, DOI 10.1378/chest.95.1.124; ERB BD, 1960, CIRCULATION, V22, P315, DOI 10.1161/01.CIR.22.2.315; Fultz PJ, 1998, AM J ROENTGENOL, V171, P351, DOI 10.2214/ajr.171.2.9694450; GERBER O, 1986, STROKE, V17, P644, DOI 10.1161/01.STR.17.4.644; Gleeson H, 2000, LANCET, V356, P826, DOI 10.1016/S0140-6736(00)02658-1; GREENWOOD WR, 1986, AM J EMERG MED, V4, P330, DOI 10.1016/0735-6757(86)90303-7; Hagan PG, 2000, JAMA-J AM MED ASSOC, V283, P897, DOI 10.1001/jama.283.7.897; HUME DM, 1963, SURGERY, V53, P122; ITZCHAK Y, 1975, AM J ROENTGENOL, V125, P559, DOI 10.2214/ajr.125.3.559; JAGANNATH AS, 1986, AM J ROENTGENOL, V147, P1123, DOI 10.2214/ajr.147.6.1123; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LARSON EW, 1984, AM J CARDIOL, V53, P849, DOI 10.1016/0002-9149(84)90418-1; LEONARD JC, 1979, Q J MED, V48, P55; LEVINSON DC, 1950, CIRCULATION, V1, P360, DOI 10.1161/01.CIR.1.3.360; LINDSAY J, 1967, CIRCULATION, V35, P880, DOI 10.1161/01.CIR.35.5.880; LUKER GD, 1994, RADIOLOGY, V193, P813, DOI 10.1148/radiology.193.3.7972830; MARIAN AJ, 1993, AM J EMERG MED, V11, P613, DOI 10.1016/0735-6757(93)90015-4; MASUDA Y, 1991, CIRCULATION, V84, P7; MATTAR SG, 1994, AM SURGEON, V60, P827; Meszaros I, 2000, CHEST, V117, P1271, DOI 10.1378/chest.117.5.1271; MILLER DC, 1979, J THORAC CARDIOV SUR, V78, P365; MORGAGNI JB, 1998, CHEST, V114, P793; MURDOCH JL, 1972, NEW ENGL J MED, V286, P804, DOI 10.1056/NEJM197204132861502; NIELSEN NC, 1961, ACTA MED SCAND, V170, P117; NIENABER CA, 1993, NEW ENGL J MED, V328, P1, DOI 10.1056/NEJM199301073280101; NIENABER CA, 1992, HERZ, V17, P398; Ohmoto Y, 1996, INT J CARDIOL, V55, P289, DOI 10.1016/0167-5273(96)02671-X; Oliver TB, 1999, CLIN RADIOL, V54, P38, DOI 10.1016/S0009-9260(99)91238-2; Pacifico L, 1999, CLIN CARDIOL, V22, P353; PATE JW, 1976, AM SURGEON, V42, P395; PINET F, 1984, CARDIOVASC INTER RAD, V7, P257, DOI 10.1007/BF02625108; PUMPHREY CW, 1986, BRIT HEART J, V55, P106; Pyeritz RE, 2000, ANNU REV MED, V51, P481, DOI 10.1146/annurev.med.51.1.481; Rashid J, 1996, AM HEART J, V132, P1301, DOI 10.1016/S0002-8703(96)90486-X; ROBERTSON GSM, 1988, LANCET, V1, P877; Rogers FB, 1996, J TRAUMA, V41, P906, DOI 10.1097/00005373-199611000-00028; Rosman HS, 1998, CHEST, V114, P793, DOI 10.1378/chest.114.3.793; Sarasin FP, 1996, ANN EMERG MED, V28, P278, DOI 10.1016/S0196-0644(96)70026-4; SAVESODERBERGH J, 1986, JAMA-J AM MED ASSOC, V255, P493, DOI 10.1001/jama.255.4.493; Singer AJ, 1996, ARCH INTERN MED, V156, P2005, DOI 10.1001/archinte.156.17.2005; SLATER EE, 1976, AM J MED, V60, P625, DOI 10.1016/0002-9343(76)90496-4; SPITTELL PC, 1993, MAYO CLIN PROC, V68, P642, DOI 10.1016/S0025-6196(12)60599-0; STRONG WW, 1974, J THORAC CARDIOV SUR, V68, P815; Sullivan PR, 2000, AM J EMERG MED, V18, P46, DOI 10.1016/S0735-6757(00)90047-0; Sybert VP, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.1.e11; VILJANEN T, 1986, ANN CHIR GYNAECOL FE, V75, P328; von Kodolitsch Y, 2000, ARCH INTERN MED, V160, P2977, DOI 10.1001/archinte.160.19.2977; von Kodolitsch Y, 2000, THORAC CARDIOV SURG, V48, P342, DOI 10.1055/s-2000-8346; 1958, MEDICINE, V37, P217	59	209	217	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2262	2272		10.1001/jama.287.17.2262	http://dx.doi.org/10.1001/jama.287.17.2262			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980527				2022-12-28	WOS:000175260600027
J	Grant, M				Grant, M			Secondary persistent infection with hepatitis C virus: a challenge for adaptive immunity	LANCET			English	Editorial Material							CELLS		Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, Program Immunol, St Johns, NF A1B 3V6, Canada	Memorial University Newfoundland	Grant, M (corresponding author), Mem Univ Newfoundland, Fac Med, Div Basic Med Sci, Program Immunol, St Johns, NF A1B 3V6, Canada.							Bassett SE, 2001, HEPATOLOGY, V33, P1479, DOI 10.1053/jhep.2001.24371; Bonacini M, 2001, J ACQ IMMUN DEF SYND, V26, P340, DOI 10.1097/00126334-200104010-00008; Chen M, 1999, GASTROENTEROLOGY, V116, P135, DOI 10.1016/S0016-5085(99)70237-4; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; Gruner NH, 2000, J INFECT DIS, V181, P1528, DOI 10.1086/315450; Kao JH, 1996, J MED VIROL, V50, P303, DOI 10.1002/(SICI)1096-9071(199612)50:4&lt;303::AID-JMV4&gt;3.0.CO;2-C; LAI ME, 1994, LANCET, V343, P388, DOI 10.1016/S0140-6736(94)91224-6; Proust B, 2000, J CLIN MICROBIOL, V38, P3125, DOI 10.1128/JCM.38.8.3125-3127.2000; Tsai SL, 1997, HEPATOLOGY, V25, P449; Zibert A, 1997, HEPATOLOGY, V25, P1245, DOI 10.1002/hep.510250530	10	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1452	1452		10.1016/S0140-6736(02)08466-0	http://dx.doi.org/10.1016/S0140-6736(02)08466-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988241				2022-12-28	WOS:000175279100005
J	Jameson, J; Ugarte, K; Chen, N; Yachi, P; Fuchs, E; Boismenu, R; Havran, WL				Jameson, J; Ugarte, K; Chen, N; Yachi, P; Fuchs, E; Boismenu, R; Havran, WL			A rote for skin gamma delta T cells in wound repair	SCIENCE			English	Article							KERATINOCYTE GROWTH-FACTOR; ANTIGEN RECEPTORS; EPIDERMAL-CELLS; THY-1 ANTIGEN; EXPRESSION; REEPITHELIALIZATION; CLONING; FGF10; MODEL; LIMB	gammadelta T cell receptor-bearing dendritic epidermal T cells (DETCs) found in murine skin recognize antigen expressed by damaged or stressed keratinocytes. Activated DETCs produce keratinocyte growth factors (KGFs) and chemokines, raising the possibility that DETCs play a role in tissue repair. We performed wound healing studies and found defects in keratinocyte proliferation and tissue reepithelialization in the absence of wild-type DETCs. In vitro skin organ culture studies demonstrated that adding DETCs or recombinant KGF restored normal wound healing in gammadelta DETC-deficient skin. We propose that DETCs recognize antigen expressed by injured keratinocytes and produce factors that directly affect wound repair.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Scripps Research Institute; Howard Hughes Medical Institute; University of Chicago	Havran, WL (corresponding author), Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA.				NIAID NIH HHS [5T32 AI07244, AI36964, AI32751] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007244, R21AI032751, R01AI036964, R29AI032751, R01AI032751] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLISON JP, 1991, ANNU REV IMMUNOL, V9, P679, DOI 10.1146/annurev.iy.09.040191.003335; Beer HD, 1997, ONCOGENE, V15, P2211, DOI 10.1038/sj.onc.1201383; BERGSTRESSER PR, 1983, J INVEST DERMATOL, V81, P286, DOI 10.1111/1523-1747.ep12518332; BOISMENU R, 1994, SCIENCE, V266, P1253, DOI 10.1126/science.7973709; BOTTARO DP, 1993, J BIOL CHEM, V268, P9180; CHEN Y, IN PRESS P NATL ACAD; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HAVRAN WL, 1989, P NATL ACAD SCI USA, V86, P4185, DOI 10.1073/pnas.86.11.4185; HAVRAN WL, 1991, SCIENCE, V252, P1430, DOI 10.1126/science.1828619; Hayday AC, 2000, ANNU REV IMMUNOL, V18, P975, DOI 10.1146/annurev.immunol.18.1.975; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Jaakkola P, 1998, FASEB J, V12, P959, DOI 10.1096/fasebj.12.11.959; JAMESON JR, UNPUB; Jimenez PA, 1999, J SURG RES, V81, P238, DOI 10.1006/jsre.1998.5501; Mallick-Wood CA, 1998, SCIENCE, V279, P1729, DOI 10.1126/science.279.5357.1729; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sakai S, 2000, J INVEST DERMATOL, V114, P1184, DOI 10.1046/j.1523-1747.2000.00992.x; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; STAIANOCOICO L, 1993, J EXP MED, V178, P865, DOI 10.1084/jem.178.3.865; Tagashira S, 1997, GENE, V197, P399, DOI 10.1016/S0378-1119(97)00187-X; TSCHACHLER E, 1983, J INVEST DERMATOL, V81, P282, DOI 10.1111/1523-1747.ep12518326; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; Xia YP, 1999, J PATHOL, V188, P431, DOI 10.1002/(SICI)1096-9896(199908)188:4<431::AID-PATH362>3.0.CO;2-B; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918	28	480	510	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					747	749		10.1126/science.1069639	http://dx.doi.org/10.1126/science.1069639			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976459				2022-12-28	WOS:000175281700059
J	Wilson, RI; Nicoll, RA				Wilson, RI; Nicoll, RA			Neuroscience - Endocannabinoid signaling in the brain	SCIENCE			English	Review							LONG-TERM POTENTIATION; CANNABINOID RECEPTOR ANTAGONIST; CEREBELLAR PURKINJE-CELLS; ROSTRAL VENTROMEDIAL MEDULLA; RAT HIPPOCAMPAL-NEURONS; INHIBIT N-TYPE; SYNAPTIC TRANSMISSION; CB1 RECEPTOR; CALCIUM CHANNELS; INDUCED ANTINOCICEPTION	The primary psychoactive ingredient in cannabis, Delta(9)-tetrahydrocannabinol (Delta(9)-THC), affects the brain mainly by activating a specific receptor (CB1). CB1 is expressed at high levels in many brain regions, and several endogenous brain lipids have been identified as CB1 ligands. In contrast to classical neurotransmitters, endogenous cannabinoids can function as retrograde synaptic messengers: They are released from postsynaptic neurons and travel backward across synapses, activating CB1 on presynaptic axons and suppressing neurotransmitter release. Cannabinoids may affect memory, cognition, and pain perception by means of this cellular mechanism.	Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; California Institute of Technology	Nicoll, RA (corresponding author), Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, 513 Parsassus ave, San Francisco, CA 94143 USA.		Wilson, Rachel/E-2227-2012; Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Wilson, Rachel/0000-0001-8573-9266				Banks MI, 2000, NEURON, V25, P449, DOI 10.1016/S0896-6273(00)80907-1; Beinfeld MC, 2001, NEUROSCI LETT, V301, P69, DOI 10.1016/S0304-3940(01)01591-9; Beltramo M, 1997, SCIENCE, V277, P1094, DOI 10.1126/science.277.5329.1094; Bisogno T, 1999, BIOCHEM BIOPH RES CO, V256, P377, DOI 10.1006/bbrc.1999.0254; Breivogel CS, 2001, MOL PHARMACOL, V60, P155, DOI 10.1124/mol.60.1.155; Brodkin J, 1997, J PHARMACOL EXP THER, V282, P1526; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; Calignano A, 1997, EUR J PHARMACOL, V337, pR1, DOI 10.1016/S0014-2999(97)01297-1; Compton DR, 1996, J PHARMACOL EXP THER, V277, P586; Cravatt BF, 2001, P NATL ACAD SCI USA, V98, P9371, DOI 10.1073/pnas.161191698; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Diana MA, 2002, J NEUROSCI, V22, P200, DOI 10.1523/JNEUROSCI.22-01-00200.2002; DIMARZO V, 1994, NATURE, V372, P686, DOI 10.1038/372686a0; Egertova M, 2000, J COMP NEUROL, V422, P159, DOI 10.1002/(SICI)1096-9861(20000626)422:2<159::AID-CNE1>3.0.CO;2-1; Egertova M, 1998, P ROY SOC B-BIOL SCI, V265, P2081, DOI 10.1098/rspb.1998.0543; Elphick MR, 2001, PHILOS T R SOC B, V356, P381, DOI 10.1098/rstb.2000.0787; FIELDS HL, 1991, ANNU REV NEUROSCI, V14, P219, DOI 10.1146/annurev.neuro.14.1.219; GEREAU RW, 1995, J NEUROSCI, V15, P6879; Giuffrida A, 2000, EUR J PHARMACOL, V408, P161, DOI 10.1016/S0014-2999(00)00786-X; Hajos N, 2000, EUR J NEUROSCI, V12, P3239, DOI 10.1046/j.1460-9568.2000.00217.x; Hajos N, 2001, NEUROSCIENCE, V106, P1, DOI 10.1016/S0306-4522(01)00287-1; Hampson RE, 2000, J NEUROSCI, V20, P8932; HERKENHAM M, 1991, J NEUROSCI, V11, P563, DOI 10.1523/jneurosci.11-02-00563.1991; Hoffman AF, 2000, J NEUROSCI, V20, P2470; Hohmann AG, 1999, NEUROSCIENCE, V90, P923, DOI 10.1016/S0306-4522(98)00524-7; IVERSEN LL, 2000, SCI MARIJUANA, P36; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Katona I, 2000, NEUROSCIENCE, V100, P797, DOI 10.1016/S0306-4522(00)00286-4; Katona I, 1999, J NEUROSCI, V19, P4544; Kreitzer AC, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-20-j0005.2001; Kreitzer AC, 2001, NEURON, V29, P717, DOI 10.1016/S0896-6273(01)00246-X; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Levenes C, 1998, J PHYSIOL-LONDON, V510, P867, DOI 10.1111/j.1469-7793.1998.867bj.x; LICHTMAN AH, 1991, J PHARMACOL EXP THER, V258, P517; Lichtman AH, 1996, J PHARMACOL EXP THER, V276, P585; LLANO I, 1991, NEURON, V6, P565, DOI 10.1016/0896-6273(91)90059-9; Lujan R, 1997, J CHEM NEUROANAT, V13, P219, DOI 10.1016/S0891-0618(97)00051-3; MACKIE K, 1992, P NATL ACAD SCI USA, V89, P3825, DOI 10.1073/pnas.89.9.3825; Maejima T, 2001, NEURON, V31, P463, DOI 10.1016/S0896-6273(01)00375-0; Manzanares J, 1999, TRENDS PHARMACOL SCI, V20, P287, DOI 10.1016/S0165-6147(99)01339-5; Marsicano G, 1999, EUR J NEUROSCI, V11, P4213, DOI 10.1046/j.1460-9568.1999.00847.x; Martin LA, 2001, J PHYSIOL-LONDON, V532, P685, DOI 10.1111/j.1469-7793.2001.0685e.x; Martin WJ, 1998, NEUROSCI LETT, V242, P33, DOI 10.1016/S0304-3940(98)00044-5; MATSUDA LA, 1993, J COMP NEUROL, V327, P535, DOI 10.1002/cne.903270406; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Meng ID, 1998, NATURE, V395, P381, DOI 10.1038/26481; Misner DL, 1999, J NEUROSCI, V19, P6795, DOI 10.1523/JNEUROSCI.19-16-06795.1999; Morisset V, 2001, J NEUROPHYSIOL, V86, P40, DOI 10.1152/jn.2001.86.1.40; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Ohno-Shosaku T, 2001, NEURON, V29, P729, DOI 10.1016/S0896-6273(01)00247-1; Paton GS, 1998, NEUROPHARMACOLOGY, V37, P1123, DOI 10.1016/S0028-3908(98)00096-3; Piomelli D, 1998, NEUROBIOL DIS, V5, P462, DOI 10.1006/nbdi.1998.0221; PITLER TA, 1992, J NEUROSCI, V12, P4122; Reibaud M, 1999, EUR J PHARMACOL, V379, pR1, DOI 10.1016/S0014-2999(99)00496-3; Richardson JD, 1997, EUR J PHARMACOL, V319, pR3, DOI 10.1016/S0014-2999(96)00952-1; Shen MX, 1998, BRAIN RES, V783, P77, DOI 10.1016/S0006-8993(97)01195-5; Stella N, 2001, EUR J PHARMACOL, V425, P189, DOI 10.1016/S0014-2999(01)01182-7; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; Sullivan JM, 1999, J NEUROPHYSIOL, V82, P1286, DOI 10.1152/jn.1999.82.3.1286; Takahashi KA, 2000, J NEUROPHYSIOL, V83, P1167, DOI 10.1152/jn.2000.83.3.1167; Terranova JP, 1996, PSYCHOPHARMACOLOGY, V126, P165, DOI 10.1007/BF02246352; TERRANOVA JP, 1995, N-S ARCH PHARMACOL, V352, P576, DOI 10.1007/BF00169393; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; Tsou K, 1999, NEUROSCIENCE, V93, P969, DOI 10.1016/S0306-4522(99)00086-X; Twitchell W, 1997, J NEUROPHYSIOL, V78, P43, DOI 10.1152/jn.1997.78.1.43; Varma N, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-24-j0003.2001; VARMA N, 2001, SOC NEUR ABSTR, P973; Vaughan CW, 1999, BRIT J PHARMACOL, V127, P935, DOI 10.1038/sj.bjp.0702636; Vaughan CW, 2000, MOL PHARMACOL, V57, P288; Wagner JJ, 1996, J PHYSIOL-LONDON, V495, P107, DOI 10.1113/jphysiol.1996.sp021577; Walker JM, 1999, P NATL ACAD SCI USA, V96, P12198, DOI 10.1073/pnas.96.21.12198; Wilson RI, 2001, NEURON, V31, P453, DOI 10.1016/S0896-6273(01)00372-5; Wilson RI, 2001, NATURE, V410, P588, DOI 10.1038/35069076; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	76	926	955	2	200	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					678	682		10.1126/science.1063545	http://dx.doi.org/10.1126/science.1063545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976437				2022-12-28	WOS:000175281700037
J	Kimple, RJ; Kimple, ME; Betts, L; Sondek, J; Siderovski, DP				Kimple, RJ; Kimple, ME; Betts, L; Sondek, J; Siderovski, DP			Structural determinants for GoLoco-induced inhibition of nucleotide release by G alpha subunits	NATURE			English	Article							DISSOCIATION INHIBITOR; G-PROTEINS; GDP; G(I-ALPHA-1); ACTIVATION; MECHANISM; ARGININE; COMPLEX; SYSTEM; MOTIF	Heterotrimeric G-proteins bind to cell-surface receptors and are integral in transmission of signals from outside the cell. Upon activation of the Galpha subunit by binding of GTP, the Galpha and Gbetagamma subunits dissociate and interact with effector proteins for signal transduction. Regulatory proteins with the 19-amino-acid GoLoco motif(1,2) can bind to Galpha subunits and maintain G-protein subunit dissociation in the absence of Galpha activation(3-7). Here we describe the structural determinants of GoLoco activity as revealed by the crystal structure of Galpha(il)-GDP bound to the GoLoco region of the 'regulator of G-protein signalling' protein RGS14. Key contacts are described between the GoLoco motif and Ga protein, including the extension of GoLoco's highly conserved Asp/Glu-Gln-Arg triad into the nucleotide-binding pocket of Ga to make direct contact with the GDP alpha- and beta-phosphates. The structural organization of the GoLoco-Galpha(il) complex, when combined with supporting data from domain-swapping experiments, suggests that the Galpha all-helical domain and GoLoco-region carboxy-terminal residues control the specificity of GoLoco- Galpha interactions.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, UNC Neurosci Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Siderovski, DP (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.	dsiderov@med.unc.edu	Siderovski, David Peter/AAA-9603-2019; Kimple, Randall/L-6460-2019	Siderovski, David Peter/0000-0002-0688-8210; Kimple, Randall/0000-0001-8336-8000; Sondek, John/0000-0002-1127-8310	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008570] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008570] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bourne HR, 1997, NATURE, V389, P673, DOI 10.1038/39470; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coleman DE, 1998, BIOCHEMISTRY-US, V37, P14376, DOI 10.1021/bi9810306; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Graham DL, 1999, BIOCHEMISTRY-US, V38, P985, DOI 10.1021/bi9821770; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mittal R, 1996, SCIENCE, V273, P115, DOI 10.1126/science.273.5271.115; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Neubig RR, 2002, NAT REV DRUG DISCOV, V1, P187, DOI 10.1038/nrd747; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Paulin FEM, 2001, CURR BIOL, V11, P55, DOI 10.1016/S0960-9822(00)00025-7; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Remmers AE, 1999, BIOCHEMISTRY-US, V38, P13795, DOI 10.1021/bi990887f; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Wall MA, 1998, STRUCTURE, V6, P1169, DOI 10.1016/S0969-2126(98)00117-8; [No title captured]	30	203	206	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	2002	416	6883					878	881		10.1038/416878a	http://dx.doi.org/10.1038/416878a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976690				2022-12-28	WOS:000175163800058
J	Edhouse, J; Brady, WJ; Morris, F				Edhouse, J; Brady, WJ; Morris, F			ABC of clinical electrocardiography - Acute myocardial infarction - Part II	BRITISH MEDICAL JOURNAL			English	Review									Stepping Hill Hosp, Stockport SK2 7JE, Lancs, England; Univ Virginia, Dept Emergency Med, Charlottesville, VA USA; No Gen Hosp, Sheffield S5 7AU, S Yorkshire, England	University of Virginia; Northern General Hospital	Edhouse, J (corresponding author), Stepping Hill Hosp, Stockport SK2 7JE, Lancs, England.								0	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 20	2002	324	7343					963	966		10.1136/bmj.324.7343.963	http://dx.doi.org/10.1136/bmj.324.7343.963			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544UF	11964344	Green Published			2022-12-28	WOS:000175179500021
J	Hamano, H; Kawa, S; Ochi, Y; Unno, H; Shiba, N; Wajiki, M; Nakazawa, K; Shimojo, H; Kiyosawa, K				Hamano, H; Kawa, S; Ochi, Y; Unno, H; Shiba, N; Wajiki, M; Nakazawa, K; Shimojo, H; Kiyosawa, K			Hydronephrosis associated with retroperitoneal fibrosis and sclerosing pancreatitis	LANCET			English	Article								Sclerosing pancreatitis is associated with raised concentrations of IgG4. We treated 22 patients with sclerosing pancreatitis, and identified and followed-up three with concomitant hydronephrosis caused by ureteral mass, later diagnosed as retroperitoneal fibrosis. We histologically examined the ureteral and pancreatic lesions of these patients and noted abundant infiltration of IgG4-bearing plasma cells in both tissues. Treatment with corticosteroids lowered serum concentrations of IgG4. IgG4 might also have a pathological role in a systemic fibrosing process that includes pancreatic and retroperitoneal lesions.	Shinshu Univ, Sch Med, Dept Internal Med 2, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Pathol, Matsumoto, Nagano 3908621, Japan; Ina Cent Hosp, Ina, Saitama 3968555, Japan; Shinonoi Gen Hosp, Nagano 3888004, Japan	Shinshu University; Shinshu University	Kawa, S (corresponding author), Shinshu Univ, Sch Med, Dept Internal Med 2, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	skawapc@hsp.md.shinshu-u.ac.jp		Nakazawa, Koh/0000-0002-3213-560X				Erkelens GW, 1999, LANCET, V354, P43, DOI 10.1016/S0140-6736(99)00603-0; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Levey JM, 1998, AM J GASTROENTEROL, V93, P640; RENNER IG, 1980, GASTROENTEROLOGY, V79, P348; YOSHIDA K, 1995, DIGEST DIS SCI, V40, P1561, DOI 10.1007/BF02285209	5	399	433	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	2002	359	9315					1403	1404		10.1016/S0140-6736(02)08359-9	http://dx.doi.org/10.1016/S0140-6736(02)08359-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978339				2022-12-28	WOS:000175076200014
J	Cheng, Y; Austin, SC; Rocca, B; Koller, BH; Coffman, TM; Grosser, T; Lawson, JA; FitzGerald, GA				Cheng, Y; Austin, SC; Rocca, B; Koller, BH; Coffman, TM; Grosser, T; Lawson, JA; FitzGerald, GA			Role of prostacyclin in the cardiovascular response to thromboxane A(2)	SCIENCE			English	Article							INHIBITS PLATELET-AGGREGATION; CORONARY ANGIOPLASTY; PROSTAGLANDIN ENDOPEROXIDES; RECEPTOR; BIOSYNTHESIS; EXPRESSION; RESTENOSIS; CYCLOOXYGENASE-2; DESENSITIZATION; ACTIVATION	Thromboxane (Tx) A(2) is a vasoconstrictor and platelet agonist. Aspirin affords cardioprotection through inhibition of TxA(2) formation by platelet cyclooxygenase (COX-1). Prostacyclin (PGI(2)) is a vasodilator that inhibits platelet function. Here we show that injury-induced vascular proliferation and platelet activation are enhanced in mice that are genetically deficient in the PGI(2) receptor (IP) but are depressed in mice genetically deficient in the TxA(2) receptor (TP) or treated with a TP antagonist. The augmented response to vascular injury was abolished in mice deficient in both receptors. Thus, PGI(2) modulates platelet-vascular interactions in vivo and specifically limits the response to TxA(2). This interplay may help explain the adverse cardiovascular effects associated with selective COX-2 inhibitors, which, unlike aspirin and nonsteroidal anti-Inflammatory drugs (NSAIDs), inhibit PGI(2) but not TxA(2).	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ N Carolina, Dept Med, Chapel Hill, NC 27559 USA; Duke Univ, Dept Med, Durham, NC 27705 USA	University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; Duke University	FitzGerald, GA (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, 153 Johnson Pavil,3620 Hamilton Walk, Philadelphia, PA 19104 USA.		rocca, bianca/K-3922-2018; Grosser, Tilo/A-1057-2007; FitzGerald, Garret A/A-4222-2010	Grosser, Tilo/0000-0001-8569-8396; 	NHLBI NIH HHS [HL 62250, HL 54500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062250, P50HL054500] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barry OP, 1998, J CLIN INVEST, V102, P136, DOI 10.1172/JCI2592; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; BRADEN GA, 1991, CIRCULATION, V84, P679, DOI 10.1161/01.CIR.84.2.679; BUNTING S, 1976, PROSTAG OTH LIPID M, V12, P897, DOI 10.1016/0090-6980(76)90125-8; Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; Caughey GE, 2001, J BIOL CHEM, V276, P37839; Cheng Y., UNPUB; Cheung WM, 1999, ARTERIOSCL THROM VAS, V19, P3014, DOI 10.1161/01.ATV.19.12.3014; Cimetiere B, 1998, BIOORG MED CHEM LETT, V8, P1375, DOI 10.1016/S0960-894X(98)00220-0; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; FITZGERALD GA, 1984, NEW ENGL J MED, V310, P1065, DOI 10.1056/NEJM198404263101701; FITZGERALD GA, 1991, AM J CARDIOL, V68, pB11, DOI 10.1016/0002-9149(91)90379-Y; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; MARCUS AJ, 1980, J CLIN INVEST, V66, P979, DOI 10.1172/JCI109967; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; MURRAY R, 1990, J BIOL CHEM, V265, P21670; NAMBA T, 1994, J BIOL CHEM, V269, P9986; NICHOLSON NS, 1984, THROMB RES, V35, P183, DOI 10.1016/0049-3848(84)90213-5; NOWAK J, 1989, J CLIN INVEST, V83, P380, DOI 10.1172/JCI113895; Patrono C, 2001, CHEST, V119, p39S, DOI 10.1378/chest.119.1_suppl.39S; PEDERSEN ML, 1983, THROMB RES, V35, P99; Rocca B, 2000, NAT MED, V6, P219, DOI 10.1038/72334; ROY L, 1985, CIRCULATION, V71, P434, DOI 10.1161/01.CIR.71.3.434; SAVAGE MP, 1995, CIRCULATION, V92, P3194, DOI 10.1161/01.CIR.92.11.3194; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; Thomas DW, 1998, J CLIN INVEST, V102, P1994, DOI 10.1172/JCI5116; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Walsh MT, 2000, J BIOL CHEM, V275, P20412, DOI 10.1074/jbc.M907881199	32	654	704	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					539	541		10.1126/science.1068711	http://dx.doi.org/10.1126/science.1068711			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964481				2022-12-28	WOS:000175179400048
J	Zhang, K; Rathod, PK				Zhang, K; Rathod, PK			Divergent regulation of dihydrofolate reductase between malaria parasite and human host	SCIENCE			English	Article							FALCIPARUM THYMIDYLATE SYNTHASE; PLASMODIUM-FALCIPARUM; ESCHERICHIA-COLI; GENE; PYRIMETHAMINE; PROTEIN; 5-FLUOROOROTATE; PURIFICATION; TRANSLATION; CYCLOGUANIL	For half a century, successful antifolate therapy against Plasmodium falciparum malaria has been attributed to host-parasite differences in drug binding to dihydrofolate reductase-thymidylate synthase (DHFR-TS). Selectivity may also arise through previously unappreciated differences in regulation of this drug target. The DHFR-TS of Plasmodium binds its cognate messenger RNA (mRNA) and inhibits its own translation. However, unlike translational regulation of DHFR or TS in humans, DHFR-TS mRNA binding is not coupled to enzyme active sites. Thus, antifolate treatment does not relieve translational inhibition and parasites cannot replenish dead enzyme.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Seattle Biomed Res Inst, Seattle, WA 98109 USA	University of Washington; University of Washington Seattle; Center for Infectious Disease Research	Rathod, PK (corresponding author), Univ Washington, Dept Chem, Seattle, WA 98195 USA.				NIAID NIH HHS [AI40956, AI26912, R01 AI026912] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040956, R01AI026912, R29AI026912] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERTINO JR, 1964, J BIOL CHEM, V239, P476; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; Breman JG, 2001, AM J TROP MED HYG, V64, pIV, DOI 10.4269/ajtmh.2001.64.iv; CANFIELD CJ, 1993, AM J TROP MED HYG, V49, P121, DOI 10.4269/ajtmh.1993.49.121; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1993, MOL PHARMACOL, V43, P527; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; ErcikanAbali EA, 1997, BIOCHEMISTRY-US, V36, P12317, DOI 10.1021/bi971026e; FERONE R, 1969, MOL PHARMACOL, V5, P49; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; Fidock DA, 2000, MOL BIOCHEM PARASIT, V110, P1, DOI 10.1016/S0166-6851(00)00249-8; FOOTE SJ, 1990, P NATL ACAD SCI USA, V87, P3014, DOI 10.1073/pnas.87.8.3014; GARRETT CE, 1984, MOL BIOCHEM PARASIT, V11, P257, DOI 10.1016/0166-6851(84)90070-7; HekmatNejad M, 1996, ANTIMICROB AGENTS CH, V40, P1628, DOI 10.1128/AAC.40.7.1628; HekmatNejad M, 1997, EXP PARASITOL, V85, P303, DOI 10.1006/expr.1997.4145; HITCHINGS GH, 1960, CLIN PHARMACOL THER, V1, P570; KEYOMARSI K, 1993, J BIOL CHEM, V268, P15142; PETERSON DS, 1990, P NATL ACAD SCI USA, V87, P3018, DOI 10.1073/pnas.87.8.3018; PHILLIPS MA, 1988, J BIOL CHEM, V263, P17933; Prapunwattana P, 1996, MOL BIOCHEM PARASIT, V83, P93, DOI 10.1016/S0166-6851(96)02756-9; RATHOD PK, 1992, ANTIMICROB AGENTS CH, V36, P704, DOI 10.1128/AAC.36.4.704; SANO G, 1994, MOL BIOCHEM PARASIT, V63, P265, DOI 10.1016/0166-6851(94)90062-0; Shallom S, 1999, J BIOL CHEM, V274, P37781, DOI 10.1074/jbc.274.53.37781; Zhang K. Y., UNPUB	24	116	119	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					545	547		10.1126/science.1068274	http://dx.doi.org/10.1126/science.1068274			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964483	Green Accepted			2022-12-28	WOS:000175179400050
J	Moreno, E; Basler, K; Morata, G				Moreno, E; Basler, K; Morata, G			Cells compete for Decapentaplegic survival factor to prevent apoptosis in Drosophila wing development	NATURE			English	Article							CELLULAR GROWTH; DPP; GRADIENT; BRINKER; DEATH; COMPARTMENTS; PARAMETERS; DIVISION; SEQUENCE; HOMOLOG	During the growth of Drosophila imaginal discs a process called 'cell competition'(1) eliminates slow-proliferating but otherwise viable cells. We report here that cell competition requires the function of the brinker (brk) gene, whose expression is normally repressed by Decapentaplegic (Dpp) signalling(2-4) but is upregulated in slow-growing Minute/+ cells. Excess brk expression activates the c-Jun amino-terminal kinase pathway, which in turn triggers apoptosis in these cells. We propose that slow-proliferating cells upregulate Brk levels owing to a disadvantage in competing for, or in transducing, the Dpp survival signal. This sequence of events might represent a general mechanism by which weaker cells are eliminated from a growing population, and might serve as a method of controlling cell number and optimizing tissue fitness and hence organ function.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; UAM, CSIC, Ctr Biol Mol, Madrid 28049, Spain	University of Zurich; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Basler, K (corresponding author), Univ Zurich, Inst Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	basler@molbio.unizh.ch; gmorata@cbm.uam.es	Moreno, Eduardo/D-7262-2011	Basler, Konrad/0000-0003-3534-1529; moreno, eduardo/0000-0001-5040-452X; Morata, Gines/0000-0003-3274-5173				Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Burke R, 1996, DEVELOPMENT, V122, P2261; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; Entchev EV, 2000, CELL, V103, P981, DOI 10.1016/S0092-8674(00)00200-2; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; HAY BA, 1994, DEVELOPMENT, V120, P2121; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; Lambertsson A, 1998, ADV GENET, V38, P69, DOI 10.1016/S0065-2660(08)60142-X; Lawrence PA, 2001, NAT CELL BIOL, V3, pE151, DOI 10.1038/35083096; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; Minami M, 1999, NATURE, V398, P242, DOI 10.1038/18451; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; SIMPSON P, 1979, DEV BIOL, V69, P182, DOI 10.1016/0012-1606(79)90284-7; SIMPSON P, 1981, DEV BIOL, V85, P299, DOI 10.1016/0012-1606(81)90261-X; Struhl G, 1997, DEVELOPMENT, V124, P2155; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Zhang HL, 2001, GENE DEV, V15, P261, DOI 10.1101/gad.861201	27	325	332	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	2002	416	6882					755	759		10.1038/416755a	http://dx.doi.org/10.1038/416755a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961558				2022-12-28	WOS:000175033500046
J	Takayanagi, H; Kim, S; Matsuo, K; Suzuki, H; Suzuki, T; Sato, K; Yokochi, T; Oda, H; Nakamura, K; Ida, N; Wagner, EF; Taniguchi, T				Takayanagi, H; Kim, S; Matsuo, K; Suzuki, H; Suzuki, T; Sato, K; Yokochi, T; Oda, H; Nakamura, K; Ida, N; Wagner, EF; Taniguchi, T			RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta	NATURE			English	Article							LYMPH-NODE ORGANOGENESIS; OSTEOCLAST DIFFERENTIATION; DEFECTIVE INTERLEUKIN-1; TRANSCRIPTION FACTORS; TARGETED DISRUPTION; GENE INDUCTION; KEY REGULATOR; CROSS-TALK; MICE; OSTEOPROTEGERIN	Osteoclasts are cells of monocyte/macrophage origin that erode bone matrix: regulation of their differentiation is central to the understanding of the pathogenesis and treatment of bone diseases such as osteoporosis(1,2). Signalling by RANKL (receptor activator of NF-kappaB ligand), also known as Tnfsf11, is essential for the induction of osteoclast differentiation(3-5), and it must be strictly regulated to maintain bone homeostasis. But it is not known whether RANKL signalling to the cell interior is linked to any regulatory mechanisms. Here we show that RANKL induces the interferon-beta (IFN-beta) gene in osteoclast precursor cells, and that IFN-beta inhibits the differentiation by interfering with the RANKL-induced expression of c-Fos, an essential transcription factor for the formation of osteoclasts. This IFN-beta gene induction mechanism is distinct from that induced by virus, and is dependent on c-Fos itself. Thus an autoregulatory mechanism operates-the RANKL-induced c-Fos induces its own inhibitor. The importance of this regulatory mechanism for bone homeostasis is emphasized by the observation that mice deficient in IFN-beta signalling exhibit severe osteopenia (loss of bone mass) accompanied by enhanced osteoclastogenesis. Our study places the IFN-beta system in a new context, and may offer a molecular basis for the treatment of bone diseases.	Univ Tokyo, Fac Med, Dept Immunol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan; Res Inst Mol Pathol, A-1030 Vienna, Austria; NILS, Aichi 4748522, Japan; Toray Industries Ltd, Pharmaceut Res Labs, Kanagawa 2488555, Japan	University of Tokyo; University of Tokyo; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Toray Industries, Inc.	Taniguchi, T (corresponding author), Univ Tokyo, Fac Med, Dept Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		Matsuo, Koichi/K-5695-2012	Matsuo, Koichi/0000-0002-1490-8955; Wagner, Erwin F/0000-0001-7872-0196; Suzuki, Hiroshi/0000-0003-4682-5086				Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hida S, 2000, IMMUNITY, V13, P643, DOI 10.1016/S1074-7613(00)00064-9; Kimura T, 1996, GENES CELLS, V1, P115, DOI 10.1046/j.1365-2443.1996.08008.x; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; SAMUEL CE, 1993, J BIOL CHEM, V268, P7603; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Takayanagi H, 2000, ARTHRITIS RHEUM-US, V43, P259, DOI 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Takayanagi H, 1999, J CLIN INVEST, V104, P137, DOI 10.1172/JCI6093; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Wagner EF, 2001, CURR OPIN GENET DEV, V11, P527, DOI 10.1016/S0959-437X(00)00228-8; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	30	544	567	4	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					744	749		10.1038/416744a	http://dx.doi.org/10.1038/416744a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961557				2022-12-28	WOS:000175033500044
J	Dirix, LY; van Oosterom, AT				Dirix, LY; van Oosterom, AT			Gene-expression profiling to classify soft-tissue sarcomas	LANCET			English	Editorial Material							GASTROINTESTINAL STROMAL TUMORS; KIT		AZ St Augustinus, B-2610 Antwerp, Belgium; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven	Dirix, LY (corresponding author), AZ St Augustinus, B-2610 Antwerp, Belgium.	luc.dirix@pandora.be	Dirix, Luc/AAI-8880-2020					Allander SV, 2001, CANCER RES, V61, P8624; Fletcher CDM, 2001, J CLIN ONCOL, V19, P3045, DOI 10.1200/JCO.2001.19.12.3045; Ladanyi M, 2002, CANCER RES, V62, P135; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rubin BP, 2001, CANCER RES, V61, P8118; Tamborini E, 2001, BRIT J CANCER, V85, P405, DOI 10.1054/bjoc.2001.1935; Van Glabbeke M, 1999, J CLIN ONCOL, V17, P150, DOI 10.1200/JCO.1999.17.1.150; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7	8	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	2002	359	9314					1263	1264		10.1016/S0140-6736(02)08281-8	http://dx.doi.org/10.1016/S0140-6736(02)08281-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965266				2022-12-28	WOS:000174989700003
J	Nasrallah, JB				Nasrallah, JB			Recognition and rejection of self in plant reproduction	SCIENCE			English	Article							S-RECEPTOR KINASE; BRASSICA-CAMPESTRIS; HIGHLY DIVERGENT; INCOMPATIBILITY; LOCUS; DETERMINANT; HAPLOTYPES; SEQUENCES; EVOLUTION; ALLELES	Plant self-incompatibility (SI) systems are unique among self/nonself recognition systems in being based on the recognition of self rather than nonself. SI in crucifer species is controlled by highly polymorphic and co-evolving genes linked in a complex. Self recognition is based on allele-specific interactions between stigma receptors and pollen ligands that result in the arrest of pollen tube development. Commonalities and differences between SI and other self/nonself discrimination systems are discussed.	Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA	Cornell University	Nasrallah, JB (corresponding author), Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA.	jbn2@cornell.edu						Azevedo C, 2001, TRENDS PLANT SCI, V6, P354, DOI 10.1016/S1360-1385(01)01960-4; Boyes DC, 1997, PLANT CELL, V9, P237, DOI 10.1105/tpc.9.2.237; Brown AJ, 2001, TRENDS GENET, V17, P393, DOI 10.1016/S0168-9525(01)02343-5; BURNET FM, 1971, NATURE, V232, P230, DOI 10.1038/232230a0; Cabrillac D, 2001, NATURE, V410, P220, DOI 10.1038/35065626; Charlesworth D, 2000, CURR BIOL, V10, pR184, DOI 10.1016/S0960-9822(00)00347-X; Cui YH, 2000, P NATL ACAD SCI USA, V97, P3713, DOI 10.1073/pnas.050480297; Ferris PJ, 1997, P NATL ACAD SCI USA, V94, P8634, DOI 10.1073/pnas.94.16.8634; Ferris PJ, 2002, GENETICS, V160, P181; Giranton JL, 2000, P NATL ACAD SCI USA, V97, P3759, DOI 10.1073/pnas.070025097; Hatakeyama K, 2001, PLANT J, V26, P69, DOI 10.1046/j.1365-313x.2001.01009.x; Hughes AL, 1999, CELL MOL LIFE SCI, V56, P94, DOI 10.1007/s000180050010; Ida K, 2001, J MOL BIOL, V314, P103, DOI 10.1006/jmbi.2001.5127; Kachroo A, 2001, SCIENCE, V293, P1824, DOI 10.1126/science.1062509; Klein J, 1998, ANNU REV ECOL SYST, V29, P1, DOI 10.1146/annurev.ecolsys.29.1.1; KLEIN J, 1986, NATURAL HIST MAJOR H; Kusaba M, 2002, PLANT PHYSIOL, V128, P17, DOI 10.1104/pp.010790; Kusaba M, 2001, PLANT CELL, V13, P627, DOI 10.1105/tpc.13.3.627; Matton DP, 1999, PLANT CELL, V11, P2087, DOI 10.1105/tpc.11.11.2087; Nasrallah JB, 2000, CURR OPIN PLANT BIOL, V3, P368, DOI 10.1016/S1369-5266(00)00098-4; Nettancourt, 2001, INCOMPATIBILITY INCO; Nishio T, 2000, ANN BOT-LONDON, V85, P141, DOI 10.1006/anbo.1999.1041; NOU IS, 1993, SEX PLANT REPROD, V6, P79, DOI 10.1007/BF00227652; Rudd JJ, 2001, NEW PHYTOL, V151, P7, DOI 10.1046/j.1469-8137.2001.00173.x; Schopfer CR, 1999, SCIENCE, V286, P1697, DOI 10.1126/science.286.5445.1697; Shiba H, 2001, PLANT PHYSIOL, V125, P2095, DOI 10.1104/pp.125.4.2095; Shiu SH, 2001, P NATL ACAD SCI USA, V98, P10763, DOI 10.1073/pnas.181141598; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; Stone SL, 1999, SCIENCE, V286, P1729, DOI 10.1126/science.286.5445.1729; Takasaki T, 2000, NATURE, V403, P913, DOI 10.1038/35002628; Takayama S, 2000, P NATL ACAD SCI USA, V97, P1920, DOI 10.1073/pnas.040556397; Takayama S, 2001, NATURE, V413, P534, DOI 10.1038/35097104; Uyenoyama MK, 2001, GENETICS, V157, P1805; UYENOYAMA MK, 1995, GENETICS, V139, P975; Vanoosthuyse V, 2001, PLANT MOL BIOL, V46, P17, DOI 10.1023/A:1010664704926; Watanabe M, 2000, FEBS LETT, V473, P139, DOI 10.1016/S0014-5793(00)01514-3	36	94	99	2	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	2002	296	5566					305	308		10.1126/science.296.5566.305	http://dx.doi.org/10.1126/science.296.5566.305			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951033				2022-12-28	WOS:000175000300044
J	Macfarlane, J				Macfarlane, J			Severe pneumonia and a second antibiotic	LANCET			English	Editorial Material							COMMUNITY-ACQUIRED PNEUMONIA; ETIOLOGY		City Hosp Nottingham, Clin Resp Med Unit, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital	Macfarlane, J (corresponding author), City Hosp Nottingham, Clin Resp Med Unit, Hucknall Rd, Nottingham NG5 1PB, England.	john.macfarlane@tinyworld.co.uk						Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; Davidson R, 2002, NEW ENGL J MED, V346, P747, DOI 10.1056/NEJMoa012122; Jokinen C, 2001, CLIN INFECT DIS, V32, P1141, DOI 10.1086/319746; Kalin M, 2000, J INFECT DIS, V182, P840, DOI 10.1086/315760; Lieberman D, 1996, THORAX, V51, P179, DOI 10.1136/thx.51.2.179; Lim WS, 2001, THORAX, V56, P296, DOI 10.1136/thorax.56.4.296; Macfarlane J, 2001, THORAX, V56, P109, DOI 10.1136/thorax.56.2.109; Mandell LA, 2000, CLIN INFECT DIS, V31, P422, DOI 10.1086/313965; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; Roson B, 2001, CLIN INFECT DIS, V33, P158, DOI 10.1086/321808; Waterer GW, 2001, RESP MED, V95, P78, DOI 10.1053/rmed.2000.0977; Waterer GW, 2001, ARCH INTERN MED, V161, P1837, DOI 10.1001/archinte.161.15.1837	12	8	8	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 6	2002	359	9313					1170	1172		10.1016/S0140-6736(02)08250-8	http://dx.doi.org/10.1016/S0140-6736(02)08250-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955532				2022-12-28	WOS:000174846300004
J	Crabtree, GR; Olson, EN				Crabtree, GR; Olson, EN			NFAT signaling: Choreographing the social lives of cells	CELL			English	Review							ACTIVATED T-CELLS; DEPENDENT TRANSCRIPTIONAL PATHWAY; GLYCOGEN-SYNTHASE KINASE-3-BETA; SKELETAL-MUSCLE HYPERTROPHY; INDUCED CARDIAC-HYPERTROPHY; CAPACITATIVE CALCIUM-ENTRY; SYNDROME CRITICAL REGION; CYCLOSPORINE-A; GENE-EXPRESSION; NUCLEAR FACTOR	Calcium signaling activates the phosphatase calcineurin and induces movement of NFATc proteins into the nucleus, where they cooperate with other proteins to form complexes on DNA. Nuclear import is opposed by kinases such as GSK3, thereby rendering transcription continuously responsive to receptor occupancy. Disruptions of the genes involved in NFAT signaling are implicating this pathway as a regulator of developmental cell-cell interactions.	Stanford Univ, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Dept Pathol, Stanford, CA 94305 USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Crabtree, GR (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA.	crabtree@cmgm.stanford.edu						Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; BATIUK TD, 1995, TRANSPLANTATION, V59, P1400, DOI 10.1097/00007890-199505270-00007; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; Calvo S, 1999, MOL CELL BIOL, V19, P515; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CHOI MSK, 1994, IMMUNITY, V1, P179, DOI 10.1016/1074-7613(94)90096-5; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Deng LL, 2001, J CARDIOVASC ELECTR, V12, P1055, DOI 10.1046/j.1540-8167.2001.01055.x; DIEHN M, 2002, IN PRESS P NATL ACAD; Dunn SE, 1999, J BIOL CHEM, V274, P21908, DOI 10.1074/jbc.274.31.21908; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Esau C, 2001, J EXP MED, V194, P1449, DOI 10.1084/jem.194.10.1449; Fatkin D, 2000, J CLIN INVEST, V106, P1351, DOI 10.1172/JCI11093; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Frey N, 2000, P NATL ACAD SCI USA, V97, P14632, DOI 10.1073/pnas.260501097; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 2001, P NATL ACAD SCI USA, V98, P5740, DOI 10.1073/pnas.101602398; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Handen JS, 1997, J BIOL CHEM, V272, P1665, DOI 10.1074/jbc.272.3.1665; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Kegley KM, 2001, DEV BIOL, V232, P115, DOI 10.1006/dbio.2001.0179; Kelsell DP, 2001, TRENDS CELL BIOL, V11, P2, DOI 10.1016/S0962-8924(00)01866-3; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; Kinoshita S, 1998, CELL, V95, P595, DOI 10.1016/S0092-8674(00)81630-X; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; Kumar P, 2000, EDN, V45, P127; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LEDEIST F, 1995, BLOOD, V85, P1053, DOI 10.1182/blood.V85.4.1053.bloodjournal8541053; Leinwand LA, 2001, P NATL ACAD SCI USA, V98, P2947, DOI 10.1073/pnas.051033698; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu SF, 1997, EMBO J, V16, P143, DOI 10.1093/emboj/16.1.143; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Sakata Y, 2000, CIRCULATION, V102, P2269; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; Serrano AL, 2001, P NATL ACAD SCI USA, V98, P13108, DOI 10.1073/pnas.231148598; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shimoyama M, 2000, CIRCULATION, V102, P1996, DOI 10.1161/01.CIR.102.16.1996; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; SIEBENLIST U, 1986, MOL CELL BIOL, V6, P3042, DOI 10.1128/MCB.6.9.3042; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Sussman MA, 1998, SCIENCE, V281, P1690, DOI 10.1126/science.281.5383.1690; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; Weiss DL, 2001, IMMUNOL REV, V179, P35, DOI 10.1034/j.1600-065X.2001.790104.x; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; WOODROW M, 1993, J EXP MED, V178, P1517, DOI 10.1084/jem.178.5.1517; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; Zhang W, 1996, J EXP MED, V183, P413, DOI 10.1084/jem.183.2.413; ZHOU B, 2002, IN PRESS J BIOL CHEM; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2; Zou YZ, 2001, CIRCULATION, V104, P97, DOI 10.1161/01.CIR.104.1.97	98	1045	1089	2	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR	2002	109			S			S67	S79		10.1016/S0092-8674(02)00699-2	http://dx.doi.org/10.1016/S0092-8674(02)00699-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	544UY	11983154	Bronze			2022-12-28	WOS:000175181100007
J	Kim, JJ; Wright, TC; Goldie, SJ				Kim, JJ; Wright, TC; Goldie, SJ			Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-PAPILLOMAVIRUS INFECTION; CERVICAL INTRAEPITHELIAL NEOPLASIA; GENITAL HUMAN-PAPILLOMAVIRUS; THINPREP PAP TEST; NATURAL-HISTORY; PAPANICOLAOU SMEAR; CYTOLOGIC ABNORMALITIES; RISK-FACTORS; YOUNG-WOMEN; GYNECOLOGIC CYTOLOGY	Context Every year approximately 2 million US women are diagnosed as having a cervical cytological result of atypical squamous cells of undetermined significance (ASC-US). Objective To determine the most efficient and cost-effective management strategy for women in the United States diagnosed as having ASC-US. Design and Setting Cost-effectiveness analysis of data from clinical trials, prospective studies, and other published literature. A computer-based model was used to compare 4 management strategies for a cytological result of ASC-US: immediate colposcopy; human papillomavirus (HPV) triage, which includes colposcopy if high-risk HPV types are detected; repeat cytology, which includes follow-up cytology at 6 and 12 months and referral for colposcopy if a repeat abnormal result occurs; and reclassifying ASC-US as normal in which a cytological result of ASC-US is ignored. Reflex HPV DNA testing uses either residual liquid-based cytological specimens or samples co-collected at the time of the initial screening for conventional cytology. Another method, referred to as the 2-visit HPV DNA triage, requires a woman with an ASC-US result to return within 1 month to provide another speciman sample. Main Outcome Measures Years of life saved (YLS), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. Results The least costly strategy for biennial screening was to reclassify ASC-US as normal, resulting in a reduction in total cancer incidence of 75% for conventional cytology and 84% for liquid-based cytology compared with no screening. The next least costly strategy was HPV DNA testing resulting in a reduction in total cancer incidence of 86% for conventional cytology and 90% for liquid-based cytology, followed by immediate colposcopy with a reduction of 87% and 91%, respectively. Compared with reflex HPV DNA testing, a strategy of repeat cervical cytology or delayed HPV testing costs more but is less effective. When all strategies were compared simultaneously, varying frequency and type of cytological test, biennial (vs every 3 years) liquid-based cytology with reflex HPV testing had a cost of $174200 per YLS. In a similar comparison, liquid-based cytology with reflex HPV testing conducted every 3 years (vs every 5 years) had a cost of $59 600 per YLS and was more effective and less costly than a strategy of conventional cytology incorporating repeat cytology or immediate colposcopy conducted biennially. Conclusion Reflex HPV DNA testing provides the same or greater life expectancy benefits and is more cost-effective than other management strategies for women diagnosed as having ASC-US.	Harvard Univ, Ctr Risk Anal, Dept Hlth Policy & Management, Sch Publ Hlth, Boston, MA 02115 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Columbia University	Goldie, SJ (corresponding author), Harvard Univ, Ctr Risk Anal, Dept Hlth Policy & Management, Sch Publ Hlth, 718 Huntington Ave,2nd Floor, Boston, MA 02115 USA.							Ashfaq R, 1999, ACTA CYTOL, V43, P81, DOI 10.1159/000330872; Bai HW, 2000, DIAGN CYTOPATHOL, V23, P19, DOI 10.1002/1097-0339(200007)23:1<19::AID-DC4>3.0.CO;2-K; Barry MJ, 2002, ANN INTERN MED, V136, P127, DOI 10.7326/0003-4819-136-2-200201150-00010; BAUER HM, 1993, SEX TRANSM DIS, V20, P274, DOI 10.1097/00007435-199309000-00007; Bergeron C, 2000, OBSTET GYNECOL, V95, P821, DOI 10.1016/S0029-7844(00)00795-X; Brown AD, 1999, JAMA-J AM MED ASSOC, V281, P347, DOI 10.1001/jama.281.4.347; Burk RD, 1996, J INFECT DIS, V174, P679, DOI 10.1093/infdis/174.4.679; Burk RD, 1996, SEX TRANSM DIS, V23, P333, DOI 10.1097/00007435-199607000-00013; COX JT, 2000, J LOW GENIT TRACT DI, V4, P99; CUZICK J, 1999, HEALTH TECHNOL ASSES, V3, P14; Diaz-Rosario LA, 1999, ARCH PATHOL LAB MED, V123, P817; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; Fahs MC, 1996, PHARMACOECONOMICS, V9, P211, DOI 10.2165/00019053-199609030-00004; FAHS MC, 1992, ANN INTERN MED, V117, P520, DOI 10.7326/0003-4819-117-6-520; Ferris DG, 1998, J FAM PRACTICE, V46, P125; Ferris DG, 1998, J FAM PRACTICE, V46, P136; Franco EL, 1999, J INFECT DIS, V180, P1415, DOI 10.1086/315086; Franco EL, 1999, AM J OBSTET GYNECOL, V181, P382, DOI 10.1016/S0002-9378(99)70586-7; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002; Gold MR, 1996, COST EFFECTIVENESS H; Goldie SJ, 2001, JAMA-J AM MED ASSOC, V285, P3107, DOI 10.1001/jama.285.24.3107; Goldie SJ, 1999, ANN INTERN MED, V130, P97, DOI 10.7326/0003-4819-130-2-199901190-00003; Goldie SJ, 2001, AM J MED, V111, P140, DOI 10.1016/S0002-9343(01)00780-X; GOLDIE SJ, 2001, MED DECIS MAKING, V20, P529; Graham JD, 1998, ANNU REV PUBL HEALTH, V19, P125, DOI 10.1146/annurev.publhealth.19.1.125; GUSTAFSSON L, 1992, CANCER CAUSE CONTROL, V3, P125, DOI 10.1007/BF00051652; Gustafsson L, 1997, INT J CANCER, V71, P159, DOI 10.1002/(SICI)1097-0215(19970410)71:2<159::AID-IJC6>3.0.CO;2-#; Helms LJ, 1999, MED CARE, V37, P652, DOI 10.1097/00005650-199907000-00005; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Ho GYF, 1998, INT J CANCER, V78, P281, DOI 10.1002/(SICI)1097-0215(19981029)78:3&lt;281::AID-IJC3&gt;3.0.CO;2-R; Hopman EH, 2000, BRIT J OBSTET GYNAEC, V107, P600, DOI 10.1111/j.1471-0528.2000.tb13299.x; Hutchinson ML, 1999, CANCER CYTOPATHOL, V87, P48, DOI 10.1002/(SICI)1097-0142(19990425)87:2&lt;48::AID-CNCR2&gt;3.0.CO;2-D; Jones BA, 2000, ARCH PATHOL LAB MED, V124, P672; Jones BA, 2000, ARCH PATHOL LAB MED, V124, P665; Kinney WK, 1998, OBSTET GYNECOL, V91, P973, DOI 10.1016/S0029-7844(98)00080-5; Kotloff KL, 1998, SEX TRANSM DIS, V25, P243, DOI 10.1097/00007435-199805000-00005; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Koutsky LA, 1999, SEXUALLY TRANSMITTED, P347; KUNTZ KM, 2000, MED DECIS MAKING, V20, P484; KURMAN RJ, 1994, JAMA-J AM MED ASSOC, V271, P1866, DOI 10.1001/jama.271.23.1866; Lawson HW, 1998, OBSTET GYNECOL, V92, P745, DOI 10.1016/S0029-7844(98)00257-9; Lin CT, 2000, J REPROD MED, V45, P345; LIU TP, 1995, CANCER EPIDEM BIOMAR, V4, P373; Londesborough P, 1996, INT J CANCER, V69, P364; Lonky NM, 1999, AM J OBSTET GYNECOL, V181, P560, DOI 10.1016/S0002-9378(99)70493-X; Malik SN, 1999, ACTA CYTOL, V43, P376, DOI 10.1159/000331084; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; MCCRORY DC, 1999, AHCPR PUBLICATION; MELKERT PWJ, 1993, INT J CANCER, V53, P919, DOI 10.1002/ijc.2910530609; Melnikow J, 1998, OBSTET GYNECOL, V92, P727, DOI 10.1016/S0029-7844(98)00245-2; Moscicki AB, 1999, PEDIATR CLIN N AM, V46, P783, DOI 10.1016/S0031-3955(05)70152-8; Moscicki AB, 1998, J PEDIATR-US, V132, P277, DOI 10.1016/S0022-3476(98)70445-7; Mount SL, 1999, PEDIATRICS, V103, P539, DOI 10.1542/peds.103.3.539; MULLER C, 1990, COSTS EFFECTIVENESS; Myers ER, 2000, AM J EPIDEMIOL, V151, P1158, DOI 10.1093/oxfordjournals.aje.a010166; Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009; *NAT CTR HLTH STAT, 2001, STAT ABSTR US; *NCI, 1997, SURV EP END RES SEER; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; PETTERSSON F, 1985, INT J EPIDEMIOL, V14, P521, DOI 10.1093/ije/14.4.521; PONTEN J, 1995, INT J CANCER, V60, P1, DOI 10.1002/ijc.2910600102; Quddus MR, 2001, CANCER CYTOPATHOL, V93, P16, DOI 10.1002/1097-0142(20010225)93:1<16::AID-CNCR9002>3.0.CO;2-A; REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305; Rozendaal L, 1996, INT J CANCER, V68, P766, DOI 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z; Sawaya GF, 2000, OBSTET GYNECOL, V96, P219, DOI 10.1016/S0029-7844(00)00882-6; SCHIFFMAN MH, 1995, J NATL CANCER I, V87, P1345, DOI 10.1093/jnci/87.18.1345; Schlecht NF, 2001, JAMA-J AM MED ASSOC, V286, P3106, DOI 10.1001/jama.286.24.3106; Sellors JW, 1999, CAN FAM PHYSICIAN, V45, P245; SELLORS JW, 1999, CAN FAM PHYSICIAN, V45, P252; SherlawJohnson C, 1997, INT J CANCER, V72, P210, DOI 10.1002/(SICI)1097-0215(19970717)72:2&lt;210::AID-IJC2&gt;3.0.CO;2-U; Sherman ME, 1999, MODERN PATHOL, V12, P335; Shireman TI, 2001, INT J TECHNOL ASSESS, V17, P146, DOI 10.1017/S0266462301104137; Shlay JC, 2000, OBSTET GYNECOL, V96, P410, DOI 10.1016/S0029-7844(00)00907-8; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; SOLOMON D, 2001, TERMINOLOGY REPORTIN; Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903; SYRJANEN K, 1992, OBSTET GYNECOL, V79, P675; *US BUR LAB STAT, 2001, PUBL US BUR LAB STAT; *US CENS BUR, 2001, POP EST PROGR; Weinstein MC, 1999, ANN INTERN MED, V130, P857, DOI 10.7326/0003-4819-130-10-199905180-00021; Wright TC, 1998, AM J OBSTET GYNECOL, V178, P962, DOI 10.1016/S0002-9378(98)70531-9; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120; WRIGHT TC, 1995, OBSTET GYNECOL, V85, P202, DOI 10.1016/0029-7844(94)00373-L; Wright TC, 1994, BLAUSTEINS PATHOLOGY, P229; 2001, NATL PHYSICIAN FEE S; 1994, MMWR MORB MORTAL WKL, V43, P530; 2001, 2001 CLIN DIAGNOSTIC	93	205	215	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 8	2002	287	18					2382	2390		10.1001/jama.287.18.2382	http://dx.doi.org/10.1001/jama.287.18.2382			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	548PF	11988059	Bronze			2022-12-28	WOS:000175397000027
J	Gournay, V; Savagner, C; Thiriez, G; Kuster, A; Roze, JC				Gournay, V; Savagner, C; Thiriez, G; Kuster, A; Roze, JC			Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants	LANCET			English	Article								We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation. Echocardiography showed severely decreased pulmonary blood flow. Hypoxaemia resolved quickly on inhaled nitric oxide therapy. We suggest that investigators involved In similar trials pay close attention to pulmonary pressure if hypoxaemia occurs after prophylactic administration of ibuprofen.	Univ Hosp, Dept Perinatol, Nantes, France; Univ Hosp, Dept Perinatol, Angers, France; Univ Hosp, Dept Perinatol, Besancon, France	Nantes Universite; CHU de Nantes; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite de Franche-Comte; CHU Besancon	Roze, JC (corresponding author), Hop Mere & Enfant, Serv Reanimat Neonatal, Quai Moncousu, F-44000 Nantes, France.		roze, jean christophe/B-5433-2012; Rozé, Jean-Christophe/AAS-1314-2021	Roze, Jean-Christophe/0000-0003-3367-512X				Knight D B, 2001, Semin Neonatol, V6, P63, DOI 10.1053/siny.2000.0036; Narayanan M, 2000, J PEDIATR-US, V136, P330, DOI 10.1067/mpd.2000.103414; Schmidt B, 2001, NEW ENGL J MED, V344, P1966, DOI 10.1056/NEJM200106283442602; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; VELVIS H, 1991, PEDIATR RES, V30, P62, DOI 10.1203/00006450-199107000-00013	5	82	85	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1486	1488		10.1016/S0140-6736(02)08424-6	http://dx.doi.org/10.1016/S0140-6736(02)08424-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988250				2022-12-28	WOS:000175279100014
J	Gershon, D				Gershon, D			Microarray technology - An array of opportunities	NATURE			English	Article																			0	113	131	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					885	+		10.1038/416885a	http://dx.doi.org/10.1038/416885a			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976691	Bronze			2022-12-28	WOS:000175163800059
J	Althabe, F; Belizan, JM; Bergel, E				Althabe, F; Belizan, JM; Bergel, E			Episiotomy rates in primiparous women in Latin America: hospital based descriptive study	BRITISH MEDICAL JOURNAL			English	Article								Current scientific evidence shows that routine episiotomy is not justified: it has no benefit for mother or infant, increases the need for perineal suturing and the risk of complications to the healing process at seven days post partum, produces unnecessary pain and discomfort, and has potentially harmful long term effects.(1-3) We report rates of episiotomy in primiparous women in Latin American hospitals according to characteristics of hospitals and caregivers.	WHO, Pan Amer Hlth Org, Latin Amer Ctr Perinatol, Montevideo 11000, Uruguay	Pan American Health Organization; World Health Organization	Althabe, F (corresponding author), WHO, Pan Amer Hlth Org, Latin Amer Ctr Perinatol, Casilla Correos 627, Montevideo 11000, Uruguay.			Belizan, Jose/0000-0002-8412-3010				Carroli G., 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000081, DOI 10.1002/14651858.CD000081]; SCHWARCZ R, 1987, Journal of Perinatal Medicine, V15, P9; Signorello LB, 2000, BRIT MED J, V320, P86, DOI 10.1136/bmj.320.7227.86; Woolley R J, 1995, Obstet Gynecol Surv, V50, P821, DOI 10.1097/00006254-199511000-00021	4	35	39	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 20	2002	324	7343					945	946		10.1136/bmj.324.7343.945	http://dx.doi.org/10.1136/bmj.324.7343.945			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544UF	11964339	Bronze, Green Published			2022-12-28	WOS:000175179500016
J	Remuzzi, G; Ruggenenti, P; Perico, N				Remuzzi, G; Ruggenenti, P; Perico, N			Chronic renal diseases: Renoprotective benefits of renin-angiotensin system inhibition	ANNALS OF INTERNAL MEDICINE			English	Review							CONVERTING ENZYME-INHIBITION; PASSIVE HEYMANN NEPHRITIS; BLOOD-PRESSURE CONTROL; GROWTH-FACTOR-BETA; DIABETIC-NEPHROPATHY; ACE-INHIBITION; NEPHROTIC SYNDROME; PROGRESSIVE NEPHROPATHIES; INTERSTITIAL INFLAMMATION; LIPOPROTEIN ABNORMALITIES	Progression to renal parenchymal damage and end-stage renal disease, which seems to be largely independent of the initial insult, is the final common pathway for chronic, proteinuric nephropathies in animals and humans. The key event is enhanced glomerular capillary pressure; this impairs glomerular permeability to proteins and permits excessive amounts of proteins to reach the lumen of the proximal tubule. The secondary process of reabsorption of filtered proteins can contribute to renal interstitial injury by activating intracellular events, including upregulation of the genes encoding vasoactive and inflammatory mediators, Both interstitial inflammation and progression of disease can be controlled by such drugs as angiotensin-converting enzyme inhibitors, which strengthen the glomerular permeability barrier to proteins and thereby limit proteinuria and filtered protein-dependent inflammatory signals. Clinical data strongly suggest that remission can now be achieved in some patients with chronic renal disease. Because of the current lag time between starting treatment and remission, however, a substantial proportion of patients still progress to end-stage renal disease before renal function begins to stabilize. A multimodal approach that centers on reducing or removing all risk factors associated with the progression of renal disease may decrease the time to remission of the disease for most patients with proteinuric nephropathies.	Mario Negri Inst Pharmacol Res, I-24125 Bergamo, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	Remuzzi, G (corresponding author), Mario Negri Inst Pharmacol Res, Via Gavazzeni 11, I-24125 Bergamo, Italy.	gremuzzi@marionegri.it	Perico, Norberto/ABH-3222-2020; Remuzzi, Giuseppe/V-9766-2017	Perico, Norberto/0000-0002-3147-4327; Remuzzi, Giuseppe/0000-0002-6194-3446				Abbate M, 1998, J AM SOC NEPHROL, V9, P1213; ADDIS T, 1940, T ASSOC AM PHYSICIAN, V55, P223; ANDERSON S, 1986, J CLIN INVEST, V77, P1993, DOI 10.1172/JCI112528; AZIZI M, 1995, CIRCULATION, V92, P825, DOI 10.1161/01.CIR.92.4.825; Bakris GL, 1998, KIDNEY INT, V54, P1283, DOI 10.1046/j.1523-1755.1998.00083.x; Benigni A, 1998, KIDNEY INT, V54, P353, DOI 10.1046/j.1523-1755.1998.00011.x; BERTANI T, 1986, KIDNEY INT, V30, P488, DOI 10.1038/ki.1986.212; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRENNER BM, 1982, NEW ENGL J MED, V307, P652, DOI 10.1056/NEJM198209093071104; Breyer JA, 1996, KIDNEY INT, V50, P1651, DOI 10.1038/ki.1996.481; Bruzzi I, 1997, AM J PATHOL, V151, P1241; Buter H, 1998, NEPHROL DIAL TRANSPL, V13, P1682, DOI 10.1093/ndt/13.7.1682; CAMERON J, 1988, NEPHROTIC SYNDROME, V8, P999; CHURG J, 1970, LANCET, V1, P1299; CLAPP WL, 1988, LAB INVEST, V58, P549; EDDY AA, 1995, KIDNEY INT, V47, P1546, DOI 10.1038/ki.1995.218; Eddy AA, 1996, J AM SOC NEPHROL, V7, P2495; Eppel GA, 1999, KIDNEY INT, V55, P1861, DOI 10.1046/j.1523-1755.1999.00424.x; *ESRD, 1999, AM J KIDNEY DIS, V34, pS124; *ESRD, 1999, AM J KIDNEY DIS, V34, pS40; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; Giatras I, 1997, ANN INTERN MED, V127, P337, DOI 10.7326/0003-4819-127-5-199709010-00001; HANNEDOUCHE T, 1994, BRIT MED J, V309, P833, DOI 10.1136/bmj.309.6958.833; HAYSLETT JP, 1969, NEW ENGL J MED, V281, P181, DOI 10.1056/NEJM196907242810402; Hebert LA, 2000, KIDNEY INT, V57, P343, DOI 10.1046/j.1523-1755.2000.00852.x; HEEG JE, 1989, KIDNEY INT, V36, P272, DOI 10.1038/ki.1989.190; HOSTETTER TH, 1994, KIDNEY INT, V46, P266, DOI 10.1038/ki.1994.269; HOSTETTER TH, 1981, AM J PHYSIOL, V241, pF85, DOI 10.1681/ASN.V1261315; HOSTETTER TH, 1995, PRINCIPLES PRACTICE, P202; Hovind P, 2001, KIDNEY INT, V60, P277, DOI 10.1046/j.1523-1755.2001.00797.x; IKOMA M, 1991, KIDNEY INT, V40, P195, DOI 10.1038/ki.1991.200; KAMPER AL, 1995, NEPHROL DIAL TRANSPL, V10, P1182, DOI 10.1093/ndt/10.7.1182; Kasiske BL, 1998, AM J KIDNEY DIS, V31, P954, DOI 10.1053/ajkd.1998.v31.pm9631839; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; Lloyd GM, 1997, J EXP MED, V185, P1371, DOI 10.1084/jem.185.7.1371; MACKENSENHAEN S, 1992, CLIN NEPHROL, V37, P70; MALLICK NP, 1987, NEPHRON, V46, P113, DOI 10.1159/000184325; Maschio G, 1996, NEW ENGL J MED, V334, P939, DOI 10.1056/NEJM199604113341502; MCGOVERN VJ, 1964, AUSTRALAS ANN MED, V13, P306; NADASDY T, 1994, RENAL PATHOLOGY CLIN, P330; Ong A. C. M., 1993, Journal of the American Society of Nephrology, V4, P473; ORISIO S, 1993, KIDNEY INT, V43, P354, DOI 10.1038/ki.1993.53; Orth SR, 2000, NEPHROL DIAL TRANSPL, V15, P1509, DOI 10.1093/ndt/15.10.1509; PARVING HH, 1987, BRIT MED J, V294, P1443, DOI 10.1136/bmj.294.6585.1443; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; Pinto-Sietsma SJ, 2000, ANN INTERN MED, V133, P585, DOI 10.7326/0003-4819-133-8-200010170-00008; PLATT R, 1952, BMJ-BRIT MED J, V1, P1372, DOI 10.1136/bmj.1.4773.1372; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; REMUZZI A, 1993, J AM SOC NEPHROL, V4, P40; REMUZZI A, 1990, J CLIN INVEST, V85, P541, DOI 10.1172/JCI114470; Remuzzi A, 1999, AM J KIDNEY DIS, V34, P626, DOI 10.1016/S0272-6386(99)70385-9; Remuzzi G, 1998, J AM SOC NEPHROL, V9, P1321; Remuzzi G, 1998, NEW ENGL J MED, V339, P1448, DOI 10.1056/NEJM199811123392007; Remuzzi G, 1999, AM J KIDNEY DIS, V33, P807, DOI 10.1016/S0272-6386(99)70241-6; RICH AR, 1957, B JOHNS HOPKINS HOSP, V100, P173; RISDON RA, 1968, LANCET, V2, P363; Ruggenenti P, 1999, J AM SOC NEPHROL, V10, P997; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 1998, J AM SOC NEPHROL, V9, P2096; Ruggenenti P, 1998, LANCET, V352, P1252, DOI 10.1016/S0140-6736(98)04433-X; Ruggenenti P, 1997, Kidney Int Suppl, V63, pS54; Ruggenenti P, 2001, LANCET, V357, P1601, DOI 10.1016/S0140-6736(00)04728-0; RUILOPE LM, 1990, J HYPERTENS, V8, P525, DOI 10.1097/00004872-199006000-00005; Russo D, 1999, AM J KIDNEY DIS, V33, P851, DOI 10.1016/S0272-6386(99)70416-6; SAMUELSSON O, 1994, NEPHROL DIAL TRANSPL, V9, P1580; Samuelsson O, 1997, NEPHROL DIAL TRANSPL, V12, P1908, DOI 10.1093/ndt/12.9.1908; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHNAPER HW, 1997, DIS KIDNEY, P1725; SHARMA K, 1993, SEMIN NEPHROL, V13, P116; Tang WW, 1997, J IMMUNOL, V159, P870; Valderrabano F, 1996, NEPHROL DIAL TRANSPL, V11, P2; Wang YP, 1997, J AM SOC NEPHROL, V8, P1537; WEHRMANN M, 1989, CLIN NEPHROL, V31, P67; WEIDMANN P, 1995, NEPHROL DIAL TRANSPL, V10, P39; Weinberg Marc S., 2000, Journal of the American Society of Nephrology, V11, p79A; WHITE RHR, 1970, LANCET, V1, P1353; Wilmer WA, 1999, AM J KIDNEY DIS, V34, P308, DOI 10.1016/S0272-6386(99)70360-4; YOSHIOKA T, 1986, KIDNEY INT, V30, P538, DOI 10.1038/ki.1986.219; YOSHIOKA T, 1987, CIRC RES, V61, P531, DOI 10.1161/01.RES.61.4.531; ZATZ R, 1986, J CLIN INVEST, V77, P1925, DOI 10.1172/JCI112521; Zoccali C, 1997, NEPHROL DIAL TRANSPL, V12, P234, DOI 10.1093/oxfordjournals.ndt.a027738; Zoja C, 1996, EXP NEPHROL, V4, P213; Zoja C, 1998, EXP NEPHROL, V6, P121; Zoja C, 1998, KIDNEY INT, V53, P1608, DOI 10.1046/j.1523-1755.1998.00905.x; Zoja C, 1995, AM J KIDNEY DIS, V26, P934, DOI 10.1016/0272-6386(95)90058-6	87	203	206	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 16	2002	136	8					604	615		10.7326/0003-4819-136-8-200204160-00010	http://dx.doi.org/10.7326/0003-4819-136-8-200204160-00010			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	543WY	11955029				2022-12-28	WOS:000175125800006
J	Campbell, JC				Campbell, JC			Health consequences of intimate partner violence	LANCET			English	Article							POSTTRAUMATIC-STRESS-DISORDER; DOMESTIC VIOLENCE; PHYSICAL ABUSE; BIRTH-WEIGHT; RISK-FACTORS; PRIMARY-CARE; WIFE ABUSE; LONGITUDINAL ANALYSIS; WOMENS RESPONSES; PREGNANT-WOMEN	Intimate partner violence, which describes physical or sexual assault, or both, of a spouse or sexual intimate, Is a common health-care issue. In this article, I have reviewed research on the mental and physical health sequelae of such violence. Increased health problems such as injury, chronic pain, gastrointestinal, and gynaecological signs including sexually-transmitted diseases, depression, and post-traumatic stress disorder are well documented by controlled research in abused women In various settings. Intimate partner violence has been noted in 3-13% of pregnancies in many studies from around the world, and is associated with detrimental outcomes to mothers and infants. I recommend increased assessment and Interventions for intimate partner violence in health-care settings.	Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21205 USA	Johns Hopkins University	Campbell, JC (corresponding author), Johns Hopkins Univ, Sch Nursing, 525 N Wolfe St, Baltimore, MD 21205 USA.							AMARO H, 1990, AM J PUBLIC HEALTH, V80, P575, DOI 10.2105/AJPH.80.5.575; [Anonymous], 1999, Popul Rep L, P1; Bachman R., 1995, BUREAU JUSTICE STAT; BERGMAN B, 1991, ACTA PSYCHIAT SCAND, V83, P380, DOI 10.1111/j.1600-0447.1991.tb05560.x; BROCK K, 1999, WHEN MEN MURDER WOME; Brookoff D, 1997, JAMA-J AM MED ASSOC, V277, P1369, DOI 10.1001/jama.277.17.1369; BULLOCK LF, 1989, AM J NURS, V89, P1153, DOI 10.2307/3426112; Campbell J, 1999, AM J EPIDEMIOL, V150, P714; Campbell J, 1998, J INTERPERS VIOLENCE, V13, P743, DOI 10.1177/088626098013006005; Campbell J C, 1993, AWHONNS Clin Issues Perinat Womens Health Nurs, V4, P343; Campbell J. C., 1997, VIOLENCE AGAINST WOM, V3, P271, DOI DOI 10.1177/1077801297003003004; Campbell J.C., 1999, VIOLENCE AGAINST WOM, V5, P1017, DOI [10.1177/1077801299005009003, DOI 10.1177/1077801299005009003]; Campbell JC, 1999, J INTERPERS VIOLENCE, V14, P21, DOI 10.1177/088626099014001002; Campbell JC, 1997, PSYCHIAT CLIN N AM, V20, P353, DOI 10.1016/S0193-953X(05)70317-8; CAMPBELL JC, IN PRESS ARCH INTERN; CAMPBELL R, 1995, PSYCHOL WOMEN QUART, V19, P237, DOI 10.1111/j.1471-6402.1995.tb00290.x; Cascardi M, 1999, J FAM VIOLENCE, V14, P227, DOI 10.1023/A:1022827915757; CHALK R, 1998, HLTH CARE INTERVENTI; Champion J D, 1998, Issues Ment Health Nurs, V19, P463; Coker A L, 1998, Afr J Reprod Health, V2, P61; Coker AL, 2000, ARCH FAM MED, V9, P451, DOI 10.1001/archfami.9.5.451; Collett BJ, 1998, BRIT J OBSTET GYNAEC, V105, P87, DOI 10.1111/j.1471-0528.1998.tb09356.x; COUNTS DA, 1987, SUICIDE LIFE-THREAT, V17, P194; CRAWFORD M, 1997, INTIMATE FEMICIDE ON; CURRY MA, 1998, EMPOWERING SURVIVORS; Dearwater SR, 1998, JAMA-J AM MED ASSOC, V280, P433, DOI 10.1001/jama.280.5.433; Diaz-Olavarrieta C, 1999, ARCH NEUROL-CHICAGO, V56, P681, DOI 10.1001/archneur.56.6.681; DROSSMAN DA, 1995, ANN INTERN MED, V123, P782, DOI 10.7326/0003-4819-123-10-199511150-00007; Ellsberg M, 1999, AM PSYCHOL, V54, P30, DOI 10.1037/0003-066X.54.1.30; ELLSBERG MC, IN PRESS SOC SCI MED; *FAM VIOL PREV FUN, 1999, PREV DOM VIOL CLIN G; Fikree FF, 1999, INT J GYNECOL OBSTET, V65, P195, DOI 10.1016/S0020-7292(99)00035-1; GARTNER R, 1990, AM SOCIOL REV, V55, P92, DOI 10.2307/2095705; Gazmararian J A, 2000, Matern Child Health J, V4, P79, DOI 10.1023/A:1009514119423; Gazmararian JA, 1996, JAMA-J AM MED ASSOC, V275, P1915, DOI 10.1001/jama.275.24.1915; GAZMARARIAN JA, 1995, OBSTET GYNECOL, V85, P131; Gielen A C, 2000, Matern Child Health J, V4, P111, DOI 10.1023/A:1009522321240; Glander SS, 1998, OBSTET GYNECOL, V91, P1002, DOI 10.1016/S0029-7844(98)00089-1; Golding JM, 1999, J FAM VIOLENCE, V14, P99, DOI 10.1023/A:1022079418229; Grisso JA, 1999, NEW ENGL J MED, V341, P1899, DOI 10.1056/NEJM199912163412506; Humphreys J C, 1999, Image J Nurs Sch, V31, P139; Jejeebhoy SJ, 1998, STUD FAMILY PLANN, V29, P300, DOI 10.2307/172276; Jones AS, 1999, WOMEN HEALTH ISS, V9, P295; Kilpatrick DG, 1997, J CONSULT CLIN PSYCH, V65, P834, DOI 10.1037/0022-006X.65.5.834; KOSS MP, 1991, ARCH INTERN MED, V151, P342, DOI 10.1001/archinte.151.2.342; Kulka R.A., 1990, TRAUMA VIETNAM WAR G; Kyriacou DN, 1999, NEW ENGL J MED, V341, P1892, DOI 10.1056/NEJM199912163412505; Lempert LE, 1996, J FAM VIOLENCE, V11, P269, DOI 10.1007/BF02336945; Leserman J, 1998, PSYCHOL MED, V28, P417, DOI 10.1017/S0033291797006508; Letourneau EJ, 1999, WOMEN HEALTH ISS, V9, P115, DOI 10.1016/S1049-3867(98)00031-0; Maman S, 2000, SOC SCI MED, V50, P459, DOI 10.1016/S0277-9536(99)00270-1; *MARCH DIM BIRTH D, 2001, PROT CAR BATT WOM; Martin S L, 1998, Matern Child Health J, V2, P85, DOI 10.1023/A:1022988722277; Martin SL, 1999, JAMA-J AM MED ASSOC, V282, P1967, DOI 10.1001/jama.282.20.1967; MCCAULEY J, 1995, ANN INTERN MED, V123, P737, DOI 10.7326/0003-4819-123-10-199511150-00001; McFarlane J, 1996, NURS RES, V45, P37, DOI 10.1097/00006199-199601000-00007; MEZEY G, 2001, EXPLORATION PREVALEN; Muhajarine N, 1999, CAN MED ASSOC J, V160, P1007; Murphy CC, 2001, CAN MED ASSOC J, V164, P1567; Parker B, 1999, RES NURS HEALTH, V22, P59; PARKER B, 1993, NURS RES, V42, P173; Parsons LH, 1999, OBSTET GYNECOL, V94, P990, DOI 10.1016/S0029-7844(99)00466-4; PEARLMAN MD, 1990, NEW ENGL J MED, V323, P1609; Plichta S. B., 1996, WOMENS HLTH COMMONWE; Rand M., 1997, VIOLENCE RELATED INJ; RATNER PA, 1993, CAN J PUBLIC HEALTH, V84, P246; SCHEI B, 1989, BRIT J OBSTET GYNAEC, V96, P1379, DOI 10.1111/j.1471-0528.1989.tb06298.x; Schrieber, 1999, HE MUST GIVE ME MONE; Sharps PW, 2001, AM J ADDICTION, V10, P122; Silva C, 1997, J WOMENS HEALTH, V6, P543, DOI 10.1089/jwh.1997.6.543; Soeken K., EMPOWERING SURVIVORS; Stark E, 1996, WOMEN RISK DOMESTIC; STEWART DE, 1993, CAN MED ASSOC J, V149, P1257; Strauss M.A., 1990, PHYS VIOLENCE AM FAM, P29; Sutherland C, 1998, Womens Health, V4, P41; Tollestrup K, 1999, PREV MED, V29, P431, DOI 10.1006/pmed.1999.0552; Watts C, 1997, SAfAIDS News, V5, P2; WIDDING L, 1999, ACTA OBSTET GYNECOL, V78, P310; Wiist WH, 1999, AM J PUBLIC HEALTH, V89, P1217, DOI 10.2105/AJPH.89.8.1217; Wingood GM, 1997, AM J PUBLIC HEALTH, V87, P1016, DOI 10.2105/AJPH.87.6.1016; Wisner CL, 1999, J FAM PRACTICE, V48, P439; Wood K, 1997, Gend Dev, V5, P41; Zierler S, 2000, AM J PUBLIC HEALTH, V90, P208, DOI 10.2105/AJPH.90.2.208	83	2341	2374	10	363	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1331	1336		10.1016/S0140-6736(02)08336-8	http://dx.doi.org/10.1016/S0140-6736(02)08336-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	541NB	11965295				2022-12-28	WOS:000174989700031
J	Causier, B; Kieffer, M; Davies, B				Causier, B; Kieffer, M; Davies, B			Plant biology: MADS-Box genes reach maturity	SCIENCE			English	Editorial Material									Univ Leeds, Ctr Plant Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Causier, B (corresponding author), Univ Leeds, Ctr Plant Sci, Leeds LS2 9JT, W Yorkshire, England.			Kieffer, Martin/0000-0002-0987-2716; Causier, Barry/0000-0001-5942-7031; Davies, Brendan/0000-0002-9282-3789				Brummell DA, 2001, PLANT MOL BIOL, V47, P311, DOI 10.1023/A:1010656104304; Giovannoni J, 2001, ANNU REV PLANT PHYS, V52, P725, DOI 10.1146/annurev.arplant.52.1.725; Grierson D, 1996, NAT BIOTECHNOL, V14, P828, DOI 10.1038/nbt0796-828b; Gutierrez-Cortines ME, 2000, TRENDS PLANT SCI, V5, P471, DOI 10.1016/S1360-1385(00)01761-1; Kieffer M, 2001, SEMIN CELL DEV BIOL, V12, P373, DOI 10.1006/scdb.2001.0266; Stepanova AN, 2000, CURR OPIN PLANT BIOL, V3, P353, DOI 10.1016/S1369-5266(00)00096-0; Vrebalov J, 2002, SCIENCE, V296, P343, DOI 10.1126/science.1068181	7	54	59	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					275	276		10.1126/science.1071401	http://dx.doi.org/10.1126/science.1071401			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951024				2022-12-28	WOS:000175000300035
J	Simpson, GG; Dean, C				Simpson, GG; Dean, C			Flowering - Arabidopsis, the rosetta stone of flowering time?	SCIENCE			English	Review							MADS DOMAIN PROTEIN; PHYTOCHROME-B; MERISTEM IDENTITY; GENE-EXPRESSION; VERNALIZATION; THALIANA; ENCODES; TRANSITION; MUTATIONS; LOCUS	Multiple environmental and endogenous inputs regulate when plants flower. The molecular genetic dissection of flowering time control in Arabidopsis has identified an integrated network of pathways that quantitatively control the timing of this developmental switch. This framework provides the basis to understand the evolution of different reproductive strategies and how floral pathways interact through seasonal progression.	John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Dean, C (corresponding author), John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England.							Aubert D, 2001, PLANT CELL, V13, P1865, DOI 10.1105/tpc.13.8.1865; Aukerman MJ, 1997, PLANT CELL, V9, P1317, DOI 10.1105/tpc.9.8.1317; BERNIER G, 1988, ANNU REV PLANT PHYS, V39, P175, DOI 10.1146/annurev.arplant.39.1.175; Blazquez M, 2001, EMBO REP, V2, P1078, DOI 10.1093/embo-reports/kve254; Blazquez MA, 2000, NATURE, V404, P889, DOI 10.1038/35009125; Blazquez MA, 1999, PLANT PHYSIOL, V120, P1025, DOI 10.1104/pp.120.4.1025; BLAZQUEZ MA, COMMUNICATION; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; Brock HW, 2001, CURR OPIN GENET DEV, V11, P175, DOI 10.1016/S0959-437X(00)00176-3; Chandler J, 2000, PLANTA, V210, P677, DOI 10.1007/s004250050059; Childs KL, 1997, PLANT PHYSIOL, V113, P611, DOI 10.1104/pp.113.2.611; CLACK T, 1994, PLANT MOL BIOL, V25, P413, DOI 10.1007/BF00043870; Colasanti J, 1998, CELL, V93, P593, DOI 10.1016/S0092-8674(00)81188-5; COUPLAND G, 1995, TRENDS GENET, V11, P393, DOI 10.1016/S0168-9525(00)89122-2; Devlin PF, 1998, PLANT CELL, V10, P1479, DOI 10.1105/tpc.10.9.1479; Gendall AR, 2001, CELL, V107, P525, DOI 10.1016/S0092-8674(01)00573-6; Gomez-Mena C, 2001, PLANT CELL, V13, P1011, DOI 10.1105/tpc.13.5.1011; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; JACOBSEN SE, 1993, PLANT CELL, V5, P887, DOI 10.1105/tpc.5.8.887; Johanson U, 2000, SCIENCE, V290, P344, DOI 10.1126/science.290.5490.344; Kardailsky I, 1999, SCIENCE, V286, P1962, DOI 10.1126/science.286.5446.1962; Kieffer M, 2001, SEMIN CELL DEV BIOL, V12, P373, DOI 10.1006/scdb.2001.0266; Kinoshita T, 2001, P NATL ACAD SCI USA, V98, P14156, DOI 10.1073/pnas.241507798; Kobayashi Y, 1999, SCIENCE, V286, P1960, DOI 10.1126/science.286.5446.1960; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Larsson AS, 1998, GENETICS, V149, P597; Laurie DA, 1997, PLANT MOL BIOL, V35, P167, DOI 10.1023/A:1005726329248; Lee H, 2000, GENE DEV, V14, P2366, DOI 10.1101/gad.813600; Lee HJ, 2001, GENE DEV, V15, P912, DOI 10.1101/gad.866801; LEE I, 1994, CELL, V6, P75; Levy YY, 1998, PLANT CELL, V10, P1973, DOI 10.1105/tpc.10.12.1973; Lin CT, 2000, PLANT PHYSIOL, V123, P39, DOI 10.1104/pp.123.1.39; Liu JY, 2001, PLANT PHYSIOL, V125, P1821, DOI 10.1104/pp.125.4.1821; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MACKNIGHT R, UNPUB; MARTINEZZAPATER JM, 1990, PLANT PHYSIOL, V92, P770, DOI 10.1104/pp.92.3.770; Mas P, 2000, NATURE, V408, P207, DOI 10.1038/35041583; Michaels SD, 1999, PLANT CELL, V11, P949, DOI 10.1105/tpc.11.5.949; Michaels SD, 2001, PLANT CELL, V13, P935, DOI 10.1105/tpc.13.4.935; Micheals SD, 1999, DEV GENET, V25, P194, DOI 10.1002/(SICI)1520-6408(1999)25:3&lt;194::AID-DVG2&gt;3.0.CO;2-2; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; Mockler TC, 1999, DEVELOPMENT, V126, P2073; NAPP-ZINN K., 1961, Zuchter, V31, P128, DOI 10.1007/BF00709087; Neff MM, 1998, PLANT PHYSIOL, V118, P27, DOI 10.1104/pp.118.1.27; Nilsson O, 1998, GENETICS, V150, P403; Onouchi H, 2000, PLANT CELL, V12, P885, DOI 10.1105/tpc.12.6.885; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; QUESADA V, UNPUB; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; REED JW, 1994, PLANT PHYSIOL, V104, P1139, DOI 10.1104/pp.104.4.1139; Reeves PH, 2001, PLANT PHYSIOL, V126, P1085, DOI 10.1104/pp.126.3.1085; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; Samach A, 2000, SCIENCE, V288, P1613, DOI 10.1126/science.288.5471.1613; Schomburg FM, 2001, PLANT CELL, V13, P1427, DOI 10.1105/tpc.13.6.1427; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; Sheldon CC, 2000, P NATL ACAD SCI USA, V97, P3753, DOI 10.1073/pnas.060023597; Sheldon CC, 1999, PLANT CELL, V11, P445, DOI 10.1105/tpc.11.3.445; SIMPSON GS, UNPUB; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; Sugano S, 1999, P NATL ACAD SCI USA, V96, P12362, DOI 10.1073/pnas.96.22.12362; Takahashi Y, 2001, P NATL ACAD SCI USA, V98, P7922, DOI 10.1073/pnas.111136798; Thomas B., 1997, PHOTOPERIODISM PLANT; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; Weller JL, 2001, PLANT J, V26, P283, DOI 10.1046/j.1365-313X.2001.01027.x; Wilkosz R, 2000, PLANT MOL BIOL, V44, P777, DOI 10.1023/A:1026536724779; WILSON RN, 1992, PLANT PHYSIOL, V100, P403, DOI 10.1104/pp.100.1.403; Yano M, 2000, PLANT CELL, V12, P2473, DOI 10.1105/tpc.12.12.2473; Yanovsky MJ, 2001, CURR OPIN PLANT BIOL, V4, P429, DOI 10.1016/S1369-5266(00)00196-5; Yoshida N, 2001, PLANT CELL, V13, P2471, DOI 10.1105/tpc.13.11.2471	71	753	834	6	234	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					285	289		10.1126/science.296.5566.285	http://dx.doi.org/10.1126/science.296.5566.285			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951029				2022-12-28	WOS:000175000300040
J	Angelini, GD; Taylor, FC; Reeves, BC; Ascione, R				Angelini, GD; Taylor, FC; Reeves, BC; Ascione, R			Early and midterm outcome after off-pump and on-pump surgery in Beating Heart Against Cardioplegic Arrest Studies (BHACAS 1 and 2): a pooled analysis of two randomised controlled trials	LANCET			English	Article							CORONARY-BYPASS SURGERY; CARDIOPULMONARY BYPASS; REVASCULARIZATION; ANGIOPLASTY	Background Although no randomised controlled trial has assessed the midterm effects of coronary-artery bypass surgery on the beating heart, this technique is being used in more and more patients. We did two randomised trials to compare the short-term morbidity associated with off-pump and on-pump myocardial revascularisation. Our aim was to pool the results to assess midterm outcomes. Methods From March, 1997, to November, 1999, we randomly allocated 200 patients to off-pump and 201 to on-pump coronary surgery. In Beating Heart Against Cardioplegic Arrest Study (BHACAS) 1, we excluded patients who had had myocardial infarction in the past month or who required grafting of the circumflex artery distal to the first obtuse marginal branch. In BHACAS 2, we included such patients. Primary outcomes were all-cause mortality and cardiac-related events at midterm follow-up (1-3 years). Analysis was by intention to treat. Findings Analyses of combined data from both trials showed the following risk differences with off-pump compared with on-pump surgery: atrial fibrillation -25% (95% Cl -33% to -16%); chest infection -12% (-19% to -5%); inotropic requirement -18% (-25% to -10%); transfusion of red blood cells -31% (-41 to -21); and hospital stay longer than 7 days -13% (-21 to -5). Mean follow-up was 25.0 months (SID 9.1) for BHACAS 1 and 13.7 months (5.5) for BHACAS 2. Four (2%) of 200 patients in the off-pump groups died from any cause, compared with seven (3%) of 201 in the on-pump group (hazard ratio 0.57, 95% Cl 0.17-1.96). 33 (17%) of 200 patients in the off-pump group died or had a cardiac-related event, compared with 42 (21%) of 201 in the on-pump group (0.78, 0.49-1.22). Interpretation off-pump coronary surgery significantly lowers in-hospital morbidity without compromising outcome in the first 1-3 years after surgery compared with conventional on-pump coronary surgery.	Univ Bristol, Bristol Heart Inst, Bristol, Avon, England; London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1, England	University of Bristol; University of London; London School of Hygiene & Tropical Medicine	Angelini, GD (corresponding author), Bristol Royal Infirm & Gen Hosp, Bristol Heart Inst, Bristol BS2 8HW, Avon, England.		Ascione, Raimondo/H-9967-2014	angelini, gianni/0000-0002-1753-3730				Ascione R, 2000, CIRCULATION, V102, P1530, DOI 10.1161/01.CIR.102.13.1530; Ascione R, 1999, ANN THORAC SURG, V68, P493, DOI 10.1016/S0003-4975(99)00566-4; Ascione R, 1999, ANN THORAC SURG, V68, P2237, DOI 10.1016/S0003-4975(99)01123-6; Buffolo E, 1996, ANN THORAC SURG, V61, P63, DOI 10.1016/0003-4975(95)00840-3; BUTLER J, 1993, ANN THORAC SURG, V55, P552, DOI 10.1016/0003-4975(93)91048-R; CALAFIORE AM, 1995, ANN THORAC SURG, V59, P398, DOI 10.1016/0003-4975(94)00843-V; Caputo M, 2001, ANN THORAC SURG, V71, P1215, DOI 10.1016/S0003-4975(00)02686-2; Cartier R, 2000, J THORAC CARDIOV SUR, V119, P221, DOI 10.1016/S0022-5223(00)70176-0; Cooley DA, 2000, ANN THORAC SURG, V70, P1779, DOI 10.1016/S0003-4975(00)02052-X; Gundry SR, 1998, J THORAC CARDIOV SUR, V115, P1273, DOI 10.1016/S0022-5223(98)70209-0; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON JR, 1993, LANCET, V341, P573; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; KIRKLIN JK, 1983, J THORAC CARDIOV SUR, V86, P845; Lucchetti V, 1999, EUR J CARDIO-THORAC, V15, P255, DOI 10.1016/S1010-7940(99)00005-6; Poirier NC, 1999, J THORAC CARDIOV SUR, V117, P292, DOI 10.1016/S0022-5223(99)70425-3; Puskas JD, 1998, ANN THORAC SURG, V66, P1068, DOI 10.1016/S0003-4975(98)00657-2; RICKARDS AF, 1995, LANCET, V346, P1179; Roach GW, 1996, NEW ENGL J MED, V335, P1857, DOI 10.1056/NEJM199612193352501; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P271; Watters MPR, 2001, EUR J CARDIO-THORAC, V19, P34, DOI 10.1016/S1010-7940(00)00603-5	21	450	461	0	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 6	2002	359	9313					1194	1199		10.1016/S0140-6736(02)08216-8	http://dx.doi.org/10.1016/S0140-6736(02)08216-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	539AB	11955537				2022-12-28	WOS:000174846300009
J	Dobrosotskaya, IY; Seegmiller, AC; Brown, MS; Goldstein, JL; Rawson, RB				Dobrosotskaya, IY; Seegmiller, AC; Brown, MS; Goldstein, JL; Rawson, RB			Regulation of SREBP processing and membrane lipid production by phospholipids in Drosophila	SCIENCE			English	Article							BOUND TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; CHOLESTEROL; METABOLISM; SPHINGOLIPIDS; PROTEOLYSIS	Animal cells exert exquisite control over the physical and chemical properties of their membranes, but the mechanisms are obscure. We show that phosphatidylethanolamine, the major phospholipid in Drosophila, controls the release of sterol regulatory element-binding protein (SREBP) from Drosophila cell membranes, exerting feedback control on the synthesis of fatty acids and phospholipids. The finding that SREBP processing is controlled by different lipids in mammals and flies (sterols and phosphatidylethanolamine, respectively) suggests that an essential function of SREBP is to monitor cell membrane composition and to adjust lipid synthesis accordingly.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brown, MS (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NHLBI NIH HHS [HL-20948] Funding Source: Medline; NIGMS NIH HHS [GM 08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; BROWN MS, 1975, J BIOL CHEM, V250, P4025; CLARK AJ, 1959, J BIOL CHEM, V234, P2578; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; CULLIS PR, 1985, BIOCH LIPIDS MEMBRAN, pCH2; Dickson RC, 1999, BBA-MOL CELL BIOL L, V1438, P305, DOI 10.1016/S1388-1981(99)00068-2; DOBROSOTSKAYA IY, UNPUB; Edwards PA, 2000, BBA-MOL CELL BIOL L, V1529, P103, DOI 10.1016/S1388-1981(00)00140-2; Goldstein JL, 2002, ARCH BIOCHEM BIOPHYS, V397, P139, DOI 10.1006/abbi.2001.2615; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; JONES HE, 1992, LIPIDS, V27, P984, DOI 10.1007/BF02535576; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Lange Y, 1999, J LIPID RES, V40, P2264; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Rizzo WB, 1998, MOL GENET METAB, V65, P63, DOI 10.1006/mgme.1998.2728; Rosenberger TA, 2002, J LIPID RES, V43, P59; Seegmiller AC, 2002, DEV CELL, V2, P229, DOI 10.1016/S1534-5807(01)00119-8; SNYDER F, 1985, BIOCH LIPIDS MEMBRAN, pCH9; Storey MK, 2001, J BIOL CHEM, V276, P48539, DOI 10.1074/jbc.M109043200; VANVELDHOVEN PP, 1993, ADV LIPID RES, V26, P69; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Yeagle P., 1993, MEMBRANES CELLS, P1	26	242	246	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					879	883		10.1126/science.1071124	http://dx.doi.org/10.1126/science.1071124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988566				2022-12-28	WOS:000175442500035
J	de Jong, K; Mulhern, M; Ford, N; Simpson, I; Swan, A; van der Kam, S				de Jong, K; Mulhern, M; Ford, N; Simpson, I; Swan, A; van der Kam, S			Psychological trauma of the civil war in Sri Lanka	LANCET			English	Editorial Material									Med Sans Frontieres, London EC1R 5DJ, England; Med Sans Frontieres, Amsterdam, Netherlands; Med Sans Frontieres, Colombo, Sri Lanka	Doctors Without Borders; Doctors Without Borders	Ford, N (corresponding author), Med Sans Frontieres, 124-32 Clerkenwell Rd, London EC1R 5DJ, England.			van der Kam, Saskia/0000-0002-3608-8054				DEJONG K, 2001, ASSESSING TRAUMA SRI; Reilley B, 2002, BRIT MED J, V324, P361; *WHO, 2000, SUIC RAT	3	22	22	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1517	1518		10.1016/S0140-6736(02)08420-9	http://dx.doi.org/10.1016/S0140-6736(02)08420-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988266				2022-12-28	WOS:000175279100030
J	Grech, V; Savona-Ventura, C; Vassallo-Agius, P				Grech, V; Savona-Ventura, C; Vassallo-Agius, P			Unexplained differences in sex ratios at birth in Europe and North America	BRITISH MEDICAL JOURNAL			English	Article									St Lukes Hosp, Dept Paediat, MSD-09 Guardamangia, Malta; St Lukes Hosp, Dept Obstet & Gynaecol, MSD-09 Guardamangia, Malta; Univ Malta, Sch Med, MSD-06 Msida, Malta	University of Malta	Grech, V (corresponding author), St Lukes Hosp, Dept Paediat, MSD-09 Guardamangia, Malta.		Savona-Ventura, Charles/W-2351-2019	Savona-Ventura, Charles/0000-0001-9143-4311				Grech V, 2000, J EPIDEMIOL COMMUN H, V54, P244, DOI 10.1136/jech.54.4.244	1	57	58	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 27	2002	324	7344					1010	1011		10.1136/bmj.324.7344.1010	http://dx.doi.org/10.1136/bmj.324.7344.1010			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	547UP	11976243	Green Published, Bronze			2022-12-28	WOS:000175350900021
J	Poynard, T				Poynard, T			Individual and evidence-based	LANCET			English	Editorial Material									Grp Hosp Pitie Salpetriere, Serv Hepatogastroenterol, F-75651 Paris 13, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Poynard, T (corresponding author), Grp Hosp Pitie Salpetriere, Serv Hepatogastroenterol, F-75651 Paris 13, France.		Poynard, Thierry/C-1355-2010	Poynard, Thierry/0000-0002-3726-7230; Poynard, Thierry/0000-0002-2050-640X					0	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 27	2002	359	9316					1514	1514		10.1016/S0140-6736(02)08418-0	http://dx.doi.org/10.1016/S0140-6736(02)08418-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988264				2022-12-28	WOS:000175279100028
J	Willett, WC				Willett, WC			Balancing life-style and genomics research for disease prevention	SCIENCE			English	Editorial Material							CORONARY HEART-DISEASE; RISK FACTOR; METHYLENETETRAHYDROFOLATE REDUCTASE; COLON-CANCER; WOMEN; DIET; MEN; POLYMORPHISMS; CHOLESTEROL; LIPIDS	Genetic and environmental factors, including diet and life-style, both contribute to cardiovascular disease, cancers, and other major causes of mortality, but various lines of evidence indicate that environmental factors are most important. Overly enthusiastic expectations regarding the benefits of genetic research for disease prevention have the potential to distort research priorities and spending for health. However, integration of new genetic information into epidemiologic studies can help clarify causal relations between both life-style and genetic factors and risks of disease. Thus, a balanced approach should provide the best data to make informed choices about the most effective means to prevent disease.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Willett, WC (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 665 Huntington Ave, Boston, MA 02115 USA.		Deschepper, Reginald/B-8103-2013	Deschepper, Reginald/0000-0002-4222-3945	NCI NIH HHS [P01CA55075] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOKI K, 1992, DEATH RATES MALIGNAN; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; Chen J, 1996, CANCER RES, V56, P4862; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Ensrud KE, 1999, J BONE MINER RES, V14, P1637, DOI 10.1359/jbmr.1999.14.10.1637; Ferlay J, 2001, IARC CANCERBASE; Giovannucci E, 1998, ANN INTERN MED, V129, P517, DOI 10.7326/0003-4819-129-7-199810010-00002; Hines LM, 2001, NEW ENGL J MED, V344, P549, DOI 10.1056/NEJM200102223440802; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; KATO H, 1973, AM J EPIDEMIOL, V97, P372, DOI 10.1093/oxfordjournals.aje.a121518; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; London SJ, 2000, LANCET, V356, P724, DOI 10.1016/S0140-6736(00)02631-3; MILLER BA, 1996, NIH PUBL; Platz EA, 2000, CANCER CAUSE CONTROL, V11, P579, DOI 10.1023/A:1008999232442; Prosser LA, 2000, ANN INTERN MED, V132, P769, DOI 10.7326/0003-4819-132-10-200005160-00002; Rimm EB, 1999, BMJ-BRIT MED J, V319, P1523, DOI 10.1136/bmj.319.7224.1523; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; Stampfer MJ, 2000, NEW ENGL J MED, V343, P16, DOI 10.1056/NEJM200007063430103; VANDERPUT NMJ, 1995, LANCET, V346, P1070, DOI 10.1016/S0140-6736(95)91743-8; Wald NJ, 1999, BMJ-BRIT MED J, V319, P1562, DOI 10.1136/bmj.319.7224.1562; Winkelmann BR, 2000, AM HEART J, V140, pS11, DOI 10.1067/mhj.2000.109636	23	553	588	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 26	2002	296	5568					695	698		10.1126/science.1071055	http://dx.doi.org/10.1126/science.1071055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	546PD	11976443				2022-12-28	WOS:000175281700042
J	Crystal, E; Connolly, SJ				Crystal, E; Connolly, SJ			Evolution of the implantable cardioverter defibrillator	LANCET			English	Editorial Material							HEART-FAILURE		McMaster Univ, Div Cardiol, Hamilton, ON L8L 2X2, Canada	McMaster University	Connolly, SJ (corresponding author), McMaster Univ, Div Cardiol, Hamilton, ON L8L 2X2, Canada.	connostu@hhsc.ca						Boriani G, 1998, INT J CARDIOL, V66, P261, DOI 10.1016/S0167-5273(98)00239-3; Butter C, 2001, CIRCULATION, V104, P3026, DOI 10.1161/hc5001.102229; Butter C, 2001, CIRCULATION, V104, P2533, DOI 10.1161/hc4601.099463; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Connolly SJ, 2000, EUR HEART J, V21, P2071, DOI 10.1053/euhj.2000.2476; Fotuhi PC, 1999, AM J CARDIOL, V83, p24D; Glikson M, 2001, LANCET, V357, P1107, DOI 10.1016/S0140-6736(00)04263-X; Huikuri HV, 2001, NEW ENGL J MED, V345, P1473, DOI 10.1056/NEJMra000650; Leclercq C, 2002, J AM COLL CARDIOL, V39, P194, DOI 10.1016/S0735-1097(01)01747-8; Moss AJ, 2002, NEW ENGL J MED, V346, P877, DOI 10.1056/NEJMoa013474	10	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	2002	359	9315					1362	1363		10.1016/S0140-6736(02)08389-7	http://dx.doi.org/10.1016/S0140-6736(02)08389-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978329				2022-12-28	WOS:000175076200004
J	Evans, JMM; Wang, JX; Morris, D				Evans, JMM; Wang, JX; Morris, D			Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; MORTALITY; CARE	Objective To compare risks of cardiovascular outcomes between patients with type 2 diabetes and patients with established coronary heart disease. Design Cross sectional study and cohort study using routinely collected datasets. Setting Tayside, Scotland (population 400 000) during 1988-95. Subjects In the cross sectional study, among patients aged 45-64,1155 with type 2 diabetes were compared with 1347 who had had a myocardial infarction in the preceding 8 years. In the cohort stud), 3477 patients of all ages with newly diagnosed type 2 diabetes were compared with 7414 patients who had just had a myocardial infarction. Main outcome measures Risk ratios for death from all causes, cardiovascular death, and hospital admission for myocardial infarction were calculated by Cox proportional hazards analysis and adjusted for age and sex. Results In the cross sectional study the adjusted risk ratio for death from all causes was 2.27 (95% confidence interval 1.82 to 2.83) for patients who had had myocardial infarction compared with those with diabetes, and the risk ratio for hospital admission for myocardial infarction was 1.33 (1.14 to 1.55). In die cohort study, patients who had just had a myocardial infarction had a higher risk of death from all causes (adjusted risk ratio 1.35 (1.25 to 1.44)), cardiovascular death (2.93 (2.54 to 3.41)), and hospital admission for myocardial infarction (3.10 (2.57 to 3.73)). Conclusions Patients with type 2 diabetes were at lower risk of cardiovascular outcomes than patients with established coronary heart disease.	Ninewells Hosp, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland; Ninewells Hosp, Dept Clin Pharmacol, Dundee DD1 9SY, Scotland; Ninewells Hosp, Dept Med, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Evans, JMM (corresponding author), Ninewells Hosp, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Byrne CD, 2000, BRIT MED J, V320, P1554, DOI 10.1136/bmj.320.7249.1554; Calltorp J, 1996, LANCET, V347, P587, DOI 10.1016/S0140-6736(96)91278-7; Claudi T, 2000, J INTERN MED, V248, P492, DOI 10.1046/j.1365-2796.2000.00759.x; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Haffner SM, 2000, J CLIN ENDOCR METAB, V85, P2108, DOI 10.1210/jc.85.6.2108; McAlpine R, 1998, PHARMACOEPIDEM DR S, V7, P311, DOI 10.1002/(SICI)1099-1557(199809/10)7:5<311::AID-PDS371>3.3.CO;2-F; Morris AD, 1997, BMJ-BRIT MED J, V315, P524, DOI 10.1136/bmj.315.7107.524; Simons LA, 1998, NEW ENGL J MED, V339, P1714; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405	11	248	256	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 20	2002	324	7343					939	942A		10.1136/bmj.324.7343.939	http://dx.doi.org/10.1136/bmj.324.7343.939			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544UF	11964337	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000175179500014
J	Kopko, PM; Marshall, CS; MacKenzie, MR; Holland, PV; Popovsky, MA				Kopko, PM; Marshall, CS; MacKenzie, MR; Holland, PV; Popovsky, MA			Transfusion-related acute lung injury - Report of a clinical look-back investigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONCARDIOGENIC PULMONARY-EDEMA; ANTIBODIES	Context Transfusion-related acute lung injury (TRALI) is a syndrome that includes dyspnea, hypotension, bilateral pulmonary edema, and fever. TRALI is the third leading cause of transfusion-related mortality, but it is probably underdiagnosed and underreported. Objective To determine if blood products from a frequent plasma donor, whose blood product was implicated in a fatal case of TRALI, caused symptoms of TRALI in other recipients of her plasma. Design, Setting, and Participants Retrospective chart review (conducted from November 2000 through April 2001) of 50 patients who received blood components within 2 years (October 1998 through October 2000) from a donor linked to a transfusion-related fatality. Main Outcome Measure Occurrence of mild/moderate (dyspnea with fever, chills, hypotension, and/or hypoxemia) or severe (acute pulmonary edema or need for mechanical ventilation) reaction associated with transfusion. Results Superimposed illness prevented assessment of TRALI in 14 patients. Of the 36 patient charts that could be reviewed, 7 mild/moderate reactions were reported in 6 patients (16.7%) and 8 severe reactions were reported in 8 patents (22.2%). Of 5 patients who received multiple transfusions from the same donor, 2 experienced 2 reactions: one had 2 mild/moderate reactions and the other had both a mild/moderate and a severe reaction. While 5 of the 7 mild/moderate reactions were reported to the hospital transfusion service, only 2 of the 8 severe reactions were reported. Only 2 reactions (1 mild/ moderate and 1 severe) were reported to the regional blood collection facility. Conclusions TRALI was frequently underdiagnosed and underreported in recipients of blood products from a donor whose blood products may have caused TRALI in several transfusion recipients. Clinical education and awareness of this often-overlooked diagnosis are imperative for appropriate prevention and treatment.	Sacramento Blood Ctr, Sacramento, CA 95816 USA; Univ Calif Davis, Med Ctr, Dept Pathol, Sacramento, CA 95817 USA; Haemonet Corp, Braintree, MA USA	University of California System; University of California Davis	Kopko, PM (corresponding author), Sacramento Blood Ctr, 1625 Stockton Blvd, Sacramento, CA 95816 USA.	patricia.kopko@smfbc.org						AUSLEY MB, 1987, AM J FOREN MED PATH, V8, P287, DOI 10.1097/00000433-198712000-00004; Boshkov LK, 2001, BLOOD, V98, p828A; BRITTINGHAM T E, 1957, Vox Sang, V2, P242; CLARKE G, 1994, BLOOD, V84, pA465; *CTR BIOL EV RES, 2001, TRANSF REL AC LUNG I; HASHIM SW, 1984, AM J SURG, V147, P560, DOI 10.1016/0002-9610(84)90022-9; Kopko PM, 1999, BRIT J HAEMATOL, V105, P322, DOI 10.1111/j.1365-2141.1999.01357.x; Kopko PM, 2001, TRANSFUSION, V41, P1244, DOI 10.1046/j.1537-2995.2001.41101244.x; LEVY GJ, 1986, TRANSFUSION, V26, P278, DOI 10.1046/j.1537-2995.1986.26386209388.x; MCCULLOUGH J, 1986, BLOOD, V67, P522; MENITOVE J, 1994, CLIN LAB MED, P1783; OCONNOR PC, 1981, BRIT MED J, V282, P379, DOI 10.1136/bmj.282.6261.379; PAYNE R, 1962, BLOOD, V19, P411, DOI 10.1182/blood.V19.4.411.411; Popovsky M A, 2000, Immunohematology, V16, P157; POPOVSKY MA, 1985, TRANSFUSION, V25, P573, DOI 10.1046/j.1537-2995.1985.25686071434.x; Rizk A, 2001, TRANSFUSION, V41, P264, DOI 10.1046/j.1537-2995.2001.41020264.x; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; SEEGER W, 1990, BLOOD, V76, P1438; Silliman CC, 1997, TRANSFUSION, V37, P719, DOI 10.1046/j.1537-2995.1997.37797369448.x; VANLEEUWEN A, 1964, VOX SANG, V9, P431	20	305	319	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2002	287	15					1968	1971		10.1001/jama.287.15.1968	http://dx.doi.org/10.1001/jama.287.15.1968			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NC	11960539	Bronze			2022-12-28	WOS:000174989800025
J	Clark, D				Clark, D			Between hope and acceptance: the medicalisation of dying	BRITISH MEDICAL JOURNAL			English	Article									Univ Sheffield, Trent Palliat Care Ctr, Acad Palliat Med Unit, Sheffield S11 9NE, S Yorkshire, England	University of Sheffield	Clark, D (corresponding author), Univ Sheffield, Trent Palliat Care Ctr, Acad Palliat Med Unit, Sykes House, Sheffield S11 9NE, S Yorkshire, England.		Clark, David/A-1645-2009					AHMEDZAI S, 1997, PROGR PALLIATIVE CAR, V5, P235; Ahronheim JC, 1996, ARCH INTERN MED, V156, P2094, DOI 10.1001/archinte.156.18.2094; Audit Commission, 1999, CRIT SUCC PLAC EFF E; Bauman Zygmunt, 1992, MORTALITY IMMORTALIT; Bion J, 1996, BRIT J ANAESTH, V77, P1; Biswas B., 1993, FUTURE PALLIATIVE CA, P135; Clark D, 1999, SOC SCI MED, V49, P727, DOI 10.1016/S0277-9536(99)00098-2; CLARK D, 1999, REFLECTIONS PALLIATI; Clark David, 1999, MORTALITY, V4, P225, DOI 10.1080/713685979; CLINCH JJ, 1998, OXFORD TXB PALLIATIV; Doyle D, 1993, Palliat Med, V7, P253, DOI 10.1177/026921639300700401; Good P, 2001, PALLIATIVE MED, V15, P493, DOI 10.1191/026921601682553987; Illich I., 1976, LIMITS MED MED NEMES; KEARNEY M, 1992, Palliative Medicine, V6, P39, DOI 10.1177/026921639200600107; Mathers N, 1997, BRIT J GEN PRACT, V47, P177; Moskowitz E, 1995, HASTINGS CENT REP  S, P53; Mount B, 1997, HOSPICE CARE INT SCE; Paci E, 2001, J PAIN SYMPTOM MANAG, V21, P179, DOI 10.1016/S0885-3924(01)00263-9; Seymour J., 2001, CRITICAL MOMENTS DEA; *SMAC SNMAC, 1992, PRINC PROV PALL CAR; [No title captured]	21	169	170	0	20	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					905	907		10.1136/bmj.324.7342.905	http://dx.doi.org/10.1136/bmj.324.7342.905			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950744	Green Published			2022-12-28	WOS:000175052200030
J	Palme, H				Palme, H			Planetary science: A new solar system basalt	SCIENCE			English	Editorial Material									Univ Cologne, Inst Mineral & Geochem, D-50674 Cologne, Germany	University of Cologne	Palme, H (corresponding author), Univ Cologne, Inst Mineral & Geochem, Zulpicherstr 49B, D-50674 Cologne, Germany.							Lodders K., 1998, PLANETARY SCI COMPAN; LOVE SG, 1995, METEORITICS, V30, P269, DOI 10.1111/j.1945-5100.1995.tb01125.x; Yamaguchi A, 2002, SCIENCE, V296, P334, DOI 10.1126/science.1069408	3	14	14	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 12	2002	296	5566					271	+		10.1126/science.1070768	http://dx.doi.org/10.1126/science.1070768			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951022				2022-12-28	WOS:000175000300033
J	McGrayne, SB				McGrayne, SB			Portraits of science - Damn the torpedoes. Full speed ahead!	SCIENCE			English	Biographical-Item											McGrayne, SB (corresponding author), 5233 Pullman Ave NE, Seattle, WA 98105 USA.								0	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					851	852		10.1126/science.1069830	http://dx.doi.org/10.1126/science.1069830			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988556				2022-12-28	WOS:000175442500023
J	Mayberry, RI; Lock, E; Kazmi, H				Mayberry, RI; Lock, E; Kazmi, H			Development - Linguistic ability and early language exposure	NATURE			English	Article							CRITICAL PERIOD; ACQUISITION; AGE		McGill Univ, Sch Commun Sci & Disorders, Montreal, PQ H3G 1A8, Canada; Univ Ottawa, Fac Med, Ottawa, ON K1H 8L6, Canada; Univ Western Ontario, Elborn Coll, Sch Commun Sci & Disorders, London, ON N6G 1H1, Canada	McGill University; University of Ottawa; Western University (University of Western Ontario)	Mayberry, RI (corresponding author), McGill Univ, Sch Commun Sci & Disorders, 1266 Pine Ave W, Montreal, PQ H3G 1A8, Canada.							COLOMBO J, 1982, PSYCHOL BULL, V91, P260, DOI 10.1037/0033-2909.91.2.260; EMMOREY K, 1995, APPL PSYCHOLINGUIST, V16, P1, DOI 10.1017/S0142716400006391; Goldberg MC, 2001, DEV NEUROPSYCHOL, V19, P53, DOI 10.1207/S15326942DN1901_5; GREENOUGH WT, 1992, MINN SYM CHILD PSYCH, V24, P155; JOHNSON JS, 1989, COGNITIVE PSYCHOL, V21, P60, DOI 10.1016/0010-0285(89)90003-0; Kolb B, 1998, NEUROSCI BIOBEHAV R, V22, P143, DOI 10.1016/S0149-7634(97)00008-0; Lenneberg, 1967, BIOL FDN LANGUAGE, DOI 10.1080/21548331.1967.11707799; MAYBERRY RI, 1993, J SPEECH HEAR RES, V36, P1258, DOI 10.1044/jshr.3606.1258; MAYBERRY RI, 1991, J MEM LANG, V30, P486, DOI 10.1016/0749-596X(91)90018-F; MAYBERRY RI, IN PRESS CHILD NEURO; NEWPORT EL, 1990, COGNITIVE SCI, V14, P11, DOI 10.1207/s15516709cog1401_2; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0	12	169	171	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	2002	417	6884					38	38		10.1038/417038a	http://dx.doi.org/10.1038/417038a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	546ZM	11986658	Bronze			2022-12-28	WOS:000175307200030
J	Coleman, RE				Coleman, RE			Value of FDG-PET scanning in management of lung cancer	LANCET			English	Editorial Material							CELL; CARCINOMA		Duke Univ, Sch Med, Dept Radiol, Div Nucl Med, Durham, NC 27710 USA	Duke University	Coleman, RE (corresponding author), Duke Univ, Sch Med, Dept Radiol, Div Nucl Med, Durham, NC 27710 USA.							Ahuja V, 1998, CANCER, V83, P918, DOI 10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.0.CO;2-Y; Dwamena BA, 1999, RADIOLOGY, V213, P530, DOI 10.1148/radiology.213.2.r99nv46530; Gambhir SS, 1996, J NUCL MED, V37, P1428; Gambhir SS, 1998, J CLIN ONCOL, V16, P2113, DOI 10.1200/JCO.1998.16.6.2113; Gould MK, 2001, JAMA-J AM MED ASSOC, V285, P914, DOI 10.1001/jama.285.7.914; Marom EM, 1999, RADIOLOGY, V212, P803, DOI 10.1148/radiology.212.3.r99se21803; Pieterman RM, 2000, NEW ENGL J MED, V343, P254, DOI 10.1056/NEJM200007273430404	7	14	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1361	1362						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978328				2022-12-28	WOS:000175076200003
J	Fatovich, DM				Fatovich, DM			Recent developments - Emergency medicine	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CERVICAL-SPINE; CARDIAC-ARREST; RULE		Royal Perth Hosp, Perth, WA 6000, Australia	Royal Perth Hospital; University of Western Australia	Fatovich, DM (corresponding author), Royal Perth Hosp, Wellington St, Perth, WA 6000, Australia.	Daniel.Fatovich@health.wa.gov.au	Fatovich, Daniel/J-5510-2013	Fatovich, Daniel/0000-0001-9414-6905				*AUSTR COLL EM MED, 2000, GUID MAN DEL SELF HA; *AUSTR COLL EM MED, 2001, POL DOC STAND TERM; Bottiger BW, 2001, LANCET, V357, P1583, DOI 10.1016/S0140-6736(00)04726-7; Boyer EW, 2001, NEW ENGL J MED, V344, P1721, DOI 10.1056/NEJM200105313442215; Brewster L R, 2001, Issue Brief Cent Stud Health Syst Change, P1; Burns MJ, 2001, J TOXICOL-CLIN TOXIC, V39, P1, DOI 10.1081/CLT-100102873; Derlet RW, 2000, ANN EMERG MED, V35, P63, DOI 10.1016/S0196-0644(00)70105-3; Eitzen EM, 1999, ANN EMERG MED, V34, P221, DOI 10.1016/S0196-0644(99)70233-7; FATOVICH DM, 2002, EMERGEN MED, V14, pA9; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hoffman JR, 2000, NEW ENGL J MED, V343, P94, DOI 10.1056/NEJM200007133430203; Mainie I, 2001, LANCET, V357, P1624, DOI 10.1016/S0140-6736(00)04770-X; McLaughlin SA, 2000, ANN EMERG MED, V36, P133, DOI 10.1067/mem.2000.108183; Newman DH, 2000, ANN EMERG MED, V35, P472, DOI 10.1067/mem.2000.105600; SPILLER HA, 1994, AM J EMERG MED, V12, P43, DOI 10.1016/0735-6757(94)90195-3; Stiell IG, 2001, LANCET, V358, P105, DOI 10.1016/S0140-6736(01)05328-4; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; *VICT GOV DEP HUM, 2001, EM DEM MAN; Vinson DR, 2001, ANN EMERG MED, V37, P237, DOI 10.1067/mem.2001.112728; Willerson JT, 2000, CIRCULATION, V102, P1	20	59	60	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 20	2002	324	7343					958	962		10.1136/bmj.324.7343.958	http://dx.doi.org/10.1136/bmj.324.7343.958			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544UF	11964343	Green Published			2022-12-28	WOS:000175179500020
J	Fukuda, M; Fukuda, K; Shimizu, T; Andersen, CY; Byskov, AG				Fukuda, M; Fukuda, K; Shimizu, T; Andersen, CY; Byskov, AG			Parental periconceptional smoking and male : female ratio of newborn infants	LANCET			English	Article							SEX-RATIO	We assessed whether the smoking habits of parents around the time of conception affects the likelihood of the offspring being male or female. We found that the offspring sex ratio (male to female) was lower when either one or both of the parents smoked more than 20 cigarettes per day compared with couples in which neither of the parents smoked. We found the lowest sex ratio among children whose mothers and fathers both smoked more than 20 cigarettes per day (p<0.0001). Parental periconceptional smoking might be a contributing factor to a lower male to female sex ratio of offspring.	Fukuda Ladies Clin, Ako, Hyogo 6780239, Japan; Shimizu Womens Clin, Takarazuka, Hyogo 6650011, Japan; Univ Copenhagen Hosp, Reprod Biol Lab, Sect 5712, DK-2100 Copenhagen, Denmark	University of Copenhagen	Fukuda, M (corresponding author), Fukuda Ladies Clin, 30-9 Kariya, Ako, Hyogo 6780239, Japan.			Andersen, Claus Yding/0000-0001-7681-253X				BUTLER NR, 1969, PERINATAL PROBLEMS, P339; Fukuda M, 1998, HUM REPROD, V13, P2321, DOI 10.1093/humrep/13.8.2321; Mocarelli P, 2000, LANCET, V355, P1858, DOI 10.1016/S0140-6736(00)02290-X; Moller H, 1996, LANCET, V348, P828, DOI 10.1016/S0140-6736(05)65253-1; Sakamoto M, 2001, ENVIRON RES, V87, P92, DOI 10.1006/enrs.2001.4293	5	118	120	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1407	1408		10.1016/S0140-6736(02)08362-9	http://dx.doi.org/10.1016/S0140-6736(02)08362-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978342				2022-12-28	WOS:000175076200017
J	Fleury, V; Watters, WA; Allam, L; Devers, T				Fleury, V; Watters, WA; Allam, L; Devers, T			Rapid electroplating of insulators	NATURE			English	Article							ELECTROCHEMICAL DEPOSITION; RAMIFIED ELECTRODEPOSITS; GROWTH; PATTERNS	Electrochemical techniques for depositing metal films and coatings(1) have a long history(2-5). Such techniques essentially fall into two categories, with different advantages and disadvantages. The first, and oldest, makes use of spontaneous redox reactions to deposit a metal from solution, and can be used on both insulating and metallic substrates. But the deposition conditions of these processes are difficult to control in situ, in part because of the variety of salts and additives present in the solution. The second approach-electroplating-uses an electric current to reduce metal ions in solution, and offers control over the quantity (and, to some extent, grain size) of deposited metal. But application of this technique has hitherto been restricted to conducting substrates. Here we describe an electroplating technique that permits coating of insulating substrates with metals having controlled grain size, thickness and growth speed. The basis of our approach is the progressive outward growth of the metal from an electrode in contact with the substrate, with the cell geometry chosen so that the electron current providing the reduction passes through the growing deposit. Such an approach would normally form dendritic or powdery deposits, but we identify a range of conditions in which uniform films rapidly form.	Ecole Polytech, CNRS, Phys Mat Condensee Lab, F-91128 Palaiseau, France; IUT Chartres, Lab Phys Electron, F-28000 Chartres, France	Centre National de la Recherche Scientifique (CNRS); Institut Polytechnique de Paris	Fleury, V (corresponding author), Ecole Polytech, CNRS, Phys Mat Condensee Lab, F-91128 Palaiseau, France.							BENJACOB E, 1990, NATURE, V343, P523, DOI 10.1038/343523a0; BERGSTRESSER TR, 1995, DEFECT STRUCTURE, MORPHOLOGY AND PROPERTIES OF DEPOSITS, P115; Chazalviel JN, 1996, J ELECTROANAL CHEM, V407, P61, DOI 10.1016/0022-0728(95)04477-9; CHAZALVIEL JN, 1990, PHYS REV A, V42, P7355, DOI 10.1103/PhysRevA.42.7355; Despic A.R., 1972, MOD ASPECTS ELECTROC, V7, P199, DOI [10.1007/978-1-4684-3003-5_4, DOI 10.1007/978-1-4684-3003-5_4]; DINI JW, 1992, ELECTRODEPOSITION; FLEURY V, 1990, J ELECTROANAL CHEM, V290, P249, DOI 10.1016/0022-0728(90)87434-L; FLEURY V, 1991, PHYS REV A, V44, P6693, DOI 10.1103/PhysRevA.44.6693; Fleury V, 1997, NATURE, V390, P145, DOI 10.1038/36522; Fleury V, 1996, EUROPHYS LETT, V36, P253, DOI 10.1209/epl/i1996-00218-2; FLEURY V, 1991, J MATER RES, V6, P1169, DOI 10.1557/JMR.1991.1169; Fleury V., 1998, ARBRES PIERRE CROISS; FLEURY V, 2000, Patent No. 02757; GARIK P, 1989, PHYS REV LETT, V62, P2703, DOI 10.1103/PhysRevLett.62.2703; KIRCHER A, 1664, MUNDUS SUBTERRANEUS, V6; Kircher Athanasius, 1667, CHINA MONUMENTIS QUA; MATSUSHITA M, 1984, PHYS REV LETT, V53, P286, DOI 10.1103/PhysRevLett.53.286; Meakin P., 1988, FRACTALS SCALING GRO; MELROSE JR, 1990, PHYS REV LETT, V65, P3009, DOI 10.1103/PhysRevLett.65.3009; NEEDHAM J, 1984, SCI CIVILIZATION CHI, V5; PELCE P, 1991, DYNAMICS CURVED FRON; ROSSO M, 1994, ELECTROCHIM ACTA, V39, P507, DOI 10.1016/0013-4686(94)80094-4; Vicsek T, 1992, FRACTAL GROWTH PHENO	23	67	69	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					716	719		10.1038/416716a	http://dx.doi.org/10.1038/416716a			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961549				2022-12-28	WOS:000175033500036
J	Atkin, WS; Cook, CF; Cuzick, J; Edwards, R; Northover, JMA; Wardle, J				Atkin, WS; Cook, CF; Cuzick, J; Edwards, R; Northover, JMA; Wardle, J		UK Flexible Sigmoidoscopy Screenin	Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial	LANCET			English	Article							FECAL-OCCULT-BLOOD; ASYMPTOMATIC ADULTS; UNITED-KINGDOM; OLDER ADULTS; NEOPLASIA; YIELD; BOWEL; ACCEPTABILITY; COLONOSCOPY; POPULATION	Background This randomised controlled trial is examining the hypothesis that a single flexible sigmoidoscopy screening offered at around age 60 years can lower the incidence and mortality of colorectal cancer. We report here on acceptability, safety, feasibility, and yield. Methods Men and women aged 55-64 years, in 14 UK centres, who responded to a mailed questionnaire that they would attend for flexible sigmodoscopy screening if invited, were randomly assigned screening or control (ratio one to two). The control group was not contacted. Small polyps were removed during screening, and colonoscopy was undertaken if high-risk polyps (three or more adenomas, size 1 cm or greater, villous, severely dysplastic, or malignant) were found. Findings Of 354 262 people asked about their interest in having flexible sigmoidoscopy screening, 194 726 (55%) responded positively, and 170 432 eligible individuals were randomised. Attendance among those assigned screening was 71% (40 674 of 57 254). 2131 (5%) were classified as high-risk and referred for colonoscopy; 38 525 with no polyps or only low-risk polyps detected were discharged. Distal adenomas were detected in 4931 (12.1%) and distal cancer in 131 (0.3%). Proximal adenomas were detected in 386 (18.8% of those undergoing colonoscopy) and proximal cancer in nine cases (0.4%). 62% of cancers were Dukes' stage A or locally excised. There was one perforation after flexible sigmoidoscopy and four after colonoscopy. An average of 48 people were screened, and two or three colonoscopy referrals generated, per centre each week. Interpretation Our flexible sigmoidoscopy screening regimen is acceptable, feasible, and safe. The prevalence of neoplasia is high, and colonoscopy referral rates of 5% are acceptable.	St Marks Hosp, Colorectal Canc Unit, Canc Res UK, Harrow HA1 3UJ, Middx, England	Cancer Research UK; Imperial College London	Atkin, WS (corresponding author), St Marks Hosp, Colorectal Canc Unit, Canc Res UK, Northwick Pk, Harrow HA1 3UJ, Middx, England.			Atkin, Wendy/0000-0001-9073-9658	MRC [G9615910] Funding Source: UKRI; Medical Research Council [G9615910] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Anderson ML, 2000, AM J GASTROENTEROL, V95, P3418, DOI 10.1111/j.1572-0241.2000.03356.x; Atkin WS, 2000, BRIT MED J, V320, P1504, DOI 10.1136/bmj.320.7248.1504; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; Atkin WS, 2001, J MED SCREEN, V8, P137, DOI 10.1136/jms.8.3.137; Atkin WS, 1998, GUT, V42, P560, DOI 10.1136/gut.42.4.560; Calman K, 1994, J Med Screen, V1, P101; CANNONALBRIGHT LA, 1994, AM J GASTROENTEROL, V89, P827; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P162; Church TR, 1997, JNCI-J NATL CANCER I, V89, P1440, DOI 10.1093/jnci/89.19.1440; Hanson JM, 1998, BRIT J SURG, V85, P1385; Imperiale TF, 2000, NEW ENGL J MED, V343, P169, DOI 10.1056/NEJM200007203430302; Jorgensen H, 1996, SCAND J GASTROENTERO, V31, P825, DOI 10.3109/00365529609010360; Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7; Levin Theodore R, 2002, Gastrointest Endosc Clin N Am, V12, P23, DOI 10.1016/S1052-5157(03)00055-2; Lieberman DA, 2000, NEW ENGL J MED, V343, P162, DOI 10.1056/NEJM200007203430301; Lieberman DA, 2001, NEW ENGL J MED, V345, P555, DOI 10.1056/NEJMoa010328; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MULLER AD, 1995, ANN INTERN MED, V123, P904, DOI 10.7326/0003-4819-123-12-199512150-00002; Prorok PC, 2000, CONTROL CLIN TRIALS, V21, p273S, DOI 10.1016/S0197-2456(00)00098-2; Rabeneck L, 2001, GASTROENTEROLOGY, V120, pA65; REX DK, 1993, AM J GASTROENTEROL, V88, P825; Robinson MHE, 1999, GUT, V45, P588, DOI 10.1136/gut.45.4.588; SAUNDERS BP, 1994, GASTROINTEST ENDOSC, V40, P418, DOI 10.1016/S0016-5107(94)70203-9; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; Senore C, 1996, J Med Screen, V3, P72; Smith RA, 2001, CA-CANCER J CLIN, V51, P38, DOI 10.3322/canjclin.51.1.38; Sutton S, 2000, J MED SCREEN, V7, P99, DOI 10.1136/jms.7.2.99; Taylor T, 2000, J MED SCREEN, V7, P38, DOI 10.1136/jms.7.1.38; UJSZASZY L, 1985, ENDOSCOPY, V17, P109, DOI 10.1055/s-2007-1018473; Verne JECW, 1998, BRIT MED J, V317, P182, DOI 10.1136/bmj.317.7152.182; Wardle J, 2000, PREV MED, V31, P323, DOI 10.1006/pmed.2000.0725; WHERRY DC, 1994, SURG ENDOSC-ULTRAS, V8, P393, DOI 10.1007/BF00642439; Woodman C B, 1995, J Med Screen, V2, P71	35	391	394	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1291	1300		10.1016/s0140-6736(02)08268-5	http://dx.doi.org/10.1016/s0140-6736(02)08268-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965274				2022-12-28	WOS:000174989700011
J	Schneider, LS				Schneider, LS			Galantamine for vascular dementia: some answers, some questions	LANCET			English	Editorial Material									Univ So Calif, Keck Sch Med, Dept Psychiat & Neurol, Los Angeles, CA 90033 USA; Univ So Calif, Leonard Davis Sch Gerontol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Schneider, LS (corresponding author), Univ So Calif, Keck Sch Med, Dept Psychiat & Neurol, Los Angeles, CA 90033 USA.							Chui H, 1999, ALZ DIS ASSOC DIS, V13, pS124, DOI 10.1097/00002093-199912003-00018; Kittner B, 1999, ALZ DIS ASSOC DIS, V13, pS166, DOI 10.1097/00002093-199912001-00023; Pratt RD, 2002, 7 INT GEN SPRINGF S	3	12	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1265	1266		10.1016/S0140-6736(02)08283-1	http://dx.doi.org/10.1016/S0140-6736(02)08283-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965268				2022-12-28	WOS:000174989700005
J	Rosei, F; Schunack, M; Jiang, P; Gourdon, A; Laegsgaard, E; Stensgaard, I; Joachim, C; Besenbacher, F				Rosei, F; Schunack, M; Jiang, P; Gourdon, A; Laegsgaard, E; Stensgaard, I; Joachim, C; Besenbacher, F			Organic molecules acting as templates on metal surfaces	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPY; SINGLE MOLECULES; CONFORMATIONAL-CHANGES; ROOM-TEMPERATURE; MANIPULATION; ELECTRONICS; SCIENCE; DEVICES; ATOMS; WIRE	The electronic connection of single molecules to nanoelectrodes on a surface is a basic, unsolved problem in the emerging field of molecular nanoelectronics. By means of variable temperature scanning tunneling microscopy, we show that an organic molecule (C90H98), known as the Lander, can cause the rearrangement of atoms on a Cu(110) surface. These molecules act as templates accommodating metal atoms at the step edges of the copper substrate, forming metallic nanostructures (0.75 nanometers wide and 1.85 nanometers long) that are adapted to the dimensions of the molecule.	CNRS, CEMES, F-31055 Toulouse, France; Aarhus Univ, Inst Phys & Astron, DK-8000 Aarhus C, Denmark; Aarhus Univ, CAMP, DK-8000 Aarhus C, Denmark	Centre National de la Recherche Scientifique (CNRS); Aarhus University; Aarhus University	Besenbacher, F (corresponding author), CNRS, CEMES, 29 Rue J Marvig,POB 4347, F-31055 Toulouse, France.	fbe@ifa.au.dk	Gourdon, André/C-9799-2009; Besenbacher, Flemming/A-9623-2010; Rosei, Federico/AAH-1159-2021	Gourdon, André/0000-0002-0370-1019; 				Besenbacher F, 1996, REP PROG PHYS, V59, P1737, DOI 10.1088/0034-4885/59/12/004; Bohringer M, 1999, PHYS REV LETT, V83, P324, DOI 10.1103/PhysRevLett.83.324; Bohringer M, 1997, PHYS REV B, V55, P1384, DOI 10.1103/PhysRevB.55.1384; Braun KF, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.096801; Cui XD, 2001, SCIENCE, V294, P571, DOI 10.1126/science.1064354; Datta S, 1997, PHYS REV LETT, V79, P2530, DOI 10.1103/PhysRevLett.79.2530; Donhauser ZJ, 2001, SCIENCE, V292, P2303, DOI 10.1126/science.1060294; EIGLER DM, 1991, NATURE, V352, P600, DOI 10.1038/352600a0; Fishlock TW, 2000, NATURE, V404, P743, DOI 10.1038/35008030; GIESENSEIBERT M, 1993, PHYS REV LETT, V71, P3521, DOI 10.1103/PhysRevLett.71.3521; GIMZEWSKI JK, 1994, PHYS REV LETT, V72, P1036, DOI 10.1103/PhysRevLett.72.1036; Gimzewski JK, 1999, SCIENCE, V283, P1683, DOI 10.1126/science.283.5408.1683; Hipps KW, 2001, SCIENCE, V294, P536, DOI 10.1126/science.1065708; Hla SW, 2000, PHYS REV LETT, V85, P2777, DOI 10.1103/PhysRevLett.85.2777; Ito T, 2000, NATURE, V406, P1027, DOI 10.1038/35023233; Joachim C, 2000, NATURE, V408, P541, DOI 10.1038/35046000; Jung TA, 1996, SCIENCE, V271, P181, DOI 10.1126/science.271.5246.181; Kuhnle A, 2002, NATURE, V415, P891, DOI 10.1038/415891a; Laegsgaard E, 2001, REV SCI INSTRUM, V72, P3537, DOI 10.1063/1.1389497; Langlais VJ, 1999, PHYS REV LETT, V83, P2809, DOI 10.1103/PhysRevLett.83.2809; Manoharan HC, 2000, NATURE, V403, P512, DOI 10.1038/35000508; Moresco F, 2001, PHYS REV LETT, V86, P672, DOI 10.1103/PhysRevLett.86.672; Okawa Y, 2001, NATURE, V409, P683, DOI 10.1038/35055625; Pease AR, 2001, ACCOUNTS CHEM RES, V34, P433, DOI 10.1021/ar000178q; SAUTET P, 1991, CHEM PHYS LETT, V185, P23, DOI 10.1016/0009-2614(91)80133-I; Schunack M, 2001, ANGEW CHEM INT EDIT, V40, P2623, DOI 10.1002/1521-3773(20010716)40:14<2623::AID-ANIE2623>3.0.CO;2-X; Schunack M, 2001, PHYS REV LETT, V86, P456, DOI 10.1103/PhysRevLett.86.456; Weckesser J, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.096101; Weckesser J, 2001, J CHEM PHYS, V115, P9001, DOI 10.1063/1.1410391; Yokoyama T, 2001, NATURE, V413, P619, DOI 10.1038/35098059; Zambelli T, 2001, CHEM PHYS LETT, V348, P1, DOI 10.1016/S0009-2614(01)01095-8	31	195	196	1	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	2002	296	5566					328	331		10.1126/science.1069157	http://dx.doi.org/10.1126/science.1069157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	541TJ	11951041				2022-12-28	WOS:000175000300052
J	Winoto, A; Littman, DR				Winoto, A; Littman, DR			Nuclear hormone receptors in T lymphocytes	CELL			English	Review							ACTIVATION-INDUCED APOPTOSIS; ORPHAN STEROID-RECEPTOR; TRANSCRIPTION FACTOR NUR77; RETINOIC ACID RECEPTOR; ROR-GAMMA-T; GLUCOCORTICOID RECEPTOR; NEGATIVE SELECTION; CELL APOPTOSIS; CYTOCHROME-C; GENE NUR77	Among the numerous steroid and orphan nuclear receptors encoded within mammalian genomes, several are involved in regulating immune system functions. We review here recent studies on the glucocorticoid receptor and the orphan receptors Nur77 and RORgamma. These molecules play key roles in the development and the effector functions of T lymphocytes.	NYU, Sch Med, Skirball Inst Biomol Med, Howard Hughes Med Inst, New York, NY 10016 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, LSA 469, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; New York University; University of California System; University of California Berkeley	Littman, DR (corresponding author), NYU, Sch Med, Skirball Inst Biomol Med, Howard Hughes Med Inst, 540 1st Ave, New York, NY 10016 USA.	winoto@uclink4.berkeley.edu; littman@saturn.med.nyu.edu						Alcamo E, 2002, J EXP MED, V195, P233, DOI 10.1084/jem.20011885; ALROY I, 1995, MOL CELL BIOL, V15, P5789; Amsen D, 1999, P NATL ACAD SCI USA, V96, P622, DOI 10.1073/pnas.96.2.622; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BISSONNETTE RP, 1995, MOL CELL BIOL, V15, P5576; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; CALNAN BJ, 1995, IMMUNITY, V3, P273; Chan FKM, 1998, J IMMUNOL, V161, P4252; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; Dawson MI, 2001, CANCER RES, V61, P4723; DeYoung AL, 2000, J IMMUNOL, V165, P6170, DOI 10.4049/jimmunol.165.11.6170; Esau C, 2001, J EXP MED, V194, P1449, DOI 10.1084/jem.194.10.1449; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Feske S, 2001, NAT IMMUNOL, V2, P316, DOI 10.1038/86318; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Fu YX, 1999, ANNU REV IMMUNOL, V17, P399, DOI 10.1146/annurev.immunol.17.1.399; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Glass CK, 2000, GENE DEV, V14, P121; Godfrey DI, 2001, TRENDS IMMUNOL, V22, P243, DOI 10.1016/S1471-4906(01)01916-0; HARMSEN A, 2002, IN PRESS J IMMUNOL; He YW, 1998, IMMUNITY, V9, P797, DOI 10.1016/S1074-7613(00)80645-7; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; Jamieson CAM, 2000, P NATL ACAD SCI USA, V97, P7319, DOI 10.1073/pnas.97.13.7319; Jondal M, 2001, TRENDS IMMUNOL, V22, P185, DOI 10.1016/S1471-4906(01)01871-3; Kang HJ, 2000, EXP CELL RES, V256, P545, DOI 10.1006/excr.2000.4832; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kim D, 2000, J EXP MED, V192, P1467, DOI 10.1084/jem.192.10.1467; Kishimoto H, 1999, J EXP MED, V190, P65, DOI 10.1084/jem.190.1.65; Kuang AA, 1999, EUR J IMMUNOL, V29, P3722, DOI 10.1002/(SICI)1521-4141(199911)29:11<3722::AID-IMMU3722>3.0.CO;2-N; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kurebayashi S, 2000, P NATL ACAD SCI USA, V97, P10132, DOI 10.1073/pnas.97.18.10132; LEE SL, 1995, SCIENCE, V269, P532, DOI 10.1126/science.7624775; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Littman DR, 1999, COLD SPRING HARB SYM, V64, P373, DOI 10.1101/sqb.1999.64.373; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; Moore KJ, 2001, CURR OPIN LIPIDOL, V12, P519, DOI 10.1097/00041433-200110000-00007; MOSER M, 1995, EUR J IMMUNOL, V25, P2818, DOI 10.1002/eji.1830251016; ORTIZ MA, 1995, MOL ENDOCRINOL, V9, P1679, DOI 10.1210/me.9.12.1679; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Pratt WB, 1997, ANNU REV PHARMACOL, V37, P297, DOI 10.1146/annurev.pharmtox.37.1.297; Purton JF, 2000, IMMUNITY, V13, P179, DOI 10.1016/S1074-7613(00)00018-2; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; Sparrow DB, 1999, EMBO J, V18, P5085, DOI 10.1093/emboj/18.18.5085; Staples JE, 1999, J IMMUNOL, V163, P4168; Sun ZM, 2000, SCIENCE, V288, P2369, DOI 10.1126/science.288.5475.2369; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0; Takeuchi A, 1998, J IMMUNOL, V160, P209; Toth R, 2001, EUR J IMMUNOL, V31, P1382, DOI 10.1002/1521-4141(200105)31:5<1382::AID-IMMU1382>3.0.CO;2-Y; Towers TL, 1999, MOL CELL BIOL, V19, P4191; Tzameli I, 2001, TRENDS ENDOCRIN MET, V12, P7, DOI 10.1016/S1043-2760(00)00332-5; Vieira PL, 1998, J IMMUNOL, V161, P5245; Villey I, 1999, EUR J IMMUNOL, V29, P4072, DOI 10.1002/(SICI)1521-4141(199912)29:12<4072::AID-IMMU4072>3.0.CO;2-E; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; YANG YL, 1995, J EXP MED, V181, P1673, DOI 10.1084/jem.181.5.1673; Yannoutsos N, 2001, J EXP MED, V194, P471, DOI 10.1084/jem.194.4.471; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; YOON JK, 1993, J BIOL CHEM, V268, P9148; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhang J, 1999, COLD SPRING HARB SYM, V64, P363, DOI 10.1101/sqb.1999.64.363; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879	88	202	211	2	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR	2002	109			S			S57	S66		10.1016/S0092-8674(02)00710-9	http://dx.doi.org/10.1016/S0092-8674(02)00710-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	544UY	11983153	Bronze			2022-12-28	WOS:000175181100006
J	Hoeflich, KP; Ikura, M				Hoeflich, KP; Ikura, M			Calmodulin in action: Diversity in target recognition and activation mechanisms	CELL			English	Review							ADENYLATE-CYCLASE; CALCIUM; PROTEIN	Recent structural studies on calmodulin complexes with anthrax adenylyl cyclase and rat Ca2+-activated K+ channel have uncovered unexpected ways by which calmodulin interacts with target proteins.	Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Ikura, M (corresponding author), Ontario Canc Inst, Div Mol & Struct Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	mikura@uhnres.utoronto.ca		Ikura, Mitsuhiko/0000-0002-9524-1303				Bayer KU, 2001, NATURE, V411, P801, DOI 10.1038/35081080; Chin D, 2000, TRENDS CELL BIOL, V10, P322, DOI 10.1016/S0962-8924(00)01800-6; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; DeMaria CD, 2001, NATURE, V411, P484, DOI 10.1038/35078091; Drum CL, 2002, NATURE, V415, P396, DOI 10.1038/415396a; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Kurokawa H, 2001, J MOL BIOL, V312, P59, DOI 10.1006/jmbi.2001.4822; LEPPLA SH, 1984, ADV CYCLIC NUCL PROT, V17, P189; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MUNIER H, 1993, J BIOL CHEM, V268, P1695; Pitt GS, 2001, J BIOL CHEM, V276, P30794, DOI 10.1074/jbc.M104959200; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; Schumacher MA, 2001, NATURE, V410, P1120, DOI 10.1038/35074145; Wissmann R, 2002, J BIOL CHEM, V277, P4558, DOI 10.1074/jbc.M109240200; Yuan T, 1998, J BIOL CHEM, V273, P30328, DOI 10.1074/jbc.273.46.30328	18	561	587	2	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 22	2002	108	6					739	742		10.1016/S0092-8674(02)00682-7	http://dx.doi.org/10.1016/S0092-8674(02)00682-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	534AT	11955428	Bronze			2022-12-28	WOS:000174563000004
J	Brookes, ST; Donovan, JL; Peters, TJ; Abrams, P; Neal, DE				Brookes, ST; Donovan, JL; Peters, TJ; Abrams, P; Neal, DE			Sexual dysfunction in men after treatment for lower urinary tract symptoms: evidence from randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							BENIGN PROSTATIC HYPERPLASIA; COMPARING TRANSURETHRAL RESECTION; TRANS-URETHRAL RESECTION; LASER THERAPY; PROSTATECTOMY; CLASP; RETENTION	Objective To examine the impact on sexual function of treatments for lower urinary tract symptoms in men. Design Multicentre pragmatic randomised controlled trial of standard surgery (transurethral resection of the prostate), non-contact laser therapy, and conservative management (no active intervention). Setting Three clinical centres in the United Kingdom. Participants 340 men aged between 48 and 90 years with lower urinary tract symptoms related to benign prostatic enlargement. Main outcome measures ICSsex questionnaire items concerned with erectile stiffness, ejaculatory volume, pain or discomfort on ejaculation, whether sex life was spoilt by urinary symptoms. Results Erectile and ejaculatory dysfunction were common (70%) and problematic at baseline and showed the expected trends with ageing. After treatment, reduced ejaculation was reported in all groups but was not significantly worse after standard surgery than after laser therapy. Erectile function was significantly improved after standard surgery; no significant difference was found between standard surgery and laser therapy (odds ratio 0.70, 95% confidence interval 0.36 to 1.38). Standard surgery was significantly better at relieving pain or discomfort on ejaculation than either conservative management (0.06, 0.007 to 0.49) or laser therapy (0.09, 0.01 to 0.73). Conclusions Compared with laser therapy standard surgery for lower urinary tract symptoms has a beneficial effect oil aspects of sexual function-particularly in improving erectile function and reducing reported pain or discomfort oil ejaculation. Older men who need treatment and want to retain or improve sexual function may thus want to consider standard surgery rather than non-contact laser therapy.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Southmead Gen Hosp, Bristol Urol Inst, Bristol BS10 5NB, Avon, England; Univ Newcastle Upon Tyne, Sch Surg & Reprod Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	University of Bristol; Southmead Hospital; Newcastle University - UK	Brookes, ST (corresponding author), Univ Bristol, Dept Social Med, Canynge Hall, Bristol BS8 2PR, Avon, England.			Peters, Tim/0000-0003-2881-4180; Neal, David/0000-0002-6033-5086				ANSON K, 1995, UROLOGY, V46, P305, DOI 10.1016/S0090-4295(99)80211-8; Armitage P., 2001, STAT METHODS MED RES; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BARRY MJ, 1995, J UROLOGY, V154, P1770, DOI 10.1016/S0022-5347(01)66780-6; Bender R, 1997, J ROY COLL PHYS LOND, V31, P546; BOON TA, 1995, WORLD J UROL, V13, P123, DOI 10.1007/BF00183628; Bortz WM, 1999, J GERONTOL A-BIOL, V54, pM237, DOI 10.1093/gerona/54.5.M237; Chacko KN, 2001, J UROLOGY, V166, P166, DOI 10.1016/S0022-5347(05)66101-0; COCKETT AT, 1991, P WHO INT CONS EPH 1; COCKETT AT, 1991, P WHO INT CONS BPH 1; Donovan JL, 2000, J UROLOGY, V164, P65, DOI 10.1016/S0022-5347(05)67450-2; Donovan JL, 1996, BRIT J UROL, V77, P554, DOI 10.1046/j.1464-410X.1996.93013.x; Dunn KM, 1998, FAM PRACT, V15, P519, DOI 10.1093/fampra/15.6.519; Frankel SJ, 1998, J CLIN EPIDEMIOL, V51, P677, DOI 10.1016/S0895-4356(98)00044-4; GRAVERSEN PH, 1989, J UROLOGY, V141, P475, DOI 10.1016/S0022-5347(17)40864-0; Gujral S, 2000, J UROLOGY, V164, P59, DOI 10.1016/S0022-5347(05)67449-6; KABALIN JN, 1995, J UROLOGY, V153, P94, DOI 10.1097/00005392-199501000-00033; Keoghane SR, 1996, EUR UROL, V30, P424; LIBMAN E, 1987, UROLOGY, V29, P467, DOI 10.1016/0090-4295(87)90031-8; Macfarlane GJ, 1996, J CLIN EPIDEMIOL, V49, P1171, DOI 10.1016/0895-4356(96)00213-2; Namasivayam S, 1998, BRIT J UROL, V82, P842; OESTERLING JE, 1995, NEW ENGL J MED, V332, P99, DOI 10.1056/NEJM199501123320207; Soderdahl DW, 1996, J UROLOGY, V156, P1354, DOI 10.1016/S0022-5347(01)65585-X; *STAT, 1999, STAT STAT SOFTW REL; *US DEP HHS, 1994, BEN PROST HYP DIAGN; WASSON JH, 1995, NEW ENGL J MED, V332, P75, DOI 10.1056/NEJM199501123320202	26	107	114	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 4	2002	324	7345					1059	1061		10.1136/bmj.324.7345.1059	http://dx.doi.org/10.1136/bmj.324.7345.1059			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	549YY	11991908	Bronze, Green Published			2022-12-28	WOS:000175476500016
J	Zhu, Y; Ghosh, P; Charnay, P; Burns, DK; Parada, LF				Zhu, Y; Ghosh, P; Charnay, P; Burns, DK; Parada, LF			Neurofibromas in NF1: Schwann cell origin and role of tumor environment	SCIENCE			English	Article							PERIPHERAL NERVOUS-SYSTEM; TYPE-1; SUPPRESSOR; SHEATH; CANCER; GAP	Neurofibromatosis type 1 (NF1) is one of the most prevalent dominantly inherited genetic diseases of the nervous system. NF1 encodes a tumor suppressor whose functional loss results in the development of benign neurofibromas that can progress to malignancy. Neurofibromas are complex tumors composed of axonal processes, Schwann cells, fibroblasts, perineurial cells, and mast cells. Through use of a conditional (cre/lox) allele, we show that loss of NF1 in the Schwann cell lineage is sufficient to generate tumors. In addition, complete NF1-mediated tumorigenicity requires both a loss of NF1 in cells destined to become neoplastic as well as heterozygosity in non-neoplastic cells. The requirement for a permissive haploinsufficient environment to allow tumorigenesis may have therapeutic implications for NF1 and other familial cancers.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Ecole Normale Super, F-75230 Paris, France	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Parada, LF (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.		Zhu, Yuan/ABF-8405-2020; Parada, luis F/B-9400-2014	Charnay, Patrick/0000-0002-3847-6042	NINDS NIH HHS [R01 NS034296-06, R01 NS034296] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034296] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; Coussens LM, 2000, CELL, V103, P481, DOI 10.1016/S0092-8674(00)00139-2; HALLIDAY AL, 1991, J NEUROSURG, V74, P248, DOI 10.3171/jns.1991.74.2.0248; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; KIM HA, 1995, ONCOGENE, V11, P325; KLEIHUES P, 2000, PATHOLOGY GENTICS TU; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; Korf BR, 1999, AM J MED GENET, V89, P31, DOI 10.1002/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W; MARTUZA R, COMMUNICATION; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; Serra E, 2000, HUM MOL GENET, V9, P3055, DOI 10.1093/hmg/9.20.3055; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; TOPILKO P, 1994, NATURE, V371, P796, DOI 10.1038/371796a0; Voiculescu O, 2000, GENESIS, V26, P123, DOI 10.1002/(SICI)1526-968X(200002)26:2<123::AID-GENE7>3.0.CO;2-O; Woodruff JM, 1999, AM J MED GENET, V89, P23, DOI 10.1002/(SICI)1096-8628(19990326)89:1<23::AID-AJMG6>3.0.CO;2-#; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101; Zhu Y, 2001, EXP CELL RES, V264, P19, DOI 10.1006/excr.2000.5138	21	435	453	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 3	2002	296	5569					920	922		10.1126/science.1068452	http://dx.doi.org/10.1126/science.1068452			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	549KF	11988578	Green Accepted			2022-12-28	WOS:000175442500047
J	Gupta, S; Kahn, RA				Gupta, S; Kahn, RA			Left ventricular thrombus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Mt Sinai Med Ctr, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Gupta, S (corresponding author), Mt Sinai Med Ctr, New York, NY 10029 USA.								0	1	1	0	2	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					E5	E5		10.1056/NEJMicm010457	http://dx.doi.org/10.1056/NEJMicm010457			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546MZ	11986406				2022-12-28	WOS:000175279000006
J	Haberer, JE; Ix, JH; Tierney, LM				Haberer, JE; Ix, JH; Tierney, LM			One foot away	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE-CHAIN-REACTION; GENITOURINARY TUBERCULOSIS; DIAGNOSIS		Univ Calif San Francisco, Dept Med, San Francisco, CA USA	University of California System; University of California San Francisco	Tierney, LM (corresponding author), Vet Affairs Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA.		Haberer, Jessica/AAH-7976-2019	Haberer, Jessica/0000-0001-5845-3190				*CDC NCHSTP DTBE H, 2002, DIV TUB EL 2002; Elder N C, 1992, Arch Fam Med, V1, P91, DOI 10.1001/archfami.1.1.91; Goodman SN, 1999, ANN INTERN MED, V130, P1005, DOI 10.7326/0003-4819-130-12-199906150-00019; Hemal AK, 2000, UROLOGY, V56, P570, DOI 10.1016/S0090-4295(00)00668-3; Janis EM, 1996, AM J MED, V100, P186, DOI 10.1016/S0002-9343(97)89457-0; Mortier E, 1996, BRIT MED J, V312, P27, DOI 10.1136/bmj.312.7022.27; Moussa OM, 2000, J UROLOGY, V164, P584, DOI 10.1016/S0022-5347(05)67427-7; Raviglione M. C., 2001, HARRISONS PRINCIPLES, P1024; VictorioNavarra STG, 1996, SEMIN ARTHRITIS RHEU, V26, P628, DOI 10.1016/S0049-0172(96)80013-8; WEIR MR, 1985, AM J MED, V79, P467, DOI 10.1016/0002-9343(85)90034-8	10	2	2	0	0	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 02	2002	346	18					1394	1397		10.1056/NEJMcps013305	http://dx.doi.org/10.1056/NEJMcps013305			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546MZ	11986414				2022-12-28	WOS:000175279000009
J	Inglesby, TV; O'Toole, T; Henderson, DA; Bartlett, JG; Ascher, MS; Eitzen, E; Friedlander, AM; Gerberding, J; Hauer, J; Hughes, J; McDade, J; Osterholm, MT; Parker, G; Perl, TM; Russell, PK; Tonat, K				Inglesby, TV; O'Toole, T; Henderson, DA; Bartlett, JG; Ascher, MS; Eitzen, E; Friedlander, AM; Gerberding, J; Hauer, J; Hughes, J; McDade, J; Osterholm, MT; Parker, G; Perl, TM; Russell, PK; Tonat, K		Working Grp Civilian Biodef	Anthrax as a biological weapon, 2002 - Updated recommendations for management	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ORAL-OROPHARYNGEAL ANTHRAX; BACILLUS-ANTHRACIS; INHALATION ANTHRAX; RHESUS-MONKEYS; OUTBREAK; WARFARE; DOXYCYCLINE; PENICILLIN; TERRORISM; SPORES	Objective To review and update consensus-based recommendations for medical and public health professionals following a Bacillus anthracis attack against a civilian population. Participants The working group included 23 experts from academic medical centers, research organizations, and governmental, military, public health, and emergency management institutions and agencies. Evidence MEDLINE databases were searched from January 1966 to January 2002, using the Medical Subject Headings anthrax, Bacillus anthracis, biological weapon, biological terrorism, biological warfare, and biowarfare. Reference review identified work published before 1966. Participants identified unpublished sources. Consensus Process The first draft synthesized the gathered information. Written comments were incorporated into subsequent drafts. The final statement incorporated all relevant evidence from the search along with consensus recommendations. Conclusions Specific recommendations include diagnosis of anthrax infection, indications for vaccination, therapy, postexposure prophylaxis, decontamination of the environment, and suggested research. This revised consensus statement presents new information based on the analysis of the anthrax attacks of 2001, including developments in the investigation of the anthrax attacks of 2001; important symptoms, signs, and laboratory studies; new diagnostic clues that may help future recognition of this disease; current anthrax vaccine information; updated antibiotic therapeutic considerations; and judgments about environmental surveillance and decontamination.	Johns Hopkins Univ, Johns Hopkins Ctr Civilian Biodef Strategies, Baltimore, MD 21202 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21202 USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD 21202 USA; Dept Hlth & Human Serv, Baltimore, MD USA; USA, Med Res Inst Infect Dis, Frederick, MD USA; Ctr Dis Control & Prevent, Atlanta, GA USA; Univ Minnesota, Sch Publ Hlth, Ctr Infect Dis Res & Policy, Minneapolis, MN USA; Dept Hlth & Human Serv, Off Emergency Preparedness, Rockville, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Centers for Disease Control & Prevention - USA; University of Minnesota System; University of Minnesota Twin Cities	Inglesby, TV (corresponding author), Johns Hopkins Univ, Johns Hopkins Ctr Civilian Biodef Strategies, Candler Bldg,Suite 830,111 Market Pl, Baltimore, MD 21202 USA.							ABRAMOVA FA, 1993, P NATL ACAD SCI USA, V90, P2291, DOI 10.1073/pnas.90.6.2291; *AGR PDMD, 1946, PREM PART FIEVRE CHA; ALBRINK WS, 1960, AM J PATHOL, V36, P457; Alibek K, 1999, BIOHAZARD CHILLING T; ALTMAN LK, 2001, NY TIMES        1025, pB6; *AM HOSP FORM SERV, 1996, AHFS DRUG INF; *AM PUBL HLTH ASS, 1995, CONTR COMM DIS MAN, P18; Barakat LA, 2002, JAMA-J AM MED ASSOC, V287, P863, DOI 10.1001/jama.287.7.863; BARNES JM, 1947, J PATHOL BACTERIOL, V194, P113; Borio L, 2001, JAMA-J AM MED ASSOC, V286, P2554, DOI 10.1001/jama.286.20.2554; Brachman P S, 1980, Ann N Y Acad Sci, V353, P83, DOI 10.1111/j.1749-6632.1980.tb18910.x; Brachman P. S., 1999, VACCINES, P629; Brachman P.S., 1994, INFECT DIS, P1003; BRACHMAN PS, 1962, AM J PUBLIC HEALTH N, V52, P632, DOI 10.2105/AJPH.52.4.632; Brookmeyer R, 2001, Biostatistics, V2, P233, DOI 10.1093/biostatistics/2.2.233; Bush LM, 2001, NEW ENGL J MED, V345, P1607, DOI 10.1056/NEJMoa012948; Carter A, 1998, FOREIGN AFF, V77, P80, DOI 10.2307/20049132; CARUCCI JA, 2001, J AM ACAD DERMATOL; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P909; CHINN KS, 1996, PUBLICATION; Choe CH, 2000, ANTIMICROB AGENTS CH, V44, P1766, DOI 10.1128/AAC.44.6.1766-1766.2000; Christopher GW, 1997, JAMA-J AM MED ASSOC, V278, P412, DOI 10.1001/jama.278.5.412; *CIA, 2002, CIA REP DOC GLOB WEA; *COMM ASS SAF EFF, 2002, ANTHR VACC IS IT SAF; DAHLGREN CM, 1960, AM J HYG, V72, P24, DOI 10.1093/oxfordjournals.aje.a120131; DALLDORF FG, 1971, ARCH PATHOL, V92, P418; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; DOGANAY M, 1991, SCAND J INFECT DIS, V23, P333, DOI 10.3109/00365549109024319; DRAGON DC, 1995, CAN VET J, V36, P295; DRUETT HA, 1953, J HYG-CAMBRIDGE, V51, P359, DOI 10.1017/S0022172400015795; DUTZ W, 1970, GUT, V11, P352, DOI 10.1136/gut.11.4.352; Enserink M, 2002, SCIENCE, V295, P1442, DOI 10.1126/science.295.5559.1442; Fellows PF, 2001, VACCINE, V20, P635, DOI 10.1016/S0264-410X(01)00411-X; Franz DR, 1997, JAMA-J AM MED ASSOC, V278, P399, DOI 10.1001/jama.278.5.399; Freedman A, 2002, JAMA-J AM MED ASSOC, V287, P869, DOI 10.1001/jama.287.7.869; FRIEDLANDER A, 1997, TXB MILITARY MED MED, P467; Friedlander AM, 2001, NATURE, V414, P160, DOI 10.1038/35102660; FRIEDLANDER AM, 1993, J INFECT DIS, V167, P1239, DOI 10.1093/infdis/167.5.1239; GLASSMAN HN, 1966, BACTERIOL REV, V30, P657, DOI 10.1128/MMBR.30.3.657-659.1966; GLEISER CA, 1963, BRIT J EXP PATHOL, V44, P416; Grinberg LM, 2001, MODERN PATHOL, V14, P482, DOI 10.1038/modpathol.3880337; GUILLERMIN J, 1999, ANTHRAX INVESTIGATIO; Hail AS, 1999, MIL MED, V164, P833, DOI 10.1093/milmed/164.12.833; Hanna PC, 1999, TRENDS MICROBIOL, V7, P180, DOI 10.1016/S0966-842X(99)01507-3; HATCH TF, 1961, BACTERIOL REV, V25, P237, DOI 10.1128/MMBR.25.3.237-240.1961; HENDERSON D. W., 1956, JOUR HYG, V54, P28; HSU SS, 2002, WASHINGTON POST 0307, pA7; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Ivins B.E., 1996, SALISBURY MED B, V87, P125; Jernigan JA, 2001, EMERG INFECT DIS, V7, P933, DOI 10.3201/eid0706.010604; KAYE E, 2001, HARRISONS TXB MED; Keim P, 2001, J CLIN MICROBIOL, V39, P4566, DOI 10.1128/JCM.39.12.4566-4567.2001; KELLY DJ, 1992, J INFECT DIS, V166, P1184, DOI 10.1093/infdis/166.5.1184; Kennedy H., 2001, NEW YORK DAILY  1031, P5; KOHOUT E, 1964, AM J MED SCI, V247, P565, DOI 10.1097/00000441-196405000-00006; Kournikakis B., 2001, RISK ASSESSMENT ANTH; LEW D, 1995, PRINCIPLES PRACTICE, P1885; Lightfoot NF., 1990, SALISBURY MEDICAL B, V68, P95; LINCOLN R. E., 1965, P759; LINCOLN RE, 1965, J INFECT DIS, V115, P481, DOI 10.1093/infdis/115.5.481; MANCHEE RJ, 1988, CHEM BR          JUL, P690; Mayer TA, 2001, JAMA-J AM MED ASSOC, V286, P2549, DOI 10.1001/jama.286.20.2549; MESELSON M, 1994, SCIENCE, V266, P1202, DOI 10.1126/science.7973702; Michigan department of Public Health, 1978, ANTHR VACC ADS; MILLER J, 2001, NY TIMES        0904, pA1; Mina B, 2002, JAMA-J AM MED ASSOC, V287, P858, DOI 10.1001/jama.287.7.858; *MONT I INT STUD C, 2001, CHEM BIOL WEAP; Mourez M, 2001, NAT BIOTECHNOL, V19, P958, DOI 10.1038/nbt1001-958; MYENYE KS, 1996, CENT AFR J MED, V42, P312; *NAT I ALL INF DIS, 2002, COUNT BIOT RES AG; ODENDAAL MW, 1991, ONDERSTEPOORT J VET, V58, P17; PENN CC, 1998, INFECT DIS, P1575; PERKINS WA, 1961, BACTERIOL REV, V25, P347, DOI 10.1128/MMBR.25.3.347-355.1961; Peters CJ, 2002, LANCET, V359, P710, DOI 10.1016/S0140-6736(02)07792-9; PIENAAR UDV, 1967, FED PROC, V26, P1496; Pile JC, 1998, ARCH INTERN MED, V158, P429, DOI 10.1001/archinte.158.5.429; Pitt MLM, 2001, VACCINE, V19, P4768, DOI 10.1016/S0264-410X(01)00234-1; Pitt MLM, 1999, J APPL MICROBIOL, V87, P304, DOI 10.1046/j.1365-2672.1999.00897.x; Pittman PR, 2001, VACCINE, V20, P972, DOI 10.1016/S0264-410X(01)00387-5; *PUBL HLTH SERV OF, 1995, P SEM RESP CONS CHEM; REGIS E, 1999, HIST AM SECRET GERM; Resnick I. G., 1990, PUBLICATION, P1; ROSS JM, 1957, J PATHOL BACTERIOL, V73, P485, DOI 10.1002/path.1700730219; Simon JD, 1997, JAMA-J AM MED ASSOC, V278, P428, DOI 10.1001/jama.278.5.428; SIRISANTHANA T, 1984, AM J TROP MED HYG, V33, P144, DOI 10.4269/ajtmh.1984.33.144; SIRISANTHANA T, 1988, AM J TROP MED HYG, V39, P575, DOI 10.4269/ajtmh.1988.39.575; SMITH H, 1954, NATURE, V173, P869, DOI 10.1038/173869a0; Stepanov AV, 1996, J BIOTECHNOL, V44, P155, DOI 10.1016/0168-1656(95)00092-5; STEVENS DL, 1988, J INFECT DIS, V158, P23, DOI 10.1093/infdis/158.1.23; TITBALL R W, 1991, Society for Applied Bacteriology Symposium Series, p9S; TURNBULL PCB, 1991, VACCINE, V9, P533, DOI 10.1016/0264-410X(91)90237-Z; *US ARM MED RES I, 1998, MED RESP BIOL WARF T; *US C, 1993, PUBL; *US DEP DEF, 1986, PUBL; VESSAL K, 1975, CLIN RADIOL, V26, P471, DOI 10.1016/S0009-9260(75)80100-0; WALKER JS, 1967, FED PROC, V26, P1539; Welkos S, 2001, MICROBIOL-SGM, V147, P1677, DOI 10.1099/00221287-147-6-1677; Wiesen AR, 2002, JAMA-J AM MED ASSOC, V287, P1556, DOI 10.1001/jama.287.12.1556; WILLIAMS RP, 1986, INFECT DIS MED MICRO, P270; World Health Organization, 1970, HLTH ASP CHEM BIOL W; WUDUNN S, 1998, NY TIMES        0410, pA1; WUDUNN S, 1998, NY TIMES        0526, P6; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418; 2001, MMWR MORB MORTAL WKL, V50, P1014; 1999, MMWR MORB MORTAL WKL, V48, P69; 2001, MMWR MORB MORTAL WKL, V50, P677; 2001, MMWR MORB MORTAL WKL, V50, P1077; 2000, MMWR MORB MORTAL WKL, V49, P341; 2001, MMWR MORB MORTAL WKL, V50, P1051; 2001, MMWR MORB MORTAL WKL, V50, P941; 2001, MMWR MORB MORTAL WKL, V50, P1087; 1994, MMWR MORB MORTAL WKL, V43, P70	112	732	776	0	151	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	2002	287	17					2236	2252		10.1001/jama.287.17.2236	http://dx.doi.org/10.1001/jama.287.17.2236			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546EZ	11980524				2022-12-28	WOS:000175260600024
J	Durelli, L; Verdun, E; Barbero, P; Bergui, M; Versino, E; Ghezzi, A; Montanari, E; Zaffaroni, M				Durelli, L; Verdun, E; Barbero, P; Bergui, M; Versino, E; Ghezzi, A; Montanari, E; Zaffaroni, M		INCOMIN Trial Study Grp	Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)	LANCET			English	Article							NEUTRALIZING ANTIBODIES; BIOAVAILABILITY; MS	Background The three interferon beta preparations approved for treatment of relapsing-remitting multiple sclerosis (MS) differ in dose and frequency of administration. Interferon beta-1a 30 mug is administered once a week, interferon beta-1a 22 mug or 44 mug is given three times a week, and interferon beta-1b 250 mug is administered on alternate days. No clinical study directly comparing the different regimens has been published. The INCOMIN study was designed to compare the clinical and magnetic resonance imaging (MRI) benefits of on-alternate-clay interferon beta-1b 250 mug with once-weekly interferon beta-1a 30 mug. Methods INCOMIN was a 2-year, prospective, randomised, multicentre study. 188 patients with relapsing-remitting MS were assigned to interferon beta-1b (n=96) or interferon beta-1a (n=92). Primary outcome measures were the proportion of patients free from relapses and that of patients free from new proton density/T2 lesions at MRI assessment. Several secondary outcome measures were also assessed. Analysis was by intention to treat. Findings Over 2 years, 49 (51%) individuals administered interferon beta-1b remained relapse-free compared with 33 (36%) given interferon beta-1a (relative risk of relapse 0.76; 95% CI 0.59-0.9; p=0.03); and 42 (55%) compared with 19 (26%), respectively, remained free from new T2 lesions at MRI (relative risk of new T2 lesion 0.6; 0.45-0.8; p<0.0003). In both groups, the differences between the two treatments increased during the second year. There were also significant differences in favour of interferon beta-1b in most of the secondary outcome measures, including delay of confirmed disease progression. Interpretation High-dose interferon beta-1b administered every other day is more effective than interferon beta-1a given once a week.	Univ Turin, Dipartimento Neurosci, I-10126 Turin, Italy; Azienda Osped S Antonio Abate, Gallarate, Italy; Osped Civile, Fidenza, Italy	University of Turin	Durelli, L (corresponding author), Univ Turin, Dipartimento Neurosci, I-10126 Turin, Italy.	luca.durelli@unito.it	Versino, Elisabetta/AAO-4612-2020; bergui, mauro/AAY-2430-2021; Macedo, Ana/L-9912-2018; ghezzi, angelo/AAJ-9606-2020	bergui, mauro/0000-0002-5336-695X; Macedo, Ana/0000-0002-6978-8989; 				Antonelli G, 1998, J INTERF CYTOK RES, V18, P345, DOI 10.1089/jir.1998.18.345; BOUZAS EA, 1993, NEUROLOGY, V43, P622, DOI 10.1212/WNL.43.3_Part_1.622; COYLE P, 2001, J NEUROL SCI S1, V187, pS436; Deisenhammer F, 1999, NEUROLOGY, V52, P1239, DOI 10.1212/WNL.52.6.1239; Deisenhammer F, 2000, NEUROLOGY, V54, P2055, DOI 10.1212/WNL.54.11.2055; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; Duquette P, 1996, NEUROLOGY, V47, P889; Ebers G, 1999, NEUROLOGY, V53, P679; Ebers GC, 1998, LANCET, V352, P1498, DOI 10.1016/S0140-6736(98)03334-0; Filippi M, 1995, BRAIN, V118, P1593, DOI 10.1093/brain/118.6.1593; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; Jonasch E, 2001, ONCOLOGIST, V6, P34, DOI 10.1634/theoncologist.6-1-34; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; MCFARLAND HF, 1992, ANN NEUROL, V32, P758, DOI 10.1002/ana.410320609; Petkau J, 1997, MULT SCLER, V3, P402, DOI 10.1177/135245859700300610; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; REVEL M, 1997, FRONTIERS MULTIPLE S, P243; Rice GPA, 1999, NEUROLOGY, V52, P1277, DOI 10.1212/WNL.52.6.1277; RICE GPA, 2001, COCHRANE LIB; Rosenthal Robert, 1994, HDB RES SYNTHESIS, V621, P231; Sackett D. L., 1997, EVIDENCE BASED MED P; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SCHUMACHER GA, 1965, ANN NY ACAD SCI, V122, P552; STONE LA, 1995, NEUROLOGY, V45, P1808, DOI 10.1212/WNL.45.10.1808; Sturzebecher S, 1999, J INTERF CYTOK RES, V19, P1257, DOI 10.1089/107999099312920; Williams GJ, 1998, J INTERF CYTOK RES, V18, P967, DOI 10.1089/jir.1998.18.967; WILLOUGHBY EW, 1989, ANN NEUROL, V25, P43, DOI 10.1002/ana.410250107; Zhao GJ, 2000, NEUROLOGY, V54, P200, DOI 10.1212/WNL.54.1.200	30	418	433	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	2002	359	9316					1453	1460		10.1016/S0140-6736(02)08430-1	http://dx.doi.org/10.1016/S0140-6736(02)08430-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	546NA	11988242				2022-12-28	WOS:000175279100006
J	Yakir, D				Yakir, D			Global enzymes - Sphere of influence	NATURE			English	Editorial Material									Weizmann Inst Sci, Dept Environm Sci & Energy Res, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Yakir, D (corresponding author), Weizmann Inst Sci, Dept Environm Sci & Energy Res, IL-76100 Rehovot, Israel.		Yakir, Dan/K-1500-2012					BERRY J, 1992, PRIMARY PRODUCTIVITY, P411; BIGELEISEN J, 1965, SCIENCE, V147, P463, DOI 10.1126/science.147.3657.463; GRIFFITH H, 1998, STABLE ISOTOPES INTE	3	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 25	2002	416	6883					795	795		10.1038/416795a	http://dx.doi.org/10.1038/416795a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544MH	11976659	Bronze			2022-12-28	WOS:000175163800029
J	Ferguson, E; James, D; Madeley, L				Ferguson, E; James, D; Madeley, L			Factors associated with success in medical school: systematic review of the literature	BMJ-BRITISH MEDICAL JOURNAL			English	Review							UNDERREPRESENTED-MINORITY STUDENTS; NBME PART-I; ACADEMIC-PERFORMANCE; LEARNING-STYLE; CLINICAL-PERFORMANCE; MCAT SCORES; CLERKSHIP PERFORMANCE; ADMISSION INTERVIEW; GENDER DIFFERENCES; PERSONAL CHARACTERISTICS		Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England; Queens Med Ctr, Fac Med, Sch Human Dev, Nottingham NG7 2UH, England	University of Nottingham; University of Nottingham	Ferguson, E (corresponding author), Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England.	eamonn.ferguson@nottingham.ac.uk		Ferguson, Eamonn/0000-0002-7678-1451				ACKERMAN PL, 1997, PSYCHOL BULL, V12, P171; AHMED B, 1988, MED EDUC, V22, P506, DOI 10.1111/j.1365-2923.1988.tb00794.x; ALDRICH CK, 1987, J MED EDUC, V62, P658; ALDULRAZZAQ YM, 1993, MED TEACH, V15, P243; ALFAYEZ SF, 1990, MED EDUC, V24, P230, DOI 10.1111/j.1365-2923.1990.tb00006.x; ARNOLD L, 1995, ACAD MED, V70, P715, DOI 10.1097/00001888-199508000-00016; BLUMBERG P, 1985, J MED EDUC, V60, P721; BROOKS CM, 1981, J MED EDUC, V56, P767; Bryk A. S., 1992, HIERARCHICAL LINEAR; Calkins E V, 1982, J Natl Med Assoc, V74, P625; CALKINS EV, 1987, J MED EDUC, V62, P682; CAMPOSOUTCALT D, 1994, ACAD MED, V69, P577, DOI 10.1097/00001888-199407000-00015; CariagaLo LD, 1997, ACAD MED, V72, pS69, DOI 10.1097/00001888-199710001-00024; CARLINE JD, 1977, J MED EDUC, V58, P18; Chan-Ob T, 1999, J Med Assoc Thai, V82, P604; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; COLLINS JP, 1995, MED EDUC, V29, P22, DOI 10.1111/j.1365-2923.1995.tb02795.x; CULLEN TJ, 1980, J MED EDUC, V55, P393; Davies SM, 1997, TEACH LEARN MED, V9, P131, DOI 10.1080/10401339709539827; DAWSONSAUNDERS B, 1981, J MED EDUC, V56, P295; DEARY IJ, 2001, INTELLIENCE VERY SHO; DIGMAN JM, 1990, ANNU REV PSYCHOL, V41, P417, DOI 10.1146/annurev.psych.41.1.417; DONNELLY M, 1986, J MED EDUC, V61, P123; ELAM CL, 1992, ACAD MED, V67, pS28, DOI 10.1097/00001888-199210000-00029; ELAM CL, 1994, ACAD MED, V69, P155, DOI 10.1097/00001888-199402000-00025; Elam CL, 1997, TEACH LEARN MED, V9, P181, DOI 10.1080/10401339709539838; ELAM CL, 1994, ACAD MED, V69, P852, DOI 10.1097/00001888-199410000-00018; ELMOUZAN MI, 1992, MED EDUC, V26, P123, DOI 10.1111/j.1365-2923.1992.tb00137.x; ERDMANN JB, 1992, ACAD MED, V67, P860, DOI 10.1097/00001888-199212000-00014; ESMAIL A, 1995, BRIT MED J, V310, P501, DOI 10.1136/bmj.310.6978.501; EVANS DA, 1975, J MED EDUC, V50, P934; EVANS RG, 1980, J RES PERS, V14, P76, DOI 10.1016/0092-6566(80)90042-2; Ferguson E, 2000, J OCCUP ORGAN PSYCH, V73, P321, DOI 10.1348/096317900167056; FINDLEY MJ, 1983, J PERS SOC PSYCHOL, V44, P419, DOI 10.1037/0022-3514.44.2.419; GLASER K, 1992, EDUC PSYCHOL MEAS, V52, P395, DOI 10.1177/0013164492052002015; GOLMON ME, 1981, J MED EDUC, V56, P981; GONNELLA JS, 1983, J MED EDUC, V58, P679; GOUGH HG, 1975, J MED EDUC, V50, P940; GOUGH HG, 1978, J MED EDUC, V53, P291; GOUGH HG, 1964, J APPL PSYCHOL, V48, P218, DOI 10.1037/h0041092; GREEN A, 1991, MED EDUC, V25, P343, DOI 10.1111/j.1365-2923.1991.tb00076.x; GROVER PL, 1981, J MED EDUC, V56, P727; HALEY JV, 1972, J MED EDUC, V47, P446; HALL FR, 1992, ACAD MED, V67, P842, DOI 10.1097/00001888-199212000-00010; HALL ML, 1995, ACAD MED, V70, P230, DOI 10.1097/00001888-199503000-00015; HART ME, 1981, J MED EDUC, V56, P137; HERMAN MW, 1981, MED EDUC, V15, P363, DOI 10.1111/j.1365-2923.1981.tb02415.x; HESS TG, 1977, J MED EDUC, V52, P68; HILLIARD RI, 1995, TEACH LEARN MED, V7, P201, DOI DOI 10.1080/10401339509539745; HOBFOLL SE, 1981, MED EDUC, V15, P231, DOI 10.1111/j.1365-2923.1981.tb02638.x; HOBFOLL SE, 1982, MED EDUC, V16, P251, DOI 10.1111/j.1365-2923.1982.tb01260.x; HOJAT M, 1988, J MED EDUC, V63, P323; Hojat M, 1996, ACAD MED, V71, pS103, DOI 10.1097/00001888-199610000-00059; HOWELL MA, 1966, J APPL PSYCHOL, V50, P451, DOI 10.1037/h0024044; Huff KL, 1999, ACAD MED, V74, pS41, DOI 10.1097/00001888-199910000-00035; Hunter John E., 1990, METHODS META ANAL; HUXHAM GJ, 1980, MED EDUC, V14, P97, DOI 10.1111/j.1365-2923.1980.tb02620.x; Iputo JE, 1999, S AFR MED J, V89, P550; JOHNSON D, 1960, J MED EDUC, V50, P925; JOHNSON DG, 1986, J MED EDUC, V61, P629; Johnson H C, 1977, J Natl Med Assoc, V69, P551; JOHNSON V, 1963, J MED EDUC, V38, P591; JONES BJ, 1991, ACAD MED, V66, pS22, DOI 10.1097/00001888-199109000-00029; JONES RF, 1984, J MED EDUC, V59, P455; KNEHR CA, 1959, J PSYCHOL, V47, P297, DOI 10.1080/00223980.1959.9916331; Koenig JA, 1998, ACAD MED, V73, P1095, DOI 10.1097/00001888-199810000-00021; KORMAN M, 1971, J MED EDUC, V46, P670; Kosower E, 1996, AM J MED SCI, V312, P214, DOI 10.1097/00000441-199611000-00004; LACORTE MA, 1993, MED EDUC, V27, P165, DOI 10.1111/j.1365-2923.1993.tb00247.x; LAZIN R, 1991, MED EDUC, V25, P396, DOI 10.1111/j.1365-2923.1991.tb00087.x; LEIDEN LI, 1990, ACAD MED, V65, P395, DOI 10.1097/00001888-199006000-00009; LEONARDSON GR, 1985, J MED EDUC, V60, P719; LEONARDSON GR, 1987, J MED EDUC, V62, P21; LINN BS, 1984, J MED EDUC, V59, P7; LIPTON A, 1988, MED EDUC, V22, P381, DOI 10.1111/j.1365-2923.1988.tb00771.x; LIPTON A, 1984, MED EDUC, V18, P203, DOI 10.1111/j.1365-2923.1984.tb01011.x; Lumb AB, 2000, BRIT MED J, V320, P82, DOI 10.1136/bmj.320.7227.82; Lynch TG, 1998, AM J SURG, V176, P62, DOI 10.1016/S0002-9610(98)00107-X; MARKERT RJ, 1984, PSYCHOL REP, V55, P331, DOI 10.2466/pr0.1984.55.1.331; MARKERT RJ, 1985, MED EDUC, V19, P9, DOI 10.1111/j.1365-2923.1985.tb01133.x; MARKERT RJ, 1986, PERCEPT MOTOR SKILL, V62, P781, DOI 10.2466/pms.1986.62.3.781; MARKERT RJ, 1993, ACAD MED, V68, pS31, DOI 10.1097/00001888-199302000-00027; Martin IG, 2000, MED EDUC, V34, P530, DOI 10.1046/j.1365-2923.2000.00489.x; Mawhinney B S, 1976, Med Educ, V10, P87; McCrae RR, 1997, AM PSYCHOL, V52, P509, DOI 10.1037/0003-066X.52.5.509; McDonough CM, 2000, MED EDUC, V34, P30; MCGUIRE FL, 1982, J MED EDUC, V57, P60; MCGUIRE FL, 1980, J MED EDUC, V55, P405; McManus IC, 1998, BRIT MED J, V316, P345, DOI 10.1136/bmj.316.7128.345; McManus IC, 1996, MED EDUC, V30, P195, DOI 10.1111/j.1365-2923.1996.tb00742.x; MCMANUS IC, 1986, MED EDUC, V20, P181, DOI 10.1111/j.1365-2923.1986.tb01165.x; McManus IC, 1998, BRIT MED J, V317, P1111; MCMANUS IC, 1995, BRIT MED J, V310, P496, DOI 10.1136/bmj.310.6978.496; McManus IC, 1999, BRIT MED J, V319, P542, DOI 10.1136/bmj.319.7209.542; MCMANUS IC, 1986, BRIT MED J, V293, P124, DOI 10.1136/bmj.293.6539.124; MENNIN SP, 1993, ACAD MED, V68, P616, DOI 10.1097/00001888-199308000-00012; MEREDITH KE, 1982, J MED EDUC, V57, P743; MILSTEIN RM, 1981, J MED EDUC, V56, P77; MURDEN R, 1978, J MED EDUC, V53, P711; Muthen LK, 2000, MPLUS COMPREHENSIVE; NEWBLE DI, 1986, MED EDUC, V20, P162, DOI 10.1111/j.1365-2923.1986.tb01163.x; NNODIM JO, 1994, MED EDUC, V28, P200, DOI 10.1111/j.1365-2923.1994.tb02699.x; NOWACEK GA, 1987, J MED EDUC, V62, P989; ODONNELL MJ, 1982, J MED EDUC, V57, P868; Oggins J, 1988, J Am Med Womens Assoc (1972), V43, P171; PAMPHLETT R, 1995, MED EDUC, V29, P297, DOI 10.1111/j.1365-2923.1995.tb02852.x; PARKER GB, 1993, MED J AUSTRALIA, V158, P747, DOI 10.5694/j.1326-5377.1993.tb121955.x; Patterson F, 2000, BRIT J GEN PRACT, V50, P188; PETEK JM, 1991, ACAD MED, V66, P425, DOI 10.1097/00001888-199107000-00014; PETERS AS, 1992, ACAD MED, V67, P413, DOI 10.1097/00001888-199206000-00017; POWIS DA, 1988, BRIT MED J, V296, P765, DOI 10.1136/bmj.296.6624.765; POWIS DA, 1992, AUST NZ J MED, V22, P692, DOI 10.1111/j.1445-5994.1992.tb04872.x; PRAT HM, 1993, ACAD MED, V11, P856; RAMOS SM, 1986, J NATL MED ASSOC, V78, P601; RAMSBOTTOMLUCIER M, 1995, ACAD MED, V70, P236, DOI 10.1097/00001888-199503000-00016; Raudenbush SM, 2000, HLM5 HIERARCHICAL LI; RICHARDS JM, 1962, J APPL PSYCHOL, V46, P142, DOI 10.1037/h0039288; RICHARDS JM, 1965, J APPL PSYCHOL, V49, P79, DOI 10.1037/h0021960; Richardson PH, 1998, MED EDUC, V32, P294, DOI 10.1046/j.1365-2923.1998.00225.x; RIPLEY RM, 1981, MED EDUC, V15, P298; ROLFE IE, 1995, LANCET, V346, P1329, DOI 10.1016/S0140-6736(95)92344-6; Roman S A Jr, 1979, J Natl Med Assoc, V71, P661; RONAI AK, 1984, J MED EDUC, V59, P341; Roth KS, 1996, ACAD MED, V71, P176, DOI 10.1097/00001888-199602000-00026; Roth PL, 1996, J APPL PSYCHOL, V81, P548, DOI 10.1037/0021-9010.81.5.548; Schmidt FL, 1998, PSYCHOL BULL, V124, P262, DOI 10.1037/0033-2909.124.2.262; SCOTT CS, 1988, MED EDUC, V22, P389, DOI 10.1111/j.1365-2923.1988.tb00772.x; Shen HK, 1997, ACAD MED, V72, P781, DOI 10.1097/00001888-199709000-00013; SMITH SR, 1986, J MED EDUC, V61, P404; SMITH SR, 1991, ACAD MED, V66, P474, DOI 10.1097/00001888-199108000-00012; Stewart SM, 1999, MED EDUC, V33, P243; Strayhorn G, 1999, ACAD MED, V74, P435, DOI 10.1097/00001888-199904000-00043; TETT RP, 1991, PERS PSYCHOL, V44, P703; TOOTH D, 1989, MED EDUC, V23, P416, DOI 10.1111/j.1365-2923.1989.tb00896.x; TRACZ SM, 1992, EDUC PSYCHOL MEAS, V52, P879, DOI 10.1177/0013164492052004007; TURNER EV, 1974, J MED EDUC, V49, P338; Tutton PJM, 1996, ACAD MED, V71, P181, DOI 10.1097/00001888-199602000-00027; VANDERPLOEG HM, 1979, PSYCHOL REP, V45, P223, DOI 10.2466/pr0.1979.45.1.223; Veloski JJ, 2000, ACAD MED, V75, pS28, DOI 10.1097/00001888-200010001-00009; WALLACE WFM, 1988, ULSTER MED J, V57, P149; Webb CT, 1997, J NATL MED ASSOC, V89, P173; WEINBERG E, 1973, J MED EDUC, V48, P240; WEISS M, 1988, MED EDUC, V22, P492, DOI 10.1111/j.1365-2923.1988.tb00791.x; WILLOUGHBY TL, 1981, J MED EDUC, V56, P717; XU G, 1993, ACAD MED, V68, P82, DOI 10.1097/00001888-199301000-00013; YENS DP, 1982, J MED EDUC, V57, P429; Yerkes RM, 1908, J COMP NEUROL PSYCHO, V18, P459, DOI 10.1002/cne.920180503	147	490	512	1	67	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 20	2002	324	7343					952	957		10.1136/bmj.324.7343.952	http://dx.doi.org/10.1136/bmj.324.7343.952			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	544UF	11964342	Green Published, Bronze			2022-12-28	WOS:000175179500019
J	Mercieri, A; Mercieri, M; Armanini, M; Raiteri, M				Mercieri, A; Mercieri, M; Armanini, M; Raiteri, M			Exertional haematuria	LANCET			English	Editorial Material							NUTCRACKER SYNDROME; DIAGNOSIS		Osped S Isidore, Nephrol & Dialysis Unit, Bergamo, Italy; Osped S Isidore, Internal Med Unit, Bergamo, Italy; Univ Roma La Sapienza, Fac Med & Chirurg 2, Osped S Andrea, Dept Anesthesiol & Intens Care, Rome, Italy; Osped Maggiore Milano, IRCCS, Div Vasc Surg & Transplant, Milan, Italy	Sapienza University Rome; Azienda Ospedaliera Sant'Andrea	Mercieri, A (corresponding author), Piazza San Paolo 20, I-24128 Bergamo, Italy.			Mercieri, Marco/0000-0003-4321-6525				BARNES RW, 1988, J VASC SURG, V8, P415, DOI 10.1067/mva.1988.avs0080415; Kim SH, 1996, RADIOLOGY, V198, P93, DOI 10.1148/radiology.198.1.8539413; Okada M, 1998, CLIN NEPHROL, V49, P35; SHOKEIR AA, 1994, BRIT J UROL, V74, P139, DOI 10.1111/j.1464-410X.1994.tb16574.x; Takebayashi S, 1999, AM J ROENTGENOL, V172, P39, DOI 10.2214/ajr.172.1.9888735	5	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 20	2002	359	9315					1402	1402		10.1016/S0140-6736(02)08354-X	http://dx.doi.org/10.1016/S0140-6736(02)08354-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542ZQ	11978338				2022-12-28	WOS:000175076200013
J	Walshe, K				Walshe, K			The rise of regulation in the NHS	BRITISH MEDICAL JOURNAL			English	Article							HEALTH		Univ Calif Berkeley, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Walshe, K (corresponding author), Univ Manchester, Manchester Ctr Healthcare Management, Manchester M13 9PL, Lancs, England.			Walshe, Kieran/0000-0002-0696-480X				ALTMAN SH, 1999, REGULATING MANAGED C; [Anonymous], 1994, W EUROPEAN POLITICS; Ayres I, 1992, RESPONSIVE REGULATIO, P21; Baldwin R., 1999, UNDERSTANDING REGULA; Bardach E., 1982, GOING BOOK PROBLEM R; Brennan T., 1996, NEW RULES REGULATION; Breyer Stephen, 1982, REGULATION ITS REFOR; Chorafas D. N., 2000, NEW REGULATION FINAN; CLOUGH R, 1994, INSIGHTS INSPECTION; CUNNINGHAM N., 1998, SMART REGULATION; DAY P, 1987, MILBANK Q, V65, P303, DOI 10.2307/3349942; Day P., 1990, INSPECTING INSPECTOR; Department of Health, 2001, BUILD SAF NHS PAT; Department of Health, 1999, SUPP DOCT PROT PAT; Department of Health, 2000, NHS PLAN PLAN INV PL; Department of Health, 1997, NEW NHS MOD DEP; Ferlie E., 1996, NEW PUBLIC MANAGEMEN; Ham C, 1999, BRIT MED J, V319, P1490, DOI 10.1136/bmj.319.7223.1490; HANCHER L, 1989, CAPITALISM CULTURE R; Hood C, 1998, PUBLIC MONEY MANAGE, V18, P61, DOI 10.1111/1467-9302.00117; Hood C, 1999, REGULATION INSIDE GO; Kagan R., 1984, ENFORCING REGULATION, P67, DOI DOI 10.1007/978-94-017-5297-8_4; Klein, 1987, ACCOUNTABILITIES 5 P; Noll Roger G., 1985, REGULATORY POLICY SO, P9; OGUS A, 1994, REGULATION LEGAL FOR; Power M., 1997, AUDIT SOC RITUALS VE; Reiss A.J., 1984, ENFORCING REGULATION, P23; SCRIVENS E, 1995, ACCREDITATION PROTEC; Selznick P., 1985, REGULATORY POLICY SO, P363; The Bristol Royal Infirmary Inquiry, 2001, LEARN BRIST REP PUBL; Walshe K, 1999, QUAL HEALTH CARE, V8, P191, DOI 10.1136/qshc.8.3.191; Wilcox B., 1996, INSPECTING SCH HOLDI	32	52	52	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 20	2002	324	7343					967	970		10.1136/bmj.324.7343.967	http://dx.doi.org/10.1136/bmj.324.7343.967			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	544UF	11964345	Green Published			2022-12-28	WOS:000175179500022
J	Goldberg, DE				Goldberg, DE			Parasitology: When the host is smarter than the parasite	SCIENCE			English	Editorial Material							PLASMODIUM-FALCIPARUM; EXPRESSION; SEQUENCE; MALARIA; DRUGS		Washington Univ, Howard Hughes Med Inst, Dept Med, St Louis, MO 63130 USA; Washington Univ, Dept Mol Microbiol, St Louis, MO 63130 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Goldberg, DE (corresponding author), Washington Univ, Howard Hughes Med Inst, Dept Med, St Louis, MO 63130 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007172] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Breman JG, 2001, AM J TROP MED HYG, V64, pIV, DOI 10.4269/ajtmh.2001.64.iv; CHU E, 1993, BIOCHEMISTRY-US, V32, P4756, DOI 10.1021/bi00069a009; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; ELION GB, 1986, ANTIVIRAL CHEMOTHERA, P118; ERICKANABALI EA, 1997, BIOCHEMISTRY-US, V36, P12317; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gero AM, 1999, NUCLEOS NUCLEOT, V18, P885, DOI 10.1080/15257779908041593; Hayward RE, 2000, MOL MICROBIOL, V35, P6, DOI 10.1046/j.1365-2958.2000.01730.x; Johnston Martin, COMMUNICATION; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Mamoun CB, 2001, MOL MICROBIOL, V39, P26, DOI 10.1046/j.1365-2958.2001.02222.x; PHILLIPS MA, 1988, J BIOL CHEM, V263, P17933; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Zhang K, 2002, SCIENCE, V296, P545, DOI 10.1126/science.1068274	16	7	7	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					482	483		10.1126/science.1071206	http://dx.doi.org/10.1126/science.1071206			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964467				2022-12-28	WOS:000175179400032
J	Walker, NJ				Walker, NJ			A technique whose time has come	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; PCR; AMPLIFICATION		NIEHS, Environm Toxicol Program, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Walker, NJ (corresponding author), NIEHS, Environm Toxicol Program, POB 12233, Res Triangle Pk, NC 27709 USA.		Walker, Nigel J/D-6583-2012	Walker, Nigel J/0000-0002-9111-6855				Gibbs WW, 2001, SCI AM, V285, P52, DOI 10.1038/scientificamerican0801-52; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GUYER RL, 1989, SCIENCE, V246, P1543, DOI 10.1126/science.2688087; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Ideker T, 2001, ANNU REV GENOM HUM G, V2, P343, DOI 10.1146/annurev.genom.2.1.343; Ideker T, 2001, SCIENCE, V292, P929, DOI 10.1126/science.292.5518.929; Lobenhofer EK, 2001, ENVIRON HEALTH PERSP, V109, P881, DOI 10.2307/3454988; Mitchell P, 2001, NAT BIOTECHNOL, V19, P717, DOI 10.1038/90754; MULLIS KB, 1990, SCI AM, V262, P56, DOI 10.1038/scientificamerican0490-56; Nicholson JK, 1999, XENOBIOTICA, V29, P1181, DOI 10.1080/004982599238047; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Walker NJ, 2001, J BIOCHEM MOL TOXIC, V15, P121, DOI 10.1002/jbt.8; White B. A., 1993, PCR PROTOCOLS CURREN, V15	16	246	259	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 19	2002	296	5567					557	+		10.1126/science.296.5567.557	http://dx.doi.org/10.1126/science.296.5567.557			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	544UE	11964485				2022-12-28	WOS:000175179400054
J	Schnitzer, MJ				Schnitzer, MJ			Biological computation: Amazing algorithms	NATURE			English	Editorial Material									Bell Labs, Lucent Technol, Dept Biol Computat & Theoret Phys, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Schnitzer, MJ (corresponding author), Bell Labs, Lucent Technol, Dept Biol Computat & Theoret Phys, 600 Mt Ave, Murray Hill, NJ 07974 USA.							[Anonymous], [No title captured]; Carew T., 2000, BEHAV NEUROBIOLOGY; Von Neumann J., 2012, COMPUTER BRAIN; Wandell B., 1995, FDN VISION; WEINER N, 1961, CYBERNETICS	5	5	5	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	2002	416	6882					683	683		10.1038/416683a	http://dx.doi.org/10.1038/416683a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961533	Bronze			2022-12-28	WOS:000175033500022
J	Shinohara, M; Terada, Y; Iwamatsu, A; Shinohara, A; Mochizuki, N; Higuchi, M; Gotoh, Y; Ihara, S; Nagata, S; Itoh, H; Fukui, Y; Jessberger, R				Shinohara, M; Terada, Y; Iwamatsu, A; Shinohara, A; Mochizuki, N; Higuchi, M; Gotoh, Y; Ihara, S; Nagata, S; Itoh, H; Fukui, Y; Jessberger, R			SWAP-70 is a guanine-nucleotide-exchange factor that mediates signalling of membrane ruffling	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; PHOSPHOINOSITIDE 3-KINASE; LIPID PRODUCTS; PHOSPHATIDYLINOSITOL-3 KINASE; PLECKSTRIN HOMOLOGY; RAS; BINDING; TRANSDUCTION; CELLS	Phosphoinositide-3-OH kinase (PI(3) K), activated through growth factor stimulation, generates a lipid second messenger, phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5) P-3)(1-5). PtdIns(3,4,5) P-3 is instrumantal in signalling pathways that trigger cell activation, cytoskeletal rearrangement, survival and other reactions. However, some targets of PtdIns( 3,4,5) P3 are yet to be discovered(1-7). We demonstrate that SWAP-70, a unique signalling protein(8-10), specifically binds PtdIns(3,4,5) P-3.On stimulation by growth factors, cytoplasmic SWAP-70, which is dependent on PI(3) K but independent of Ras, moved to cell membrane rearrangements known as ruffles. However, mutant SWAP-70 lacking the ability to bind PtdIns(3, 4, 5) P-3 blocked membrane ruffling induced by epidermal growth factor or platelet-derived growth factor. SWAP-70 shows low homology with Rac-guanine nucleotide exchange factors (GEFs), and catalyses PtdIns( 3,4,5) P-3-dependent guanine nucleotide exchange to Rac. SWAP-70-deficient fibroblasts showed impaired membrane ruffling after stimulation with epidermal growth factor, and failed to activate Rac fully. We conclude that SWAP-70 is a new type of Rac-GEF which, independently of Ras, transduces signals from tyrosine kinase receptors to Rac.	Univ Tokyo, Fac Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Tokyo 1138657, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; Int Med Ctr Japan, Dept Pathol, Shinjuku Ku, Tokyo 1628640, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Mt Sinai Sch Med, Carl C Icahn Inst Gene Therapy & Mol Med, New York, NY 10029 USA	University of Tokyo; Kirin Brewery Company Limited; National Center for Global Health & Medicine - Japan; University of Tokyo; Icahn School of Medicine at Mount Sinai	Fukui, Y (corresponding author), Univ Tokyo, Fac Agr & Life Sci, Dept Appl Biol Chem, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.	ayfukui@mail.ecc.u-tokyo.ac.jp	Fukui, Yasuhisa/E-8806-2010; Nagata, Satoshi/B-5781-2008	Shinohara, Masahiro/0000-0002-5532-1042; Nagata, Satoshi/0000-0001-9156-5215				Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Borggrefe T, 1999, EUR J IMMUNOL, V29, P1812, DOI 10.1002/(SICI)1521-4141(199906)29:06<1812::AID-IMMU1812>3.0.CO;2-J; Borggrefe T, 2001, EUR J IMMUNOL, V31, P2467, DOI 10.1002/1521-4141(200108)31:8<2467::AID-IMMU2467>3.0.CO;2-P; CAMPBELL DJ, 1966, NATURE, V210, P756, DOI 10.1038/210756b0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Fleming IN, 2000, BIOCHEM J, V351, P173, DOI 10.1042/0264-6021:3510173; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Fukui Y, 1998, J BIOCHEM-TOKYO, V124, P1; GROSS B, IN PRESS EUR J IMMUN; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; Kita Y, 1998, J CELL SCI, V111, P907; LENZEN C, 1995, METHOD ENZYMOL, V255, P95; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; Martin SS, 1996, ENDOCRINOLOGY, V137, P5045, DOI 10.1210/en.137.11.5045; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Masat L, 2000, P NATL ACAD SCI USA, V97, P2180, DOI 10.1073/pnas.040374497; Missy K, 1998, J BIOL CHEM, V273, P30279, DOI 10.1074/jbc.273.46.30279; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Shirai R, 1998, TETRAHEDRON LETT, V39, P9485, DOI 10.1016/S0040-4039(98)02151-0; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Tanaka K, 1999, J BIOL CHEM, V274, P3919, DOI 10.1074/jbc.274.7.3919; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	31	176	179	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	2002	416	6882					759	763		10.1038/416759a	http://dx.doi.org/10.1038/416759a			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	542FU	11961559				2022-12-28	WOS:000175033500047
J	Kirsner, JB				Kirsner, JB			The most powerful therapeutic force	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		Charon R, 2001, JAMA-J AM MED ASSOC, V286, P1897, DOI 10.1001/jama.286.15.1897; CLUFF LE, 2001, LOST ART CARING CHAL; Cohen JJ, 2001, JAMA-J AM MED ASSOC, V286, P1957; COUSINS N, 1989, BIOL HOPE; EISENBERG L, 1980, AM J MED, V69, P277, DOI 10.1016/0002-9343(80)90389-7; Kiecolt-Glaser JK, 1999, BRAIN BEHAV IMMUN, V13, P61, DOI 10.1006/brbi.1999.0552; KIRSNER JB, 1986, PERSPECT BIOL MED, V29, P227; KIRSNER JB, 1992, ARCH INTERN MED, V152, P2184, DOI 10.1001/archinte.152.11.2184; LASTER L, 1992, WASHINGTON POST  SEP; MELLINKOFF SM, 1975, J MED EDUC, V50, P1005; MOSER RH, 1999, PHAROS           FAL, P15; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; SHORTER E, 1993, COMPANION ENCY HIST, V2, P783; Smyth JM, 1999, JAMA-J AM MED ASSOC, V281, P1304, DOI 10.1001/jama.281.14.1304; Spiegel D, 1999, JAMA-J AM MED ASSOC, V281, P1328, DOI 10.1001/jama.281.14.1328; Turner J, 2000, WESTERN J MED, V172, P124, DOI 10.1136/ewjm.172.2.124	16	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	2002	287	15					1909	1910		10.1001/jama.287.15.1909	http://dx.doi.org/10.1001/jama.287.15.1909			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NC	11960516				2022-12-28	WOS:000174989800001
J	Benn, CS; Balde, A; George, E; Kidd, M; Whittle, H; Lisse, IM; Aaby, P				Benn, CS; Balde, A; George, E; Kidd, M; Whittle, H; Lisse, IM; Aaby, P			Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau	LANCET			English	Article								We have previously reported that vitamin A supplementation with measles vaccine at age 9 months increases measles-specific antibody concentrations In children at age 18 months compared with placebo. We examined these children when they reached age 6-8 years. Fewer vitamin A-supplemented children had non-protective antibody concentrations (p=0.0095); among children with protective antibody levels, vitamin A-supplemented children tended to have higher geometric mean antibody titres (p=0.09). Thus, simultaneous administration of vitamin A and measles vaccine at age 9 months had a long-term effect on measles-specific antibody levels and may contribute to Improved measles control In less-developed countries.	State Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Copenhagen, Denmark; MRC Labs, Fajara, Gambia	Aarhus University; Statens Serum Institut; MRC Laboratory Molecular Biology				Aaby, Peter/0000-0001-8331-1389				Benn CS, 1997, LANCET, V350, P101, DOI 10.1016/S0140-6736(96)12019-5; CHEN RT, 1990, J INFECT DIS, V162, P1036, DOI 10.1093/infdis/162.5.1036; SAMB B, 1995, PEDIATR INFECT DIS J, V14, P203, DOI 10.1097/00006454-199503000-00007; *UNICEF TUL U, 1998, PROGR CONTR VIT A DE; Whittle H, 1999, PEDIATR INFECT DIS J, V18, P53, DOI 10.1097/00006454-199901000-00013	5	42	44	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 13	2002	359	9314					1313	1314		10.1016/S0140-6736(02)08274-0	http://dx.doi.org/10.1016/S0140-6736(02)08274-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	541NB	11965280				2022-12-28	WOS:000174989700017
J	Wise, MEJ; Mistry, K; Reid, S				Wise, MEJ; Mistry, K; Reid, S			Neuropsychiatric complications of nevirapine treatment	BRITISH MEDICAL JOURNAL			English	Letter									Hammersmith Hosp, Dept Psychol, London W2 0HS, England; Paterson Ctr Mental Hlth, London W2 2PD, England	Imperial College London	Wise, MEJ (corresponding author), Hammersmith Hosp, Dept Psychol, London W2 0HS, England.							*JOINT FORM COMM, 2001, BRIT NAT FORM; World Health Organisation, 1993, ICD 10 CLASSIFICATIO	2	34	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 13	2002	324	7342					879	879		10.1136/bmj.324.7342.879	http://dx.doi.org/10.1136/bmj.324.7342.879			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542PA	11950737	Green Published, Bronze			2022-12-28	WOS:000175052200022
J	Angulo, P				Angulo, P			Medical progress - Nonalcoholic fatty liver disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TUMOR NECROSIS FACTOR; INSULIN-RESISTANCE; OBESE PATIENTS; HEPATIC IRON; RISK-FACTORS; FOLLOW-UP; CRYPTOGENIC CIRRHOSIS; ALCOHOLIC HEPATITIS; OVERWEIGHT PATIENTS; DIABETES-MELLITUS		Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	Angulo, P (corresponding author), Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	angulohernandez.paul@mayo.edu	Wong, Grace LH/L-8586-2014; rinella, mary/AAJ-4065-2021; Nobili, Valerio/K-8670-2018; Sirlin, Claude/AAU-1376-2020; Wong, Vincent WS/K-3864-2014	Wong, Grace LH/0000-0002-2863-9389; rinella, mary/0000-0003-0620-9705; Sirlin, Claude/0000-0002-6639-9072; Wong, Vincent WS/0000-0003-2215-9410				Abdelmalek MF, 2001, AM J GASTROENTEROL, V96, P2711; Adinolfi LE, 2001, HEPATOLOGY, V33, P1358, DOI 10.1053/jhep.2001.24432; ADLER M, 1979, AM J MED, V67, P811, DOI 10.1016/0002-9343(79)90740-X; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; ANDERSEN T, 1991, J HEPATOL, V12, P224, DOI 10.1016/0168-8278(91)90942-5; Angulo P, 1999, HEPATOLOGY, V30, P1356, DOI 10.1002/hep.510300604; Assy N, 2000, DIGEST DIS SCI, V45, P1929, DOI 10.1023/A:1005661516165; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; BALDRIDGE AD, 1995, J PEDIATR-US, V127, P700, DOI 10.1016/S0022-3476(95)70156-7; Basaranoglu M, 1999, J HEPATOL, V31, P384, DOI 10.1016/S0168-8278(99)80243-8; Becker U, 1996, HEPATOLOGY, V23, P1025, DOI 10.1002/hep.510230513; Bellentani S, 1997, GUT, V41, P845, DOI 10.1136/gut.41.6.845; Bellentani S, 2000, ANN INTERN MED, V132, P112, DOI 10.7326/0003-4819-132-2-200001180-00004; BIRD GLA, 1988, MOL ASPECTS MED, V10, P97, DOI 10.1016/0098-2997(88)90017-9; Boden G, 1997, DIABETES, V46, P536; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Bonkovsky HL, 1999, J HEPATOL, V31, P421, DOI 10.1016/S0168-8278(99)80032-4; Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x; *BUR CENS, 2001, 2000 CENS POP HOUS; Caldwell SH, 1999, HEPATOLOGY, V29, P664, DOI 10.1002/hep.510290347; Caldwell SH, 1999, J HEPATOL, V31, P430, DOI 10.1016/S0168-8278(99)80033-6; Caldwell SH, 2001, AM J GASTROENTEROL, V96, P519; Charlton M, 2001, LIVER TRANSPLANT, V7, P608, DOI 10.1053/jlts.2001.25453; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Clark JM, 2001, GASTROENTEROLOGY, V120, pA65; Cohen B, 1996, SCIENCE, V274, P1185, DOI 10.1126/science.274.5290.1185; Contos MJ, 2001, LIVER TRANSPLANT, V7, P363, DOI 10.1053/jlts.2001.23011; Cortez-Pinto H, 1999, JAMA-J AM MED ASSOC, V282, P1659, DOI 10.1001/jama.282.17.1659; Creutzfeldt W, 1970, Prog Liver Dis, V3, P371; CURZIO M, 1985, INT J TISSUE REACT, V7, P137; Daniel S, 1999, AM J GASTROENTEROL, V94, P3010, DOI 10.1111/j.1572-0241.1999.01451.x; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; Debaere C, 1998, J Belge Radiol, V81, P174; DIEHL AM, 1988, GASTROENTEROLOGY, V95, P1056, DOI 10.1016/0016-5085(88)90183-7; Dixon JB, 2001, GASTROENTEROLOGY, V121, P91, DOI 10.1053/gast.2001.25540; DRENICK EJ, 1970, NEW ENGL J MED, V282, P829, DOI 10.1056/NEJM197004092821502; ERIKSSON S, 1986, ACTA MED SCAND, V220, P83; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Faggioni R, 1999, AM J PHYSIOL-REG I, V276, pR136, DOI 10.1152/ajpregu.1999.276.1.R136; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Franzese A, 1997, DIGEST DIS SCI, V42, P1428, DOI 10.1023/A:1018850223495; George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Hasegawa T, 2001, ALIMENT PHARM THERAP, V15, P1667, DOI 10.1046/j.1365-2036.2001.01083.x; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Hug H, 1997, J BIOL CHEM, V272, P28191, DOI 10.1074/jbc.272.45.28191; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; ITOH S, 1987, AM J GASTROENTEROL, V82, P650; JOSEPH AEA, 1991, CLIN RADIOL, V43, P26, DOI 10.1016/S0009-9260(05)80350-2; Knobler H, 1999, QJM-MON J ASSOC PHYS, V92, P73, DOI 10.1093/qjmed/92.2.73; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; Laurin J, 1996, HEPATOLOGY, V23, P1464; Lavine JE, 2000, J PEDIATR-US, V136, P734, DOI 10.1016/S0022-3476(00)05040-X; Leclercq IA, 2000, J CLIN INVEST, V105, P1067, DOI 10.1172/JCI8814; LEE RG, 1989, HUM PATHOL, V20, P594, DOI 10.1016/0046-8177(89)90249-9; Leonarduzzi G, 1997, FASEB J, V11, P851, DOI 10.1096/fasebj.11.11.9285483; LONGO R, 1995, JMRI-J MAGN RESON IM, V5, P281, DOI 10.1002/jmri.1880050311; LUDWIG J, 1980, MAYO CLIN PROC, V55, P434; Luyckx FH, 1998, INT J OBESITY, V22, P222, DOI 10.1038/sj.ijo.0800571; MADDUX BA, 1995, NATURE, V373, P448, DOI 10.1038/373448a0; Manton ND, 2000, MED J AUSTRALIA, V173, P476, DOI 10.5694/j.1326-5377.2000.tb139299.x; Marchesini G, 1999, AM J MED, V107, P450, DOI 10.1016/S0002-9343(99)00271-5; Marchesini G, 2001, LANCET, V358, P893, DOI 10.1016/S0140-6736(01)06042-1; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Mendler MH, 1999, GASTROENTEROLOGY, V117, P1155, DOI 10.1016/S0016-5085(99)70401-4; MITCHELL DG, 1992, RADIOLOGY, V185, P1; NOMURA H, 1988, JPN J MED, V27, P142, DOI 10.2169/internalmedicine1962.27.142; OSHIBUCHI M, 1991, J GASTROEN HEPATOL, V6, P165, DOI 10.1111/j.1440-1746.1991.tb01459.x; PALMER M, 1990, GASTROENTEROLOGY, V99, P1408, DOI 10.1016/0016-5085(90)91169-7; Pinto HC, 1996, DIGEST DIS SCI, V41, P172, DOI 10.1007/BF02208601; POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114; Rashid M, 2000, J PEDIATR GASTR NUTR, V30, P48, DOI 10.1097/00005176-200001000-00017; Ratziu V, 2000, GASTROENTEROLOGY, V118, P1117, DOI 10.1016/S0016-5085(00)70364-7; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; ROZENTAL P, 1967, AM J DIG DIS, V12, P198, DOI 10.1007/BF02233443; Ruderman N, 1998, DIABETES, V47, P699, DOI 10.2337/diabetes.47.5.699; Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256; SASTRE J, 1989, LIFE SCI, V45, P183, DOI 10.1016/0024-3205(89)90293-2; SCHAFFNER F, 1986, PROG LIVER DIS, V8, P283; SILVERMAN JF, 1990, AM J GASTROENTEROL, V85, P1349; SILVERMAN JF, 1989, PATHOL ANNU, V24, P275; Struben VMD, 2000, AM J MED, V108, P9, DOI 10.1016/S0002-9343(99)00315-0; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1002/hep.1840220616; TOMINAGA K, 1995, DIGEST DIS SCI, V40, P2002, DOI 10.1007/BF02208670; Ueno T, 1997, J HEPATOL, V27, P103, DOI 10.1016/S0168-8278(97)80287-5; VAJRO P, 1994, J PEDIATR-US, V125, P239, DOI 10.1016/S0022-3476(94)70202-0; VANNESS MM, 1989, ANN INTERN MED, V111, P473, DOI 10.7326/0003-4819-111-6-473; WANLESS IR, 1990, HEPATOLOGY, V12, P1106, DOI 10.1002/hep.1840120505; Watson AM, 1999, DRUG METAB DISPOS, V27, P695; Weltman MD, 1998, HEPATOLOGY, V27, P128, DOI 10.1002/hep.510270121; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; Younossi ZM, 1999, HEPATOLOGY, V30, P847, DOI 10.1002/hep.510300407; ZATLOUKAL K, 1991, LAB INVEST, V64, P200	96	4035	4228	24	560	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 18	2002	346	16					1221	1231		10.1056/NEJMra011775	http://dx.doi.org/10.1056/NEJMra011775			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	542FT	11961152				2022-12-28	WOS:000175033400008
